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Abstract 
Background: Traditionally, coping and decision making have been viewed as 
separate concepts. However, analysis of the role of emotions during decision 
making in healthcare suggests that coping with health threats, and associated 
emotions, should be viewed as an integral part of deliberation processes. This 
thesis reports on the development of a framework that merges deliberation and 
coping processes. Subsequently, this framework is operationalised by adapting it to 
specifically describe deliberations about risk-reducing salpingo-oophorectomy 
(RRSO) by women at increased genetic risk of ovarian cancer.   
Methods: A narrative review of the literature on decision making and coping 
theories informed the development of a novel framework that integrates theories 
from both fields. A multi-methods approach, which included a systematic literature 
search and qualitative methods, examined women’s decision making about RRSO 
and informed adaptation of the framework to specifically describe such decisions. 
The adapted framework was then used to develop a decision support intervention 
for women at increased risk of ovarian cancer in the UK. Incremental prototypes of 
the intervention were reviewed by a group of stakeholders and usability of the final 
prototype was tested using cognitive interviews. 
Results: The Coping in Deliberation (CODE) framework describes deliberations as 
multi-step appraisal and coping processes. The framework was successfully adapted 
to decisions about RRSO and used to develop a two part patient decision support 
intervention, consisting of a brief paper-based tool (Option Grid) and a longer 
website (the Oophorectomy Decision Explorer, OvDex).  
Conclusions: Emotions and coping are integral parts of deliberations in healthcare 
and the CODE framework, which acknowledges the importance of these concepts 
during deliberations, can be used to guide the development of patient decision 
support interventions. Future research should apply this framework to other 
healthcare decisions. The intervention developed in this thesis requires field testing 
to assess its impact before implementation in clinical practice. 
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1 Introduction and Thesis Overview 
 
1.1 Introduction 
 Previous research suggests that emotions and coping are integral parts of 
decision processes and that emotions influence people’s predictions of how 
different options might affect their life (Balneaves and Long 1999, Gilbert et al. 
2002, Wilson and Gilbert 2003). It has also been proposed that medical decisions 
are in fact coping behaviours aimed at regulating a health threat and associated 
emotions (Balneaves and Long 1999, Luce 2005, Power et al. 2011). To date, 
however, decision making theorists have largely ignored the role of emotions and 
coping in healthcare decision making. Patient decision support interventions are 
tools designed to facilitate decision making processes, which should ideally be 
grounded in theory (Charles et al. 2005, Durand et al. 2008). As coping is an integral 
part of decision making, coping theories could be used alongside decision making 
theories to support the development of such interventions. However, as decision 
making theorists have largely ignored the role of emotions and coping, so have 
decision support developers largely ignored coping theory (Elwyn et al. 2011b). In 
fact, many decision support interventions have been found to be atheoretical 
(Durand et al. 2008). There is a need for a framework that considers emotions and 
coping as intrinsic parts of deliberation processes and that can be used as a basis 
for the development of decision support interventions. This thesis aims to propose 
such a framework to describe deliberations about preference-sensitive healthcare 
choices and to guide the development of more holistic decision support materials.  
 This chapter will: 
i. provide a definition of shared decision making and patient decision support 
interventions 
ii. give an overview of coping theory and coping interventions 
iii. offer an introduction to ovarian cancer risk and risk management options 
iv. outline the objectives and structure of the thesis. 
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1.2 Shared decision making in healthcare 
1.2.1 Shared decision making 
 Traditionally, medical decision making has been described using the 
‘paternalistic’ decision making model, in which the clinician decides on the best 
course of action with very limited input from the patient (Charles et al. 1997, 
Charles et al. 1999, Emanuel and Emanuel 1992). Since the introduction and 
promotion of the idea of patient centred care (PCC), other models have been put 
forward that assume that both the clinician and the patient possess expertise that 
is important for decision making (Figure 1.1).  
Figure 1.1 - Clinical decision making styles 
 
These models describe approaches to decision making that require the exchange of 
information. The clinician is seen as the expert regarding treatment options and 
their expected efficacy, while the patient is considered the expert on their personal 
values and on how any treatment option might affect their life (Charles et al. 1997, 
Hurley et al. 1992). In the ‘Informed’, as well as the ‘Professional-as-Agent’, decision 
making models, information is transferred from one party to the other, so that 
either the patient or the physician possess both types of expertise (i.e. relevant 
medical knowledge and patient values). After considering this knowledge, either 
the patient or the professional can then make a decision independently. In 
‘Informed’ decision making, the clinician provides medical information and 
empowers the patient to make a decision, whereas in ‘Professional-as-Agent’ 
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decision making, the patient provides information about their preferences and 
empowers the clinician to make a decision. However, according to Charles et al. 
(1997) neither of these models are truly representative of ‘shared’ decision making 
(SDM). 
 SDM has previously been defined as “an approach where clinicians and 
patients share the best available evidence when faced with the task of making 
decisions, and where patients are supported to consider options, to achieve 
informed preferences.” (Elwyn et al. 2012, page 1361). SDM requires information 
sharing between two or more parties, at a minimum including a patient and their 
clinician, followed by making a shared decision that is ideally agreed by all parties 
(Charles et al. 1997, Elwyn et al. 2000). Generally, the clinician provides medical 
information on the condition and on the risks and benefits of available options, 
including probabilities and uncertainties, while the patient contributes their view 
on how they perceive those risks and benefits in the context of their personal goals 
and values (O'Connor et al. 2004). However, clinicians also have values that they 
bring to the consultation and similarly, patients may possess medical knowledge 
that they would like to discuss with the clinician (Charles et al. 1997). During a 
shared decision, medical information and values may therefore be exchanged in 
either direction. Both parties then discuss their preferences and reach an informed, 
value-adjusted decision together (Charles et al. 1997, Charles et al. 1999). 
 Some have argued that SDM should ethically be done in any consultation 
(Schneider 1998, Stiggelbout et al. 2012); however, it is especially important in 
situations of medical equipoise, where no medically superior option exists and 
where harms and benefits of different options are balanced (Coulter 2010, Elwyn et 
al. 2000, Elwyn et al. 2009a). Such decisions are characterised by inherent 
uncertainty, as the clinician cannot make a firm recommendation as to what the 
best course of action for any individual patient may be without considering the 
patient’s values with regard to the risks and benefits of the different options (Elwyn 
et al. 2009a). Therefore, these decisions are said to be ‘preference-sensitive’, i.e. 
depending on the goals, values and preferences of the individual patient and 
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requiring trade-offs between risks and benefits of different available options 
(Wennberg et al. 2002). Examples of such decisions include treatment options in 
early stage breast cancer (Kiebert et al. 1991), management of chronic kidney 
disease (Morton et al. 2010), participation in prenatal screening (Santalahti et al. 
1998) and preventative options for breast and ovarian cancer in the context of 
increased genetic risk (Howard et al. 2009a).  
 Accepting that there is no medically recommended option can be difficult 
for patients, who are often more used to a paternalistic approach to medical 
decision making, i.e. being told what the best course of action is (Elwyn et al. 2000, 
Elwyn et al. 2009a). Uncertainty expressed by the clinician and being asked to play 
an active role in the decision making process may be perceived as a burden and 
cause a sense of worry, upset or even abandonment (Dresser 2012, Olthuis et al. 
2013, Quill and Cassel 1995, Say et al. 2006). Patients may, for example, interpret 
the mention of uncertainty as a sign that the clinician lacks the necessary 
knowledge to make a recommendation. To counteract this, it has been noted that a 
clear distinction should be made between uncertainty due to a lack of clinical 
evidence for superiority of one option over another, and uncertainty due to a lack 
of knowledge on part of the clinician (Elwyn et al. 2000).  
 In some circumstances patients may also feel overwhelmed by the existence 
of choice (Dresser 2012, Olthuis et al. 2013). Therefore, considering patients’ 
emotional states, vulnerability and willingness to participate in SDM is essential 
before asking them to play an active role (Olthuis et al. 2013). Unfortunately, during 
consultations, health professionals’ assessments of their patients’ desire for SDM 
are not necessarily accurate (Coulter 2007, Cox et al. 2007). Patients’ preferences 
for involvement in the decision vary and may depend on the type of medical 
decision at hand, patient personality and socio-demographic variables, as well as 
the skill of the clinician (Bruera et al. 2001, Coulter 2003, 2007, Elwyn et al. 2000, 
Guadagnoli and Ward 1998). Hence, the extent of actual involvement may also 
differ, depending on the patient’s preferences and the clinician’s commitment to 
SDM (Deber et al. 1996, Deber et al. 2007, Thistlethwaite et al. 2006). Therefore, 
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preferences for involvement should ideally be discussed with patients prior to 
decision making (Coulter 2007, Cox et al. 2007). The process of SDM deliberations is 
outlined in detail in Chapter 2.  
1.2.2 Patient decision support interventions 
 So-called patient decision support interventions or ‘decision aids’ are tools 
that have been developed to support and, to a degree, standardise the process of 
SDM by providing evidence-based medical information, teasing out preferences and 
stimulating discussion (O'Connor et al. 2004, Thistlethwaite et al. 2006). In recent 
years, the use of decision support interventions has become more widespread with 
the promotion of PCC and SDM in many healthcare systems, including the UK 
(Coulter 2009a, 2010, Coulter et al. 2011, Dagnone 2009, Department of Health 
2011, Elwyn et al. 2010b, Patient Protection and Affordable Care Act 2010, 
Secretary of State for Health 2010). Patient decision support interventions are tools 
designed to facilitate SDM in situations of medical equipoise (Coulter 2009a, Elwyn 
et al. 2000, Elwyn et al. 2009a). They should be distinguished from behaviour 
change interventions, which aim to modify patients’ behaviour to improve health 
outcomes (Elwyn et al. 2009a). Decision support interventions, in contrast, are non-
prescriptive and should include a balanced representation of the risks and benefits 
of all available options, including the option of doing nothing, where appropriate, to 
help patients clarify their preferences (Coulter 2003, Elwyn et al. 2009b, Joseph-
Williams et al. 2013). 
 It has been shown that patient decision support interventions can 
significantly improve not only patients’ knowledge and accuracy of risk perceptions, 
but also alignment between a chosen option and patients’ preferences and, 
ultimately, decision satisfaction (Stacey et al. 2011). Therefore, this type of decision 
support goes beyond the mere provision of information regarding the health 
problem and associated options. These interventions offer a means to directly 
compare options, predict future feelings and evaluate possible outcomes to 
facilitate preference construction and SDM (Elwyn et al. 2009a). They engage 
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patients with their own healthcare and empower them to play an active part in 
decisions about their health, thereby addressing a number of healthcare quality 
improvement goals (Coulter and Ellins 2006).  
 Numerous interventions have been developed over the years. Since the first 
systematic review of patient decision support interventions in 1999 (O'Connor et 
al.), which included 17 trials of 11 different interventions, numbers have increased 
dramatically and in the latest Cochrane review, published in 2011 (Stacey et al.), 86 
trials of more than 70 different interventions were analysed. These interventions 
come in a number of different formats, ranging from paper-based booklets to video 
interventions and sophisticated computer-based clinical guidance programmes 
(Anderson et al. 2011, Kaufman et al. 2003, Ottawa Hospital Research Institute 
2013, Pell et al. 2002). Most of these extensive tools are designed for independent 
use by the patient, either before or after a consultation. However, embedding such 
tools into clinical practice has been difficult and many never proceeded to full 
implementation following initial development and research trials (Elwyn et al. 2008, 
Elwyn et al. 2013b, Frosch et al. 2011, Harter et al. 2011). Chapter 6 reviews 
previously developed patient decision support interventions that include the option 
of risk-reducing ovarian surgery with a view to assessing their format, content and 
availability. 
 In parallel to extensive decision support interventions, some groups started 
to develop much briefer tools, which are designed to be used in clinical encounters 
(Breslin et al. 2008, Elwyn et al. 2004, Whelan et al. 2004). Most recently, the use of 
a type of brief paper-based tool called ‘Option Grid’ was shown to support SDM in 
the clinical setting, stimulating discussions and resulting in a standardised way of 
presenting options to patients (Elwyn et al. 2013b, Marrin et al. 2013). Although 
Option Grids require further research regarding their effectiveness, these tools 
have the potential to be embedded in clinical practice more readily than extensive 
interventions and may solve some of the implementation problems observed with 
longer, more complex tools (Elwyn et al. 2013b, Elwyn et al. 2013c).  
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 Although decision support interventions have been shown to have positive 
effects on patient knowledge and decision making (Stacey et al. 2011), to date 
there seems to have been a distinct lack of thorough use of theories in the 
development of patient decision support (Durand et al. 2008, Elwyn et al. 2011b). 
Interventions that state a theoretical basis usually refer to either ‘Expected Utility 
Theory’ (EUT) or the ‘Ottawa Decision Support Framework’ (Bernoulli 1954, Durand 
et al. 2008, O'Connor 2006). EUT is a normative theory of decision making. It 
describes how individuals should identify the best option based on mathematical 
principles (Bernoulli 1954). The Ottawa Decision Support Framework is a 
combination of several concepts and theories. It postulates that patients’ decision 
needs affect decision quality, actions and impact and may be addressed through 
decision support (O'Connor 2006). A number of other theories have also been 
suggested as appropriate for use during development of decision support (Elwyn et 
al. 2011b). However, the emphasis has so far been on theories that describe 
decision making only, although additional types of theories may be applicable here, 
such as those that describe the process of coping. Chapter 2 provides a detailed 
review of decision making and relevant theories in preference-sensitive medical 
contexts. 
1.3 Coping with health threats 
1.3.1 Coping theory 
 In their theory of stress, appraisal and coping, Lazarus and Folkman (1984) 
define coping as “constantly changing cognitive and behavioural efforts to manage 
specific external and/or internal demands that are appraised as taxing or exceeding 
the resources of a person” (page 141). They describe the appraisal process in terms 
of two interacting phases, labelled ‘primary’ and ‘secondary’ appraisal, which result 
in a coping effort to manage the demands of the situation (Figure 1.2). During 
primary appraisal, an event’s meaning is appraised as either irrelevant, benign- 
positive or stressful (Lazarus and Folkman 1984, Park and Folkman 1997). 
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Figure 1.2 - The appraisal and coping process in response to threats 
 
 
Events that are appraised as stressful will result in a coping response. According to 
Lazarus and Folkman (1984) secondary appraisal “is a complex evaluative process 
that takes into account which coping options are available, the likelihood that a 
given coping option will accomplish what it is supposed to, and that one can apply a 
particular strategy or set of strategies effectively” (page 35). Once the event and 
possible coping options have been appraised, a coping response may be initiated. 
Chapter 2 provides a more detailed description of coping and associated theories. 
 Until recently, emotions and coping processes have largely been neglected 
by decision making theorists and have rarely been used to inform interventions that 
are designed to support deliberations (Balneaves and Long 1999, Power et al. 
2011). In the context of medical decision making, coping plays an important role, as 
having to make a decision may be seen as taxing and/or exceeding an individual’s 
coping resources (Power et al. 2011). Being given a diagnosis, being told about 
different treatment options and being asked to get involved in SDM may thus result 
in a coping effort to understand the meaning and to manage the emotions and 
demands of the situation. Furthermore, emotions may be experienced in response 
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to making predictions about future outcomes of options (Gilbert and Ebert 2000, 
Wilson and Gilbert 2003, 2005). Therefore, emotions and coping should be viewed 
as an integral part of decision making (Balneaves and Long 1999, Power et al. 2011). 
Consequently, decision support interventions should ideally incorporate a coping 
component, to facilitate not only decision making processes, but also the process of 
coping with difficult medical decisions and associated emotions.  
1.3.2 Coping interventions 
 To date, a wide range of interventions to facilitate coping processes in 
cancer, chronic disease and other contexts has been developed. Often, however, 
coping is not explicitly mentioned as an outcome or mediating variable in 
publications relating to these interventions, which can make their identification 
difficult (de Ridder and Schreurs 2001). Therefore psychosocial interventions, such 
as group therapy, problem solving training, stress management and cognitive 
behavioural therapy, that aim to address conceptual equivalents to coping, should 
be included when searching for interventions aimed to facilitate coping in these 
contexts (de Ridder and Schreurs 2001). Several reviews of such psychosocial 
interventions have found that these have positive effects on outcomes, including 
quality of life, self-efficacy and emotional well-being (Astin et al. 2002, Badr and 
Krebs 2012, de Ridder and Schreurs 2001, Scott-Sheldon et al. 2008). However, 
others have not confirmed these findings, especially in the context of cancer care 
(Coyne et al. 2006, Lepore and Coyne 2006, Meyer and Mark 1995). These 
discrepant results may be explained by the variety of psychosocial interventions 
that exist, the different healthcare contexts in which they are used and the range of 
outcome measures with which they are evaluated. While a detailed review of 
coping interventions is beyond the scope of this thesis, a brief overview of cancer-
specific coping interventions is presented below. 
 Coping and/or psychosocial interventions in the context of cancer come in a 
variety of formats, however, most are face-to-face interventions either delivered in 
a one-on-one (Audrain et al. 1999, Schwartz et al. 1998) or group setting (Cousson-
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Gélie et al. 2011, Edgar et al. 2001, Hamilton et al. 2011, Hosaka et al. 2000, 
Wellisch et al. 1999). There are a number of interventions concerned with 
facilitating or enhancing coping with a cancer diagnosis or cancer survival (Edgar et 
al. 2001, Hinds et al. 2000, Lee et al. 2006, McMillan et al. 2006, Radziewicz et al. 
2009, Reavley et al. 2009, Weber et al. 2004), many specifically aimed at breast 
cancer patients (Cousson-Gélie et al. 2011, Hamilton et al. 2011, Hosaka et al. 2000, 
Lev et al. 2001, Maeda et al. 2008, Wengström et al. 2001). However, some have 
also been targeted at caregivers of cancer patients (Berila et al. 2009), while others 
were developed to support coping in women at increased risk of cancer (Esplen et 
al. 1998, Wellisch et al. 1999) or first degree relatives of women with breast cancer 
(Audrain et al. 1999, Schwartz et al. 1998).  
 As with extensive decision support interventions, implementation of 
psychosocial interventions that require a face-to-face format is not without its 
challenges, primarily due to the required staff time and training (Backer et al. 1986, 
Jacobsen 2009, Sin and Scully 2008). Some researchers have therefore developed 
cancer-specific coping interventions that are delivered in a paper- or web-based 
format and do not require specialist nurses or educators for delivery (Appleton et 
al. 2004a, Beatty et al. 2011, Phelps et al. 2006). These interventions were shown to 
reduce stress, enhance social functioning, improve quality of life and support 
coping (Appleton et al. 2004b, Beatty et al. 2011, Beatty et al. 2010a, Beatty et al. 
2010b, Bennett et al. 2007, Phelps et al. 2013, Vilela et al. 2006). Paper-/web-based 
psychosocial interventions may be easier to implement compared to 
nurse/educator led programmes, as they do not require the same levels of staff 
time or training. To facilitate coping as well as decision making, elements of such 
interventions could potentially be embedded within paper- or web-based decision 
support tools. Alternatively, decision support tools could signpost users to relevant 
coping interventions. Chapter 7 describes the development of a decision support 
tool that includes elements of coping advice and signposting to external coping 
interventions with a view to support coping efforts and emotional well-being. 
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1.4 Ovarian Cancer Risk 
 The theoretical framework developed as part of this thesis will be applied to 
a specific healthcare context in order to determine whether it is a feasible model to 
guide the development of decision support interventions. Application of the 
framework will focus on decisions about risk management in the context of 
increased genetic risk of ovarian cancer, specifically decisions regarding risk-
reducing bilateral salpingo-oophorectomy (RRSO). The justification for selecting this 
preference-sensitive decision is twofold. Firstly, ovarian cancer poses a 
considerable burden due to the lack of effective screening, late diagnosis and poor 
outcomes (Cancer Research UK 2011). This especially affects those at the highest 
risk for this disease, of whom up to two in five may develop ovarian cancer in their 
lifetime (Antoniou et al. 2003, Chen and Parmigiani 2007). Secondly, previous 
research has shown the inherent complexity of decisions regarding RRSO, including 
the role of emotions, past experiences, personal preferences and the variety of 
coping responses that may be employed (Fang et al. 2005, Howard et al. 2011, 
Howard et al. 2009a, Howard et al. 2010c, Miller et al. 1999). Hence, it has been 
proposed that decision support interventions may be of benefit in this context 
(Fang et al. 2005, Howard et al. 2009a). These factors make this decision an ideal 
candidate for depiction in a framework that describes appraisal and coping during 
deliberations and for the development of a tailored, theory-based decision support 
intervention that integrates deliberation and coping processes. 
1.4.1 Ovarian cancer risk and family history 
 In the UK, ovarian cancer is the fifth most common cancer and second most 
common gynaecological cancer diagnosed in women (Cancer Research UK 2011). In 
England, approximately 6,000 new cases of ovarian cancer are diagnosed and 3500 
ovarian cancer related deaths are reported annually (Trent Cancer Registry 2012). 
Due to the current lack of effective screening and vagueness of symptoms, these 
cancers are often detected at later stages (Stage III and above) and prognosis is 
relatively poor (Cancer Research UK 2011, Engel et al. 2002, Stearns et al. 2007). 
Five year survival rates for ovarian cancer are below 50% and for stage III and stage 
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IV disease survival rates are around 20% and 5%, respectively (Cancer Research UK 
2011, Engel et al. 2002, Stearns et al. 2007). Lifetime risk of ovarian cancer in the 
general population is estimated to be around 2% (Cancer Research UK 2011). With 
most cases occurring sporadically in those over the age of 70 years, ovarian cancer 
in the general population is primarily a disease of older age; however, around 10% 
of ovarian cancers may be attributed to a family history and/or genetic mutation 
(Cancer Research UK 2011, Risch et al. 2001, Trent Cancer Registry 2012). 
 If a woman is found to have a family history of ovarian, breast or other 
cancers, either during a routine visit with her General Practitioner (GP) or as a result 
of an exploration of her family history after a cancer diagnosis, she may be referred 
to a clinical genetics service (Figure 1.3; Appendix 1.1). There, her family history will  
 
Figure 1.3 - The referral and family history assessment pathway (see also: Appendix 1.1) 
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be assessed in detail and she will be given cancer risk estimates, for example for 
breast and ovarian cancer. Depending on her family history, she may be at 
‘average’, ‘moderate’ or ‘high’ risk of ovarian cancer (Cancer Genetics Service for 
Wales 2006). The average, or sometimes termed ‘low’, risk group is estimated to 
have a risk that is the same or similar to that of the general population, whereas the 
moderate and high risk groups have an elevated risk. Moderate and high risk groups 
may be offered a consultation with the clinical genetics service and other 
specialists, as appropriate. Genetic testing may also be offered to some individuals, 
especially those thought to be at high risk, to determine whether a genetic 
mutation runs in the family (Cancer Genetics Service for Wales 2006). Risk 
management options, including additional screening and risk-reducing surgeries, 
such as mastectomy for breast cancer risk and salpingo-oophorectomy for ovarian 
cancer risk, may also be discussed. 
 Women who have relatives that have been diagnosed with ovarian, breast 
or a number of other cancers, may be at increased risk for ovarian cancer (Hanna 
and Adams 2006, Negri et al. 2003, Stratton et al. 1998). The number of and 
relation to affected relatives and the age of the woman herself, as well as the age of 
relatives at time of diagnosis, all play a role in determining whether an individual 
woman is at risk and in estimating her risk level (Cancer Genetics Service for Wales 
2006, Stratton et al. 1998). Stratton et al. (1998) performed a meta-analysis to 
determine the effects of family history on risk of ovarian cancer. Overall, they found 
an approximate lifetime risk of ovarian cancer of 4% for women who had one first 
degree relative with ovarian cancer. More specifically, those whose mother was 
diagnosed with ovarian cancer had a lifetime risk of around 7.5%, whereas those 
with an affected sister had a lifetime risk of around 5% (Stratton et al. 1998). For 
women with more than one relative with ovarian cancer the lifetime risk was 
approximately 14%. It should be noted that these lifetime risks were lower for 
women who were over 45 at the time of their relative’s diagnosis (Stratton et al. 
1998). Others’ estimates have varied between 2-5% for those with one first degree 
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relative and 7-23% for those with two or more affected relatives, depending on 
study design (Evans et al. 2009b, Kerlikowske et al. 1992, Negri et al. 2003). 
 A family history of other cancers, including breast, lung, stomach, intestine 
and lymphoma has also been found to confer an increased risk of ovarian cancer 
with corresponding odds ratios of 2.3, 1.3, 1.5, 1.7 and 2.3, respectively (Negri et al. 
2003). By far the highest risk of ovarian cancer, however, is conferred by genetic 
mutations associated with Hereditary Breast and Ovarian Cancer (HBOC) and Lynch 
Syndrome (formerly Hereditary Non-Polyposis Colorectal Cancer, HNPCC) (Gayther 
and Pharoah 2010, Schorge et al. 2010). These mutations may be identified through 
genetic testing following risk assessment at the clinical genetics service. 
1.4.2 Breast Cancer genes 1 and 2 
 Hereditary breast and ovarian cancer (HBOC) is associated with germline 
mutations in the BReast CAncer genes (BRCA) 1 and 2, which confer high risks of 
breast as well as ovarian cancer (Antoniou et al. 2003, Chen and Parmigiani 2007, 
Tranin 2005). The frequency of BRCA1 and 2 mutations among the population is 
very low at around 0.128% and 0.172%, respectively (Antoniou et al. 2000). 
However, in individuals of Ashkenazi Jewish decent frequency has been shown to 
be much higher, with a combined BRCA1/2 frequency of above 2% (Roa et al. 1996). 
Women with mutations in BRCA1 or BRCA2 make up the vast majority of non-
sporadic, familial ovarian cancers (Antoniou et al. 2000, Risch et al. 2001). 
 Individual studies have produced a range of different cancer risk estimates 
for carriers of mutations in BRCA1/2 genes and it has been shown that 
heterogeneity of risk exists between families and depending on the position of the 
mutation on the gene (Antoniou et al. 2003, Easton et al. 1995, Evans et al. 2008, 
King et al. 2003, Struewing et al. 1997). In research combining several such studies, 
carriers of a BRCA1 mutation have on average been estimated to have a cumulative 
risk of breast cancer of 54%-65% and risk of ovarian cancer of 39% by age 70 
(Antoniou et al. 2003, Chen and Parmigiani 2007). Carriers of a BRCA2 mutation on 
average have slightly lower cancer risks, with an estimated cumulative risk of breast 
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cancer of 45% and risk of ovarian cancer of 11-16% by age 70 (Antoniou et al. 2003, 
Chen and Parmigiani 2007).  
1.4.3 Lynch syndrome 
 Lynch Syndrome is associated with mutations in a number of DNA mismatch 
repair genes, such as MLH1, MSH2, MSH6, PMS1 and PMS2 (Liu et al. 1996, Lynch 
and De la Chapelle 2003). While primarily associated with colorectal cancer, these 
mutations additionally confer an increased risk for a variety of other cancers in both 
sexes (Hampel et al. 2005, Vasen et al. 1996). In women, Lynch Syndrome 
mutations have been associated with a high risk of endometrial cancer and an 
elevated risk of ovarian cancer. One of the major issues with Lynch Syndrome 
associated cancers is the comparatively early age of onset, with the average age at 
endometrial and ovarian cancer diagnosis under 50 years (Brown et al. 2001, Lu et 
al. 2005). 
 Estimates for the lifetime risk of endometrial and ovarian cancer have varied 
between studies and exact risks depend on the type of genetic mutation, as well as 
other factors, such as year of birth (Barrow et al. 2009, Vasen et al. 2001, Watson et 
al. 2008). Average risk of endometrial cancer for all genes has previously been 
estimated at 28.2% (Barrow et al. 2009), 43% (Aarnio et al. 1995), 54% (Hampel et 
al. 2005) and 62% (Aarnio et al. 1999). Average risk of ovarian cancer has previously 
been estimated at 6.1% (Barrow et al. 2009), 6.7% (Watson et al. 2008), 6.9% 
(Vasen et al. 2001), 7.1% (Vasen et al. 1996), 12% (Aarnio et al. 1999) and 13.5% 
(Hampel et al. 2005). As stated earlier, the risk differs depending on the affected 
gene, which might explain some of the variation in pooled risk estimates, as the 
proportion of carriers of different mutations might vary between studies. Vasen et 
al. (2001), for example, found the risk of ovarian cancer by age 70 in carriers of 
MLH1 mutations to be 3.4%, compared to 10.4% in carriers of MSH2 mutations. 
Similarly, Barrow et al. (2009) estimated cumulative risk in individuals with MLH1 
mutations to be 5.5%, compared to 7.5% in those with MSH2 mutations. Further 
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discrepancies between studies may be explained by additional factors, such as 
study design and birth cohort (Watson et al. 2008). 
1.4.4 Ovarian cancer risk management options 
 Women from HBOC and Lynch Syndrome families, as well as those with no 
confirmed genetic mutation but a significant family history, live with an increased 
risk of ovarian cancer (Table 1.1).  
Table 1.1 - Estimates of absolute lifetime risk of ovarian cancer 
Family history or genetic mutation Lifetime risk of  
ovarian cancer 
General population ≤2% 
One first degree relative with ovarian cancer 2-7.5%1 
Two or more relatives with ovarian cancer ≥7%2 
Confirmed BRCA1 mutation 39% 
Confirmed BRCA2 mutation 11-16% 
Lynch Syndrome family history and/or associated mutation 6-12% 
1
risk depends on exact relationship with patient (i.e. mother, sister, daughter) and age at diagnosis 
2
risk depends on number of relatives, exact relationship and age at diagnosis 
 As the American Society for Clinical Oncology noted in its statement on 
genetic testing for cancer susceptibility (1996), “the […] ability to identify 
individuals at highest risk of cancer holds the promise of improved prevention and 
early detection of cancers. It also poses potential medical, psychological and other 
personal risks that must be addressed […].” (page 1730). While these risks include 
those which need to be addressed prior to genetic testing as part of an informed 
consent process, they also include issues following a positive gene test result. The 
American Society for Clinical Oncology therefore emphasises the need for follow-up 
care and discussion of effective risk management options post-testing. 
 Since 1996, the statement has been updated twice (2003, 2010); however, 
the basic principle of offering advice and guidance, as well as management options, 
following testing for genetic mutations remains an important aspect. For risk of 
breast cancer for example, management options include enhanced surveillance, 
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chemoprevention with Tamoxifen or risk-reducing mastectomy (Brekelmans et al. 
2001, Cuzick et al. 2007, Cuzick et al. 2003, Hartmann et al. 1999, Rebbeck et al. 
2004). In the case of increased risk of ovarian cancer, the management options 
offered to women at high risk are somewhat more limited, due to the lack of 
effective screening (Appendix 1.2). 
 1.4.4i Ovarian cancer screening: While several researchers have explored 
the effectiveness of screening for ovarian cancer using annual trans-vaginal 
ultrasound scans and blood tests for biomarker Cancer Antigen (CA)125, successful 
early detection (at Stage I-II) and a gain in survival for screen detected cancers has 
not been fully established and routine screening has not been implemented (Bell et 
al. 1998, Jacobs and Menon 2004, Kauff et al. 2005). In the UK, the Familial Ovarian 
Cancer Screening (UK FOCS) study Phase I used annual trans-vaginal scans and 
CA125 blood tests to detect ovarian cancer in women at ≥10% risk, but did not find 
a sufficiently high proportion of early stage cancers through screening to 
recommend introduction of a routine screening programme for high risk women 
(Long and Kauff 2012, Rosenthal et al. 2013a). Phase II of the UK FOCS study 
increased CA125 testing frequency to 4-monthly intervals and made a range of 
other modifications (Institute for Women's Health 2010, Rosenthal et al. 2013a). 
This study has only recently (summer 2011) concluded. While women gained 
considerable reassurance from this screening program (Brain et al. 2012, Lifford et 
al. 2013), results establishing the clinical effectiveness of this type of screening are 
not yet available. Similarly, another trial of ovarian cancer screening in the general 
population, the UK Collaborative Trial of Ovarian Cancer Screening (UK CTOCS), 
which may provide evidence of effects of screening on mortality, has also only 
recently concluded (end of 2011) and has not reported results yet. Until the 
complete results of the UK FOCS study Phase II and UK CTOCS have been published, 
the recommendations from the UK National Screening Committee (2006) and the 
guideline published by the National Comprehensive Cancer Network (2012) do not 
recommend routine screening for ovarian cancer in high risk women. 
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 1.4.4ii Risk-reducing surgery: In the absence of medically proven screening 
for ovarian cancer, the only active management option currently available and 
recommended is risk-reducing bilateral salpingo-oophorectomy (RRSO) (National 
Comprehensive Cancer Network 2012). RRSO involves surgical removal of both 
ovaries and fallopian tubes to prevent ovarian cancer. This operation substantially 
reduces ovarian cancer risk by up to 80% in the highest risk groups (Rebbeck et al. 
2009). Additional benefits of RRSO include a substantial reduction in breast cancer 
risk of up to 50% if surgery is performed before the menopause (Kramer et al. 2005, 
Rebbeck et al. 2009). This is especially relevant in carriers of mutations in the BRCA 
genes, who are at high risk of breast cancer and who may choose to undergo RRSO 
to reduce their breast cancer risk (Metcalfe 2009). Domcheck et al. (2006, 2010) 
showed that RRSO reduces ovarian and breast cancer specific mortality, as well as 
all-cause mortality, in carriers of BRCA mutations. RRSO is most effective if done at 
or before age 40 in carriers of BRCA1 and BRCA2, but it still confers a survival 
benefit if done at a later age (Kurian et al. 2010, Latosinsky et al. 2011). 
 However, RRSO is not without its drawbacks. The surgery itself can usually 
be performed as a keyhole procedure, but does have a complication rate of 4% that 
should be considered when discussing surgery (Manchanda et al. 2011). 
Additionally, surgical removal of the ovaries before age of natural menopause 
results in infertility and oestrogen deprivation. These effects may have far reaching 
medical as well as psychosocial consequences for patients. In the short-term, the 
sudden lack of oestrogen results in a surgically induced menopause, which may 
cause severe menopausal symptoms, including headaches, hot flushes, night 
sweats, mood swings, sleep disturbances, weight gain, depression, vaginal dryness 
and reduced libido (Finch et al. 2011, Finch and Narod 2011, Hallowell et al. 2012). 
These in turn may affect social functioning and relationships, including sexual 
relationships with partners, as well as body image and perception of gender 
identity (Finch et al. 2011, Hallowell et al. 2012). 
 In the longer term, it has been suggested that oestrogen deprivation may 
also affect bone density, cardiovascular health and cognitive functioning (Aitken et 
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al. 1973, Gordon et al. 1978, Parker 2010, Parker et al. 2009, Rocca et al. 2009). The 
lack of oestrogen following surgery increases bone density loss, thereby enhancing 
risk of osteoporosis and fractures (Challberg et al. 2011). Similarly, some studies 
have shown an increased risk of cardiovascular events in women who underwent 
RRSO, especially in those under the age of 45 at time of surgery (Atsma et al. 2006, 
Falkeborn et al. 2000, Rivera et al. 2009). However, data on the exact level of bone 
density and cardiovascular disease is controversial and research is still ongoing 
(Andrews et al. 2012, Jacoby et al. 2009). Effects of RRSO on cognitive functioning, 
including risk of Parkinson’s and dementia, have also been noted and found to be 
more pronounced in women who are pre-menopausal at time of surgery (Rocca et 
al. 2007, Rocca et al. 2008a, Rocca et al. 2008b). Exact risk figures for these long-
term health outcomes for any individual woman may depend on her age at the time 
of RRSO, her lifestyle and her family history of osteoporosis, dementia and 
cardiovascular disease. 
 Despite these drawbacks, RRSO in women at high risk of ovarian cancer is 
warranted and does confer an overall survival benefit (Domchek et al. 2006, 
Domchek et al. 2010, Kerlikowske et al. 1992). To mitigate the short- and long-term 
effects of oestrogen deprivation at a young age, women who undergo RRSO before 
the age of 45 are recommended to take hormone replacement therapy (HRT) until 
the age of natural menopause (Challberg et al. 2011, Finch et al. 2011, National 
Institute for Health and Care Excellence 2013). While HRT has previously been 
linked to an increased risk of breast cancer, it has been shown to be safe in women 
at high risk if taken until the age of natural menopause to supplement the sudden 
lack of oestrogen following surgery (Beral and Collaborators 2003, Eisen et al. 2008, 
Rebbeck et al. 2005). 
 It should be noted that, while the risk of ovarian cancer is dramatically 
reduced by RRSO, it is not completely eliminated. Studies have found varying 
residual risks of primary peritoneal cancer for women with a family history and/or 
BRCA mutation ranging from 0% (Evans et al. 2009a), 0.8% (Rebbeck et al. 2002), 
1.3% (Domchek et al. 2006), 1.9% (Piver et al. 1993), 2% (Rabban et al. 2009) to 
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4.3% (Finch et al. 2006). The differences in risk estimates between studies may be 
explained by differing inclusion criteria, varying proportions of women with BRCA1 
versus BRCA2 mutations, differing protocols for post-surgical cytology assessment 
(at which ovarian cancers may be identified) and varying length of follow-up 
(Manchanda et al. 2012b, Powell 2006). Generally, women with mutations in BRCA1 
were found to be at higher risk for post-surgical primary peritoneal cancer than 
women with mutations in BRCA2 (Finch et al. 2006, Rabban et al. 2009). The 
remaining risk of primary peritoneal cancer therefore needs to be discussed with 
women prior to surgery. 
 In the case of Lynch Syndrome, the significantly elevated risk of endometrial 
cancer warrants a risk-reducing hysterectomy (RRH; surgical removal of the uterus), 
which should be discussed during consultations about risk management (Chu and 
Coukos 2006, Lindor et al. 2006). RRSO is usually considered as a concomitant 
procedure with RRH for women with Lynch Syndrome. Studies have found that RRH 
with concomitant RRSO is highly effective in reducing risk of endometrial and 
ovarian cancer (Schmeler et al. 2006a). However, a small risk of primary peritoneal 
cancer also remains in this population (Schmeler et al. 2010). 
 1.4.4iii Symptom awareness: As noted earlier, effectiveness of screening for 
ovarian cancer has not yet been proven and therefore RRSO is the only active 
management option available to women at increased risk (Schorge et al. 2010). 
Women who decide to delay or reject surgery are recommended to be aware of the 
symptoms of ovarian cancer and seek immediate professional help if any persistent 
symptoms develop, to improve the chances of early detection (Schorge et al. 2010). 
The symptoms of ovarian cancer include persistent abdominal distension, early 
satiety and loss of appetite, pelvic or abdominal pain and  increased urinary 
frequency (National Institute for Health and Care Excellence 2011). 
  1.4.4iv Chemoprevention and other risk-reducing measures: Pre-menopausal 
women who do not want to undergo surgery may also explore the possibility of 
chemoprevention using the oral contractive pill (OCP). This has been shown to 
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reduce the risk of ovarian cancer (Cibula et al. 2011, Iodice et al. 2010). The NICE 
clinical guidance (2013) notes that the OCP should be discussed with women from 
HBOC families, however, due to its potentially increasing effects on risk of breast 
cancer, does not recommend the OCP purely for cancer prevention (Brohet et al. 
2007). Other chemoprevention options for ovarian cancer are not available. It has 
been shown that parity exerts a protective effect from ovarian cancer that 
increases with the number of pregnancies experienced, likely due to suppression of 
ovulation, a similar protective mechanism as that achieved through OCP use 
(Cramer et al. 1983). A review of women’s decision making regarding management 
of increased risk of ovarian cancer is presented in Chapters 3 and 4. 
1.5 Thesis overview 
 Two research gaps are addressed in this thesis. Firstly, to date, decision 
making and coping have rarely been considered as simultaneous, interdependent 
processes. SDM in healthcare has been endorsed and promoted by various 
governments, but the role of emotions and coping during decision making and their 
possible influence on the process of SDM have been neglected. Patients who are 
worried or anxious and patients who do not use effective coping strategies may not 
feel equipped to deal with the added pressure of participating in SDM. Therefore, 
to advance the field of SDM, there is a need to consider how coping and decision 
making processes overlap. A clear understanding of how emotions and coping may 
influence appraisals and deliberations could shine a light on how they may 
facilitate, instead of hinder, SDM. Therefore, this thesis sets out to develop a novel 
framework that integrates the concepts of deliberation and coping in healthcare 
contexts. 
 Secondly, developers of patient decision support interventions, which aim to 
facilitate SDM, have also failed to use coping theory to inform the design and 
content of their interventions. In fact, many do not draw on theory at all, despite 
repeated calls for theoretical underpinning of such tools (Charles et al. 2005, 
Durand et al. 2008, Elwyn et al. 2011b). Interventions guided by coping, as well as 
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decision making, theory may be able to provide more holistic decision support than 
those developed to date. However, as no attempts have been made to use coping 
theory to guide development of patient decision support interventions, it is unclear 
whether use of such theories is feasible in this context. For this reason, and using 
decisions about RRSO in women at increased risk of ovarian cancer as an example, 
this thesis aims to outline and test how a framework that integrates coping and 
decision making theories may be operationalised to assess the content of existing 
interventions and to guide the development of new interventions.  
1.5.1 Objectives and methods 
 The thesis is based on reviews of the literature and qualitative research 
methods, including focus groups and interviews. The objectives of this thesis are: 
1. To undertake a narrative review of the theoretical literature on decision 
making and coping applicable to healthcare contexts. 
2. To develop a novel framework that integrates decision making and coping 
theory to describe preference-sensitive medical decisions from a patient 
perspective. 
3. To describe in detail the decision making and coping processes regarding 
risk management in the context of increased genetic risk of ovarian cancer 
using data from a systematic search of the literature, as well as focus groups 
with affected patients and interviews with health professionals. 
4. To adapt the novel framework to specifically describe decision making 
regarding risk management in the context of increased genetic risk of 
ovarian cancer. 
5. To operationalise the adapted framework by using it: 
a. to assess how previously developed decision support interventions, 
identified through a systematic literature search, facilitate appraisal 
and coping processes regarding ovarian cancer risk management. 
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b. to develop a novel decision support intervention for women at 
increased genetic risk of ovarian cancer in the UK, following the MRC 
guidelines for the development of complex interventions (Craig et al. 
2008). 
6. To assess usability of this novel decision support intervention using cognitive 
interviews. 
1.5.2 Thesis structure 
 This thesis contains eight further chapters. With exception of Chapters 2 and 
9, each chapter contains four main sections on background, methods, results and 
discussion. 
Chapter 2 - Decision making and coping in healthcare: The Coping in Deliberation 
(CODE) framework 
This chapter reviews the existing theoretical literature on decision making and 
coping with a specific focus on those theories applicable to preference-sensitive 
medical contexts. It then goes on to propose a novel framework called the ‘Coping 
in Deliberation’ (CODE) framework, which integrates decision making and coping 
theories, to describe preference-sensitive medical decisions from a patient 
perspective as a multi-step coping process. 
Chapter 3 - Risk-reducing bilateral salpingo oophorectomy: A dilemma for patients 
Chapter three presents a review of the literature, published between 1996 and July 
2012, regarding women’s decision making about RRSO. It delineates the medical, 
psychological, social, demographic and other considerations important and 
influential in women’s decision making and describes women’s expectations of 
decision support. 
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Chapter 4 - Patients’ and health professionals’ perspectives on decisions about risk-
reducing bilateral salpingo-oophorectomy 
This chapter reports on the findings of a focus group and interview study conducted 
between June 2011 and April 2012 with women at increased risk of ovarian cancer 
and health professionals involved in their care. It outlines considerations important 
during decision making about RRSO in the UK context and proposes a decision 
making pathway to describe such decisions. 
Chapter 5 - Adapting the CODE framework: Decisions about risk-reducing bilateral 
salpingo-oophorectomy 
Chapter five describes an adaptation of the generic CODE framework to decisions 
about RRSO in the context of increased genetic risk of ovarian cancer. Using the 
considerations identified in Chapters 3 and 4, the contents of the framework are 
adapted and then validated by mapping them onto a retrospective, in-depth report 
of one woman who went through this decision. 
Chapter 6 - Applying the CODE framework: A review of decision support 
interventions that include the option of risk-reducing oophorectomy 
This chapter applies a checklist, as well as the adapted CODE framework, as an 
assessment tool to evaluate previously developed decision support interventions’ 
coverage of considerations important during appraisal of cancer risk and RRSO and 
of coping advice. 
Chapter 7 - Developing a decision support intervention for women at increased risk 
of ovarian cancer 
Chapter seven presents the development of a decision support intervention for 
women at increased risk of ovarian cancer who are considering RRSO. Based on the 
adapted CODE framework and informed by feedback from health professionals and 
women at risk of ovarian cancer, the intervention consists of an Option Grid and an 
“Oophorectomy Decision Explorer” (OvDex) website/booklet. It is designed to 
facilitate deliberation and coping processes during decision making about RRSO. 
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Chapter 8 - Usability testing of a decision support intervention for patients 
considering risk-reducing bilateral salpingo-oophorectomy 
Chapter eight reports on the findings of a usability testing study using cognitive 
interviews conducted in March 2013. It outlines reviewers’ feedback on usability, 
accessibility, layout and understanding of the contents of the Option Grid and 
OvDex and any changes made in response.  
Chapter 9 – General Discussion 
This concluding chapter discusses the findings of the thesis within the wider context 
of patient centred care and shared decision making. Key findings are summarised 
and methodological limitations are discussed. Possible future applications of the 
generic CODE framework are explored and suggestions for further evaluation, and 
ultimately implementation, of the decision support intervention in clinical practice 
are provided. 
 In summary, the thesis outlines the development of a novel theoretical 
framework that acknowledges the importance of emotions and coping during 
deliberations about healthcare decisions, followed by operationalisation of this 
framework through adaptation and subsequent application in the assessment and 
design of decision support interventions for decisions about RRSO in the context of 
increased genetic risk of ovarian cancer. 
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2 Decision making and coping in healthcare: The Coping in 
Deliberation (CODE) framework 
2.1 Introduction 
In the face of medical uncertainty, when there is no single recommended 
option, healthcare decisions are dependent on personal circumstances, values and 
preferences of the patient (Elwyn et al. 2009a). These preference-sensitive 
decisions may be complex, unfamiliar and difficult for patients, as they are required 
to process a wealth of new medical information and to play an active role in 
decisions about their own health. Deliberation and coping processes in these 
situations are not well understood and rarely described in detail (Noone 2002). A 
thorough description of the deliberation and coping processes undergone by 
patients throughout the deliberation process could be helpful to understand the 
different issues and concerns involved in preference-sensitive medical decisions and 
to improve the support available to patients in those situations. 
There are a number of theories addressing decision making or coping 
processes which have been applied in healthcare settings (e.g. Bravata et al. 2002, 
Goldstein and Gigerenzer 2009, Henderson et al. 2006, Janis and Mann 1977, 
Kahneman and Tversky 1979, Lazarus and Folkman 1984, Leventhal et al. 1980, 
Reyna 2008, Svenson 1992). However, traditional decision making theories do not 
consider the relationships between decision making and coping processes, despite 
the interdependency of these processes in real life. More recently, researchers have 
begun to integrate coping and decision making theories and thereby describe more 
fully the processes individuals go through when making preference-sensitive 
medical decisions, such as treatment decisions in breast cancer (Balneaves and Long 
1999, Power et al. 2011). However, there is scope for integration and further 
extension of these theories to produce a more detailed framework of decision 
making and coping in order to describe more accurately the multidimensional 
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interactions between these processes and to specifically highlight the questions and 
issues that patients face during preference-sensitive decision making. 
Building on previous integrative approaches, this chapter1 aims to (i) describe 
current theoretical approaches to decision making and coping in healthcare, and (ii) 
develop a multidimensional, interactive framework of patients’ appraisal and coping 
responses in preference-sensitive medical decisions. The process of decision making 
in healthcare settings is explored, followed by a description of appraisal and coping 
responses to health threats. These processes are then integrated in one overarching 
framework that aims to describe coping in deliberations about preference-sensitive 
medical decisions and thereby provide a theoretical basis for developing decision 
support materials. 
2.2 Methodology 
2.2.1 Literature search strategy 
The literature review of decision making and coping theories was conducted 
using a narrative search strategy (Baumeister and Leary 1997, Rother 2007). The 
narrative search strategy lends itself to integrative theorizing, thereby feeding into 
the process of developing a novel framework from theories identified by the review, 
which was the ultimate aim of this study (Baumeister and Leary 1997). 
Reviews of patient decision support interventions and their use of theory 
were initially used to identify relevant theories that had previously been used in the 
development of decision support and similar interventions the healthcare contexts 
(Bekker et al. 1999, Durand et al. 2008, Elwyn et al. 2011b). Subsequently, a 
snowballing approach was used to identify further theories relevant to decision  
 1 Parts of this chapter have been published as Witt J, Elwyn G, Wood F and Brain K (2012) 
Decision making and coping in healthcare: The Coping in Deliberation (CODE) framework. 
Patient Education and Counseling Vol. 88(2): 256-261 [Appendix 2.1] 
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making and coping processes in a medical context. Additional hand searches were 
carried out in issues of Patient Education and Counselling and Medical Decision 
Making published in 2008-2011, to identify novel theories not yet used in 
intervention development or included in earlier reviews. 
Rather than being comprehensive, this approach was selected to include 
those theories most relevant to coping and deliberations in healthcare settings, 
ultimately leading to a novel framework that could form the basis for the 
development of decision support materials. Theories of behaviour change were 
excluded from the analysis, as the aim was to explore decision making in situations 
of medical equipoise, when the choice is preference-sensitive and depends on 
patient values (Elwyn et al. 2009a). 
2.2.2 Framework development 
Theories were summarised and emerging decision making and coping 
processes were integrated into a new framework. Face validity of the framework 
was evaluated in group meetings with members of the decision laboratory and 
health psychology research teams at Cardiff University.  
2.3 Deliberation in preference-sensitive medical contexts 
2.3.1 Overview 
Many decisions regarding the best course of action in healthcare, such as 
what medication to prescribe for a specific disease, are mainly influenced by 
established medical efficacy. Although these decisions should be discussed with the 
patient, the health professional will usually be able to make a firm recommendation 
as to what course of medication or action would result in the best outcome. From a 
patient perspective, such decisions may not require an extensive deliberative effort.  
Extensive deliberation processes will only ensue when there is more than 
one choice and an individual experiences conflict as to which choice might result in 
the most favourable outcome (Janis and Mann 1977). For a patient, this may be the 
case in situations of equipoise when no clear medical guidance is available, when 
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two or more types of treatment may be equally effective and when decisions are 
preference-sensitive (Elwyn et al. 2009a). The deliberation process in such 
situations may be described in several stages, including pre-decisional deliberation, 
decision determination and consolidation (Elwyn et al. 2012, Elwyn and Miron-Shatz 
2009, Svenson 1992) (Figure 2.1).  
 
 
Figure 2.1 - The deliberation process in preference-sensitive healthcare decisions 
 
 
 
2.3.2 Presentation of the health threat and introduction of choice 
Before the main deliberation process is initiated, the health threat is 
presented to the patient in the form of a diagnosis, test result or risk assessment. 
This is then followed by the presentation of choice, which introduces the patient to 
the idea that there is more than one option and that options have risks and 
benefits, which require the patient to consider their own values and preferences 
and play an active role in decision making. This is often a new and unfamiliar 
concept for patients in a medical context and may result in surprise, upset or even 
feelings of abandonment (Elwyn et al. 2000, Quill and Cassel 1995, Say et al. 2006).  
Patients’ reactions to a health threat (and the idea of choice) may depend on 
a large number of contextual influences, such as personal interpretations of the 
health threat, values and goals, past experiences and social support (Leventhal et al. 
1980, Shaw 1999). Interpretations of information, reactions to the idea of choice 
and to being asked to play an active role in the decision making process also depend 
on the current emotional and health state of the patient (Kahneman and Tversky 
1979).  
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For instance, a diagnosis of the common cold may be appraised as a 
relatively minor threat, which according to past experience will be fully cured in a 
few days and have little or no consequence to personal goals, therefore instilling 
little or no anxiety. Thus the deliberation process, if one is initiated, is relatively 
effortless. The patient may for example choose to take painkillers and decongestant 
treatment or may decide not to medicate, but whatever decision they take, they are 
likely to make a full recovery. In contrast, a diagnosis of early stage breast cancer 
will usually be appraised as a major threat, which will have far reaching 
consequences for one’s own future and that of others in the family, thus instilling 
high levels of anxiety (Burgess et al. 2005). The patient may choose between two 
types of surgery, lumpectomy and mastectomy, both of which have similar efficacy 
and therefore depend on personal preferences. This is likely to be a complex and 
difficult deliberation process and such decisions ideally require careful 
consideration of the patient’s values, goals and preferences, therefore warranting a 
discussion of choice.  
Individual differences in self-efficacy or perceived control may influence a 
patient’s perceived ability to make a decision themselves and may affect coping 
responses (Bandura 1977, Davison and Degner 1997, Skinner and Zimmer-Gembeck 
2011). The concept of self-efficacy describes beliefs in one’s ability to perform a 
certain behaviour or achieve a certain goal, such as making a preference-sensitive 
decision. Individuals with high self-efficacy may wish to be more active throughout 
deliberation, whereas patients with low self-efficacy may prefer a more passive role 
(Orom et al. 2009). Similarly, individuals with high health literacy may prefer to be 
involved in decision making whereas those with low literacy may not (DeWalt et al. 
2007). Either preference is acceptable, and it may be beneficial to discuss preferred 
level of involvement at the point of introduction of choice. Early stage breast cancer 
patients, for example, have reported various preferences for their level of 
involvement in the deliberation process, which should be catered for by health 
professionals involved in their care to achieve informed, value-adjusted decisions 
(Degner and Sloan 1992, Hack et al. 2006). It has previously been shown that a 
match between patient preference for involvement and perceived actual 
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involvement is associated with better outcomes post-decision (Keating et al. 2002). 
However, irrespective of desired role, patients should always be informed about 
their options and their values and goals should be considered before a decision is 
made, if that decision is preference-sensitive (Levenstein 1984, Say and Thomson 
2003). 
2.3.3 Presentation of options and preference construction 
An essential part of the deliberation process is the provision of information 
about options and the mapping of those options onto the patient’s values and 
goals, to enable them to construct a preference. Hence, following presentation of 
the health threat and the idea of choice, the main deliberation process is initiated. 
Options are described to, and interpreted by, patients, while preferences are 
constructed. When faced with decisions in healthcare, patients are often given a 
substantial amount of information that is new, relatively complex and threatening. 
Both the quantity and content of this information may cause distress. It is likely that 
patients struggle to remember all the information they are given during a 
consultation (Reyna 2008). Patient preferences may therefore be based on the parts 
of the information that were understood and remembered, rather than exact 
numerical values and associations (Reyna 2008). Affect heuristics and intuition have 
also been considered important in preference construction, especially in situations 
where patients do not have much time to consider their options, for instance when 
parents are asked to decide about amniocentesis (Durand et al. 2011, Goldstein and 
Gigerenzer 2009). 
Emotions such as distress and anxiety can have detrimental effects on 
deliberations as they may impede understanding of medical information and careful 
consideration of values. As a result, they may lead to poor decisions (Janis and 
Mann 1977). Loewenstein et al. (2001) distinguished two broad types of emotions 
in decision making: anticipatory and anticipated emotions. Each phase of the 
decision making process in healthcare is influenced by both types of emotions. 
Anticipatory emotions arise in response to the immediate issue of being faced with 
a health threat and with the need to make a decision. These can include emotions 
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such as worry, fear or anxiety. Anticipated emotions are predicted emotions, which 
the patient expects they will experience when one or more of the possible 
outcomes associated with the decision occur. These may include relief, regret or 
anger. Both types of emotions will form during the deliberation process, in response 
to the health threat and the presentation of available options. For instance, a 
patient will emotionally react to being told about a health threat (anticipatory 
emotions) and may simultaneously imagine what this threat might mean for their 
future and how they would feel in this predicted future (anticipated emotions). 
Similarly, each possible option and associated outcomes will give rise to anticipated 
emotions during the presentation of options. However, individuals may struggle to 
accurately predict anticipated emotions, over- or underestimating their duration 
and intensity (Wilson and Gilbert 2003, 2005). Therefore, anticipated emotions can 
lead to biases in the decision making process, as patients may base their decision 
partly on inaccurate predictions of their future emotions (Kermer et al. 2006). 
2.3.4 A model of cognitive-emotional decision making 
Power and colleagues (2011) developed a framework of medical decision 
making which considers the importance of emotions as a motivational factor in 
decisions (Figure 2.2). “Cognitive-emotional decision making” distinguishes 
cognitive processes from emotional processes formed in response to the health 
threat and the decision. This distinction allows consideration of each cognitive and 
emotional aspect of decision making in turn, and of the motivational influence 
emotions have on cognitive processes. For example, emotions often influence risk 
estimates, as patients struggle to understand the concept of risk (Loewenstein et al. 
2001). Therefore they use their emotional responses to the threat (e.g. ovarian 
cancer) to interpret their risk (Zikmund-Fisher et al. 2010). A numerical estimate 
such as ‘7 in 100 women like you will get ovarian cancer’ may not mean much to a 
patient. However, if that same patient has seen a relative die of the disease, then 
their interpretation of that risk will be formed whilst they re-live emotions of fear 
and loss associated with their past experience of ovarian cancer (anticipatory 
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Figure 2.2 - Model of cognitive-emotional decision making (adapted from Power et al. 2011) 
 
emotions) and imagine what a diagnosis might mean for them in the future 
(anticipated emotions) (Dagan and Goldblatt 2009, Howard et al. 2011). Therefore, 
their interpretation of that risk may be high, which can in turn influence decisions 
relating to that risk (Howard et al. 2011). Power’s (2011) model of cognitive-
emotional decision making clearly distinguishes emotional from cognitive 
processes, emphasising the importance of emotions in the decision making process 
and their influence on cognitive representations of both the health threat and the 
decision. 
Therefore, regulating both anticipatory and anticipated emotions is an 
important motivational target in decision making (Power et al. 2011). Strong 
negative anticipatory emotions may lead to avoidant behaviour, which allows 
patients to temporarily regulate these emotions (Anderson 2003). For example, a 
patient may display avoidant behaviour in response to being asked to make a 
decision if they feel overwhelmed by, and anxious about, the prospect of having to 
make a decision about their health. However, unless the situation is out of the 
patient’s control, non-avoidant behaviours lead to better long-term outcomes 
(Krohne 1993, Rippetoe and Rogers 1987, Stanton and Snider 1993).  
2.3.5 Post-decisional consolidation 
Once preference construction has been completed to identify the preferred 
option, a decision can be made, either by the patient, by the health professional or 
in collaboration. Decisions may be final or may be revised at a later stage. Following 
the decision, consolidation of that decision may protect the decision maker from 
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regret in the future and is especially important in irreversible decisions, such as 
those about surgical procedures (Connolly and Reb 2005, Svenson 1992). Post-
decisional consolidation may be described as a way of coping with the outcomes of 
a decision once that decision has been made. This should be distinguished from 
coping with the deliberation process itself, which is described in section 2.4. It 
should be noted that, if a decision is deferred or avoided (Anderson 2003), post-
decisional consolidation does not occur until a decision is made. 
2.4 Coping in deliberation during preference-sensitive medical decision making 
2.4.1 Overview 
Coping describes efforts to actively manage events which are appraised as 
‘stressful’ (Lazarus and Folkman 1984). Any event can result in a coping response, if 
it is appraised as having resulted in harm or loss, as having the potential to result in 
harm or loss (i.e. being a ‘threat’), or as being a challenge (Lazarus and Folkman 
1984). In other words, an event is appraised as stressful if it is incongruent with an 
individual’s perceived global meaning, i.e. a person’s goals, beliefs or sense of self 
(Park 2011, Pergament 1997). A single stressful event may lead to several coping 
responses and may also result in future events, which can stimulate appraisal and 
coping responses. For instance, the loss of a limb in an accident is an event which 
results in harm and loss and will require a coping response. Future events induced 
by this initial event, such as having to have several rounds of surgery to repair 
damage, can be appraised as stressful in their own right and therefore lead to 
further coping responses. 
In a medical context, patients who are required to play an active role in 
decisions about their healthcare have to cope with a number of different potentially 
stressful events. As outlined in section 2.3.2, these individuals need to cope with 
the fact that they are either ill or at risk of disease, in which case the diagnosis or 
risk statement would be the ‘threat’ that requires a coping response. Additionally, 
they need to come to terms with the fact that there are several options, and that 
they are being asked to play an active role in decision making. Here, the burden of 
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having to decide may be perceived as a threat or challenge in its own right. Further 
still, as described in section 2.3.3, patients then have to consider the different 
options and all their potential outcomes in order to make that decision. These 
options, and risks linked to them, may be appraised as bearing the potential for loss 
or harm in the future and can therefore be perceived as stressful as well, requiring a 
coping response in their own right. 
Researchers have explored appraisal and coping processes in healthcare, for 
example using Leventhal’s Self-Regulatory Model (SRM) of illness representations 
(1980) and Lazarus and Folkman’s transactional theory of stress, appraisal and 
coping (1984). Both these models suggest that illness representations are formed 
during appraisal of the diagnosis or health threat and ultimately determine the 
coping response. An integrated outline of the appraisal and coping process as 
described by these models is presented in Figure 2.3.     
 
 
Figure 2.3 - Appraisal of and coping with health threats 
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2.4.2 Primary appraisal 
 According to Lazarus and Folkman (1984), events are appraised in two ways. 
During primary appraisal an event may be appraised as irrelevant, benign-positive 
or stressful. The two former appraisal types (irrelevant and benign-positive) usually 
do not warrant or require further appraisal or a coping response, while the latter 
appraisal type, which categorises an event as ‘stressful’, does. Lazarus and Folkman 
(1984) distinguish three types of ‘stress appraisals’: harm/loss, threat and challenge. 
Aldwin et al. (1996) proposed three additional appraisal types: ‘hassle/annoyance’, 
‘uncertainty’ and ‘worry about others’, which may also require a coping response 
and therefore be defined as ‘stressful’ appraisals (Folkman 2011). 
In the medical context, the patient cognitively and emotionally appraises the 
diagnosis or risk estimate they have been given, its severity and its relevance to 
their life. A diagnosis may be appraised as harm/loss, if it is already debilitating, 
and/or as a threat, if the patient expects future harms/losses due to the diagnosis. 
Being at risk for a certain disease may be appraised as a threat that carries potential 
for future harm/loss. If the disease has a genetic component, then it may also result 
in worry about others, including children, siblings and parents. As proposed by 
Leventhal et al. (1980), cognitive representations (or appraisals) of a health threat 
are based on the patient’s understanding and interpretation of five dimensions of 
the threat: identity, cause, time line, consequences and possibilities for cure/control 
(Leventhal et al. 2008, Weinman et al. 1996). In other words, cognitive 
representations of illness are formed by assessing: what the illness is and what the 
illness label, e.g. ‘cancer’, means to the patient, what the causal mechanisms 
behind the illness are, how long the illness will last, what its consequences might be 
and whether and how the illness might be controlled or even cured (Weinman et al. 
1996). Emotional representations (or appraisals) of a health threat may be linked to 
anticipatory and anticipated emotions induced by the threat (Loewenstein et al. 
2001).  
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2.4.3 Secondary appraisal 
Secondary appraisal is focused on what can (or cannot) be done in response 
to the stressful event (Lazarus and Folkman 1984). Lazarus and Folkman (1984) 
themselves note that the chosen terminology of primary and secondary appraisal 
was inadequate and potentially misleading, as it may be interpreted as a ranking of 
importance or indicate a sequential process. They refrain from suggesting new 
terms; however they stress that neither is more important than the other and that 
they may occur in parallel (Lazarus and Folkman 1984). Primary and secondary 
appraisal may also form a feedback loop, in which a quick primary appraisal and 
initial assessment of the most important coping resources may then be followed by 
a more in-depth primary and secondary appraisal (Shaw 1999). 
During secondary appraisal the patient assesses the coping potential, i.e. 
whether anything can be done to actively deal with the threat (problem-focused 
coping potential) and/or the emotions it causes (emotion-focused coping potential). 
This is followed by a more detailed assessment of the coping options or resources 
i.e. what can be done to deal with the threat and associated emotions. This includes 
an appraisal of whether these can be implemented effectively and how likely they 
are to achieve the desired outcome (Lazarus and Folkman 1984). Lazarus and 
Folkman (1984) distinguish ‘problem-focused’ coping options, designed to relieve 
the threat directly, and ‘emotion-focused’ options, designed to regulate the 
emotions experienced in response to the threat (Lazarus 1993). Some coping 
options may be a source for both problem- and emotion-focused coping. For 
instance social contacts may provide informational and instrumental support 
(problem-focused) and at the same time be a source of love, affection and 
reassurance (emotion-focused) (Helgeson and Cohen 1996). Kramer (1993, O'Brien 
and DeLongis 1996) made a further addition to the ways of coping by describing 
relationship-focused coping, which is designed to moderate social relationships and 
is especially important in caregiver coping. 
Others have proposed alternative ways to categorise coping, such as 
engagement (approach) versus disengagement (avoidance) coping and cognitive 
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versus behavioural coping, which should be acknowledged (Carver and Connor-
Smith 2010, Latack and Havlovic 1992, Roth and Cohen 1986). The 
engagement/disengagement distinction differentiates coping which brings an 
individual closer to a stressor (approach) from that which allows the individual to 
distance themselves from the stressor (avoidance) (Carver and Connor-Smith 2010, 
Roth and Cohen 1986). For example, seeking social support would be defined as 
engagement coping, whereas distraction would be defined as disengagement 
coping. Similarly, the cognitive/behavioural distinction discriminates coping that 
occurs internally (cognitive) from that which requires external action (behavioural) 
(Latack and Havlovic 1992, Skinner et al. 2003). For instance, seeking social support 
would be defined as behavioural coping and positive re-appraisal as cognitive 
coping. Rather than being mutually exclusive, these ways of categorising coping 
overlap. Information seeking may be labelled as problem-focused, engagement and 
behavioural coping. Similarly, wishful thinking may be defined as disengagement 
and cognitive coping.  
Due to this multidimensionality of coping some have gone so far as to 
suggest that coping should not be categorised in binary form at all, proposing a 
hierarchical system instead (Skinner et al. 2003). They suggest that binary 
approaches to categorisation are prone to misclassification and are therefore 
inadequate. Alternatively, they propose a hierarchical system with twelve 
overarching families of coping approaches (Skinner et al. 2003). Examples of 
families are problem-solving, information seeking, escape and support seeking. 
Each family has a specific function and includes several approaches (Skinner et al. 
2003). Such a detailed categorisation may be most appropriate in research 
specifically studying individual coping responses. However, it may still be useful to 
use a binary categorisation in other contexts. Therefore, rather than there being 
one correct approach, the way in which coping is categorised becomes a question of 
preferred terminology, perhaps depending on the purpose of the study in which the 
categorisation is used. Whichever categorisation is selected, a clear statement of 
why it was chosen is essential. 
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Building on the models proposed by Power et al. (2011) and Balneaves and 
Long (1999), the framework presented in this chapter adopts Leventhal’s (1980) 
distinction between cognitive and emotional representations, or appraisals, of the 
health threat and Lazarus and Folkman’s (1984) categorisation of problem-focused 
and emotion-focused coping. This allows a similar breakdown of processes during 
primary and secondary appraisal, into cognitive or problem-focused approaches on 
the one hand and emotional processes on the other (Figure 2.2). Therefore coping 
strategies are referred to as problem- or emotion-focused in this chapter. However, 
it is acknowledged that other categorisations exist, and might apply, in parallel. 
2.4.4 Coping responses 
Once a threat has been appraised in primary and secondary appraisal, the 
individual selects one or more coping resources and initiates a coping response by 
implementing the selected strategies. This response seeks to reduce discrepancies 
between an appraised meaning of a specific situation and an individual’s global 
meaning, which describes the person’s understanding of themselves and the world  
(Park 2011, Pergament 1997). Selected coping strategies may include a mixture of 
problem- and emotion-focused approaches to facilitate meaning making. For 
instance, an individual may turn to their family for emotional support and actively 
seek information about the threat and available options in order to take action 
against it. The preferred coping strategy may be influenced by personal factors and 
characteristics, such as self-efficacy beliefs, past experiences and social settings 
(Carver and Connor-Smith 2010, Lazarus and Folkman 1984, O'Brien and DeLongis 
1996, Shaw 1999, Smyth and Filipkowski 2010). Situational and temporal factors 
may also play a role in shaping appraisal and coping responses (Folkman 2011, 
Lazarus and Folkman 1984) and they may also depend on the patient’s preferred 
coping style (Miller 1987, Miller et al. 1988). Miller (1987) distinguishes two coping 
styles: monitoring and blunting. While high monitors choose to seek out threat-
relevant information and show low levels of distracting activity, high blunters 
choose to ignore or avoid threat-relevant information and show high levels of 
distracting activity (Miller 1987, Miller et al. 1988). Coping strategies may be 
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selected according to these styles. High monitors may lean towards strategies such 
as information seeking, while high blunters preferably chose strategies such as 
avoidance and withdrawal.  
Once a coping strategy has been implemented the threat may be 
reappraised and strategies may be adapted if the desired outcome was not 
achieved (Lazarus and Folkman 1984). The effectiveness of a coping strategy 
depends on its appropriateness or ‘goodness of fit’ for the situation (Lazarus 1993, 
Lazarus et al. 1985, Lazarus and Folkman 1984).  Problem-focused approaches may 
be adaptive for modifiable situations, for instance when there is a choice between 
treatments for a medical condition, whereas emotion-focused approaches appear 
more effective in situations when nothing can be done, such as periods of waiting 
for the results of medical tests (Lazarus and Folkman 1984, Smyth and Filipkowski 
2010). Coping flexibility describes the ability of individuals to adapt their coping 
strategy to cater for the coping demands of a specific situation (Cheng 2001).  
2.4.5 The embedded decisional model of stress and coping 
The embedded decisional model of stress and coping (Balneaves and Long 
1999) describes the decision making process by outlining a series of questions 
informed by decision making and coping theory. The authors embed Lazarus and 
Folkman’s transactional model and their illustration of system variables for stress 
(Lazarus et al. 1985, 1984) within Janis and Mann’s conflict theory of decision 
making (1977). The resulting model acknowledges the transactional and 
multidimensional nature of decision making and coping. It explores causal 
antecedents, mediating processes and short- and long-term effects of a decision 
through a series of five questions: “What are the antecedent circumstances in 
making this treatment decision?”, “What is at stake in making this treatment 
decision?”, “What are my options in making this treatment decision?”, “What are 
the possible ways of coping with this decision?” and “What are the adaptational 
outcomes of this decision?”. These questions address different considerations 
important in the decision making process, including antecedents (such as personal 
beliefs, values and commitments), potential coping resources and temporal 
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influences. Balneaves and Long (1999) were among the first to integrate decision 
making and coping in an attempt to provide a more holistic vision of the 
deliberation process.  
2.5 The Coping in Deliberation (CODE) framework 
2.5.1 Introduction to the CODE framework 
Coping with a health threat and its potential short- and long-term 
consequences is an integral part of the deliberation process in preference-sensitive 
healthcare decisions. Without appraisal and coping strategies, individuals may not 
be able to make informed, value-adjusted decisions, as their emotional state would 
hinder an effective analysis of the situation and their options (see section 2.3.3). 
The transactional functions of coping aid the decision maker in regulating their 
emotional state whilst going through the decision making process and may also 
allow them to devise active strategies to deal with a given threat. Therefore, 
integrating decision making theory and coping theory is a useful exercise, as it 
allows for a more holistic vision of human decision making in preference-sensitive 
healthcare contexts. By proposing a detailed framework of coping processes during 
deliberation, this chapter attempts to build on the ideas of Balneaves and Long 
(1999) as well as Power et al. (2011).  
 Balneaves and Long (1999) embedded Janis and Mann’s (1977) conflict 
theory within Lazarus and Folkman’s theory of stress, appraisal and coping (1984), 
proposing a model which considers antecedents, appraisal of options and potential 
coping resources associated with a decision. Power et al. (2011) emphasised the 
motivational role of emotions in decision making and made a clear distinction 
between threat- and decision-associated cognitive and emotional processes. The 
Coping in Deliberation (CODE) framework integrates and extends these ideas in the 
context of preference-sensitive deliberations in healthcare by proposing that each 
phase in deliberation (presentation of the health threat, choice, options, preference 
construction) results in cognitive and emotional appraisal and stimulates a coping 
process in its own right, the result of which can influence a patient’s questions, 
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attitude and behaviour in other stages of deliberation. Deliberation in the CODE 
framework is therefore described as a multidimensional coping process, depicted in 
Figure 2.4 on the horizontal axis (‘Deliberation’) and vertical- axis (‘Coping’). The 
framework applies to preference-sensitive decisions in healthcare contexts, 
meaning those which require the consideration of patient values and allow patient 
input as no clear medically recommended option exists. 
2.5.2 Framework structure 
 The patient may move through the process depicted in Figure 2.4 from top 
to bottom and from left to right. At the start of the deliberation process the patient 
is presented with a health threat. During primary appraisal, they appraise this threat 
cognitively and emotionally by exploring questions relating to the threat itself and 
their feelings about it. During secondary appraisal, they appraise the coping 
potential and the coping options that could be helpful in dealing with this threat, for 
example their ability to find out more (problem-focused coping option) and the 
possibility of seeing a positive side to the situation (emotion-focused coping 
option). Then, they may select one or more coping strategies that could be helpful 
in dealing with this health threat. For instance they may prefer a problem-focused 
approach and decide to find out as much as possible about the diagnosis and their 
options, or they may decide to turn to their faith (emotion-focused). The 
background colour in Figure 2.4 indicates the question type as forming part of 
cognitive (light) or emotional (dark) appraisal and as being a problem-focused (light) 
or emotion-focused (dark) coping option. The shading depicts the overlap between 
the two, i.e. where a question may contribute to both cognitive and emotional 
appraisal and where a coping option may be both problem- and emotion-focused. 
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Figure 2.4 - The Coping in Deliberation (CODE) framework (Witt et al. 2012) 
4
3 
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 The coping options selected and implemented in response to the 
presentation of the health threat will determine the patient’s reaction to, and 
interest in, the idea of choice and the different treatment or prevention options, 
which will be presented in the next stages of the deliberation process (see sections 
2.3.2 and 2.3.3). For instance, a patient who feels extremely anxious after being 
told about a certain health threat may initially lean towards an avoidant coping 
behaviour to regulate the anticipatory emotion that they are experiencing. This 
patient may then be less interested in the presentation of choice and options, as 
this would require them to confront the health threat again. In contrast, a patient 
who feels hopeful that knowing about the health threat presented will empower 
them to act upon the threat may be very interested in the presentation of choice 
and available options, as this would cater for their preferred problem-focused 
coping style. 
While this description depicts a relatively linear approach to decision making 
and coping, one has to consider that coping is interactive, multidimensional and 
transactional (Lazarus and Folkman 1984). Primary and secondary appraisals can 
occur simultaneously and individuals may revisit certain threats, reappraise their 
situation and readjust their coping efforts. For instance, the patient who felt 
anxious after initial presentation of the health threat and chose an avoidant coping 
behaviour may over time come to the realisation that avoidance does not reduce 
their worry. They may then decide that confronting the threat and learning about 
options available to counteract it may be more adaptive and therefore readjust 
their coping effort. 
Individuals may also skip certain steps in the process, or first appraise a 
threat briefly to return later for a more comprehensive appraisal (Shaw 1999). The 
framework aims to portray this possibility of moving through the process in a non-
linear fashion by using double-pointed arrows. Until a final decision is reached and 
implemented, a decision maker may re-appraise any phase of the coping and 
deliberation process. After considering the options, they may, for instance, 
reappraise the threat and decide that the risks associated with the options are 
45 
 
 
more threatening to them than the original threat itself at this point in time, 
therefore delaying a decision. In another example, the decision maker may initially 
appraise the choice as a challenge and prefer to cope by playing an active role in 
decision making. However, after considering the options, they may feel 
overwhelmed and reappraise the choice as a threat, preferring their doctor to make 
a decision for them instead. 
2.5.3 Adaptability of the framework 
In the CODE framework, a series of questions outline possible cognitive and 
emotional appraisals and possible problem- and emotion-focused coping resources 
that a patient might explore in response to each deliberation phase. The questions 
in the generic version of the CODE framework were designed to be adaptable to 
different healthcare decisions. Statements at the end of each column represent 
some of the coping strategies a patient might select, which may again be adapted 
to different medical contexts. The framework was designed to accommodate a 
wide range of preference-sensitive medical decisions, ranging from decisions about 
genetic testing and cancer prevention to those about choices between different 
medications or types of surgery. To illustrate the adaptability of the framework, 
consider the following three healthcare decisions and how questions within the 
framework may be adapted to these contexts. 
 2.5.3i Increased genetic risk of ovarian cancer: Women from families with a 
high incidence of ovarian, and some other, cancers may be at increased risk of 
ovarian cancer. A woman with such a family history may initially appraise her risk. 
To do this she may ask what ovarian cancer is, what genetic risk means and how 
threatening this risk is to her health. She will also respond to the threat emotionally 
and explore how she feels about being at increased risk, potentially drawing on past 
experiences of observing ovarian cancer in relatives. She may then appraise the 
resources that could help her deal with that risk. She may wonder whether she 
could seek more information, talk to her clinician or family, or try to find a positive 
side to the situation. During the presentation of choice she may ask why there is a 
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choice at all, may inquire about the timescale she has for making this decision and 
may wonder who she should involve. She may also explore coping resources which 
could help her to make this decision, such as support from her clinician and/or 
family and friends. Similarly, during the deliberation about options, the woman may 
ask specific questions about the risks and benefits of options such as risk-reducing 
salpingo-oophorectomy (i.e. surgery to remove healthy ovarian tissue) and the 
effects of surgery on her life, and she may consider follow-on decisions such as 
hormone replacement therapy (HRT) and alternatives such as ovarian screening 
(Rosenthal and Jacobs 2006). She may also emotionally appraise potential 
outcomes of different options, for example she might predict that she will feel a 
sense of loss if she chose to have surgery, because she would lose her fertility. Past 
experiences of others who have made this decision – for instance a sister who has 
opted for surgery – might help her in forming anticipatory emotions about options. 
She may also explore the coping resources at her disposal that could help her deal 
with the potential consequences of options and the decision, such as emotional and 
instrumental support. 
The questions within the framework can be adapted accordingly to reflect 
these cognitive and emotional processes. It should be noted that questions and 
coping strategies will vary not only depending on the decision at hand, but also on 
situational factors and the characteristics of the individual patient. In addition to 
preferred coping style, other influences such as life stage, experience, self-efficacy 
and values will play a role (Carver and Connor-Smith 2010, O'Brien and DeLongis 
1996, Shaw 1999, Smyth and Filipkowski 2010). In the example used above, a 
patient at risk of ovarian cancer who is aged 55 may not consider HRT, whereas a 
woman in her early 40s might explore that option in detail. Similarly, a single 
mother would not look to a partner for coping support, but might turn to her 
clinician, family or friends, whereas someone in a relationship might value input 
from her partner and explore how risk-reducing surgery would affect their 
relationship. A religious person might explore whether she could find strength in 
her faith as a coping resource. 
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 2.5.3ii Amniocentesis: To demonstrate the flexibility of the CODE 
framework, consider a different healthcare decision, such as amniocentesis. Parents 
are required to cope with the fact that a routine test has indicated a potential 
problem and are now faced with the decision of whether or not to explore this 
further. During appraisal of the health threat to their unborn child they may ask 
what the current result means, how it might affect their pregnancy and who they 
could rely on for support. During deliberation of the options they may consider the 
risks and benefits of amniocentesis, ask themselves what they would do if the test 
confirmed an abnormality, consider termination of pregnancy and explore their 
coping resources for different scenarios. During preference construction they may 
ask whether they both agree and how likely they are to experience regret.  
 2.5.3iii Coronary artery disease (CAD): Another example may be selected 
from the context of CAD, where patients may be asked whether they would like to 
have a catheter investigation to check for CAD or whether they would prefer 
medical therapy. Patients in this situation need to appraise and cope with the fact 
that they are at risk of CAD and what this means for their life. They are also 
required to appraise their options, such as catheter investigation, asking about the 
risks and benefits and exploring how they might feel about these. Knowing 
someone who went through this procedure might help them with primary 
appraisal. During secondary appraisal they may explore whether they can turn to 
others for support or simply avoid dealing with the situation if they feel 
overwhelmed. 
These three examples depict preference-sensitive medical decisions and 
illustrate the flexibility of the framework, which allows the addition, removal or 
adaptation of questions depending on the decision at hand. The generic framework 
can be revised to describe any preference-sensitive decision. Furthermore, 
questions may then be added, removed or adapted depending on the individual 
patient’s coping style, life-stage and experiences, if a specific patient’s decision 
needs to be described in detail. 
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2.5.4 Links to theoretical concepts 
Incorporated in the CODE framework are many of the concepts found within 
both coping and decision making theories (see sections 2.3 and 2.4). The questions 
posed during the appraisal process were selected to represent a wide range of 
considerations and influences. For instance, personal values and goals, which can 
affect the interpretation of different options, are considered when the patient 
assesses the relevance of the health threat and again when they evaluate the 
potential effects of options on their life (Balneaves and Long 1999, Leventhal et al. 
1980, Shaw 1999). Emotional responses are incorporated when patients explore 
how they feel about a threat, the choice and options (Loewenstein et al. 2001, 
Power et al. 2011). 
The coping resources and strategies in the framework were selected to 
represent different coping strategies that patients may use, such as vigilance, 
avoidance and seeking social support (Henderson et al. 2006, Janis and Mann 
1977). It should be noted that not all possible coping strategies are included, as this 
would be beyond the scope of the framework. However, any coping strategy may 
be incorporated when adapting the framework. Preferred coping strategies may 
also change over time or vary from one deliberation stage to another, as coping is 
transactional and multidimensional (Lazarus and Folkman 1984). 
The contents of the CODE framework are not aiming to be comprehensive, 
rather they reflect a variety of different questions and coping options that a patient 
may consider whilst going through the deliberation process, maintaining the 
multidimensional and transactional functions of coping (Balneaves and Long 1999). 
The framework does not propose that one coping strategy is more effective than 
another, as different strategies may be appropriate in different situations (Lazarus 
and Folkman 1984). It therefore includes a range of strategies and allows decision 
makers to select any number and adapt their approach at a later time, if necessary. 
The number and types of questions asked, the answers to these questions, the 
choice of coping strategies and ultimately the decision itself will depend on the type 
49 
 
 
of health threat, the options, the patient’s coping style, their preferences, past 
experiences, personal values and ability to forecast feelings accurately.  
The framework also includes a consolidation phase following the actual 
decision. Consolidation is in essence a coping mechanism designed to defend a 
decision from regret in the future (Connolly and Reb 2005, Svenson 1992). The 
inclusion of this phase allows the framework to describe deliberation beyond the 
actual decision and acknowledges that the consequences of a decision should be an 
integral part of any decision making model, as patients ultimately have to live with 
their decision and its consequences. 
2.6 Discussion 
2.6.1 The CODE framework in context 
Leventhal et al. (1980) were the first to consider the importance of emotions 
in addition to purely cognitive processes in response to threats. More recently, 
Power et al. (2011)  distinguished cognitive and emotional representations formed 
in response to a health threat from those formed in response to the need for a 
decision. They also argued that emotions play an important motivational role 
during decision making. Following on from this idea, the preliminary CODE 
framework proposes a further distinction between the different stages within the 
decision and postulates that each of these stages gives rise to its own individual 
cognitive and emotional appraisal process, essentially adding a further degree of 
detail to Power et al.’s model, which only differentiated the threat and the decision. 
This additional distinction allows a more fine-grained analysis of the appraisals 
which occur during the different deliberation stages. In agreement with Power et al. 
(2011) and other theorists, such as Lazarus and Folkman (1984), the CODE 
framework considers emotional appraisal and emotion-focused coping processes to 
be of equal importance to cognitive appraisal and problem-focused coping 
processes. Both occur in parallel, influence each other and are essential for good 
decision making. 
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The embedded decisional model of stress and coping describes decision 
making as a series of relatively general questions (Balneaves and Long 1999). The 
CODE framework similarly identifies questions relating to deliberation and coping 
processes, but does so in a more detailed fashion. For instance, what Balneaves and 
colleagues (1999) cover with the question “What are my options in making this 
decision?”, the CODE framework explores with a series of more detailed questions 
about benefits and risks, effects on life and possible follow-on decisions. Similarly, 
Balneaves’ question “What are the possible ways of coping with this decision?” is 
split into a series of several individual questions during secondary appraisal, 
describing different coping strategies at different stages in the deliberation process, 
such as “Can I talk to my family/friends?”, “Can I change how I feel about this?” and 
“Can I transfer this decision?”. Balneaves’ questions “What are the antecedent 
circumstances in making this treatment decision?” and “How is the nature of the 
decision shifting over time?” are integrated more indirectly. The questions within 
the CODE framework can be adapted according to antecedent circumstances that 
apply to a patient. Throughout the framework, multiple questions relate to 
personal values and past experiences, such as “Do I have experiences that could 
help me imagine what it could be/feel like?” and “Is this option congruent with my 
goals and values?” The potential for shift over time is acknowledged by the non-
linear structure, which allows decision makers to revisit stages, reappraise threats 
and adopt new coping strategies at any time. 
Additionally, the framework includes a consolidation phase following the 
decision, as proposed by Svenson (1992). This allows a description of the 
deliberation process beyond the point of decision making. Consolidation is a way of 
coping with a decision and its outcome and may be especially important in 
irreversible decisions to avoid regret. In the case of reversible decisions, inclusion of 
the consolidation stage in the framework is also warranted, as these types of 
decisions may be revisited, starting a renewed deliberation process, if the decision 
maker finds that they did not make the right decision during consolidation. Similarly 
to Balneaves’ and Long’s (1999) model, the CODE framework explores deliberation 
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from the patient perspective, which may allow practitioners to develop a more 
detailed understanding of patients’ appraisal processes during deliberations in 
healthcare. 
2.6.2 Practice implications and future research 
Patient-centred care (PCC) and shared decision making (SDM) are becoming 
increasingly important in healthcare, especially in the context of preference-
sensitive decisions which require patient input (Coulter 2009a, Coulter et al. 2011, 
Elwyn et al. 2000, Elwyn et al. 2009a, O'Grady and Jadad 2010, Secretary of State 
for Health 2010, Svenson 1992). In order to provide PCC, practitioners are expected 
to understand their patients’ needs and concerns and to address them accordingly. 
The preliminary CODE framework provides a description of preference-sensitive 
decision making from a patient perspective, which may ultimately – when adapted 
to specific decisions – help practitioners to better understand their patients’ 
questions and concerns by shedding light on underlying cognitive and emotional 
processes.  
Notably, the framework can also provide a theoretical underpinning, and 
potentially practical guidance, for the development of decision support 
interventions which are designed to support SDM. Currently, many of these tools 
lack a theoretical basis and may therefore be of questionable benefit to patients 
(Durand et al. 2008). The CODE framework was developed with this purpose in 
mind. It proposes specific questions at each stage of the deliberation process, 
which could – either directly or in adapted form – be integrated in decision support 
materials. A tool based on the framework would include information to support 
cognitive appraisal as well as coping advice to encourage adaptive coping. 
Interventions guided by the CODE framework – which itself is based on theoretical 
models of decision making and coping by Lazarus and Folkman (1984), Balneaves 
and Long (1999), Power et al. (2011) and others – would have a solid theory base. 
Therefore, it would avoid the pitfall of many currently available patient decision 
support interventions, which lack the theoretical underpinning that is important to 
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enable predictions about the likely effects of the intervention (Durand et al. 2008, 
Elwyn et al. 2011b). The framework may also be adapted to decisions for which 
interventions are already available. It could then be used to assess whether the 
content of these interventions addresses the issues patients explore during 
deliberation, as outlined in the adapted framework. 
 The framework clearly needs to be adapted to actual decisions in healthcare 
and tested with patients to explore its applicability and provide feedback on validity 
and potential amendments that may be needed. The adaptation of the preliminary 
framework to specific decisions should take into account the views of stakeholders 
involved in those decisions, including patients, patient organisations and health 
professionals, to allow for an accurate representation of questions and coping 
strategies patients may explore. Adaptation may be achieved by following a three 
step process (Figure 2.5). Once adapted versions are available, empirical evidence 
about the use of such versions as a guide for practitioners in consultations, an 
assessment tool for existing interventions and a basis for decision support 
development should also be gathered. 
 
Figure 2.5 - Guide for the adaptation of the CODE framework 
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2.6.3 Strengths and limitations  
The preliminary CODE framework is a theoretical description of deliberation 
and coping processes, purposefully generic and designed to be applicable to a range 
of preference-sensitive decisions. While this makes it extremely flexible and allows 
a variety of potential uses in different medical contexts, the framework now needs 
to be adapted to specific decisions and tested with patients. A thorough adaptation 
should firstly focus on determining considerations important in a selected decision 
(see Chapter 3 and 4). These considerations, alongside an understanding of the 
specific decision making process in the selected context (e.g. short or long 
deliberation time and existing barriers and facilitators), should then be used to 
operationalise the questions proposed in the framework (Chapter 5). Following 
adaptation, a retrospective investigation of one, or ideally more, actual decisions 
should be conducted to reveal whether decisions were described accurately by the 
framework, before it can then be used in further research or development work. 
To date, the framework has only undergone face validity testing and has not 
been subjected to content validity assessment (Anastasi 1988, Carmines and Zeller 
1977). This limits the certainty with which it can be assumed that each question 
within the framework is truly representative of the suggested associated 
deliberation and appraisal/coping phases. In the future, the CODE framework would 
benefit from content validation through a group of reviewers with expertise in 
decision making and coping theory. The questions may then be adapted. Similarly, 
the framework may also benefit from convergent validity testing to evaluate 
whether it maps onto validated measures of appraisal, coping and deliberation, 
such as the brief COPE (Carver 1997) and the decisional conflict scale (O'Connor 
1995). 
Few theories to date have specifically considered emotional and cognitive 
appraisal processes in conjunction with coping efforts when patients are making 
decisions about their health. The questions included in the CODE framework 
attempt to describe issues explored during patients’ appraisals at each stage of the 
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deliberation process. This may provide health professionals with a basis for looking 
at the variety of patients’ questions and concerns. The framework also draws 
attention to the fact that deliberation and coping processes are closely linked and 
therefore may help practitioners to explore coping resources together with their 
patients, potentially adding a new element to PCC.  
In the future, the framework may benefit from an extension which allows 
the inclusion of patient information and coping needs, identifying specifically what 
help patients would like to be available to support their coping effort at each stage 
in the process. This would additionally strengthen the framework’s value as a 
support tool for PCC and a guide for the development of patient decision support. 
Some limitations to the applicability of the CODE framework should also be 
noted. The framework is only applicable to preference-sensitive healthcare 
decisions that require a relatively elaborate exploration of choice and options. 
Medical decisions that have only one clinically recommended option would not fall 
within this remit and are therefore not described by the framework. However, 
certain sections of the framework, such as issues explored during primary and 
secondary appraisal of the health threat, might still apply to such situations. 
As discussed earlier, the questions and coping strategies in the framework 
do not represent an exhaustive list of possible issues explored. Instead they act as 
examples that can be changed and adapted to any specific preference-sensitive 
decision and any patient. Therefore, any number of considerations may be missing 
from the current framework; however it has the capacity to encompass those issues 
in future adaptations. 
Finally, as the framework is currently purely theoretical, it cannot be 
assumed that it is truly reflective of deliberations in healthcare. The framework 
now needs to be operationalised to confirm whether it accurately describes such 
preference-sensitive medical decisions and may need to be amended if it is found 
to be inaccurate. 
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2.6.4 Conclusions 
This chapter described decision making and coping as it emerges from current 
theory. It also presented the development of a multidimensional, process-oriented 
framework of patients’ coping responses during deliberations in healthcare. The 
preliminary CODE framework has the potential to be adapted to a number of 
preference-sensitive medical decisions and to act as a support tool for medical 
practitioners and as a guide for the assessment and/or development of patient 
decision support interventions. 
One such example of adaptation is shown in Chapter 5, which reports on the 
development of a CODE framework adapted to describe decision making about risk-
reducing salpingo-oophorectomy by women at increased risk of ovarian cancer. This 
adapted framework is then used to assess currently available decision support 
interventions that include the option of risk-reducing salpingo-oophorectomy 
(Chapter 6) and to develop a new intervention for this context, specifically for 
women located in the UK (Chapter 7). Adaptations to other decisions may follow.
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3 Risk-reducing bilateral salpingo oophorectomy: A dilemma for 
patients 
3.1 Introduction 
Women with a family history indicative of hereditary breast and ovarian 
cancer (HBOC) or Lynch Syndrome may be at increased risk of ovarian cancer 
(Chapter 1; Barrow et al. 2009, Chen and Parmigiani 2007). In the UK, women found 
to be at moderate to high risk of this cancer may be offered risk-reducing salpingo-
oophorectomy (RRSO), which involves surgical removal of healthy ovarian tissue 
and has been shown to substantially reduce the risk of ovarian and breast cancer 
(Rebbeck et al. 2009, Schmeler et al. 2006a). However, RRSO has a number of 
drawbacks including risks associated with surgery, but also issues such as infertility 
and surgical menopause in women who are pre-menopausal prior to the procedure. 
Therefore the decision to undergo, defer or decline RRSO is preference-sensitive, 
depending on the goals and values of the individual patient (Chapter 1; Elwyn et al. 
2009a). Preference sensitive decisions require the patient to play an active part in 
the deliberation process, become knowledgeable about available options, weigh 
positive and negative attributes of these options and clarify their own values in 
order to ultimately make a decision in line with their personal preferences. The 
process of preference-sensitive decision making and coping has been described 
previously in the Coping in Deliberation (CODE) framework (see Chapter 2 and Witt 
et al. 2012). 
How women make decisions about RRSO in the context of familial risk has 
been explored in a number of quantitative and qualitative studies to date. A 
detailed understanding of the decision making process, and issues that are 
influential during this period, is essential in order to provide appropriate 
counselling to these women and to develop suitable decision support materials. 
The aim of this chapter is to summarise the knowledge generated in previous 
research regarding (i) the concerns and issues which are explored by women during 
deliberations about RRSO and (ii) what these women expect or desire in terms of 
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support materials or interventions designed to facilitate decision making. The 
search focused on women’s expectations of decision support, rather than coping 
advice, as this project aimed to develop a decision support intervention with coping 
components, rather than a coping intervention per se. The results presented here 
may be helpful as a guide when developing materials for these women and will be 
mapped onto the generic CODE framework in Chapter 5 of this thesis to produce an 
RRSO-adapted version of the CODE framework. 
3.2 Methodology 
3.2.1 Literature search strategy 
A systematic search of the literature about women’s decision making 
regarding RRSO was conducted in July 2012 to identify issues considered during 
deliberations about this surgery. Databases (Embase, MEDLINE, MEDLINE In-
Process and PsycINFO) were searched via Ovid for studies published between 1996 
and July 2012. Search terms used in the title search are detailed in Table 3.1. 
Duplicates were removed using the Ovid de-duplicate function prior to review of 
the abstracts. No grey literature was included in this review. 
3.2.2 Inclusion and exclusion criteria 
 Abstracts of identified publications were then reviewed and primary 
exclusion criteria applied. Publications were excluded if they were not concerned 
with (i) decision making processes, (ii) personal cancer risk reduction or prevention, 
(iii) ovarian cancer and/or oophorectomy or (iv) if they exclusively included 
participants who were not at increased risk of ovarian or breast cancer, such as 
those considering oophorectomy in the context of a planned hysterectomy for a 
benign indication. Increased risk was defined as risk assessed to be above that of 
the general population. In a secondary exclusion step, publications which did not 
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Table 3.1 - Search terms for title search in Ovid 
Term 1  Term 2 
 
AND 
Risk reducing salpingo oophorectomy 
 Risk reducing oophorectomy 
 Prophylactic salpingo oophorectomy 
Decision$ Prophylactic oophorectomy 
Choice$ Prophylactic surgery 
Option$ Risk reducing strategies 
Discussion$ Risk reducing strategy 
Decide Ovarian cancer risk 
Deciding Ovarian cancer screening 
Choose Ovarian cancer prevention 
Choosing Inherited ovarian cancer 
Perception$ Inherited breast ovarian cancer 
Concern$ Inherited ovarian breast cancer 
Question$ Familial ovarian cancer 
Perspective$ Familial breast ovarian cancer 
 Familial ovarian breast cancer 
 
BRCA  
Lynch 
Hereditary non-polyposis colorectal 
cancer / HNPCC 
 
explore (i) women’s self-reported intentions, opinions and concerns or (ii) women’s 
demographic characteristics associated with decisions about RRSO were also 
excluded, as the current research aimed to specifically determine factors that 
influence women’s decisions about RRSO. Excluded in this step were papers which 
exclusively focused on health professionals’ decision making (Plusguin et al., 2011; 
Stany et al, 2010), those which described decision analysis using Markov models 
(Armstrong et al., 2004; van Roosmalen et al., 2002) and those which did not report 
on original research. Publications which reported on participants who were eligible 
for and expressed an intention to undergo RRSO, but had not had surgery at the 
time of the study, were included, as it has been shown that intention to undergo 
RRSO does translate into actual uptake (Tiller et al. 2002). 
3.2.3 Complementary search 
Further publications were identified through previously published reviews 
with a similar, albeit wider, focus. These often explored RRSO together with risk-
reducing mastectomy and/or breast and ovarian screening decisions. The initial 
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search identified a review on breast and ovarian cancer risk management options 
(Howard et al. 2009a), a review on psychosocial factors influencing decisions about 
risk-reducing surgeries (Fang et al. 2005) and one on predictors of breast and 
ovarian screening and risk-reducing surgery uptake (De Leeuw et al. 2008). An 
additional review on the uptake and experiences of women considering RRSO was 
also identified (Miller et al. 2010). References from these reviews were selected 
according to the criteria detailed above. All publications exclusively concerned with 
breast/ovarian cancer screening and/or prophylactic mastectomy were excluded, as 
the focus of the current review was on decisions about RRSO.   
3.2.4 Appraisal and analysis 
All publications were critically appraised using an appraisal checklist from the 
Critical Appraisal Skills Programme (CASP) collaboration (see Appendices 3.1 and 
3.2) appropriate for the study’s main method (qualitative or quantitative). The main 
results of each study were summarised and factors explored during, or associated 
with, decisions about RRSO were extracted. Similar to Howard et al.’s approach 
(2009a), the issues identified were assigned to one of five categories: 
‘medical/physical’, ‘psychological/emotional’, ‘social context’, ‘demographic’ or 
‘other’. As the review included a large number of qualitative studies, statistical 
significance was not a criterion for inclusion. Additionally publications were 
reviewed to identify any specific expectations women have of the content and 
format of support materials or interventions designed to facilitate these decisions. 
3.3 Results 
The literature search identified 115 publications of which 97 were excluded 
after application of the exclusion criteria (Figure 3.1). Thirty-one additional 
publications were identified through a complementary search of reference lists of 
previously published literature reviews (De Leeuw et al. 2008, Fang et al. 2005, 
Howard et al. 2009a, Miller et al. 2010). The final publication list includes 
quantitative (n=38) and qualitative studies (n=11) (Table 3.2). 
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Secondary Exclusion Criteria: 
i. Did not explore women’s opinions, intentions, 
needs or characteristics (e.g. provider decision 
making, Markov models) n=7 
ii. Not an original research study (e.g.  review, 
letter) or conference abstract n=18 
iii. Duplicate 
Literature Search Results: n=115 
n=45 
n=18 n=25 
n=70 
excluded 
Duplicates removed: n=2 
Excluded Publications: 
Armstrong (2004a) 
Armstrong (2004b) 
Briasoulis (2008) 
Caroll (2009)
 2 
Couzin (2003) 
de Leeuw (2008)
1 
Doll (2011)
2 
Fang (2005)
1 
Goelen (1999) 
Grann (2000) 
Hachey (2009)
2 
Howard (2009a)
1 
Howard (2009b)
2 
Howard (2010a)
2 
Howard (2010b)
2 
Julien-Reynier (2000) 
Kwong (2010b)
2 
Mahon (2001) 
Matloff (2000) 
Miller (1999) 
Plusquin (2011) 
Sinha (2011)
2 
Stany (2010) 
Tuttle (2011) 
van Roosmalen (2002) 
 
Included Publications: 
Babb (2002) 
Campfield-Bonadies (2011) 
Culver (2011) 
Fang (2002) 
Finch (2009) 
Fry (2001) 
Hallowell (1998) 
Hallowell (2001) 
Howard (2010c) 
Howard (2011) 
Klitzman (2009) 
Kwong (2010a) 
Lerman (2000) 
Mellon (2009) 
Morris (2001) 
Stuckey (2010) 
Swisher (2001) 
Verhoeven (2011) 
 
1
previous review paper of 
women’s decision making 
 
2
conference abstract 
Primary Exclusion Criteria: 
i. Not about decision making (e.g. papers on clinical management) n=33 
ii. Not about personal cancer risk reduction / prevention (i.e. about 
decisions other than risk reduction, for example genetic testing decisions or 
fertility decisions or screening only) n=21 
iii. Not about ovarian cancer / oophorectomy (e.g. about breast cancer only 
etc.) n=13 
iv. Does not include women at increased risk (e.g. decisions of having RRSO 
with a planned hysterectomy for women at population risk) n=3 
 
Figure 3.1 - Results of the literature search via Ovid 
61 
 
 
Table 3.2 - Publications included in final review  (1 from Howard et al., 2009; 2 from Miller et al., 2010; 3 from de Leeuw et al., 2008; 4 from Fang et al., 2005) 
First Author Year Study Mode of data collection Study population 
Antill
1 
(2006) Quant. Structured self-administered 
questionnaire 
182 women at moderate (12.5-25%) or high (25-85%) risk of breast cancer who 
attended Familial Cancer Clinics in New South Wales / Victoria between 1999 and 
2000 
Babb (2002) Qual. Semi-structured telephone 
interview 
60 women who had undergone prophylactic oophorectomy (n=30) or ovarian 
cancer surveillance (n=30) at Washington University 
Beattie
2
 (2009) Quant. Medical records 240 BRCA positive women enrolled in the Cancer Risk Program at the University of 
California (USA) who received genetic test results between 1996 and 2006 
Botkin
1,2
 (2003) Quant. Structured telephone interview 129 women from the K2082 kindred in Utah of whom 37 were BRCA1 positive and 
92 were BRCA1 negative when tested for the kindred-specific BRCA1 mutation 
Bradbury
1
 (2008) Quant. Medical Records 88 BRCA positive women who had received clinical services at the University of 
Chicago Cancer Risk Clinic between 1996 and 2003 
Brain
1
 (2004) Qual. Semi-structured interview 10 women newly identified as being at increased risk of developing familial ovarian 
cancer by the Cancer Genetics Service for Wales (UK) 
Campfield-
Bonadies 
(2011) Quant. Structured self-administered 
questionnaire (incl. 3 open ended 
questions) 
98 BRCA positive women who had undergone prophylactic bilateral salpingo-
oophorectomy and received counselling at the Yale Cancer Genetic Program 
Claes
1
 (2005) Quant. Structured self-administered 
questionnaire and semi-structured 
interview 
68 women from BRCA positive families who underwent genetic testing at the Centre 
for Human Genetics, University of Leuven (Belgium), of whom 34 were BRCA 
positive and 34 were BRCA negative 
Culver (2011) Qual. Focus group 11 BRCA positive breast cancer survivors who had elected RRSO (=1), RRM (n=1), 
both (n=8) or screening (n=1) and were enrolled in the City of Hope Clinical Cancer 
Genetics Hereditary Cancer Registry (USA) 
Evans
2
 (2009b) Quant. Medical records 211 BRCA positive women assessed at the Breast Cancer Family History Clinic of the 
regional genetics service for the Northwest of England in Manchester (UK) [Cohort 
in which uptake of bilateral risk-reducing salpingo oophorectomy was examined] 
Fang (2002) Quant. Structured telephone interview 80 unaffected women who have a first degree relative with ovarian cancer and were 
enrolled in the Family Risk Assessment Program at Fox Chase Cancer Centre (USA) 
Fang
1
 (2003) Quant. Structured self-administered 
questionnaire 
76 women with a family history of ovarian cancer enrolled in the Family Risk 
Assessment Program at Fox Chase Cancer Centre (USA) 6
1 
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First Author Year Study Mode of data collection Study population 
Finch (2009) Quant. Structured self-administered 
questionnaire 
127 BRCA positive women who had undergone prophylactic salpingo-oophorectomy 
at the University Health Network, Toronto (Canada) 
Friebel
1
 (2007) Quant. Structured self-administered 
questionnaire and medical records 
537 BRCA positive women tested between 1994 and 2006 in one of 17 centres in 
North America and Europe 
Fry (2001) Quant. Structured self-administered 
questionnaire 
58 women who had undergone prophylactic oophorectomy (n=30) or annual 
ovarian cancer screening (n=28) registered on the Family Ovarian Cancer Clinic 
database of Western General Hospital (Edinburgh, UK) 
Hamilton
1
 (2009) Qual. Semi-structured telephone or email 
interview 
44 BRCA positive women recruited from two internet sites for BRCA carriers 
(www.facingourrisk.org and www.youngsurvival.org) 
Hallowell (1998) Qual. Semi-structured telephone 
interview and observations 
41 women with a family history of breast and/or ovarian cancer who attended 
genetic counselling at the Cambridge Cancer Family History Clinic (UK) 
Hallowell
1
 (2000) Qual. Semi-structured face-to-face 
interview 
23 women who had had prophylactic bilateral oophorectomy before age 46; 
recruited from the UK Cancer Coordinating Committee Familial Ovarian Cancer 
Register 
Hallowell (2001) Qual. Semi-structured face-to-face 
interview 
49 women who had undergone prophylactic oophorectomy (n=23) or ovarian 
cancer screening (n=26) and were registered on the UK Cancer Coordinating 
Committee Familial Ovarian Cancer Register, the Risk Advisory Clinic at St 
Bartholomew’s Hospital (London) or the Cancer Family History Clinic at Royal 
Marsden (London) 
Howard (2010c) Qual. Semi-structured face-to-face 
interview 
22 BRCA positive women (16 had had risk-reducing oophorectomy, 3 had had risk-
reducing mastectomy) participating in a hereditary cancer program at the University 
of British Columbia (Canada) 
Howard (2011) Qual. Semi-structured telephone 
interview 
22 BRCA positive women (16 had had risk-reducing oophorectomy, 3 had had risk-
reducing mastectomy) participating in a hereditary cancer program at the University 
of British Columbia (Canada) 
Hurley
1 
(2001) Quant. Structured telephone interview 94 women with a family history of breast and/or ovarian cancer enrolled in the 
Family Risk Assessment Program at Fox Chase Cancer Centre (USA) 
Klitzman (2009) Qual. Semi-structured face-to-face 
interview 
32 women at risk of breast cancer of whom 8 were BRCA positive, 10 were BRCA 
negative, 1 had an indeterminate result and 13 were untested ; recruited through 
various methods via Columbia University, New York (USA) 
Table 3.2 cont. - Publications included in final review 
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First Author Year Study Mode of data collection Study population 
Kram
2
 (2006) Quant. Structured self-administered 
questionnaire 
99 women tested for a BRCA mutation at the Hadassah Hebrew University Hospital 
in Jerusalem (Israel) between 1995 and 2001, of whom 43 were BRCA positive and 
56 were BRCA negative 
Kwong (2010a) Quant. Medical records 31 breast and ovarian cancer index patients positive for BRCA and 41 family 
members of index patients positive for BRCA who participated in genetic counseling 
and testing in genetic centres in China 
Lerman (2000) Quant. Structured telephone interview 216 female members of BRCA1/2 linked families enrolled in a prospective 
observational study from 1994 to 1997, of whom 84 were BRCA positive, 83 were 
BRCA negative and 49 declined to receive test results 
Madalinska
2
 (2005) Quant. Structured self-administered 
questionnaire 
846 women from a hereditary breast and/or ovarian cancer family who has sought 
advice about preventative measures at a gynecology department in one of eight 
hospitals in the Netherlands between 1996 and 2001 
Madalinska
1,2
 (2007) Quant. Structured self-administered 
questionnaire 
160 BRCA positive women over the age of 35 who did not wish to have more 
children; recruited between 2002 and 2004 from gynecology departments in seven 
of eight hospitals in the Netherlands that have a clinical genetics centre  
Meijers-
Heijboer
2
 
(2000) Quant. Medical records 682 unaffected family members from 53 consecutive families with known BRCA 
mutations; recruited through the Rotterdam Family Cancer clinic (the Netherlands) 
between 1994 and 1998 
Meijers-
Heijboer
1,2
 
(2003) Quant. Medical record and structured 
interviews 
220 women with breast and/or ovarian cancer from 112 families with known BRCA 
mutations; recruited through the Rotterdam Family Cancer clinic (the Netherlands) 
before 2000 
Meiser
1
 (1999) Quant. Structured self-administered 
questionnaire 
95 women with a family history of breast and ovarian cancer who approached one 
of 14 Familial Cancer Clinics in five Australian States between 1996 and 1999 
Meiser
1 
(2003) Quant. Structured self-administered 
questionnaire 
371 women with a family history of breast cancer enrolled in the Kathleen-
Cunningham Consortium for Research into Familial Breast Cancer (Australia) 
Mellon (2009) Quant. Structured face-to-face interviews 
and structured self-administered 
questionnaire 
146 women with invasive breast or ovarian cancer identified through the 
Metropolitan Detroit Cancer Surveillance System and 146 female blood relatives 
(one relative per cancer patient) 
Metcalfe
2
 (2008a) Quant. Structured telephone/mail 
questionnaire 
2677 BRCA positive women assessed for genetic risk at one of 41 centres in 9 
countries 
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First Author Year Study Mode of data collection Study population 
Metcalfe
1,2
 (2008b) Quant. Structured telephone/mail 
questionnaire 
517 BRCA positive women assessed for genetic risk at one of 11 centres in Canada 
Morris (2001) Quant. Unclear 83 women who underwent in-depth family history evaluation for breast and/or 
ovarian cancer 
Phillips
1 
(2006) Quant. Structured questionnaire 
(interviewer and self-administered) 
142 BRCA positive women enrolled in the Kathleen-Cunningham Consortium for 
Research into Familial Breast Cancer (Australia) who, between 2001 and 2005,  had 
completed the questionnaire sent out 3 years after study entry  
Ray
1 
(2005) Quant. Structured self-administered 
questionnaire (incl. 2 open ended 
questions) 
62 women enrolled in the Hereditary Cancer Risk Database Project at the Arizona 
Cancer Centre (USA), who met criteria for hereditary risk of breast or ovarian cancer 
and had at least one breast or both ovaries remaining 
Scheuer
1 
(2002) Quant. Structured self-administered and 
telephone questionnaire 
251 BRCA positive individuals (includes 18 males) who received genetic test results 
at Memorial Sloan-Kettering Cancer Centre (USA) between 1995 and 2000 
Schmeler
1 
(2006b) Quant. Medical Records 106 BRCA positive women registered on the University of Texas MD Anderson 
Cancer Centre Clinical Cancer Genetics database who had received test results 
between 1996 and 2005 
Schwartz
2
 (2003) Quant. Structured telephone 
questionnaire 
289 women at perceived high risk who had received genetic counseling and testing 
through the Lombardi Cancer Centre (USA) Cancer Assessment and Risk Evaluation 
program between 1995 and 2000 
Skytte
2
 (2010) Quant. Medical Records 306 BRCA positive women who were unaffected by cancer and has not had risk-
reducing surgery and who were registered on the Danish Departments of Clinical 
Genetics and the Danish National Pathology Registry databases between 1998 and 
2008 
Stuckey (2010) Quant. Medical Records 90 BRCA positive women (39 had undergone risk-reducing bilateral salpingo-
oophorectomy, 13 had undergone  risk-reducing mastectomy and 44 had not 
undergone a risk-reducing surgery) evaluated in the Cancer Risk Assessment and 
Prevention Program between 1998 and 2006 at the Warren Alpert Medical School 
of Brown University (USA) 
Swisher (2001) Qual. Semi-structured telephone 
interview 
60 women who had undergone prophylactic oophorectomy (n=30) or ovarian 
cancer surveillance (n=30) at Washington University 
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First Author Year Study Mode of data collection Study population 
Tiller
1,2 
(2005) Quant. Self-administered structured 
questionnaire 
129 women at potentially high risk of ovarian cancer who had discussed ovarian 
cancer screening and/or prevention at one of 6 Familial Cancer Clinics in New South 
Wales / Victoria (Australia) 
Tiller
3 
(2002) Quant. Self-administered structured 
questionnaire 
68 women from breast/ovarian cancer families who attended one of 14 Familial 
Cancer Clinics in New South Wales / Victoria / South Australia / Queensland / 
Western Australia (Australia) between 1996 and 1999 
Uyei
2
 (2006) Quant. Medical Records 554 women who had undergone testing for a BRCA mutation at the University of 
Texas MD Anderson Cancer Centre between 2001 and 2005 of whom 78 were 
BRCA1 positive, 54 were BRCA2 positive and 410 were BRCA negative 
Verhoeven (2011) Quant. Structured questionnaire 119 pre-symptomatic individuals (includes 43 males) recruited from the Medical 
Genetics Centre at the University Ziekenhuis Gent (Belgium) of whom 54 were BRCA 
positive and 65 were BRCA negative 
Wagner
4 
(2000) Quant. Structured self-administered 
questionnaire 
90 BRCA positive individuals (includes 2 males) from 35 families with a known BRCA 
mutation; recruited through the genetic counselling service of the Division of 
Senology at the University of Vienna (Austria) 
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3.3.1 Medical and physical issues 
The main medical and physical issues explored in a number of studies were 
mutation status, prior cancer diagnosis, cancer risk reduction, surgical menopause, 
HRT and the risks of surgery (Table 3.3).  
Mutation status: A number of studies considered knowledge of BRCA 
mutation status as a factor during RRSO decision making (Antill et al. 2006, Culver 
et al. 2011, Kram et al. 2006, Madalinska et al. 2005, Schwartz et al. 2003, Uyei et 
al. 2006, Verhoeven et al. 2011). Ray et al. (2005) showed that women felt that 
genetic testing was the most influential factor in their decision. Phillips et al. (2006) 
found that women who are aware of their positive mutation status were seven 
times more likely to undergo screening or risk reducing surgery than women who 
did not know their mutation status. Similarly, Meijers-Heijboer (2003) found that 
receipt of positive genetic test results increased the likelihood that women would 
consider RRSO as an option. Conversely, negative test results did not reduce the 
number of women considering surgery in this study. The authors suggest that 
women may be aware that a negative test result does not necessarily indicate the 
absence of a mutation, as there are mutations which cannot be identified with 
currently available methods. Alternatively, women may disbelieve negative results 
based on their strong family history and perceived risk (Dillard et al. 2006). It was 
frequently found that uptake of surgery varied between women who carry 
mutations in BRCA1 and BRCA2, with the former more likely to undergo surgery 
(Evans et al. 2009b, Metcalfe et al. 2008b, Schwartz et al. 2003). This may reflect 
the differential risk profiles, as carriers of mutations in BRCA1 have a higher risk of 
ovarian cancer than those with mutations in BRCA2. However, others did not 
confirm these findings (Skytte et al. 2010, Stuckey et al. 2010). Participation in 
screening was also associated with BRCA mutation carrier status (Schwartz et al. 
2003). However, Lerman et al. (2000) found that a positive BRCA test did not lead to 
increased screening adherence nor higher uptake of risk-reducing surgery. 
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              Table 3.3 - Issues associated with/considered during decision making about RRSO 
Medical and physical: 
Mutation status 
Previous cancer diagnosis 
Cancer risk reduction 
Issues with surgical menopause and HRT 
Surgical complications 
Benign gynaecological issues 
Previous positive screening results 
Residual cancer risk 
Sexuality / loss of libido 
Recovery time from surgery 
Physical discomfort 
Cessation of menstruation 
Psychological and emotional: 
Perceived cancer risk 
Cancer-related distress/worry/anxiety 
Beliefs in screening / detection effectiveness 
Family planning / fertility 
Perception of femininity 
Issues of female identity 
Dislike of screening methods / wish to discontinue screening 
Beliefs in effectiveness of surgery 
Attitude towards surgical procedures 
Fear of death 
Wish to reduce uncertainty 
Coping style 
General self-efficacy 
Social and family context: 
Personal experiences and family history 
Closeness / role in relation to cancer suffers 
Family obligations 
Sexual relationships 
Family communication 
Partner’s coping style 
Demographic: 
Age 
Parity 
Income 
Education 
Employment  
Marital status 
Other: 
Physician recommendation 
Readiness of healthcare system 
Social support 
Effects on insurance 
Incidental benefits 
Avoidance of surgery when healthy 
Inconvenience of attending the clinic 
Possibility for alternative therapy 
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 Cancer diagnosis: A previous diagnosis of cancer, especially breast cancer, 
was associated with decisions to undergo RRSO in several studies (Beattie et al. 
2009, Hamilton et al. 2009, Madalinska et al. 2005, Metcalfe et al. 2008a, Stuckey et 
al. 2010). One study found that the stage of breast cancer at diagnosis was 
influential, with early stage cancer patients opting for RRSO more frequently 
(Meijers-Heijboer et al. 2003). Another study found a higher rate of uptake of RRSO 
among affected index patients compared to unaffected family members (Kwong et 
al. 2010a). However, others did not find such a relationship (Tiller et al. 2005). Non-
cancerous gynaecological problems were also associated with decisions to undergo 
RRSO in one study (Swisher et al. 2001). 
 Risk reduction: Several studies specifically mentioned ovarian cancer risk 
reduction as a contributing factor to decisions about RRSO (Claes et al. 2005, Fry et 
al. 2001, Hallowell 1998). One study found that reducing ovarian cancer morbidity 
and mortality were named as reasons by women when asked retrospectively why 
they had opted for RRSO (Kram et al. 2006). Reduction of breast cancer risk 
following RRSO was a factor considered especially important by women with prior 
breast cancer (Culver et al. 2011). In a hypothetical scenario, in which women at 
increased risk were asked to indicate their leaning towards different management 
options in the context of differing degrees of hypothetical risk (unknown, 10% and 
60%), the number of women leaning towards surgery for risk reduction increased 
with higher risk (Tiller et al. 2005). 
 Menopause and HRT: In a number of studies issues with surgical menopause 
and HRT appeared to be essential considerations when making decisions about 
RRSO, particularly for pre-menopausal women. Often mentioned as a drawback or 
‘cost’ of surgery, these issues were discussed by many women in qualitative studies 
(Brain et al. 2004, Fang et al. 2002, Hallowell 1998, Swisher et al. 2001). Ray et al. 
(2005) found that one of the reasons women remained undecided about RRSO was 
uncertainty about the menopause. Some perceived the menopause to be an 
important natural event that should not be induced surgically (Hallowell 1998). 
Many women also had concerns about HRT and its effects on their body, as well as 
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its potential link to increased risk of breast cancer (Fang et al. 2002, Hallowell et al. 
2001, Swisher et al. 2001). 
 Risk of surgery: The potential for surgical complications was explored in 
several studies (Brain et al. 2004, Hallowell 1998, Hurley et al. 2001). Women 
considered risks associated with surgery as well as recovery time after surgery, both 
of which could impact on their final decision (Brain et al. 2004, Fang et al. 2003, Fry 
et al. 2001). Some women chose to avoid surgery, as they felt it was an unnecessary 
risk (Claes et al. 2005). Similarly, fears and concerns in relation to surgical 
procedures influenced some women in their decisions (Hallowell et al. 2001, Ray et 
al. 2005).  
 Other, less frequently mentioned medical or physical considerations during 
deliberations about RRSO also emerged from previous studies. Residual cancer risk, 
not only in terms of the low remaining risk of primary peritoneal cancer after RRSO, 
but also in terms of the risk of cancer developing elsewhere, was also an issue 
brought up by women. This deterred some women from considering surgery, as 
they saw cancer as an inevitable and uncontrollable event, which would simply 
occur elsewhere in the body if they removed one organ (Hallowell 1998). In 
contrast, abnormal screening results and discomfort during screening led women to 
revisit surgery as an option (Howard et al. 2010c). The effects of surgery on 
sexuality and sexual experience (Babb et al. 2002, Klitzman and Chung 2009), 
including the loss of libido and cessation of menstruation (Fry et al. 2001), and the 
effects of surgery, such as recovery time (Fry et al. 2001, Swisher et al. 2001) and 
physical discomfort (Swisher et al. 2001), were also considerations identified as 
playing a role in some women’s decision making.  
3.3.2 Psychological and emotional issues 
 Psychological and emotional issues were frequently explored in studies of 
decisions about RRSO. These included perceived cancer risk, cancer-related anxiety 
or worry, beliefs in the effectiveness (or otherwise) of screening and factors relating 
to a desire to have children and preservation of fertility. 
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 Perceived cancer risk: Perceived or subjective risk refers to the 
understanding of a patient about their own risk and is often independent of 
objective or actual risk. Women at increased familial risk often tend to 
overestimate their personal risk or the reduction in risk achieved by RRSO (Finch et 
al. 2009, Lerman et al. 1995). Some women thought that their cancer risk was fully 
eliminated following surgery (Finch et al. 2009). Perceptions of ovarian cancer risk 
and risk reduction following surgery were frequently found to play a role in many 
women’s decision making processes (Babb et al. 2002, Brain et al. 2004, Hallowell 
et al. 2001, Hamilton et al. 2009). Women who perceived their risk to be greater 
opted for surgery more frequently (Claes et al. 2005, Fang et al. 2003, Kram et al. 
2006, Madalinska et al. 2007, Schwartz et al. 2003) and reported higher interest in, 
and intention to undergo, surgery (Hurley et al. 2001, Meiser et al. 2003). Morris et 
al. (2001) found that of eight women who were not considered to be at high risk 
after evaluation of their family history, four still chose to have prophylactic surgery 
due to a high perceived cancer risk. 
 Cancer worry/anxiety: Several studies found that cancer-related worry, 
distress, fear and anxiety also influence decisions about RRSO (Culver et al. 2011, 
Fry et al. 2001, Hallowell 1998, Hamilton et al. 2009, Howard et al. 2011). Some 
studies found that higher levels of cancer worry, anxiety and fear were significantly 
associated with decisions to undergo RRSO (Madalinska et al. 2007, Meiser et al. 
1999, Schwartz et al. 2003). However, others did not find such a relationship (Antill 
et al. 2006, Botkin et al. 2003, Meiser et al. 2003). Retrospectively, women in a 
questionnaire study stated that anxiety reduction was influential in their decision 
making process (Kram et al. 2006) and many women noted that relief from worry 
and fear was an important factor (Culver et al. 2011, Fang et al. 2003, Fry et al. 
2001). One study found that intrusive thoughts about ovarian cancer were 
positively correlated with interest in surgery, and that anxiety and uncertainty 
reduction were the strongest predictors of interest in RRSO (Hurley et al. 2001). 
 Beliefs about ovarian cancer screening: Several studies found that beliefs in 
the effectiveness of screening and women’s perceived ability to detect symptoms 
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themselves were influential in the decision making process (Brain et al. 2004, Fang 
et al. 2002). Women who doubted the efficacy of screening were more likely to 
select surgery (Claes et al. 2005, Fang et al. 2003, Kram et al. 2006), whereas those 
who believed that screening would detect cancer early were more likely to choose 
surveillance (Howard et al. 2011, Madalinska et al. 2007). Similarly, those women 
who felt that ovarian cancer could be cured easily tended to prefer screening over 
surgery (Madalinska et al. 2007).  
 Family planning and fertility: In a number of studies the desire for children, 
or more children, was explored as a potential issue considered by women who had 
been offered RRSO (Culver et al. 2011, Skytte et al. 2010). Infertility following 
surgery can be particularly burdensome for pre-menopausal women and the desire 
for children, or more children, is usually associated with deferral or rejection of 
surgery (Fang et al. 2002, Fang et al. 2003). However, even women who have 
completed childbearing may be concerned about the loss of fertility following 
surgery (Swisher et al. 2001).  
 Femininity and female identity: Linked to the concept of fertility are the 
expected effects that loss of fertility will have on femininity and female identity 
(Babb et al. 2002, Hallowell 1998, Wagner et al. 2000). In one study women saw 
their fertility as an important part of ‘being a woman’ and voiced concerns over 
having their ovaries removed, fearing the loss of their female identity following 
surgery (Hallowell 1998).  
 Other, less frequently explored psychological and emotional factors 
included dislike of screening methods (Fry et al. 2001) and beliefs in the 
effectiveness and benefits of surgery (Hurley et al. 2001, Madalinska et al. 2007), 
both of which could result in an increased interest in RRSO. Similarly, a reduction in 
uncertainty was seen as a potential benefit of surgery by some women (Fang et al. 
2002). Attitudes towards surgical procedures (Hallowell et al. 2001, Wagner et al. 
2000) and fear of cancer and/or death (Babb et al. 2002, Swisher et al. 2001) were 
also found to influence women’s decisions. Fear of surgical procedures was found 
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to lead to deferral or complete rejection of surgery (Hallowell et al. 2001, Wagner 
et al. 2000), whereas the wish to reduce the fear of cancer and/or death was found 
to be linked to decisions to undergo RRSO (Babb et al. 2002). Women’s, and their 
partner’s, preferred coping style and general self-efficacy, i.e. belief in one’s 
competence, also played a role in decision making (Mellon et al. 2009), particularly 
with regards to seeking information. Women who showed higher self-efficacy and 
who preferred a high monitoring coping style were more likely to actively seek 
information about cancer risk and management options (Mellon et al. 2009, Wilson 
and Gilbert 2005). 
3.3.3 Social context issues 
 The main social context issues addressed in studies were family history and 
familial obligations. However a few other issues, including parity, sexual 
relationships and family communication, and their impact on decisions about RRSO, 
were also discussed. 
 Family history: Several studies explored family history, both in terms of its 
medical and social aspects (Bradbury et al. 2008, Friebel et al. 2007, Uyei et al. 
2006). Family history influenced not only the decision itself, but also the way 
women approached decisions about RRSO (Hamilton et al. 2009, Mellon et al. 
2009). All women who had opted for surgery in a retrospective study by Swisher et 
al. (2001) mentioned family history as a reason for their decision, while some of the 
women in this study who had opted for surveillance did not. However, others did 
not find family history to be predictive of choice to undergo RRSO (Antill et al. 2006, 
Botkin et al. 2003, Scheuer et al. 2002). Personal experience of ovarian cancer in 
close relatives and the role women played in the life of cancer sufferers also 
influenced their decisions about RRSO (Babb et al. 2002, Hallowell et al. 2001, 
Howard et al. 2010c). One study found that women whose mother or sister had 
been diagnosed with ovarian cancer were more likely to opt for surgery than those 
who did not have a first degree relative with ovarian cancer (Metcalfe et al. 2008b); 
however others did not find such a relationship (Tiller et al. 2005). 
73 
 
 
 Familial obligations: Studies also explored family and social obligations as 
factors influencing RRSO decision making (Bradbury et al. 2008, Brain et al. 2004, 
Howard et al. 2010c). Similar to age (see section 3.3.4), family obligations could be 
associated with decisions to undergo or decline surgery (Brain et al. 2004, Hallowell 
1998, Hallowell et al. 2001).  Some women argued that they wanted to undergo 
RRSO to be able to be there for their family in the long-term, while others deferred 
surgery as they felt that they could not cease to fulfil their familial obligations in the 
short-term. Additionally, the potential effects of surgery on sexual relationships 
were perceived by women to be a ‘cost’ of surgery that may put a strain on their 
relationship with their partner (Hallowell 1998). 
 A few other social context influences were discussed in previous studies. 
Family/partner communication and partner’s coping style were found to influence 
women’s information seeking behaviour (Mellon et al. 2009). Women who reported 
good family communication and who had partners displaying a high monitoring 
coping style were more active in seeking information about cancer risk and 
management options (Mellon et al. 2009, Wilson and Gilbert 2005).  
3.3.4 Demographic factors 
 Age: Several studies explored the influence of age on decision outcomes 
(Brain et al. 2004, Fry et al. 2001, Meiser et al. 1999, Skytte et al. 2010, Tiller et al. 
2002). Age was associated with decisions both for and against RRSO (Claes et al. 
2005). Older age was frequently linked to decisions to undergo RRSO (Bradbury et 
al. 2008, Brain et al. 2004, Fang et al. 2003, Madalinska et al. 2007, Phillips et al. 
2006, Scheuer et al. 2002, Schmeler et al. 2006b). However, it has also been shown 
that from age 60, uptake of RSSO decreased as women were more concerned about 
their daughters’ risks than their own (Beattie et al. 2009). 
 Parity: Some studies found that parity was associated with election of risk-
reducing surgery (Schmeler et al. 2006b, Stuckey et al. 2010) and one study found 
that having two or more children was predictive of uptake of RRSO (Skytte et al. 
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2010). However, others did not find parity or the number of co-habiting children to 
be predictive of RRSO uptake (Antill et al. 2006, Tiller et al. 2002). 
 Additional demographic factors assessed in several studies included marital 
status (Fang et al. 2002, Madalinska et al. 2007), education (Fang et al. 2002, 
Madalinska et al. 2005, Meiser et al. 2003), income (Antill et al. 2006, Botkin et al. 
2003) and employment status (Antill et al. 2006). Most studies found that these 
variables did not influence the decision of whether or not to undergo RRSO (Antill 
et al. 2006, Botkin et al. 2003, Fang et al. 2002). One study concluded that being 
married and less educated were predictive of uptake of RRSO (Madalinska et al. 
2007). 
3.3.5 Other issues 
A few issues that did not fall within the four previous categories were also 
considered during, or associated with, decision making about RRSO.  
Physician recommendation: The recommendation from a physician for RRSO 
was an influential factor, usually associated with uptake of RRSO. This indicates that 
women valued their physician’s opinion (Claes et al. 2005, Kram et al. 2006, Swisher 
et al. 2001). Others found that a physician’s recommendation against RRSO was 
similarly influential (Fang et al. 2002).  
A number of other, less frequently explored considerations included the 
availability of social support (Mellon et al. 2009) and the readiness of the 
healthcare system, i.e. perceptions of when the healthcare system could 
accommodate women and when referrals could be made  (Howard et al. 2010c), 
both of which could influence women’s decisions about RRSO. Incidental benefits of 
surgery, such as the resolution of other gynaecological problems (Hallowell 1998), 
and a parallel decision to undergo prophylactic mastectomy (Beattie et al. 2009, 
Madalinska et al. 2005) were associated with more positive attitudes towards RRSO 
and/or undergoing this surgery. In contrast, avoiding surgery when it was not 
necessary was found to be a motive to opt for screening rather than RRSO (Claes et 
al. 2005). The potential of RRSO to negatively affect future insurance contributions 
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was considered by women living in countries where health provision is regulated 
through insurance, such as the US (Hurley et al. 2001). A few women also felt that 
inconvenience of attending the clinic (Fry et al. 2001) or availability of information 
about alternative therapies (Klitzman and Chung 2009) were important factors in 
their decision making.  
3.3.6 Women’s expectations of decision support 
Eight studies described what women expected or desired in terms of 
support during deliberations about RRSO (Babb et al. 2002, Campfield Bonadies et 
al. 2011, Hallowell 2000, Howard 2010, Ray et al. 2005, Swisher et al. 2001, Tiller et 
al. 2005), a summary of which is shown in Table 3.4. 
 
    Table 3.4 - Women’s expectations of decision support content 
Information support: 
Ovarian function and the menopause 
Personal medical history 
Cancer family history 
Cancer risk assessment / mutation status 
Ovarian cancer screening 
RRSO (procedure, recovery time etc.) 
Ovarian and breast cancer risk-reduction after surgery 
Effectiveness of surgery 
Residual cancer risk 
Surgical risks 
HRT 
Timing of surgery 
Types of surgery 
Effects of surgery (on sexuality and menopause) 
Effects of surgery (on heart disease and osteoporosis) 
Possible adjunctive surgery 
Psychological and emotional support: 
Control, empowerment 
Future hope (alleviate fear of death) 
Strategies for coping with the consequences of surgery 
Availability of sex counselling 
Reduction in uncertainty 
Social support: 
Availability of social support  
Building trust 
Effective communication (from doctors, friends, family) 
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 Unsurprisingly, women’s expectations in terms of information provision to 
support the decision mapped well onto the issues explored by women during 
deliberations as discussed in previous sections. Most importantly, women wanted 
accessible, comprehensive information materials, which covered the areas of risk 
and potential mutation status, as well as management options, such as RRSO or 
screening (Babb et al. 2002, Klitzman and Chung 2009, Ray et al. 2005). The 
information required with regards to surgery included details of the procedure, 
recovery time after surgery, risks and effectiveness, as well as effects concerning 
fertility, sexuality and menopause (Babb et al. 2002, Campfield Bonadies et al. 2011, 
Hallowell 2000). The vast majority of women in one study indicated that they 
wanted as much information as possible, including good and bad outcomes of 
management options (Tiller et al. 2005). Background information on ovarian 
function, the menopause and potential use of HRT were also areas where 
information was requested (Hallowell 2000, Swisher et al. 2001). One study found 
that women desired information about insurance issues regarding both genetic 
testing and cost of surgery (Ray et al. 2005). Women reporting retrospectively on 
information they would have liked to have had before having surgery mentioned 
that effects of surgery on sexuality and the availability of sex counselling had been 
neglected in pre-surgery consultations (Campfield Bonadies et al. 2011). More than 
40 per cent of women in this study also felt that further pre-surgery information 
about changes in heart disease, osteoporosis risk and body image would have been 
helpful. The use of HRT and its effects on breast cancer risk, which women were 
concerned about, was also a topic seen as important by women post-surgery 
(Swisher et al. 2001).  
 In addition to information content, women also desired psychological and 
emotional support, wanted to feel in control and to build trust with medical 
professionals (Babb et al. 2002). Women expected effective communication 
between themselves and their clinician, as well as family and friends, which to them 
was vital to establish rapport and an appropriate support network (Babb et al. 
2002). Women also desired information about, or help with, strategies to deal with 
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the consequences of surgery and to support coping efforts (Howard 2010). 
Although most of what women expected or desired in terms of support during 
deliberations about RRSO referred to specific information materials, some women 
also voiced additional desires that might be catered for with carefully designed 
decision support. These include stimulating effective communication between the 
patient, health professionals and family, enhancing patient empowerment and 
sense of control, and offering coping advice.   
3.4 Discussion 
3.4.1 Discussion of findings 
 This chapter reviewed the issues considered during, and associated with, 
decisions about RRSO in women at increased risk of ovarian cancer. Unsurprisingly, 
the number of issues identified was relatively large, thus exposing the complexity of 
this decision and the challenges women face whilst going through the appraisal and 
deliberation process. By far the largest proportion of issues fell within the 
‘medical/physical’ and ‘psychological/emotional’ categories.  
 3.4.1i Medical and physical issues: Personal medical history, such as 
knowledge of a positive mutation status (particularly BRCA1), prior cancer diagnosis 
or a benign gynaecological problem, was often found to be associated with 
decisions to undergo surgery (Beattie et al. 2009, Evans et al. 2009b, Hamilton et al. 
2009, Kwong et al. 2010a, Madalinska et al. 2005, Manchanda et al. 2012a, Meijers-
Heijboer et al. 2003, Metcalfe 2009, Metcalfe et al. 2008b, Phillips et al. 2006, 
Stuckey et al. 2010, Swisher et al. 2001). Hence, the finding that women reported 
wanting information about their risk and mutation status to facilitate decisions 
about RRSO was not surprising (Babb et al. 2002, Klitzman and Chung 2009, Ray et 
al. 2005). Dagan and Goldblatt (2009) confirmed that knowledge of risk, especially 
of a confirmed genetic mutation, was perceived by women as empowering. These 
findings suggest that women who are aware of their risk due to a confirmed 
mutation understand themselves as ‘patients’ and feel as though they have a 
‘diagnosis’ upon which they can act (Scott et al. 2005). Hence, they may perceive 
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more benefits to surgery compared to those who do not know their mutation status 
and therefore may not have an exact risk estimate on which to base their decision. 
However, one study did not find a correlation between positive BRCA status and 
surgery uptake (Lerman et al. 2000). This study had a short follow-up time of one 
year post-genetic test disclosure. In contrast, Phillips at al. (2006) found that 
confirmation of a BRCA mutation did lead to increased uptake of surgery with a 
follow-up time of three years. Therefore time elapsed from point of disclosure may 
influence women’s risk management choices at time of assessment and results 
should be interpreted with this in mind. Differences in uptake of RRSO between 
carriers of mutations in BRCA1 and BRCA2 may be explained by the differing 
ovarian cancer risk estimates, which are higher for carriers of mutations in BRCA1 
than for those with mutations in BRCA2 (Chen and Parmigiani 2007). Therefore 
increased uptake by women with BRCA1 mutations, as reported in many studies, 
may reflect a realistic estimation of personal risk. Studies which did not find a 
difference in uptake combined RRSO and risk-reducing mastectomy in their analysis 
(Stuckey et al. 2010) or were conducted in a country with very high (>75%) uptake 
of surgery amongst carriers of mutations in BRCA1/2 (Skytte et al. 2010). 
 It should be noted that studies regarding positive mutation status and 
uptake of RRSO only assessed BRCA carrier status. The influence of Lynch Syndrome 
mutation status on decisions regarding RRSO was not explored by studies in this 
review. This may be due to the increased risk of endometrial and colorectal cancer 
associated with Lynch Syndrome, which may be of primary concern for most 
affected women. RRSO in this context may mainly be considered as an adjunct to 
risk-reducing hysterectomy (RRH) for endometrial cancer risk reduction, rather than 
a stand-alone procedure. It may also be due to lower rates of positive mutation 
tests in women from families with Lynch Syndrome, as many mutations are not 
detectable using currently available methods and risk reduction decisions are often 
based solely on family history. 
 Those women who had already experienced cancer themselves, and those 
who viewed RRSO as a solution to other gynaecological issues (as well as a means to 
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reduce cancer risk), may be more likely to opt for RRSO (Manchanda et al. 2012a). 
These patients may perceive there to be more benefits to the operation than those 
who have not been affected by cancer or suffered from benign gynaecological 
problems (Kwong et al. 2010a, Meijers-Heijboer et al. 2003, Stuckey et al. 2010, 
Swisher et al. 2001).  
 Effects of surgery on cancer risk were specifically mentioned by relatively 
few studies as an issue explored during decision making about RRSO (Claes et al. 
2005, Culver et al. 2011, Fry et al. 2001, Hallowell 1998, Kram et al. 2006); however 
this issue is arguably the main reason why RRSO would be considered in the first 
place and is likely to play a significant role in most decisions although it was not 
explored by all studies. Both, the reduction in ovarian and breast cancer risk may be 
important for women, as many come from HBOC families and face a substantial risk 
of breast cancer in addition to their elevated risk of ovarian cancer. 
 Physical effects of surgery, particularly in relation to surgical menopause 
and the potential need for HRT, were frequently found to influence decisions about 
RRSO (Brain et al. 2004, Fang et al. 2002, Hallowell 1998, Hallowell et al. 2001, Ray 
et al. 2005, Swisher et al. 2001). These findings are unsurprising, as infertility and 
surgical menopause are irreversible and often seen as the main drawbacks to 
surgery by pre-menopausal women. Menopausal symptoms, which may be more 
severe following surgery when compared to the natural menopause, can affect 
women’s quality of life (Elit et al. 2001, Hallowell et al. 2012). Fears of, and 
concerns about, the short- and long-term effects of surgical menopause are 
therefore an important factor influencing decisions about RRSO (Hallowell 1998, 
Ray et al. 2005). While HRT can relieve some of the symptoms of the menopause, 
women are often reluctant to take HRT due to concerns about the effects of HRT on 
breast cancer sparked primarily by the media coverage of a study on post-
menopausal women (Beral and Collaborators 2003, Fang et al. 2002, Rossouw et al. 
2002, Swisher et al. 2001). It must be noted that findings from the study which 
caused these concerns have now been widely discredited (Shapiro et al. 2011a, b, 
Shapiro et al. 2011c, Shapiro et al. 2012) and it has been shown that HRT is safe for 
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the vast majority of women with a family history, if it is only taken until the age of 
natural menopause (Eisen et al. 2008, Rebbeck et al. 2005). Therefore, it is essential 
that women are provided with up-to-date information regarding surgical 
menopause and HRT when making decisions about RRSO, especially in light of their 
self-reported information needs (Hallowell 2000, Swisher et al. 2001). 
 Similar to concerns about the surgical menopause and HRT, fear of and 
concerns about risks of surgery were also found to influence women’s decision 
making (Claes et al. 2005, Hallowell et al. 2001, Ray et al. 2005). Any surgery bears 
risks and these may be perceived as higher by individuals considering risk-reducing 
surgery, i.e. surgery in the absence of clear clinical findings, as opposed to surgery 
as a treatment option for a current health problem. It has been previously reported 
that women see their decision as a weighing up of the ‘dominant fear’, either fear 
of cancer or fear of the risks of surgery (Dagan and Goldblatt 2009). Therefore it is 
unsurprising that surgical risks were explored in a number of studies and that 
women themselves also reported a need for information about risks and 
effectiveness of surgery (Babb et al. 2002, Campfield Bonadies et al. 2011, Hallowell 
2000, Howard 2010, Tiller et al. 2005).  
 3.4.1ii Psychological and emotional issues: Perceived cancer risk can 
influence women’s decision making regarding RRSO dramatically, even though it 
may be discrepant from their objective risk estimate (Cull et al. 2001, Mellon et al. 
2008). Many studies found a high perceived risk to be associated with intention to 
undergo, or actual uptake of, RRSO (Claes et al. 2005, Fang et al. 2003, Kram et al. 
2006, Madalinska et al. 2007, Schwartz et al. 2003). This may indicate that the 
emotional burden of a high perceived risk can be enough to persuade women to 
select surgery, despite a relatively low actual risk. This is supported by the fact that 
some women who have been found to be at or near population risk based on their 
family history still choose to undergo RRSO (Morris et al. 2001). Previous findings 
also suggest that emotional responses to test results are influenced by pre-existing 
concepts about risk and that some individuals appear to ‘distrust’ a negative 
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genetic test result (Dillard et al. 2006, Hilgart et al. 2010, Lerman et al. 1995, Michie 
et al. 1996).  
 Higher perceived risk tends to co-exist with higher cancer worry and can be 
resistant to change despite a low risk assessment (Brain et al. 2011). Relief from this 
worry or anxiety has been found to motivate women to undergo surgery (Culver et 
al. 2011, Fang et al. 2003, Fry et al. 2001, Madalinska et al. 2007, Meiser et al. 1999, 
Schwartz et al. 2003) and confirms that emotional cues, such as distress and 
anxiety, play a vital role in decision making processes, which may be geared 
towards regulating these emotions. However, a number of studies did not agree 
with these findings (Antill et al. 2006, Botkin et al. 2003, Meiser et al. 2003). Such 
contradictory findings may be explained by different measures used to assess 
anxiety and distress, or by the varied follow-up times in the different studies. 
Additionally, two of these studies were evaluating factors predictive of RRSO 
uptake; therefore they were not simply considering issues that may be important in 
the decision (Antill et al. 2006, Botkin et al. 2003). Anxiety and worry may still be an 
important issue in these decisions; however it may not be predictive of RRSO 
uptake, as some anxious or worried women may opt for screening instead, if 
available. 
 Women’s beliefs in the effectiveness of screening and their own ability to 
detect symptoms were also explored in several studies (Brain et al. 2004, Claes et 
al. 2005, Fang et al. 2002, Fang et al. 2003, Madalinska et al. 2007). Those who felt 
that screening is an effective means of detecting ovarian cancer or that they would 
be able to detect symptoms themselves were more likely to lean towards 
surveillance. In contrast, those who perceived screening efficacy or their ability to 
detect symptoms to be low showed more interest in surgery. Similarly, an 
unfulfilled wish to have a child or issues concerning fertility meant that women 
would defer or decline surgery (Culver et al. 2011, Fang et al. 2002, Fang et al. 2003, 
Skytte et al. 2010). Perhaps more surprising was the finding that the issue of fertility 
remained a consideration even for those women who had completed their family 
(Swisher et al. 2001). These data may point towards a more emotive role of fertility 
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in the decision making process, which may be linked to perceptions of femininity, 
womanhood and body image that may be affected by RRSO (Babb et al. 2002, 
Wagner et al. 2000). 
 3.4.1iii Social context issues: Family history was found to influence decisions 
about RRSO in terms of the number of affected relatives and types of cancers, as 
well as in terms of the closeness of affected members to women and the role 
women played in sufferers’ lives (Bradbury et al. 2008, Friebel et al. 2007, Mellon et 
al. 2009, Uyei et al. 2006). It is likely that women draw on their own experiences of 
ovarian cancer in the family, and perhaps RRSO in other relatives, to facilitate 
affective forecasting when making decisions about this surgery (Wilson and Gilbert 
2005). Therefore, it is unsurprising that the number, closeness and outcomes of 
relatives’ ovarian cancers would influence their decisions. Dagan and Goldblatt 
(2009) found that cancer outcomes witnessed in the family, particularly their 
mothers’ experience with ovarian cancer, influenced how women perceived their 
own ability to cope with this cancer, thus indirectly affecting choice of risk 
management. Studies looking at predictors of choices of risk management 
strategies, however, did not find family history to be predictive of RRSO uptake 
(Antill et al. 2006, Botkin et al. 2003, Scheuer et al. 2002). Similar to cancer worry, 
family history may play a role in decision making but may be equally predictive of 
choice of screening and surgery, therefore failing to be a significant predictor of one 
or the other in these studies.  
 Familial obligations also played a role in women’s decision making about 
RRSO. Some women argued that their survival was key, so that they could fulfil 
their familial obligations in the long-term future, and therefore selected surgery. 
Others decided that the recovery time associated with surgery would mean that 
they would not be able to fulfil their familial obligations in the short-term, and 
therefore declined surgery (Brain et al. 2004, Hallowell 1998, Hallowell et al. 2001). 
Women in the literature often considered the impact surgery might have on their 
family, both in terms of obligations, such as taking care of their children or elderly 
and vulnerable relatives, as well as in terms of their relationship with their partner. 
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Women reported a need for more information on the effects of surgery on sexuality 
and the availability of sex counselling, indicating that these issues were important 
to them (Campfield Bonadies et al. 2011). 
 3.4.1iv Demographic factors: Older age was frequently found to be 
associated with increased uptake (Botkin et al. 2003, Bradbury et al. 2008, Brain et 
al. 2004, Fang et al. 2003, Manchanda et al. 2012a, Scheuer et al. 2002, Schmeler et 
al. 2006b). This is unsurprising as age has an effect on many of the issues discussed 
above, including cancer risk and menopausal status. Awareness that ovarian cancer 
risk rises with age may therefore lead to increased uptake of surgery (Lifford et al. 
2012). Additionally, the impact of RRSO on the life of older patients, particularly 
those who have completed childbearing and natural menopause, is significantly 
reduced, therefore potentially reducing the negative effects associated with 
surgery. Age may also play a role in women’s decision making with regards to their 
mother’s age at diagnosis or death, which may be seen as an important point to 
reach in their own lives (Dagan and Goldblatt 2009). 
 Parity was also found by several studies to be associated with uptake of 
surgery (Schmeler et al. 2006b, Skytte et al. 2010, Stuckey et al. 2010). This finding 
may be explained by women’s sense of responsibility towards their children and a 
wish of wanting to avoid their children growing up without their mother or seeing 
their mother go through cancer treatment. 
 3.4.1v Other issues: Unsurprisingly, a recommendation for or against RRSO 
from a physician was also found to influence women’s decisions (Claes et al. 2005, 
Fang et al. 2002, Kram et al. 2006, Swisher et al. 2001). It is logical that women 
would take into account or simply follow their physician’s recommendation, as 
most lack medical expertise and may be used to a paternalistic approach to decision 
making about their health, readily accepting a plan of action from their physician. 
However, due to the preference-sensitive nature of this decision it may not be 
productive for a physician to make a recommendation early on in the decision 
making process. Rather it may be preferable to make the patient aware of her 
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options, including the risks and benefits, and to help her clarify her values with 
regards to RRSO. If the patient then still wishes the physician to make a 
recommendation, this should be in line with the patient’s values. 
 The literature search found a large number of other factors that were 
considered during, or associated with, decisions about RRSO. These included 
residual cancer risk, reduction in uncertainty and the availability of social support. 
Most of these factors are considerations that will be explored with, or by, most 
patients when they go through the appraisal and deliberation process. Additionally, 
this study explored what women expected in terms of support during decision 
making and found that women reported a need for detailed information materials 
as well as for psychological support, empowerment, effective communication and 
coping advice (Babb et al. 2002, Howard 2010). The variety of factors contributing 
to appraisal and deliberation processes, and the support needs uncovered here and 
in previous reviews, highlight the complexity of decisions about RRSO and the need 
for additional decision support to augment that which is currently provided in 
clinical settings (De Leeuw et al. 2008, Fang et al. 2005, Howard et al. 2009a, Miller 
et al. 2010).  
3.4.2 Results in context 
 Decisions about RRSO cannot be seen as isolated decisions. They are being 
made before, in parallel to or after other decisions, which are of similar complexity. 
These include decisions about genetic testing, other risk-reducing strategies, such 
as risk-reducing mastectomy or risk-reducing hysterectomy, the use of HRT and 
decisions about disclosure to others, such as partners, children and other family 
members. Another additional pressure on patients at the time of decision making 
about their own risk management strategies may be the need for disclosure of that 
risk, or even a positive mutation status, to other family members and the worry of 
the impact of their risk on close relatives, such as their children (Hopwood and 
Watson 2010).  
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 Therefore, decisions about RRSO are often being made under conditions of 
high worry and low comprehension (Fang et al. 2005). It has been suggested that 
under these circumstances patients may not comprehend the full scope of the 
information presented to them and hence may be making decisions that are not 
fully informed and based on gist rather than verbatim memories of exact risk and 
effectiveness of options (Lloyd et al. 2001, Reyna and Hamilton 2001). Findings that 
perceived cancer risk and anxiety influence RRSO decision making support this 
suggestion (Claes et al. 2005, Hurley et al. 2001, Madalinska et al. 2007). Even after 
discussing management options at a familial cancer clinic, women were found to 
have a number of misconceptions about the available risk-reduction strategies and 
their effectiveness (Tiller et al. 2005). Evidence-based decision support 
interventions may be helpful in supporting patients’ accurate understanding of 
their risk and have been shown to improve knowledge and alignment of decisions 
with personal preferences (Stacey et al. 2011). Furthermore, these materials can be 
designed for use in the patient’s own home and may be shown to other members 
of the family, including husbands, sisters or mothers, thereby facilitating disclosure 
and discussions within the family about risk and potential management options. 
 Women make decisions about RRSO in the context of their everyday lives 
and consider a range of issues to do with their personal and familial circumstances, 
such as their age and menopausal status as well as their family and work obligations 
and the impact surgery might have on these. Women not only make a decision 
about whether or not to have the surgery, they also deliberate about when to have 
the surgery. Perceptions of the right time to go ahead with surgery can vary and 
depend on considerations such as life plans (for example, completion of family), 
resolution of conflicts with self and others, readiness of the healthcare system and 
cognitive and emotional readiness of the woman herself (Howard et al. 2010c, 
Lifford et al. 2012). Therefore, women may defer the decision initially and 
deliberations may take several years. Decision support materials, which can be 
accessed by women outside the clinical context, could be useful here. These allow 
women to come back to this decision and review the information when they are 
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ready before making an appointment with a physician or genetic counsellor, which 
could be particularly useful as women may not be seen on a regular basis at 
genetics centres to follow up on their decision making (Howard et al. 2010c, Tiller 
et al. 2003, Wonderling et al. 2001). 
 In order to develop adequate support materials for these women it is 
essential to understand the issues that influence women’s decisions and what they 
desire in terms of information and support. The current review explored these 
issues and the results presented here may be helpful as a guide when developing 
decision support materials for these women. In Chapter 5, these results will be 
applied to the generic version of the CODE framework to create an RRSO-adapted 
version. This will then be used to develop a decision support intervention tailored 
to the needs of women at increased genetic risk of ovarian cancer (Chapter 7). 
3.4.3 Strengths and limitations 
 This review offers a detailed analysis of the factors potentially considered by 
women during deliberations about RRSO and additionally explores what women 
expect and desire in terms of support during decision making. It includes a number 
of qualitative and quantitative research studies and therefore provides a more 
holistic view of issues important in the decision making process than previous 
reviews of an exclusively or mainly quantitative nature (De Leeuw et al. 2008, Miller 
et al. 2010). Furthermore, to be as inclusive as possible, the review was not limited 
to one specific category, such as medical or psychological issues, as others have 
done before (Fang et al. 2005).  
 A few limitations to this review should be noted. Firstly, as with any review, 
the quality of the studies which were included determines the strength of the 
conclusions that can be drawn. As this review aimed to be as inclusive as possible, 
the design and quality of studies varied considerably. Although all studies were 
critically appraised before inclusion, the differing study populations, varying sample 
sizes, wide range of measures, follow-up times and modes of data collection used 
should be noted. However, it is reassuring that the same or similar issues were 
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often explored in a number of different studies, thus demonstrating some 
consistency, despite the range of studies included, and lending credibility to the 
findings. 
 Secondly, factors found not to be statistically significant or predictive of a 
certain decision were not excluded. Arguably, this could lead to over-emphasis of 
factors that do not influence the decision either way or of issues that are only 
considered by a minority of patients. However, as this review was seen as the basis 
for further research into the issues considered by a specific cohort of patients – 
women at increased risk of ovarian cancer in the UK – such factors should not be 
dismissed at this point.  
 Thirdly, this review brought together the findings of studies from a number 
of different countries, including the US (Schmeler et al. 2006b), Canada (Howard et 
al. 2010c), the UK (Brain et al. 2004), the Netherlands (Meijers-Heijboer et al. 2003), 
Denmark (Skytte et al. 2010), Australia (Hallowell 1998) and China (Kwong et al. 
2010a). Intra- and inter-country differences related to issues considered by women 
making decisions about risk-reducing surgery, and discrepancies in rates of uptake 
of such strategies, have been identified in previous studies (Julian-Reynier et al. 
2000, Metcalfe et al. 2008a, Metcalfe et al. 2008c). These differences may be due to 
discrepant cultural norms or differences in healthcare systems (Metcalfe et al. 
2008a). Countries such as Norway or the USA see very high rates of uptake, around 
70%, while others, such as Poland and Italy, report much lower rates, around 50% 
or below (Metcalfe et al. 2008a). This could indicate that the general attitude 
towards risk-reducing surgery may vary between populations. Furthermore, due to 
differences in healthcare systems, women in the US considered insurance issues an 
important factor during decision making (Hurley et al. 2001), whereas in countries 
with state funded healthcare, such as the UK, this is not an issue women usually 
take into account.  
 Additionally to covering a number of countries, the studies in this review 
included a variety of patient populations, ranging from unaffected women with only 
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a family history to women with a diagnosis of breast cancer and confirmed genetic 
mutation. These differing populations may consider different issues during 
deliberations about RRSO. The results of this study therefore are not directly 
transferable to any specific at-risk population, such as women with a family history 
in the UK. Further research is needed to determine which of the issues identified 
here are of importance to women at increased risk of ovarian cancer in the UK, 
particularly if these may be used to guide the content of genetic counselling 
sessions and decision support materials for this patient cohort. However, the 
current review does provide a list of potential issues that could be important during 
deliberations about RRSO on which to base future research and analysis of results 
from focus groups and interviews with specific populations. 
 Finally, the current review was limited to women’s characteristics, 
intentions, emotions, thoughts and considerations. Studies of the views of 
healthcare providers or others involved in these decisions were not included and 
therefore no inference can be made about what providers regard as important 
considerations during these deliberations. However, it has previously been shown 
that providers consider age and menopausal status as well as medical history, 
screening and family history when making decisions about risk-reducing surgery 
(Plusquin et al. 2011, Stany et al. 2010). This maps well onto some of the medical 
and demographic considerations explored by studies of women’s decisions. 
3.4.4 Conclusions 
 This chapter reports on the currently available empirical evidence regarding 
issues considered during, and associated with, women’s deliberations about RRSO. 
It also explored what women expect or desire in terms of support materials or 
interventions designed to facilitate appraisal and deliberation processes. The 
variety of issues reported in this chapter highlights the complexity of decisions 
about RRSO. It also provides evidence that there is scope for decision support 
materials to be developed for women at increased risk of ovarian cancer who are 
trying to make these decisions.  
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 As the number of issues raised was relatively large, and as there are 
concerns about the applicability of these issues to specific populations, any 
inferences to the UK population should be made with great care. Therefore, before 
developing any support materials, it is necessary to specifically investigate the 
issues important to women who are making decisions about RRSO in a UK context 
(Chapter 4). Together with the findings of the literature search, these will then be 
used to adapt the CODE framework to describe deliberation and coping processes 
relating to RRSO decisions in women at increased risk of ovarian cancer in the UK 
(Witt et al. 2012). The adapted framework will then be used as a theoretical basis to 
facilitate the development of decision support materials specifically designed to 
help patients who are considering RRSO (Chapter 7). 
 
90 
 
 
4 Patients’ and health professionals’ perspectives on decisions about 
risk-reducing bilateral salpingo-oophorectomy in the UK 
4.1 Introduction 
The previous chapter demonstrated that the decision making process about 
RRSO in the context of cancer genetic risk is complex and involves a wide range of 
issues that women may consider (Chapter 3; De Leeuw et al. 2008, Fang et al. 2005, 
Howard et al. 2009a, Miller et al. 2010). These issues can include medical, 
psychological, demographic and social context factors, including gene mutation 
status, cancer worry, age and familial obligations. They may vary between different 
populations and between countries, depending on cultural attitudes and norms, as 
well as healthcare systems (Metcalfe et al. 2008a). 
In the UK, healthcare is provided through the National Health Service (NHS). 
The service is fully tax-funded and therefore provides healthcare free at the point of 
access to patients. Therefore, issues around cost of surgery and impact on 
insurance are less important in the UK than they may be elsewhere. However, 
private health insurance is also available in the UK and surgery may affect life 
insurance premiums. As previously described in Chapter 1, women with a family or 
personal history of cancer may be referred to a genetics service by their GP or 
oncologist, where the patient’s family history will be assessed and a risk estimate 
based on this information will be provided (Wood et al. 2003). Women may then be 
offered appropriate screening or risk-reducing options. In the case of elevated risk 
of ovarian cancer, this includes risk-reducing bilateral salpingo-oophorectomy 
(RRSO) from age 35. A trial examining the efficacy of ovarian cancer screening in 
high risk women with a trans-vaginal ultrasound once  a year and CA125 blood tests 
three times a year has only recently concluded and results are not expected until 
late 2013 (Institute for Women's Health 2010). Therefore, screening for ovarian 
cancer is not routinely available in the NHS; symptom awareness is recommended 
as an alternative (UK National Screening Committee 2006). 
It is important to understand the risk management options available in the UK 
and women’s decision making and coping processes when faced with these options. 
91 
 
 
This is an essential step towards developing decision support materials specifically 
aimed at these women and their health professionals. The aim of this chapter is (i) 
to explore issues associated with decisions about RRSO specifically for women in 
the UK and (ii) to create a model of the preference construction pathway for 
women making decisions about RRSO in the UK. The results presented here will be 
used to adapt the generic CODE framework to specifically describe decisions about 
RRSO by women at increased risk of ovarian cancer (Chapter 5). 
4.2 Methodology 
This study received approval from the Multi-Centre Ethics Committee for 
Wales (Ref: WA-11-0094) and Research and Development departments at all 
participating centres (Cardiff, Swansea and London) (Appendix 4.1).  
4.2.1 Recruitment for focus groups 
Focus groups are a method of qualitative data collection that allows the 
researcher to explore perceptions, opinions, beliefs and attitudes with participants 
using a relatively informal approach that may lead to more honest, in-depth 
answers than would be achieved in questionnaire studies (Adams and Cox 2008, 
Bloor et al. 2000, Krueger 1994, Morgan and Krueger 1997, Puchta and Potter 
2004). Participants may also build on each other’s answers and so explore topics 
that they may not have thought of in an individual interview (Slaughter et al. 1999). 
An additional advantage of focus groups is the possibility of asking the group to find 
a consensus (Stewart et al. 2006). This can then be used by the researcher to create 
a hierarchy of issues discussed during the meeting. In the context of the current 
study, focus groups were deemed appropriate as they allowed detailed discussion 
of women’s views of decision making about RRSO, as well as exploration of the 
relative importance of the issues that influence their decisions. Furthermore, the 
focus group approach was suitable for examining participants’ views of, and ideas 
for, a decision support intervention in the RRSO context (reported in Chapter 7). 
Women were identified from the databases of three centres in Wales and 
England (the Cancer Genetics Service for Wales based at the University Hospital of 
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Wales, Cardiff, and Singleton Hospital, Swansea, and the Familial Cancer Clinic at 
University College London Hospital). Women were eligible if they were at moderate 
to high risk of ovarian cancer (estimated lifetime-risk ≥10%), aged 30 to 80, and if 
they had not yet made a decision about RRSO. Women who had already opted for 
RRSO were not eligible to take part in the focus groups. Seventy-seven eligible 
patients were identified and invited by health professionals, who provided them 
with an information pack, either directly after a consultation or by post. This 
number represents all eligible women registered with the three centres at the time 
of the study. Interested patients then contacted the researcher and were invited to 
attend a focus group. Full written consent was obtained on the day of the meeting. 
Focus groups were held in meeting rooms on the premises of the Cancer Genetics 
Service for Wales (Cardiff, Swansea) and the Institute for Women’s Health (UCL, 
London). 
4.2.2 Focus groups 
During the focus group, participants were asked (i) to discuss the decision 
making pathway, exploring catalysts and barriers to the decision, and (ii) to share 
their ideas for the content and format of a patient decision support intervention 
(reported in Chapter 7). A topic guide for the group can be found in Appendix 4.2. 
Discussions were guided by a moderator (Jana Witt) and supported by a moderator 
aid. After discussing the decision pathway, participants were asked to rank the 
issues raised by placing prompt cards (compiled by the moderator aid) along a scale 
(from least important to most important) in order to gain an understanding of the 
relative importance of each issue. At the end of the meeting, the focus group 
participants were invited to become part of a ‘virtual reference group’ to give them 
an opportunity to remain involved in the study (see Chapter 7, section 7.2.1). Focus 
groups were convened between January and April 2012. Participant validation was 
carried out by sending women a short summary of the issues raised during the 
focus group discussion one week after the meeting, asking them whether they felt 
the summary was a fair reflection of the group’s views.  
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4.2.3 Interviews with health professionals 
Due to the busy schedule and geographical spread of health professionals in 
the field of genetics, convening a focus group was not a practical method of data 
collection for this group. Therefore, semi-structured interviews were deemed more 
appropriate to explore the opinions and views of health professionals (Kvale 1996). 
Semi-structured interviews ensure a certain set of topics is covered during the 
interview, but allow the researcher to deviate from the interview guide to further 
explore any issues raised (Friesen 2010, Harrell and Bradley 2009, King and Horrocks 
2010). In the context of this research, a semi-structured approach allowed 
exploration of professionals’ views of women’s decision making about RRSO and 
their ideas for a possible patient decision support intervention in this context 
(reported in Chapter 7), whilst also allowing issues that were important to the 
professionals to emerge.  
A purposive sample of healthcare professionals who worked with women at 
increased risk of ovarian cancer, and those involved in the psychological and/or 
emotional support of women in this situation, was identified through personal 
contacts and institutional websites. Eligible professionals either worked for genetics 
services, hospitals or charities in England, Wales and Scotland. They were contacted 
directly by the researcher and sent an information sheet to explain the study. Full 
written consent was obtained before the interview. The researcher (Jana Witt) 
conducted interviews in the professionals’ office or a meeting room at their 
workplace. One interview was conducted over the phone. Interviews focused on (i) 
professionals’ experience and perceptions of women’s decision making regarding 
RRSO and (ii) their views on, and ideas for, the content and format of a decision 
support intervention (reported in Chapter 7). An interview topic guide is included in 
Appendix 4.3. Interviews took place between June 2011 and February 2012. 
4.2.4 Data analysis 
All focus groups and interviews were audio-recorded with participants’ 
consent and later transcribed for analysis. An initial coding frame was developed 
from the topic guides for focus groups and interviews (Boyatzis 1998, Fereday and 
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Muir-Cochrane 2006). After careful reading of the transcripts, the coding frame was 
amended as new themes and codes emerged from the data (Appendix 4.4; Boyatzis 
1998, Fereday and Muir-Cochrane 2006). Sixty per cent of focus groups and over 
eighty per cent of interviews were double-coded and discrepancies between coders 
were discussed until an agreement was reached. The coded extracts were then 
managed and analysed in the data analysis software Nvivo8 (QSR International Pty 
Ltd 2008). Codes were arranged under five themes: ‘Background information’; 
‘Needs, questions and concerns’; ‘Decision making’; ‘Decision support’ and 
‘Miscellaneous’. In this chapter only data within the ‘Background information’; 
‘Needs, questions and concerns’; ‘Decision making’ and ‘Miscellaneous’ themes are 
discussed. Data within the ‘Decision support’ theme, which includes codes 
discussing format and content of a possible intervention, are reported in Chapter 7. 
Samples of coded transcripts are included in Appendix 4.5 and 4.6. 
Analysis focused on identifying factors that were perceived to influence the 
decision, which were categorised as either ‘medical or physical’, ‘psychological and 
emotional’, ‘social context’, ‘demographic’ or ‘other’ factors. Further, these factors 
were then reviewed to identify specific barriers and facilitators to decision making. 
‘Barriers’ were defined as factors that were thought to complicate the decision, 
contribute to remaining undecided and lead to unnecessary delay. ‘Facilitators’ on 
the other hand were defined as factors that made deliberation easier and could 
lead to a decision being made, either for or against RRSO. 
Quotes presented in this chapter were selected as examples of themes and 
codes that emerged from the data. Quotes from focus groups are denoted as 
P[1/2/3][S/C/L], where the number describes the participant and the final letter 
indicates the location (S=Swansea, C= Cardiff and L=London). Quotes from health 
professionals are denoted with HP. Quotes were edited to remove word repetitions 
and irrelevant sections. Where content was removed this is indicated by a […].  
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4.3 Results 
4.3.1 Response rates 
Response rates for this study were low amongst patients invited through the 
genetics or familial cancer clinic services. Response rates to focus group invitations 
for the three sites in the study are shown in Table 4.1. Initial response rate across 
the three sites was 16.9% (13 of a total of 77 women approached), which, while 
disappointing, is not unusual for a focus group study, as recruitment is known to be 
difficult for this method (Bloor et al. 2000, Phelps et al. 2006). Final participation 
was three in Swansea (one participant cancelled due to personal health problems 
and one did not attend on the day), three in Cardiff and three in London (one was 
unable to attend due to family illness and one could not attend on the chosen date 
due to work commitments). Final participation of those who initially registered their 
interest was 69.2% (9 of 13). Data regarding the characteristics of non-responders 
and non-attendees were not collected.  
All participants were registered patients with a clinical genetics service and 
had been assessed as being at increased risk of ovarian cancer. Patient 
characteristics collected during the study are shown in Table 4.2. Five women were 
pre-menopausal, with three reporting experiencing some menopausal symptoms 
(peri-menopausal) and one having completed the menopause. One participant had 
received a negative genetic test result before the date of the focus group, one came  
 
Table 4.1 - Response rates to focus group invitations by study site 
Site: Cardiff 
n (% of invited) 
London 
n (% of invited) 
Swansea 
n (% of invited) 
Total patients invited 25 32 20 
Registered for study 3 (12%) 5 (15%) 5 (25%) 
Final focus group participation 3 (12%) 3 (9%) 3 (15%) 
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Table 4.2 - Focus group participant characteristics (self-reported) 
 Number Percent 
Menopausal status 
     Pre-menopausal 5 56% 
     Peri-menopausal 3 33% 
     Post-menopausal 1 11% 
Genetic mutation status / Lynch syndrome 
     Unknown status 7 78% 
     Confirmed positive (BRCA1/BRCA2/Lynch) 0 0% 
     Confirmed negative 1 11% 
     Lynch syndrome family history 1 11% 
Prior cancer 
     Yes (Breast cancer) 1 11% 
     No 8 89% 
Participated in UK familial ovarian cancer screening study 
     Yes 8 89% 
     No 1 11% 
from a Lynch syndrome family and seven had not been tested or had not yet 
received their test results. The majority of participants had taken part in the UK 
FOCS study (Brain et al. 2012, Rosenthal et al. 2013a). The average duration of focus 
groups was 79 minutes (range: 77 to 83 minutes). 
Response rate for health professional interviews was 65% (11/17). 
Professionals included four genetic counsellors, four gynae-oncologists, one health 
psychologist, one clinical nurse specialist, from hospitals in England (n=3), Wales 
(n=6) and Scotland (n=1), and one nurse working for a national charity support line. 
Eight interviewees were female and three were male. The average duration of 
interviews was 45 minutes (range: 24 to 80 minutes). 
4.3.2 Medical and physical issues 
Mutation status: Confirmation of a genetic mutation was identified by women and 
health professionals as the main motivator for RRSO decision making. The certainty 
that comes with knowledge of gene carrier status and associated risk estimates was 
often interpreted by women as a ‘diagnosis’, which then acted as a trigger to opt for 
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surgery. This effect is clearly illustrated by one woman who had just consented to 
be tested. 
P2S: Now if [the gene test] is a ‘Yes’ then I’ll be seriously… 
P1S: That’s the decision made for you, isn’t it? 
P2S: Yeah and that’s the conversation that I have had with my husband that 
if the letter comes back to say: ‘Yes, you have got the gene which is 
more likely to develop into ovarian cancer’ I’ll be in [for surgery]. 
 
Another participant who had tested negative before the date of the focus group 
also confirmed the role of gene mutation status as catalyst for surgery. 
P3L: Had I tested positive for one of the genes I was going to have surgery 
[…] that was my action plan. 
 
Similarly, health professionals reported that confirmation of carrier status was 
associated with decision making and often interpreted as a ‘diagnosis’ that needed 
‘treatment’. 
HP7: …I suppose having a BRCA mutation confirmed kind of makes it very 
clear that: “This is what my risk level is. This is a diagnosis, now it‘s 
clear, might as well have the treatment”… 
 
HP2: …If people have a clear […] awareness of a gene mutation that makes 
it very clear in their minds that they need to consider different 
options... 
 
Women also interpreted a negative test result as a facilitator to their decision, as 
even a negative test result was believed to result in a more exact risk estimate on 
which to base decision making. 
P3C: Because I think [genetic testing] influences so much. 
P1C: That could be the end, you could stop there. 
P3C: Yeah, exactly. 
P1C: If you haven’t got the gene, couldn’t you? 
P3C: Yeah. 
P2C: Because if you haven’t got the gene then obviously the percentage is 
so-and-so and that influences your decision. 
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However, one health professional voiced concern that women’s interpretation of a 
negative test result may be overly simplistic, emphasising that a negative test does 
not necessarily mean a ‘low’ risk, as there are genetic variants that cannot be 
detected through currently available tests. Deferral of surgery based on a negative 
test result may therefore not be appropriate.  
HP4: …women where the test comes back negative […] might think: “Oh, 
right, so the test has come  back negative, that means I am not at 
increased risk of it, or maybe I am not at the increased risk of the 
BRCA1/BRCA2 type, so maybe I don’t need to think about surgery yet.” 
 
Cancer diagnosis: A previous cancer diagnosis was often discussed by health 
professionals as an influence on RRSO decisions. Most felt it was a catalyst to 
wanting surgery. 
HP7: …[Patients argue:] ”[I] have had chemo in the past, definitively don‘t 
want to have that again!“ And so I suppose having had breast cancer in 
the past makes it more real and so they then opt for surgery... 
 
Conversely, several professionals mentioned that a prior cancer diagnosis could act 
in the opposite way to deter a patient from opting for RRSO in order to avoid a 
hospital stay and/or surgery while they are healthy. 
HP9: …Particularly for women who have had cancer [...] there are two 
groups: there are the ones who have already been through [cancer 
treatment] once and cannot face having chemotherapy again […] and 
there are the ones who have been ill with cancer and then find it very 
hard to contemplate having an operation which is not because they 
are sick… 
 
Women in the focus groups did not discuss the influence of prior breast cancer on 
decision making as only one of the participants had directly been affected by cancer 
and therefore this consideration did not apply to the majority of participants. 
Risk-reduction: As the main reason for recommending surgery is to reduce a 
woman’s ovarian cancer risk, ovarian cancer risk reduction was a key issue 
discussed by health professionals. One professional remarked upon ovarian cancer 
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risk reduction as the main focus for women who do not wish to have children or 
have completed family planning. 
HP2: …Some individuals that I have worked with, they have been very clear 
that they don’t want children and therefore their highest priority and 
the greatest value that they have attached to their decision making is 
reducing their risk... 
 
Risk reduction was also mentioned when professionals spoke about balancing the 
positive effect of surgery on cancer risk with the potential negative effects of 
surgery, such as surgical risks, hospital infections and oestrogen deprivation. 
HP8: …But of course it’s a balance of risk and benefit. I think that’s the 
bottom line: How much […] risk is there from ovarian cancer and how 
much benefit from removing the ovaries that are technically healthy 
and normal? 
 
During the focus groups, women themselves did not discuss ovarian cancer risk 
reduction specifically as a factor in their decision making; however they did discuss 
breast cancer risk reduction. When women found out during the focus group that 
breast cancer risk was also reduced by RRSO, they saw this as a positive effect that 
could influence their decision. 
P1C: I didn’t know that having your ovaries removed would reduce the risk 
of breast cancer. 
P2C: No I didn’t know. By up to 50%. 
P1C: And that would influence my decision certainly because I feel that in 
my family – even though my mother had ovarian cancer – that my risks 
are higher in terms of breast cancer. 
 
Menopause and hormone replacement: For most women, surgically-induced 
menopause was one of their main concerns, as illustrated by one participant’s 
comment: 
P1S: I know from having discussed [surgery] that it throws you into an early 
menopause, which for me is what is making me stick my head in the 
sand a bit at the moment. […] I think that’s really what my primary 
concern would be. 
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Women were worried about psychological changes following surgery and surgical 
menopause and how those might affect their lives. 
P1L: […] Is [surgery] going to change your personality? Like your hormones. 
And are you going to turn into this mad, neurotic […] woman that no 
one recognises? 
 
Women were also aware of the physical symptoms of surgical menopause, such as 
hot flushes, night sweats, weight gain and skin changes, and were considering how 
to counteract those changes.  
P2L: I was thinking: “Oh God, if I have [surgery] I need to lose weight before 
I have it […] just in case everything explodes” [laughter] and “I have to 
invest in very rich face creams” and stuff like that. […] I think a lot of it 
was physical things. 
 
Consequently, women not only wanted to know about the exact effects of surgical 
menopause, but they also needed information about different management options 
for menopausal symptoms, including (but not limited to) hormone replacement 
therapy (HRT). 
P3C: I think in conjunction with it there needs to be a lot more information 
about the menopause and different treatments, whether they are 
conventional treatments, alternative treatments or combinations of 
them. Because I think that will address a lot of women’s fears because 
it’s […] the fear of what comes next, head first into the menopause. 
[…] 
P2C: I agree with that. […] A friend of mine has had her ovaries removed 
and she said: “[Name] I would really really [...] consider it really really a 
lot because”, she said, “you just suddenly go into menopause and you 
don’t know whether you’re on your head or your backside.” 
 
Health professionals also picked up on the issue of early menopause as a major 
concern for women and it was clear that within consultations a lot of time was 
spent on answering women’s questions and allaying their fears and concerns 
regarding this issue. 
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HP9: …One of the most important things for those women […] is the issue 
of HRT and having an early menopause and how that’s going to be for 
them in terms of their mood and their lifestyle and their bones and 
their husband and all of those things… 
 
HP7: …For the younger ones it has to do with the menopause and what it 
would mean for them, what the implications are, what the 
menopausal symptoms are likely to be… 
 
HP6: …For most of them menopause is the issue. Premature menopause. So 
there’s a clear discussion about that. If someone is really anxious we 
[…] make sure they meet the menopause team… 
 
Although menopausal symptoms only affect women who have not yet completed 
natural menopause at the time of surgery, one professional mentioned that even 
older women were concerned about the menopause. 
HP1: …They are worried about what lack of oestrogen is going to do and all 
sorts of things. […] Definitely the younger ones, but surprisingly also 
with the older women, even if they have gone through the 
menopause… 
 
Women had also heard about the potential association between HRT and breast 
cancer risk and were concerned about this, especially in the context of an already 
increased breast cancer risk. 
P1S:She [doctor] said: “You could go on HRT”, but of course HRT then 
brings up the increased breast cancer and where do you pitch it? 
P3S: Yeah, where is the risk? 
P1S: Yeah. 
 
Correspondingly, professionals reported their concern about women delaying 
surgery due to fears about HRT and breast cancer risk and appeared determined to 
explain to patients that short-term HRT was safe, even for individuals with a family 
history.  
HP5: …Women often ask about HRT and they get messages from their GPs 
that HRT is really bad if you have a family history of breast cancer, 
whereas in actual fact […] the amount of HRT you are on after risk-
reducing oophorectomy would be a lot less than your body would 
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produce if you still had your ovaries. So, […] it’s important for women 
actually to be on HRT at least up until the age they would normally 
have gone through menopause to protect their bones and all of those 
other benefits… 
 
HP7: …As soon as you say HRT then the next question that kind of comes up 
is: “Well, I thought HRT increases your risk of breast cancer?” or “Isn’t 
it associated with breast cancer?” And so you have to unravel and 
undo a lot of the stuff they have heard in the media… 
 
Health professionals understood decisions about HRT to be an integral part of the 
decision making process about RRSO. They felt that HRT and its implications should 
be discussed with women in order to make informed, value-adjusted decisions. 
HP2: …Some women may not understand very much about the implications 
of taking HRT and menopause and I think […] it is very important that 
they […] do process that and have good information with which to 
make those judgements… 
 
Professionals felt that HRT was essential for women who have surgery before the 
age of 45, due to the potential negative long-term health effects of oestrogen 
deprivation. 
HP8: …[We discuss] hormone replacement therapy if surgery is done at an 
early age. Sometimes if a woman comes at 48, and they are worried 
then I think the issue of hormone replacement therapy becomes more 
flexible and debatable, but if somebody is […] under 45, then the 
recommendation is that hormone replacement therapy should be 
discussed and offered… 
 
HP6: …There is a mortality issue if they don’t have oestrogen until 45 and 
after that it’s a quality of life issue. […] but below 45 if someone says 
they don’t want to take HRT, we would be very reluctant to undertake 
surgery in the absence of any contra-indication for HRT, just because 
they don’t want to take it… 
 
From a medical perspective, contra-indications to HRT were also an important 
influence on decision making, particularly with regards to prior breast cancer 
diagnosis. 
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HP11: …Unless of course they have got breast cancer [...] in which case you 
can‘t really give them HRT, so that‘s [a] very difficult decision for 
them. Because if they are in their 30s [...] and they have got a long 
time before natural menopause [...] the menopausal symptoms are 
much much more severe [...]… 
 
HP7: …For that younger group the most difficult will be […] those who have 
had breast cancer in the past, […] because obviously they can’t have 
HRT. And some of them […] can be distressed and anxious, because 
they’ve [...] had breast cancer young, they don’t want to have ovarian 
cancer, but what are they going to do […] if they can’t take HRT?... 
 
Women in the focus groups did not discuss contra-indications to HRT, as they either 
were not aware of any contra-indications affecting them or were post-menopausal 
and therefore did not need to consider HRT. 
Risks of surgery: Some women were aware of the risks of the surgical procedure 
itself and the risks of acquiring a hospital infection. These participants voiced 
concerns about taking those risks whilst being healthy.  
P1L: I’m 42, it is quite early I […] feel and putting yourself through surgery 
when – touch wood – there isn’t actually anything wrong with me at 
the moment you think: Any surgery has risks, doesn’t it? And I think 
that’s what is kind of holding me back at the moment 
 
P3S: […] would you want to go into an NHS hospital or would you want to 
pay to have it done privately where they have not got all the infections 
that you have got in the hospitals here? Because you could just be 
adding to your problem. 
P2S: Yeah, you could, you are quite right, yeah. That is the frightening 
reality of today, isn’t it? 
 
The professionals also emphasised that RRSO is a major operation that bears risks 
which patients will be made aware of before consenting for surgery and need to 
consider before their final decision.  
HP8: …As part of the discussion of surgery, you explain to them what the 
surgery involves, what are the potential risks of surgery, complications, 
anaesthetic, operative, post-operative. That comes as part of the 
surgical explanation… 
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HP10: …It’s a major operation, so that is one of the minus points […] and 
there are potential complications, serious complications, so that is 
the minus points […] it’s essentially doing a prophylactic operation 
without any cancer there… 
 
One professional acknowledged that concerns about surgical risks were a factor 
that could prevent women from opting for surgery. 
HP6: …For some people it’s [difficult] because they never had surgery and 
the risk of complications of the surgery [puts them off], because they 
would have to sign the consent form, where we have to write all sorts 
of complications… 
 
Results of screening: During the time of the current study the UK familial ovarian 
cancer screening (UK FOCS) study, which offered annual trans-vaginal ultrasounds 
and CA125 blood tests three times a year, was coming to an end. As most women in 
the focus groups had taken part in the UK FOCS study, they reported that an 
abnormal finding during one of the screens, particularly the ultrasound scan, would 
act as a facilitator to making the decision. 
P2S: If they ever said to me: “Yes, there is a change or there is something.” I 
wouldn’t hesitate. I wouldn’t even want to read up on it. You could 
book me in, I’ll go in the next day. No, I wouldn’t bat an eyelid. 
 
P2C: If I saw something on the scan that looked untoward and they said it 
looked untoward then I would be a bit like: “Oh Yeah, just get rid of it 
now then.” […] I guess I wouldn’t think about the after, I’d just think at 
the time: “Just get rid of it!” 
 
One of the professionals also noted that abnormal findings during the screening 
could act as a catalyst for patients to consent for surgery. 
HP3: …The main precipitant to the decision, I found, has been a jog from us 
for whatever reason […]. In fact that’s perhaps the big benefit of 
screening […] it scared quite a few people into surgery…  
 
Other: A number of other medical and physical factors were briefly discussed by 
both women and health professionals during the study. These included operative 
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procedure, residual risk after surgery and possibility of finding cancer during 
surgery. 
4.3.3 Psychological and emotional issues 
Perceived cancer risk: Health professionals discussed the role of perceived risk in 
women’s deliberations about surgery. They reported that a woman’s perception of 
her risk of ovarian cancer could make her lean one way or the other. Perception of 
risk was understood as independent of the objective risk as determined by family 
history and/or gene carrier status. 
HP9: …often for those women who come in saying they know they 
definitively want to have the surgery, it’s [...] their understanding of 
the risk or how they perceive the risk [that] is important… 
 
HP10: …We used to have people with very high risk disease, you know, 
BRCA1 positive, who wouldn’t have an operation and people come 
with low risk disease, who really didn’t need to come to clinic, who 
would want a hysterectomy and the works. […] I think an individual’s 
perception, […] that’s the thing. […] The perceived risk… 
 
One professional explained that while a woman’s perception of her risk may make 
her lean towards having or not having the surgery, this may be counterbalanced by 
her perception of the risks of surgery. 
HP4: …It comes down to the woman’s perception of her risk. She might 
have a relatively small risk – at least as far as we are concerned – but if 
her perception of that risk is really high, then she’ll make a clear cut 
decision. […] Whereas if we might think she’s got a relatively high risk, 
but her perception of that risk is not so high or maybe if her perception 
of the cost of surgery is going to be so much higher, then she’ll find it 
much more difficult making a decision… 
 
Women themselves only briefly discussed their ovarian cancer risk levels. They 
spoke about it using the estimates they had been given in clinic; however some 
provided their own interpretation of the level of risk as well. 
P3C: I’m sort of the high-end of medium risk. […] because it’s only my 
mother and her mother, that’s clear that it was ovarian cancer. 
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P1L: They said to me that I’m 70% risk of ovarian and about 80% risk of 
bowel cancer, so yeah it’s sort of quite high. 
 
One participant spoke about her perceived risk of breast cancer as opposed to 
ovarian cancer. 
P1C: I feel that in my family – even though my mother had ovarian cancer – 
that my risks are higher in terms of breast cancer. 
 
Women’s interpretation of their risk appeared to depend not only on the estimates 
provided in clinic, but also on their experiences of cancer within the family. 
Cancer worry and anxiety: Both women and health professionals mentioned cancer 
worry and anxiety as factors influencing decision making. Women explained that 
their at-risk status was a constant worry to them and could not be fully understood 
by others, who were not in their position. 
P2S: Unless you are in this bubble, the outside people don’t understand. 
People just don’t comprehend for one minute, I think, the worry, 
because it is a worry. 
 
Women also described that the intensity of cancer worry was not static, but rather 
that it varied from day to day depending on external factors and their own state of 
mind. 
P2S: Depending on what mood you are in, you might think: “Oh, it’s actually 
not quite important to me today” or “That is really important!” 
 
Similarly, professionals considered patients’ emotional burden when giving advice 
about RRSO decisions. They felt that women who were experiencing extreme 
cancer worry or anxiety could sometimes benefit from surgery. 
HP8: …The quality of life is affected, so you have to take that element into 
consideration for surgery. I mean if she says: “I can’t deal with it 
emotionally.” […] I think it’s fair to listen… 
 
HP1: …Some people have a cancer phobia, haven’t they? So if you’ve got a 
cancer phobia you are going to want to have [surgery] done… 
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Belief in screening: As most women in the focus groups had participated in the 
national screening study, many reported that screening had been a welcome 
alternative to surgery and had given them a ‘safety net’ or ‘peace of mind’. 
P2C: I was happy to have the screening. While they offered me the 
screening I was absolutely over the moon. I thought: “Well, they can 
keep track of my ovaries every six months and […] if there is anything 
they’ll find it.” […] I was really, really happy to be on the ovarian 
screening thing. 
P1C: I was as well. It’s the reassurance. 
P2C: Reassurance, yeah. […] 
P3C: It felt a bit like a safety net I think. 
 
P2S: Wrongly or rightly I always felt that it was a bit of a safety net being on 
the [screening] programme, because I have my blood tests quarterly 
[…] I was coming here every January for scans and although I knew […] 
it’s not a guarantee you just think that it’s early detection. […] I felt 
that I was getting a lot of benefit out of it. A little peace of mind, 
wrongly or rightly it did feel like peace of mind and I have felt very 
vulnerable since it has come to an end. 
 
These positive feelings towards screening remained true even for those women 
who were clearly aware that screening offered as part of the trial was not yet 
medically proven and that there was a possibility of false negative results, as 
illustrated by two participants’ comments. 
P3C: I was told by a genetic counsellor even with the trans-vaginal scan that 
it’s not infallible […]. That women who have had those and CA125 tests 
[…] then developed ovarian cancer […]. So it’s not 100% but it gives 
you a better chance, doesn’t it? Because at least you’re being 
monitored. 
 
P1L: Obviously it was made clear to you [screening] was not 100% 
guarantee so it may not have picked up any abnormalities but […] you 
felt as though at least you’re doing something positive towards 
checking early signs of any problems. 
 
Professionals on the other hand often felt that the availability of screening as part 
of the trial might have given women a false sense of security. They wondered if 
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women’s faith in / reliance on screening prevented them from opting for surgery, 
despite surgery being the only medically recommended option. 
HP5: …It was always a worry that I had that I felt [patients] were putting too 
much store in ovarian screening, even though we […] always would 
point out to women that not only are there lots of false positives, but 
there are also lots of false negatives and that there’s no guarantee that 
the screening would actually be any use. But in spite of saying that, 
they still put a lot of store and a lot of hope [into screening] and gained 
a lot of reassurance from [it]… 
 
HP4: …If you can have screening then no matter how useless we might say 
it is, or not helpful we might say it is, some women still hold on to it 
[…]. It’s falsely reassuring if we can’t say it is definitively useful… 
 
HP7: …it’s a very mysterious relationship these high risk women have with 
screening I think and it’s not always easy to understand, especially 
since the information we give is clear, the message we give face-to-
face is clear, but they still […] gain more reassurance or have a higher 
expectation of screening than they ought to have… 
 
One professional spoke about a group of patients who had had negative screening 
experiences, such as a false negative result, and who therefore put less trust into 
screening. She remarked that this group had a more accurate understanding of the 
reliability of screening, which could be influential in their decision making. 
HP6: …Some of the patients have obviously had breast cancer before and 
some of the breast cancers have been missed on mammography, so 
then their understanding of screening is better, in the sense that it’s 
not foolproof and I think their belief is correct […] so it helps them 
make their decision… 
 
Family planning and fertility: As RRSO leads to infertility, the implications of 
infertility must be fully considered before opting for surgery. Professionals 
emphasised the importance of women considering their family plans and confirmed 
that women delayed making decisions about surgery based on their desire to have 
children, or more children. 
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HP7: …We generally standardly say that one of the criteria is that you know 
you have completed your family. […] There is some who delay it on 
that basis that they want to have another child… 
 
HP9: …The issue of children, there are some women where that will stop 
them because […] they haven’t had children yet […] and they may not 
even have a partner, but they can’t quite put themselves in a position 
where they can no longer have that possibility… 
 
In agreement with this, one participant confirmed that a desire to have children 
would take priority over cancer risk reduction. 
P1L: If […] you want more children then that’s going to be your first choice, 
first consideration I would’ve thought. 
 
The loss of fertility as a separate issue to family planning issues also played a role in 
health professionals’ discussions of women’s decision making. One professional 
stated that allaying concerns about fertility could lead to a deferral of decision 
making. 
HP2: …The anxiety I think from a lot of health professionals is […] the […] 
loss of fertility. [..]. The decision making process for ovarian cancer 
management is kind of pushed off because clinicians are trying […] to 
help women to manage those concerns about losing their fertility with 
surgical interventions… 
 
Women themselves did not discuss loss of fertility as an issue directly. This may be 
due to the fact that women in the focus groups reported having completed their 
families and therefore did not consider their fertility to be an important issue.  
Femininity and body image: The psychological consequences of surgery with regards 
to body image and femininity were discussed by both groups of stakeholders. 
Women were concerned about how they might feel following surgery and whether 
their personality and perception of themselves might change. One woman, who had 
previously had breast surgery, observed that surgery could have a psychological 
impact, even if no changes were visible externally.  
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P3L: Any surgery can affect things like body image and how you feel about 
yourself afterwards, totally regardless of physical stuff. 
 
Health professionals recognised the importance of femininity and body image in 
women’s decision making processes and spoke about women’s concerns and 
questions regarding those issues. 
HP6: …Body image [as a] barrier is a very big thing. […] Because […] some of 
the women who don’t want to have [surgery] say: “Oh god, I’ll 
suddenly become old and my skin won’t be quite the same…” […] For 
some people it’s a huge issue… 
 
HP7: …Women do wonder: “How will I change if I lose my ovaries?”, “Will I 
lose my femininity?”, “Will I be less of a woman?” […] those questions 
are asked… 
 
One professional spoke about perceptions of the difference between mastectomy 
and oophorectomy in terms of visibility of the results and the differential impact on 
women’s body image and perceptions of their femininity. This professional 
emphasised that, despite not being visible, the removal of ovaries and the womb, in 
the case of a full hysterectomy, could affect women’s self- concept. 
HP9: …Some people that I have spoken to don’t think [having 
oophorectomy] is as important for a woman as having her breasts 
removed. Perhaps because it’s inside and not visible and it’s quicker 
and for some women it’s the same, but for some women it really is 
very important, […] because […] their womb is a very emotive area to 
do with their femininity… 
 
Other: A few other psychological and emotional issues were briefly discussed 
primarily by health professionals. These included perceptions and fear of hormone 
replacement, which are linked to the concerns about breast cancer risk discussed 
earlier. Other psychological influences on decisions mentioned by health 
professionals related to hospital anxiety and to the effects of prior cancer. 
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4.3.4 Social context issues 
Family history: Women at increased risk of ovarian cancer often have seen and 
experienced cancer in close relatives. The types of cancer their relatives suffered 
from influenced women’s attitude towards ovarian cancer. This influence was 
evident both in terms of the importance women attributed to the cancer their 
relative had compared to other cancers and in terms of women’s perception of the 
usefulness of RRSO. The comment below illustrates the awareness that the 
participant is not only at risk for ovarian cancer and may develop a different cancer 
even if she opted for RRSO. 
P3S: Even if [RRSO] was 100% I mean I have got people in my family who 
have had other cancers so you’d then think: “Right, okay, well that one 
is out of the way.” 
P1S: Sods law I’ll get something else now. 
P3S: Yeah. “What is it going to be, what symptoms should you be looking 
out for now?” You know. Or “Is there some kind of surgery I can have 
to make sure I don’t get that one either?” 
 
Health professionals also confirmed that the type of cancer women observed in 
their relative could influence their perception of their own risk for that cancer and 
other cancers, which may be independent of their objective risk for those cancers. 
HP5: …Women whose mothers have died from breast cancer want to have 
risk-reducing mastectomies and women whose mothers have died 
from ovarian cancer want to have their ovaries out, even though the 
highest risk they have is to breast cancer… 
 
Additionally, some professionals noted that a woman’s relationship with a cancer 
sufferer and the role they played in their care could influence decision making. 
HP2: …what they do, it’s often very dependent upon […] their perceptions 
of what it means to be at increased risk and the closeness with which 
they have observed or they haven’t observed the experience of cancer 
as a result of the high risk inherited factors… 
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Women were aware that the age at which a family member developed or died of 
cancer would be a significant time point in their own lives in terms of a requirement 
for decision making.  
P1L: They did say because my mum was 48 when she died […] I should be 
thinking of [surgery] in the next year or so really. So it’s […] difficult.  
 
Professionals pointed out that certain events within the family might act as triggers 
for women to make a decision. These included a new cancer diagnosis within the 
family and a close relative deciding to have surgery.  
HP6: …I think somebody in the family getting ovarian cancer while you are 
waiting to make that decision […] is a big thing to come and have 
surgery. [Or a] sibling or cousin you are close to having risk-reducing 
surgery… 
 
One woman in the focus group reported having recently lost her mother to cancer. 
However, while she did experience this event as a catalyst for coming into the 
genetics service and considering RRSO, she still did not want to have surgery.  
P3S: My mother has been quite ill up until recently with ovarian cancer and 
she has literally just died […] but I still don’t feel like […] I want to have 
everything done now, so I would say that that is a good indication that 
I’m not going to want to have it done for the minute. 
 
Women in the focus groups often spoke about their own experiences of cancer in 
their mothers or sisters. They talked about their worry that what happened to their 
mother or sister might happen to them, and how this might affect their children. 
However, although they did voice these concerns, women remained undecided 
about surgery. 
P2L: You think about your children. I’ve seen my sister whose children don’t 
have their mother and I think: “Oh for goodness sake, I’m worried 
about my hair getting a bit thin” and I’d much rather be there for my 
children. 
 
P1L: I was eight when my mum died of ovarian cancer and I think just 
because I’ve got a 4 year old and a 13 year old and I don’t want them 
to go through that. 
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Familial and work obligations: Women thought about the potential effects surgery 
could have on their life and ability to fulfil their duties in regard to their family and 
their career. While some women were primarily concerned with their familial 
obligations, such as the ‘school run’ and similar duties, others were more worried 
about the impact of surgery on their career. 
P1L: I think it’s having time off from the school run and doing all that […] it’s 
not like you’ve just got yourself to worry about, it’s other people to 
think of. 
 
P3L: My personal situation is that I work for a very small organisation […], if 
it had been guaranteed keyhole: all well and good. If it went full works 
I would lose my job. […] Obviously my life is worth more than my job 
but I wasn’t going to lose the job unless I had to. 
 
The question of recovery time after surgery was also discussed. Women in focus 
groups debated the effect longer recovery periods after different types of surgery 
might have on their families. 
P3C: I think also the surgery technique is, whether it’s keyhole or whether 
it’s open surgery, is that keyhole is […] far less invasive because with 
open surgery you can’t drive for something like 8 weeks and you can’t 
lift and you can’t walk and you can’t do this, that and the other, which 
impacts on your work, well just your life. 
P2C: Getting the kids places everywhere, yeah. 
P3C: Just everything, doesn’t it? Whereas keyhole surgery appears to be a 
lot easier to recover from. 
 
Health professionals also recognised familial and work obligations as issues that 
influenced decision making about RRSO. It was generally noted that the potential 
effect of surgery upon a woman’s ability to carry out her normal life duties was an 
important consideration. 
HP4: …for some women [recovery time] is actually an important factor as to 
whether or not they decide to go ahead with surgery […] because they 
might be a single mum and have children to look after, they might be a 
carer for somebody else who is off sick, ill, an elderly parent who they 
have to look after and so how long they would be off sick is important 
to them…  
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HP6: ...I think work plays into it, definitively. [...] Everybody is frightened 
[...], everybody is worried, not that they lose their job or anything, but 
about the impact of [taking time off for surgery] on other people at 
work. [...] Especially because it is prophylactic... 
 
Relationship effects: Surgical removal of the ovaries and resulting infertility and 
surgical menopause may affect women’s sex life post-surgery and thereby also 
change their relationship with their partner. Women were aware of the loss of 
libido following surgery and were concerned about the potential effect this might 
have on their relationship. 
P3C: It’s another thing: potential problems with relationships… 
P2C: Exactly. 
P3C: …because of [loss of libido]. For some people it’s not going to be an 
issue but for others it is. 
P2C: For me it would be. […] I have got a good relationship with my 
husband and it would cause a problem. Potentially it could cause a 
problem. 
 
Health professionals also mentioned the potential of surgery to affect sexual 
functioning.  
HP5: …I would always bring it up as a menopausal symptom, that women 
have vaginal dryness and that that can make their sex life less 
satisfying for them. […] patients differ in how they respond to that…  
 
One professional was speaking about her experience of women reporting lack of 
libido after surgery. She remarked upon the difficulty of counselling a woman and 
her partner if the partner is unable to accept the changes in the patient’s sexuality 
following surgery. 
HP11: …We get lots of patients […] with problems with libido. […] And they 
are very difficult to handle then, […] because they might have come 
to terms with their lack of libido, but the partner hasn’t…  
 
Major life events: Women and health professionals also referred to other events 
occurring in the social surroundings of a patient at the time of decision making, 
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which could lead to a final decision either being made or deferred. These included 
positive events, such as a child graduating or getting married or a grand-child being 
born, which may stimulate a wish to avoid cancer at all costs. 
HP9: …I suppose a major life event for some people has been something 
that has […] made them think. […] Their son graduates from university 
and they think “I want to see the next one come through”, some of 
those kinds of things will trigger that… 
 
Similarly, some negative events may also make a decision to have surgery more 
likely. These may include diagnosis or death of a relative or withdrawal of a service, 
such as the screening. 
HP1: …If somebody has been found to have ovarian cancer and that has put 
them from having one member into having two, to put them in a 
higher risk group, […] that’s when they might phone up because they 
are worried… 
 
HP7: …Certainly since the [familial ovarian cancer screening] trial started to 
wind down and has now stopped, [...] there‘s greater interest in 
surgery, there is no doubt about that, yeah. Definitively there‘s an 
increase... 
 
However, one woman remarked that despite feeling vulnerable initially when 
screening was withdrawn, competing life events and commitments had reduced the 
relative importance of making a decision about surgery to a point where she was 
now no closer to a decision than when screening was available. 
P3S: When I found out that [the screening] was all stopping I was like: “Oh 
Gosh, this is it!” but then after a while […] other things happen and it’s 
not at the forefront until something happens or you hear about 
somebody that you actually think about it. Well I don’t. I try not to. 
 
In agreement with this, one professional noted that other life events, especially 
negative ones, may take priority over the ovarian cancer risk and therefore lead to 
deferral of surgery in favour of dealing with the current event. 
HP9: …When […] a major life event happens which is a negative thing [..] it 
pushes [the ovarian cancer risk] back in their minds in terms of 
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importance […] – if there is a tragedy in the family [..] or someone 
leaves them – then they no longer can think about something like 
surgery… 
 
4.3.5 Demographic factors 
Age: Health professionals recognised that a patient’s age played a major role in 
decision making and issues to do with life stage could influence attitude towards 
surgery. 
HP5: …I think women think differently depending on what age they are and 
what stage of life they are at. […] Some women might be finished 
[with] their family at 26, but then others might not start their families 
until they are 36… 
 
HP7: …I suppose it depends on […] the age group. If you are near 60s or 
your 70s you just think: “Well actually I have had a good run of it and 
why should I go to theatre if I don’t have to.” And so they are living 
comfortably with that… 
 
One professional remarked upon the difference between individuals that were 
familiar with their at-risk status from a young age and those who found out about 
their at-risk status in later life. Adjusting to the thought that medical intervention 
might be necessary was suggested as a particular difficulty. 
HP6: …The younger people, they know their status, so they already have a 
lot of medical context [and] they come for screening […] but some of 
the old people who know their status only when they are 60 […] for 
them it is much more difficult, because they have been really healthy 
and well… 
 
Age was also mentioned in terms of the effects of surgery, which are reduced for 
women who opt for surgery when they have completed the natural menopause. 
HP7: …I think it is easier for women who are post-menopausal […] I think 
the younger the women are the harder it is, especially if they haven’t 
had any children yet… 
 
Women in the focus groups did not specifically discuss age as a factor, but did refer 
to their own ages on occasion. One woman who had been very worried about 
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surgical menopause for example stated that she had now reached 50 and was 
therefore likely to go through the natural menopause in the near future. 
P2L: I’m 50, and my thing was “Oh my God, I’m going to be plunged into 
menopause” but then worked out it’s 90% that are going to go through 
it between 49 and 51 or something, so chances are it’s going to 
happen anyway. 
 
Other: Apart from age no other demographic factors were mentioned; however 
some of the women talked about ‘wanting to be there’ for their children, which may 
be an indication that parenthood or parity might be a factor influencing decisions. 
However, even those women remained undecided and therefore no clear 
conclusions can be drawn. 
4.3.6 Other issues 
Physician recommendation: Some of the health professionals clearly supported 
RRSO as the best management option for women at increased risk and were 
recommending this option to their patients. 
HP7: …I mean we are very emphatic that surgery is the thing that we 
recommend. And that really, you know, if you are in your 40s and 
certainly if you are over 50, you should be having your ovaries out… 
 
HP6: …Everyone of us has to die, but I feel very strong that women don’t 
have to die of ovarian cancer. It might [be] easier to have a heart 
attack… 
 
Others, however, were keen to emphasise that they engaged in shared decision 
making about decisions and wanted the patients to take an active role in the 
process. While these professionals personally felt that RRSO was the best option, 
they sought to avoid being ‘directive’. 
HP5: …I would be very happy if all my patients who were at risk for ovarian 
cancer had oophorectomies. I wouldn’t want to push oophorectomies 
on them, but rationally it is the best way to manage that risk, but 
ultimately it’s the woman’s own decision… 
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HP9: …we don’t tell people that they should be having this at all […] it is 
very non-directive the way that we do our counselling, […] and so we 
do tell them that for some people this isn’t the right decision and that 
[…] there are complications after surgery and all of those kind of 
things, but it’s a balance… 
 
Women also discussed the recommendations they had been given from different 
health professionals. It emerged that in many cases specialised consultants had 
been recommending surgery to patients quite strongly, as one woman 
remembered: 
P2C: I think the general opinion of the consultants I‘ve had is just like: “I 
don‘t know what you‘re making all the fuss about, you don‘t need your 
ovaries. It‘s not a question of if you are going to get it, it‘s when, so 
why are you not making this decision? Just get rid of the things!” [...] 
That‘s the opinion I‘ve had […]. 
 
However, the same patient emphasised that she would not make this decision 
based solely on the consultant’s recommendation. 
P2C: I couldn’t just have it done with [my consultant] alone just saying it, I 
think I’d have to have other things to back it up. 
P3C: Definitely! 
P2C: That wouldn’t be my main decision just because the surgeon said it. 
 
In contrast, GPs appeared to be more reluctant to recommend surgery to their 
patients. In some instances, this reluctance seemed to reduce women’s resolve to 
explore surgery in more detail.  
P2L: I went to my GP and she said to me: “Just really think about it.” 
Because she had had a patient that had come back and had problems 
with adhesions and stuff afterwards and said that if she’d known it was 
going to be like that she’d never have had the operation done. 
 
P2S: “You are just as likely to be knocked down by a bus, so do you want to 
take that course of action?” that’s what my GP told me. […] and when 
you get that off your GP you think: “Oh, I don’t know if I’ll consider 
that any further now.” You know, I had gone with a serious 
conversation of considering it. 
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There was a considerable range in the recommendations that women had received 
from different health professionals, which contributed to their confusion about the 
most appropriate course of action. 
Elective procedure: The fact that RRSO is an elective procedure which would be 
undertaken in the absence of a clear diagnosis, while a woman was well and 
healthy, appeared to constitute one of the main concerns for women when they 
were trying to make a decision. 
P2S: Well, I think it’s difficult to, well essentially going in for surgery of your 
own choice. […] there are so many other things that could go wrong. 
[…] it’s going in with […] no symptoms or no issue. You haven’t been 
diagnosed. It’s quite a big step. 
 
Women distinguished between surgery that was required as treatment for a cancer 
diagnosis and risk-reducing surgery, which would be done to avoid cancer 
developing. They felt that surgery as a treatment was an easy, clear-cut decision; 
however they struggled with the idea of elective surgery in the absence of a clear 
diagnosis.  
P3S: If somebody said to you: “You have got ovarian cancer” you would 
literally […] be like “Okay, yeah, no problems.” You know, well ‘Yes’ 
straight away. 
P1S: But you wouldn’t cut your arm off if there was nothing wrong with it, 
would you? 
 
Women also remarked upon the difficulty of making the decision on their own and 
about actively asking for surgery as opposed to being told that they needed to have 
it. 
P1C: In the back of my mind it is: “Well, should I be looking at this?” There’s 
nobody prompting me, I don’t see anyone to look at it, so it would be 
me taking it forward and requesting [surgery]. 
 
Trust in the medical profession: Women discussed their relationship with clinical 
staff and their level of trust in their GP, which was a factor that was important, 
especially with regards to identification of symptoms.  
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P3L: I think there’s another factor which is how much you trust your GP […]. 
I have trust that if I go to my GP with any of the symptoms on the 
ovarian cancer check box, she – knowing my history – is not going to 
mess around. […] So that’s another comfort level for me. […] 
P1L: It’s having the confidence in your first port of call really, isn’t it? 
P3L: Yes. 
 
In agreement with this, one professional remarked upon women’s experience of 
having witnessed a failure by a GP during the care of a close relative. Again, 
women’s trust in their GP’s ability to identify and act upon symptoms was seen as 
an important influence upon their decision about surgery. 
HP1: …I think they may just want to get on with [surgery] because of their 
lack of trust. If you tell somebody to think about the symptoms they 
may say: “Oh well that’s what my mother did and look what 
happened!” So, they would rather not trust that, they would rather 
just get on and have it done… 
 
Women also explored the expertise of different surgeons at different hospitals and 
how this might influence their choice of location if they decided to opt for surgery.  
P3L: My genetic counsellor who I saw locally […], she said you get the 
choice [of where to have surgery] and I thought: ‘Well, that’s no real 
choice! I know where I’m coming!’ 
 
P1L: Yeah, so I think if […] in five years’ time  something happens and I’ve 
got to have it done […] I probably would look back and regret not 
having it done here where it’s under someone that’s got a good 
reputation. 
 
Availability of screening: Women in the focus groups generally felt that screening 
had provided them with reassurance and that they would be happy to continue 
screening if it was offered after the trial completed.  
P1C: Just feeling a little bit in limbo and would go to any further [screening] 
if it would reassure me and potentially help others […] I would 
probably be quite grateful if I could have the CA125 annually or 
something just for that reassurance if nothing else. 
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Therefore the availability of screening appeared to reduce the attractiveness of the 
surgery option and the current lack of screening made women reconsider, albeit not 
opt for, surgery. 
P2S: For me [the end of screening] has made me think more […] about 
surgery, but it hasn’t made me opt for surgery. I don’t think I am any 
closer to it than I was a couple of years ago, but I just feel like: ‘Should 
I be really considering that now?’ Because to me at the moment that is 
the only way I have got of being screened then in some respects. 
Putting a full stop on that avenue. But I am no closer to having it. 
 
Other: Stakeholders additionally mentioned some other issues that might be 
influential when making decisions about RRSO, such as patient personality and the 
vagueness of ovarian cancer symptoms. Women and health professionals also 
discussed the availability and importance of peer support on decision making about 
RRSO, with most feeling that information from a peer could facilitate decisions.  
HP3: …The other thing I suppose is what no woman has and would like at 
any point in making a decision is to talk to somebody who has already 
had it done… 
 
4.3.7 Relative importance of considerations 
 The relative importance of different factors in the decision making process 
was explored with a ranking exercise during the three focus groups, in which 
participants were asked to collectively arrange factors mentioned during the group 
discussion in order of importance. Results of the ranking exercise are illustrated in 
Figure 4.1. 
 The effects of surgery and specifically the symptoms of surgical menopause 
were discussed in all groups. The groups differed in the importance they attributed 
to these effects; however all felt that they were at least moderately important. The 
second factor that was discussed by all groups was further information and details 
about cancer risk and risks of surgery. One group specified a wish for better 
statistical information. All groups rated the availability of information as one of the 
most important factors for their decision making. Two groups also discussed genetic
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Figure 4.1 - Ranking exercise outcomes from focus groups 
Focus Group 1 
Focus Group 2 
Focus Group 3 
1
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test results and exact risk estimates as important influential factors in their 
deliberations.   
 A range of other factors was discussed, including abnormal findings on 
screening and availability of screening. Interestingly, the former was rated very 
differently by the two groups that considered these. One group felt abnormal 
screening results were the most important factor and would result in consent for 
surgery, while the other group did not rate abnormal findings during screening as 
particularly important. In contrast, both groups felt that availability of screening 
and the associated possibility of knowing if something was wrong was an important 
factor. These two groups also rated the importance of a recommendation from a 
health professional very differently. Again, the first group rated it as very important 
and the second group as less important. The effects of surgery on the family and 
the ability to fulfil familial obligations were seen as moderately important factors by 
two groups. Other considerations discussed by individual groups included others 
being diagnosed with cancer, effects on work, type of surgery and numerous 
others, most of which were of moderate or low importance to group members. 
4.3.8 The preference construction pathway 
 Due to the variety of factors that may influence appraisals and deliberations, 
the preference construction pathway women go through when making decisions 
about RRSO is complex. It may not only depend on the patient’s values and past 
experiences, but also on the medical, psychological and social factors that could 
complicate or facilitate the decision, as highlighted by the current study. Figure 4.2 
shows the preference construction process as it emerged from the data.  
  Once women knew about their increased risk and the option of RRSO, they 
would draw on their own experiences and look at their personal goals to form an 
initial opinion about this option. Some women were able to form a preference and 
make an immediate decision based on these factors alone. Health professionals 
particularly emphasised the role of past experience of cancer in close relatives as a 
reason to undergo surgery to avoid the same fate as their relative.   
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Figure 4.2 - The preference construction pathway during decision making about RRSO 
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HP3: …Some I think have almost made their mind up straight away, 
because mum and gran had it, or sister had it and [they argue]: “I’m 
not going to have that happen to me.” Near experience, that really 
colours it…  
 
HP10: …Often it’s seeing a relative die of the disease […] relatively young 
and I think that memory is something which drives people […]. Mum 
died of ovarian cancer at 51 and they didn’t have a very pleasant 
pathway to their death […]. That can be a very strong motivator 
actually, very strong I found… 
 
Similarly, having been directly affected by cancer and having gone through cancer 
treatment was identified by health professionals as a catalyst for making an 
immediate decision, both for and against surgery.  
HP6: …Having the breast cancer does drive people to want to have surgery 
[…] while for some other people the whole thing of having the breast 
cancer works in the opposite way […] they have been in hospital so 
much that they just don’t want anything for a couple of [years]… 
   
HP9: …Most women if they have had cancer don’t want to go back through 
chemotherapy and the treatment side of things […]. And there are 
some women where actually because of their prognosis from their 
breast cancer, they really want to go ahead and have their ovaries 
out…   
 
Others may be able to make an immediate decision based on their personal 
goals and values, such as wanting to complete their family. In this case RRSO is not 
an option they would consider further until their goal was completed. Therefore, 
they would decide against surgery at the point of first discussion, but may come 
back to the decision later on.  
 In rare cases women may be suffering from hospital phobia. Under these 
circumstances a decision against surgery as a risk-reducing option is likely to be 
made very quickly. One professional’s quote illustrates such a case. 
HP7: …[The patient] was just completely paralytic […] this poor thing was 
just like completely falling apart and everything. […] It was very very 
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extreme. She is definitively not going to have surgery, she is 
definitively not going to come in for an operation... 
 
 However, for many women a decision for or against surgery is not as clear 
cut, and is not made immediately. These women remain undecided for longer 
periods of time and may neither be able to fully commit to surgery nor to 
completely reject surgery. In these cases the deliberation process is prolonged and 
influenced by a range of factors that can act as barriers or facilitators to decision 
making (Table 4.3 and 4.4). 
Table 4.3 - Barriers to decision making about RRSO 
Medical & Physical  Psychological & 
Emotional  
Social context  Other  
Unable to get tested 
for a gene 
Difficulty in adjusting 
to the reality of the 
situation 
Familial and work 
obligations 
Jargon / 
Communication 
problems 
Inability to take HRT Fear of effects of 
surgery / surgical 
menopause 
Discrepancies between 
patient‘s and partner‘s 
preference 
Health professional 
hesitation / differential 
recommendations 
Concerns about 
surgical risks 
Uncertainty about 
goals (e.g. wanting a 
family) 
Competing life events Concerns about 
procedure being 
elective 
 Fear of or uncertainty 
about HRT 
 Problems with follow-
up / GP as gatekeeper 
 Unresolved 
bereavement 
 Gender of health 
professional 
 
Personality 
  
Table 4.4 - Facilitators to decision making about RRSO 
Medical & Physical  Psychological & 
Emotional  
Social context  Other  
Getting a genetic test 
result / precise risk 
estimate 
Personal goal(s) 
reached 
Input from family Availability of 
screening 
Natural menopause 
Reached / completed 
Age at which relative 
developed cancer 
reached 
Input from partner New GP / Review by 
GP 
Possible symptoms 
experienced 
 Salient life event (e.g. 
child graduates) 
Follow-up 
consultation(s) 
Finding on scan  Peer support Personal time plan 
Salient personal health 
event (other than 
cancer) 
 Someone else gets 
cancer 
Physician 
recommendation 
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 Many of the considerations identified by women and health professionals as 
influencing decisions could readily be labelled as barriers or facilitators. For 
instance, fear of the menopause and concerns about HRT emerged as barriers, 
while confirmation of a genetic mutation and physician recommendation appeared 
to act as facilitators. It transpired that a single facilitator may result in a decision, or 
several facilitators may act in synergy to drive preference construction, depending 
on the number of barriers in place. Facilitators may have differing effects for 
different individuals, for instance one woman may be able to make a final decision 
when she receives a positive genetic test result, whereas another might remain 
undecided even after receiving confirmation of a genetic mutation. 
 To illustrate how barriers and facilitators emerged from the data, consider 
the example of one woman who voiced her concerns about an early menopause. 
This was a barrier for her and prevented her from making a clear cut decision for 
surgery. She later stated that reaching the natural menopause would reduce her 
worries about surgery and therefore act as a facilitator; however she added that 
this alone would not trigger a decision for surgery. 
P3S: My main thing would be the menopause […] starting, […] because 
[natural menopause] happens gradually, your body sort of gets used 
to what’s going on, but where you have your ovaries out it literally 
starts straight away, doesn’t it? […] 
 
P3S: I’m waiting for the menopause to happen naturally so that I can think: 
“Oh right, this is it. It’s okay we can go ahead now, I don’t have to 
worry about that bit anymore.” […] 
 
P3S: I think if I had started the menopause then I might find it easier but I 
still think something else would have to happen to push me to have 
surgery. 
 
The interview data from health professionals also confirmed that entering the 
natural menopause was a facilitator which resulted in women re-evaluating 
surgery. 
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HP6: …as they go into the menopause […] then they are like ‘okay’. They 
are re-visiting it [surgery] […] at that point, they kind of consider it 
again. 
 
4.4 Discussion and Conclusions 
4.4.1 Discussion of findings 
 The current chapter identified considerations during decision making about 
RRSO that may be important to women at increased risk of ovarian cancer in the 
UK. A model was also proposed in this chapter of the preference construction 
pathway during deliberations about RRSO, identifying specific barriers and 
facilitators which may play a role in decision making. 
 4.4.1i Medical and physical issues: As previously revealed in the literature 
search (Chapter 3; Howard et al. 2009a), medical and physical issues appeared to 
play an important role in decision making. Women and health professionals in the 
current study discussed genetic testing as an important event that could result in 
more accurate risk estimates on which to base their decision. This is in agreement 
with previous research, which found that confirmation of a genetic mutation 
appears to be a key event in women’s decision making processes (Meijers-Heijboer 
et al. 2003, Phillips et al. 2006, Ray et al. 2005). It should be noted that others have 
not found a positive genetic test result to translate into high uptake of surgery 
(Lerman et al. 2000). However, this finding could be due to the relatively short 
follow-up time of 12 months in this study or may be caused by the lack of additional 
facilitators to trigger a final decision. 
 Health professionals spoke about the differential impact a prior cancer 
diagnosis might have on attitudes to risk-reducing surgery, stating that most 
affected women opt for surgery, while some might decline surgery to avoid 
returning to hospital when they are healthy. Earlier studies have mostly reported a 
positive association between prior cancer diagnosis and decisions to undergo RRSO 
(Beattie et al. 2009, Hamilton et al. 2009, Madalinska et al. 2005, Stuckey et al. 
2010). However, one study did not find such a link (Tiller et al. 2005), which may 
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indicate that a prior cancer diagnosis may influence the decision either way, as 
suggested by health professionals in this study. 
 Ovarian and breast cancer risk reduction were mainly discussed by health 
professionals in the current study. Women did not specifically mention ovarian 
cancer risk reduction; however, previous research has found that women do 
consider this during decision making (Claes et al. 2005, Fry et al. 2001, Hallowell 
1998, Kram et al. 2006). This discrepancy in findings may be due to the fact that 
women in the current study perceived ovarian cancer risk reduction to be the main 
and obvious reason why they might consider RRSO at all and therefore did not think 
to mention it specifically. Most of the previous studies were quantitative and 
provided women with a set of possible answers as part of a questionnaire (Claes et 
al. 2005, Fry et al. 2001, Kram et al. 2006), therefore it cannot be determined 
whether women would have discussed these issues of their own accord. 
Alternatively, women in this study may have experienced a higher number of breast 
cancers in their family and therefore felt that this was their primary concern. The 
women in the current study did discuss breast cancer risk reduction and its 
influence on their decision, similarly to other research (Culver et al. 2011).  
 Surgical menopause and HRT have been established as important 
considerations by earlier research (Brain et al. 2004, Fang et al. 2002, Hallowell 
1998, Ray et al. 2005, Swisher et al. 2001). In agreement with these findings, 
women and health professionals in the current study discussed issues regarding 
surgical menopause and HRT at length, with some women citing this as their main 
concern. 
 Finally, the risks of surgery were also discussed by women and health 
professionals, especially in terms of their short-term effects and potential for 
complications. Women seemed particularly concerned about going into hospital 
whilst healthy and about the potential for hospital infections, which may be due to 
the recent media attention given to this topic. Earlier research has also found that 
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the potential for complications during and after surgery was a consideration 
addressed by women (Brain et al. 2004, Hallowell 1998, Hurley et al. 2001).   
 In contrast to previous studies, participants in the current study specifically 
discussed the impact of screening on decisions about RRSO in detail. This may be 
due to the involvement of women and professionals in the UK FOCS study (Institute 
for Women's Health 2010). Earlier research rarely reported influences of screening 
on decision making about RRSO. This is most likely explained by the lack of an 
ovarian cancer screening programme. Howard et al. (2010c), who noted that 
anxiety, discomfort and abnormal findings during screening may lead women to 
reconsider risk-reducing surgery, refer primarily to breast screening rather than 
ovarian cancer screening. The current study offers an insight into the potential 
effects of an ovarian cancer screening programme on women’s decision making. In 
agreement with others (Brain et al. 2012, Howard et al. 2010c, Lifford et al. 2012), 
participants in this study reported that an abnormal screening result would lead 
women to revisit the surgery decision.  
 4.4.1ii Psychological and emotional issues: Psychological and emotional 
factors also played a role in women’s decision making in this study, confirming the 
findings of the literature search (see Chapter 3; Fang et al. 2005). Perceived cancer 
risk was discussed by health professionals in the current study and others have 
previously noted that women’s perceived risk was associated with decisions to 
undergo or decline surgery (Babb et al. 2002, Brain et al. 2004, Fang et al. 2003, 
Hallowell et al. 2001, Madalinska et al. 2007). Cancer fear, worry and anxiety, which 
are often linked to women’s perceived risk, were discussed by women and health 
professionals. Professionals suggested that high levels of worry, anxiety or fear are 
linked to decisions to undergo surgery. However, despite being worried, women in 
the current study had not yet opted for surgery. In agreement with health 
professionals, earlier research has suggested that fear, worry and anxiety do play a 
role in decision making (Kram et al. 2006, Madalinska et al. 2007, Meiser et al. 
2003, Schwartz et al. 2003). Considering previous evidence and the indecision of 
women in the current study despite their self-reported worry, it could be suggested 
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that worry or anxiety alone are not deciding factors, but that they may act as 
facilitators in combination with other factors. 
 Many of the participants in this study had been involved in the UK FOCS 
study and therefore discussed beliefs regarding the effectiveness of screening. In 
agreement with previous studies, women in the current study reported high levels 
of reassurance from screening despite receiving abnormal screening results (Brain 
et al. 2012). This could be expected, as earlier research had shown that women who 
perceived screening to be effective were more likely to opt for surveillance and 
none of the women in the focus groups had opted for surgery at the time of the 
study (Howard et al. 2011, Madalinska et al. 2007). Health professionals reported 
that women’s beliefs in screening could deter them from making a decision about 
surgery and voiced concerns over the reassurance women gained from screening in 
the absence of proof of efficacy. 
 Women’s fertility, femininity and female identity were discussed by both 
women and health professionals. Professionals emphasised the need for 
consideration of family planning and discussed the questions and concerns women 
voiced in the clinic regarding the effects of the surgery on the body and psyche. 
While women in the focus groups had completed their families and therefore did 
not specifically discuss fertility, they did consider the effects of surgery on their 
body, personality, mood and identity. Earlier research also found that these are 
important considerations in women’s decision making (Babb et al. 2002, Hallowell 
1998, Hallowell et al. 2012).  
 Health professionals discussed a number of further, less frequently 
encountered considerations. These included fear of hospitals, which had also been 
identified as a factor in earlier research (Hallowell et al. 2001, Wagner et al. 2000). 
Two other issues raised in this study - fear of HRT and psychological effects of a 
prior cancer - had not been specifically explored in previous research. However, 
both of these are linked to medical and physical discussions about the menopause, 
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HRT and prior cancer, and may therefore have been included in this context, rather 
than being explored as standalone psychological factors. 
 Earlier studies have highlighted a number of other emotional and 
psychological issues that may play a role in decision making, including coping style 
and self-efficacy (Chapter 3; Mellon et al. 2009). These were not mentioned in the 
current study. However, these are arguably relatively abstract concepts that 
indirectly affect decision making. Therefore, it could be argued that this study’s 
design could not be expected to identify such factors, especially as participants 
were not explicitly asked about self-efficacy and coping during the focus groups. 
 4.4.1iii Social context issues: Participants in the current study explored a 
number of social context factors, namely family history, work and family obligations 
and effects on relationships. Women and health professionals discussed the type of 
cancer women had observed in relatives, which was commonly more than one, and 
how this influenced women’s attitude toward RRSO. From health professionals’ 
comments, it appeared that women’s perceptions of their genetic risk were 
heightened by the emotional, rather than the genetic, bond between relatives; i.e. 
interpretation of their own risk depended on their experience of certain types of 
cancer in emotionally close relatives (Howard et al. 2011).  
 Women mentioned the age at which their relative developed cancer as an 
important time point in their life regarding the decision making. Health 
professionals identified a new cancer diagnosis in the family or a relative opting for 
surgery as facilitators to decision making. This is in agreement with earlier research 
identified in Chapter 3, which found that experience of ovarian and other cancers in 
the family played a role in decision making (Babb et al. 2002, Dagan and Goldblatt 
2009, Hallowell et al. 2001, Metcalfe et al. 2008b, Swisher et al. 2001). Closeness of 
women to the relative who had cancer was not specifically discussed by women in 
the focus groups, but others found that experiencing cancer in a first degree 
relative may influence decision making in favour of surgery (Howard et al. 2011, 
Metcalfe et al. 2008b). 
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 The impact of surgery on work and familial obligations played a major role in 
women’s discussions about RRSO in the current study. Previous research had also 
found this to be an important consideration (Bradbury et al. 2008, Brain et al. 2004, 
Howard et al. 2010c). Health professionals in the current study confirmed that the 
impact on a woman’s day-to-day life was an issue that was explored during decision 
making in clinic. 
 Earlier research also found that the impact of surgery on sexual 
relationships was an issue that women explored (Hallowell 1998). In agreement 
with this, women in the focus groups discussed potential problems that having 
RRSO might cause in their relationship, and health professionals emphasised the 
need to include partners in discussions about surgery. 
 The current study identified major life events as one additional social 
context factor which had not been explored specifically in previous studies. The 
influence of a major event, such as a graduation, wedding or death in the family, 
was perceived by health professionals as a facilitator to decisions. In contrast, 
women mentioned that other life events could reduce the relative importance of 
ovarian cancer worry and therefore lead to delaying the decision. Specifically 
considering other major life events with women when exploring the option of RRSO 
in clinic may be beneficial in clarifying how these may impact on their decision 
making and to work on a specific time plan to fit the decision into a woman’s life. 
 4.4.1iv Demographic factors: Age was the only demographic factor 
specifically mentioned in the current study. It was discussed by women and health 
professionals primarily in the context of pre- and postmenopausal status, as 
postmenopausal women do not enter the menopause after surgery and do not 
need to consider infertility. Therefore the potential negative consequences of 
surgery in older age are reduced, which can make the decision for surgery easier. In 
agreement with this, earlier research has found that older age is frequently linked 
to decisions to undergo RRSO (Brain et al. 2004, Fry et al. 2001, Skytte et al. 2010). 
However, several health professionals mentioned that older patients chose not to 
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opt for surgery and this is in agreement with a previous study by Beattie et al., 
(2009), who found that from age 60 uptake of RRSO decreased. Therefore different 
age groups and associated life stages can influence the decision. 
 Earlier research had found that parity may be linked to RRSO (Schmeler et 
al. 2006b, Stuckey et al. 2010). As the current study was a qualitative study, the 
number of children and its influence on the decision making process for women in 
the focus groups is unknown. However, several women mentioned that they 
wanted to ‘be there’ for their children and family, which may indicate that having 
children does play a role in decision making. 
 Previous quantitative studies have investigated a range of other 
demographic factors, such as marital and employment status, education and 
income. However, none of those was found to be influential in decision making and 
participants in the current study did not explore any of these issues.  
 4.4.1v Other issues: A number of other factors were identified as 
considerations during decision making by women and health professionals. A 
recommendation from a health professional could act as a facilitator to decision 
making, either for or against surgery. Women in the focus groups quoted a whole 
range of recommendations they had received from their care teams and explored 
their reactions to those recommendations, indicating that they do have an effect on 
decision making. In agreement with this, earlier research also highlights the 
influence of physician recommendations, both for and against surgery (Claes et al. 
2005, Fang et al. 2002, Kram et al. 2006). This range of recommendations indicates 
that there is a need for evidence-based, reliable information materials and decision 
support interventions to counteract confusion and facilitate decision making. 
 Women in the current study highlighted the fact that RRSO is an elective 
procedure and voiced concerns about having to actively seek this surgery by taking 
it forward themselves. In earlier research Claes et al. (2005) found that women who 
wanted to avoid surgery when they felt it was not necessary opted for screening, 
which may explain why participants in the current study picked up on the issue of 
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elective surgery. Most of the women in this study had initially opted for screening 
when it was available as part of a trial and therefore are likely to represent the 
population that perceives surgery as an extreme measure. 
 Trust in the medical profession was an issue discussed by participants in the 
current study, yet has received only limited attention in previous research about 
RRSO. Women’s relationships with clinical staff, including their GP, genetic 
counsellor and gynaecologist, were remarked upon both by women themselves and 
by health professionals. Trust (or the lack thereof) may influence decisions either 
way. One professional explained that women who had seen a relative suffer from a 
cancer that had been missed in primary care would be reluctant to trust their GP 
and would want surgery. Women confirmed that trust in their GP and their ability 
to recognise symptoms is important. Women also discussed their trust in the 
expertise of the surgeons at different hospitals and how this might influence their 
decision in terms of where to have surgery. Trust may also be linked to adherence 
to health professional recommendations. The importance of trust has previously 
been shown to be linked to consent and treatment adherence in different medical 
contexts (Davies 1997, De Achaval et al. 2010, Stall et al. 1996), indicating that it is 
likely to play a role in decisions about RRSO as well. 
 As expected, a number of other factors identified in previous studies, such 
as the impact of RRSO on insurance contributions (Hurley et al. 2001) and the 
readiness of the healthcare system (Howard et al. 2010c), did not come up in the 
current study as they are not usually relevant to the UK population. However, some 
UK specific factors were explored in the current study. These included the 
availability of ovarian cancer screening on the NHS and/or privately. Currently, 
there is no routine ovarian cancer screening programme offered in the UK; however 
several areas might offer privately funded screening. Women in the focus groups 
did discuss the end of the screening trial and the potential for obtaining private 
screening, both of which appeared to influence their attitude towards surgery. 
Some women had sought information about private screening, while others had 
reconsidered surgery once the screening stopped. However, none had made a final 
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decision. The current situation regarding screening in the UK is complex, as the UK 
FOCS trial concluded in 2011 and results are not expected until late 2013. In the 
interim period, women who previously received screening were informed that they 
would no longer have this option until evidence emerges regarding its clinical 
effectiveness. However, some women may be able to obtain privately funded 
screening during this period, which could provide false reassurance in the absence 
of proven clinical effectiveness (Brain et al. 2012). Availability and beliefs in 
screening will therefore remain an important consideration in the decision making 
process until clear clinical guidance is available. 
 4.4.1vi Relative importance of considerations: The current study not only 
identified facts that might influence the decision, but explored their relative 
importance to women through a ranking exercise. This revealed that women 
frequently ranked further information, details and statistics about their cancer risk, 
such as a genetic test result, and the effects of surgery, including the menopause 
and HRT, highly, and felt these would help them in making a decision. This is in 
agreement with previous studies, which showed that women wanted reliable 
information about ovarian cancer risk and management options (Babb et al. 2002, 
Hallowell 2000, Klitzman and Chung 2009, Ray et al. 2005, Tiller et al. 2005).  
 In contrast, there was some discrepancy between groups in their rankings of 
‘findings on screens’ and ‘being recommended to have surgery’, with one group 
ranking these very important in their decision making while the other attributed 
low importance to both these factors. This discrepancy may be explained by the 
differential experiences of group members. In the group that ranked both of these 
factors as very important, no one had experienced an abnormal finding on a scan or 
blood test, whereas in the other group two women had been recalled after an 
abnormal finding on a blood test. Both had been cleared and returned to routine 
screening after it was established that the abnormal finding was not ovarian cancer. 
Therefore, these women were aware that an abnormal screening result may not 
necessarily translate into a cancer diagnosis and may have felt less inclined to see 
an abnormal screen as an important factor in their decision. In agreement with the 
137 
 
 
first set of women, who felt a finding on a screen would be important in their 
decision, previous research has shown that women are more likely to consent for 
surgery after an abnormal screening result (Brain et al. 2012, Lifford et al. 2012). 
Therefore, this may be described as a facilitator to the decision. However, as is 
evident in the second group, some women may not opt for surgery despite an 
abnormal finding. Similarly, women in the first group had not received a strong 
recommendation for surgery from a health professional, with one even reporting 
that her GP actively discouraged her. In the group which attributed low importance 
to this factor, at least one member had received strong recommendations from a 
professional and yet still felt reluctant to decide. This demonstrates how differential 
experience can affect what women consider most and least important in their 
decision making. It also highlights the importance of trust between women and 
health professionals. 
 4.4.1vii Preference construction: According to the preference construction 
pathway, which emerged from the data, women may approach the decision in two 
ways. Some decide very quickly based on their past experiences and personal goals 
(immediate deciders), while others decide more slowly due to a number of barriers, 
which may lead to delay (delayed deciders). The first approach may resemble fast 
and frugal decision making based on heuristics, while the second may describe 
more deliberative decision making, following vigilant information seeking and a 
differentiation and consolidation approach (Gigerenzer and Goldstein 1996, 
Goldstein and Gigerenzer 2009, Janis and Mann 1976, Svenson 1992). During both 
these approaches, decision makers must appraise their risk and their options in 
order to construct a preference, whilst also regulating their emotional responses 
and appraising the coping resources at their disposal (Chapter 1; Lazarus and 
Folkman 1984, Power et al. 2011, Witt et al. 2012). For immediate deciders, this 
appraisal process may be fast and frugal, in accordance with heuristics (Gigerenzer 
and Goldstein 1996, Goldstein and Gigerenzer 2009). For delayed deciders, it may 
be slow and deliberative in accordance with the conflict model of decision making, 
differentiation and consolidation theory and a monitoring coping style (Janis and 
138 
 
 
Mann 1976, Miller 1987, Miller et al. 1988, Svenson 1992). The Coping in 
Deliberation (CODE) framework proposes a number of questions that decision 
makers may ask whilst going through the appraisal processes (Chapter 1; Witt et al. 
2012). Using the considerations identified in the current study, along with the 
findings from the literature search (Chapter 3), adapting this framework may be 
useful in describing in detail the appraisal processes women go through when 
making decisions about RRSO (see Chapter 5). 
4.4.2 Results in context 
 Overall, findings of the current study mapped well onto the results of 
previous research investigating women’s appraisals of, and deliberations about, 
RRSO. However, a number of issues that were discussed at length among women 
who took part in the current study had rarely been explored in earlier research. 
Factors women may consider during decision making about RRSO depend on the 
local healthcare system and availability of options, may be influenced by cultural 
norms, may change over time and are likely to be influenced by current scientific 
developments and media reports.  
 The current study was conducted at a point in time at which a national 
ovarian cancer screening study for women at increased risk of ovarian cancer had 
just come to an end (Institute for Women's Health 2010). Consequently, many 
women in the study had participated in screening and were now faced with a 
situation where this option was no longer freely available. Therefore, belief in 
screening and the availability of screening was discussed at length by women in this 
study. Women who had participated in the ovarian cancer screening trial may 
arguably constitute a somewhat unusual population that has experienced screening 
in the past and is no longer offered it currently, although this may change once the 
results of the trial are available. In the absence of medical proof, women can now 
opt for private screening. This does however have cost implications. Alternatively, 
they can decide to have surgery or simply do nothing. Women who have 
experienced screening in the past may be more likely to opt for private screening to 
139 
 
 
achieve the same reassurance they experienced during the trial and may be less 
likely to opt for surgery because of this reassurance (Brain et al. 2012). However, it 
should be noted that health professionals provided anecdotal evidence of higher 
rates of uptake of surgery after the screening trial had stopped, indicating that 
some women do opt for surgery once they are faced with a decision of whether to 
have surgery, do nothing or pay for private screening. 
 Women in the current study voiced concerns about the risks of surgery, 
specifically the risks of hospital infections. In recent years there has been an 
increase on media reports of hospital infections, with a focus on pathogens such as 
methicillin resistant Staphylococcus Aureus and Claustridium difficile, that could 
influence public opinion of UK hospitals (Boyce et al. 2009). This could have 
resulted in women perceiving the risks of surgery and hospital infections to be 
relatively high during this study, which could partially explain women’s reluctance 
to opt for surgery. The incidence of hospital infections in the UK is decreasing 
(Health Protection Agency 2012); however the way media report on these types of 
infections may contribute to a sustained high perception of these risks, which in 
turn influences decision making about surgery. 
Another media driven issue seen in the current study was that of women’s 
concerns about the link between HRT and breast cancer, which had been widely 
reported in the media (Beral and Collaborators 2003). Additionally, the discussions 
with health professionals revealed that there is mounting confusion regarding the 
safety of HRT post-RRSO in women at risk of breast cancer and women who had 
breast cancer, even among health professionals. Few research studies to date have 
studied these groups specifically and more data are needed to make firm 
recommendations regarding the use of HRT in these patients. However, some 
studies have been published which confirm that short-term use of HRT up to the 
age of natural menopause in patients who have not had breast cancer themselves 
appears to be safe. These studies suggest that, given the long-term health effects of 
oestrogen deprivation, HRT should be recommended to patients who have surgery 
before the age of 45 (Eisen et al. 2005, Rebbeck et al. 2005). Furthermore, the study 
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linking HRT to breast cancer risk has now also been widely criticised (Shapiro et al. 
2011a, b, Shapiro et al. 2011c, Shapiro et al. 2012). However, attitudes towards HRT 
remain cautious.  
As the above discussion has shown, issues raised by both women and health 
professionals in this study need to be considered in the context of current 
developments. They may be subject to change as new evidence becomes available. 
However, the salient issues frequently discussed by women and health 
professionals in the current study relating to cancer risk, the menopause, HRT and 
ovarian screening are likely to remain important, even as evidence changes. 
Information provided to women by health professionals and/or through decision 
support materials regarding these issues will need to be updated on a regular basis 
to ensure women can base their decisions on the latest evidence. Furthermore, 
psychological factors (e.g. cancer worry), social factors (e.g. family history and 
obligations) and other factors (e.g. physician recommendations) are likely to play a 
role in decision making regardless of research developments. Therefore the results 
of this study provide a valuable insight into issues considered during decision 
making about RRSO despite the fact that some of those issues may shift in their 
relative importance or underlying information content. 
4.4.3 Strengths and limitations 
 The current study combined the use of interviews with health professionals 
and focus groups with women at risk of ovarian cancer. This approach allows for a 
comprehensive and, at the same time, in-depth analysis of the decision making 
process. Women in the focus groups explored their personal situation and decision 
making in detail, providing the researcher with an in-depth understanding of 
individual’s decision making. In contrast, health professionals drew on their 
experience of supporting a number of women to make decisions about RRSO, 
allowing the researcher to obtain a relatively comprehensive overview of issues 
that may be considered by women. This also enabled the researcher to distinguish 
common, salient issues mentioned by several health professionals and by women in 
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focus groups, from rarer considerations, which only played a role in a minority of 
women’s decision making. A thorough understanding of both types of 
considerations may be important when developing patient decision support 
designed to cater for all women. Additionally, considerations which were explored 
by several members of the focus groups were confirmed as salient issues in 
interviews. This validates the conclusions drawn about the most important 
considerations. 
 Unsurprisingly, many considerations were discussed by health professionals, 
but not women themselves. These included prior cancer, perceived risk and 
fertility. There are several possible explanations for this. The first is that women in 
the focus groups had not experienced a certain issue, such as a diagnosis of breast 
cancer, or that a certain consideration was no longer relevant to them, such as 
completion of family. Hence, these were not considerations which played a role in 
their decision making. This may indicate that due to the low response rate to focus 
group invitations, women in the current study were not representative of the range 
of women who may face decisions about RRSO. However, it should be noted that 
representativeness is not a goal of qualitative research. Another reason for the lack 
of discussion of seemingly salient considerations by focus group participants may 
be that they assumed an issue to be obvious or self-evident. For example, ovarian 
cancer risk reduction was not mentioned specifically in focus groups as a 
consideration. However, it may have been interpreted by women as the main 
reason why they would consider surgery in the first place, therefore not warranting 
specific discussion (see Chapter 3). Alternatively, women may have been reluctant 
to discuss ovarian cancer risk reduction, as this issue may have been too 
emotionally charged. However, this is unlikely as women discussed various other 
emotional topics during the focus groups. As the topic guide for focus groups was 
designed to let participants explore issues freely and of their own accord, the lack 
of discussion of some seemingly salient considerations may also be due to the lack 
of prompting by the facilitator to draw out such issues. The final explanation may 
be a lack of awareness of the role of emotional or psychological factors. For 
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instance ‘perceived cancer risk’, which was mentioned by several professionals, was 
not discussed in focus groups. This may be due to the nature of ‘perceived’ risk 
being perceived by the individual as actual or objective risk. The fact that women 
did not mention ‘perceived’ risk may simply imply that they discussed this as their 
actual risk. 
It may be argued that this lack of discussion of several issues highlights the 
limitations of focus groups with affected individuals, as their contributions are 
limited by their own personal circumstances and experiences. However, for this 
reason the current study included interviews with health professionals to 
complement the focus group data and to present a more holistic view of the 
decision making process. 
 Despite the inclusion of a range of health professionals from different areas 
and specialities in this study, additional professional groups, who were not 
included, could have made valuable contributions to this study. For example, GPs 
and their view of the decision making process regarding RRSO may have been an 
interesting group whose views are not included in the current study. Given 
women’s comments about recommendations received from GPs, and the 
importance of trust between patients and their GPs, this appears to be a group that 
should be considered in future research. However, including all professional groups 
that were potentially relevant to this study was beyond the scope of the current 
research.  
 One further limitation should be noted. While the moderator was the same 
in all the focus groups, different individuals were fulfilling the task of moderator 
aid. During the initial discussion of decision making, the moderator aid was required 
to make notes of the points discussed by participants, which were then used as 
prompts in the ranking exercise. As moderator aids changed, it cannot be assumed 
that the same points were picked up consistently between groups, which may 
reduce comparability of the ranking exercise outcomes. However, the moderator 
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(Jana Witt) was present at each group to ensure that the salient and most 
frequently mentioned points were picked up and included in the ranking exercise.  
4.4.4 Conclusions 
 This chapter explored decision making about RRSO in a UK context, 
postulated a model of preference construction and identified barriers and 
facilitators to decision making. In agreement with other research (see Chapter 3), 
the range of issues considered by women in the UK was large and varied depending 
on personal experiences and goals. Women reported a variety of recommendations 
given to them by different health professionals, which resulted in confusion about 
which option was best. Taken together with the fact that both women and health 
professionals felt that more information and details on various issues would be 
helpful in making a decision, this provides evidence that there is a place for decision 
support materials targeting women at increased risk of ovarian cancer in the UK 
who are making decisions about RRSO. 
 Using the issues highlighted by women and health professionals in this 
chapter, together with the results of the literature search (Chapter 3), the CODE 
framework will now be adapted to specifically describe the deliberation and coping 
processes relating to RRSO decisions in women at increased risk of ovarian cancer in 
the UK (see Chapter 5). This adapted framework will then act as a theoretical basis 
for the development of the content of a patient decision support intervention 
(Chapter 7). The model of preference construction, which emerged from the data, 
distinguishes two approaches to deliberations: a heuristic approach leading to an 
immediate or quick decision, and a deliberative approach leading to a more 
protracted decision. This suggests that a two part intervention, which has the ability 
to support heuristic as well as more deliberative decision making, may be most 
effective in ensuring that both groups of decision makers reach an informed 
decision. The development of such an intervention is described in Chapter 7. 
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5 Adapting the CODE framework: Decisions about risk-reducing 
bilateral salpingo-oophorectomy 
5.1 Introduction 
 Preference-sensitive medical decisions in situations of equipoise, when no 
medical treatment is clearly indicated or when treatments bear substantial risks, 
require the patient to play an active role in the decision making process. The 
preliminary Coping in Deliberation (CODE) framework attempts to describe 
deliberation and coping processes in such preference-sensitive situations from a 
patient perspective (Chapter 2; Witt et al. 2012). The framework was developed to 
be applicable to various situations and its flexibility allows adaptation to a number 
of different healthcare decisions. An example of a preference-sensitive medical 
decision is that of electing risk-reducing salpingo-oophorectomy (RRSO) to reduce 
ovarian cancer risk in women with a substantial family history and/or genetic 
mutation predisposing them to this cancer. As explained in Chapters 1 and 4, 
screening for ovarian cancer is not routinely available in the UK, as effectiveness has 
not been established (Menon and Jacobs 2002, Rosenthal et al. 2013a, Rosenthal 
and Jacobs 2006). Therefore, the only clinically recommended management option 
for women at increased risk of ovarian cancer is RRSO. As discussed in Chapters 3 
and 4, the decision of whether and when to undergo surgery is complex and may be 
influenced by a number of internal and external factors. Thus, deliberation and 
coping processes undergone by women when making decisions about RRSO may be 
described using the CODE framework (Witt et al. 2012). 
 Following the recommendations for adaptation of the CODE framework 
outlined in Chapter 2 (Figure 2.5), the aims of this chapter are (i) to adapt the 
generic version of the CODE framework to specifically describe decisions about 
RRSO using findings from Chapters 3 and 4, and (ii) to map the adapted framework 
against a retrospective report of a decision about RRSO. Figure 5.1 outlines the 
framework adaptation process for RRSO decisions. 
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Figure 5.1 - Process of adapting the CODE framework to decisions about risk-reducing bilateral salpingo-oophorectomy in the context of genetic risk 
1
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5.2 Methods 
5.2.1 Data from literature search, focus groups and interviews 
 The framework adaptation presented in this chapter is based on data 
presented in Chapters 3 and 4. Search strategy and inclusion/exclusion criteria for 
the systematic literature search were outlined in detail in Chapter 3 (see section 
3.2). Factors important during decision making identified using this search strategy 
were also discussed in depth in Chapter 3 (see section 3.3). Similarly, recruitment to 
focus groups and interviews, and analysis of data collected, was described in detail 
in Chapter 4 (see section 4.2). The resulting themes and subthemes were also 
discussed in Chapter 4 (see section 4.3.2-6).  
5.2.2 Framework adaptation 
 Items within the original CODE framework (Chapter 2) are generic and 
widely applicable. Items within adapted versions need to have a narrower, more 
defined focus in order to be relevant to the specific health threat and decision. The 
issues considered by women going through deliberations about RRSO in general 
(Chapter 3), and in the UK in particular (Chapter 4), were used to inform the 
adaptation of the preliminary CODE framework. The items within the framework 
were modified to specifically reflect issues that had been identified during the 
literature review and analysis of focus group and interview data. Additional items 
were added if they were supported by data and helped to portray appraisal 
processes in further detail. For instance, data indicated that, during primary 
appraisal of risk, women explore the reasons for their increased risk, especially with 
regards to their family history. Therefore, the generic question ‘What caused this?’ 
was adapted to: ‘What caused me to have an increased risk of ovarian cancer?’ and 
‘How does my family history influence my ovarian cancer risk?’. Any references to 
specific information or support needs made by women were also integrated into 
the items outlined in the appraisal sections of the framework. For example, women 
felt that evidence-based information and speaking to peers would be beneficial as 
potential coping resources. This was integrated into secondary appraisal sections in 
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the adapted framework by adding questions about the availability of further 
information and peer support. Some items within the generic framework did not 
appear relevant in the context of the RRSO decision after data analysis and were 
therefore not incorporated in the adapted version. 
5.2.3 Face validation 
 The adapted CODE framework was mapped against an interview with one 
woman who had opted for RRSO with hysterectomy and retrospectively explored 
her decision. She was recruited through the Cancer Genetics Service for Wales in 
Cardiff by invitation from her genetic counsellor. Full written consent was obtained 
on the day of the interview. During the interview the woman explored in detail her 
decision making regarding risk-reducing surgery, including the coping resources she 
had used and the information she had gathered before her final decision. The 
interview schedule is included in Appendix 5.1. The interview began as a narrative 
interview with an open question regarding her decision making pathway (Friesen 
2010, Kvale 1996). Prompts were available to the interviewer if required; however 
the woman was left to tell her story relatively freely. Towards the end of the 
interview a semi-structured approach was taken to discuss her needs for, and views 
of, decision support for women in her situation. The CODE framework was not used 
to guide the interview, as the patient was encouraged to explore her experience 
freely to minimise the influence of the research framework on her account. The 
RRSO-adapted CODE framework was then applied during analysis. 
5.2.4 Data analysis 
 The interview was audio-recorded, transcribed and analysed thematically 
using a coding frame based on the adapted CODE framework (Appendix 5.2; 
Boyatzis 1998, Braun and Clarke 2006, Joffe and Yardley 2004). In this way, the 
adapted CODE framework was mapped against the experience of the patient to 
examine whether it adequately described the questions and coping options 
explored by the patient during her appraisal and deliberation process. A sample of 
the coded transcript is included in Appendix 5.3. 
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5.3 Results 
5.3.1 Mapping of the RRSO decision onto the CODE framework 
 The CODE framework describes specific events associated with the process 
of preference-sensitive decision making as ‘deliberation phases’. It further proposes 
that each phase gives rise to a primary and secondary appraisal process and coping 
response. Patients at risk of ovarian cancer may experience several potentially 
stressful ‘events’ or go through potentially stressful ‘phases’ while deciding how to 
manage their risk of ovarian cancer. These can be mapped onto the deliberation 
phases delineated in the CODE framework. Figure 5.2 summarises how the phases 
in the generic framework can be adapted to decisions about RRSO. 
Figure 5.2 - Deliberation phases in the generic and adapted CODE framework 
 
 The first event of interest when considering preference-sensitive decision 
making is the health threat, in this case the disclosure of an elevated risk of ovarian 
cancer to the patient. Cancer risk may be appraised as a threat, as it has the 
potential to result in significant future loss or harm (Lazarus and Folkman 1984). 
The perceived level of threat depends on the patient’s past experiences, goals and 
values. For instance, someone who cared for a relative suffering from ovarian 
cancer and witnessed them dying of the disease may conceive their own risk as a 
high level threat, whereas a woman who only knows of a distant relative who 
recovered from ovarian cancer might view it as a lower level threat (Dagan and 
Goldblatt 2009, Howard et al. 2011). Depending on the perceived level of threat, 
the patient may differentially appraise the coping resources needed to manage 
their ovarian cancer risk. 
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 A further event in the deliberation process is the presentation of choice, 
which may be appraised as a threat or challenge, depending on the woman’s 
experiences, values, level of health literacy and perception of control or self-efficacy 
(Bandura 1977, Lazarus and Folkman 1984). For example, someone who has high 
self-efficacy and believes in their ability to make good decisions might appraise the 
fact that they are being asked to play an active role in decision making as a 
challenge. In contrast, someone with low self-efficacy, who feels they have 
insufficient medical knowledge to make this decision, might appraise being asked to 
contribute to a decision about their health as a threat. Preferences for involvement 
in decision making will vary accordingly. Coping resources will again vary depending 
on whether choice is appraised as a threat or challenge (Lazarus and Folkman 1984). 
 The options available in case of increased genetic risk of ovarian cancer are 
RRSO and symptom awareness, as screening is currently not recommended. The 
presentation of these options may also be distinguished as a specific ‘event’ or 
phase in the deliberation process in which the patient is required to appraise each 
option in turn, including its risks and benefits, as well as the potential impact on her 
life. Options themselves may be appraised as threats. For example, RRSO bears the 
potential for future loss or harm due to surgical risks as well as the lack of oestrogen 
following surgery. Similarly, rejecting or deferring surgery means that cancer risk 
remains high, potentially resulting in future loss or harm in the form of ovarian 
cancer. Some of the individual outcomes of RRSO are very complex and may be 
appraised as threats in their own right, such as surgical menopause and the 
subsequent need for hormone replacement. 
 Preference construction is an essential phase in every deliberation process. 
At this point the patient differentiates one option as superior to the other(s) and 
begins to form a preference, which may later translate into a decision (Svenson 
1992). At this point the potential option will be mapped onto personal and 
important others’ goals and values, further details of the preferred option will be 
explored and timing considered. This phase may be perceived as threatening, as the 
decision maker is nearing a final decision and has to face losing the freedom of 
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making a different choice, particularly if the preferred option is irreversible. Once 
preference construction is complete, a decision for or against RRSO is made and 
may be consolidated (Svenson 1992). 
 Overall, the events occurring during consultations about increased genetic 
risk of ovarian cancer and associated clinical management options can readily be 
mapped onto the deliberation phases in the preliminary CODE framework (see 
Figure 2.4, Chapter 2). Therefore, the questions within the generic framework can 
subsequently be adapted to represent questions specific to the RRSO context 
arising in response to each phase or event during deliberations about this surgery. 
5.3.2 The threat - adapting primary appraisal content 
 Primary appraisal describes the process of cognitively and emotionally 
appraising an event’s meaning, relevance and level of threat (see section 2.4.2 
Chapter 2; Lazarus and Folkman 1984). According to Leventhal’s (1980) self-
regulatory model of illness representations, cognitive appraisal explores the identity 
of the threat, its causes, timeline, consequences and opportunities for control 
(Diefenbach and Leventhal 1996, Lau et al. 1989, Leventhal et al. 1984, Weinman et 
al. 1996). In other words, during primary appraisal individuals examine what the 
threat is, what it means to them, what caused it, how long it will last and how it 
might change over time, what consequences they are likely to experience (including 
the potential severity of such consequences and impact on all aspects of life) and 
whether and how they might be able to control the threat (Weinman et al. 1996). 
Questions regarding possibilities for control might initiate secondary appraisal of 
coping resources available to manage the threat (see section 5.3.3).  
 Emotional appraisal is guided by anticipatory and anticipated emotions 
induced by the threat and can influence cognitive appraisal processes (Loewenstein 
et al. 2001, Power et al. 2011). Anticipatory emotions are those emotions 
experienced in response to the threat itself, whereas anticipated emotions are 
those which the decision maker predicts they will experience if certain future 
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events linked to the threat occur. Both types of emotions may be based on past 
experiences and beliefs, such as perceived self-efficacy. 
 As discussed in section 5.3.1, there are four potentially stressful ‘events’ 
which require appraisal by patients during deliberations about RRSO: disclosure of 
ovarian cancer risk status, presentation of choice, presentation of options and 
preference construction. Below, each of these phases is considered in turn and the 
considerations important during the phase, as they emerged from the data 
presented in Chapters 3 and 4, are expressed in the form of questions. 
 5.3.2i Disclosure of ovarian cancer risk status: The first phase is comprised of 
a discussion about the patient’s ovarian cancer risk, which is influenced by her 
family history and genetic status. Figure 5.3 depicts the specific questions a patient 
might explore in response to being told she is at increased risk of ovarian cancer. 
Figure 5.3 - Considerations during primary appraisal of increased genetic ovarian cancer risk 
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The identity of ovarian cancer and ovarian cancer risk may be explored by patients 
using their own ideas about the label ‘ovarian cancer’ and the nature of this 
disease, as well as information provided by the health professional and acquired 
elsewhere (Sivell et al. 2008). Risk is an abstract concept, which again will be 
appraised using the patient’s view of what risk is and any information provided in 
consultations (Kelly et al. 2005). The clinical level of risk (average or ‘population’, 
moderate or high) will play a role in the appraisal process and perceived level of risk 
may be influenced by personal beliefs, experiences and external influences (Kelly et 
al. 2005, Lancastle et al. 2011). For instance, as found in the literature search and in 
focus groups and interviews, a previous cancer diagnosis or having witnessed 
ovarian cancer in a close relative were identified as important factors in the decision 
and may influence how patients perceive their own risk during primary appraisal 
(Babb et al. 2002, Dagan and Goldblatt 2009, Hallowell et al. 2001, Hamilton et al. 
2009, Stuckey et al. 2010).  
 The causes of the increased risk may be explored in terms of the patient’s 
family history and potential genetic mutation. Patients may also consider lifestyle or 
environmental factors that could influence their risk. This exploration of ovarian 
cancer risk was evident in the focus groups and interviews, as health professionals 
and women emphasised the importance of exact risk estimates, ideally with 
confirmation of a genetic mutation. Evidence from the literature search also 
confirmed the importance of information about gene mutation status during 
deliberations (Antill et al. 2006, Culver et al. 2011, Kram et al. 2006, Madalinska et 
al. 2005, Schwartz et al. 2003, Uyei et al. 2006, Verhoeven et al. 2011). Some 
patients in the focus groups felt that, if their increased risk was due to a genetic 
mutation, then they would be able to make a clear cut decision, as this would 
change their appraisal of their risk. Previous research, and health professionals in 
this study, found that a patient’s interpretation or perception of their risk may 
influence decisions. This indicates that patients may base their appraisal of risk on 
past experiences and beliefs, rather than objective estimates (Finch et al. 2009, 
Lerman et al. 1995). Beliefs about ovarian cancer and perceived levels of risk may 
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result in emotions, such as worry and anxiety, as part of the emotional appraisal 
process (Culver et al. 2011, Howard et al. 2011, Lancastle et al. 2011). 
 Patients may explore the timeline and consequences of their cancer risk, for 
example how their risk might change over time and how their risk will affect their 
own and their offspring’s life (MacDonald et al. 2010). Health professionals involved 
in RRSO decisions stressed that women younger than 35 were at a relatively low risk 
and should not have surgery at this age; however as age increases, so does the 
cancer risk, and therefore professionals emphasised the importance of considering 
RRSO around age 40-45. In the focus groups women discussed the effects that the 
knowledge of their risk status has had on their life and described the lack of 
understanding from people in their surroundings. Women were also concerned 
about the effects of their own risk status on their children, both in terms of the 
possibility that they may develop cancer and no longer be able to fulfil their 
parental role, as well as in terms of the children’s cancer risk. Evidence from the 
literature search indicated that parity may be associated with higher uptake of 
RRSO, which could be due to women’s desire to be there for their children in the 
future (Skytte et al. 2010). Emotional appraisal of the cancer threat will depend on 
the patient’s knowledge about, and past experiences of, ovarian cancer. Finally, 
during primary appraisal of cancer risk, women may also ask what they can do to 
reduce their risk, and this will prompt a discussion of choice and options. 
 5.3.2ii Presentation of choice: The health professional will introduce the idea 
that there is more than one option and may initiate a discussion about choice. 
Figure 5.4 delineates the questions a patient might explore in the context of 
increased ovarian cancer risk when faced with the fact that there is a choice and 
that they are being asked to play an active role in decision making. The identity of 
the choice, i.e. the meaning of ‘choice’ in the context of increased genetic risk of 
ovarian cancer, is determined by what the woman understands by the term ‘choice’ 
and by the number and characteristics of options available. Some women might 
view this decision as relatively simple and immediately prefer one option over the 
other, as was mentioned by health professionals, who spoke about women being 
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able to make a clear cut decision almost immediately due to a prior cancer 
diagnosis, past experiences of ovarian cancer or hospital phobia (Chapter 4). For 
these women a detailed appraisal of the choice may not be necessary.  
Others may struggle more with the concept of choice in this context and find 
it difficult to settle for one option. This was illustrated by women in the focus 
groups, who had not been able to make a decision due to a number of barriers. For 
these women detailed appraisal of the choice may be necessary in order to prepare 
for decision making. They may want to know the cause for the choice, i.e. why there 
is no clear medical recommendation. They may explore the timeline of the choice to 
determine at what point in time a decision should or could be made (Howard et al. 
2010c). Additionally, they may explore the possibilities for control over the choice 
by considering who (apart from themselves) could make or be involved in the 
choice, whether the choice is reversible or not and how they should approach this 
choice. 
Figure 5.4 - Considerations during primary appraisal of the choice 
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Furthermore, women may want to explore the potential consequences of making a 
choice and the effects those will have on their lives, such as the loss of fertility 
following RRSO. This will prompt a discussion of the available options and their 
attributes. Emotionally, the availability of choice may instil anticipatory emotions, 
such as anxiety about having to make a difficult decision, as well as anticipated 
emotions, such as an anticipated feeling of regret if one makes the wrong decision.  
 Considerations that play into how choice is appraised in this context include 
a woman’s trust in the medical profession and recommendations by clinical staff. As 
discussed by women and health professionals, trust was an issue during decision 
making and may therefore also influence how women view the choice and their role 
in it. Similarly, recommendations from clinical staff, especially those who are 
strongly favouring one option, may also influence appraisal of choice; in the 
presence of a strong recommendation, choice may no longer seem relevant (Claes 
et al. 2005, Fang et al. 2002, Kram et al. 2006, Swisher et al. 2001). 
 5.3.2iii Presentation of options: The appraisal of options is very complex and 
therefore may be split into a number of sub-phases for each option. In the context 
of increased genetic risk of ovarian cancer, the options are RRSO and ‘symptom 
awareness’. During the appraisal of RRSO, the decision maker may additionally need 
to cognitively appraise the possibility of an early menopause and of whether or not 
to take hormone replacement. Therefore the primary appraisal processes for the 
presentation of options phase presented below are split according to these 
different considerations. 
 The surgery itself may be appraised as a threat due to surgical risks and the 
impact it has on a patient’s life. Figure 5.5 details questions that may be explored 
during primary appraisal of the surgery option. The identity of RRSO may be 
explored in terms of what this surgery is and what it involves. The cause 
necessitating RRSO would be the woman’s increased risk of ovarian cancer; 
therefore there is no detailed exploration of the cause within the presentation of 
options phase. Women in the focus groups discussed RRSO as being ‘elective 
surgery’ and found it difficult to make the conscious choice for surgery when they  
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Figure 5.5 - Considerations during primary appraisal of risk-reducing ovarian surgery 
 
were feeling healthy and well, appraising this as an extreme step. Health 
professionals emphasised that it is a major surgery and has a number of risks. 
 The timeline for RRSO may be explored in terms of its disruptive impact on 
the patient’s life. Women in the focus groups discussed how surgery might affect 
familial or work obligations, such as going on the school run or carrying out one’s 
job. Various such obligations may impact on women’s appraisal of RRSO as a viable 
option (Bradbury et al. 2008, Brain et al. 2004, Howard et al. 2010c). Further, a 
detailed exploration of the consequences of surgery is necessary to fully appraise 
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this option. In this context women may explore the risks and benefits of RRSO, 
possible complications, after effects and impact on their life. Women in the focus 
groups discussed surgical risks, particularly the likelihood of hospital infection, as 
well as the impact surgery may have on their family and/or career. Evidence from 
the literature search also highlighted risks of surgery as an important consideration 
(Brain et al. 2004, Fang et al. 2003, Hallowell 1998, Hurley et al. 2001). Furthermore, 
women may also discuss the possibility of, or need for, a hysterectomy with RRSO 
and may explore the likelihood of a cancer diagnosis during surgery, as was 
mentioned by health professionals. 
 In terms of possibilities for control, women may explore the scope for 
influencing where the operation takes place, i.e. a local versus specialist hospital 
unit, and linked to this, the surgeon’s expertise, in order to reduce the risks of 
surgical complications and hospital infections. This was evident in women’s 
discussions regarding possible locations for surgery and reputation of different 
hospitals and surgeons during focus groups. Women may also seek to find out how 
others, who have already made a decision, fared, in order to adjust their own 
appraisal of what to expect from RRSO, which was evident from enquiries about 
and discussions of peer-support.  
 Finally, RRSO will also be appraised emotionally based on past experiences, 
personal goals and values. Women may have relatives or friends who have 
previously had good or bad experiences of RRSO that could influence the woman’s 
own emotional appraisal. For instance, someone who has seen a relative struggle to 
adjust after surgery might be more fearful than someone whose relative had a very 
good surgical experience and strongly recommends RRSO. Someone with hospital 
phobia may react with extreme anxiety in response to learning about RRSO, 
whereas someone who is very scared of cancer might react with relief when the 
option of RRSO is presented. Emotional appraisal will also include exploration of 
how one feels about the short- and long-term consequences of RRSO, such as the 
surgical menopause and the option of HRT, if appropriate. 
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 For women who are considering RRSO before the age of the natural 
menopause, oestrogen deprivation following surgery is a major concern, as was 
clear from data obtained in the literature search, interviews and focus groups (Brain 
et al. 2004, Fang et al. 2002, Hallowell 1998, Ray et al. 2005, Swisher et al. 2001). 
Therefore, appraisal of surgical menopause, as part of the consequences of RRSO, 
may result in a number of questions (Figure 5.6). The identity, causes and timeline 
of a surgical menopause may be explored to understand what a surgical menopause 
is, why RRSO will result in a menopause and how long it would be expected to affect 
one’s life. Women in the focus groups were especially concerned about the 
consequences of a surgical menopause, its potential effects on their body and their 
mental state in both the short- and long-term. Health professionals confirmed that 
the menopause was a major concern for most premenopausal women and an 
important consideration in terms of bone and cardiovascular health. 
 
Figure 5.6 - Considerations during cognitive appraisal of surgical menopause* 
 
*As appraisal of the surgical menopause is part of the appraisal of RSSO and its outcomes, 
emotional appraisal processes have not been outlined here, as these form part of the 
appraisal of the RRSO option 
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 Possibilities for controlling the effects of a surgical menopause may also be 
explored during appraisal and may depend on perceived self-efficacy, i.e. the belief 
that one can cope with these effects, and coping resources. Options for control that 
might be considered include psychological and medical interventions, primarily 
hormone replacement therapy (HRT). Similar to the surgical menopause, 
deliberations about HRT are complex and therefore may also result in a number of 
more detailed questions (Figure 5.7). Evidence from the literature search also 
highlighted questions and concerns about HRT as a major consideration during 
deliberations about RRSO (Fang et al. 2002, Hallowell et al. 2001, Swisher et al. 
2001). Women may explore what HRT is and who would be eligible to take it, 
especially with a view to their own family history of breast cancer. Women in the 
focus groups voiced concerns about the potential for HRT to increase breast cancer 
risk which had been reported in the media. Women might also explore why HRT is 
recommended for premenopausal women and how long they would have to take it.  
Figure 5.7 - Considerations during cognitive appraisal of hormone replacement therapy* 
 
*As appraisal of HRT is part of the appraisal of RSSO and its outcomes, emotional appraisal 
processes have not been outlined here, as these form part of the appraisal of the RRSO option 
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In terms of the consequences, women may explore the risks and benefits of HRT 
and its potential to counteract and control the symptoms and long-term health 
consequences of a surgical menopause. As there are different types of HRT, women 
may also consider what method of delivery best suits their needs and whether they 
can influence the type of HRT and potentially the length of treatment they receive. 
Women in the focus groups were also keen to discuss alternatives to HRT, which 
they could administer themselves, therefore exploring options of controlling 
menopausal symptoms without HRT.  
 Finally, the second available option for women at increased genetic risk of 
ovarian cancer is to reject RRSO and become aware of the symptoms of ovarian 
cancer. This alternative also requires an appraisal process (Figure 5.8). Women may 
first explore what the alternatives to surgery are and upon being informed that the 
only clinically recommended alternative is symptom awareness, they may then 
consider this option in more detail, including looking into why this is the only 
alternative, what might happen if they rejected surgery and whether there might be  
Figure 5.8 - Considerations during primary appraisal of alternatives to RRSO 
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anything else they could do. Women in the focus groups discussed the possibility of 
privately funded screening and considered whether this might be an option. Health 
professionals also noted that women frequently enquired about screening and 
other alternatives to surgery. Evidence from the literature search also showed that 
belief in, and availability of, alternatives to RRSO were important considerations 
(Brain et al. 2004, Fang et al. 2002, Howard et al. 2011, Madalinska et al. 2007).  
 Similar to emotional appraisal of RRSO, the emotional appraisal of symptom 
awareness depends on past experiences, the patient’s knowledge of symptoms of 
ovarian cancer and self-efficacy beliefs regarding the ability to detect those 
symptoms (Brain et al. 2004, Fang et al. 2002).  
 5.3.2iv Preference Construction: The final phase before decision 
determination is not readily split into the five aspects of cognitive appraisal 
suggested by Leventhal et al. (1980). However, during this phase patients explore 
important questions regarding timing and value-adjustment, before making a final 
choice. Questions which may be explored in this phase are suggested in Figure 5.9. 
Figure 5.9 - Considerations during primary appraisal of the preferred option 
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 Considerations which might impact on the appraisal of timing during 
preference construction include major life events, age and work, as well as familial, 
commitments. As discussed by women and health professionals, the relative 
importance of ovarian cancer depends on other events and responsibilities in a 
person’s life and timing of the decision has to be right (Howard et al. 2010c). Age 
played a role in timing as well, as the consequences of surgery differ for different 
age groups. For example, a postmenopausal woman does not need to consider 
menopause and HRT, whereas a thirty year old may be deemed too young to have 
this surgery due to loss of fertility and the long-term health effects of oestrogen 
deprivation.  
 Women may also explore the congruence of a selected option with their 
own and important others’ goals and values. In the case of surgery, one such 
important goal is the completion of family planning. RRSO will be at odds with a 
wish to have children, or more children, and therefore not congruent with an 
important personal goal (Culver et al. 2011, Fang et al. 2002, Fang et al. 2003, Skytte 
et al. 2010). The input from important others, such as partners, mothers or sisters, 
might also be sought at this point to seek their approval and prepare for the chosen 
option together. Additionally, physician recommendation may influence this part of 
the appraisal process, as congruence of the chosen option with a GP’s or surgeon’s 
recommendation can be reassuring for patients (Claes et al. 2005, Kram et al. 2006, 
Swisher et al. 2001). Practical aspects, such as ability to book time off work for the 
surgery or knowledge of ovarian cancer symptoms, may also be appraised at this 
point. 
 During emotional appraisal in preference construction, the woman may 
explore whether she feels ready to decide and attempt to predict possible regret 
following the decision (Connolly and Reb 2005). If a chosen option is at odds with 
one’s own or an important other’s goal or value, then this phase can be emotionally 
stressful. For example, if a woman is extremely anxious about cancer but has not 
yet completed her family, she may choose to delay surgery. This option is at odds 
with her desire to reduce her cancer anxiety; however it is in line with her goal of 
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having a child. Therefore, her emotional appraisal of any option will be difficult, as 
she will anticipate regret with either option. The final decision will depend on which 
goal is more important to her at that moment in time.  
 5.3.2v Consolidation: The generic CODE framework includes a consolidation 
phase following the decision, which has not been discussed here. The review of 
decision making regarding RRSO presented in Chapter 3 and the study of women 
and health professionals reported in Chapter 4, which act as the basis for this 
adaptation, focus on the pre-decisional process of appraisal of the threat and 
differentiation of options (Svenson 1992). An adaptation of the questions 
associated with these processes will allow the creation of an RRSO-adapted CODE 
framework which describes pre-decisional deliberation. This may act as a guide for 
consultations and decision support materials designed to facilitate decision making. 
In contrast, post-decisional consolidation occurs once a decision has been made to 
further differentiate the chosen option and thereby avoid regret (Svenson 1992). 
Hence, an adaptation of the consolidation phase was not included in the current 
chapter, as it is not relevant to materials that aim to support pre-decisional 
differentiation, such as patient decision support interventions. 
5.3.3 Coping resources - adapting secondary appraisal content 
 During secondary appraisal the individual appraises the coping potential (i.e. 
whether anything can be done) and options (i.e. what can be done) to manage a 
stressful event (see section 2.4.3, Chapter 2; Lazarus and Folkman 1984). Potential 
coping options that might be implemented in response to the threat may be 
defined as problem- or emotion-focused, depending on whether their primary aim 
is to deal with the threat directly or to regulate emotions experienced in response 
to the threat (Lazarus and Folkman 1984). 
 As previously described, there are four potentially stressful phases during 
deliberations about RRSO: disclosure of ovarian cancer risk status, presentation of 
choice, presentation of options and preference construction. Below, these phases 
are considered in terms of the secondary appraisal they stimulate, with a view to 
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exploring potential coping strategies that might be appraised by patients going 
through these phases. Secondary appraisal during the presentation of options and 
preference construction is represented as one process (section 5.3.3iii), as these 
two phases are closely linked and coping options explored during these phases are 
interchangeable. 
 5.3.3i Disclosure of ovarian cancer risk status: Once women are aware of 
their risk, they may begin to appraise the coping potential and options at their 
disposal to manage their risk and their emotional response to that risk. Firstly, they 
may assess whether there is potential for dealing with the threat directly and/or for 
regulating emotions. Then they may further appraise individual coping options, such 
as seeking information, seeking social support and using avoidance, in order to find 
those best suited to deal with the current threat (Figure 5.10). Potential coping 
options considered initially may include some that have not been appraised as 
currently available or suitable. These will then not be used as a resource. 
Figure 5.10 - Secondary appraisal of coping options in response to disclosure of cancer risk 
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If a woman appraises that she can take a direct approach to dealing with the 
threat, she might explore possibilities for obtaining further information through 
communicating with others, such as her doctor, family or peers (Babb et al. 2002). If 
she also appraises that there is the need for and potential to regulate emotions in 
response to the threat, she might explore the possibility of finding comfort in her 
faith or using distraction or relaxation techniques (Pergament 1997, Phelps et al. 
2006). For example, women in focus groups explored the possibilities for obtaining 
information and mentioned issues around trusting clinical staff. Health 
professionals noted that peer support would be a useful resource for women. Many 
situations, such as cancer risk, will be appraised as having problem-focused as well 
as emotion-focused coping potential and some coping options (e.g. seeking social 
support) may be problem- and emotion-focused at the same time, as indicated in 
Figure 5.10. 
 5.3.3ii Presentation of choice: When presented with the fact that there is 
choice, and that personal goals and preferences play a role in this decision, women 
may appraise the coping options available to help them deal with making the 
decision (Figure 5.11). As discussed earlier, the availability of choice may be 
appraised as a threat or a challenge during primary appraisal, depending on 
personal factors, such as self-efficacy (DeWalt et al. 2007). Depending on the 
outcome of this appraisal, the coping options considered during secondary appraisal 
may vary. Someone who appraised choice as a challenge may be more likely to 
consider options for approaching the decision and resources of instrumental and 
informational support, focusing on those coping options that directly deal with the 
choice. In contrast, someone who appraised choice as a threat may explore options 
for emotional support through social contacts or may consider avoidance options, 
such as transferring responsibility for the decision to someone else.  
 Women in the focus groups discussed their feelings about recommendations 
they had received and whether they could trust health professionals to provide 
good information and make the right decision for them (Babb et al. 2002).They also 
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Figure 5.11 - Secondary appraisal of coping options in response to presentation of choice 
 
explored the possibility of deferring the choice. In contrast, health professionals 
emphasised the importance of involving others, such as partners, and of having a 
personal time plan when approaching this decision (Howard et al. 2010c).  
 5.3.3iii Presentation of options and preference construction: During 
secondary appraisal of options and preference construction, patients may assess 
whether there is potential for dealing with the threat posed by the options directly 
or for regulating emotions in response to the options presented (Howard 2010).  
Patients may then explore individual coping options that could help them make and 
implement the decision and subsequently deal with its outcomes (Figure 5.12). For 
example, a woman who appraised that there are ways she can deal with the threat 
directly may explore weighing her options and seek to speak to a peer who has 
already made this decision (Babb et al. 2002, Kenen et al. 2007). A woman who has 
appraised that there are ways she can regulate her emotions might consider 
whether her options include social support or whether she might be able to employ 
distraction or relaxation techniques (Phelps et al. 2006). Instrumental and 
emotional support from a partner during and after decision making was an 
important issue discussed by women and health professionals in focus groups and 
interviews, respectively. Participants also discussed how best to compare options 
and whether there was any way of facilitating the differentiation process. 
167 
 
 
Figure 5.12 - Secondary appraisal of coping options in response to presentation of options 
 
5.3.4 The RRSO-adapted CODE framework 
 The individual appraisal processes outlined in sections 5.3.2 and 5.3.3 were 
combined and summarised to form the content of an RRSO-adapted CODE 
framework that specifically describes deliberations and coping in the context of 
RRSO decisions (Figure 5.13). The preliminary framework includes a wide range of 
possible issues. The exact questions explored and the problem- and emotion-
focused coping options that will be appraised, selected and used will vary 
depending on the individual decision maker and her personal situation. Patients 
may consider only a few or many of the questions and coping options proposed. 
They may explore questions in a similar order to which they are listed in the 
framework, or they may jump between phases and questions in a non-sequential 
manner. 
 The RRSO-adapted CODE framework, therefore, is not necessarily a model 
that accurately describes a selected patient’s deliberation pathway or predicts 
which questions will be asked and coping options will be selected by which patient. 
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Figure 5.13 - The RRSO-adapted CODE framework 
1
68
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Rather, it offers a dissected view of deliberation and coping processes that was 
constructed by an analytical process, using input from a number of stakeholders. It 
is a model that helps to identify the kind of support that women may require while 
going through the deliberation pathway. It therefore acts as a framework to help 
those who strive to facilitate decision making, in consultations or otherwise, to 
provide sufficient information, support affective forecasting and encourage coping. 
Hence, the RRSO-adapted CODE framework is a conceptual framework that may 
guide the development of support methods and materials for women at increased 
genetic risk of ovarian cancer. 
5.3.5 Face validation 
The RRSO-adapted CODE framework was validated through an interview 
with a carrier of a mutation in BRCA1 who had undergone RRSO with a risk-reducing 
hysterectomy in the preceding six months and had been premenopausal at the time 
of surgery. The patient described issues considered during decision making as well 
as coping strategies used throughout her deliberation process. The issues explored 
whilst going through the deliberation process described by the patient in this 
interview map onto many of the questions delineated in the RRSO-adapted CODE 
framework (Figure 5.14). 
 5.3.5i Ovarian cancer risk status: When appraising her cancer risk, the 
patient used her experience of observing ovarian cancer in her mother and breast 
cancer in her aunt to appraise the level of threat. Her appraisal of her own risk was 
high, as both her mother and aunt had died of cancer. While she acknowledged that 
there was a genetic component to the disease, she also felt that stress was a causal 
factor. This initial appraisal maps onto the questions delineated in the framework 
about ovarian cancer, risk, causes, family history and past experiences. 
…my mum and my aunt they’ve had cancer after a really traumatic time in 
their life and […] I just think that maybe there just must be some form of a 
link […] I know that’s not in any way […] scientific but I don’t know, I just 
think stress seemed to be […] a crucial part of things in our family… 
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Figure 5.14 - Questions within the RRSO-adapted CODE framework explored by one patient (in red and bold) 
1
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She went on to describe how her emotional reaction to her aunt’s cancer led her to 
avoid taking action to manage her own risk initially and select an avoidant coping 
strategy, until another event in her life reminded her of the importance of confronting 
her cancer risk.  
…my aunt […] lived with breast cancer […] for eight years and she died three 
years ago. So after she died, me and my cousins were saying: “We really need 
to get back involved in the genetic counselling” […]. But actually we didn’t do 
anything about it, because I think to be honest it was just so awful, it was such 
an awful time […]. I think we just thought: “This is just too awful to 
contemplate really.” And then I found a lump in my breast and […] if it wasn’t 
for that lump in my breast maybe I might have just put my head in the sand for 
a little while longer… 
This describes coping options explored and employed during and after appraisal of the 
health threat: while she first explored whether she could ignore the information, and 
subsequently chose avoidance to cope with the emotions in response to her aunt’s 
death, she later came back to the decision and re-evaluated her coping options, 
concluding that she wanted to take action and could find out more by contacting the 
genetics service. 
 There, she was offered genetic testing for a BRCA gene mutation. The patient 
described her struggle with this decision, as she had already appraised her cancer risk 
as very high and she feared that her worries would remain, even if no mutation was 
found. 
…first of all I decided I wasn’t going to have the tests but I wanted to have a 
hysterectomy […]. I know that sounds a bit all round the wrong way but […] in 
my head [I] thought if I haven’t got the gene obviously that would be brilliant 
but I’ll still want to have a hysterectomy because […] I don’t trust my own 
mind that I’ll be able to relax… 
Therefore, she initially evaluated her cancer risk considering both possibilities, by 
talking “a lot about statistically how likely it is that I would [develop ovarian cancer] if I 
was BRCA1 or not BRCA1”. However, she did eventually recognise the importance of 
confirming the genetic mutation for her children and wider family and decided to go 
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ahead with testing following a relative’s decision to get tested. This process maps onto 
the exploration of cancer risk in terms of genetics and effects on offspring as detailed 
in the CODE framework. 
…[…] they found that she [cousin] did have the BRCA1 mutation and […] I think 
talking to her made me think: “Actually, what am I doing? I need to know 
really for my boys and I need to know for our family.” […] So then a year ago I 
went along and had the test and so then found out that I did have the BRCA1 
mutation… 
Confirmation of the mutation resulted in elevated anxiety and made her want to press 
ahead with surgery urgently. However, she did not have surgery until one year after 
receiving her test result and described how taking the time to consider the impact of 
the confirmed mutation, as well as carefully familiarising herself with the benefits and 
risks of surgery, was important before committing to the operation. 
…the first panic […] when you find out you’ve got the BRCA1 just makes you 
think: “Right, get me in, I’ll have it all done, just quick as a flash […]”. But 
actually I think you really do need a certain amount of time just to come to 
terms with it all and […] make sure you do know the in’s and out’s of what the 
operation means and what it means afterwards and what the BRCA1 gene 
means with regards to yourself and your whole family… 
During these deliberations, she turned to support from her family to help her cope and 
was particularly close to her cousin, who also carried a mutation in the BRCA1 gene 
and was making decisions about risk-reducing options at the same time. This maps 
onto the coping options of instrumental, informational and emotional support from 
family and friends outlined in the CODE framework. While the patient acknowledged 
that it was sometimes difficult for others to understand her worries and she didn’t 
“want people to think that you’re just trying to make something out of nothing”, she 
emphasised repeatedly how support from relatives helped her to cope with her cancer 
risk, and indeed the decision making process. 
…I do speak to my cousin about it, so obviously we’re all totally on the same 
page and my dad and our outside family are very supportive […], but I think 
[…] it’s harder for people who haven’t directly seen the effects of ovarian and 
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breast cancer […] to understand perhaps where we’re coming from […]. There 
is the mind set of: “Why don’t you just enjoy your life and see what happens?” 
and I can understand that, because I’ve sort of thought that myself: “Let’s just 
[…] put our heads down and just enjoy life […]”. It’s just whether you really can 
do that or whether it would just always be at the back of your mind… 
 5.3.5ii Presentation of choice: The patient described how she had suspected 
that she was at an increased risk of cancer since her mother’s diagnosis, and had 
already at that point started to contemplate risk-reducing surgery. 
…For me, it’s not been something that I’ve suddenly had to make a decision on 
[…]. I had my mum and talked about it with her and then […] came to it sort of 
fairly gradually… 
Therefore, the discussion of choice and being asked to play an active role in the 
decision making process came as no surprise when introduced by the genetic 
counsellor. Hence, this patient did not explore many of the questions outlined in the 
choice section of the CODE framework in any detail. However, she did describe her 
feelings of empowerment in response to being given the opportunity to decide how 
she would manage her cancer risk. 
…obviously it would be much better if nobody had to worry about any of these 
things but that’s not life, is it? […] It is better to confront things head on, 
because this way we’re getting […] the control to be able to do what we can 
[…]. If you’ve got a bit of control about it […] it really can [relieve] anxieties… 
Describing herself as a ‘worrier’ she felt that any action she could take to reduce her 
risk of cancer would be worthwhile.  
…I know what I’m like as a person and I’m a worrier and I know that I would 
just be always second guessing any problem that I had […]. This is because of 
what happened to mum and I just would always be thinking it […]. I do think 
that the mind plays such a massive role in this… 
 5.3.5iii Presentation of options: When discussing her surgical options, due to 
her concerns about cancer, the patient considered a full risk-reducing hysterectomy 
(RRH) with bilateral salpingo-oophorectomy, instead of RRSO alone. 
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…we talked about should I just have an oophorectomy or should I have the 
hysterectomy and I just felt that if I was going to have surgery, I might as well 
limit any other risks that might be there… 
During appraisal of the option of RRSO plus RRH, she reported having considered many 
of the issues included in the CODE framework, such as risks and benefits of surgery, 
surgical menopause, hormone replacement, potential complications and residual risk.  
…I was obviously concerned about […] any complications and of course there is 
always a risk […] with any kind of surgery… 
…the other […] concern obviously was HRT […] and we talked about the 
problems of not being on HRT and we also talked about […] the link with 
breast cancer […] and the fact that really everything should be OK […] until I 
was at natural menopausal age anyway. So that definitely was something that 
I was concerned about… 
…I know that […] there is a risk with regards to the stomach lining […], but 
what I’m doing is limiting my risk and if something still happens then, well, I 
just know that I’ve done absolutely everything I can and then I’ve got the 
peace of mind and that’s what I was really needing I think. […] I think I’m just 
of the opinion that if I’m still going to get it, then […] that is what is supposed 
to be […] the course of my life… 
While she remembered that these concerns were addressed fully and to her 
satisfaction at the genetics service, she acknowledged that contact with a peer who 
had already made the decision for surgery would have been a valuable resource. This 
indicates that she would have liked to seek instrumental, informational and/or 
emotional support from a peer to help her make her decision and to explore questions 
such as ‘What did others decide?’ and ‘How did they fare?’, although this option was 
not available to her at the time. 
…I think a person to talk to would be brilliant […] to help you clarify your own 
thoughts […] against somebody who’s actually been through the surgery […]. I 
haven’t been offered anything up here, having said that I’m not lacking 
anything […]. Obviously it would be good to talk to somebody who’d been 
through the operation but […] the genetic counsellors are absolutely 
fantastic… 
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 5.3.5iv Preference construction: Linked to her description of herself as a 
‘worrier’, the patient considered the reduction in cancer risk (which would most likely 
result in a reduction in her cancer worry) as the most important factor in her 
preference construction for surgery. 
…the most important thing is the impact on life […]. You will feel less worried 
about developing ovarian cancer. And then everything else that you have to 
cope with is absolutely fine, because if you can just limit your worries there 
then you will put up with anything […] to a degree of course but […] the 
balance is: not having to worry about ovarian cancer… 
Drawing on her past experience of cancer, she continued to explain that having 
surgery would enable her to look after her children and that worries about other 
issues, such as the risks of surgery or subsequent oestrogen deprivation, appeared 
small in comparison. This shows her exploration of personal values and goals (e.g. 
seeing her children grow up) during preference construction. 
…if I can do anything […] then I would because I don’t want my children to 
have to go through what I went through […] and obviously because I want to 
be there… 
…[I] probably wasn’t really that worried about it all I think. That’s because I’d 
just seen how awful it was with my mum and then how awful it was with my 
aunt and then any operations are not going to come close to those kinds of 
things… 
The patient explained that she “was lucky […] I was already married and had the 
children and I was pregnant when I was offered the test” and therefore did not have to 
consider the issue of family planning. This addresses the question of whether her 
family was complete, as outlined in the CODE framework.  
 During the final stages of decision making she then also described how 
practicalities, such as childcare and work obligations, played an important role in 
planning whether it was the right time and whether she was ready for surgery.  
…The main things I think were practical issues of how long I was going to be in 
[hospital] for just from […] the point of view of who was going to have the 
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children, how long I would be off work for […] and just the kind of expectations 
of that… 
…He [the consultant] just said: “You guys think about when is going to be 
practically speaking a good time for you and then we’ll slot you in”. So I said: 
“Well, actually October would be good”, because […] my oldest son was 
starting school and I wanted him to start and be settled before I had the op 
and I knew that we could rely on some grandparents to come and stay at that 
time… 
As she had throughout her deliberation process, she used emotional and instrumental 
support from her family to cope with preference construction, decision making and the 
time after decision making. However, she did feel that others in her surroundings 
found it hard to understand why she wanted to have surgery. She explained how she 
had based her final decision on the information she had been given about her 
increased risk.  
…It is such […] an unusual thing to be deciding to do […]. Sometimes [I] think: 
“Gosh, am I just going mad here even considering these things?” […] People 
might say to you: “You wouldn’t like just chop your hand off just because you 
might […] get cancer in your little finger […]”. In a way they’ve got a point, you 
can’t go round chopping off bits of your body […], but at the same time […] the 
statistics are so high and the evidence is so stacked that way that […] that’s 
what’s making me make the decision, it’s not just on a whim… 
Finally, she explained how taking her time to approach the decision and considering 
the impact her cancer risk and surgery might have on her life was an important process 
to go through in order to make an informed, value-adjusted decision. 
…when it was time for me to […] sign on the dotted line that I was going to 
have it done I just felt absolutely fine about it […]. I didn’t feel I’d been pushed 
into anything, I’d been given all of the statistics, I’d had time to digest it all and 
discuss it all and talk to [husband] about it all […] and that was […] really 
important. So I didn’t feel concerned at all once I’d made my decision… 
Overall, this patient explored a wide range of issues and coping options outlined in the 
RRSO-adapted CODE framework during her deliberation process (Figure 5.14). 
However, some issues and coping options were not explored. For instance, she did not 
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appraise symptom awareness as an option in any detail, as she was relatively focused 
on surgery. She also did not report considering or using emotional coping options, such 
as religious coping or relaxation techniques. As discussed earlier, the questions in the 
RRSO-adapted CODE framework that are explored in any given deliberation process 
will vary depending on the individual decision maker and her personal situation. 
However, while patients may vary in their experiences, beliefs, values and personal 
goals, and therefore in the exact issues they will explore, the overall framework 
appears to describe the general deliberation process and associated appraisals 
relatively accurately. Additionally, this demonstrates that a single woman may explore 
many of the questions proposed in the framework when appraising the deliberation 
phases and her coping options. 
5.4 Discussion 
5.4.1 The RRSO-adapted CODE framework in context 
 The framework presented in this chapter represents the first adapted version 
of the CODE framework and describes in detail the deliberation process about RRSO by 
women at increased genetic risk of ovarian cancer.  
 The generic CODE framework was developed based on a number of prominent 
decision making and coping theories, which informed the structure and the questions 
amenable to adaptation within the framework. Theories included Svenson’s (1992) 
differentiation and consolidation theory, Power’s (2011) model of cognitive-emotional 
decision making, Leventhal’s (1980, 1984) Self-Regulatory Model, Balneave and Long’s 
(1999) embedded decisional model of stress and coping, and Lazarus and Folkman’s 
(1984) transactional theory of stress, appraisal and coping. The adaptation of the CODE 
framework was therefore also guided by these theories. 
 In the past, Leventhal’s (1980) Self-Regulatory Model was mainly applied to 
illness cognition in the context of chronic diseases, such as diabetes (Scollan-
Koliopoulos et al. 2005) or HIV (Reynolds et al. 2007). However, some have also used 
this model to explore patients’ representations of cancer risk (Decruyenaere et al. 
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2000, Kelly et al. 2005, Lancastle et al. 2011). In agreement with these studies, the 
current adaptation of the CODE framework using the Self-Regulatory Model 
demonstrates that representations of illness threats, rather than chronic conditions, 
may also be formed using the five dimensions of identity, cause, timeline, 
consequences and control.  
 The issues explored, and questions posed, by women (Chapter 3 and 4) during 
appraisal of ovarian cancer and their risk fit readily within these five dimensions. 
Furthermore, these dimensions could also be used to describe cognitive appraisal of 
the meaning of choice and management options, both of which could be seen as 
threats and were explored by women in a similar fashion in order to form 
representations of the meaning of choice and individual options. While this does not 
propose that Leventhal’s dimensions may be used to describe cognitive appraisal of 
any condition or option, it shows that representations of illness, illness threats or other 
threats (such as treatment options) may be described using these five dimensions, 
which may be useful in future adaptations of the CODE framework to other decisions. 
The RRSO-adapted framework includes many of the questions important to 
women making this decision as determined by previous research highlighted in 
Chapter 3. These include questions exploring the meaning of ovarian cancer and 
elevated risk (Howard et al. 2011, Meijers-Heijboer et al. 2003, Ray et al. 2005), the 
effects of surgery, surgical menopause and HRT (Brain et al. 2004, Fang et al. 2002, 
Hallowell 1998), the availability of support (Howard et al. 2011, Mellon et al. 2009) and 
the timing of surgery (Howard et al. 2010c). Therefore, the framework combines the 
knowledge accumulated in previous research on women’s deliberations about RRSO 
with a study of women’s decision making (Chapter 4) to propose a detailed patient-
centred description of this process. 
 Previously, Howard et al. (2011) proposed the ‘Preserving-the-self’ theory to 
describe decision making about management options in carriers of mutations in 
BRCA1/2, which includes breast screening, RRSO and risk-reducing mastectomy. The 
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‘Preserving-the-self’ theory postulates that being at risk threatens four aspects of the 
‘self’: physical health, self-identity, relationships and emotional well-being, and that 
women’s decision making is geared toward preserving these aspects (Howard et al. 
2011). Through interviews, Howard et al. (2011) explore women’s deliberations and 
propose seven decision making approaches, such as ‘weighing the pros and cons’, 
‘taking time’, ‘paying attention to emotions’ and ‘engaging with others’. Combinations 
of these approaches then describe five distinct decision making styles: Snap, Intuitive, 
Deliberative, If-Then and Deferred style (Howard et al. 2011). 
 The RRSO-adapted CODE framework sits well alongside the ‘Preserving-the-self’ 
theory, as it proposes questions that patients may explore during deliberations. 
Howard et al. (2011) did not discuss specific questions and issues women explore 
during deliberations, but rather focused on the process, identifying individual decision-
making approaches and styles. As previously discussed (Chapter 2), the questions 
within the CODE framework may differ between and can be adapted to individuals, 
depending on their preferred decision making and/or coping style. Therefore, the 
approaches and styles identified by Howard et al. (2011) may be used to determine 
which questions might be most important to a certain individual. For instance, a 
woman may select approaches representative of the intuitive decision making style, 
which include looking inward and reflecting on emotions (Howard et al. 2011). In this 
case, the questions in the framework focusing on emotional responses to the threats 
and emotional coping options would be most relevant. In contrast, if a woman uses 
approaches representative of the deliberative style, which include making sense of the 
numbers and weighing the pros and cons, questions relevant to cognitive appraisal and 
problem-focused coping, such as information seeking, might be more relevant 
(Howard et al. 2011). It should be noted that women may use a number of different 
approaches and decision-making styles throughout the process, just as women may 
use several coping strategies (Howard et al. 2011, Lazarus and Folkman 1984). 
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5.4.2 Practice implications and future research 
The CODE framework was developed to provide a description of preference-
sensitive decision making from a patient perspective in order to (i) help practitioners 
better understand their patients’ questions and concerns, (ii) provide a theoretical 
underpinning for the development of decision support and (iii) act as an assessment 
tool to test whether existing decision support truly addresses issues patients explore 
during deliberation. Overall, the framework could thus support patient-centred care 
(PCC) and provide a theoretical underpinning for decision support materials (Durand et 
al. 2008, Elwyn et al. 2000, Elwyn et al. 2009a, O'Grady and Jadad 2010, Secretary of 
State for Health 2010). 
By adapting the framework to a specific decision the relevance of the phases 
and questions is increased, thereby providing an even more accurate description of 
decision making in a specific context. The RRSO-adapted CODE framework presented 
in this chapter describes deliberations about increased genetic risk of ovarian cancer 
and associated management options. This adapted version may now be useful in 
assessing currently available decision support aimed at women at increased risk of 
ovarian cancer and in developing tailored decision support, if such support is not 
available or not adequate. 
Future research using the RRSO-adapted CODE framework may focus on 
additional validation, for example content validity assessment with a group of experts 
and further face validity testing in focus groups or interviews with health professionals 
and/or patients. Furthermore, the framework may be applied to assess and develop 
decision support interventions. As demonstrated in this chapter, the CODE framework 
is readily adaptable to a specific context and the results of this research may guide 
further adaptations to other preference-sensitive decisions, such as catheter 
investigation for coronary artery disease (CAD) or amniocentesis to assess foetal 
health. 
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5.4.3 Strengths and limitations 
The current chapter delineates the adaptation of the CODE framework to a 
specific preference-sensitive decision using information obtained from a literature 
review, as well as focus groups with patients and interviews with health professionals 
(Chapter 3 and 4). This approach to adaptation results in a thorough understanding of 
the issues important during deliberation about the specific decision (i.e. RRSO) in a 
specific population and context (i.e. women at increased genetic risk in the UK). 
Therefore the adapted version of the framework is grounded in a literature review as 
well as data collected from stakeholders and reflects important aspects explored by 
patients and health professionals. Other approaches to adaptation, limited to either a 
literature review or data from a small group of patients and/or health professionals 
only, may not be as accurate or reflective of a specific decision in a specified 
population/context and may therefore be less useful in supporting PCC and the 
development of decision support materials. 
Arguably, the questions posed in the adapted framework are not exhaustive 
and there may be a whole range of other aspects women might explore during primary 
and secondary appraisal. However, by using a broad literature review in combination 
with interviews and focus groups with stakeholders to inform the issues included in 
the adapted framework, the current adaptation likely covers the most common and 
salient points that may be explored during deliberations about RRSO. Furthermore, 
while it cannot provide information about the exact questions a given individual 
patient might explore, it offers an overview of those issues most frequently considered 
and those deemed important by health professionals. Therefore, any consultation or 
support material which addresses the questions included within the adapted 
framework will likely cover the more common issues. This may leave more time to 
discuss any additional individual questions a patient may have after receiving the initial 
information.  
As with the generic framework, the adapted framework attempts to describe 
both cognitive and emotional processes, as well as appraisal of coping options. This 
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comprehensive view of deliberation and coping as intricately linked processes allows a 
more holistic description of decision making. This means that decision support 
materials based on the framework may support adaptive coping and emotion 
regulation in addition to providing information to facilitate cognitive appraisal and 
affective forecasting. 
The RRSO-adapted framework was validated using one retrospective account of 
coping and deliberation processes, which may have been subject to recall bias. 
However, the patient had undergone surgery only six months before the interview and 
was recalling events that had led up to her decision in the year preceding the surgery. 
Therefore, the time delay between decision making and interview was relatively short. 
The patient had a confirmed BRCA mutation and had completed her family, hence 
some may argue that her decision was comparatively easy and free from conflict. 
However, the patient was under 40 years of age at the time of her decision, which 
means she had to consider the effects of a premature menopause and whether or not 
to take HRT. Additionally, although she had had two children, she had to be sure her 
family was complete before making her final decision and also had to consider the 
potential effects surgery would have on her relationship with her husband. The in-
depth account of her decision making shows that, despite being BRCA positive and 
having completed her family, this patient did take her time with making this decision 
and explored how outcomes would affect her life before undergoing surgery, 
indicating a thorough deliberation worth mapping onto the RRSO-adapted CODE 
framework. 
Further interviews with other patients recounting their deliberation process 
would have been beneficial. However, recruitment was extremely difficult as many 
women who opt for surgery leave the genetic service and are difficult to contact 
thereafter. Although the current study attempted to recruit more patients, this was 
not successful due to the low response rate, as well as time and area restrictions. 
However, the interview that was conducted included an in-depth narrative account of 
a deliberation process, which was analysed using thematic analysis (Braun and Clarke 
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2006). The richness of this dataset allowed accurate mapping onto the CODE 
framework and provides a detailed insight into this patient’s deliberation and coping 
strategies that may not have been possible with a larger dataset from several patients. 
A prospective validation using observations and interviews with patients as 
they go through the deliberation process would also have added to the adapted 
framework’s credibility. Similarly, content validity assessment with a group of experts 
examining whether adapted questions truly represent the suggested associated 
deliberation and appraisal phases would have been advantageous. However, such 
approaches were beyond the scope of the current study. Despite this limitation, the 
retrospective exploration carried out was appropriate as an initial validation 
procedure. It demonstrated that the patient’s deliberation process mapped well onto 
the framework and was accurately reflected by a selection of the questions within it. 
The RRSO-adapted framework may benefit from further validation in the future. 
5.4.4 Conclusions 
 In this chapter it was demonstrated that the generic CODE framework can be 
readily adapted to a selected preference-sensitive decision using information about 
salient issues important in that decision. These considerations were derived from focus 
groups and interviews with stakeholders, as well as a literature review (Chapters 3 and 
4). Adaptations to other decisions using this approach are possible and enable the 
generic CODE framework to be applied to a variety of different preference-sensitive 
medical decisions. 
 The RRSO-adapted framework will be used to assess currently available 
decision support interventions that include the option of RRSO and their coverage of 
issues considered during primary and secondary appraisal (Chapter 6). Subsequently, it 
will be used as a guide for the development of a patient decision support intervention 
for women at increased genetic risk of ovarian cancer in the UK, where currently no 
tailored decision support outside the clinic is available (Chapter 7). 
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6 Applying the CODE framework: A review of decision support 
interventions that include the option of risk-reducing 
oophorectomy 
 
6.1 Introduction 
Decisions about management in the context of increased genetic risk of 
cancer are inherently difficult, as they affect otherwise healthy individuals who are 
making a decision on how to manage a potential future risk (Fang et al. 2005, 
Howard et al. 2009a, Miller et al. 1999). Furthermore, risk in itself is an abstract 
concept, which can be difficult to understand for individuals of all ages and abilities 
(Gigerenzer and Edwards 2003, Zikmund-Fisher et al. 2010). Women at increased 
genetic risk of ovarian cancer are required to appraise their cancer risk, as well as 
the risks and benefits associated with available management options. Additionally, 
they should consider their personal values and preferences and, ideally, actively 
participate in shared decision making (SDM) to reach an informed, preference-
adjusted decision. They may be expected to do all this in a psychologically aroused 
state and while experiencing a number of anticipated and anticipatory emotions 
(Loewenstein et al. 2001, Wilson and Gilbert 2003). Therefore, in order to reach 
truly informed and value-adjusted decisions, regulating emotions during decision 
making is essential. Hence, coping with the threat and associated emotions is an 
integral part of deliberation processes, as suggested by the Coping in Deliberation 
(CODE) framework (Chapter 2; Witt et al. 2012). 
Decision support interventions are tools that aim to provide information, 
facilitate risk communication, ease value clarification and support SDM (O'Connor 
et al. 2004, Thistlethwaite et al. 2006). Such interventions have been shown to have 
positive effects on patient knowledge, accuracy of risk perceptions and decision 
satisfaction by increasing alignment between the chosen option and patient values 
(O'Connor et al. 2009, Stacey et al. 2011). Currently several generic decision support 
interventions are available which may be used in a number of different medical 
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contexts (Ottawa Hospital Research Institute 2013). Additionally, a range of tailored 
patient decision support interventions has been published for a large number of 
medical decisions, from acne treatment and cancer care to genetic testing and 
weight control (Ottawa Hospital Research Institute 2013, Stacey et al. 2011). Some 
are designed to address the needs of specific patient populations, for instance, 
those with a family history of cancer who are considering genetic testing for a BRCA 
mutation (Wakefield et al. 2008a, Wakefield et al. 2008b) or those with early stage 
breast cancer who are deciding between lumpectomy and mastectomy (Sivell et al. 
2012b).  
The aim of this chapter is (i) to identify patient decision support interventions 
that include information about risk-reducing salpingo-oophorectomy (RRSO), (ii) to 
examine their format, design, content, effectiveness and use of theory and (iii) to 
map the contents of these interventions onto the RRSO-adapted Coping in 
Deliberation (CODE) framework (Chapter 5; Witt et al. 2012). 
6.2 Methodology 
6.2.1 Literature Search 
For the purpose of this Chapter, patient decision support interventions were 
defined as “evidence-based tools designed to prepare clients to participate in 
making specific and deliberated choices among healthcare options” (Stacey et al. 
2011, page 3).  
To identify relevant decision support interventions and associated 
publications, a systematic literature search was carried out (Table 6.1). A title search 
was conducted in July 2012 via Ovid. Databases included Medline In-Process 1996 
to July week 4 2012, Medline without Revisions 1996 to July week 4 2012, EMBASE 
1996 to 2012 July and PsycINFO 2002 to July week 4 2012. Duplicates which had 
been found in more than one database were removed.  
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Table 6.1 - Search-terms used for title search via Ovid 
Term 1  Term 2  Term 3 
 
AND 
 
AND 
Ovarian cancer 
Decision$ Aid$ Oophorectomy 
Decide Tool$ BRCA 
Deciding Intervention$ BRCA1 
Choose Support BRCA2 
Choosing Explorer Lynch 
 Clinical guidance 
programme$ 
Hereditary non-polyposis  
colorectal cancer 
  HNPCC 
 
6.2.2 Exclusion Criteria 
The study aimed to identify original research that was concerned with the 
development and/or evaluation of decision support interventions that included the 
option of RRSO. Therefore, reviews and editorials were excluded. Furthermore, 
publications were excluded if (i) they were not concerned with decision support 
interventions, (ii) they exclusively focused on supporting decisions on genetic 
testing, disclosure of at-risk status or treatment of ovarian cancer or (iii) they were 
exclusively concerned with breast cancer prevention by screening or mastectomy. 
6.2.3 Other Methods of Identification 
A supplementary search was performed manually by searching the Ottawa 
Hospital Research Institute decision aid A-Z inventory (2013), the Informed Medical 
Decision Foundation website (2012) and the New South Wales Centre for Genetics 
Education website (2008) to identify further relevant interventions.   
6.2.4 Analysis 
 Wherever possible an effort was made to obtain the full decision support 
intervention and associated materials, if it had been published and was accessible 
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to patients. In cases where an intervention was not publicly available, the author of 
corresponding publications was contacted to provide additional information. 
The interventions were assessed using a specially designed data extraction 
form (Appendix 6.1). The form was developed using the International Patient 
Decision Aid Standards (IPDAS) checklist items on intervention content as a guide 
(Elwyn et al. 2006). The items within the checklist were adapted to assess 
information about ovarian cancer risk and associated management options. 
Additionally, the form assessed format and accessibility, as well as information on 
choice, value clarification content, opportunity for personalisation and 
effectiveness. Where interventions had been evaluated, study design and outcomes 
were also examined. The extraction form was then applied to two decision support 
interventions (Healthwise 2011b, New South Wales Centre for Genetics Education 
2008) and subsequently amended to include additional items relevant to decisions 
on RRSO that had previously been omitted. Two interventions were assessed by two 
independent raters. Inter-rater consistency was >85% and any discrepancies were 
resolved by discussion until a consensus was reached. 
6.2.5 Application of the CODE framework 
The CODE framework describes decision making and coping using a number of 
questions (Chapters 2). It has been proposed that this framework could act as an 
underlying theoretical framework for decision support interventions (Witt et al., 
2012). In this study, the RRSO-adapted version of the CODE framework (Chapter 5) 
was mapped onto the content of decision support interventions identified during 
the review in order to determine how many of the questions raised in the 
framework were addressed in each intervention (Appendix 6.2). A question was 
deemed ‘addressed’ if: 
i. there was information directly relating to the question (e.g. Question: “What is 
risk-reducing bilateral salpingo oophorectomy?” was addressed by 
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“Prophylactic bilateral salpingo-oophorectomy: Removal of both ovaries and 
fallopian tubes before cancer occurs” (Kurian et al. 2012, in glossary) 
ii. users were encouraged to consider or discuss an item or were made aware of 
an issue indirectly (e.g. Question: “Have I completed my family?” was 
addressed in a flowchart by the statement: “You may want children/more 
children” (New South Wales Centre for Genetics Education 2008, page 14) 
Two interventions were assessed this way by two independent raters (inter-rater 
consistency >80%) and discrepancies were discussed until a consensus was reached.  
6.3 Results 
6.3.1 Available Interventions 
The literature search yielded a total of 51 results, of which 27 were 
duplicates found in more than one database (Figure 6.1). The results of a manual 
search on relevant websites (n=4) were added to the 24 publications identified 
through the databases to yield a total of 28 publications for further analysis. Four 
publications did not present original research or were not concerned with decision 
support interventions. Of the 24 remaining publications, five were concerned with 
interventions focused on genetic testing or disclosure to family members and three 
were concerned with ovarian cancer treatment, rather than prevention, and were 
subsequently excluded. A total of 16 publications remained for detailed analysis, 
encompassing 11 different decision support interventions that included the option 
of RRSO. These included interventions aimed at carriers of mutations in BRCA1/2 
(Culver et al. 2011, Healthwise 2011b, Kurian et al. 2012, Mayo Clinic 2011, New 
South Wales Centre for Genetics Education 2008, Tiller et al. 2003, van Roosmalen 
et al. 2004a) and at women considering RRSO in the context of a planned 
hysterectomy (Bhavnani et al. 2002, Healthwise 2012, Pell et al. 2002).  
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Figure 6.1 - Results of the literature search 
Publications chosen for more 
detailed review 
n = 28 
Primary exclusion criteria  
(not concerned with decision support interventions): 
i. Not concerned with interventions (n=2) 
ii. Literature review, editorial (n=2) 
Secondary exclusion criteria (does not consider risk-reducing oophorectomy): 
i. Intervention focused exclusively on genetic testing or disclosure decisions (n=5) 
ii. Intervention focused exclusively on ovarian cancer treatment (n=3) 
Publications included in review 
n = 16 (incl. those considering RRSO in the 
context of BRCA mutation or hysterectomy) 
Bhavnani et al. (2002) 
Culver et al. (2011) 
Healthwise (2011b) 
Healthwise (2012) 
Hooker et al. (2011) 
Kaufman et al. (2003) 
Kurian et al. (2012) 
Mayo Clinic (2011) 
Metcalfe et al. (2007) 
NSW Centre for Genetics Education (2008) 
Pell et al. (2002) 
Schwartz et al. (2009) 
Tiller et al. (2003) 
Tiller et al. (2006) 
Van Roosmalen et al. (2004a) 
Van Roosmalen et al. (2004b) 
Publications excluded from 
review n = 8 
Anderson et al. (2011) 
Clarke et al. (2010) 
Juan et al. (2008) 
Juraskova et al. (2010a) 
Juraskova et al. (2010b) 
Peshkin et al. (2010) 
Wakefield et al. (2008a) 
Wakefield et al. (2008b) 
Interventions within these publications: n=11 
Excluded: n = 4 
 
Relevant publications identified 
through supplementary search  
n = 4 
 
Literature Search 
n = 24 
n = 24 
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A total of six interventions were available for analysis at the time of the study 
(Healthwise 2011b, 2012, Kaufman et al. 2003, Mayo Clinic 2011, New South Wales 
Centre for Genetics Education 2008, Stanford Medicine 2012) and five interventions 
were analysed based on the information provided in publications and through 
discussions with their developers (Bhavnani et al. 2002, Culver et al. 2011, Metcalfe 
et al. 2007, Pell et al. 2002, van Roosmalen et al. 2004a, van Roosmalen et al. 
2004b). None of the five interventions assessed through publications were available 
to patients at the time of the study. A summary of the 11 interventions which were 
included in the review is presented in Table 6.2.  
6.3.2 Format and Design 
The interventions varied widely in format and design, from booklets and 
videos to computerised guidance programmes and websites (Table 6.2). Most 
interventions (n=7) were designed to be used independently by the patient outside 
of clinical encounters (Healthwise 2011b, 2012, Kaufman et al. 2003, Mayo Clinic 
2011, Metcalfe et al. 2007, Tiller et al. 2003, van Roosmalen et al. 2004b). Four 
interventions were designed to be used together with a facilitator or health 
professional in the clinic or on the phone (Bhavnani et al. 2002, Kurian et al. 2012, 
Pell et al. 2002, van Roosmalen et al. 2004a). Of these, three interventions were 
delivered in a single face-to-face session (Bhavnani et al. 2002, Kurian et al. 2012, 
Pell et al. 2002) and one intervention was delivered in three separate sessions: two 
face-to-face encounters and one telephone interview (van Roosmalen et al. 2004a). 
The latter was a SDM intervention, which differed substantially from the other 
decision support interventions in this study. 
 Five interventions were available freely online (Healthwise 2011b, 2012, 
Kurian et al. 2012, Mayo Clinic 2011, New South Wales Centre for Genetics 
Education 2008) and one was available through practitioners as a CD-Rom (Kaufman 
et al. 2003). The remaining five interventions were not available publicly at the time 
of the study. 
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Table 6.2 - Decision support interventions included in the review 
Format Publication Year Country Decision Target Audience Options included 
Online tool Kurian (2012) USA RM/RRSO/Screening 
in BRCA1/2 positive 
women 
BRCA1/2 positive women - Risk-reducing mastectomy and RRSO 
- Breast cancer screening and RRSO 
- Risk-reducing mastectomy without RRSO 
Online tool Healthwise (2012) USA RRSO with 
hysterectomy 
Women who are undergoing 
a planned hysterectomy 
- Hysterectomy with RRSO 
- Hysterectomy alone 
Online tool Healthwise (2011b) USA RRSO for high risk 
women 
Women at high risk - Have RRSO 
- Don't have RRSO 
Online tool Mayo 
Clinic 
(2011) USA RRSO in BRCA1/2 
positive women 
BRCA1/2 positive women - Have RRSO 
- Don’t have RRSO (alternatives: screening, RRM, OCP) 
Online tool Metcalfe (2007) Canada RRM/RRSO/ 
chemoprevention 
BRCA1/2 positive women - Have / Don’t have RRM 
- Have / Don’t have RRSO 
- Take / Don’t take Chemoprevention 
Booklet and 
Video 
Van 
Roosmalen 
(2004b) NL RRSO in BRCA1/2 
positive women 
BRCA1/2 positive women - Risk-reducing mastectomy and RRSO 
- Breast cancer screening and RRSO 
- Risk-reducing mastectomy and ovarian cancer screening 
- Breast cancer screening and ovarian cancer screening 
Shared 
Decision 
Making 
Intervention 
Van 
Roosmalen 
(2004a) NL RRSO in BRCA1/2 
positive women 
BRCA1/2 positive women - Risk-reducing mastectomy and RRSO 
- Breast cancer screening and RRSO 
- Risk-reducing mastectomy and ovarian cancer screening 
- Breast cancer screening and ovarian cancer screening 
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Format Publication Year Country Decision Target Audience Options included 
CD-Rom Kaufman (2003) USA RM/RRSO/Screening 
in BRCA1/2 positive 
women 
BRCA1/2 positive women - Risk-reducing mastectomy and RRSO 
- Breast cancer screening and RRSO 
- Risk-reducing mastectomy and ovarian cancer screening 
- Breast cancer screening and ovarian cancer screening 
Booklet Tiller (2003) AUS RRSO for high risk 
women 
Women at high or 
potentially high risk 
- Have RRSO 
- Don't have RRSO 
Decision 
Chart 
Bhavnani (2002) UK RRSO with 
hysterectomy 
Women who are undergoing 
a planned hysterectomy 
- Hysterectomy with RRSO 
- Hysterectomy alone 
- Use of HRT 
Clinical 
Guidance 
Program 
Pell / 
Bhavnani 
(2002) UK RRSO with 
hysterectomy 
Women who are undergoing 
a planned hysterectomy 
- Hysterectomy with RRSO 
- Hysterectomy alone 
- Use of HRT 
Table 6.2 cont. – Decision support interventions included in the review 
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Two of these targeted women in the UK who were undergoing a planned 
hysterectomy. These had not been published due to a change in NICE guidelines, 
which no longer recommended RRSO with planned hysterectomy in women not at 
increased risk of ovarian cancer (Bhavnani et al. 2002, Clarke 2010, National 
Institute for Health and Care Excellence 2007, Pell et al. 2002). Similarly, two Dutch 
interventions for carriers of mutations in BRCA1/2 had never been implemented in 
clinical practice (Stalmaier 2010, van Roosmalen et al. 2004a, van Roosmalen et al. 
2004b). The fifth unpublished intervention was still being used in trials and was 
therefore not publicly available at the time of the study (Culver et al. 2011, Metcalfe 
et al. 2007). 
6.3.3 Information Content 
 The scope and depth of information presented in interventions varied widely 
and depended on the target decision and audience (Table 6.3). Only five 
interventions were specifically designed to facilitate decisions about RRSO to reduce 
increased risk of ovarian cancer due to genetic predisposition (Healthwise 2011b, 
Mayo Clinic 2011, Tiller et al. 2003, van Roosmalen et al. 2004a, van Roosmalen et 
al. 2004b). Three of these were specifically aimed at women with a confirmed 
mutation in BRCA1/2 (Mayo Clinic 2011, van Roosmalen et al. 2004a, van 
Roosmalen et al. 2004b). Three other interventions considered RRSO as a 
concomitant procedure in women scheduled for hysterectomy (Bhavnani et al. 
2002, Healthwise 2012, Pell et al. 2002) and three interventions mainly focused on 
the reduction in risk of breast, rather than ovarian, cancer (Kaufman et al. 2003, 
Kurian et al. 2012, Metcalfe et al. 2007). Culver et al. (2011) adapted the 
intervention designed by Metcalfe et al. (2007), but it remained focused on breast 
cancer risk reduction and was therefore considered as a single intervention. 
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Table 6.3 - Information content of interventions that include the option of risk-reducing salpingo-oophorectomy (RRSO) 
 RRSO to prevent ovarian cancer RRSO to prevent breast cancer RRSO with planned hysterectomy 
Content Item 
Healthwise 
2011 
Tiller   
2003 
Roosmalen 
2004 
Roosmalen 
2004* 
Mayo 
Clinic 2011 
Kurian 
2012 
Metcalfe 
2007 
Kaufmann 
2003 
Healthwise 
2012 
Bhavnani 
2002  
Pell      
2002  
Information about the health condition 
Information about the 
function of ovaries 
• • ?    ?  • ? ? 
Information about ovarian 
cancer 
 • •    ?  • • ? 
Information about 
symptoms of ovarian cancer 
 • ?    ?   ? ? 
Risk of ovarian cancer 
explained 
• • •   • ? • • ? ? 
Explanation of 
familial/hereditary cancer 
• • •    • • • • ? 
Information about genetic 
testing 
• • •    ?  • ? ? 
Information about risk-reducing surgery 
Information about what 
RRSO entails  
• • • • • • •  • ? ? 
Information about recovery 
time 
• • •  •  ?  • ? ? 
Information about surgical 
menopause 
• • •  • • • • • ? • 
Information about hormone 
replacement therapy 
 • •  •  ?  • • ? 
Information about infertility • • ?  •  •   ? ? 194
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 RRSO to prevent ovarian cancer RRSO to prevent breast cancer RRSO with planned hysterectomy 
Content Item 
Healthwise 
2011 
Tiller   
2003 
Roosmalen 
2004 
Roosmalen 
2004* 
Mayo 
Clinic 2011 
Kurian 
2012 
Metcalfe 
2007 
Kaufmann 
2003 
Healthwise 
2012 
Bhavnani 
2002  
Pell      
2002  
Information on psychosocial 
issues after surgery 
 • •  •  ?   ? ? 
Information about residual 
risk after surgery 
• • •  • • •   ? ? 
Risks / Negative features 
explained 
• • •  •  • • • ? ? 
Benefits / Positive features 
explained 
• • •  • • • • • ? ? 
Information about watchful waiting / symptom awareness 
Information about what 
option entails 
• •      •    
Information about 
symptoms 
 •          
Risks / Negative features 
explained 
 •    •      
Benefits / Positive features 
explained 
 •          
Information about screening for ovarian cancer 
Information about what 
option entails 
• • • • •  • •    
Risks / Negative features 
explained 
 • ?  •  ? •    
Benefits / Positive features 
explained 
 • •  •  ? •    
            
Table 6.3 cont. – Information content of interventions that include the option of risk-reducing salpingo-oophorectomy (RRSO) 
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 RRSO to prevent ovarian cancer RRSO to prevent breast cancer RRSO with planned hysterectomy 
Content Item 
Healthwise 
2011 
Tiller   
2003 
Roosmalen 
2004 
Roosmalen 
2004* 
Mayo 
Clinic 2011 
Kurian 
2012 
Metcalfe 
2007 
Kaufmann 
2003 
Healthwise 
2012 
Bhavnani 
2002  
Pell      
2002  
Information about chemoprevention with oral contraceptives 
Information about what 
option entails 
• •   •   •    
Risks / Negative features 
explained 
• •   •       
Benefits / Positive features 
explained 
• •   •       
*Individuals receiving this intervention had previously been given the booklet and video intervention (van Roosmalen 2003, 2004). 
• = item present (either checked directly with available interventions, mentioned / shown in associated publications or through correspondence with author) 
? = intervention not available for direct review, therefore not possible to determine whether item is present or absent 
Table 6.3 cont. – Information content of interventions that include the option of risk-reducing salpingo-oophorectomy (RRSO) 
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 Generally, interventions designed for independent use by patients included 
information materials on the health condition and at least one management option, 
usually RRSO (Healthwise 2011b, 2012, Kaufman et al. 2003, Metcalfe et al. 2007, 
Tiller et al. 2003, van Roosmalen et al. 2004b). In contrast, interventions delivered 
by facilitators or health professionals either only included a minimum amount or no 
standard information (Bhavnani et al. 2002, Kurian et al. 2012, van Roosmalen et al. 
2004a). However, information may be obtained or discussed prior to delivery of the 
intervention in a consultation or using another intervention (van Roosmalen et al. 
2004a, van Roosmalen et al. 2004b). Alternatively, information may also be 
provided during the delivery of the intervention through discussions of options with 
the health professional (Bhavnani et al. 2002, Kurian et al. 2012, Pell et al. 2002). 
 The majority of patient decision support interventions included some 
information about the option of RRSO; however the amount and level of detail of 
this information differed greatly. While some included comprehensive information 
on operative procedures, surgical menopause and hormone replacement (Mayo 
Clinic 2011, Tiller et al. 2003), others only included a short definition (Kurian et al. 
2012). Psychosocial consequences of surgery, such as effects on sexuality, 
relationships and perception of femininity, were also only discussed briefly, if at all 
(Mayo Clinic 2011, Tiller et al. 2003, van Roosmalen et al. 2004b). Information on 
other management options, such as screening or symptom awareness, was similarly 
varied. While some interventions contained extensive information on screening, 
symptom awareness and the oral contraceptive pill (Tiller et al. 2003), others 
merely mentioned these options briefly (Healthwise 2011b). Interventions aimed at 
women undergoing a planned hysterectomy included no information about 
alternative management options for ovarian cancer risk, as the target populations 
were not at increased risk for this cancer (Bhavnani et al. 2002, Healthwise 2012). 
Similarly, interventions mainly concerned with reductions in breast cancer risk often 
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did not include management options focused on ovarian cancer risk (Kurian et al. 
2012, Metcalfe et al. 2007), although some did discuss these options briefly (Culver 
et al. 2011, Kaufman et al. 2003). 
 The SDM intervention developed by van Roosmalen et al. (2004a) included 
the least amount of information. However, this was preceded by the video and 
booklet intervention also developed by this group. Therefore, patients could be 
assumed to have received this information prior to going through the time-trade-off 
exercises in the SDM intervention (van Roosmalen et al. 2004a, van Roosmalen et 
al. 2004b). 
6.3.4 Value Clarification 
 Most interventions included a type of value clarification exercise. This was 
either completed by the patient herself (n=5) (Healthwise 2011b, 2012, Kaufman et 
al. 2003, Metcalfe et al. 2007, Tiller et al. 2003), by the patient with guidance from a 
facilitator (n=2) (Bhavnani et al. 2002, Pell et al. 2002) or by a trained facilitator or 
health professional with input from the patient (n=2) (Kurian et al. 2012, van 
Roosmalen et al. 2004a). Two interventions did not appear to include a value 
clarification exercise (Mayo Clinic 2011, van Roosmalen et al. 2004b). However, one 
of these was complemented by a separate SDM intervention (van Roosmalen et al. 
2004a, van Roosmalen et al. 2004b).  
Most of the explicit, self-administered value clarification exercises asked 
patients to score, rank or weigh different features of options using sliders, five point 
Likert scales or shaded weights (Culver et al. 2011, Healthwise 2011b, 2012, 
Kaufman et al. 2003, Metcalfe et al. 2007, Tiller et al. 2003). It should be noted that 
the intervention by Kaufman et al. (2003), while including an explicit value 
clarification exercise, did not include the option of RRSO within this exercise, as it 
exclusively focused on decision making about breast cancer risk management. 
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Other interventions, including the SDM intervention, established patient values with 
time trade-off exercises requiring the patient to attribute values to potential future 
health states associated with different options (e.g. with/without RRSO, 
with/without HRT) (Pell et al. 2002, van Roosmalen et al. 2004a). Life expectancy 
and quality adjusted life expectancy were then calculated based on the information 
provided by patients.  
The interventions by Kurian et al. (2012) and Bhavnani et al. (2002) explored 
patient values more indirectly than the explicit value clarification exercises in other 
tools. The intervention designed by Kurian et al. (2012) allowed visualisation of the 
effects of different management strategies on cancer incidence and life expectancy, 
so that individual values and trade-offs could be discussed. In the decision chart 
developed by Bhavnani (2002), patients were first presented with graphical, textual 
and quantitative information for each of four possible outcomes, then individual 
risk factors and their effects on outcome probabilities were discussed and women 
could express their thoughts and feelings about the different options. 
6.3.5 Additional Outputs 
 Five interventions allowed patients to personalise the information or the 
probabilities presented by considering personal risk factors such as age, smoking 
and disease history (Bhavnani et al. 2002, Kaufman et al. 2003, Kurian et al. 2012, 
Pell et al. 2002, Tiller et al. 2003). The Australian decision support booklet clearly 
distinguished between pre- and post-menopausal women and informed post-
menopausal women that certain sections in the booklet did not apply to them (Tiller 
et al. 2003). On the CD-Rom, patients could enter personal data such as age and 
previous cancer history to view more tailored information (Kaufman et al. 2003). 
The web-based intervention by Kurian et al. (2012) allowed users to tailor content 
by age and mutation status. In the other two interventions, personal information 
was elicited by the facilitator (Bhavnani et al. 2002, Pell et al. 2002).  
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 Three interventions allowed patients to add their own reasons to the value 
clarification exercise (Healthwise 2011b, 2012, Metcalfe et al. 2007). Four 
interventions left space for personal notes, which could be used to summarise 
information or note down questions to ask the clinician (Healthwise 2011b, 2012, 
Kaufman et al. 2003, Tiller et al. 2003). One intervention included a list of nine 
questions to ask the healthcare provider (Mayo Clinic 2011). 
 The inclusion and usefulness of personal stories in patient decision support 
interventions is controversial (Winterbottom and Bekker 2009). While stories can 
add credibility, break up complex medical information and help patients imagine 
different outcomes and how they could affect their life, there is a danger that 
patients may identify with some of the patients in the stories and may base their 
decision on what happened to that individual patient. Furthermore, as patient 
stories are often biased, portraying potential outcomes in a balanced way using 
patient stories is also seen as problematic (Redelmeier et al. 1993, Winterbottom 
and Bekker 2009). Despite this on-going debate, almost half of the interventions in 
this study (n=5) included a form of personal story or account (Healthwise 2011b, 
2012, Kaufman et al. 2003, Tiller et al. 2003, van Roosmalen et al. 2004b). Three of 
these presented personal stories as written quotes and two included audio-visual 
accounts of patients’ experiences. 
 More than half the interventions included in this study (n=7) referenced the 
sources they used to enable patients to obtain further information if they wished 
(Healthwise 2011b, 2012, Kurian et al. 2012, Mayo Clinic 2011, Metcalfe et al. 2007, 
Tiller et al. 2003, van Roosmalen et al. 2004b). The Australian booklet also included 
contact details of genetics services throughout Australia and referred to a number 
of websites with further information, such as the cancer council (New South Wales 
Centre for Genetics Education 2008, Tiller et al. 2003). The intervention by Metcalfe 
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et al. (2007) additionally provided quality statements about the evidence used to 
support the included information and risk estimates. 
6.3.6 Evaluation 
Seven of the decision support interventions included in the analysis had been 
evaluated before publication. Four interventions were evaluated in five randomised 
trials (Hooker et al. 2011, Schwartz et al. 2009, Tiller et al. 2006, van Roosmalen et 
al. 2004a, van Roosmalen et al. 2004b) and three were piloted with small groups of 
women (Bhavnani et al. 2002, Metcalfe et al. 2007, Pell et al. 2002). Three 
interventions had been developed by commercial producers (Healthwise 2011b, 
2012, Mayo Clinic 2011) and one had only been published in 2011 (Kurian et al. 
2012), therefore no information was available on evaluation of these interventions. 
The Australian decision support booklet developed by Tiller et al. (2003) was 
compared to an educational pamphlet in a randomised controlled trial with 109 
women (Tiller et al. 2006). The study measured changes in knowledge, intrusive 
thoughts, anxiety, decisional conflict and uncertainty over three time points. 
Additionally, acceptability and helpfulness of the material, as well as its influence on 
the decision, were assessed at the final time point. The trial found higher levels of 
acceptability of materials in the intervention group, but no difference in perceived 
helpfulness when compared to an educational leaflet. There were no significant 
differences in any of the psychological outcomes and only small to medium effect 
size differences associated with knowledge between intervention and control 
group. The only significant outcome measure was decisional conflict, which was 
reduced in the intervention group 2 weeks post-intervention; however this effect 
was no longer significant at 6 months. Those who had received the intervention 
were also significantly more likely to indicate that it had influenced their decision. 
No differences in the actual decisions were noted. 
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Schwartz et al. (2009) evaluated the interactive CD-Rom developed by 
Kaufman et al. (2003) in a randomised trial with 214 women. The study assessed 
changes in decisional conflict and decision satisfaction, as well as effects on decision 
making in an intervention group compared to a control group that received usual 
care. Among women who reported being undecided at the point of randomisation, 
the intervention significantly increased the number of individuals who could decide 
on a management option. In this group, it also significantly decreased decisional 
conflict and increased satisfaction. In contrast, the intervention did not significantly 
influence these outcomes in individuals who had already made a management 
decision at the point of randomisation. The authors therefore suggest that the 
intervention may only benefit those individuals who struggle to make a decision, 
and not those who have already made a decision shortly after receiving their test 
result (Schwartz et al. 2009). Hooker et al. (2011) reported on the same trial, but 
focused on effects of the intervention on several measures of distress. They found 
that receipt of the intervention after BRCA testing resulted in higher sustained 
cancer-specific and genetic testing-specific distress at 1 month post-intervention. 
The authors suggest that sustained distress may be indicative of enhanced cognitive 
processing and deliberation about decision relevant information in the short-term 
(Hooker et al. 2011). 
In a combined randomised trial of two interventions, van Roosmalen et al. 
(2004a, 2004b) trialled a booklet/video and SDM intervention. Measures included 
well-being, treatment choice and decision-related outcomes. Additionally, 
outcomes were assessed for the information booklet and video intervention 
through knowledge, perceived amount of and satisfaction with information and risk 
perception. Patients (n=384) were randomised after providing a blood sample for a 
BRCA mutation test (van Roosmalen et al. 2004b). The intervention group received 
the booklet and video before, and the control group after, they had received their 
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test result. No significant effects of the booklet/video were found on measures of 
well-being or decision related outcomes between groups. However, the 
intervention significantly improved subjective knowledge and satisfaction with the 
information provided and more women in the intervention group favoured surgery 
before disclosure of the results. Some improvements in risk accuracy in the 
intervention group were also noted. Once mutation status was confirmed, 88 
carriers of mutations in BRCA were randomised a second time to receive the SDM 
intervention or usual care (van Roosmalen et al. 2004a). This intervention showed 
long-term significant positive effects on depression and intrusive thoughts, which 
declined, and general health, which improved. No significant effects were found on 
anxiety, treatment choice and decision-related outcomes, with the exception that 
the intervention group had stronger preferences and felt that they had weighed the 
risks and benefits of the available options. 
Bhavnani et al. (2002) conducted a pilot evaluation through a qualitative 
study using semi-structured interviews with 29 women before and after they had 
used one of two interventions: a decision chart (n=10) or clinical guidance 
programme (n=19) with a facilitator in the clinic. Women were asked about their 
expectations of the intervention, the process of using the intervention, the impact it 
had on their decision and their reaction to the output. Most women were satisfied 
with the chart’s output, some even felt empowered after using it, but it did not 
appear to change women’s initial attitudes towards their preferred management 
option. The chart did, however, encourage communication between patients and 
facilitators. The clinical guidance program was more difficult to use and women 
appeared surprised about the definitive statement provided at the end of the 
intervention, which read: ‘Given the information you have provided, the CGP 
recommends the [option]’ (Bhavnani et al. 2002). When this guidance statement 
differed from women’s preferred management option, they tended to reject the 
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program’s advice and used it instead to consolidate their decision by arguing that 
there was almost no difference between the quality adjusted life expectancy gained 
with either option. 
Metcalfe et al. (2007) developed and piloted their intervention in a non-
randomised, before and after evaluation with 21 carriers of mutations in BRCA1/2. 
Outcomes assessed in this study included knowledge, decisional conflict, choice 
predisposition, cancer-specific distress and acceptability of the materials. Overall, 
the intervention appeared to increase knowledge and reduce decisional conflict. 
However, it had no effect on cancer-related distress. The majority of women 
reported high acceptability (Metcalfe et al. 2007). This intervention was further 
adapted by Culver et al. (2011). 
6.3.7 Theoretical basis or framework 
Three interventions were based on at least one theory, model or framework 
that was specified in associated publications (Culver et al. 2011, Kaufman et al. 
2003, Metcalfe et al. 2007, Schwartz et al. 2009, Tiller et al. 2003). Eight 
interventions did not provide information on underlying theory through associated 
publications or the intervention itself (Bhavnani et al. 2002, Healthwise 2011b, 
2012, Kurian et al. 2012, Mayo Clinic 2011, Pell et al. 2002, van Roosmalen et al. 
2004a, van Roosmalen et al. 2004b). 
The Ottawa Decision Support Framework (ODSF) (O'Connor 2006, O'Connor 
et al. 1998) was quoted as the underlying framework in all interventions that 
specified a theory base (Metcalfe et al. 2007, Schwartz et al. 2009, Tiller et al. 2003). 
The ODSF attempts to guide the design of patient decision support interventions by 
identifying modifiable determinants of decisions, such as inadequate knowledge, 
unclear values, lack of support and undesirable stressors, that should be addressed 
by interventions (O’Connor, 1998). Publications did not specify how the ODSF was 
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used to guide development (Metcalfe et al. 2007, Schwartz et al. 2009, Tiller et al. 
2003).  
Expectancy-value decision theories were mentioned in relation to the 
Australian decision support booklet (Fishbein 1963, Tiller et al. 2003). Expectancy-
value decision theories postulate that values are central in determining a person’s 
attitude towards an option and thus their final choice. Value clarification exercises 
in decision support interventions therefore aid decision making by helping decision 
makers examine their values and beliefs about the different options. However, no 
details on how these theories informed the design of the Australian intervention 
were provided (Tiller et al., 2003). 
Multi-attribute Utility Theory (MAU), which is derived from Expected Utility 
Theory (Bernoulli 1954), was used in the development of the interactive CD-Rom 
intervention by Kaufman et al. (2003). MAU theory postulates that the best option 
is the one which maximises positive and minimises negative outcomes and can be 
identified by weighing different attributes of options (Carter et al. 1986, Keeney and 
Raiffa 1993, Torrance et al. 1982, Weber and Borcherding 1993). The authors 
describe in detail how MAU theory was applied during development of the value 
clarification exercise in this intervention (Kaufman et al. 2003).  
Overall, few of the interventions included in this study stated an underlying 
theory and in those that did, most did not report how this theory was actually 
applied to the development process. Furthermore, those theories which were used 
primarily applied to the information and value clarification components of the 
interventions and did not explicitly cover appraisal and coping as processes that are 
intrinsically related to decision making. 
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6.4 Applying the CODE framework 
 The CODE framework, which describes patient decision making and coping 
as interlinked processes, has been discussed elsewhere (see Chapter 2; Witt et al. 
2012). In the previous chapter, this framework was applied to decisions about 
RRSO. The content of patient decision support interventions and materials in this 
study was mapped onto the questions within the RRSO-adapted CODE framework 
to determine which questions were addressed by these tools, and which were not. 
Interventions that address most of the questions proposed within the RRSO-
adapted CODE framework may support decision making, as well as coping 
processes, in the context of increased risk of ovarian cancer, thereby providing a 
more holistic support tool for deliberations about RRSO.  
6.4.1 Coverage of primary appraisal content 
 During analysis, two types of interventions had to be distinguished: those for 
independent use by patients and those for use with a facilitator or health 
professional. The former generally covered many questions posed during primary 
appraisal within their information content, while the latter covered far fewer 
questions, mainly in the ‘presentation of options’ and ‘preference construction’ 
phases (Figure 6.2; Bhavnani et al. 2002, Kurian et al. 2012, Pell et al. 2002, van 
Roosmalen et al. 2004a). However, it should be noted that, while not explicitly 
stated, questions may be discussed in conversation with the health professional 
delivering the intervention. 
 Interventions for women at increased risk of ovarian cancer that consider 
RRSO as a strategy to prevent ovarian cancer covered information regarding ovarian 
cancer, risk, RRSO and other management options most often, thereby supporting 
cognitive appraisal of the health condition and management options (Healthwise 
2011b, Mayo Clinic 2011, Tiller et al. 2003, van Roosmalen et al. 2004b).  
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Figure 6.2 - The CODE framework assessment sheet and coverage of questions during primary appraisal by interventions in the review 
 
Disclosure of ovarian cancer risk 
status  Presentation of choice  Presentation of options (RRSO or symptom awareness)  Preference construction  
 
 
 
 
Cognitive 
 
 
 
 
Primary 
Appraisal 
 
 
 
 
 
Emotional 
What is ovarian cancer (OC)?
2,3a,4,8
 
What is OC risk?
1,2,3a,7,8
 
How high is my risk?
3a,5,6,7
 
What caused me to have an 
increased risk of OC?
2,3a
 
How does my family history 
influence OC risk?
1,2,3a,7,8
 
Do I have a faulty gene?
1,2,3a
 
Does my risk change over time?
2,7
 
How could my risk affect my 
children? 
How will my risk affect my life? 
What can be done about my OC 
risk?
1,2,3a,4,7,8
 
What are my past experiences of 
OC? 
How do I feel about OC and my 
risk?  
What does ‘choice’ mean 
in this context? 
Why is there a choice for 
women at risk of OC? 
When should I decide?
2,4
 
What is at stake in this 
choice?
2
 
Who can decide?
1,5,8
 
Who else should I 
involve?
2
 
Can I change my mind? 
How can I decide?
1,2
 
How do I feel about 
choosing? 
Can I deal with choosing 
myself?  
What is risk-reducing bilateral salpingo oophorectomy (RRSO) / 
symptom awareness?
1,2,3a,4,5,6,7,8
 
Why is symptom awareness the only alternative? 
What does RRSO involve?
1,2,3a,4,5,6,7,8
 
How long would it take to recover from RRSO?
1,2,3a,4,6,8
 
What would happen if I do not have surgery?
1,5,8
 
What are the risks and benefits of RRSO / symptom 
awareness?
1,2,3a,3b,4,6,7,8
 
What are the complications of RRSO?
2,3a,4,6
 
Would I go into an early menopause?
1,2,3a,4,5,6,7,8
 
Would I have to take hormone replacement?
2,3a,4,6,8,9,10
 
How would RRSO affect my life?
2,3a,3b,4,6,9,10
 
Do I need to have my womb removed as well?
2,4,8
 
Is there a chance cancer might be found during RRSO?
1
 
Is there any screening available for OC?
1,2,3a,3b,4,7
 
Is there anything else I can do to avoid OC?
1,2,4,7
 
What did others decide? How did they fare?
1,2,3a,7
 
Can I make sure I get a good surgeon in a good hospital? 
Do I have experiences that could help me imagine what it would 
be/feel like if I had / didn’t have RRSO? 
How do I feel about having / not having RRSO? 
Is this the right time to 
decide?
2,3b,4
 
Is RRSO / not having RRSO 
congruent with my/my 
family’s/partner’s/doctor’s 
beliefs goals and 
values?
1,2,3b,6,8,9,10
 
Have I completed my 
family?
2,4,6
 
Can I afford to take time off? 
Could I get screening or some 
other additional care?
1,2,3a,3b,4,7
 
Do I think I could detect the 
symptoms of OC? 
Do I feel ready to decide?
1,2,3b,8
 
How likely is it that I will regret 
having / not having RRSO?  
Intervention number indicated in superscript if item is addressed (items that were not addressed in any of the interventions indicated in red): 
RRSO to prevent breast cancer: 
5 – Kurian 2012 
6 – Metcalfe 2007 & Culver 2011 
7 – Kaufman 2003 
RRSO with planned hysterectomy: 
8 – Healthwise 2012 
9 – Bhavnani 2002 
10 – Pell 2002 
 RRSO to prevent ovarian cancer: 
1 – Healthwise 2011 3b –  Roosmalen 2004a 
2 – Tiller 2003  4 – Mayo Clinic 2011 
3a – Roosmalen 2004b 
2
07
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In contrast, interventions focused on RRSO as an option to prevent breast cancer 
included less information about effects of surgery on ovarian cancer risk, although 
some did make reference to the reduction in risk of ovarian cancer following RRSO 
(Culver et al. 2011, Kaufman et al. 2003, Kurian et al. 2012, Metcalfe et al. 2007). 
Similarly, interventions for women undergoing a planned hysterectomy only 
included limited information on ovarian cancer risk or alternative management 
options, as these interventions were not aimed at women with an increased risk of 
ovarian cancer (Bhavnani et al. 2002, Healthwise 2012, Pell et al. 2002). 
 Overall, coverage of questions during primary appraisal of the health threat 
and available options was adequate, with the majority of interventions addressing 
at least one, and frequently more, questions posed in the framework. Most 
supported cognitive appraisal processes by providing factual information. Fewer 
supported emotional appraisal by encouraging patients to envisage how their risk 
and potential outcomes of options might affect their life and to consider their own 
experiences and feelings. None explained why watchful waiting / symptom 
awareness is the only official alternative management option to RRSO. However, 
this may be due to the fact that none of the interventions aimed at high risk women 
was developed for the UK population (which currently has no ovarian screening 
programme) and guidelines for ovarian cancer screening and chemoprevention may 
differ between countries. Therefore, while other management options may be 
recommended in some countries, the UK guidelines currently do not recommend 
ovarian screening or chemoprevention (National Institute for Health and Care 
Excellence 2011, 2013). 
 Coverage of questions regarding choice was less comprehensive. Only five 
interventions addressed questions posed within the primary appraisal of choice 
section of the framework (Healthwise 2011b, 2012, Kurian et al. 2012, Mayo Clinic 
2011, Tiller et al. 2003). The decision support booklet by Tiller et al. (2003) gave an 
indication of when surgery is most effective, listed disadvantages, encouraged 
209 
 
 
 
patients to involve others, such as genetic counsellors and family members, and 
provided a step by step guide to reaching a decision. Conscious appraisal of 
emotional responses to the choice was not encouraged by interventions in this 
review; therefore, content was again biased towards cognitive appraisal. 
 Preference construction was supported by interventions that included 
explicit value clarification exercises and thereby helped patients to assess 
congruence between options and values, to consider timing and to appraise 
readiness to decide (Bhavnani et al. 2002, Culver et al. 2011, Healthwise 2011b, 
2012, Metcalfe et al. 2007, Pell et al. 2002, Tiller et al. 2003, van Roosmalen et al. 
2004a). Items within most of these value clarification exercises exclusively covered 
medical or physical attributes of option(s), such as reduction in cancer risk and side 
effects (Bhavnani et al. 2002, Pell et al. 2002, Tiller et al. 2003, van Roosmalen et al. 
2004a). Psychological and emotional aspects, such as worry, anxiety and body 
image, were included less frequently (Culver et al. 2011, Metcalfe et al. 2007). The 
intervention by Kurian et al. (2012) showed the effects of different management 
strategies, but did not explicitly ask the patient to attribute values to these 
outcomes. The intervention by Kaufman et al. (2003) included a value clarification 
exercise; however, as stated earlier, it did not include options for risk reduction of 
ovarian cancer. 
6.4.2 Coverage of secondary appraisal content 
 Coverage of questions posed during secondary appraisal of cancer risk, 
choice and options was poor (Figure 6.3). While most interventions included 
information about ovarian cancer, risk and available options, enabling patients to 
find out more by themselves and referring patients to health professionals for 
further discussion, only one encouraged seeking informational, instrumental and 
emotional support from family and friends (Tiller et al. 2003). None touched on 
emotion focused coping options such as religious coping, positive reframing, 
relaxation or meditation. 
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Figure 6.3 - The CODE framework assessment sheet and coverage of questions during secondary appraisal by interventions in the review 
 
Disclosure of ovarian cancer risk 
status  Presentation of choice  Presentation of options (RRSO or symptom awareness)      & Preference construction 
 
 
Problem-
focused 
 
 
 
Secondary 
Appraisal 
 
 
 
Emotion-
focused 
Can I find out more?
1,2,3a,4,6,7,8
 
Can my doctor help?
1,2,3a,4,5,6,7,8 
Can I trust my doctor? 
Can I seek instrumental / 
informational support from my 
family / friends / a peer or 
support  group?
2
 
Can I seek emotional support 
from my family / friends / a peer 
or support group?
2
 
Can I turn to my faith? 
Can I change how I feel about 
knowing my OC risk? 
Can I express my fear of cancer? 
Can I do something to stop 
thinking about my OC risk? 
Can I do something to reduce the 
stress my OC risk is causing me? 
Could I ignore my OC risk? 
Can I create an action 
plan to approach this 
decision?
1,8
 
Can I seek instrumental 
/ informational support 
from my family / friends 
/ a peer or support 
group?
2
 
Can I seek emotional 
support from my family 
/ friends / a peer or 
support group?
2
 
Can I let someone else 
decide for me?
1,8
 
Could I refuse to choose 
and just not make this 
decision?  
Is there someone or something that could help me to compare and weigh my 
options?
1,2,3b,5,6,8,9,10
 
Can I speak to someone who has already made this decision and is living with the 
consequences? 
Can I seek instrumental / informational support from my family / friends/ a peer or 
support group?
2
 
Can I seek emotional support from my family / friends / a peer or support group?
2
 
Can I do something to stop thinking about this decision? 
Can I do something to reduce the stress this decision is causing me?  
Intervention number indicated in superscript if item is addressed (items that were not addressed in any of the interventions indicated in red): 
RRSO to prevent breast cancer: 
5 – Kurian 2012 
6 – Metcalfe 2007 & Culver 2011 
7 – Kaufman 2003 
RRSO with planned hysterectomy: 
8 – Healthwise 2012 
9 – Bhavnani 2002 
10 – Pell 2002 
 RRSO to prevent ovarian cancer: 
1 – Healthwise 2011 3b –  Roosmalen 2004a 
2 – Tiller 2003  4 – Mayo Clinic 2011 
3a – Roosmalen 2004b 
2
10
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Two interventions allowed users to create an action plan using their preliminary 
decision as a starting point to decide about the next steps they would take  
(Healthwise 2011b, 2012). These aids also emphasised that patients could let their 
doctor make a recommendation for them.  
 Interventions with explicit value clarification exercises indirectly supported 
coping by providing a means of comparing and weighing options, thereby 
addressing the corresponding question posed during secondary appraisal in the 
option and preference construction section of the framework. The intervention by 
Kurian et al. (2012) allowed users to directly see the effects of having/not having 
RRSO on survival and therefore also allowed comparison of options, although 
individual patient values were not considered explicitly. None of the interventions 
provided information about peer support and possibilities to hear from or contact 
others who have gone through the decision.  
6.5 Discussion 
6.5.1 Discussion of findings 
In the current chapter, eleven decision support interventions were identified 
that included the option of RRSO. These were examined with regards to their 
format, design, information content, value clarification components, effectiveness, 
and use of an underlying theory or framework. Interventions varied widely in their 
format and design as well as in the types and detail of information included. Two 
basic formats of interventions were distinguished: those designed for independent 
use by patients, and those delivered by trained facilitators or health professionals. 
Previous research has found that most interventions available to date fall within the 
former category (Elwyn et al. 2010a). Therefore, it is not surprising that the majority 
of interventions in this study were comprised of self-administered booklets, 
websites or other types of decision support materials. Among interventions 
delivered by trained personnel, Elwyn et al. (2010a) make a further distinction, 
differentiating between interventions for use in face-to-face clinical encounters and 
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interventions delivered across several socially-mediated encounters. The former 
may include interventions such as those described by Bhavanani et al. (2002) and 
Kurian et al. (2012), which are administered in face-to-face encounters. The latter 
may include interventions such as that trialled by van Roosmalen et al. (2004a), 
delivered over a number of encounters, which may be face-to-face or via phone 
(Elwyn et al. 2010a). 
6.5.1i Information content: The information provided within these formats 
differed greatly. Interventions designed for independent use by patients tended to 
include more comprehensive information on the decision and management 
options, plus additional materials, such as patient stories. Interventions delivered 
by trained personnel usually only included a minimum amount of information. 
These types of interventions are often preceded by counselling sessions or other 
written materials that provide information relevant to the decision. Their primary 
aim, therefore, is not to support the exchange of information, but rather to 
facilitate the preference construction stage of decision making (Charles et al. 2005). 
However, some have argued that a requirement for a minimum amount of 
information in all patient decision support interventions would be advantageous to 
achieve a level of standardisation (Elwyn et al. 2009b, Joseph-Williams et al. 2013).  
6.5.1ii Value clarification: Most interventions in the current study included a 
type of value clarification exercise to elicit patient preferences. Interactive value 
clarification exercises allow patients to become more engaged and to actively 
attribute their personal values to different outcomes (Llewellyn-Thomas 2009). This 
can help to visualise values, both for the patients themselves and others, such as 
their clinician or family (Llewellyn-Thomas 2009). Explicit value clarification 
exercises have been shown to lead to more informed, value-adjusted decisions, 
hence it is not surprising that many interventions included a means of value 
clarification (Stacey et al. 2011).  
6.5.1iii Evaluation: A number of interventions had been evaluated in 
randomised trials and small pilot studies. A popular outcome measure for trials of 
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patient decision support interventions is decisional conflict (Charles et al. 2005, 
O'Connor 1995). Three studies in the current analysis used this as the primary 
outcome measure (Metcalfe et al. 2007, Schwartz et al. 2009, Tiller et al. 2006). All 
found a significant reduction in decisional conflict post-intervention. This is in 
accordance with the most recent Cochrane review of patient decision support 
interventions, which concluded that decisional conflict was reduced by 
interventions (Stacey et al. 2011). However, reduction in decisional conflict was no 
longer significant at 6 months post-intervention in one study (Tiller et al. 2006) and 
was only significant in the group of patients that was undecided at randomisation in 
another study (Schwartz et al. 2009). This indicates that there may be limitations to 
the effects of decision support interventions on decisional conflict. Decision regret 
may be a more appropriate measure of the longer-term effects of patient decision 
support interventions (Joseph-Williams et al. 2010). 
Information transfer is another popular outcome to evaluate intervention 
effectiveness, most commonly measured using knowledge assessments (Charles et 
al. 2005). Three studies included a measure of knowledge (Metcalfe et al. 2007, 
Tiller et al. 2006, van Roosmalen et al. 2004b). Two of these found significant 
improvements in knowledge post-intervention (Metcalfe et al. 2007, van 
Roosmalen et al. 2004b), whereas one study showed small to medium 
improvements that were significant at 2 weeks post-intervention, but did not 
persist 6 month post-intervention (Tiller et al. 2006). Overall, these findings are in 
agreement with those of the Cochrane review, which showed that decision support 
interventions increase knowledge (Stacey et al. 2011). 
Psychological outcomes, such as distress, anxiety and intrusive thoughts, 
were assessed in four studies. Tiller et al. (2006) found no significant effect of their 
decision support booklet on psychological outcome measures, including anxiety and 
intrusive thoughts. Similarly, Metcalfe et al. (2007) found no significant effect of 
their intervention on cancer-specific distress. Van Roosmalen et al. (2004a) showed 
that their SDM intervention led to significant long-term reductions in depression, 
214 
 
 
 
intrusive thoughts and general health, but not anxiety. Hooker et al. (2011) found 
that a CD-Rom based intervention (Kaufman et al. 2003) led to sustained higher 
levels of distress 1 month post-intervention. The results of the 2011 Cochrane 
review confirm these contrasting findings, as the authors were unable to establish 
fully whether patient decision support interventions had significant effects on 
anxiety, distress or intrusive thoughts, indicating that the evidence for such effects 
is variable (Stacey et al. 2011). 
6.5.1iv Theoretical basis or framework: Only three of eleven interventions 
explicitly mentioned one or more theories that had guided development (Kaufman 
et al. 2003, Metcalfe et al. 2007, Tiller et al. 2003). This is in agreement with a 
previous study analysing theory use in a set of patient decision support 
interventions included in a meta-analysis (O'Connor et al. 2007), which found that 
only 34% were grounded in theory (Durand et al. 2008). Due to this apparent lack of 
theories to guide goal setting, development, testing and evaluations of patient 
decision support interventions, assessing and explaining the impact of these tools is 
difficult (Charles et al. 2005, Durand et al. 2008). Without a theoretical basis or 
framework, selected outcome measures may not accurately measure concepts 
linked to the goals set out during development of the intervention (Charles et al. 
2005). Elwyn et al. (2011b) examined a number of popular decision making models 
with a view to identify their potential to contribute to the development of 
information and deliberation components and to inform the selection of outcome 
measures. They noted that most theories describe how people make decisions, but 
do not readily address how interventions might help people during this process 
(Elwyn et al. 2011b). Therefore, it may not be surprising that many interventions in 
the current study were found to be lacking a solid theory base. 
6.5.2 Use of the CODE framework as an assessment tool 
The CODE framework was developed to provide a framework that may be 
applied more readily to the development of decision support interventions (Witt et 
al. 2012). Informed by a number of theories and models relevant to decision 
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making and coping, it sets out a series of questions. Provision of answers or 
guidance relating to these questions within an intervention may support cognitive, 
as well as emotional, appraisal processes. Additionally, the framework includes 
questions exploring potential coping options, the answers to which might improve 
awareness of different coping options and ultimately lead to improved coping with 
the health threat, related decision making processes and associated emotions. 
Assessment of interventions against the RRSO-adapted version of the CODE 
framework revealed that cognitive appraisal of the health threat and available 
options was usually adequately facilitated through the provision of information 
within interventions. While cognitive appraisal appeared well supported, emotional 
aspects of appraisal were rarely addressed. This could indicate that it is too 
ambitious to expect patient decision support interventions to support emotional 
appraisal, as this process is a very personal experience that will differ greatly from 
patient to patient. However, encouraging patients to consciously consider their 
feelings and to envisage how outcomes might affect their life could facilitate 
emotional appraisals and affective forecasting (Loewenstein et al. 2001, Wilson and 
Gilbert 2005).  
There also appeared to be a substantial lack of coping advice provided within 
interventions included in the current study. As patients deliberate about healthcare 
decisions, they have to cope with a large quantity of new, and often threatening, 
information regarding their health and their options. Additionally, the mere 
existence of choice in healthcare and of being asked to play an active part in 
decision making may be a new concept for some patients that could result in 
heightened feelings of vulnerability and anxiety (Quill and Cassel 1995, Say et al. 
2006). Coping advice may therefore be beneficial in aiding patients to cope more 
effectively and to regulate their emotions in response to the various threats they 
are facing during deliberation. 
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6.5.3 Results in context 
Numerous decision support interventions have been published in recent 
years with numbers steadily increasing (Ottawa Hospital Research Institute 2013, 
Stacey et al. 2011). However, only a very small proportion of these interventions is 
aimed specifically at women at increased genetic risk of ovarian and/or breast 
cancer, such as carriers of mutations in BRCA. Of the interventions that are 
designed for this population, most are concerned with genetic testing or breast 
cancer risk reduction strategies (e.g. (Healthwise 2011a, McInerney-Leo et al. 2004, 
Wakefield et al. 2008a, Wakefield et al. 2008b). It has been noted previously that 
interventions to help women make decisions about risk management options, 
including RRSO, would be useful (Fang et al. 2005, Howard et al. 2009a). However, 
the current study only identified eleven interventions that included information 
about RRSO, only five of which specifically focused on reducing elevated ovarian 
cancer risk. 
Furthermore, interventions included in the current study were mostly 
developed for non-UK populations. Most had been developed in the United States, 
two in the Netherlands, one in Canada and one in Australia. As guidelines and 
available options may differ between countries, these interventions cannot be 
readily adopted in the UK. For example, in the USA oral contraceptives are 
recommended for carriers of mutations in BRCA1/2 to achieve a reduction in the 
risk of ovarian cancer, whereas UK guidelines do not recommend the use of oral 
contraceptives solely for this purpose (ACOG Committee on Practice Bulletins-
Gynecology 2006, National Guideline Clearinghouse 2011, National Institute for 
Health and Care Excellence 2013). This demonstrates the need for interventions 
tailored to the UK population that conform to UK policy and guidelines. 
Only two interventions had been specifically developed for UK women and 
these interventions focused on decisions regarding RRSO as a concomitant 
procedure to a planned hysterectomy (Bhavnani et al. 2002, Pell et al. 2002). This 
shows the current lack of decision support available outside clinical consultations 
217 
 
 
 
tailored to the needs of women at increased risk of ovarian cancer in the UK. It was 
previously suggested that information regarding RRSO and other options, as well as 
additional forms of support, would be beneficial to address women’s knowledge 
gaps regarding their management options and to support women during 
deliberation (Brain et al. 2004). Furthermore, women themselves noted that it was 
difficult to obtain reliable information and that they had received conflicting advice 
from different health professionals (Chapter 4). This suggests that additional 
materials and interventions would likely be well received by the target population. 
However, while decision support in healthcare is a rapidly growing field and 
more and more decision support interventions are developed, a substantial number 
of new interventions are never implemented in clinical practice (Bhavnani and 
Fisher 2010, Elwyn et al. 2010b, Frosch et al. 2011). Four of the interventions 
included in this study were not implemented after initial evaluation, including the 
two interventions developed in the UK (Bhavnani et al. 2002, Pell et al. 2002, van 
Roosmalen et al. 2004a, van Roosmalen et al. 2004b). This shows that considerable 
effort goes into the design and primary evaluation of interventions, particularly in 
academia, but only a limited number actually become available to patients 
(Bhavnani and Fisher 2010, Elwyn et al. 2008, Elwyn et al. 2013c, Frosch et al. 2011, 
Harter et al. 2011). This may be due to a variety of factors. Three of these 
interventions were designed for delivery by trained facilitators, which is associated 
with substantial staff and time requirements that may not be feasible in clinical 
practice and could hamper implementation (Bhavnani et al. 2002, Pell et al. 2002, 
van Roosmalen et al. 2004a). Two of these were also outdated by the time primary 
evaluation was complete due to a change in clinical guidance (Bhavnani et al. 2002, 
Pell et al. 2002). Others might encounter problems due to a lack of willingness on 
the part of health professionals to use and recommend them (Coulter 2010). 
This lack of implementation beyond the duration of research has led some 
authors to suggest that shorter tools, which require less time and money for 
development and slot more readily into the routine flow of consultations, may be 
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easier to implement  (Elwyn et al. 2013b, Marrin et al. 2013). These tools might 
bypass some of the practical challenges that have stifled longer, self-administered 
interventions in the past, such as a lack of time to read through and digest 
information or a need for follow-on consultations post-intervention (Bhavnani and 
Fisher 2010). However, the amount of information that can be delivered in such 
short tools is limited and may not cater for the needs of those patients who wish to 
adopt a deliberative decision making approach (e.g. delayed deciders; see section 
4.4.1vii, Chapter 4). Therefore, a ‘one-size-fits-all’ intervention may not be feasible. 
However, there may be scope to develop multipart decision support interventions 
that slot into clinical workflows and support different approaches to deliberations, 
such as fast and frugal, as well as deliberative, approaches. For instance, a two-part 
intervention consisting of a short and a more extensive tool could address these 
issues. The shorter component may be readily implemented into clinical workflows 
and could cater for the needs of immediate deciders who use fast and frugal 
heuristics to make decisions and do not wish to learn further details. The more 
extensive part could act as a complementary resource for those patients who wish 
to find out more, take a deliberative approach and/or take longer to decide 
(delayed deciders). Chapter 7 outlines the development of such a two-part decision 
support intervention. 
6.5.4 Strengths and limitations 
The current study aimed to identify a range of patient decision support 
interventions that included information about RRSO. Therefore, the search strategy 
was purposefully wide in order to include interventions with information about 
RRSO that were not aimed at women at increased risk (e.g. those which considered 
RRSO as a concomitant procedure to hysterectomy). Supplementary searches of 
patient decision support intervention databases and websites identified further 
interventions, which had been developed by commercial developers and would not 
have been identified through the literature search. Therefore, it is likely that the 
interventions analysed in this chapter represent the majority of interventions 
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developed so far that include the option of RRSO. However, due to the search 
strategy employed, interventions in languages other than English might have been 
missed, unless reports about these interventions were published in English. 
Although this may have resulted in the omission of some interventions, it is unlikely 
to have had a major effect, as most interventions to date have been published in 
English speaking countries (Stacey et al. 2011). Furthermore, non-English 
interventions with associated publications in English, such as the two Dutch 
interventions, were included in the study (van Roosmalen et al. 2004a, van 
Roosmalen et al. 2004b).  
 This is the first study to attempt using an adapted version of the CODE 
framework to assess the content of interventions (Witt et al. 2012). The 
framework’s structure allows relatively easy application as an assessment tool, as 
reviewers simply need to examine whether the intervention content addresses 
questions outlined in the framework, without the need for extensive adaptation. 
Therefore, this study demonstrates that adapted versions of the CODE framework 
may be readily used to assess the content of decision support interventions relating 
to other preference-sensitive healthcare decisions. However, as this was the first 
time the framework was employed as an assessment tool, no inferences can be 
made about the quality of interventions using only the results from assessment 
with the adapted CODE framework. Therefore, interventions were further 
examined using a data extraction form based on the IPDAS checklist to supplement 
the results of assessment with the CODE framework and to additionally provide 
information about intervention design, theory-base and effectiveness. 
Some limitations of this approach should be noted. The data extraction form 
used to assess information and other content of interventions was not validated 
prior to application. However, it was based on items in the IPDAS checklist, which 
was developed through a Delphi consensus process and has since been used to 
assess a number of patient decision support interventions (Elwyn et al. 2006, Elwyn 
et al. 2009b, Ottawa Hospital Research Institute 2013). Furthermore, during 
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development the extraction form was applied to two interventions that included 
the option of RRSO and subsequently amended to improve relevance of the items. 
Detailed validation of the form itself was not possible due to time constraints. In 
the future, the extraction form would benefit from further content, as well as 
construct, validation to ensure items are clear and assess chosen constructs 
satisfactorily. 
During analysis, only two interventions were assessed by two independent 
raters. Ideally, all interventions should have been double rated; however, due to 
time and staff limitations this was not possible. Inter-rater consistency was high and 
any discrepancies were resolved through discussion. In order to increase 
consistency in the ratings of the remaining interventions, the two interventions 
were double rated and discussions were scheduled before the other interventions 
were assessed, so that rater 1 (Jana Witt) could then rate the remaining 
interventions with this in mind. 
6.5.5 Conclusions 
 Out of eleven patient decision support interventions identified that included 
the option of RRSO, only five were focused on managing risk of ovarian cancer in 
women at increased genetic risk. None of these had been developed for the UK 
population nor conformed to UK guidelines. Therefore, none are readily adoptable 
in the UK. Furthermore, while interventions focused on information provision to 
support cognitive appraisal, most lacked guidance on emotional appraisal, coping 
and emotional well-being, thus insufficiently supporting these aspects of decision 
making. 
 Chapter 3 highlighted the complexity of decisions about RRSO and Chapter 4 
emphasised that women in the UK struggle with this decision and would welcome 
additional support materials. Therefore, there is scope for a patient decision 
support intervention tailored to the needs of women at increased genetic risk of 
ovarian cancer in the UK that conforms to UK guidelines and includes coping advice. 
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Ideally, this intervention would consist of two complementary parts, a short tool, 
which can be readily embedded into clinical workflows, and a more extensive tool, 
which provides detailed information, coping advice and a value clarification 
exercise. Chapter 7 outlines the development of such an intervention. 
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7 Developing a decision support intervention for women at 
increased risk of ovarian cancer 
 
7.1 Introduction 
Decision making regarding risk-reducing surgery in the context of increased 
genetic risk of cancer is complex, as shown in Chapters 3 and 4. Women making 
decisions about risk-reducing bilateral salpingo-oophorectomy (RRSO) consider a 
number of medical, psychological, social and other factors during their 
deliberations and often struggle with making a final decision (Chapters 3 and 4; 
Fang et al. 2005, Howard et al. 2009a, Lifford et al. 2012). Currently, decision 
support for these women is limited to consultations in genetics services and few 
evidence-based additional support materials exist. Patient decision support 
interventions that include the option of RRSO often are not specifically aimed at 
women at increased genetic risk, and many have been developed outside the UK 
context (Chapter 6). These findings suggest that an intervention specifically aimed 
at women in the UK, who are at increased genetic risk of ovarian cancer and making 
decisions about RRSO, would be useful to complement clinical genetics services. It 
has previously been argued that deliberations and coping are linked, 
interdependent processes (Chapters 2 and 5; Witt et al. 2012). Hence, an 
intervention that facilitates emotional, as well as cognitive, processing and 
appraisal of coping options might benefit patients and provide a more holistic 
approach to decision support than educational materials alone. Therefore, this 
chapter aims to use the RRSO-adapted CODE framework (Chapter 5) as a 
theoretical basis to develop a decision support intervention for women at increased 
genetic risk of ovarian cancer in the UK that supports cognitive and emotional 
appraisal, and coping processes.  
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As discussed in Chapter 4, the preference construction pathway can vary 
depending on women’s values, goals and past experiences as well as various 
barriers and facilitators that may influence deliberations (Howard et al. 2011). 
Women may be able to reach an immediate decision based on fast and frugal 
heuristics (immediate deciders) or may prefer a more deliberative approach and 
take longer to reach a decision (delayed deciders) (see section 4.4.1vii, Chapter 4). 
It is likely that these types of deciders differ in information processing styles, 
preferences for mode of delivery and amount of information, emotional appraisal 
and need for emotional support, as well as coping strategies. Therefore, a one-size-
fits-all solution to decision support in this context is unlikely. Hence, the patient 
decision support intervention developed in this chapter is split into two parts: a 
brief Option Grid and a longer tool called the ‘Oophorectomy Decision Explorer’ 
(OvDex). It was envisaged that this separation would cater for the different 
deliberation styles (i.e. immediate deciders and delayed deciders, Chapter 4) and 
would additionally aid implementation. The stand-alone Option Grid was designed 
to be used during consultations to initiate discussions about options and to enable 
patients to highlight the issues most important to them (Elwyn et al. 2013b). It may, 
in conjunction with advice from a health professional, provide sufficient 
information for immediate deciders to base their decision on. The grid can be taken 
home after the consultation to act as a memory aid and to support discussion with 
important others. If women wish to learn more about their risk and available 
management options, the grid then refers patients to OvDex. This may be especially 
helpful for delayed deciders. The Option Grid may additionally enable faster 
implementation of the whole intervention, as a short grid may be more readily 
integrated into clinical workflows than more extensive tools (see section 6.5.3, 
Chapter 6; Elwyn et al. 2013b).  
It has previously been recommended that goals of patient decision support 
interventions should be defined prior to development and that developers should 
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adhere to relevant theory throughout (Charles et al. 2005, Durand et al. 2008). The 
intervention developed in this chapter will have four main goals: 
1. Provide evidence-based information to support appraisal processes, in order 
to improve knowledge and accuracy of risk perceptions and to encourage 
deliberation about choice/options (Janis and Mann 1977, Leventhal et al. 
1980, Power et al. 2011, Svenson 1992, Witt et al. 2012); 
2. Provide information in a way that facilitates affective forecasting, in order to 
improve predictions of reactions to and impacts of future states and to 
support emotional appraisals (Wilson and Gilbert 2003, 2005); 
3. Provide coping advice to improve awareness of coping options and support 
coping efforts, in order to support deliberation and reduce emotional 
distress and anxiety (Balneaves and Long 1999, Lazarus et al. 1985, Witt et 
al. 2012); 
4. Provide tools for value clarification to support preference construction, in 
order to reduce decisional conflict and improve value-adjustment of 
decisions (Gigerenzer 2004, Janis and Mann 1977, Svenson 1992). 
The intervention developed in this chapter aims to achieve these goals by 
providing answers to the questions pertinent to the decision, as outlined in the 
RRSO-adapted CODE framework (Chapter 5). Cognitive appraisal may be supported 
by educational materials offering factual information in response to questions. In 
contrast, emotional appraisal may not be sufficiently supported by factual 
information alone, as it has been established that individuals often struggle to 
accurately forecast the duration and intensity of emotions resulting from future 
events (Wilson and Gilbert 2005). This is due to the fact that they do not consider 
other events demanding their attention at the time and tend to underestimate how 
quickly they adjust to unexpected outcomes, whether positive or negative (Wilson 
and Gilbert 2005). In particular, negative outcomes or losses are often predicted to 
225 
 
 
 
have a greater impact than they actually do, leading individuals to avoid losses 
when making decisions (Kermer et al. 2006). Individuals also tend to shy away from 
irreversible options, such as surgery, even though they may be more satisfied with 
an irreversible option (Gilbert and Ebert 2000). Furthermore, when making 
predictions about the future, emotions experienced in the present can contaminate 
imagined reactions to future events (Gilbert et al. 2002). Therefore, apart from 
providing factual information, answers should be written in such a way as to 
facilitate emotional appraisal processes, affective forecasting and consideration of 
coping options (Elwyn et al. 2011b, Wilson and Gilbert 2005). Option Grids support 
value clarification and fast and frugal decision making through direct comparison of 
options (Gigerenzer 2004, Marrin et al. 2013, Svenson 1992). Explicit value 
clarification exercises enable patients to weigh gains and losses associated with the 
option of RRSO, thereby eliciting their personal values and allowing them to 
visualise their preference (Elwyn et al. 2011b, Janis and Mann 1977, Svenson 1992). 
7.2 Methods 
7.2.1 Focus group and interview data  
Recruitment, data collection and data analysis for focus groups and 
interviews were described in detail in Chapter 4 (see section 4.2). During the focus 
groups and interviews, participants were asked to share their views on: (i) the 
decision making process about RRSO (reported in Chapter 4) and (ii) the content 
and format of a possible decision support intervention. Any comments on the latter 
items, i.e. scope for decision support, topics to be covered in an intervention, 
preferred format, style of delivery and layout, were coded under the theme of 
‘decision support’ (Coding Frame in Appendix 7.1). During these discussions 
participants were shown examples of a comparison table of options and a value 
clarification exercise. Details of the coding process and analysis are described in 
Chapter 4, along with data regarding the decision making process about RRSO. Data 
on ideas for format, layout and content are reported in section 7.3.1 of the present 
chapter. Quotes presented in this chapter were selected as examples and were 
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edited to remove word repetitions and irrelevant sections. Where content has been 
removed this is indicated by a […]. Quotes from focus groups are denoted as 
P[1/2/3][S/C/L], where the number describes the participant and the final letter 
indicates the location (S=Swansea, C=Cardiff and L=London). Quotes from health 
professionals are denoted with HP. 
7.2.2 Intervention development process 
 The development process is depicted in Figure 7.1 and followed the MRC 
recommendations for the development of complex interventions (Craig et al. 2008). 
The underlying theoretical basis, i.e. the CODE framework, was developed in 
previous chapters (Chapters 2 and 5) and best available evidence was identified 
through systematic literature searches (see sections 7.2.3 and 7.2.4). The final 
intervention comprises two parts: Option Grids for use in clinic (part 1) and a more 
extensive OvDex website / booklet (part 2). Feedback from women at increased 
genetic risk of ovarian cancer and health professionals guided decisions on format 
and design, as well as content (see section 7.3.1). The RRSO-adapted CODE 
framework acted as a theoretical and practical basis to guide development. The 
individual questions addressed in the intervention were based on questions 
proposed in the framework. Coping advice was included in the intervention in 
accordance with the CODE framework, which postulates that each phase of 
deliberation gives rise to an individual coping process.  
 The Option Grids were developed according to the Option Grid framework 
V0.5 (Option Grid Collaborative 2013) and versions of the grids were also integrated 
in OvDex. As implications of RRSO differ substantially for pre- and post-menopausal 
women, two separate Option Grids were developed, one for each population. The 
longer OvDex tool was developed following recommendations for development of 
decision support interventions outlined previously (Elwyn et al. 2011a, Volk and 
Llewellyn-Thomas 2012). The term ‘intervention’ in this chapter will refer to both 
parts of the intervention, encompassing the Option Grid as well as the longer 
OvDex tool. 
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Figure 7.1 - Intervention development process 
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 Two literature reviews were undertaken to collate evidence about ovarian 
cancer risk, risk management options and coping interventions. Information 
content was developed using the evidence generated through evidence synthesis I 
(see section 7.2.3). Coping advice in OvDex was developed using evidence 
generated through evidence synthesis II (see section 7.2.4). Prototypes of the 
Option Grid and OvDex were reviewed at multiple time points by researchers, 
health professionals and patients (see section 7.2.5-7). To reduce the burden on 
reviewers, the Option Grid was first reviewed as an integral part of the information 
content of OvDex and later developed into a separate item. 
 Development of OvDex was split into two stages: in the first stage the 
information content was developed in written format; in the second stage coping 
advice and a value clarification exercise were developed, and the content was 
converted to an online format. Design of the website was completed in Adobe 
Dreamweaver CS5.5 (Adobe Systems Incorporated 2011) and supported by the 
Cardiff School of Medicine IT office. Development of the JavaScript for the value 
clarification exercise was supported by Cardiff University Information Services 
(INSVR). The website was validated using the Mark-up Validation Service W3C® 
(W3C 2013). An Innovation grant was awarded from the charity Tenovus, which 
allowed the Cardiff-based web design company DigitalMorphosis to contribute to 
the final stages of web development. 
7.2.3 Evidence synthesis I – ovarian cancer risk and risk-reducing surgery 
A systematic literature search focused on RRSO was conducted in April 
2012. Databases (Embase, MEDLINE and PsycINFO) were searched via Ovid for 
studies published within the last ten years, between 2002 and July 2012. Search 
terms used in the key word search were: “risk reducing salpingo oophorectomy”, 
“risk reducing oophorectomy”, “prophylactic oophorectomy”, “prophylactic 
salpingo oophorectomy”, “risk reducing ovarian surgery” and “prophylactic ovarian 
surgery”. Duplicates were removed using the Ovid de-duplicate function prior to 
review of the abstracts. No grey literature was included in this review. Additional 
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papers were identified through a review of the references included in relevant 
papers. These included publications about the surgical menopause and hormone 
replacement following RRSO. Studies were critically appraised using appraisal 
checklists (Appendix 3.1 and 3.2) and results from studies were used as evidence to 
support the information content of the intervention.  
Following feedback from the virtual reference group, this same search 
approach was deployed repeatedly when the material was updated in October 
2012 and January 2013, in order to identify newly published studies relevant to the 
information content in the intervention.  
A complementary search was also carried out using keywords “Lynch 
syndrome”, “HNPCC” or “hereditary non-polyposis colorectal cancer” combined 
with “oophorectomy” and/or “hysterectomy” in October 2012 and January 2013 to 
obtain further information about risk-reducing hysterectomy in conjunction with 
oophorectomy in the context of Lynch syndrome. 
7.2.4 Evidence synthesis II – coping interventions 
A systematic review of the literature concerned with coping interventions 
was conducted in July 2012 to identify coping interventions aimed at populations 
undergoing genetic testing, at individuals at risk of genetic diseases (including 
cancer) or at cancer patients. Databases (Embase, MEDLINE and PsycINFO) were 
searched via Ovid for studies published between 1996 and July 2012. Search terms 
used in the title search are detailed in Table 7.1. Duplicates were removed using the 
Ovid de-duplicate function prior to review of the abstracts. No grey literature was 
included in this review.  
Additional papers were identified through a review of the references 
included in relevant papers. Any studies of interventions were critically appraised 
using the CASP appraisal checklists (Appendix 3.1 and 3.2) and contents of coping 
interventions were then summarised and used to inform the coping advice within 
the OvDex tool. 
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Table 7.1 - Search terms for title search in Ovid 
Term 1 
AND 
Term 2 
AND 
Term 3 
Coping 
Intervention 
Cancer 
Tool 
Aid 
Genetic risk 
Self-efficacy 
Exercise 
Advice 
Leaflet 
Genetic test 
Brochure 
 
7.2.5 Virtual reference group recruitment 
Obtaining feedback from a virtual reference group made up of patients and 
health professionals is helpful in ensuring that stakeholders in the decision 
contribute throughout the development process. This follows the suggested best 
practice for the development of web-based patient decision support interventions, 
as proposed by Elwyn et al. (2011a).  
The virtual reference group for this study consisted of patients and health 
professionals who had previously registered for focus groups or taken part in 
interviews (Chapter 4). They were recruited either directly after the focus group or 
interview, or were invited by email if they had registered for, but were unable to 
attend, the focus group. A study pack containing an information sheet and consent 
form was provided and individuals were given two weeks to consent.  
7.2.6 Virtual reference group data collection 
Feedback from the virtual reference group was obtained in August and 
November 2012. The first round of feedback focused exclusively on the information 
content of the intervention, which was provided to participants in written format. 
The second round requested feedback on all content (including a value clarification 
exercise and coping advice), as well as on design and layout. In the second round 
material was presented to participants online, with a paper version available upon 
request. Participants had three weeks to give feedback in each round. A feedback 
guide with open ended questions was also provided to support the review process; 
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however, participants were allowed to deviate from the suggested structure and 
questions in their feedback if they wished (Appendix 7.2).  
7.2.7 Virtual reference group data analysis 
Written feedback was obtained from participants and collated in one 
document. Comments were coded as ‘positive’, ‘suggestion for improvement’, 
‘emotional responses’ and ‘previously unknown facts’. Within the ‘suggestions for 
improvements’ theme several subthemes were identified according to the type of 
suggestion. These included ‘spelling and grammar errors’, ‘not relevant’, ‘confusing 
or needs rewording’, ‘additions/expansions’, ‘repetition’ and ‘other’. For Round 2 
an additional subtheme was added called ‘website issues’, which included any 
references to technical and display problems with the website. The codes were 
additionally analysed to review differences between patients’ and health 
professionals’ comments. Quotes presented from the virtual reference group are 
denoted with a VR, followed by a number. Each number corresponds to one 
participant. Whether the participant was a patient or a health professional is 
indicated in parentheses after the quote. 
7.2.8 Adaptation 
After each round of feedback from the virtual reference group, the collated 
suggestions for improvements were used to amend the content of the intervention. 
New and supplementary literature searches were conducted to obtain the latest 
research evidence to complement and update the information provided. Changes 
to the layout were made in response to feedback from Round 2 only. 
7.3 Results 
7.3.1 Focus group and interview recommendations 
In focus groups and interviews, participants were asked about their views of 
and ideas for a decision support intervention to support women’s decision making 
about RRSO in the context of increased genetic risk. The data highlighted how such 
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an intervention could be used in clinical practice and provided recommendations 
about the format and content of such a tool. 
7.3.1i Scope for decision support: Health professionals remarked upon the 
current lack of appropriate materials to give to patients, commenting on the low 
quality and on the fact that educational materials without additional features, such 
as value clarification exercises, have failed to facilitate decision making. 
HP6: I hate what we give. It’s terrible. Our patient information leaflet. 
Packed full with information in very small size. […] It’s terrible. 
 
HP7: There is information leaflets and DVDs and letters and we are still 
here today […]. So I don’t know whether information is the answer to 
the question. It will contribute to the answer, but it’s not the whole 
answer. Certainly not. 
 
Some acknowledged that other countries offered more information and advice in 
written and web-based formats, but remarked that this was not directly applicable 
to patients in the UK. 
HP10: They [patients] can read about MD Anderson Cancer Centre [USA] 
but they are never going to go there. You know, what you want to 
know is what my local hospital can offer. 
 
Patients spoke about the difficulty of finding information themselves, especially 
highlighting the problem of identifying reliable, trustworthy and relevant 
information via the internet. 
P2S: I don’t know what I haven’t had, but I just feel like there is something I 
haven’t had. There is something missing […]. They refer you to this and 
they refer you to that […].I’ve gone into [the internet] […] and you just 
get swamped. Depending on what website you look at it will tell you 
different things.  
P3S: It does yeah.  
P2S: And you just think: “Well I’ll read that one and then I’ll go into one a 
bit further down.” And I’ll think: “Well it’s the same sort of thing but 
it’s slightly different.” And I just gave up then, I thought I can’t be 
bothered.  
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P3S: Unless you’re going on the internet and you’re literally trawling 
through everything and trying to ignore all the crap and take in all 
the stuff that is relevant to you […], unless you’re a doctor really, you 
don’t know really what’s relevant to you, do you? 
 
Professionals also emphasised the need for reliable information and could see a 
role for novel materials that they would refer patients to, knowing that the 
information within it was trustworthy and up to date. 
HP2: People need to know that the decision aid is evidence-based, is reliant 
on strong research studies and therefore that they are able to use the 
important criteria when thinking about a decision… 
 
HP5: …if there was a decision aid that could give women clear information, 
I think that that would definitively be something that I could see a role 
for in my clinic […]. I think it would be a very helpful resource… 
 
Some spoke about how the intervention could be used by patients to facilitate 
deliberation and information processing in order to reach an informed, value-
adjusted decision. 
HP7: A woman could take that [home] and reflect on it as long as she wants 
to, return to it, read through it, think again and come back to it or 
whatever. And if it sort of flows logically then it’s a beginning to end 
and she can work her way through it and probably by the end make a 
decision that she is happy about. 
 
Overall, these comments suggest that an intervention to facilitate decisions about 
RRSO would be well received by patients and health professionals. 
7.3.1ii General format: Stakeholders were consulted about their preferred 
format for the intervention. The majority favoured a website, pointing to the 
numerous advantages of online formats with regards to interactivity, ease of 
updating and opportunity for tailoring information. 
HP5: I suppose my personal preference would be to have it online […] I sort 
of feel that you can do more online. […] I can see a lot of benefits of 
doing it online. 
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P1S: For me, I think I would rather have something on the web because I 
think that […] I might go back a couple of times and put the 
information in and see if it comes out with the same thing, almost to 
test the system. […] Maybe it’s a peace of mind thing, I don’t know… 
 
P2S: I know that I would also like to think – from the point of view of the 
web – that it was up to date and […] within two days there could be a 
change to it. 
 
However, many pointed out that there may be issues with accessibility, if the 
material was only online, and therefore recommended that a printed version be 
available as well for those who do not have access to the internet. 
HP5: […] but I suppose for women who don’t have internet access, it would 
be nice to have the backup of a paper-based resource as well. 
 
P3S: …my only other thing would be the people who […] haven’t got a 
computer in the house. And that’s not the kind of thing you really 
want to be reading in your local library, is it? […] So you would have to 
[have] both [web- and paper-based] options really, wouldn’t you? To 
cover everybody. 
 
Others emphasised the need for a printed version based on patient preferences, 
stating that some may prefer printed materials despite having access to the 
internet. 
HP11: It’s patient choice really, I think you should have both [paper- and 
web-based] because some people like to go on the computer, others 
just don’t, so there should be a choice available. 
 
SP2: What I tend to do is I usually [print] things off if I really need to 
concentrate on them, because I tend to take it in if I’m reading. […] I 
would like to download it from the website or I’d print from the 
website and then sit down quietly and read it. […] Because I would 
get a little bit frustrated with the screen sometimes, but I like the 
fact that it would be current and up to date. 
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P2C: I like it in writing, something that I can read and look at and that. I 
don’t, I’m not very good on the computer so, for me to have a booklet 
in my hand would be beneficial. 
 
These comments highlighted the need for different formats to cater for the varying 
needs of individual patients. It was therefore decided that the intervention material 
should be available in a web-based as well as paper-based format. 
7.3.1iii Personalisation: Health professionals pointed out that cancer risk 
varies depending on family history and mutation status as well as age, that the 
consequences of RRSO differ substantially depending on patients’ menopausal 
status and that prior breast cancer will prevent patients from taking HRT. 
Therefore, many recommended that a range of materials were needed so that the 
correct information could be given to each group of patients. 
HP9:  So I think you would […] almost have to have different ones. Because 
otherwise you will confuse the women […] who have got BRCA 
mutations from the women who have got a Lynch syndrome 
mutation because it’s different. 
 
HP6: You give me an aid, which I could use when I am 25, when I am 30, 
when I am 50 to make this decision […]. I must have the appropriate 
pamphlet for my age and not have a broad one […]. So, I must say 
personally, I very much individualise to age. 
 
HP5: I think for post-menopausal women you might have to have a 
different decision aid, because the implications are very different. 
 
In order to address these issues, it was decided to allow tailoring of the information 
within the intervention. Personalisation would be based on family history or 
mutation status, breast cancer status and age.  
7.3.1iv Information content: According to the RRSO-adapted CODE 
framework, patients go through four phases before making a decision: appraising 
cancer risk, appraising choice, understanding their options and constructing 
preferences (Chapter 5; Witt et al. 2012). The three former phases may be 
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supported by the provision of relevant information and advice, while the latter may 
additionally require value clarification. Stakeholders made a number of 
recommendations regarding information content (Table 7.2). Together with the 
questions during primary appraisal (outlined in the RRSO-adapted CODE 
framework) and evidence synthesis I, these suggestions guided development of the 
information content to achieve goals 1 and 2 of the intervention, i.e. support 
appraisal processes and affective forecasting. 
 Health professionals and patients felt that information about cancer risk 
would be important to place the decision in context and to ensure that patients 
understood their own risk and how it might change depending on family history, 
genetic mutation status and age. Furthermore, patients were concerned about 
other family members, especially their children, and how their own risk might affect 
their offspring. In terms of introducing the idea of choice, professionals felt that the 
importance of patient values in this decision should be highlighted and that criteria 
for being offered and for making the choice (e.g. being at high risk, completing 
family) should be outlined. Additionally, they felt that patients should be 
encouraged to discuss their decision with important others. 
Recommendations regarding information about the options were split into 
two sub-topics: ‘risk-reducing surgery’ and ‘other options’. Apart from stating the 
reduction in ovarian cancer risk achieved by RRSO, professionals also highlighted 
that patients should be made aware of the reduction in breast cancer risk following 
surgery and of the physical, psychological and social effects of RRSO. Patients 
themselves were keen to obtain information about surgical procedures and risks, 
chances of finding cancer during surgery and the cancer risk following surgery. For 
pre-menopausal women, premature menopause and HRT were particularly 
important issues, as previously discussed in Chapter 4. Both groups expressed a 
need for information about menopausal symptoms, HRT and non-hormonal 
alternatives.  
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Table 7.2 - Recommendations regarding information content of the patient decision support intervention 
CODE Phase / Subtopic Recommendations from patients and health professionals 
Cancer Risk 
HP9:   The information that I think is important to them [patients] is to understand the risk, and not just to understand the lifetime 
risk, […] but to get an idea at least of how the risk rises over time. 
P2L: I think you really want to know, well for me, it was important to know the statistics, you know, the percentages and the risks 
P2C: Well we have to think about our children, don’t we? […] it would be helpful to know what are the chances of me developing it so 
that they perhaps knew how it was going to affect them really, in later life. 
The Choice 
HP2:  The other thing I think that is important […] is to encourage people to think about what their preferences would be […]. 
HP7:  We generally standardly say that one of the criteria is that you know you have completed your family […]. That you are high risk 
and that you have completed your family. 
HP4: There’s the danger of going to the group that you think is the answer you want, rather than actually ask people who might 
challenge you a little bit more. And actually maybe your family, who you disagree with, […] are actually challenging you because 
they […] might be concerned that you might react differently. It’s complicated sometimes. 
Options 
Risk-reducing surgery 
HP1:  I think it might help people if they knew – and I hope this is still the case – that actually having their ovaries out might actually 
reduce your risk of having breast cancer. So[…] I think they might find that useful to know 
P2L: [Information about] what can go wrong. And probably also what exactly each operation involves, you know and how they do the 
laparoscopic [surgery]. 
HP4: [Surgery] can have a profound effect on somebody’s relationship and to be blunt about it, somehow that has to be introduced in 
the conversation beforehand 
HP4: I tend to not go into too much detail, […] but you introduce the concept of well: “look how much is it going to affect 
relationships, sexuality, your feelings of femininity, womanhood…” 
HP9:   I think it would also be important […] to know about the risks of primary peritoneal cancer after [surgery] and to know about 
the possible complications of surgery. You can’t possibly make a decision unless you know what might go wrong really. 
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Table 7.2 cont. – Recommendations regarding information content of the patient decision support intervention 
CODE Phase / Subtopic Recommendations from patients and health professionals 
Risk-reducing surgery 
P1L: I think it would be interesting if you ever have any kind of statistics of people who are given like hysterectomy or whatever, 
ovaries removed, and then those ovaries are dissected and there is  possibly pre-cancerous cells or something 
P3C: Again it’s what’s menopause after surgery like? That it’s the symptoms may be more severe. 
P3C: …there needs to be a lot more information about the menopause and different treatments whether they’re conventional 
treatments, alternative treatments and combinations of them. 
P1C: And like for the negative parts [of the menopause], is there anything that can be done to counteract that? Like, you know, the 
HRT or the loss of libido, all that kind of stuff. 
HP3:   So it isn’t a necessary thing, but they may want to know all about natural HRT […], they love that sort of thing  
Other options 
P1L: Just having information about the screening, people that it did help in a positive way, whether it would be worth your while to 
pay and to go ahead with the screening now. 
HP9:   Then they need information about ovarian cancer I guess, symptoms, but that’s very controversial. 
P3S: Like [for] how many people with ovarian cancer do the CA125 […] actually go up […]? Are there any other things [indicators of 
ovarian cancer] because all the other things [symptoms] that you get with ovarian cancer are quite vague, aren’t they? The 
symptoms themselves […]. So those are the things that I would find interesting. 
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In terms of alternative management options to RRSO, women asked for 
information about screening, which is not surprising as the majority of participants 
had been taking part in the UK Familial Ovarian Cancer Screening (UKFOCS) study 
(Rosenthal et al. 2013a). Many suggested that information about trans-vaginal 
ultrasounds and CA125 blood tests would be helpful, while health professionals 
were reluctant to recommend including such information due to the lack of 
established clinical efficacy of ovarian screening. Stakeholders also mentioned that 
information about ovarian cancer symptoms may be useful, although some 
professionals and patients voiced concerns about the vague and non-specific nature 
of early ovarian cancer symptoms.  
7.3.1v Coping content: Coping is an integral component of the CODE 
framework, which postulates that each phase of the deliberation gives rise to a 
coping process (Chapter 2, Chapter 5; Witt et al. 2012). Together with the questions 
during secondary appraisal (outlined in the RRSO-adapted CODE framework) and 
evidence synthesis II, the suggestions women and health professionals made 
regarding additional support were used to guide development of the coping advice. 
This content aimed to achieve goal 3 of the intervention; i.e. improve awareness of 
coping options and support coping. Some stakeholders discussed the need for 
content other than information, which may be labelled ‘coping content’ or ‘coping 
advice’, designed to facilitate coping processes and support the woman as a whole. 
HP7:…looking at the woman holistically, as part of your decision aid, might 
be the new thing that hasn’t been done before. 
 
One professional emphasised the need to normalise emotional reactions to threats, 
such as an increased risk of cancer, in order to validate patient’s feelings and 
reduce anxieties experienced in response to the threat. 
HP2:…if you go over expected normal psychological reactions, that can be a 
huge relief to somebody, because they realise that they understand 
their emotional reaction as being more part of the process as opposed 
to being fearful that they are going mad or anything else that is more 
extremist and catastrophic… 
240 
 
 
 
 
Encouraging patients to explore and express their feelings and share their thoughts 
with close family and friends might be one way to support coping during decision 
making about ovarian cancer risk management. According to the CODE framework, 
other coping content might include advice to seek information and professional 
help, encouragement of positive re-appraisal and guidance on relaxation 
techniques to regulate emotions and intrusive thoughts. Women and health 
professionals also mentioned the advantages of patient testimonies and peer 
support to facilitate coping and decision making.  
P3L: I think [we need] a tool which includes some facts [and] some 
anecdotal evidence from women who have been through a similar 
situation and made different decisions and had different experiences 
and with the honesty for some women to say, ‘This was hell, and I 
made the wrong decision’.  
 
HP3: The other thing I suppose is what no woman has and would like at any 
point in making a decision is to talk to somebody who has already had 
it done. 
 
Evidence regarding the effectiveness of patient stories in decision support 
interventions is controversial, as balanced portrayal of outcomes is difficult and 
such stories might bias patients’ decision making (Winterbottom and Bekker 2009, 
Winterbottom et al. 2008). However, women were keen to read about and speak to 
others who had already made the decision. Therefore, it was decided to refer users 
of the intervention to other websites that included patient blogs and videos, as well 
as signposting them to peer support groups that could cater for those needs. 
 7.3.1vi Value clarification: To achieve goal 4 of the intervention; i.e. support 
preference construction, an explicit value clarification exercise may be beneficial. 
Therefore, stakeholders’ views of the format and content of such exercises were 
sought. Focus groups and interview participants were shown an example value 
clarification exercise and were asked to comment and discuss (Figure 7.2)   
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Figure 7.2 - Example of value clarification exercise shown in focus groups and interviews 
 
From:  Decision aid “Risk Management Options for Women at Increased Risk of Developing  
 Ovarian Cancer” (New South Wales Centre for Genetics Education 2008, Tiller et al. 2003) 
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(Llewellyn-Thomas 2009, Peate et al. 2013). Stakeholders could see the advantages 
of such an exercise in terms of clarifying values and supporting the process of 
decision making. 
P1S: I think it [the value clarification exercise] focuses your mind. Whether 
it would make you anymore definite about your decision I don’t know, 
if that makes sense.  
P2S: No, it is helpful […] going through it. 
 
HP7: Well I think that this [value clarification exercise] probably would take 
someone forward, the decision making. And it may result in a consent 
for surgery or it might not. 
 
The format used in the sample exercise weighed advantages for surgery on one side 
and disadvantages on the other, using a set of scales. Stakeholders found this type 
of visualisation appealing and easy to understand. One professional noted that he 
was already using this type of visualisations in his consultations. 
HP8: It’s interesting you draw the scales there, […] because that is exactly 
what I use to explain that. It’s a balancing of the risks and benefits. 
And these go up and down and […] when you see that the risks of 
surgery outweigh the benefits, then surgery may not be ethically 
justifiable. And the other way around. 
 
However, while stakeholders liked the visualisation using the scales and the 
possibility of attributing different weights to different factors, they noted that the 
sample exercise did not allow users to input any factors of their own, which limited 
the usefulness of the exercise. 
HP9: That sort of thing itself would be quite good, […] but there might be 
other things that are important for them personally and how do you 
put those things in? 
 
P3L: Would there be the option to put personal factors in? […] So […] 
would there be a possibility of putting in, or you being able to add 
factors that mean a lot to you? […] 
P1L: Kind of an ad-hoc, yeah. 
P3L: Yea, an ‘any other’ 
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P1L: Yea, ‘any other’ that’s, yea, like an empty box. 
 
Based on this feedback, it was decided that a value clarification exercise using a set 
of scales was appropriate, on the condition that users were able to attribute 
different weights to different factors and to add their own personal factors. 
7.3.2 Prototype I 
 An initial prototype of OvDex was developed informed by the RRSO-adapted 
CODE framework (Chapter 5; Witt et al. 2012). OvDex was structured into four main 
and four supplementary sections, all of which were informed by the deliberation 
phases proposed in the CODE framework (see Appendix 7.3 for OvDex prototype I). 
The main sections corresponded to the four phases of deliberation, which include 
‘threat’, ‘choice’, ‘options’ and ‘preference construction’. Within OvDex these were 
entitled ‘cancer risk’, ‘the choice’, ‘options at a glance’ and ‘your decision’. The 
‘cancer risk’ and ‘the choice’ sections provided information about ovarian cancer 
risk and explained the choice, respectively. The ‘options at a glance’ section 
consisted of an Option Grid to provide an overview of the options (Table 7.3). The 
questions within the Option Grid were informed by questions outlined in the 
‘presentation of options’ phase in the RRSO-adapted CODE framework. The ‘your 
decision’ section would later encompass the value clarification exercise; however, 
this was not included in prototype I. In line with the content of the CODE 
framework, each of the four main sections would later also include coping advice. 
However, the initial prototype only consisted of the information content. This was 
informed by the results of evidence synthesis I. 
 The supplementary sections gave additional and more detailed information 
about the options and were entitled: ‘risk-reducing surgery’, ‘the menopause’, 
‘hormone replacement’ and ‘other options’. These were created in response to 
requests from participants, who felt detailed information about these topics would 
be particularly important. Each section contained a number of questions guided by 
the RRSO-adapted CODE framework (Table 7.4). 
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Table 7.3 - The ‘Options at a Glance’ section in prototype I (general version) 
Frequently asked 
questions  
Surgery to remove ovaries 
and fallopian tubes 
No surgery 
Will this reduce my 
ovarian cancer risk?  
Yes, removing the ovaries will greatly 
reduce your lifetime risk of ovarian cancer  
No, your risk of ovarian cancer 
will remain increased  
Will I be able to 
become pregnant?  
No.  Yes.  
Will this change how I 
feel about my risk of 
ovarian cancer?  
You may feel less worried about developing 
ovarian cancer.  
You may worry about developing 
ovarian cancer.  
Will I go into early 
menopause?  
Yes, your oestrogen levels fall and the 
menopause will start immediately.  
No.  
What is menopause 
after surgery like?  
Menopause after surgery is similar to 
natural menopause, but because it happens 
suddenly, the symptoms may be more 
severe.  
Not applicable.  
Will this change how I 
feel about myself as a 
woman?  
Most women do not notice any change in 
how they feel about themselves as a 
woman. Your desire for and/or enjoyment 
of sex may decrease a lot.  
Not applicable.  
Are there any risks 
linked to early 
menopause?  
Yes, there is a risk of bone thinning 
(osteoporosis). Some patients report 
memory changes as well.  
Not applicable.  
Will I need hormone 
replacement therapy 
(HRT)?  
HRT can reduce some of the effects of 
sudden menopause. You will need to 
discuss this possibility with your doctor.  
Not applicable  
Is HRT safe for 
women at increased 
familial risk?  
HRT is safe to take for the majority of 
women until they are 50. It is not 
recommended for women who have had 
breast cancer themselves already.  
Not applicable  
What are the risks of 
surgery?  
There is a small risk of complications 
depending on the type of surgical 
procedure (key hole or open surgery) you 
have. Discuss this with your doctor.  
Not applicable.  
How long will it take 
me to recover from 
surgery?  
Most women leave the hospital the same 
day or the day after key hole surgery and 
are back to normal in 4 weeks. For open 
surgery this is slightly longer.  
Not applicable.  
Can I get screened for 
ovarian cancer?  
No, after surgery there is no need for any 
screening because your risk will be low  
No, there is no routine screening 
available for ovarian cancer.  
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Table 7.4 - Questions within the sections of the general (non-personalised) OvDex prototype I 
Main Section Question 
Cancer risk 
What is the ovarian cancer risk if I have a family history of ovarian cancer? 
How can I find out whether I have a faulty gene? 
What would my risk be if a faulty gene is found? 
What if I cannot get tested or my genetic test is unclear? 
Does my cancer risk change over time? 
How will my ovarian cancer risk affect my life? 
How will my ovarian cancer risk affect my children? 
What can I do to reduce my risk?
 
  
The choice 
What can I do to reduce my risk?   
Why is there a choice? 
Who should decide? 
Who else should I involve in this decision? 
When should I decide? 
How can I decide? 
  
Options at a glance Options at a glance (Option grid) 
 Supplementary Sections: 
Risk-reducing surgery 
What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?  
What are the main advantages of this operation?  
What are the main disadvantages of this operation?  
What is my risk after surgery?  
What does the surgery involve?  
How long does it take to recover?  
Do I need to have my womb removed as well?  
What are the complications of RRSO?  
Can women die from RRSO? 
Could cancer be found during the surgery?  
How would RRSO affect my life?  
Surgical menopause 
What is surgical menopause?  
What is surgical menopause like? 
How could it affect my life? 
How long does surgical menopause last?  
Are there other problems linked to surgical menopause? 
Is there anything I can do to prevent the long term health 
effects of surgical menopause? 
Hormone replacement 
What is Hormone Replacement Therapy (HRT)?  
Why is HRT important?  
Who should take HRT?  
How long should I take HRT?  
Can I take HRT if I have a family history of breast cancer?  
But I have heard that HRT increases breast cancer risk?  
Will HRT reduce all the symptoms of menopause?  
Are there any alternatives to HRT? 
Other options 
Is there any screening available for ovarian cancer?  
What is the alternative to surgery?  
What would happen if I do not have surgery?  
Is there anything else I can do?  
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1. Do you have a faulty gene or a family history of Lynch Syndrome? 
 a) Yes, I have a BRCA1 faulty gene 
 b) Yes, I have a BRCA2 faulty gene 
 c) Yes, I am from a Lynch Syndrome family 
 d) Don’t know, I have not been tested for a faulty gene 
      or my genetic test was unclear 
 e) No, I have been tested and no faulty gene was identified 
2. Have you ever had breast cancer? 
 a) No, I have never had breast cancer 
 b) Yes, I have had breast cancer 
3. How old are you? 
 a) Under 35 
 b) 35-39 
 c) 40-49 
 d) Over 50 
 
 As was suggested by health professionals during the interviews, information 
might differ depending on patient variables, such as age, mutation status and 
breast cancer history. Therefore, to give users the possibility to personalise content, 
different prototype versions were developed. Patients could request and view a 
tailored version by answering three questions (Figure 7.3). 
 
 
 
 
 
 
 
 
  
 The information within the Option Grids in the ‘options at a glance’ section 
was tailored depending on personalisation. Information within the personalised 
versions also differed in sections such as cancer risk, menopause and HRT. The 
versions for patients who carry mutations in BRCA1/2 and women from families 
with Lynch syndrome provided specific cancer risk information relevant to mutation 
status / family history. The version for patients with a history of breast cancer 
stated that HRT was not recommended for this population and therefore only 
included a shortened version of the HRT information section. The version for pre-
menopausal women (under 50) included detailed information about the 
menopause and HRT. In contrast, the version for post-menopausal women (50 and 
over) did not include the sections on menopause and HRT, as these were not 
Figure 7.3 - Personalisation questions in prototype I 
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relevant to this population. A version for individuals who tested negative for a 
genetic mutation was also created, which advised women that they might be at 
average risk and therefore did not need to make this decision. This version only 
consisted of a section on risk and choice (Appendix 7.4). The draft information 
content of all versions was reviewed by a consultant clinical geneticist and 
amended according to his comments, before being sent out to the virtual reference 
group. 
7.3.3 Virtual Reference Group – Feedback Round 1 
 Ten patients and eight health professionals were invited to provide 
feedback on prototype I. Six patients and five professionals responded to the 
invitation. Most felt that the information was accessible and pitched at the right 
level. 
VR1:  One can expect the inclusion of a certain amount of facts and figures 
but the information is presented in a plain English style. (Patient) 
 
VR8:  In general I think the information is very good, and clearly explained,  
and probably aimed at the right level.  I found it easy to understand, 
and I think it would not be unduly difficult for someone with less 
knowledge in the area to understand. (Professional) 
 
One woman positively commented on the possibility to personalise information 
depending on mutation status / family history. 
VR2: It is also very useful to have personalised information for different 
groups of women where there is differentiated risk of ovarian 
cancer. Separation of information for BRCA1 and Lynch Syndrome is 
definitely helpful. (Patient) 
 
Some patients also commented on how they responded emotionally to the 
information presented in the intervention. 
VR1: It was comforting to read that the studies linking HRT with an 
increased risk of breast cancer have been criticised, as on a personal 
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level this was a major factor in holding me back from considering an 
oophorectomy pre menopause. (Patient) 
 
However, most comments from patients and health professionals regarded 
improvements that could be made to the content of the tool. The two groups did 
not differ significantly in the types of responses they provided in this round of 
feedback, most of which fell within the ‘confusing/needs rewording’ and 
‘additions/expansions’ categories. Table 7.5 shows a selection of quotes for the 
categories under the ‘suggestions for improvements’ code. 
 Unsurprisingly, compared to the comments from patients, professionals’ 
feedback was more often pointing to clinical evidence, for instance referring to the 
NICE guidance of ovarian cancer symptoms (National Institute for Health and Care 
Excellence 2011). However, patients also requested additional information that 
they had previously obtained from other sources, for example information 
regarding hysterectomy for Lynch women and the effects of premature menopause 
on cardiovascular disease. Overall, respondents made 86 actionable suggestions for 
improvements (31 from patients, 55 from professionals) that resulted in changes to 
the information content in prototype I. For a detailed list of all recommendations 
for improvements and actions taken in response see Appendix 7.5. 
7.3.4 Prototype II 
 In response to feedback from the virtual reference group, prototype II was 
developed. This prototype included two stand-alone paper-based Option Grids (one 
for pre-menopausal and one for post-menopausal women) and the OvDex tool, as 
an online and paper-based version. Option Grids also remained embedded in OvDex 
in the ‘Options at a glance’ section. Content in the grids within the ‘Options at a 
glance’ section differed slightly depending on the personalisation. Content of the 
Option Grids was amended using feedback from the virtual reference group, as well 
as suggestions from the editorial team. Changes were generally non-substantial. In 
the non-personalised version for instance, a numerical estimate of 
249 
 
 
 
Table 7.5 - Examples of suggestions for improvements by virtual reference group members: Round 1 
Code Example quotes 
Spelling / Grammar 
VR9: “What are the complications of RRSO” Last sentence of the first 
paragraph: “the surgeon has to convert to an operation or to open 
surgery.” (Professional) 
Not relevant 
VR8: Question on how can I find out whether I have a faulty BRCA1 
gene is irrelevant at this point, they already have it confirmed. 
(Professional; comment on BRCA version) 
Confusing / needs 
rewording 
VR3: On the Risk Reducing Surgery section the part detailing amount of 
women having surgery and those that are converted from keyhole to 
open surgery when I first read the explanation to the right of the grid in 
bold I thought the grid showed amount that was converted to open 
surgery…which would put a lot of people off the idea. (Patient) 
VR8: Question: When should I decide?  I am not certain about the 
phrasing in this context: “It is important you make sure you have 
completed your family before you make this choice.”  It sounds like an 
instruction. (Professional) 
VR10: The risk for ovarian cancer is still low at age 35 (your graph is 
rather misleading as quick glance by someone who doesn’t understand 
it may suggest that it is higher than it is). For this reason I would 
suggest that you change the scale of the graph. (Professional; comment 
on: under 35 versions) 
VR8: The symptoms should be the ones used in the NICE Guidance 
CG122. (Professional) 
Additions / expansions 
VR4: It mentions genetic testing. […] More information on this would 
be useful. (Patient) 
VR2: For Lynch Syndrome women the surgery would involve 
hysterectomy as well as oophorectomy. It, therefore, doesn’t make 
complete sense to consider removal of the ovaries in isolation. It would 
be useful to either include more information on the hysterectomy or to 
link to it from another source at the relevant points in the text. 
(Patient; comment on: Lynch version) 
VR1: I would like to have seen Chapter numbers and individual 
paragraph / section numbers. A minor point, but this would be helpful 
as there are quite a lot of cross references to different sections 
throughout. (Patient) 
VR10: A picture of the anatomy might be helpful as many women do 
not know their anatomy or understand the difference between the 
ovary uterus and cervix! (Professional) 
Repetition 
VR4: There was some repetition (Patient) 
VR11: “For all other women the risk of primary peritoneal cancer after 
surgery is close to zero.” – Repeated info in this paragraph. 
(Professional) 
Other 
VR5: I am clearly given the indication from the gynecologist during my 
yearly hysteroscopy that I should have my ovaries and womb removed 
as the risk of cancer outweighs my fears on being on HRT after surgery. 
(Patient) 
If comments were only applicable to a specific version, this is specified as (…comment on:…) after 
the quote 
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risk of ovarian-type cancer after surgery was added. The question on availability of 
screening for ovarian cancer was also re-worded; however, the content of Option 
Grids largely remained the same. The stand-alone versions also included a 
statement to define the target audience and the health decision (Figure 7.4a and 
Figure 7.4b). 
 The structure of the online and paper-based versions of OvDex remained 
the same as in prototype I, guided by the phases outlined in the CODE framework; 
however, the title for one of the supplementary sections changed from ‘Surgical 
menopause’ to ‘The menopause’. In the paper version, page numbers were added 
and sections and questions were also numbered to aid navigation, as suggested by 
members of the virtual reference group. Table 7.6 depicts the questions addressed 
in each of the sections of the generic, non-personalised prototype II of OvDex (see 
Appendix 7.6 for paper-based version). 
 In response to comments from the virtual reference group, the answers to 
most questions were modified and some questions were added to address 
previously omitted topics or expand on existing ones. For example, a diagram 
outlining women’s anatomy and specifying where ovarian-type cancer develops 
was added to the ‘cancer risk’ section. Furthermore, a statement about women 
who have been offered CA125 blood tests and ultrasounds was added to the ‘other 
options’ section to emphasise the lack of clinical evidence for screening, despite 
privately funded screening being available in some areas. The version for Lynch 
women underwent substantial amendments due to the inclusion of risk-reducing 
hysterectomy as an important option to reduce endometrial cancer risk in this 
population. Additionally, at the end of prototype II of OvDex, a list of research 
evidence was added to reference publications that had been used in the 
development of the intervention. 
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Figure 7.4a - The Option Grid / ‘options at a glance’ section in prototype II 
(general version for pre-menopausal women) 
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Figure 7.4b – The Option Grid / ‘options at a glance’ section in prototype II  
(general version for post-menopausal women) 
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Table 7.6 - Questions within the sections of the general (non-personalised) OvDex prototype II 
Main Section Question 
1 - Cancer risk 
Q1 Where does ovarian cancer develop?
 
Q2 What is the ovarian cancer risk if I have a family history of ovarian cancer? 
Q3 How can I find out whether I have a faulty gene? 
Q4 What would my risk be if a faulty gene is found? 
Q5 What if I cannot get tested or my genetic test is unclear? 
Q6 Does my cancer risk change over time? 
Q7 How will my ovarian cancer risk affect my life? 
Q8 How will my ovarian cancer risk affect my children? 
Q9 How can I deal with my cancer risk? (Coping advice)
 
  
2 - The choice 
Q1 What can I do to reduce my risk? 
Q2 Why is there a choice? 
Q3 Who should decide? 
Q4 Who else should I involve in this decision? 
Q5 When should I decide? 
Q6 How can I decide? 
Q7 How can I deal with the choice? (Coping advice)
 
  
3 - Options  
      at a glance 
Options at a glance (Option grid)  
Q1 How can I deal with this decision? (Coping advice)
 
 Supplementary Sections: 
4 - Risk-reducing 
surgery 
Q1 What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?  
Q2 What are the main advantages of this operation?  
Q3 What are the main disadvantages of this operation?  
Q4 What is my risk after surgery?  
Q5 What does the surgery involve?  
Q6 How long does it take to recover?  
Q7 Do I need to have my womb removed as well?  
Q8 What are the complications of RRSO?  
Q9 Could cancer be found during the surgery?  
Q10 How would RRSO affect my life?  
5 - The 
menopause 
Q1 What is surgical menopause?  
Q2 What is the menopause like? 
Q3 How could the menopause affect my life in the short term? 
Q4 How long does surgical menopause last? 
Q5 Are there any long term health effects linked to surgical menopause? 
Q6 Is there anything I can do to reduce the effects of surgical menopause? 
6 - Hormone 
replacement 
Q1 What is Hormone Replacement Therapy (HRT)?  
Q2 Why is HRT important?  
Q3 Who should take HRT?  
Q4 How long should I take HRT?  
Q5 Can I take HRT if I have a family history of breast cancer?  
Q6 But I have heard that HRT increases breast cancer risk?  
Q7 Will HRT reduce all the symptoms of menopause?  
Q8 Will HRT deal with the long term health effects of the menopause? 
Q9 Are there any alternatives to HRT? 
7 - Other options 
Q1 Is there any screening available for ovarian cancer?  
Q2 What is the alternative to surgery?  
Q3 But I have been offered CA125 blood tests and/or trans-vaginal scans
 
Q4 What would happen if I do not have surgery?  
Q5 Is there anything else I can do?  
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8 - Your decision 
Value clarification exercise
 
Q1 How can I deal with my decision?
 
  
 
 
 Personalisation within the online version was enabled using the three 
questions outlined earlier (Figure 7.3). These questions were answered sequentially 
and subsequently took users to versions of the website that were tailored to the 
answers they had provided. Once personalised, users could download a pdf copy of 
the materials or navigate the website online.  
 Coping advice and a value clarification exercise were also added to 
prototype II. Development of the coping advice was guided by items included in the 
‘secondary appraisal’ row of the RRSO-adapted CODE framework (Chapter 5) and 
evidence synthesis II (see section 7.2.4). Each of the four main sections of OvDex 
included a paragraph on coping advice. The coping advice pointed women towards 
sources of medical information and promoted problem solving and action planning 
approaches. These sections aimed to support problem-focused coping, i.e. increase 
awareness and use of problem-focused coping options and resources. Other 
sections within the coping advice encouraged women to seek social support and/or 
referred patients to external websites for further information on relaxation and 
mind-body therapies. These sections aimed to support emotion-focused coping, i.e. 
increase awareness and use of emotion-focused coping options and resources. 
Figure 7.5 shows a sample section of coping advice labelled to highlight the 
different coping options included.  
Table 7.6 cont. – Questions within the sections of the general (non-personalised) OvDex prototype II 
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Figure 7.5 - Example of coping advice in OvDex prototype II with labelled options 
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The value clarification exercise was developed based on items in the 
‘preference construction’ column of the RRSO-adapted CODE framework (Chapter 
5) and on two decision making models: the conflict model of decision making (Janis 
and Mann 1977) and differentiation and consolidation theory (Svenson 1992). The 
conflict model of decision making postulates that decisional conflict ensues when a 
decision needs to be made between options that are associated with potential 
positive outcomes (anticipated gains) and negative outcomes (anticipated losses) 
(Janis and Mann 1977). It suggests that decision makers should ideally take a 
vigilant approach to information seeking, i.e. obtain as much relevant information 
as possible about attributes associated with each option (Janis and Mann 1976). 
The model further proposes that options should then be distinguished based on 
anticipated gains and losses (Janis and Mann 1977). The best option is that which is 
associated with the most gains and least losses. Deliberation components based on 
this model could take the form of weighing or balancing exercises, enabling patients 
to identify anticipated gains and losses associated with options (Elwyn et al. 2011b). 
Differentiation and consolidation theory postulates that decision makers 
differentiate options according to the relative importance they ascribe to attributes 
associated with options (Svenson 1992, 2003). The best option is that which is 
associated with the most important positive attribute(s) and, ideally, the least 
important negative attributes (Svenson 1992, 2003). Elwyn et al. (2011b) suggested 
that deliberation components based on this theory should allow a direct 
comparison of attributes and a differentiation based on the sum of positive and 
negative attributes for each option. Ideally, these sums should take into account 
the relative importance of each attribute from the decision maker’s perspective. 
 In accordance with these models, the value clarification exercise in OvDex 
was designed to elicit the importance patients ascribe to different attributes 
(anticipated gains and losses) associated with RRSO. In line with the conflict model 
of decision making, patients were asked to decide whether attributes made them 
want to have or want to avoid surgery, i.e. whether they were perceived as 
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potential gains or potential losses if one was to choose surgery. Pre-defined 
attributes covered in the exercise included statements such as ‘surgery will reduce 
my ovarian cancer risk’ and ‘I will not be able to become pregnant after surgery’. 
Patients could also add their own attributes. In line with differentiation and 
consolidation theory, all attributes could additionally be weighed as to their relative 
importance on a scale of 1 (a little important) to 3 (very important). For example, a 
reduction in ovarian cancer risk may be perceived as a potential gain, making a 
patient want to have surgery, and be ascribed high importance (i.e. a weight of 3). 
In contrast, a change in body image may be perceived as a potential loss, making a 
patient want to avoid surgery, but be ascribed low importance (i.e. a weight of 1). 
The sum of weights ascribed to gains resulting from RRSO was then compared to 
the sum of weights ascribed to losses resulting from RRSO using a set of weighing 
scales. This allowed decision makers to visualise the overall importance they 
ascribed to gains and losses associated with RRSO. 
 The value clarification exercise was available in an interactive online format 
(Figure 7.6) and as a paper-based version (Figure 7.7 and 7.8). The online format 
allowed users to mark radio buttons to indicate whether a statement made them 
want to have or avoid surgery and the relative importance they attributed to that 
statement. The overall outcome was displayed automatically on a set of scales with 
weights that were sized according to the importance that had been attributed to 
them. In the paper-based version, women had to indicate the weight as a number 
in the correct column to indicate whether a statement made them want to have or 
avoid surgery. Women had to then calculate and transfer the total sum for each 
column into a picture of a set of scales. Three summary statements were displayed 
at the end. The statement most relevant depended on the individual outcome of 
the exercise and the tipping of the scales. Patients needed to identify the summary 
statement that applied to them. Interactive exercises, such as these, engage users 
and can enhance the decision making process (Coulter 2009a). 
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Figure 7.6 - Interactive online value clarification exercise 
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Figure 7.7 - Paper-based value clarification exercise – ranking 
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Figure 7.8 - Paper-based value clarification exercise – summary and outcome 
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7.3.5 Virtual Reference Group – Feedback Round 2 
 Ten patients and seven health professionals were invited to provide 
feedback on prototype II. One professional had opted out of the study and was 
therefore not invited in Round 2. Six patients and four professionals responded to 
the invitation. Overall, the majority of patients’ comments in this round were 
positive (n=28) and patients made few suggestions for improvements (n=12). As in 
the first round of feedback from this group, many patients commented on the 
accessibility and readability of the content. 
VR6:  It was easy to understand because it was written in plain everyday 
English, but without being patronising. I know this isn't easy and it is 
rare to find the balance struck as well as it has been here! (Patient) 
 
Patients also felt that the amount of information included in the intervention was 
appropriate. 
VR1:  I felt it has a good balance of info. It is inevitably difficult to try and 
balance the amount of information presented but I thought this gave 
sufficient detail and would prompt users to consult their GP if more 
in depth info was required. (Patient) 
 
VR6: Generally I thought there was the right amount of information. There 
were no obvious gaps, but not an information overload. (Patient) 
 
Some specifically commented on the website’s layout and design as well. They felt 
that the structure of the site was ‘easy to navigate’ and ‘flows well’. 
VR5: I was impressed with the website as it was user friendly and clear 
with headings and easy to find your way back. Overall the layout was 
excellent and I also think the branding is well done. (Patient) 
 
One respondent also noted that the online format would enable patients to return 
to the website whenever they choose, check for updates and explore whether their 
preferences had changed. 
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VR5: I believe this will definitely help women in thinking about the right 
factors for their overall decision, and something they can always 
come back to and read again and see if they feel differently about 
the issue. (Patient) 
 
The value clarification exercise section of OvDex, which had not been reviewed 
before, also received positive feedback from patients. 
VR6:  I thought that this is one of the best weighing up tools I have ever 
seen. I really did like the option of [giving] different weights to the 
factors and the option to include one's own factors. I like having the 
visual representation. Again this was achieved in a way that is easy to 
understand without being patronising. (Patient) 
 
VR1:  It is helpful to see your own thoughts set out. It focuses your mind 
and almost feels as if the pressure of making a decision is removed 
slightly as the tool comes to the conclusion albeit based on your 
answers. (Patient) 
 
VR3:  I thought that the action plan part on ‘how can I deal with my 
decision’ [is] a very good idea and one that I will personally use. 
(Patient) 
 
In contrast to patients, health professionals made fewer positive comments in this 
round and appeared to concentrate on making suggestions for improvements. The 
majority of these comments once again fell within the ‘confusing / needs 
rewording’ and ‘additions / expansions’ categories. Table 7.7 shows a selection of 
quotes for the categories under the ‘suggestions for improvements’ code in round 
2. Overall, respondents made 64 actionable suggestions for improvements (12 from 
patients, 52 from professionals). For a detailed list of all recommendations for 
improvements and actions taken in response, see Appendix 7.7. 
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Table 7.7 - Examples of suggestions for improvements by virtual reference group members: Round 2 
Code Example quotes 
Spelling / Grammar 
VR10: I thought some of the grammar could have been improved. 
Some of it was repetitive and some of the sentences were a bit long 
and clumsy. (Professional) 
VR12: “Yes HRT will recducde the risk” – Reduce (Professional) 
Not relevant 
VR7: I indicated that I had had breast cancer, I found a lot of the 
information on HRT irrelevant to me. (Patient; comment on: BRCA2 
version) 
Confusing / needs 
rewording 
VR12: “You can come back to OvDex and do this exercise again in a 
year’s time”  - why specify a year’s time. Surely we would be happy for 
someone to revisit their decision as often as they wish?? (Professional) 
VR6: The other place I did not find it helpful was the assumption that 
everyone has a partner. Not only was this unhelpful, it is also extremely 
irritating. (Patient) 
VR10: I would have major concerns about this bit [information about 
oral contraceptives in ‘Other Options’]. If a woman carries a BRCA1/2 
mutation it would not be recommended for her to go on the pill to 
reduce her risk of ovarian cancer and she could be significantly 
increasing her risk of breast cancer. (Professional) 
VR12: You refer to “navigation menu”. Nothing is called that, and 
although I guessed what is meant by it I wonder if it needs to be 
identified as such? (Professional) 
Additions / expansions 
VR8: On “How will my risk affect children....” it says boys who inherit 
the gene are not at risk of ovarian cancer (but does not say that they 
may however pass on the gene to their children) (Professional) 
VR9: Add an explanation of what the dotted lines are for Lynch women 
cancer risk in the general version (Professional; comment on: General 
version) 
VR8: Under main disadvantages of the operation - under sex can be 
painful - is it worth including the disclaimer on the menopause page, 
which gives some reassurance that help is at hand. (Professional) 
VR6: I thought that the initial surgery/no surgery section was rather 
weighted for surgery. There could have been a mention of the 
possibility of privately funded screening at this point. (Patient) 
Repetition 
VR10: “So for example, your risk of getting ovarian cancer in the next 
year when you are 35 is quite low, whereas your risk of getting ovarian 
cancer in the next year when you are 50 is higher.” Repeats ‘in the next 
year’ (Professional) 
Other 
VR6: I'm still not totally convinced by the name, but I do appreciate the 
reasons for it! (Patient) 
VR10: “You should also be aware that the yearly smear test you receive 
is designed to detect cervical cancer and will not detect ovarian 
cancer.” - I would give this a separate paragraph and make the ‘not’ 
bold! (Professional) 
Website issues 
VR3: The start of the text on the left hand side was missing all the way 
through (Patient) 
VR12: I assume/hope the balance will become an actual balance that 
tilts!?? (Professional) 
If comments were only applicable to a specific version, this is specified as (…comment on:…) 
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7.3.6 The stand-alone Option Grids 
 Following comments from the virtual reference group and the editorial 
team, the content of the stand-alone Option Grids was amended. Figure 7.9a and b 
show the stand-alone versions of the Option Grids for pre- and post-menopausal 
women as published in February 2013. The introductory paragraph was amended to 
include a definition of what is meant by ‘increased risk’. The order of the questions 
in the grids was also changed and items were re-worded to facilitate understanding. 
The grids were then formatted to conform to the guidelines recommended in the 
Option Grid Development Framework V0.5. In line with these guidelines, an 
evidence document providing the studies and publications used to inform the 
answers to frequently asked questions was also created as a reference document 
(Appendix 7.8). Ultimately, the grids may also include the web address for the 
OvDex online tool to encourage patients to visit the full intervention if they require 
more information. 
7.3.7  OvDex: the Oophorectomy Decision Explorer 
 The final version of OvDex was created from prototype II in response to 
feedback from the virtual reference group. Main sections and questions within each 
section remained the same; however, some content was re-worded and added. The 
research evidence section was extended to include evidence on coping advice and 
further references on the long-term health effects of premature menopause. 
Funders and collaborators were disclosed in a new section called ‘About OvDex’. A 
copy of the final paper-based version of OvDex is included in Appendix 7.9. 
The OvDex website was finalised by DigitalMorphosis (a Cardiff-based web 
design company). Personalisation was simplified, so that users could answer all 
three questions on one page (Figure 7.10). The online value clarification exercise 
layout was amended to include sliders instead of radio buttons, enabling users to 
weigh attributes on a scale of 1 to 10 instead of 1 to 3 (Figure 7.11). This allowed 
even further differentiation of the relative importance of different attributes. 
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Figure 7.9a - Final versions of the Option Grid (pre-menopausal women) 
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Figure 7.9b – Final versions of the Option Grid (post-menopausal women) 
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Figure 7.10 - Personalisation page on OvDex website 
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 Figure 7.11 - Example of interactive online value clarification exercise in final version 
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7.4 Discussion 
7.4.1 The oophorectomy patient decision support intervention 
 The current chapter outlines the development of a decision support 
intervention for women at increased genetic risk of ovarian cancer. Development 
was guided by the RRSO-adapted CODE framework, and other relevant theories, 
and was supported by a group of stakeholders, who provided feedback throughout. 
Figure 7.12 outlines which items within the RRSO-adapted CODE framework are 
covered by the content of the intervention. Questions relating to cognitive 
appraisal were primarily addressed by the information content within the Option 
Grids and OvDex. Emotional appraisal items were more difficult to address, as the 
questions relating to emotional appraisal are more abstract and depend on 
individuals’ past experiences and personal values. Chapter 6 showed that previously 
developed patient decision support interventions did not support emotional 
appraisal. In OvDex, these questions were indirectly addressed by some of the 
coping advice, by components designed to facilitate affective forecasting and within 
contacts and resources. For example, the questions ‘What did others decide? How 
did they fare?’ may be addressed by patient testimonials. Although OvDex did not 
include patient testimonials itself, it does refer to other websites that include 
patient blogs and to patient networks. Affective forecasting may also be supported 
by patient testimonials. Additionally, information in OvDex was worded in such a 
way as to facilitate affective forecasting by describing possible physical, 
psychological and social outcomes that may be experienced following surgery. 
Items within the secondary appraisal section, which focus on possible coping 
options, were covered by coping advice. Finally, weighing of attributes and 
alignment of options with values and goals, a part of the preference construction 
phase, was supported by the value clarification exercise. 
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 Figure 7.12 - RRSO-adapted CODE framework and items covered by Option Grid and OvDex content  (indicated in colour) 
 
Colour Code: 
Blue    –  Covered by information 
 content in OvDex 
Purple –  Covered by information 
 content in Option Grids 
 and OvDex 
Red     –  Covered by coping 
 advice 
Pink     –  Indirectly covered by 
 coping advice or 
 contacts & resources 
Yellow – Covered by value 
 clarification exercise 
Black   –  Not covered 
 
2
70
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 The intervention was split into two parts: an Option Grid, designed for use in 
clinic, and a more extensive online intervention called OvDex, designed for use by 
patients at home. It was anticipated that this separation would accommodate 
individual differences in information processing and decision making style, for 
example, catering for immediate and delayed deciders as identified in Chapter 4. 
The former are able to make a decision relatively quickly once presented with the 
options, while the latter tend to take a more deliberative approach. Hence, 
immediate deciders may appraise the health threat and their options comparatively 
briefly and are unlikely to go through all the questions proposed in the RRSO-
adapted CODE framework before being able to make a decision. Instead, they may 
use fast and frugal heuristics to identify the best option by only considering a 
limited number of questions. Heuristics have been shown to be useful in decision 
making, especially when decisions are time sensitive and only limited information is 
available (Gigerenzer 2004). Gigerenzer (2004) outlined two classes of heuristics 
based on reasoning: ‘one reason’ / ‘take-the-best’ decision making and ‘tallying’. 
The former relies on a single attribute that allows individuals to choose one option 
over another. ‘Take-the-best’ decision making requires that only the attribute with 
the highest validity is considered before a decision is made. The best option is that 
which has a positive value on the attribute with the highest validity. If options were 
identical on this attribute, the attribute with the second highest validity is 
considered and so on, until options differ. In contrast, ‘tallying’ assesses options 
based on two or more attributes. Values are assigned for each attribute and then 
added up for each available option. The best option is that which has the most 
positive values on attributes considered. 
 Option Grids are designed to facilitate heuristics based decision making, as 
they allow both ‘take-the-best’ and ‘tallying’ to be used to discern the best option 
(Elwyn et al. 2013b, Marrin et al. 2013). The questions within the Option Grid act as 
cues, allowing a direct comparison of options with regards to specific attributes. 
Immediate decision makers may select one question and base their decision on the 
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answer to that single question, a process that may be described as a ‘take-the-best’ 
approach. For example, an individual may consider a reduction of their cancer risk 
as the attribute with the highest validity due to their past experience of cancer. 
They may therefore only look at the question “Will this reduce my ovarian cancer 
risk?” and base their decision solely on the answer to this question. In this case, the 
individual would elect to have surgery, as RRSO reduces cancer risk, whereas 
avoiding surgery does not. Alternatively, decision makers may opt to consider 
several or all questions listed in the Option Grid and make a decision based on the 
answers to those questions, a process that may be described as a ‘tallying’ 
approach. For instance, they may consider the reduction in ovarian cancer risk to be 
a positive attribute of surgery; however, retaining their ability to become pregnant 
and avoiding a premature menopause may be considered positive attributes of the 
no surgery option. If no further attributes were considered, this individual would 
decide against surgery in this instance.  
 The information contained within the Option Grid may thus be sufficient for 
immediate deciders to make their choice, without the need for more elaborate 
decision support. However, for others decisions about how to manage their 
increased risk of ovarian cancer may be more complex and distributed over time 
(Rapley 2008). Therefore, fast and frugal heuristics, may not be the preferred 
decision making approach for delayed deciders. These individuals may favour a 
more deliberative process and could benefit from additional support. In agreement 
with this, a randomised trial of a CD-Rom decision support intervention for carriers 
of mutations in BRCA1/2 by Schwartz et al. (2009) found that women who struggled 
with the decision benefited from the intervention, whereas women who were able 
to make an immediate decision, did not.  
 Deliberative decision making approaches may be described by theories such 
as Janis and Mann’s (1977) conflict model of decision making and Sevenson’s (1992) 
differentiation and consolidation theory. They also map more fully onto the CODE 
framework (Witt et al. 2012), as delayed deciders are likely to consider more of the 
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questions proposed in the RRSO-adapted CODE framework than immediate 
deciders, as they seek out additional information and appraise coping options. 
Deliberative decision making includes detailed cognitive and emotional appraisal of 
information relevant to the health threat, as well as the choice and available 
options. Delayed deciders may also employ a number of problem- or emotion-
focused coping strategies in order to deal with the decision. These strategies may 
change and be adapted over time. Supporting delayed deciders therefore requires 
more extensive decision support than that needed for immediate deciders. 
 The intervention presented in this chapter therefore attempts to cater for 
this population with its two complementary parts. During clinical consultations, 
when options are first discussed, patients could receive an Option Grid. In line with 
Svenson’s (1992) differentiation and consolidation theory, Option Grids facilitate 
direct comparison of options (Elwyn et al. 2011b). They also enable patients to 
initiate a discussion about options with their clinician (Elwyn et al. 2013b). 
However, the information provided in the grid may not be perceived as sufficient by 
delayed deciders, who experience decisional conflict and report several barriers to 
decision making (Janis and Mann 1977). While they may ask their clinician for 
further information during the consultation, delayed deciders may then return 
home without having made a decision. These individuals may appreciate access to 
additional information, which they can review any time and in consultation with 
close others. For this reason, the Option Grid is complemented by a more extensive 
online tool that delayed deciders can choose to visit in order to obtain more 
information to base their decision on (Janis and Mann 1976, 1977). It should of 
course be noted that immediate deciders are also free to visit the OvDex website; 
however, they may choose not to do so. 
 The structure and content of OvDex was guided by the phases and questions 
outlined in the RRSO-adapted CODE framework (Chapter 5). Answers to questions 
were worded to facilitate the cognitive and emotional appraisal of each phase of 
the deliberation process (Power et al. 2011, Wilson and Gilbert 2003). To support 
274 
 
 
 
affective forecasting, answers encouraged patients to imagine the physical, social 
and/or psychological effects of different outcomes and to discuss these with health 
professionals and/or important others (Joseph-Williams et al. 2013). 
 Affective forecasting and emotional appraisals may also be facilitated by 
patient stories; however, the evidence for this effect is controversial (Bekker et al. 
2012, Khangura et al. 2008, Winterbottom and Bekker 2009, Winterbottom et al. 
2008). While patients generally like personal accounts, as these help them to 
imagine possible futures, there is concern that stories may bias patients’ forecasting 
and decision making, as a balanced portrayal of all possible outcomes is basically 
impossible and patients often identify with a particular person’s story (Bekker et al. 
2012). Therefore, OvDex does not include patient stories directly; however, within 
the contacts and resources list it does refer users to other sites that include patient 
stories, blogs and networks. 
 Coping advice was also provided within OvDex to support coping efforts 
during decision making (Balneaves and Long 1999, Folkman 2011, Lazarus et al. 
1985, Witt et al. 2012). Patients were encouraged to seek information, to actively 
plan their decision making and to explore their options with professionals and 
important others, all of which reflect problem-focused coping options (Lazarus et al. 
1985). Patients were also advised that emotional reactions to the situation were 
normal and were encouraged to seek emotional support from family, friends 
and/or peers and to positively reappraise the situation, which reflect emotion-
focused coping strategies (Lazarus et al. 1985). Active distraction, mind-body 
techniques and relaxation exercises were also referred to, as these may be useful 
for patients to regulate intrusive thoughts. This is especially relevant in periods 
when no action can be taken, such as when waiting for results of genetic tests 
(Phelps et al. 2013, Phelps et al. 2006). 
 Finally, the value clarification component was developed to facilitate 
preference construction during deliberative decision making. In contrast to 
immediate deciders, who may prefer fast and frugal heuristics, deliberative 
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deciders may want to consider most, or all, of the information relevant to their 
decision and prefer to decide using what they have learnt about different attributes 
and how important those attributes are to them (Janis and Mann 1976, 1977, 
Svenson 1992, 2003). The exercise within OvDex was designed to facilitate such 
deliberative approaches by allowing users to identify attributes as either gains 
(reasons to have surgery) or losses (reasons to avoid surgery) and simultaneously 
assign a value to their relative importance. While this exercise might at first glance 
resemble a tallying approach, and therefore heuristics based decision making, it is 
more complex than that. It assumes the user has done research and knows and 
understands the attributes of options and it additionally allows a weighing of 
relative importance, not usually part of tallying (Gigerenzer 2004, Janis and Mann 
1976, Svenson 1992). 
7.4.2 Practice implications and future research 
 Currently, there is a lack of decision support materials that can be used 
outside the context of clinical consultations and is specifically designed for women 
at increased genetic risk of ovarian cancer in the UK (Chapter 6). Many women in 
this situation report that they struggle to identify relevant and trustworthy 
information and that additional, non-educational materials would also be useful 
(Chapter 3 and 4; Babb et al. 2002, Hallowell 2000). Combined with face-to-face 
counselling in consultations, such materials may improve patient experience and 
satisfaction (Coulter and Ellins 2007). Therefore, a patient decision support 
intervention that integrates cognitive and emotional aspects of deliberation and 
coping processes could complement genetic services in the UK and support patients 
more holistically (Chapter 2 and 5; Witt et al. 2012). Health professionals agree that 
such materials would be helpful as complementary adjuncts to consultations. 
Hence, the intervention developed here addresses a need that has been voiced by 
patients and health professionals alike.   
 However, patient decision support interventions have faced substantial 
implementation issues in the past, partially owing to the fact that many were 
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developed for independent use by patients and were therefore not readily 
integrated into clinical pathways (Elwyn et al. 2008, Frosch et al. 2011, Harter et al. 
2011). To counteract these implementation issues, the current intervention is split 
into two parts. Implementation of the Option Grids may be more straightforward 
than implementation of more extensive self-administered interventions has been in 
the past. Immediate deciders may be able to make a decision based on information 
delivered in the grid and clinical discussion alone; however, delayed deciders may 
want more information. Therefore, the Option Grids will include a reference to 
OvDex, which patients can choose to visit following the consultation. 
 The full OvDex tool may then help those patients who struggle with the 
decision to obtain evidence-based, up to date information, to share their thoughts 
with important others and to weigh their values and preferences. It allows patients 
to explore issues over longer periods of time, to take breaks and return to the 
information whenever they wish and to examine their options in the comfort of 
their own home, before returning to clinic for more detailed discussion. As 
preferences change and develop over time, they can re-read the information and 
repeat the exercise until they are ready to make a final decision. This is in 
accordance with Rapley (2008), who put forward a model of distributed decision 
making, proposing that many decisions are not made in a single clinical 
consultation, but are distributed across time, spanning numerous encounters with 
others, various situations and interactions with technologies (Montori et al. 2006).  
 OvDex may also help those who make an immediate decision against 
surgery due to family planning issues, but who may wish to return to the decision 
and reconsider surgery at a later date after their family is complete. For these 
individuals the intervention is a resource they can come back to when they are 
finally ready to decide, as it allows them to obtain up to date information and 
clarify their values before then making an appointment to discuss further details. 
 Both the Option Grids and online tool developed here require further 
evaluation in order to assess whether they are acceptable to patients and health 
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professionals, whether they truly support decision making and coping, and whether 
they can be implemented as proposed. 
7.4.3 Strengths and Limitations 
 The development process outlined in this chapter has several strengths. 
Firstly, it was guided by recommendations and guidelines written by experts in 
relevant fields. The development of the Option Grids adhered to the protocol 
produced by the Option Grid Collaborative (2013). The development of OvDex 
followed recommendations set out by the International Patient Decision Aid 
Standards (IPDAS) collaboration (Volk and Llewellyn-Thomas 2012), as well as those 
specifically proposed for web-based decision support tools by Elwyn et al. (2011a). 
In line with these recommendations, the development process was also supported 
by a group of stakeholders, who were consulted throughout, to ensure that content 
was easy to understand and relevant to this medical decision. 
 The CODE framework was used as the practical and theoretical basis for the 
development of this patient decision support intervention (Chapter 2; Witt et al. 
2012). The structure and content of the intervention was guided by the phases and 
questions proposed in the RRSO-adapted CODE framework, which had been 
created using data from a literature review, as well as a focus group and interview 
study (Chapter 5). In addition to the CODE framework, some supplementary 
theories and models were also used to inform content, coping advice and the 
design of the value clarification exercise (Gigerenzer 2004, Janis and Mann 1976, 
Lazarus et al. 1985, Svenson 1992, Wilson and Gilbert 2003). Therefore, all parts of 
the intervention are firmly grounded in theory. 
 The development process demonstrated that an adapted version of the 
CODE framework can be used readily as the basis for the development of patient 
decision support. It clearly sets out questions, issues and coping options patients 
might explore during deliberations about specific medical decisions and therefore 
provides developers with a clear guide of what issues they should address in an 
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intervention. As this intervention is the first to use an adapted version of the CODE 
framework as theoretical basis, it is not possible to determine at this point whether 
the intervention will be able to achieve the goals set out in the introduction. 
Furthermore, there is as yet no empirical evidence to show that Option Grids have 
the same positive effects on decision making as longer tools (Stacey et al. 2011), 
although they have been shown to facilitate clinical consultations and enhance 
patient involvement in SDM (Elwyn et al. 2013b). Therefore, the effectiveness of 
the individual components of the intervention is currently unknown and will require 
detailed prospective evaluation.  
 Some further limitations should be noted. The intervention is only relevant 
to the UK context, as it conforms to NICE guidelines with respect to ovarian cancer 
screening, symptoms and chemoprevention using the oral contraceptive pill 
(National Institute for Health and Care Excellence 2011, 2013). Hence, it may need 
to be adapted if used outside the UK. Furthermore, the outcomes of the UKFOCS 
study are expected to be published soon, therefore the content of the Option Grids 
and OvDex, particularly the ‘other options’ section, will need to be updated 
regularly to guarantee their accuracy.  
 One further limitation concerns accessibility. The Option Grids are available 
for download from the Option Grid Collaborative website. Ideally, they should be 
printed by professionals and then handed to patients as a paper copy. The OvDex 
website, however, requires patients themselves to access the internet, which may 
limit its use, as those without internet access might struggle to obtain a copy. A 
paper-based version was therefore made available, which may be printed by 
professionals directly from the website for those patients who do not have ready 
access to the internet.  
7.4.4 Conclusions 
 This chapter reports on the development of a patient decision support 
intervention using an adapted version of the CODE framework (Witt et al. 2012). 
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The intervention is split into two parts that are designed to facilitate immediate and 
delayed decision making by providing an Option Grid as well as a more extensive 
tool. Although this intervention was developed in response to an identified need 
reported by stakeholders (Chapters 3 and 4) and due to a lack of appropriate 
decision support for patients in the UK (Chapter 6), it needs to undergo usability 
testing before it can be made fully available to patients. The next chapter reports 
on the results of a usability testing study. 
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8 Usability testing of a decision support intervention for patients 
considering risk-reducing bilateral salpingo-oophorectomy  
8.1 Introduction 
 Decision support interventions are designed to support decision making in 
situations when decisions are preference-sensitive and depend on the goals, values 
and preferences of patients (O'Connor et al. 2004, Stacey et al. 2011, Thistlethwaite 
et al. 2006). Developers of extensive self-administered interventions, such as 
websites, DVDs and booklets, have experienced substantial implementation issues, 
which has led some researchers to suggest that shorter tools might fit better into 
clinical pathways (Elwyn et al. 2008, Elwyn et al. 2013b, Elwyn et al. 2013c). In the 
previous chapter a two part decision support intervention for women at increased 
genetic risk of ovarian cancer was developed consisting of an Option Grid and a 
longer tool, called ‘OvDex’.  
 Before publication and dissemination, developers need to ensure that 
patient decision support interventions are user-friendly, easy to understand and 
deliver information relevant to the decision in a balanced and unbiased way (Elwyn 
et al. 2006, Elwyn et al. 2009b, Joseph-Williams et al. 2013). This may be achieved 
by involving stakeholders throughout the development process and by carrying out 
additional usability assessments (Elwyn et al. 2011a). Testing usability is especially 
important for web-based tools, such as OvDex, to ensure that websites are 
accessible, easy to use and navigate, and that functionality works as expected 
(Elwyn et al. 2011a, Hinchliffe and Mummery 2008, Hoffman et al. 2012, Reisman 
1996, Rubin and Chisnell 2008). This chapter aims to (i) assess usability of the 
patient decision support intervention developed in Chapter 7, (ii) evaluate 
perceived helpfulness of the intervention for facilitating decisions about RRSO and 
(iii) report user suggestions for implementation. 
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8.2 Methods 
 This study received approval from the Multi-Centre Ethics Committee for 
Wales (Ref: WA-11-0094, Amendment 3; Appendix 8.1). 
8.2.1 Recruitment of reviewers 
 Due to the problems experienced when recruiting through the clinical 
genetics services for previous studies (Chapter 4 and 5), it was decided that 
recruiting volunteers from a relevant charity’s database was a suitable alternative 
for usability testing. While it was hoped that this would lead to a higher response 
rate, it could also result in responses from women who were not at increased 
genetic risk of ovarian cancer and who were therefore not the intended target 
audience for the intervention. However, lay reviewers from various backgrounds 
may be able to make a valuable contribution regarding usability (Elling et al. 2012, 
Sawka et al. 2011). The only eligibility criteria for this study, therefore, were that 
participants were female and aged between 30 and 80 years. Only women who 
could not give informed consent were excluded.  
 Volunteer reviewers were recruited through the charity Target Ovarian 
Cancer, who sent out an email, Facebook and Twitter invite to their registered 
supporters. Recruitment was open for two days (1st until 2nd of November 2012) 
and was stopped once over 50 responses had been received. The study aimed to 
conduct a total of 15 telephone interviews, as previous research suggests that small 
numbers are sufficient during usability testing (Kushniruk et al. 1997, Nielsen 1994). 
Volunteers responded to the invite by registering their interest in the study. The 
first 25 respondents were sent a study pack, which contained an information sheet 
and a consent form. Contact details of all other respondents were kept on file. In 
case less than 15 of the first 25 individuals consented to take part, respondents on 
file would be sent a study pack, until at least 15 had been consented. Once consent 
had been received, participants were registered on the study and a date and time 
for interview was arranged when the OvDex website became available online. 
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8.2.2 Usability testing 
 Usability testing requires users to provide feedback about a website, or 
other product, often in interviews or focus groups, or via questionnaires (Battleson 
et al. 2001, Elwyn et al. 2011a, Hom 1998). Techniques such as cognitive interviews, 
which are usually used to validate questionnaires, may also be useful in usability 
testing (Willis 2005). The current study employed a cognitive interviewing 
technique termed ‘verbal probing’ to conduct usability testing (Willis 1999, 2005). 
During verbal probing, the interviewer asks targeted questions, which the 
participant answers. The interviewer then probes for further information, asking 
the respondent to expand upon, explain and/or qualify their answer (Boyce and 
Neale 2006). In the current study, participants were provided with the decision 
support intervention (Option Grids and access to the OvDex website/booklet) 
before the interview and could look at the materials in their own time. Participants 
could select to access the OvDex website online or request a printed copy of the 
OvDex booklet. Participants were asked to make notes on their thoughts whilst 
reviewing the materials and to have the Option Grids and OvDex tool, as well as any 
notes they had made, to hand during the telephone interview. Interviews were 
conducted in March 2013. The interview guide is included in Appendix 8.2. 
8.2.3 Data analysis 
 Interviews were audio recorded and transcribed prior to being analysed 
using thematic analysis (Boyatzis 1998). The coding frame is included in Appendix 
8.3. Four interviews (30%) were double coded by two independent coders and any 
discrepancies were discussed in meetings until agreement was reached. Coded 
extracts were managed and analysed using the data analysis software NVivo8 (QSR 
International Pty Ltd 2008). Analysis was specifically focused on (i) how information 
content was understood and processed by participants and (ii) identifying any 
problems with content, accessibility and functionality. Additionally, perceived 
helpfulness and effects were discussed and possible implementation strategies 
were explored. A sample of a coded transcript is included in Appendix 8.4. 
283 
 
 
 
 Quotes included in this chapter act as examples of themes and codes that 
emerged from the data. Sections where quotes were edited to remove repetitions 
and irrelevant portions are denoted by […]. Participant characteristics are indicated 
in parenthesis after each quote.  Characteristics are given in the following order: 
Age group (under35, 35to39, 40to49, over50), previous ovarian cancer diagnosis 
(yes/noOC), family history of breast cancer (BC) or ovarian cancer (OC) or both 
(B&OC) (noFH, BCFH, OCFH, B&OCFH) and gene status (unknown, BRCA1/2). 
8.2.4 Editing of decision support intervention 
 Following analysis of the interview data, reported problems and suggestions 
for improvements were collated and discussed within the supervisory team. In 
response, changes to the structure and content of the Option Grids and OvDex tool 
were made to improve usability and understanding.  
8.3 Results 
8.3.1 Response rates 
 The first 25 respondents to the invitation were sent an information pack and 
consent form. Of these, 19 consented to be interviewed. Due to a time delay of two 
months between consent and invitation to interview, dates were agreed with 17 of 
19 consented participants (10% attrition). Thirteen interviews were conducted in 
total. One woman cancelled due to poor health, another due to bereavement and 
two women did not answer their phone on the day of the interview (24% attrition). 
Characteristics of the 13 interviewees are outlined in Table 8.1. 
 Interviews lasted between 21 and 49 minutes, with a mean interview time 
of 35 minutes. The majority of participants were over the age of 50, had been 
directly affected by ovarian cancer and had not been tested for a genetic mutation. 
One respondent (R2) had only viewed the Option Grids, but not the OvDex tool, at 
the time of the interview. Therefore, the analysis includes feedback on Option Grids 
from 13 reviewers and comments on the OvDex tool from 12 reviewers. 
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Table 8.1 - Characteristics of interviewees 
Characteristic: 
No of women 
(n=13) 
Age 
group 
     Under 35 2 
     35 to 39 2 
     40 to 49 2 
     Over 50 7 
UK 
Region 
     North England 3 
     South England 7 
     Scotland 2 
     Wales 1 
Prior 
cancer 
     No 5 
     Yes 8 
Family 
history 
     Ovarian cancer only 2 
     Breast cancer only 4 
     Both 3 
     None 4 
Gene 
mutation 
status 
     Not tested 9 
     BRCA 1 1 
     BRCA 2 3 
     Lynch mutation / family history 0 
   
8.3.2 Option Grids 
 8.3.2i Layout and structure: The majority of participants were satisfied with 
the layout and structure of the Option Grids. They described them as ‘easy to 
follow’ and ‘clear’ and most felt that options were portrayed in a balanced way. 
R9: I could see exactly what you were doing. You had your […] frequently 
asked questions and then you were giving the answers […]. I thought it 
was very good for being able to balance things up. (Over50, yesOC, 
noFH, unknown) 
 
R2: I find the Grid a lot easier to read as well than if it was just written […] 
questions […]. If it was just questions on a paper with answers I don’t 
think it’s as easy to read as a Grid is. (Under35, noOC, B&OCFH, 
BRCA2) 
 
One respondent felt that the condensed nature of the grid allowed her to focus on 
the most salient questions first, rather than having to read through the detailed 
information included in the full online tool. 
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R12: …if I […] sat down with just your whole web page, I’d probably be a bit 
overwhelmed, so I think that the table does a really good job of just 
distilling the […] obvious things that I would expect to have concerns 
about. (Under35, noOC, OCFH, unknown) 
 
Overall, respondents seemed to like the layout and structure of the Option Grid and 
found it useful as a first summary of options, benefits and harms. One respondent 
made the suggestion that the column with the frequently asked questions should 
be more distinct from the columns with the answers, to help interpretation. 
R1: I thought they were quite good. […] from an ease to read point of view, 
there just needs to be a line to separate the frequently asked 
questions and then […] what the options were, because I read it first 
off and then was a little bit confused. (35to39, noOC, B&OCFH, BRCA2) 
 
 8.3.2ii Order: When asked about the order of the questions within the grid, 
participants’ responses were divided. Some felt that the current order was logical 
and did not need to be changed. 
R12: I thought it made perfect sense, because it starts out with the things 
that I’m most concerned about. […] I think it really made sense, it was 
very easy to read. (Under35, noOC, OCFH, unknown) 
 
R9: I think the order of them was very clear and it was quite a logical sort of 
progression. […] I didn’t think that anything there needed to be re-
jigged or anything. (Over50, yesOC, noFH, unknown) 
 
Others felt that the very last question concerned with screening for ovarian cancer 
should be moved towards the top of the grid. 
R8: I think the routine screening question should probably be closer to the 
top. Although it’s a bit of a negative then, but it’s still I think one of the 
first things you think about. (35to39, noOC, OCFH, unknown) 
 
R5: I think possibly I would say the routine screening programme should be 
higher, because that’s a major thing, because if there's some screening 
programme you wouldn’t want to go any further. (Over50, yesOC, 
noFH, unknown) 
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Other than moving the screening question further to the top of the grid, most 
respondents were satisfied with the order of questions. Only one woman 
commented on further possible restructuring; however, this respondent also added 
that the order did not ‘make much difference’. 
R2: My concerns were the menopause, the HRT and the health risks if I had 
surgery. For me they are the most important. For me they would want 
to be at the top. That’s my feeling anyway. (Under35, noOC, B&OCFH, 
BRCA2) 
 
 8.3.2iii Understanding and questions: Respondents were asked whether 
they found the information within the Option Grids easy to understand, whether 
they felt there were any problems with terminology and whether any information 
was missing. Most respondents were satisfied with the content of the grids and felt 
that the selected questions reflected the most salient issues they would explore 
when making a decision about RRSO. 
R5: I thought the questions were the sort of questions that you would be 
asking I think, definitely, and I couldn’t think of anything other. 
(Over50, yesOC, noFH, unknown) 
 
R9: There weren’t a lot of questions or queries I had about anything. There 
wasn’t a lot of things that jumped out at me and I thought: ‘Oh, I don’t 
understand that!’ […] I thought it was really very clear. (Over50, 
yesOC, noFH, unknown) 
 
R3: I thought it was quite helpful, quite clear. […] It answered all the 
questions that anybody would want to know I think. (Over50, yesOC, 
BCFH, BRCA2) 
 
A few women provided detailed accounts of how they cognitively processed the 
information presented in the Option Grids and asked questions that had arisen 
whilst reading the grid. Some of these responses highlighted specific problems with 
terminology and wording that might result in misunderstandings or 
misinterpretations. For instance, Respondent 6 queried the wording of the opening 
paragraph, which read ‘This grid is to help pre-menopausal women at increased risk 
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of ovarian cancer and their clinicians decide whether to remove the ovaries to 
reduce the risk of ovarian cancer’. 
R6: Most people will read this and think: ‘Hang on, I’m getting my ovaries 
taken out so surely that’s going to completely remove the risk of 
ovarian cancer.’ But you do […] later on explain that peritoneal cancer 
is part of the ovarian cancer class […]. I wonder if that’s really clear to 
your average person on the street.  (40to49, yesOC, BCFH, BRCA1) 
 
This respondent felt that within the Option Grid it was not clear why RRSO only 
‘reduces’ the risk of ovarian cancer, rather than eliminating it. She acknowledged 
that explanations within the OvDex tool clarified that primary peritoneal cancer was 
considered an ovarian-type cancer. However, she felt that other women may 
struggle to understand the current Option Grid opening paragraph. 
 Regarding risk estimates, one respondent felt that it was important that 
users of the Option Grid should be informed about their personal risk level before 
viewing the grid to avoid causing misunderstandings and anxiety due to the wide 
range of risk described in the opening paragraph. 
R12: In the little explanation where you talk about […] ‘life time risk varies 
from four in a hundred to forty in a hundred’ […], as a patient, will I 
have been told what, where I am on that scale before I see this grid? 
[…] Otherwise that’s quite scary information, you think: ‘Oh god, 
which one am I?’ (Under35, noOC, OCFH, unknown) 
 
Another respondent struggled with the meaning of ‘increased’ or ‘high’ risk, which 
to her, as a cancer patient, meant the likelihood of cancer spread and relapse, 
whereas within the Option Grid and the OvDex website, this term referred to the 
likelihood of cancer developing. However, she acknowledged that ultimately she 
understood how the term was used in the intervention and that women who had 
not been directly affected by cancer may not struggle with the interpretation of this 
term as she did. 
R11: Quite a lot of the time I was trying to define what was high risk. So I 
now understand what you’ve defined as high risk […]and that’s not 
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quite the same as how my [cancer care] team would define high risk 
[…]. Your high risk is predicting occurrence; their high risk was 
predicting reoccurrence.  (Over50, yesOC, noFH, unknown) 
 
One of the youngest respondents commented that the fourth question ‘Will surgery 
change how I feel about myself as a woman?’ was the least helpful question, as it 
did not provide any statistics or factual information. 
R12: The ‘how I feel’ question […], I can see why it’s in there, but I wasn’t 
entirely sure that […] the answers actually added anything. […] It 
doesn’t give you any facts, […] it’s quite bland. […] Have women who 
have had to have this operation at thirty-three, or chosen to have this 
operation at forty-three […] come back and said: ‘Oh god, I really 
regret it, I wish I hadn’t had it!’ I think that sort of information would 
be more useful. (Under35, noOC, OCFH, unknown) 
 
The same respondent also reported that other questions in the Option Grid were 
helpful in highlighting some of the important issues she would consider and in 
leading to further, more detailed, questions about these issues. 
R12: If this was something I was having to go through I had quite a lot of 
questions around the menopause […] and this box […] starts to tease 
some of those out, which I thought was really useful. […] What are the 
likely side effects of having […] this operation in terms of the 
menopause, emotionally speaking? If you have the menopause and 
you’re much younger, what have other people’s experiences been? 
(Under35, noOC, OCFH, unknown) 
 
She then acknowledged that many of the questions that had arisen whilst reading 
the Option Grid had later been addressed and resolved within the OvDex tool. 
R12: Having gone on to read the rest of the information pretty much all of 
that stuff is covered […] in the main documents, so that was really 
helpful. (Under35, noOC, OCFH, unknown) 
 
Respondent 6 described her reaction to some of the wording within the grid, 
particularly referring to the final question about the availability of screening for 
ovarian cancer. She felt that, by stating that the remaining cancer risk following 
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surgery was ‘similar’ to that of the general population, the perceived impact of 
surgery was reduced.  
R6: It says: ‘No after surgery there is no need for screening because your 
risk will be similar to that of the general population’ and I thought: 
‘Well surely it’s going to be lower actually?’ […] So I just thought well 
maybe using the word similar there isn’t really showing that there’s 
much of a difference between you having gone through the operation 
and somebody out of the general population who has not. So it’s 
almost like making you think: ‘Oh hang on a minute there’s really no 
benefit then of having the operation.’  (40to49, yesOC, BCFH, BRCA1) 
 
Some respondents had knowledge of screening or diagnostic tests that were being 
trialled or used and therefore queried the answer to the final question in the 
Option Grid, which stated that no medically effective screening was currently 
available. 
R1: [The grid] was very black and white, [either] you have surgery or you 
don’t. And it’s almost like if you don’t have surgery you take your life 
in your own hands, whereas there is the possibility of having 
ultrasounds for early detection […]. I’m lucky that I can get that done 
but I don’t know if other [NHS] Trusts […] do that, so I suppose that’s 
quite a tricky thing. (35to39, noOC, B&OCFH, BRCA2) 
 
Overall, many respondents were positive about the content of the grids and felt 
that the information was clear, easy to understand and addressed the salient 
questions they had thought of. However, some described their cognitive processing 
of wording and terminology in detail, and, in doing so, highlighted potential areas 
for improvements. Some also reported further questions that had been inspired by 
the information in the grid. Many felt that those issues were later addressed in the 
OvDex tool. 
R1: Your website bit explains it a lot better than the grid and gives you all 
the […] ups and downs and […] the time scales and everything like 
that. (35to39, noOC, B&OCFH, BRCA2) 
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 8.3.2iv Improvements: In addition to discussing issues with layout, 
terminology and content, which highlighted areas where amendments may be 
required, respondents also made a number of direct suggestions for improvements 
to the Option Grids. For example, one woman felt that, from her own experience, 
the information about recovery was insufficient and should be supplemented with 
further details. 
R13: It might be a good idea just to mention that it can be quite traumatic 
afterwards for a few weeks. (Over50, yesOC, BCFH, unknown) 
 
Another respondent felt that the answer to the last question about screening for 
ovarian cancer in the surgery column was inadequate. 
R10: If you were having surgery [the answer] didn’t answer the question. 
[…] Whereas if you were not having surgery it did answer the question, 
because there isn’t [a screening programme]. It should have said: ‘No 
there isn’t a screening programme and after surgery anyway...’ I feel it 
needs a little addition. (Over50, yesOC, BCFH, unknown) 
 
One respondent commented specifically on the Option Grid for post-menopausal 
women and felt that this should include some information about hormone 
treatment options for this population. 
R4: On the post menopausal women thing I think that there could be 
something added about taking HRT […] afterwards, because I am post 
menopausal obviously, but I was on HRT before I was diagnosed and 
have had to go back onto some oestrogen only HRT after. (Over50, 
yesOC, noFH, unknown) 
 
 8.3.2v Amendments to Option Grids: Overall, participants’ comments 
highlighted 16 areas where changes to the Option Grid content may be required. A 
full list of these, including the decisions of the supervisory team, can be found in 
Appendix 8.5. In total 10 changes were actioned (Table 8.2) and the Option Grids 
were reviewed and amended accordingly to improve layout and enhance 
understanding (Figure 8.1). Option Grids are not designed to be comprehensive; 
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Table 8.2 - Changes made to Option Grid in response to lay reviewer feedback 
Option Grid section Action / Change 
Introductory paragraph 
Wording of opening paragraph was changed to “…surgery reduces risk 
of ovarian-type cancer…” 
Layout Frequently Asked Questions column was coloured in light orange 
Question order Screening question was moved up to be the second question in the grid 
Question 3* Factual information about satisfaction with RRSO was added 
Question 4* Wording changed to “…is likely to decrease” 
Question 8* Added statement about post-surgical effects during recovery 
Question 9* 
Reworded answer to screening question in the surgery column to not 
include ‘similar to general population’ 
Question 9* 
Reworded answer to screening question in the surgery column to be 
more relevant to the question 
Question 9* 
Reworded answer to screening question to be more relevant to 
emphasise that there is no medically proven screening 
Question 9* 
Reworded answer to screening question to explain why there is no 
evidence that screening is effective (i.e. no proven survival benefit) 
*Questions are numbered according to their order in original grid viewed by lay reviewers 
 
 
instead, they are intended to provide a scaffold for better conversations about 
options between patients and health professionals in clinic. It should, therefore, be 
noted that the Option Grid was being used outside its intended context in this 
study. Hence, requests made by respondents for further information to be included 
in the grid may have been due to the unavailability of a health professional at the 
time of viewing the grid. Furthermore, limitations on the size of Option Grids, which 
should fit on one A4 page, mean that information in grids has to be selected on a 
priority basis. For these reasons, the remaining potential changes proposed by 
respondents in the current study were not actioned. Most of these were requests 
for additional information, which was available and covered in the full OvDex tool 
and/or may be discussed with health professionals whilst viewing the grid. 
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Figure 8.1- Amended version of the Option Grid for pre-menopausal women 
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8.3.3 OvDex usage, accessibility, functionality and navigation 
8.3.3i Usage: Four participants requested printed versions of OvDex, six 
used the website and two accessed the website, but then chose to view a PDF 
version. Respondents reported having spent between 20 minutes and 2 hours 
reading through the materials, with the majority taking between 30 minutes to 1 
hour. Most viewed the OvDex website/booklet alone, but one respondent shared it 
with her mother and another used it together with her husband. 
R11: I then got my husband to sit down with me and […] just go through 
this with me and I bounced questions off him. And that’s how I went 
through it. (Over50, yesOC, noFH, unknown) 
 
This respondent later also noted that the material was useful, not only to her, but 
also to her husband, indicating that shared use with important others may be 
beneficial. 
R11: I hadn’t shared anything with him prior to my having my op. He didn’t 
know what I was having done and I think had this been around at that 
time it certainly would have made things clearer for both of us. 
(Over50, yesOC, noFH, unknown) 
 
8.3.3ii Accessibility: Most respondents who chose to access the OvDex 
website (n=8) reported no problems with access. Only two women could not get 
access initially; however both were able to resolve the problem later.  
R12: The only problem I encountered, and this is potentially my own fault, 
is I couldn’t actually get onto the web link originally […]. I typed it in 
and it didn’t work, I had to actually cut and paste it. (Under35, noOC, 
OCFH, unknown) 
 
This respondent was accessing the website via an iPad and reported no further 
problems once the website was loaded. These issues with access may have been 
due to the complex path (http://medic.cf.ac.uk/OvDex/index.html) at which the 
online tool was available during usability testing. Ultimately, the online tool will be 
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accessible at a direct web-address (www.OvDex.co.uk), which should help to avoid 
such issues. 
 8.3.3iii Functionality: The OvDex website has two major interactive 
functions: the personalisation of website content and the value clarification 
exercise. As the majority of lay reviewers in this study were not at increased risk of 
ovarian cancer, most chose not to use the personalise function on the website and 
viewed the general version of the tool. However, they acknowledged that tailoring 
the information is a useful function for the target population of the intervention. 
R12: If I was one of the people who had been told that I was at high risk […] 
I would absolutely use […] the one that’s restricted to you, because it’s 
giving you the information that’s particularly relevant to you. 
(Under35, noOC, OCFH, unknown) 
 
Some users, especially those who carried a confirmed BRCA mutation, did attempt 
to personalise the site. Most of those who used the personalise function found the 
interactive question format easy to use and valued the tailored information it 
resulted in. 
R1: I think it was really good, the fact that you can personalise it from my 
point of view was really interesting. (35to39, noOC, B&OCFH, BRCA2) 
 
However, one user reported problems with this functionality and could not access 
the personalised site. 
R6: I actually tried to use the online thing because I thought: ‘Well I’ll 
personalise it to myself obviously, because I’ve got a BRCA 1 
mutation.’ […] And it didn’t seem to want to work, so it […] just came 
back to the original question. (40to49, yesOC, BCFH, BRCA1) 
 
Furthermore, some users reported not seeing the option of personalising the site, 
and others felt that the personalisation option should be more prominent. 
R5: The thing that I thought was a bit odd at first is the ‘it can be 
personalised’. I would have thought you would want it to be 
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personalised really. […] I don’t know [under] what circumstances you 
wouldn’t want to personalise it. (Over50, yesOC, noFH, unknown) 
 
R9: I would definitely try and sort it round so that you personalise it and 
then, if after you’ve read your personalised information you would like 
to just look at the general version you can do so, but try and get 
people not to waste time on the general version. (Over50, yesOC, 
noFH, unknown) 
 
The second interactive function of the website is the value clarification exercise, 
which requires users to move sliders to weigh the importance of various factors. 
Most users found this exercise easy to use and had no problems with functionality.  
R8: It was easy to move [the sliders] either way […]. I don’t think there’s 
anything that I would say to improve on. It […] seemed easy to access 
and you could […] move it back and forward and make your decision. 
(35to39, noOC, OCFH, unknown) 
 
The respondent who had used an iPad to view the site reported that the function 
differed from that of a site viewed via a PC or laptop. 
R12: It took me a couple of goes to figure out how to move the little circles 
around […] that’s because I was on an iPad rather than a laptop. […] I 
was expecting to be able to drag it across and I couldn’t […] You just 
had to click on the circle […] and then put your finger just on the line 
where you want the circle to go and it jumps there (Under35, noOC, 
OCFH, unknown) 
 
One user also commented that she occasionally moved the sliders in the wrong 
direction. Although the functions worked correctly, this may indicate a layout issue. 
R1: I did, a couple of times, get confused which way I was going with it. […] 
You’re going one way and then you do something and then you think: 
‘Oh no, I didn’t mean it [like] that!’ and you have to go back and 
change it. (35to39, noOC, B&OCFH, BRCA2) 
 
Respondents’ comments about the content, rather than functionality, of the value 
clarification exercise are outlined in section 8.3.4 below. 
296 
 
 
 
 8.3.3iv Navigation: Initial navigation to the index page of the website was 
found to be a problem for some women. One respondent described her confusion 
as she entered the website and viewed a page that assumed she had already seen 
the personalisation questions. 
R5: Right at the beginning it confused me, once I got into it, it didn’t at all, 
but the very beginning confused me. […] The way it comes in at the 
moment it just says: ‘Welcome to OvDex, please note it can be 
personalised you should have seen and answered these questions 
before viewing these pages.’ […] You think ‘Oh hang on what questions 
then?’. (Over50, yesOC, noFH, unknown) 
 
This respondent had opened the website on a different page to the index page and 
therefore had not seen the personalisation questions. However, this may again 
have been due to the complex path (http://medic.cf.ac.uk/OvDex/index.html) at 
which the online tool was available during usability testing. 
 When navigating the main part of the OvDex website, i.e. either the general 
version or a personalised version, or when reading through the OvDex booklet, 
most respondents read content in a sequential manner following the order 
suggested by the layout.  
R9: I just went through all the sections […]: the choice, the options format 
and then down through the risk reducing surgery and so on. I just 
worked my way through it. (Over50, yesOC, noFH, unknown) 
 
Some respondents followed links to specific questions or sections within the 
website, instead of reading it sequentially. These women felt that the website 
allowed them to pick and choose the information they accessed. 
R12: I like that because you can do it both ways can’t you? […] you’re going 
to come across the information anyway, but equally if that’s all you 
want to know about, then you can just go straight to it. (Under35, 
noOC, OCFH, unknown) 
 
R4: What is good about it is, you can take from it what you want. So you 
can click onto things that are perhaps key in your mind at the time and 
297 
 
 
 
find out information to answer […] [what] you’re fretting about and 
come back to it again, when you’re ready to look at some more. 
(Over50, yesOC, noFH, unknown) 
 
These respondents also felt that jumping between sections was facilitated by the 
website’s layout and links within the site.  
R4: Within every section you have ‘Go back to top’ or ‘Go to this’ and […] I 
just used the back button as well. […] If I clicked onto different tabs on 
the left it would still let me go back to […] an earlier one. It was just 
fantastic. It is fantastic the way it works. (Over50, yesOC, noFH, 
unknown) 
 
8.3.4 OvDex layout and content 
8.3.4i Layout and structure: Respondents felt that the possibility to choose 
between browsing the website and viewing, or printing, a PDF was advantageous 
and appreciated the possibility of choosing between the two. 
R5: There’s an awful lot of information to take in so I think the fact you 
have it as a PDF so people can download it and read it at leisure is a 
good idea. (Over50, yesOC, noFH, unknown) 
 
One respondent also commented positively about the colour scheme. 
R5: I know that’s only a little small thing but it links in quite nicely, because 
lots of the things to do with […] ovarian cancer and stuff obviously are 
that colour. And it kind of links it all in your mind. (Over50, yesOC, 
noFH, unknown) 
 
The majority of participants were satisfied with the layout and structure of the 
OvDex website and booklet. In particular, women felt that the natural progression 
of the sections and the list of questions at the top of each section were helpful, as 
these gave them an overview of the section’s content. 
R12: It’s a really great looking website as well. It’s really nice looking, so it’s 
really easy to surf through […] Really easy to use. (Under35, noOC, 
OCFH, unknown) 
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R9: Underneath each chapter heading […] it listed down the questions. And 
I liked that, because I could glance down through and think: ‘Oh right, 
yep, that’s what this is gonna cover.’ And then you go through each 
question and I just liked the clarity of it all and the structure of it all. 
(Over50, yesOC, noFH, unknown) 
 
R5: I  thought [the layout was] quite good, because you’ve got the risk first, 
which is the major question, and then the choices that you’ve got and 
then you break it down […] and it sort of defines it clearly. […] So I 
think that, and the fact you’ve got other contacts and resources and 
stuff as well, yeah I think it’s extremely well laid out. (Over50, yesOC, 
noFH, unknown) 
 
 8.3.4ii Information quantity: Although many respondents acknowledged 
that the tool included a lot of information, which initially could be seen as 
overwhelming, most felt that the quantity of information included in the 
intervention was appropriate and useful.  
R4: I mean I could sit here and say: ‘Well it’s really wordy!’, you know. I 
mean there’s loads of information in it, but then you know: you want 
loads of information. (Over50, yesOC, noFH, unknown) 
 
R7: I’ve got more information from this than what I’ve actually had from 
reading books that have been written by doctors […] I’ve got so much 
information from this little leaflet to what I’ve had from books that 
I’ve sat and read for hours and hours on end. (40to49, noOC, B&OCFH, 
unknown) 
 
Many noted that the information did not need to be read in one session and that 
users could come back to it when they wanted to learn more. 
R1: There’s certainly a lot of information, but I don’t think that’s a bad 
thing. And I think it’s certainly something that you don’t have to do in 
one hit. (35to39, noOC, B&OCFH, BRCA2) 
 
R5: I thought it was very good, because it’s all broken down into sections. 
So you don’t have to read the whole thing through in one minute […] 
You can keep going back to it, you can go back to sections […], you can 
print it out, you can read it again and again and keep going back as 
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much as you like until you’ve got it clear in your mind. (Over50, yesOC, 
noFH, unknown) 
 
R11: I thought the amount was quite a lot and […] the first time I looked at 
it I thought: ‘No I can’t, there’s too much here, I can’t take it all in at 
once.’ […] [but] I thought it was quite a reliable source to go back to 
[…] I can pick and choose what I want. And there’s a lot of it where I 
now think that makes sense and I’m looking for next sections and 
everything else. (Over50, yesOC, noFH, unknown) 
 
Only one respondent strongly felt that there was too much information and that 
content should be condensed. This respondent may have preferred to view just an 
Option Grid rather than the more extensive website. 
R13: It was helpful, but far too much. It could have been condensed and 
[…] probably been a lot clearer […]. Just far too much reading. 
(Over50, yesOC, BCFH, unknown) 
 8.3.4iii Understanding and questions: When respondents were asked about 
the information content within OvDex, most noted that the wording was clear and 
easy to understand. 
R7: You don’t need to be a rocket scientist to read it. It’s self-explanatory 
and even for somebody who doesn’t have much common sense it 
would be very easy to follow. (40to49, noOC, B&OCFH, unknown) 
 
R12: Really not patronising. It gave you the information that you required 
and it gave you more detail if you wanted it, so it was good. (Under35, 
noOC, OCFH, unknown) 
 
Respondent 7 also added that OvDex was very easy to understand compared to 
other information materials she had viewed previously. 
R7: I took a lot more in with this, because […] it’s so well written. I’ve read 
a lot of material since my mother has had ovarian cancer and they 
come out with big words that only doctors and nurses would possibly 
understand and […] it sounds like gobbledegook, but this is just […] so 
simple to understand. (40to49, noOC, B&OCFH, unknown) 
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Similar to feedback received about the Option Grids, some respondents gave 
detailed accounts of their cognitive processing of information and of questions that 
arose whilst reading OvDex. These highlighted areas where potential changes need 
to be made to facilitate understanding. For instance, one woman wondered why 
prevention of non-cancerous problems with the ovaries / fallopian tubes (an 
additional benefit of RRSO) might be advantageous. 
R6: It says ‘having the surgery will also prevent other non-cancer related 
problems happening with the ovaries such as cysts’ and […] maybe you 
should sort of expand on that a bit and maybe explain why it’s bad to 
have cysts. (40to49, yesOC, BCFH, BRCA1) 
 
Another respondent noted that when reading the section on alternatives to HRT, 
she wondered how and why the examples given in OvDex had been selected. 
R9: There was one bit there, […] ‘the alternatives to HRT’ […] I didn’t know 
whether the ones that were listed were the most commonly used […] I 
didn’t know why, in particular, you had listed those. (Over50, yesOC, 
noFH, unknown) 
 
This respondent later also reported struggling with the use of the word ‘alternative’ 
in the question ‘Are there any alternatives to surgery?’, as this term had previously 
been used to describe medical and herbal remedies to HRT and was now being used 
in a different context. 
R9: I think it’s that term ‘alternative’. […] I was thinking of something very 
different to surgery, so I think maybe what […] would be clearer for 
me would have been to say, ‘Are there other treatments apart from 
surgery’? […] Just on the previous page you’re reading about 
alternatives to HRT and you’re talking about herbal things and 
everything, so I’ve just gone off on that track of thinking and then I 
was distracted by the use of the word ‘alternative’ again. (Over50, 
yesOC, noFH, unknown) 
 
Women also commented on the figures, diagrams, graphs and pictograms included 
in OvDex to facilitate understanding. One woman specifically felt that the picture in 
the cancer risk section showing women’s anatomy was helpful. 
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R4: There’s a fantastic diagram. I loved the diagram you’ve got of the 
physiology of a person. (Over50, yesOC, noFH, unknown) 
 
Most respondents were positive about the pictograms showing cancer risk and risk 
of complications during surgery, and felt that these facilitated visualisation. 
Additionally, respondents appreciated that both positive and negative framing was 
used. 
R9: I thought the little pictorial things […] were very good. […] That just 
really made it clearer to you what that sort of number was looking like, 
so I liked that. It was a very simple thing. (Over50, yesOC, noFH, 
unknown) 
 
R11: I found them [the pictograms] really good actually […] I particularly 
liked that it was balanced. […] It is good to have that positive 
reaffirmation that just because you’ve been told you’ve got a 
predisposition doesn’t mean you’re going to get cancer. So I found 
that useful, I also just found it useful to break up all the text anyway, 
just give your eyes a bit of a rest. (Over50, yesOC, noFH, unknown) 
 
R5: It reminded me of a theatre seating plan. It looks exactly like an online 
booking service doesn’t it? […] But no, I think that’s really good 
because it’s a good clear display […]. The dots indicate the risk that 
you’re talking about.  (Over50, yesOC, noFH, unknown) 
 
One respondent felt that the pictograms with dots may not be the most effective 
way of portraying risk, as she struggled to understand their meaning. She suggested 
using small female signs instead. However this respondent also noted that she 
struggles with interpreting frequencies correctly and therefore sought help from 
her husband, who understood and liked the pictograms. 
R11: You know the little bits with all the circles on? […] I would change 
those to little people. […] I didn’t understand the circles. My husband 
thought they were good, but I said well no I don’t like those, because 
I don’t understand what’s good and what’s bad. […] It says ‘The 
pictures below’, but they’re not pictures and they’re sort of blobs. I 
like more sort of pictury things. (Over50, yesOC, noFH, unknown) 
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Two respondents suggested removing the pictograms completely, as they felt 
numerical information was sufficient. However, Respondent 6 later also 
acknowledged that some users may benefit from visual aids, such as these. 
R6: What I wasn’t really sure about was your pictures showing the chances 
of getting cancer […]. You seem to do this quite a lot all the way 
through. […] I suppose it’s quite a nice indication, but it’s taking up 
quite a lot of room. I don’t know if it’s totally necessary, because 
people can just as easily look at numbers. (40to49, yesOC, BCFH, 
BRCA1) 
 
R3: I think actually reading […] the writing besides [the pictograms] makes 
it clearer than the dots. I think […] you could possibly do it without 
using the dots maybe. (Over50, yesOC, BCFH, BRCA2) 
 
 8.3.4iv Coping: The OvDex tool includes four sections concerned with 
providing coping advice and links to external sites with further information about 
coping. Three respondents provided feedback on these sections specifically. 
Respondent 10 commented on the coping advice within OvDex. 
R10: I thought this was really good. [Reads from coping advice] ‘How can I 
change how I feel about my cancer risk?’ […] Find someone to talk to: 
partners, your contacts or resources list. Yeah, I thought that was very 
good. (Over50, yesOC, BCFH, unknown) 
 
R10: [Reads heading] ‘How can I deal with the choice?’ I thought this was 
really good […] I thought that was excellent. [Reads from coping 
advice]: ‘I will decide by myself using everything I have learnt. I will 
decide but will seriously consider my doctor’s opinion. The doctor and 
I should decide together. The doctor should decide but seriously 
consider my opinion and the doctor should decide’. I thought they 
were really good choices. (Over50, yesOC, BCFH, unknown) 
 
Although she found several parts of the coping advice useful, Respondent 10 also 
felt that some of the sections were repetitive and needed to be reviewed. 
R10: The thing about feelings and anxiety […] gets reproduced a lot in this 
book. But then again […] you have to do that don’t you? In a way. […] I 
think it could possibly be a little less. (Over50, yesOC, BCFH, unknown) 
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Respondent 9 described her thoughts about the terminology used in the question 
introducing the second section on coping advice within the chapter about ‘Choice’ 
and made a suggestion for changing the wording of this question. 
R9: I wasn’t sure if that was quite the right wording. Because I wasn’t 
sure what that meant […]. I did wonder whether it [should be] 
something about: ‘What will help me make the best decision for me? 
Or ‘What will help me make this decision? […] I wasn’t sure about the 
word ‘deal’. (Over50, yesOC, noFH, unknown) 
 
Respondent 4 followed the links within OvDex’s coping advice to external sites. She 
visited the Cancer Genetics Story Bank, watched the coping video and other 
content, and commented on the additional material (Iredale 2010, Phelps et al. 
2006). 
R4: There was a fantastic video regarding the waiting time. […] It’s very 
reassuring and useful tips on how to cope and ideas on how to relax 
etc I thought that was brilliant. […] And I liked all the patient stories. 
[…] I thought the testimonies were really powerful and they made me 
feel less alone as a patient watching them. (Over50, yesOC, noFH, 
unknown) 
 
Overall, few respondents provided feedback on the coping advice specifically. 
However, those who did felt that these sections, including external sites, were 
useful, although some parts may need to be reviewed to reduce repetition. 
 8.3.4v Value clarification exercise: Six women used the interactive online 
value clarification exercise. Four women had requested a printed booklet of OvDex 
and two women chose to review the pdf version online, therefore six women used 
the paper-based value clarification exercise. Many felt that weighing the options 
was a natural step in the decision making process and that this was facilitated by 
the exercise. 
R5: I thought it was great fun and it’s a nice interactive little tool. […] We all 
do the list don’t we of good and bad, for and against but to actually 
see it like that and to see the decision the effect it has what your 
304 
 
 
 
choices are I thought it was brilliant. (Over50, yesOC, noFH, unknown) 
[online version] 
 
R9: I really like this section eight, ‘Your Decision’, because, I just thought 
that this was really helping you after all the information and 
everything and it was almost like testing you on what you’d read 
(Over50, yesOC, noFH, unknown) [paper version] 
 
R12: I thought it was really useful, really interactive and I was at that point, 
at the end, […]and I was almost sitting there thinking would I have to 
write a pros and cons list and then you come to that and you think: 
‘Oh, it’s there!’ (Under35, noOC, OCFH, unknown) [online version] 
 
R6: Then I got onto chapter 8 which is ‘Your decision’ kind of questions and 
how much weighting you give the questions and everything, and I 
actually thought that was really helpful. (40to49, yesOC, BCFH, BRCA1) 
[paper version] 
 
For those using the paper-based version, the example included gave clear 
instructions on how to complete the exercise and enabled all participants to fill in 
the written version without difficulty.  
R9: [The example] made a lot of sense and actually, I think it’s a good idea 
to have an example, because that just tunes you in again to the sort of 
things that you might be considering, so I thought that was good 
having the example and then having the blank [version] on there to 
have a go at yourself. (Over50, yesOC, noFH, unknown) [paper version] 
 
The scales summarising a user’s leaning at the end of the exercise were also 
perceived as helpful visual aids by most respondents. 
R1: I thought that was really good. […] I dare say it gives you confidence in 
what you’re thinking. (35to39, noOC, B&OCFH, BRCA2) [online version] 
 
R8: It was basic, but I think it’s basic and then it covers everyone. Everyone 
can work with it, so I don’t think you want anything complicated, 
because it’s complicated decisions that people are making. (35to39, 
noOC, OCFH, unknown) [online version] 
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Following the value clarification exercise, the possibility of formulating an action 
plan and taking a printed or written version of the exercise and plan to the GP or 
consultant was an option users valued. 
R4: I thought that was really clever and the ‘My Plan’ […] that’s really useful 
for taking and discussing things with your GP. I thought that was great. 
[…] I could have printed it off with my action plan and all those 
questions I might have wanted to ask. I think that’s a brilliant section. 
(Over50, yesOC, noFH, unknown) [online version] 
 
Overall, users of the interactive online exercise understood the instructions and 
could do the exercise without major problems. Users of the paper-based version 
reported that they understood the example and were able to complete the written 
exercise without difficulty. All respondents found the exercise useful. 
 8.3.4vi Contacts, resources and research evidence: Respondents appreciated 
the list of contacts and resources towards the end of the OvDex tool. They felt that 
it provided them with reassurance that further help could be obtained from other 
sources and that the intervention materials were not the only advice available. 
R5: I think that that’s really good, to say to people these are other places 
you can go. […] You’re saying: ‘Well look if you want to have more 
you’ve got your GP, you’ve got your specialist’. You’ve got all these 
people and you’re giving them lots of places they can go to get more 
information, help, whatever they need. […] So I think that, at the end, 
is excellent.  (Over50, yesOC, noFH, unknown) 
 
R4: The other thing that you’ve done very well is […] put down: ‘For further 
information you can check out contacts and resources’ and the list of 
all those other agencies […]. In my situation it would have thrown up 
further issues and questions but I’d have then felt comfortable going 
to one of those other agencies to ask those things. (Over50, yesOC, 
noFH, unknown) 
 
Women also valued the list of research evidence at the end of the decision aid. 
Although many had not gone on to look at any of the specialist publications, they 
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felt that the references provided reassurance that factual information had come 
from reliable sources. 
R5: To actually say that this is where the evidence is from, this is where the 
information is for anybody who wants to go and look at that, that’s a 
nice touch, because very often you don’t get that. (Over50, yesOC, 
noFH, unknown) 
 
R4: I thought the research evidence was really good […] for further reading 
before deciding on what treatments you were going to have […]. I 
really like looking at research myself. (Over50, yesOC, noFH, unknown) 
 
R9: It gives it more credibility, doesn’t it? When you see lots of references 
at the end and you see all the research evidence and everything. So, 
yeah, I thought that was well worth putting in. (Over50, yesOC, noFH, 
unknown) 
 
 8.3.4vii Improvements: In addition to discussing questions and issues with 
functionality, terminology and some of the content, which highlighted areas where 
amendments to OvDex may be required, respondents also made a number of direct 
suggestions for improvements. For instance, one respondent felt that there was 
insufficient information about BRCA testing in the general version. 
R11: I wanted to know a little bit more about the BRCA test and whether or 
not it was available if I just walked in […] And also probably another 
question about how quickly results would come back and about what 
that would involve. (Over50, yesOC, noFH, unknown) 
 
As many respondents had had ovarian cancer and therefore had undergone 
oophorectomies, a number of women commented on the section describing 
recovery and recommended changes to this section based on their experiences. 
R13: I wasn’t too bad, but a lot of women can experience extreme 
tiredness […]. They need to know all this, especially if they’re looking 
after somebody or they need to work. (Over50, yesOC, BCFH, 
unknown) 
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Many women also felt that more emphasis should be put on the symptoms of 
ovarian cancer and on recommending that women who experience symptoms 
should seek professional help immediately. This may, in part, have been due to 
many of the women in this group having experienced ovarian cancer themselves. 
R8: I just think the symptoms, that didn’t really stand out on the website. 
Although everything was green and grey and black, everything was 
kept uniform and the same. I just think something like that needs to 
stand out a wee bit. (35to39, noOC, OCFH, unknown) 
 
 8.3.4viii Amendments to OvDex: Overall, participants’ comments highlighted 
39 areas where changes to the content of OvDex may be required. A full list of 
these, including the decisions of the supervisory team, can be found in Appendix 
8.6. In total 31 changes were actioned and led to a review of functions, additions to 
the instructions included on various pages and alterations to information content 
(Table 8.3). The final version of OvDex is included in Appendix 8.7.  
  Eight potential changes were not implemented. The main reason for non-
implementation was a lack of support for a given change from several other lay 
reviewers, who had commented positively about the same section. Other reasons 
included the supervisory team concurring that issues were already addressed 
satisfactorily or that additions were not sufficiently relevant to the target 
population of the OvDex tool. For instance, one respondent had suggested the 
addition of a new section on ovarian cancer, including pathology, treatment options 
and statistics; however this was rejected by the supervisory team, as it was not 
directly relevant to the target audience: women at increased risk, who have not 
been diagnosed with ovarian cancer. Additionally, the team was concerned about 
causing unnecessary anxiety among this group by including such information.  
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Table 8.3 - Changes made to OvDex in response to lay reviewer feedback 
OvDex section Action / Change 
Index page (Personalisation) Index page was made default home page for URL www.OvDex.co.uk 
Index page (Personalisation) Personalise functionality was reviewed in available browsers 
Index page (Personalisation) 
Section on Index page was reworded to emphasise benefit of 
personalisation 
Home pages 
Added statement on introductory home page to clarify that 
intervention had been entered 
Home pages 
Added statement that announces that Value Clarification Exercise 
exists and added link 
Overall (Information 
content) 
OvDex tool was checked for repetitions and those were removed 
Overall (Pictograms) Changed dots to small female signs in pictograms 
Cancer Risk (Q1)* 
Added links to CRUK statistics and Contacts & Resources for 
information about ovarian cancer 
Cancer Risk (Q3; 
General/Uninformative)* 
Added information about possibility of private testing; Emphasised 
requirements for testing on the NHS 
Cancer Risk (Q3; 
General/Uninformative)* 
Added statement about gene test, timeline and possible outcomes. 
Cancer Risk (Q6; 
General/Uninformative)* 
Shortened answer and added graph showing risk curve 
Cancer Risk (Q8)* 
Added information that if a gene mutation is confirmed in the family, 
children can choose to get tested 
The Choice (Q5)* 
Added statement about why surgery is most effective at 40 years of 
age 
Options at a Glance (Table) 
Screening question was moved up to be the second question in the 
grid 
Options at a Glance (Q1)* Reworded question title 
Cancer Risk (Q9) and 
Options at a Glance (Q1)* 
Reworded answers to make them more distinct 
Options at a Glance (Q1)* 
Added link to Genetics Story Bank and Macmillan website to 
reference in text 
Risk-reducing surgery (Q2)* Added statement to advantages of surgery about ovarian cysts 
Risk-reducing surgery (Q3)* Wording changed to “…your desire for sex is likely to decrease” 
Risk-reducing surgery (Q4)* Added statement that peritoneum cannot be removed 
Risk-reducing surgery (Q9)* 
Added information about next steps / procedures if cancer is found 
during the surgery 
Risk-reducing surgery (Q9)* Added information about HRT if ovarian cancer is found 
Risk-reducing surgery 
(Q10)* 
Added statement about post-surgical effects during recovery 
HRT (Q9)* Added statement about how examples of alternatives were selected 
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OvDex section Action / Change 
Other Options (Q1&3)* 
Reworded answers to emphasise that although screening might be 
bought privately, it is not effective at detecting cancer early and 
might provide false reassurance and to emphasise the difference 
between screening and diagnostic tests  
Other Options (Q2)* Reworded question title 
Other Options (Q2)* 
Added statement to emphasise similarity to IBS and encourage 
people to consult their GP if they notice anything unusual and link to 
symptom list 
Other Options (Q2)* 
Made symptoms box stand out more by adding colour and bold 
writing 
Your Decision (Web version) Added instructions for users of iPads 
Your Decision (S5&6)* 
Expanded statements in value clarification exercise to clarify their 
relevance to the decision 
Your Decision (Q1) 
Reworded question title and included information about what to do 
once decision is made 
*Questions(Q)/Statements(S) are numbered according to their order in original OvDex tool (General 
Version) viewed by lay reviewers. If changes only apply to a certain version this is indicated behind 
the question number. 
 
8.3.5 Perceived helpfulness 
 The majority of respondents felt that the intervention would benefit women 
at increased risk of ovarian cancer making decisions about RRSO.  
R6: I think it’s really helpful, because it does give a lot of information and it 
really makes you sort of sit down and think what your priorities are as 
well. (40to49, yesOC, BCFH, BRCA1) 
 
In particular, respondents remarked upon the emotions associated with learning 
about and living with an increased risk of ovarian cancer and how the content of 
the intervention might help women to appraise and understand their situation and 
regulate these emotions. 
R10: I think it’s very clear and if I was faced with what these poor women 
are faced with, it would certainly help. When you’ve found out 
something that’s really possibly life changing […], everything goes to 
pot really. Logic goes out the window, so you need an aid to help you. 
[…] I think they’ll be glad to have it. (Over50, yesOC, BCFH, unknown) 
Table 8.3 cont. - Changes made to OvDex in response to lay reviewer feedback 
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R1: You get a lot of information and you can’t always get your head round 
it and there’s a lot of emotion involved as well […], so […] to have 
something […] to take away, that is useful. (35to39, noOC, B&OCFH, 
BRCA2) 
 
R12: If they wake up in the middle of the night and they’re a bit worried or 
they think: ‘Really I need to get to grips with this!’, then they can refer 
to it. I think that that’s really, really useful. (Under35, noOC, OCFH, 
unknown) 
 
Respondents also felt that the ability to personalise OvDex and the opportunity to 
weigh different factors using the value clarification exercise were helpful. Women 
felt that the decision support intervention provided relevant information in a 
balanced, unbiased way and encouraged women to consider their values and 
preferences. 
R5: I think this sets it out very clearly but doesn’t […] push in any direction. 
It gives the information for the person themselves to make their 
decision without any sort of pushing, which is critical I think, because 
at the end of the day they are the ones who have got to make the 
decision and live with it. (Over50, yesOC, noFH, unknown) 
 
Respondents could imagine a number of ways in which patients with different 
preferences for information processing might use the intervention. Many stated 
that individuals with a monitoring coping style, who like to obtain as much 
information as possible, would benefit most from OvDex. Some thought that 
certain patients would not want to or need information at this level of detail, while 
others again might selectively read parts of the information that interested them. 
R12: I think if you’re the sort of person that is reflective […] [and] wants to 
sit down somewhere quietly and read through the information and 
think about it, completely to yourself, I think it works absolutely 
perfectly for those kinds of people. (Under35, noOC, OCFH, unknown) 
 
R9: I think it would be very, very helpful […] obviously not for all, because 
[…] it’s not everybody’s cup of tea to read information and think about 
it themselves. […] But I think for anybody who wants to research, read 
up and get the information themselves [..] this is a really clear simple 
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way of getting the personalised information that you need. […] I think 
most people would find this extremely useful. (Over50, yesOC, noFH, 
unknown) 
 
R11: I think some of them will completely dismiss it and say: ‘No I don’t 
need to read that.’ and I think some of them […] would look at it, and I 
think the other group would probably do it on a need-to-know basis. 
(Over50, yesOC, noFH, unknown) 
 
Respondents also felt that partners, family members and friends might benefit from 
the information included in the intervention. 
R9: I think this would be really good to be able to go back and discuss with 
family members and look through it with your partner or with your 
children. (Over50, yesOC, noFH, unknown) 
 
Beyond its intended use as a decision support intervention for women at increased 
risk of ovarian cancer, women in this study felt that OvDex could also benefit those 
directly affected by ovarian cancer and their relatives. 
R4: I think it’s brilliant for what you’ve intended it for. I just think it could 
be used for a wider audience really. [...] Not just for [those] having 
[risk-reducing] ovarian surgery, but for [those] having ovarian cancer 
[…], having treatment for it, [those] who have come through it and for 
their carers. (Over50, yesOC, noFH, unknown) 
 
R7: I would have liked something like this available when my mother had 
ovarian cancer, because there was nothing at the time. […] If 
something like this was available at the beginning of when she found 
out she had cancer it would have been quite good for us to have, […] 
not just for her, but also for the family as well (40to49, noOC, 
B&OCFH, unknown) 
 
8.3.6 Implementation of OvDex 
 Respondents were asked what they thought would be the most appropriate 
way of introducing the decision support intervention to patients and at what point 
in time they felt the intervention would be most useful to patients. Most 
respondents felt that a heath professional, particularly a genetic counsellor, would 
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be the most suitable professional to introduce the Option Grids and refer patients 
to the OvDex tool. 
R1: I mean it might be something that’s useful for either a doctor or a 
genetic counsellor to introduce. (35to39, noOC, B&OCFH, BRCA2) 
 
R6: I suppose if they are going for genetic testing then normally they’ll go 
and see a genetic counsellor, so maybe that would be the most 
appropriate person to put this in front of the patient. (40to49, yesOC, 
BCFH, BRCA1) 
 
Some respondents also suggested that provision in GP surgeries might be 
appropriate. These were the respondents who had also felt that cancer patients, 
rather than women at increased risk, could benefit from the intervention and had 
recommended a widening of the target audience.  
 Most respondents agreed that early access to the intervention would be 
beneficial for patients, preferably at the point of finding out about an increased risk 
and being introduced to clinical management options and the possibility of choice. 
R5: I would say the earlier the better for this. […] Because the more 
information they’ve got from the beginning the clearer their thought 
processes are going to become. (Over50, yesOC, noFH, unknown) 
 
R3: I suppose as soon as you know the problem that you’ve got and you’re 
trying to weigh up in your mind [whether] to have anything done 
about it or not, then this would help you[…]. So I think yes probably 
early on, as soon as you know what the problem is. (Over50, yesOC, 
BCFH, BRCA2) 
 
Respondent 7 felt that even earlier access would be beneficial; however, 
Respondent 13 opposed such early access before high risk had been confirmed. 
R7: Something like this I would have liked to have read in the earlier stages 
when I was making the enquiries, when I started looking into it at first. 
(40to49, noOC, B&OCFH, unknown) 
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R13: If I was tested and my daughter was tested and she had this gene, 
then yes [she should be given the intervention], but if she hadn’t had 
the gene, then I suppose […] it can be a quite frightening thing to give 
to a young woman. (Over50, yesOC, BCFH, unknown) 
 
One respondent felt that the Option Grid should be introduced at the end of a 
consultation and that the health professional could then decide on a case-by-case 
basis whether a patient would need instant discussion or whether it could simply be 
an aide-memoire to be taken home for further deliberation. 
R12: I don’t know that it needs somebody to go through with you because 
it’s quite self-explanatory […]. It would probably be better that it 
comes at the end of the conversation. […] It’s up to the doctor then, if 
they think that person looks like they’re going to need talking through 
it […], then they could take the time to talk them through it. (Under35, 
noOC, OCFH, unknown) 
 
8.4 Discussion 
8.4.1 Discussion of findings 
 The current study assessed usability of the patient decision support 
intervention developed in Chapter 7. Overall, lay reviewers liked the layout and 
structure of the Option Grids and felt that these were easy to understand and 
useful in providing answers to the most pressing questions. Many described how 
reading the information in the grid raised further questions that were later 
answered in the full OvDex tool. Reviewers reported few problems with 
accessibility and functionality of the OvDex website and were satisfied with the 
layout and structure of this more extensive part of the intervention. They found the 
information within OvDex easy to understand and especially valued the interactive 
features.  
 High satisfaction with layout and structure of OvDex indicates that the CODE 
framework is a good underlying framework for use in the structuring of extensive 
patient decision support interventions (Chapter 2; Witt et al. 2012). The four pre-
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decisional deliberation phases distinguished in the framework lend themselves to 
informing the content of different sections within decision support interventions. 
Questions within the first phase outline appraisal of the health threat and informed 
the content of a background section about the medical problem at hand, i.e. 
increased ovarian cancer risk, and possible coping options. Most respondents in the 
current study felt that this section was useful in setting the scene and providing 
context. Questions within the second phase describe appraisal of choice and guided 
the content of a section explaining medical uncertainty and decision making in 
healthcare contexts. Respondents in this study liked the guidance provided within 
this section regarding decision making. Questions within the third phase, 
undoubtedly the most important with regards to decision making, outline appraisal 
of options and informed the content of several sections describing properties, 
benefits and risks of the available options. The current study demonstrated that 
women liked the unbiased and comprehensive information about options covered 
in this section, and felt that it would help patients make an informed decision. 
Finally, the fourth phase, preference construction, inspired a section designed to 
actively facilitate decision making. This section includes an interactive value 
clarification exercise. Respondents particularly appreciated the exercise in OvDex 
and felt that it was a natural activity that they might have intuitively done 
themselves in the form of a pros and cons list, if it had not been provided. These 
results indicate that the structure of OvDex, which corresponds to the phases in the 
CODE framework, was perceived as logical and easy to follow by participants, 
guiding them through the decision making process. 
 Furthermore, participants in the current study felt that the majority, or all, 
of the questions they had thought of were addressed within the content of the 
OvDex tool. This content had been guided by the questions included in the RRSO-
adapted version of the CODE framework (Chapters 5 and 7). The framework does 
not aim to be comprehensive. However, as respondents had few additional 
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questions, this study shows that the framework seems to cover the most common 
and salient questions and coping options explored by women. 
 Despite the general satisfaction with the intervention materials, many 
reviewers highlighted one or more areas where improvements were necessary. The 
variety of comments received in the current study shows the range of individual 
preferences for structure, layout and types of information. For example, while most 
women felt the amount of information presented in OvDex was appropriate and 
helpful, one lady remarked that it was ‘far too much’ (see section 8.3.4ii). While 
some respondents were satisfied with the order of questions in the Option Grids, 
others preferred to have the screening question further towards the top of the grid 
(see section 8.3.2ii). While some stated that they liked the pictograms included in 
OvDex, others felt that numerical information would be sufficient (see section 
8.3.4iii). This shows that, due to the range of individual preferences, creating an 
intervention that satisfies every potential user is not feasible. However, using 
feedback from lay reviewers, a number of improvements were made to the 
intervention developed in Chapter 7 to increase usability and acceptability. 
  Amendments made to the Option Grid in response to reviewers’ comments 
focused mainly on the item addressing availability of screening, which was 
reworded and moved towards the top of the grid. This finding was unsurprising, as 
many women struggle to understand why there is currently a lack of evidence for 
ovarian cancer screening. This is especially true for those who took part in the 
recently concluded screening trial and reported having gained a lot of reassurance 
from the screening (Lifford et al. 2013). In addition, many women in this study had 
heard of CA125 and trans-vaginal ultrasound tests, some even had had those 
procedures as diagnostic tests, and therefore associated such tests with the 
detection of ovarian cancer, not discerning between screening and diagnostic tests. 
The feedback received as part of this study led to amendments in the wording of 
the answers to the screening question and a change in the order of questions 
within the grid. Other alterations included additions of statements about women’s 
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satisfaction post-RRSO and possible pain and tiredness experienced during 
recovery. Amendments to the content of OvDex made in response to reviewer’s 
comments included putting more emphasis on the personalisation function, 
conversion of dots to female signs in all pictograms and expansion and rewording of 
a number of questions for clarification purposes. Again, the variety of the issues 
highlighted shows the differences in individual preferences for structure, layout and 
information presentation. A number of minor functionality problems within the 
OvDex website were also fixed following lay reviewer’s feedback. Hence, usability 
testing was able to enhance overall acceptability and usability of the patient 
decision support intervention (Durand et al. 2012). 
 Other recommendations by lay reviewers were not acted upon. As noted 
earlier, preferences for delivery, and amount, of information differ between 
different individuals, depending on various factors. These include prior knowledge, 
health literacy and preferred information processing style. Satisfying every 
potential user is not a feasible aim of support materials. Rather, decisions about 
what information to include, and what to omit, should be made based on careful 
consideration of the needs of the majority of persons among the target audience 
and, ideally, a review by several experts. As the majority of respondents in this 
study had been directly affected by ovarian cancer, many of the comments 
regarding additions and changes to the content in the OvDex tool focused on 
information particularly relevant to cancer patients. These suggestions were 
carefully reviewed by the supervisory team in order to decide whether the changes 
requested would also be beneficial to the target audience, i.e. women at increased 
risk of ovarian cancer. Hence, some suggestions, for instance the addition of a 
section about ovarian cancer or expansion of the section explaining diagnostic 
CA125 blood tests, were not fully implemented. Instead of adding further 
information about ovarian cancer, such as survival statistics, additional links to 
external sites where such information could be found were added. This was 
deemed sufficient by the team, because information about ovarian cancer statistics 
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may not be directly relevant to the intended target population. Additionally, such 
information may cause unnecessary worry and anxiety among women at increased 
risk, which should be avoided. Further information about diagnostic CA125 blood 
tests was not included in the intervention, as the supervisory team felt that this 
might add to the confusion between screening and diagnostic testing and would 
therefore be unhelpful for women at increased risk.  
8.4.2 Implementation 
 Currently, available decision support for the decision of whether or not to 
undergo RRSO is limited (Chapter 6) and women making this decision report a 
number of unmet information and support needs (Chapters 3 and 4). By producing 
an intervention consisting of two complementary parts, the developers 
acknowledge that there is no ‘one-size-fits-all’ approach to decision support in this 
context. The feedback received in the current study indicates that women 
appreciate the individual components of the intervention and the possibility of 
choosing whether or not to view OvDex / certain components of OvDex according 
to individual preferences. Once available to health professionals and patients, the 
Option Grids and OvDex tool, in conjunction with genetics services, may contribute 
to better, more holistic support for women at increased genetic risk of ovarian 
cancer. The results presented here show that both parts of the decision support 
intervention were perceived as informative and helpful by a diverse group of lay 
reviewers. This indicates that they could, ultimately, support patients in reaching 
informed, value-adjusted decisions.  
 Women in this study additionally made recommendations about the future 
implementation of the intervention in clinical practice. In line with the 
recommendations for Option Grids, which are tools designed for use in 
consultations (Elwyn et al. 2013b, Marrin et al. 2013), lay reviewers recommended 
that health professional would be the most appropriate persons to introduce this 
tool to patients. Women who were familiar with the genetics services referral 
pathway felt that genetic counsellors, who may introduce the option of RRSO 
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initially, would be the most appropriate health professionals to introduce the 
Option Grid. Some women felt that the intervention should be available in GP 
surgeries. However, the information in the intervention was specifically designed 
for women at increased risk of ovarian cancer. Therefore, provision in GP surgeries 
may not be appropriate, as it may raise anxiety in members of the public for whom 
OvDex may not be relevant.  
 Most respondents agreed that access to the intervention should be granted 
early on in the decisional pathway, arguing that the information in the grid and 
OvDex tool would help women who had just found out they are at increased risk to 
explore their options. 
 Finally, several women felt that the information within the Option Grids and 
OvDex was useful not only to women at increased risk of ovarian cancer, but also 
those who had been diagnosed with the disease. This finding may imply that there 
is scope for a future adaptation of some of the content within OvDex to cater for 
the information needs of ovarian cancer patients and their relatives. 
8.4.3 Strengths and limitations 
 Usability testing of interventions, particularly web-based interventions, is an 
important step during development to assess acceptability and usability of 
materials to users (Elwyn et al. 2011a, Hoffman et al. 2012). Incorporating usability 
testing as a final step, before field testing, evaluation and/or publication, ensures 
that many potential problems with accessibility, functionality and terminology are 
corrected at an early stage. Therefore, this study and the amendments in which it 
resulted have made an important contribution to increasing the intervention’s 
acceptability and usability. Although subsequent studies may highlight more areas 
for improvements, a number of important changes were made to ensure that users 
can achieve the highest level of functionality, understanding and satisfaction 
possible at this point. 
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 The current study included participants from a range of backgrounds and 
with a range of experiences of ovarian cancer. This population was familiar with 
terminology relevant to ovarian cancer and was eager to contribute to the study, 
which resulted in a wide range of comments and suggestions for improvements. 
However, due to the recruitment method, many respondents were women directly 
affected by ovarian cancer. While most did understand the hypothetical nature of 
the task (of reviewing the intervention ‘as if’ one was at increased risk of ovarian 
cancer) some initially misunderstood the target audience to be individuals directly 
affected by cancer. This indicates that the information material provided 
beforehand was not clear enough and should be reviewed. Careful consideration 
was given to these misinterpretations during data analysis in order to identify and, 
if appropriate, exclude any comments that exclusively referred to cancer patients’ 
use of the intervention. 
 For this study a phone interview approach was selected, which allowed 
interviews to be conducted UK-wide, permitted women with ill health (e.g. those 
currently undergoing treatment for ovarian cancer) to take part and might have 
made respondents feel more relaxed, contributing to more honesty and open 
discussion of potentially sensitive subjects, such as sex life post-RRSO (Novick 2008, 
Opdenakker 2006). As the interviews were conducted over the phone, important 
non-verbal cues may have been missed (Aquilino 1994, Groves 1990). Such cues can 
be helpful in the interpretation of data and can give vital information about 
emotions associated with certain statements. However, previous research suggests 
that the lack of such cues does not substantially hinder or compromise the effective 
interpretation of data (Novick 2008). Hence, the advantages of using phone 
interviews for this study outweighed the importance of non-verbal cues and it was 
therefore judged a suitable method. 
 This study shows that interviews using verbal probing are able to reveal 
cognitive processing issues and retrospectively explore users’ navigation of the 
website. Some may argue that other qualitative methods, such as concurrent think-
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aloud techniques, might be more appropriate to test web-based interventions 
(Davison et al. 1997). However, the current study shows that, despite being 
retrospective, users’ accounts of how they used the intervention and of any issues 
they encountered were specific and detailed. Furthermore, this technique allows 
the interviewer to probe and question any statements and thereby obtain further 
detail, which is not possible when using think-aloud techniques. Previous research 
has also noted that retrospective accounts of usage reveal comparable numbers 
and types of problems to concurrent feedback and that having to provide 
simultaneous  feedback can be detrimental to task performance (van den Haak et 
al. 2003). Therefore, retrospective exploration of women’s use of the materials, as 
conducted in this study, may have been advantageous, as it gave women an 
opportunity to use the intervention, particularly the OvDex website, as intended 
(i.e. independently in their own home). Many participants in the current study also 
checked and referred to the intervention materials briefly whilst speaking over the 
phone, which further improved accuracy of their retrospective accounts. 
 Although the number of interviews conducted in this study was below the 
target of 15, it yielded a rich data set and was considered sufficient for a usability 
testing study (Kushniruk et al. 1997, Nielsen 1994). Some have noted that much 
larger numbers of cognitive interviews are required to uncover all potential issues 
(Conrad 2006); however, this was beyond the scope of the current project. Further 
issues may be uncovered in future evaluation studies and, as the intervention will 
be updated regularly, may be corrected at that time. 
 Ideally, usability should be tested with the target user group. Lay reviewers 
recruited to this study were not necessarily at increased risk of ovarian cancer and 
therefore were not in the target audience. This may have reduced the relevance of 
some of the comments and suggestions made. However, this approach was chosen 
due to previous issues with recruitment of the target population. Lay reviewers 
recruited through the charity Target Ovarian Cancer were deemed an appropriate 
alternative to the actual target audience, as this group would be familiar with 
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terminology specific to ovarian cancer. Furthermore, it has been suggested that lay 
audiences can make a valuable contribution to usability testing (Elling et al. 2012, 
Sawka et al. 2011). It is also important to note that three respondents, who had not 
had ovarian cancer or RRSO themselves, may, in fact, belong to the intended 
audience for the intervention, as two were carriers of mutations in BRCA2 (R1 and 
R2) and one had a family history of breast and ovarian cancer (R7).  
 Most participants in this study were over the age of 50, which may have 
resulted in higher than expected use of the paper-based version of OvDex, as older 
generations may be less familiar with the internet and/or comfortable using 
interventions online  (Millward 2003, Sourbati 2009). However, as much of the 
information and coping content in the online and paper-based versions is identical, 
many comments applied to both versions. Furthermore, the current study achieved 
a balanced use of the online and paper-based versions of OvDex, with six patients 
using and commenting on each. Therefore, this issue may be seen as an advantage, 
as it resulted in feedback from several participants on both versions. This was 
particularly beneficial with regards to the value clarification exercises, which differ 
substantially, as it allowed assessment of the usability of each version with a 
number of participants. 
 Finally, Option Grids are designed to be used within clinical consultations to 
provide a scaffold for a better conversation about a given healthcare decision 
(Elwyn et al. 2013b, Marrin et al. 2013). By asking participants to review the Option 
Grid outside clinical consultations, the current study tested usability of the grid 
outside its intended context. While lay reviewers found the grid easy to use and 
understand when looking at it in their own home, the study did not provide 
information about how it might be used in clinic and during consultations. 
Therefore, it will now be necessary to conduct a pilot trial of the intervention, 
including a trial of the Option Grid being used in its intended context, in order to 
assess its acceptability and usability in clinic. 
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8.4.4 Conclusions 
 The usability testing study reported in this chapter shows that a group of lay 
reviewers positively appraised the decision support intervention developed in 
Chapter 7. The Option Grids were deemed useful and respondents felt they 
provided clear introductory materials for women newly identified as being at 
increased risk of ovarian cancer. The full OvDex tool was appreciated for its 
comprehensive content, tailored information output and value clarification 
exercise. Usability and understanding was further improved by various suggestions 
made by lay reviewers. Additionally, women were able to make a number of 
recommendations regarding implementation of the intervention in clinical practice. 
 This study showed that a decision support intervention structured according 
to the deliberation phases outlined in the CODE framework follows a logical flow, 
which users found easy to grasp and navigate. Information as well as coping 
components, guided by the questions within the RRSO-adapted CODE framework 
were appraised positively and most reviewers felt that the questions covered the 
majority, or all, of the issues they wanted to explore. Finally, this study 
demonstrates that the cognitive interviewing technique of verbal probing may be a 
feasible technique to use, not only in the validation of questionnaires, but also 
during usability testing of information materials. A pilot study is now required to 
test acceptability, usability and effectiveness of the intervention in clinical settings 
with the intended target audience. 
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9 General Discussion 
9.1 Introduction 
The studies in this thesis outline the development and operationalisation of a 
novel framework that integrates the processes of deliberations and coping during 
preference-sensitive medical decisions. In this chapter, the principal findings of the 
thesis are discussed and placed within the wider context of patient centred care 
(PCC) and shared decision making (SDM). Possible future applications of the generic 
CODE framework are explored and suggestions for further evaluation, and 
ultimately implementation, of the decision support intervention are provided. 
Finally, methodological strengths and limitations are discussed. 
9.2 The need for holistic decision support 
 Previous assessment has shown that, compared to other countries, the UK 
has performed relatively poorly on measures of PCC, such as communication and 
engagement with patients (Coulter 2009b, Davis et al. 2010). For this reason, recent 
policy developments have pushed for more patient-centredness within the NHS 
(Department of Health 2011, National Health Service 2013, Secretary of State for 
Health 2010). An important element of such developments has been a call for SDM 
to become established as an integral part of clinical practice (van der Weijden et al. 
2013). To achieve this, a number of requirements should be met, including an 
increase in the types of decision support interventions available to patients in 
various health contexts (Coulter et al. 2011).  
 While information leaflets undoubtedly have their part to play in supporting 
patient decision making, more complex patient decision support interventions 
might be required in many settings. Such interventions have the potential to 
achieve a number of important healthcare quality goals. These include improving 
health literacy, promoting the use of SDM and enhancing the overall care 
experience (Coulter and Ellins 2006). Interventions that allow tailoring of 
information to individual patients’ circumstances may avoid overloading patients 
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with information and provide facts and figures that are more relevant to the 
patient, thereby helping them to understand  their individual circumstances and 
options (Edwards and Elwyn 1999, Thistlethwaite et al. 2006). Interactive 
components are designed to keep patients engaged and can help in teasing out 
personal values and preferences that can later be discussed with a health 
professional (Coulter 2009a, Stacey et al. 2011).  
 While these are important and worthwhile goals for decision support 
interventions, as an additional dimension, such interventions could also support 
affective forecasting and coping efforts, thus providing more holistic decision 
support and PCC (Wilson and Gilbert 2003). This dimension could encompass the 
provision of information in such a way as to facilitate affective forecasting, and the 
provision of coping advice to enhance emotional well-being during and after 
decision making. As has previously been noted, emotions and coping efforts play an 
important role during deliberations (Balneaves and Long 1999, Power et al. 2011, 
Witt et al. 2012). However, advocators and developers of patient decision support 
have largely neglected the role of emotions and coping in decision making; and the 
concepts of decision making and coping have traditionally been treated as separate 
entities. The theoretical work presented in Chapter 2 of this thesis advances the 
field by merging these concepts and by suggesting a novel framework that 
describes deliberations in preference-sensitive healthcare contexts as a multi-step 
appraisal and coping process (Witt et al. 2012). This highlights the need for the 
integration of coping support within approaches to PCC and SDM, including the 
need to embed coping elements in patient decision support interventions. 
 The integration of coping advice into such tools will facilitate information 
processing and SDM. It will also empower patients to identify and use various 
coping options, enhance emotional well-being and, ultimately, enable them to 
make better quality decisions. A patient is not a strictly rational decision maker.  
Decisions are made within the context of, and influenced by, social environment 
and emotional states. Patients are often sick, vulnerable and dependent on the 
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health professional. Additionally, decision making environments are ‘messy’ and 
often emotionally charged (Olthuis et al. 2013). Coping advice given during 
consultations and within interventions may mitigate these factors in several ways. It 
can help patients to understand and regulate their emotional responses. It can help 
them identify, and make use of, their social support network. Finally, it can outline 
problem-focused courses of action to deal with the decision. To realise these 
benefits and to support the patient holistically, coping advice should be an integral 
part of PCC and SDM. 
 This thesis demonstrates that women at increased genetic risk of ovarian 
cancer, and who are making decisions about risk-reducing surgery, have a range of 
support needs, and that these needs are not fully met by currently available 
decision support (Chapter 6). Chapters 3 and 4 showed that such women’s needs 
not only relate to medical information and care, but also include psychological 
support and effective communication. Women are keen to speak with others, who 
have either already made a decision or are in the same situation as them. They seek 
emotional support from partners, family and friends, as well as independent bodies, 
such as peer support groups and charitable organisations. They want help in finding 
reliable information, guidance on how to make a decision and, where relevant, 
strategies to deal with stress, anxiety and worry related to their cancer risk. Coping 
advice and signposting within interventions may cater to their needs by facilitating 
the use of various coping resources. Responses from women who reviewed the 
decision support intervention developed in this thesis showed that the coping 
advice included in the tool was well received (Chapter 8). This indicates that 
embedding coping components in decision support interventions is feasible and 
that these sections are valued by those using the tool. It also demonstrates that 
there is a need for more holistic decision support that may be guided by the CODE 
framework. 
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9.3 The future of the Coping in Deliberation (CODE) framework 
 The novel framework developed as part of this thesis (Chapter 2) describes 
appraisal and coping in the context of medical decision making, showing the 
transactional and interlinked nature of these processes (Witt et al. 2012). The CODE 
framework has the potential to act as the practical basis for the development of 
holistic decision support interventions, which aim to facilitate both coping and 
deliberation processes. Chapter 5 demonstrated that the CODE framework is 
readily adaptable to specific preference-sensitive healthcare decisions. Chapters 6 
and 7 showed how an adapted version of the framework might be used to assess 
and/or develop patient decision support interventions.  
9.3.1 Further validation of the CODE framework 
Currently, the CODE framework is a theory-based model of deliberation and 
coping processes, that has undergone face validation with expert groups before 
being adapted to a specific preference-sensitive healthcare decision. Validity is 
generally defined as the extent to which a given instrument, such as a 
questionnaire, “measures what it is intended to measure” (p. 328, Lynn 1986). It 
has mainly been used in the context of survey design (McGartland Rubio et al. 2003, 
Streiner and Norman 2008). However, validation may also be important in the 
context of assessing the validity of constructs and items within theoretical 
frameworks. In this context, content validity may be defined as the extent to which 
items within a framework are relevant to, and representative of, the construct(s) of 
interest (Haynes et al. 1995). In this definition, ‘item’ refers to the descriptive 
content of a framework, e.g. statements, questions or examples, and ‘construct’ 
refers to the overarching domain(s) under which items are grouped within a 
framework. For example, content validity assessment could determine whether 
questions within the CODE framework are relevant to, and truly representative of, 
the constructs they are intended to illustrate. 
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The main a priori constructs of interest within the CODE framework are 
defined as the five deliberation phases (Health Threat, Choice, Options, Preference 
Construction, Consolidation) and two coping and appraisal phases (Primary and 
Secondary). Sub-constructs include the types of primary/secondary appraisal (i.e. 
cognitive and emotional or problem- and emotion-focused). Assessment by experts 
of whether the questions within the framework reflect those constructs could lead 
to refinement and strengthening of the framework as a valid model of deliberation 
and coping processes. 
Validation of the CODE framework could be conducted using a sort task 
approach, as recently described by Cane et al. (2012). Ideally, expert participants 
should possess a good understanding of decision making theories and/or coping 
theories and should be unaware of the original framework developed by Witt et al. 
(2012). They may then be asked to perform a closed sort task, in which they are 
presented with an unpopulated framework that only shows the main constructs 
and sub-constructs. Participants could then be asked to sort the questions into the 
constructs, i.e. they can decide which deliberation phase a question represents, 
which appraisal phase a question represents and which type of appraisal 
(cognitive/problem-focused or emotional/emotion-focused) it reflects. Analysis of 
these responses would reveal how experts distribute the questions within the 
framework. A high level of overlap of sorting a certain question into a 
construct/sub-construct would indicate that this question is relevant to and 
representative of those constructs. In contrast, a low level of agreement among 
experts would indicate that a question may not be relevant to, or clearly 
representative of, a single construct/sub-construct and may apply to more than 
one. Therefore, results of such a task would provide information about the extent 
to which questions represent certain constructs and sub-constructs within the 
framework.  
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9.3.2 Testing of the CODE framework 
 The CODE framework could also be tested in clinical scenarios and/or real 
clinical settings to explore whether it genuinely acts as a model of patients’ 
questions and deliberations about preference-sensitive healthcare choices (Norman 
2004). For example, a testing study may look at consultations addressing the 
questions outlined within the framework and assess whether they lead to higher 
satisfaction with consultations and improved awareness of coping resources. It may 
be hypothesised that the more questions are addressed during a consultation, the 
higher satisfaction will be and vice versa. Results confirming this hypothesis would 
indicate that the framework is a good model of deliberation processes that 
encompasses the majority of questions patients may have. Testing of the generic 
CODE framework may be carried out using a variety of simulated or real world 
healthcare decisions to assess the extent to which the framework applies to 
differing healthcare contexts. 
 Such a study may be designed as a simulation study in which volunteers 
attend a hypothetical consultation with a clinician. The hypothetical consultation 
may follow a predefined guide in which certain questions or groups of questions 
outlined in the CODE framework are not discussed. It may be possible to develop a 
number of scenarios that cover different sets of questions. Following the 
consultation, volunteers may be asked to rate their satisfaction with the 
consultation and/or to complete a questionnaire to assess their awareness of 
different coping options. Analysis of data collected from a number of consultations 
may then provide information about whether consultations that address all, or 
most, of the questions within the framework lead to higher satisfaction and better 
awareness of coping options. Additionally, volunteers may be asked to suggest 
questions they feel had not been answered during the consultation. This could 
explore whether these questions map onto the questions that had been 
purposefully omitted from the consultation or whether volunteers have further 
questions, not yet included in the framework. 
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 Alternatively, testing could be conducted in real world settings through 
observations and assessment of real clinical consultations. Similarly to the approach 
suggested for the simulation study above, following the consultation, patients may 
be asked to rate their satisfaction with the consultation and/or to complete a 
questionnaire to assess their awareness of different coping options. Such an 
approach to testing the framework would highlight (i) which questions in the 
framework are commonly discussed / omitted during clinical consultations and (ii) 
whether patients are more satisfied and more aware of coping options following 
consultations that covered most, or all, of the questions within the framework. 
Although this approach would undoubtedly require more time and runs the risk 
that some possible scenarios would not be explored, it may produce more valid 
results than a simulation study, as it involves actual (rather than simulated) 
patients, consultations and healthcare decisions. 
9.3.3 Operationalisation of the CODE framework 
Chapter 5 described the adaptation of the generic CODE framework to a 
specific preference-sensitive healthcare decision. Adaptation allows the content of 
the framework to become more focused and relevant to a specific healthcare 
context. This is intended to result in a more accurate depiction of cognitive and 
emotional appraisal processes. This is a useful exercise when planning to use the 
framework to highlight the information and support needs of patients facing a 
specific decision. The same approach could be used to describe the support needs 
of particular sub-populations, such as elderly patients with a specific disease. For 
example, a study that is currently being conducted at the Universities of Sheffield, 
Sheffield Hallam and Cardiff specifically explores the information and support needs 
of older women with breast cancer (Brain et al. 2013, Collins 2012, Reed and Wyld 
2012). Data collected during this study may be used to adapt the CODE framework 
to specifically describe older women’s decision making about breast cancer 
treatment options. 
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Ultimately, the generic version of the CODE framework may be adapted to a 
whole range of preference-sensitive healthcare decisions, including decisions 
outside the cancer context. Examples of non-cancer related preference-sensitive 
healthcare decisions that the framework may be adapted for include treatment 
options for coronary artery disease (CAD), treatment options for osteoarthritis of 
the knee, genetic testing for familial conditions, such as Huntington’s disease, and 
prenatal testing using amniocentesis. The approach to adaptation outlined in 
Chapter 5 may guide future adaptations of the generic framework. 
Adapted versions of the framework could then be operationalised, either as 
assessment tools for already existing interventions (Chapter 6) or as a guide to 
structure and populate novel interventions (Chapter 7), as suggested in this thesis. 
The study exploring older women’s decision making about breast cancer treatment 
(see above; Brain et al. 2013, Collins 2012, Reed and Wyld 2012), for instance, 
ultimately aims to create a decision support intervention for older women who are 
making breast cancer treatment decisions. An adapted version of the CODE 
framework, that specifically describes older women’s decision making and coping 
processes in this context, could be useful to guide the development of such a tool 
and to ensure that its content caters to the needs of this sub-population.  
There are numerous decisions that could potentially be depicted using an 
adapted version of the CODE framework and that may benefit from decision 
support developed using these adapted versions. However, as this thesis is the first 
to suggest how the framework might be adapted and operationalised, there is also 
scope for further studies investigating other approaches to adaptation and 
operationalisation and potential additional applications of the framework. For 
instance, it may be possible to use a quantitative approach to framework 
adaptation, rather than the qualitative approach employed in this thesis. It may 
also be feasible to operationalise the CODE framework as an assessment tool for 
clinical consultations, rather than just written decision support materials. 
Furthermore, the framework could not only be used as a guide for the development 
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of decision support materials and interventions, but also act as a model of patients’ 
deliberation and coping pathways that enables health professionals to better 
understand these processes in a given healthcare context and to tailor the content 
of their consultations accordingly, thus enhancing PCC. Future studies may propose 
a number of changes and amendments to the framework and may suggest a variety 
of other applications in the healthcare field or elsewhere.  
9.4 The future of the Oophorectomy Option Grids and OvDex 
9.4.1 Feasibility and evaluation 
 Before the development of the Option Grids and OvDex, there were no 
decision support materials available specifically tailored to the needs of women at 
increased risk of ovarian cancer who are making decisions about RRSO in the UK 
(Chapter 6). By developing this decision support intervention, the thesis makes an 
important contribution to decision support in the context of ovarian cancer risk in 
this country. It proposes a novel, theory-based, holistic intervention that may 
support women and their clinicians whilst making decisions about ovarian cancer 
risk management. Chapters 3, 4 and 6 outlined the need for a tailored decision 
support intervention due to the complexity of the ovarian cancer risk management 
decision, the range of barriers and facilitators that might influence women’s 
deliberations about RRSO, the variety of support needs and the lack of tailored, 
theory-based support materials aimed at this population. 
 The decision support intervention developed in this thesis was the first tool 
to be based on an adapted version of the CODE framework (Chapter 7) and to be 
delivered in two parts: an Option Grid and associated online tool. The intervention 
received positive feedback in an initial usability testing study with lay reviewers 
(Chapter 8). However, studies investigating the feasibility and effectiveness of this 
intervention should now be conducted (Craig et al. 2008). This could not only show 
whether the intervention improves outcomes relating to decision making and 
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coping, but would also further validate the CODE framework as an appropriate basis 
for the development of decision support materials. 
 Many interventions are evaluated in small pilots or larger trials before 
implementation (see section 6.3.6, Chapter 6). Evaluation of novel interventions in 
such trials can establish feasibility and effectiveness, which can, ultimately, aid 
implementation. A study recently published by Schackmann et al. (2013) reported 
on the outcomes of a feasibility study testing an online decision support 
intervention previously developed by Kurian et al. (2012; Chapter 6). This study 
used the Systems Usability Scale and the Center for Healthcare Evaluation Provider 
Satisfaction Questionnaire to assess patients’ and health professionals’ attitudes 
towards the intervention (Brooke 1996, Ely and Plomp 1996). It showed that all 
stakeholders felt that the tool was easy to use and could support deliberations and 
SDM in practice. The Kurian tool was developed for carriers of mutations in 
BRCA1/2 in the US and mainly focused on breast cancer management options. 
Therefore, its target audience differed from the intended audience for the 
intervention developed in this thesis. Nevertheless, this recent study indicates that 
decision support interventions for women at increased risk of ovarian cancer, 
particularly those carrying mutations in BRCA1/2, are likely to be well received by 
stakeholder groups. 
 Field testing of the decision support intervention developed in this thesis 
with women at increased risk of ovarian cancer, and health professionals involved 
in their care, would now be beneficial to assess feasibility. This could establish 
whether the Option Grid and OvDex website are acceptable to stakeholders and fit 
into clinical workflows (Craig et al. 2008). A small pilot trial to estimate rates of 
recruitment and retention and to test intervention fidelity and possible 
measurement issues in larger trials may also be advantageous (Craig et al. 2008). 
However, many of the commonly used outcome measures for SDM interventions, 
such as knowledge, generic psychological constructs, decision effectiveness/quality 
and satisfaction, do not truly capture the range of outcomes that may be affected 
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by interventions used in clinical genetics (McAllister et al. 2011a). Recently 
McAllister et al. (2011b) proposed the Genetic Counselling Outcome Scale (GCOS-
24; Appendix 9.1), which is a 24 item patient reported outcome measure (PROM) 
that focuses on the construct of empowerment and covers five dimensions 
(Cognitive control, Decisional control, Behavioural control, Hope and Emotional 
regulation) (McAllister et al. 2011a). The development of empowerment as a PROM 
was guided by patients and clinicians and is therefore likely to cover the range of 
outcomes targeted by genetic counselling interventions. Hence, use of such a 
measure may be useful in evaluating the impact of the decision support 
intervention proposed in this thesis, as this intervention was designed as a 
complementary tool for genetic counselling. 
 The GCOS captures many of the intended outcomes of the intervention, as 
stated in Chapter 7 (McAllister et al. 2011b). It allows assessment of perceived 
knowledge of the health threat, awareness of management options and risk 
perceptions by including items on cognitive control (e.g. ‘I can explain what the 
condition means to people in my family who may need to know’; ‘I don’t know 
what could be gained from each of the options available to me’). Aspects of coping 
and emotional appraisals are assessed in the dimensions of ‘Behavioural control’ 
(e.g. ‘I know how to get the non-medical help I / my family needs’), ‘Hope’ (e.g. ‘I 
feel positive about the future’) and ‘Emotional regulation’ (e.g. ‘Having this 
condition in my family makes me feel anxious’). Reduction of decisional conflict and 
ability to make decisions is covered by items in the ‘Decisional control’ dimension 
(e.g. ‘I can make decisions about the condition that may change my child(ren)’s 
future / the future of any child(ren) I may have’).  
 However, some of these items may require adaptation for the specific 
context of increased risk of ovarian cancer. The focus on inheritance and children in 
the GCOS, for example, is less relevant in the ovarian cancer risk context than in 
many other genetic conditions; therefore, item 24 may be in need of rewording. 
Alternatively, the original GCOS-24 may be used in combination with another scale, 
334 
 
 
 
such as the DelibeRATE scale (Appendix 9.2), as used previously by Sivell et al. 
(2012a). This would additionally measure affective forecasting (e.g. ‘I can imagine 
what it would feel like to live with each option’) and the deliberation process about 
RRSO (e.g. ‘I feel I’ve given the options available to me enough thought’). 
Furthermore, although a number of items relevant to appraisal and coping are 
included in the GCOS-24, use of a measure that specifically assesses impact on 
appraisal and coping processes may also be advantageous. For example, the brief 
COPE may be an appropriate measure to use alongside GCOS-24 in a field test 
and/or small pilot of the intervention (Brain et al. 2008, Carver 1997). 
 In addition to assessing the decision support intervention’s impact on 
patients, field testing should include exploration of health professionals’ attitudes. 
The Healthcare Evaluation Provider Satisfaction Questionnaire (Appendix 9.3), as 
recently used by Schackmann et al. (2013) in a similar study, may be an appropriate 
measure to use in this context. This could provide information about professionals’ 
views of the content (e.g. ‘How useful was the information provided?’), perceptions 
of the usefulness of the intervention (e.g. ‘This tool could improve patient-doctor 
encounters’) and intentions to use and recommend the tool (e.g. ‘I would use it 
regularly in practice’). Additionally, basic information about consultation length, 
with and without Option Grids, may also be gathered during field testing. 
 Quantitative data obtained by the means discussed above may be 
supplemented by qualitative data from a sub-sample of participants to explore in 
depth any issues highlighted by the data. This could establish how the Option Grids 
affect consultations and fit into clinical workflows and how the OvDex tool is used 
by patients independently (Craig et al. 2008). Results from the field test might then 
lead to changes to the decision support intervention.  
 A similar approach, using the GCOS-24, DelibeRATE and/or brief COPE with 
patients and the Healthcare Evaluation Provider Satisfaction Questionnaire with 
health professionals, may subsequently also be used during a small pilot trial of the 
intervention. Such a pilot trial may use a before and after design or an intervention 
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versus control group design. The most appropriate study design will depend on 
expected recruitment figures. Such a trial could assess the impact of the 
intervention as a whole and could additionally explore the effects of individual 
components of the intervention (e.g. Option Grids, value clarification exercise, 
coping advice). The pilot trial should also collect data on consultation length 
with/without the Option Grid and on the use of the OvDex website by patients in 
the study, e.g. number of visits, lengths of visits, sites viewed. Pilot trial results may 
then help to estimate rates of recruitment and retention and to calculate sample 
sizes for further, larger trials (Craig et al. 2008). 
 Ultimately, a randomised controlled trial (RCT) may be conducted to confirm 
the cause-effect relationship between using the decision support intervention in 
conjunction with genetic counselling and any significant changes in outcome 
measures observed. However, the funding, time and number of participants 
required for such a large scale trial may not be feasible. For instance, the current 
project faced a number of recruitment difficulties (Chapter 4), indicating that the 
target population may not be large enough to recruit the numbers needed for an 
RCT. Additionally, it has now been widely accepted that patient decision support 
interventions have positive effects on knowledge, decrease decisional conflict and 
enhance value-adjustment of decisions (Stacey et al. 2011). Therefore, a small pilot 
trial using the GCOS-24, and potentially other measures as discussed above, may be 
sufficient to drive implementation of the intervention, without the need for a large 
scale RCT. 
9.4.2 Implementation 
In the past, patient decision support interventions have faced substantial 
implementation issues, despite their endorsement by governments and other 
public health entities (Elwyn et al. 2013a, Elwyn et al. 2013c). This may in part be 
due to a disinterest in change and new technologies that Alvesson and Spicer 
(2012) termed ‘functional stupidity’. Although this terminology may seem severe, it 
describes an organisation’s and/or individual’s inability or unwillingness to mobilise 
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cognitive capacities, such as questioning norms, seeking justifications and engaging 
in substantive reasoning (Alvesson and Sköldberg 2009). Breaking through the 
routine flow of clinical practice and changing the way consultations are done can be 
difficult, even if it only involves use of a short tool, such as an Option Grid (Elwyn et 
al. 2013b).  
To encourage uptake and integration into routine workflows, new materials 
and interventions should ideally have a champion within the organisation itself in 
order to overcome the first hurdle (Coulter et al. 2011). A clinical champion 
approach may be useful for implementing the intervention proposed in this thesis, 
as women felt that a health professional, ideally a genetic counsellor, would be the 
most appropriate person to introduce the first part of the intervention, i.e. the 
Option Grids, to patients (Chapter 8). Hence, promotion among colleagues through 
a clinical champion might increase the number of patients who are given the grids 
during consultations. As the grids bear the web-address of the full online tool, this 
in turn will also promote the OvDex tool. Ideally, the champion should be someone 
with a high profile, who is willing to support and push for implementation within 
the professional community and motivate teams to use the intervention (Elwyn and 
Thomson 2013). Throughout the development of the intervention presented in this 
thesis, a number of health professionals were consulted, two of whom (Prof Usha 
Menon, Institute for Women’s Health UCL, and Dr Mark T. Rogers, Cancer Genetics 
Service for Wales) may in future be recruited as champions to support 
implementation of the Option Grids and OvDex tool. Champions and other health 
professionals, however, often want evidence of effectiveness of an intervention 
before promoting its use in clinical practice. Therefore, it will be important to 
present the results of any trials, such as evidence of the effects of the intervention 
on consultation length and PROMs and health professionals’ satisfaction, to these 
individuals and the wider professional community.  
  Another approach to implementation may be to create demand for the 
decision support intervention among the patients who are its potential users. This 
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bottom-up approach is commonly used by pharmaceutical companies advertising 
prescription drugs in the US and may be useful when exploring alternative avenues 
to implementation (Frosch et al. 2007, Hollon 1999). The ‘Ask Three Questions’ 
campaigns in the UK and Australia (Elwyn and Thomson 2013, Shepherd et al. 
2011), for example, aimed to encourage patients to ask three key questions to 
prompt a discussion of options and to stimulate SDM in a bid to overcome the 
implementation problems facing SDM (Légaré et al. 2008, Légaré and Witteman 
2013). Similarly, encouraging patients to ask for decision support materials during 
consultations might result in a shift of attitude of health professionals towards such 
tools and may eventually result in integration of more interventions into clinical 
workflows. However, at a time when healthcare resources are limited, and in the 
absence of funding for marketing campaigns that can make patients aware of the 
existence of these tools, the potential to implement this method is limited. Patient 
networks and charities may be informed of the availability of relevant tools and 
encourage patients to ask health professionals for them, but without larger scale 
funding a bottom-up approach may not be feasible. 
 Following initial introduction of a patient decision support intervention into 
clinical practice, the next phase could be described as ‘normalisation’, which 
involves use of the intervention becoming part of routine care (Elwyn and Thomson 
2013, May and Finch 2009). Achieving normalisation is a long and complex process 
that is described by Normalisation Process Theory (NPT) (May and Finch 2009). 
Coherence (clarity about what the work is), cognitive participation (clarity about 
who does the work), collective action (agreement about how the work gets done) 
and reflexive monitoring (appraisal of the work) are the four constructs outlined in 
NPT that lead to embedding of an intervention into routine workflows (Elwyn et al. 
2013a). Normalisation of use of the RRSO Option Grids in genetic counselling 
sessions and referral of patients to the OvDex tool may ultimately be achieved 
through a combination of the implementation strategies discussed above. 
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9.4.3 Additional decision support 
 The patient decision support intervention developed in this thesis is 
designed as an adjunct to support discussions with genetic counsellors and/or 
gynaecologists and to facilitate decision making and coping. Both parts of the 
intervention emphasise the option of, and need for, further discussion with health 
professionals. The Option Grids are designed for use in clinical consultations as a 
scaffold to stimulate discussions of options and preferences during clinic visits. 
Although OvDex is designed for independent use by patients, it too encourages 
users to consult relevant health professionals and discuss their personal values and 
preferences before reaching a final decision. This is essential to ensure that any 
additional questions are answered and that any misunderstandings or 
misinterpretations are rectified. Furthermore, individual differences in information 
processing needs and preferences for delivery of information, which have been 
highlighted at various points in this thesis (Chapters 4, 7 and 8), demonstrate the 
need for the availability of additional decision support, particularly support 
delivered by health professionals. Option Grids and OvDex cannot cater for every 
possible need of every possible patient and, as has been noted previously, there is 
no one-size-fits-all intervention. Therefore, concurrent support from health 
professionals is essential and this intervention should not be seen as an isolated 
tool for women to use. Rather it forms part of a care pathway for women at 
increased risk of ovarian cancer and complements information and support 
provided by health professionals. Hence women may seek additional decision 
support from professionals at any time and are encouraged to do so. 
 In addition to the help women may receive during consultations, there are a 
number of other decision support interventions that are, or may in the future 
become, available to women at increased risk of ovarian cancer in the UK. These 
include the website by Healthwise (2011b) and the online tool by Kurian et al. 
(2012), which has recently undergone further testing and was shown to be well 
received by patients and health professionals (Schackmann et al. 2013). Patients 
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may also access the booklet previously developed by Tiller et al. (2003). While these 
interventions are available online and target women at increased risk of ovarian 
cancer, there are significant drawbacks to patients accessing and using them in the 
UK. Importantly, none of these interventions was developed for the UK context, 
therefore information may not be relevant to, or even contradict, UK guidelines. 
Furthermore, the Healthwise intervention (2011b) is a commercial product that has 
not been evaluated and does not clearly state a theory base. The intervention by 
Kurian et al. (2012) was developed for use with a health professional and is 
specifically designed for women carrying BRCA mutations, therefore it does not 
provide relevant information for women who do not know their gene mutation 
status. Finally, the Australian booklet (New South Wales Centre for Genetics 
Education 2008, Tiller et al. 2003) was last updated in 2008 and therefore, 
additionally to the fact that it contains information in line with Australian 
guidelines, may be outdated. Hence, the intervention developed in this thesis, if 
updated regularly, will provide the most relevant and tailored information for 
women living with an increased risk of ovarian cancer in the UK, despite other 
materials being available. Therefore it would be preferable if patients were guided 
to this intervention and encouraged to seek additional support from health 
professionals, rather than from other available tools they may find and access 
online. 
9.4.4 New evidence, changes in recommendations and update policy 
 RRSO remains the only clinically proven management option for women at 
increased risk, two large scale trials of ovarian cancer screening for the general 
population and high risk groups have recently been conducted in the UK. Data 
obtained from the UK Familial Ovarian Cancer Screening (UKFOCS) study is currently 
being analysed and may lead to changes in recommendations regarding CA125 
testing and trans-vaginal ultrasound scans in high risk women (Rosenthal et al. 
2013b). Depending on the results, such changes may include endorsement of 
screening in women who decline surgery and therefore lead to changes in how 
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screening is discussed with women at increased risk. This would then also have to 
be reflected in an updated version of the decision support intervention, which 
currently does not endorse screening in any context due to a lack of evidence. 
 However, it is unlikely that the UK National Screening Committee will issue a 
statement or amend the guidelines regarding ovarian cancer screening before the 
results of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) are 
available. This trial screened women from the general population and collected 
evidence on mortality benefit of screening. This evidence will be crucial in 
determining whether a national screening programme should be introduced. If 
results of the UKFOCS study and UKCTOCS support the introduction of routine 
screening, then the guidelines will be reviewed and may be changed. However, this 
process could take years and also depends on cost benefit analyses and other non-
medical influences. In light of these developments, regular checks of evidence 
regarding ovarian cancer screening and early detection should be carried out, and 
any changes to recommendations should result in updates of the information 
included in the decision support intervention to ensure that the content reflects the 
latest developments.  
 Other possible developments in the field may include publication of more 
accurate ovarian cancer risk estimates for women with mutations in BRCA, women 
from Lynch families or women with a strong family history. Additionally, gene 
variants that are currently categorised as being of “unknown significance” may in 
future be shown to be benign or associated with an increased risk of ovarian 
cancer, meaning that additional at-risk groups may be differentiated. Furthermore, 
as surgical techniques become safer and more sophisticated, data on the risks of 
complications and rates of laparoscopic versus open surgery may change. This 
should be reflected in the decision support intervention. Therefore, the Option 
Grids and the OvDex tool will be reviewed and updated on a yearly basis. 
Additionally an emergency update policy is in place regarding evidence for or 
against ovarian cancer screening, which will be monitored more frequently and 
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updated as new evidence becomes available. Finally, as the decision support 
intervention will be available freely online, users should be asked whether they 
would be willing to complete an online questionnaire at a later stage to report their 
personal outcomes. This could provide information about individual outcomes post-
intervention that may be incorporated into updates of the website (Coulter 2009a). 
9.5 Methodological strengths and weaknesses 
The research methods used in this thesis were selected to provide in-depth 
information about topics of interest to the research and were therefore of a 
qualitative nature (Black 1994, Kvale 1996, Pope and Mays 1995). Three searches of 
the literature were conducted: one narrative and two systematic searches. The 
narrative search was used to identify decision making and coping theories (Chapter 
2). Systematic searches were employed to select studies which assessed women’s 
decision making (Chapter 3) and to identify decision support interventions that 
included the option of RRSO (Chapter 6). Systematic searches were also combined 
with supplementary searches to identify additional publications that the initial 
search may have missed. The strengths of these search strategies included coverage 
of a wide range of literature and identification of a variety of relevant publications, 
all of which were subsequently critically appraised to ensure they were of an 
appropriate quality and standard. 
Qualitative research methods were used to examine women’s and health 
professionals’ views of deliberations about RRSO and the scope for decision support 
(Chapter 4), to gather feedback on prototypes of the decision support intervention 
(Chapter 7) and to assess usability of this intervention (Chapter 8). Focus groups 
were deemed most suitable to explore women’s questions, concerns, emotions and 
decision support needs during decision making about RRSO (Bloor et al. 2000, 
Krueger 1994, Pope and Mays 1995). This is because they allow mutual stimulation 
to occur and enable a collective exercise to rank different factors, providing an 
overall indication of relative importance (Slaughter et al. 1999, Kitzinger 1994). This 
study may, however, be criticised for the small number of women recruited to the 
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focus groups. Women invited via three centres in Wales and England frequently 
declined to participate in the study, which may be due to a number of different 
factors. These may include distress caused by the study invitation and/or their 
cancer risk, dislike of the focus group approach or unwillingness to travel to a 
group. Unfortunately, no data for non-responders was collected. Therefore any 
explanation as to why these women declined to participate is speculative. However, 
it has been noted that recruitment to focus groups is difficult and previous studies 
have experienced similar recruitment issues when using this method (Bloor et al. 
2000, Phelps et al. 2006). The rich data collected in the three focus groups did, 
however, provide a good indication of the salient issues that women explore while 
making decisions about RRSO. Furthermore, these data were complemented by the 
results of semi-structured interviews with health professionals as well as data from 
the literature review in order to inform the adaptation of the CODE framework and 
development of the decision support intervention.  
The intervention in this thesis was developed using an iterative approach with 
regular input from a variety of stakeholders. This approach allowed the researcher 
to tailor information to the needs of patients and to ensure that statements were in 
line with clinical guidelines and recommendations discussed in consultations. 
Additionally, this method ensured that a number of health professionals and 
patients contributed throughout the development process, potentially resulting in a 
feeling of ownership. Such feelings among stakeholder groups (particularly health 
professionals) may lead to higher uptake, as it has been suggested that feelings of 
ownership positively affect attitudes towards materials, products and guidelines, 
and may aid implementation (Orem et al. 2012, Reb and Connolly 2007).  
 Finally, a usability study assessed acceptability and usability of the 
intervention among a group of lay reviewers. Again, qualitative methodology was 
selected for this part of the study. This allowed an in-depth analysis of how the 
intervention was used by individuals and of any problems they encountered, 
including issues with functions on the website and cognitive problems (Adams and 
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Cox 2008, Boyce and Neale 2006). Some may criticise this research for the lack of 
quantitative data, especially with regards to the usability testing phase. While a 
quantitative evaluation of the effects of the decision support intervention would 
have been advantageous, it was beyond the scope of the thesis. However, the 
qualitative data obtained during these studies helped to highlight, and 
subsequently rectify, various issues with the content of the Option Grids and OvDex 
tool and has resulted in a more user-friendly intervention that may benefit from 
further testing and evaluation. 
9.6 Conclusions 
 The research presented in this thesis outlines the development and 
operationalisation of a novel framework that merges decision making and coping 
theories. It demonstrates that integration of these two processes is a worthwhile 
exercise, as it results in a more holistic model of patients’ appraisal and coping 
processes. The research further shows that the structure and content of a decision 
support intervention based on an adapted version of the novel framework was 
easily understood and well received by lay reviewers. Emotional aspects of 
deliberations, and coping efforts initiated to deal with such aspects, are an integral 
part of decision making that should be addressed within decision support 
interventions. A more holistic approach to developing and providing decision 
support, based on an understanding that emotions and coping play important roles 
in deliberations, may ultimately improve patient-centred care and promote the use 
of SDM in clinical practice. 
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Appendix 3.1 - Critical Appraisal Checklist (Quantitative) 
Quantitative research papers on women’s needs, concerns and characteristics 
Paper Title Year First Author 
   
   
Screening Questions Yes No 
Was there a clear statement of the aims of the research? 
     -was the goal stated? 
     -why is this important? 
     -how relevant is it? 
  
Is a quantitative methodology appropriate? 
     -does the research aim to illuminate the characteristics/demographics  
      of participants or assesses their opinions/attitudes? 
  
Is it worth continuing?   
 
Detailed Questions Comments 
Was the research design appropriate to address the aim of the research? 
     -has the research design been justified? 
 
Was the recruitment strategy appropriate to the aims of the research 
study? 
     -has the researcher explained how participants were selected? 
     -has the researcher explained why the participants were appropriate  
      to provide answers to the research question? 
     -has the researcher discussed non-participants and their reasons? 
     -has the researcher discussed response rate? 
     -has the researcher discussed how the control group was selected and  
      why (if appropriate)? 
     -were demographic variables of respondents discussed? 
 
Were the data collected in a way that addressed the research issue? 
     -was mode of data collection justified (medical records / 
      questionnaires etc.)? 
     -is it clear how data was collected? 
     -has the researcher made methods explicit? 
     -if a survey was used, was the survey piloted? 
     -    -“-     , were there open questions? How were they analysed? 
 
Has the relationship between researcher and participants been adequately 
considered? 
     -has the researcher considered their own role, potential bias and   
       influence? 
          1. during formulation of research questions 
          2. during recruitment and data collection (if data collected from       
              participants through face-to-face or telephone survey) 
     -has the researcher considered the implications of any changes in the  
      research design and events during the study? 
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Have ethical issues been taken into consideration? 
     -were ethical standards maintained (if enough information provided)? 
     -has approval been sought from ethics committee? 
 
Was the data analysis sufficiently rigorous? 
     -has an in-depth description of data analysis been provided? 
     -is it clear which statistical tests were used / were the tests  
      appropriate to answer the research question? 
     -is sufficient data presented to support the findings? 
     -to what extend was contradictory data taken into account? 
 
Is there a clear statement of findings? 
     -are the findings explicit? 
     -is there adequate discussion of the evidence for and against the  
      researcher’s arguments? 
     -has the researcher discussed the credibility of their findings? 
     -are findings discussed in relation to other research? 
 
How valuable is the research? 
     -has the researcher discussed the contribution his study makes to  
      existing knowledge? 
     -does the researcher identify areas for further research? 
     -has the researcher discussed whether findings can be transferred to  
      other populations or considered ways the research can be used? 
 
Further comments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from the national Critical Appraisal Skills Programme (CASP) collaboration Critical Appraisal 
Checklist 
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Appendix 3.2 - Critical Appraisal Checklist (Qualitative) 
Qualitative research papers on women’s needs, concerns and characteristics 
Paper Title Year First Author 
   
 
Screening Questions Yes No 
Was there a clear statement of the aims of the research? 
     -was the goal stated? 
     -why is this important? 
     -how relevant is it? 
  
Is a qualitative methodology appropriate? 
     -does the research aim to illuminate the actions/experiences/opinions  
      and subjective views of participants? 
  
Is it worth continuing?   
 
Detailed Questions Comments 
Was the research design appropriate to address the aim of the research? 
     -has the research design been justified? 
 
Was the recruitment strategy appropriate to the aims of the research 
study? 
     -has the researcher explained how participants were selected? 
     -has the researcher explained why the participants were appropriate  
      to provide answers to the research question? 
     -has the researcher discussed non-participants and their reasons? 
 
Were the data collected in a way that addressed the research issue? 
     -was the setting for data collection justified? 
     -is it clear how data was collected? 
     -has the researcher made methods explicit? 
     -is the form of data clear? 
     -has the researcher discussed saturation of data? 
 
Has the relationship between researcher and participants been 
adequately considered? 
     -has the researcher considered their own role, potential bias and  
      influence? 
          1. during formulation of research questions 
          2. during recruitment and data collection 
     -has the researcher considered the implications of any changes in the 
       research design and events during the study? 
 
Have ethical issues been taken into consideration? 
     -were ethical standards maintained (if enough information provided)? 
     -has approval been sought from ethics committee? 
 
Was the data analysis sufficiently rigorous? 
     -has an in-depth description of data analysis been provided? 
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     -is it clear how categories/themes were derived (if used)? 
     -has the researcher explained how data extracts were selected? 
     -is sufficient data presented to support the findings? 
     -to what extend was contradictory data taken into account? 
Is there a clear statement of findings? 
     -are the findings explicit? 
     -is there adequate discussion of the evidence for and against the  
      researcher’s arguments? 
     -has the researcher discussed the credibility of their findings? 
     -are findings discussed in relation to other research? 
 
How valuable is the research? 
     -has the researcher discussed the contribution his study makes to  
      existing knowledge? 
     -does the researcher identify areas for further research? 
     -has the researcher discussed whether findings can be transferred to  
      other populations or considered ways the research can be used? 
 
Further comments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from the national Critical Appraisal Skills Programme (CASP) collaboration Critical Appraisal 
Checklist 
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Appendix 4.2 - Topic Guide for Focus Groups (Needs Assessment) 
Focus Groups introduction (approx 15 minutes) 
Researcher introduces the team and states the aims of the research. Discussion of rules of 
conduct and confidentiality before proceeding to the discussion. 
PART I - explore needs, concerns and questions (approx 45 minutes) 
Participants are given and read vignettes about fictional woman ‘Emma’ [Vignette reads: 
Emma is 38 years old. Her sister was recently diagnosed with ovarian cancer aged 40. Their 
mother developed breast cancer when she was 45 and their aunt had breast cancer when 
she was 56. Emma does not know whether there is a faulty gene in the family at the 
moment. Her genetic counsellor has said she could have surgery to remove her ovaries to 
reduce her cancer risk. Emma is struggling to make a decision about whether or not she 
wants to have surgery.] 
What do you think this woman’s questions would be? What kinds of things do you think 
she would consider when making a decision about whether or not to have an 
oophorectomy? What are the possible reasons why she might struggle with the decision? 
 Prompts (if needed):  
- she is very young, so maybe she wants children 
 - she could be quite frightened about the surgical menopause 
 - she is approaching the age at which her mother was diagnosed 
 - she may have children and feel some kind of obligation towards them 
 - she may be scared of surgery 
And in your view, what are the really important questions that should be answered when 
women such as Emma are asked to make a decision about oophorectomy?  
 Prompts (if needed): 
- These could be things like ‘how much will my risk be reduced?’ 
- or ‘how will surgery affect my life?’ and so on… 
- anything you can think of that is really important and should be discussed 
And is there something, some reason or some event that could sway that decision one way 
or the other in your opinion? So I guess what I am asking is whether one of the 
considerations we have just talked about (such as… NAME TWO CONSIDERATIONS AS 
EXAMPLE) might outweigh others and then tip the scale… Like with other important 
decisions, such as buying a house, if you had to choose would you buy the bigger house or 
buy the smaller house with a bigger garden? So in this case as an example, should Emma 
accept the risk of having surgery now to reduce her cancer risk in the future?  
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Is there something you can think of that might help to compare the options and to bring 
out the differences? Maybe a certain way of presenting the information that might make it 
easier to understand and compare? 
Ranking exercise: 
What I would like to do next is to do a ranking exercise and see which reasons are most and 
which are least important. So I have got a sheet here with ‘most important’ and one with 
‘least important’ and if we put these on opposite ends of the table and say that we create a 
scale, then anything that is very important goes here and anything that’s just a bit 
important goes somewhere there. And what I would like you to do is take these reasons 
that we just talked about and place them somewhere along this line. And this should be a 
collective exercise, so you should all discuss and decide together where each reason goes. 
You may not all agree, but that’s absolutely fine, I really want you all to speak up and 
discuss what you think should go where and if you don’t think something is in the right 
place, just say so. Please try not to speak on top of each other though. 
 
PART II - discuss expectations of a potential tool (approx 20-30 minutes) 
I would like to move on now, for the last (MINUTES LEFT) to chat a little bit about this idea 
for developing a decision aid, so something that can help women who are struggling to 
make up their mind (one way or the other). Are we all okay for time or does anyone need 
to leave early? 
So, first of all, what do you think such a decision aid could look like? 
 Prompts (if needed): 
What kind of format do you think would work best? Something on paper, like a      
 Brochure or maybe something online, like a website… what would be best to use?  
 What would you feel most comfortable using? 
And, from your own experience, how do you think women in this situation, who really 
struggle to make a decision, could be supported through a (WEBSITE or BOOKLET)?  
 Prompts (if needed): 
- For example, how should information be presented? 
- What do you think about this (show option grid / value clarification ex.)? 
Researcher sums up main points discussed in Part II and closes discussion. 
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Appendix 4.3 - Topic Guide for Interviews (Needs Assessment) 
Introduction and reiteration of the study’s purpose 
 
Could you just explain what your actual role is, what do you do on a day-to-day basis? 
And for women who have been found to be at risk of cancer, specifically ovarian or breast 
cancer, what is your contact experience with them? And how do you get involved with 
them? 
So, when women talk to you about risk-reducing surgery, what do they usually want to talk 
about? What are their main questions / concerns? 
- I’m particularly interested in women asking about oophorectomy: what is 
important for them? 
- And what do you think are the most important / essential points that need to 
be discussed in this context? 
- For example, are they interested in the different options to reduce their risk, 
the risk of family members, genetic testing, etc.? 
- When it comes to women with mainly or only breast cancer family history, do 
they know about oophorectomy and its reduction in breast cancer risk? 
And could you just explain to me from your own experience, what you think the most 
important needs (information wise and emotional) are of women who are told they are at 
increased risk of ovarian / breast cancer? 
- Are they looking for facts and information or do you feel they just want to get 
some emotional support? Or both? 
- Are there differences between women who have just been told and women 
who have known for a while and maybe return to the service? 
- A lot of the time women who are at risk for ovarian cancer are also at risk for 
other cancers, especially breast, do you see one taking a priority over the 
other? 
Do you have any experience of women’s decision making, regarding oophorectomy? [If yes: 
Could you maybe tell me a little bit about your experience of the decision making process 
when it comes to managing ovarian cancer risk?]  
- Do women take a long time? 
- Do they involve you in the decision; do they involve their family or others? 
- Do they try to get lots of information? Where do you think they get this from? 
- What is their attitude towards this option when they come to see you? 
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What do you think are the main challenges/barriers and catalysts for women who are 
trying to make a decision about prophylactic oophorectomy or maybe other strategies to 
address their cancer risk? 
- For example do they find it hard to find reliable information? Or do they just want 
to talk to someone to talk it through? 
Could you describe for me what you think would be the most important points 
(information or otherwise) that should be covered in a decision aid that would be designed 
to help women make this decision? So just a little bit in terms of content... 
- For example, what kinds of information should be in it? 
- Could you think of anything apart from information about options that could be 
covered? Maybe something that would help the women with their emotional 
turmoil? Or you mentioned earlier [... maybe family issues, worry for relatives...] 
Option grid example – participant view the printed option grid 
Value Clarification example – participant views a printed value clarification exercise 
What do you think of these? Do you think they might be helpful? 
Thinking about a decision aid for those women, what do you think might be the best format 
for this? 
 Web-based / paper / video? 
Final run through issues mentioned in the literature [Select issues that have NOT been 
mentioned in previous conversation] 
Age 
Ovarian cancer family history and personal experiences 
BRCA1/2 mutation 
Previous cancer diagnosis 
Loss of fertility / Wish to have more children 
Perception of femininity and fertility 
Sexuality and sexual relationships 
Perceived cancer risk/cancer-related distress/worry/anxiety 
Availability of screening / Beliefs in screening / Detection effectiveness 
Family obligations 
Issues with surgical menopause and HRT 
Surgical complications / Recovery time from surgery 
Residual cancer risk 
Is there anything else that we have not covered today, that you think might be relevant or 
important and that you would like to talk about? 
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Code Theme Definition 
Background 
Information 
Participant information Any information pertaining to the participant; age; workplace; marital status; medical history (other 
than ovarian cancer), job responsibilities 
Organisation information 
(professionals ONLY
1
) 
Any information regarding the workplace (cancer genetics service; charity; network), main purpose / 
mission, what the organisation offers 
Experience of working with / 
supporting women at risk 
(professionals ONLY
1
) 
Any information regarding facts about experience of working with / supporting women at risk; length 
in role; average number of women seen / spoken to; mode of contact (face-to-face, telephone, email) 
Experience of being at risk 
(patients ONLY
2
) 
Family history of cancer, when realised at increased risk; feelings about risk; others’ reaction to risk; 
past experiences of ovarian cancer / cancer risk; coping with risk 
 
  
 
Women’s needs, 
questions and 
concerns 
Initial diagnosis Process of finding out about risk, how  and when this came about, any remarks on the process of 
genetic testing to confirm mutation status, comments about genetics service / risk assessment 
process 
Information requests re 
Ovarian cancer / genetics 
Women’s questions and concerns about ovarian cancer, risk, genetic testing (NOT management 
options and their consequences – see L; NOT information requests sparked by media/research hypes 
– see H) 
Emotional needs Any needs relating to non-information, requests for support groups, need to talk to someone, 
consideration of counselling for emotional support, contact with charities / families / friends / support 
groups; coping needs 
Responses to media /research Reactions to media and research hype, concerns specifically raised by such hypes 
Group and time differences What is important to which group (pre- / post-menopausal; high / medium risk;  family history only / 
gene mutation; ovarian-only / breast-only / ovarian/breast family); when do certain issues become 
important (time-point in process / in relation to each other); women who have had breast cancer 
(special needs regarding decision / possibility of HRT); women who have been on UKFOCS screening 
 
1
This code is specific for 
professional interviews 
 
2
This code is specific for focus 
groups 
 
 
 
 
4
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Decision making 
about ovarian 
cancer risk 
management 
Facts about management 
options 
Factual information / comments about available options, their properties, availability, usefulness, 
what is involved, (EXCEPT where speaking of consequences of option as a specific consideration 
during decision making); please specify: 
1. Surgery – anything factual relating to the option of surgery, who can do it, what is done, HRT 
2. Other options – anything factual relating to options other than surgery, including screening, oral 
contraceptives, watchful waiting, symptom awareness 
Process of decision making Information about the timescale and logistics of decision making; who is involved in decision; how it 
came/comes about, process of consultation(s); pressures on decision making 
Considerations during 
decision making 
Factors that were / are being considered during decision making; factors that influence(d) the 
decision; questions regarding those factors; including specific catalysts / facilitators / barriers or 
anything that contributes to remaining undecided; please specify: 
1. Medical and physical – anything relating to medical history (e.g. previous cancer diagnosis, benign 
findings, false positives in screening), age, genetic mutation status, family history (regarding types of 
cancer, frequency, age at which diagnosed, outcomes), menopausal status, loss of oestrogen, issues 
with HRT, risk category, risk reduction (objective), effects of surgery on physical condition, surgical 
procedures, scars, co-morbidities 
2. Psychological and emotional – anything relating to perceived risk, perceived effectiveness of 
options, distress, worry, anxiety (due to cancer risk, screening scare etc.), perceptions of femininity / 
sexuality / body image, goals and values (e.g. wish to have more children), self-efficacy, coping ability, 
indecisiveness, health beliefs, fear of hospitals / doctors / surgery 
3. Social Context – anything relating to family obligations (e.g. bringing the kids to school, being a 
carer), family history (regarding closeness to affected family members, role in their care), family 
communication, sexual relationships with partner, work commitments 
4. Other considerations – anything relating to physician recommendation, healthcare system, 
demographics, recovery time, time in hospital,  other logistics, alternative therapies, social support, 
availability of screening and other alternatives to surgery, pressure from others, distrust of medical 
profession, relationship with clinic staff, vagueness of symptoms of ovarian cancer 
Catalyst / tipping point Any remarks on salient events that sway(ed) the decision one way or the other 
Facilitators to decision making Remarks specifically referring to anything that made/makes the decision easier 
Barriers to decision making Remarks specifically referring to anything that made/makes the decision harder or more difficult, 
anything that results in unnecessary delay of the decision or confusion; Remarks specifically referring 
4
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to anything that contributes to being undecided 
Coping with decision making 
and decision outcome 
Coping strategies employed whilst making the decision / after the decision 
 
  
 
 
Decision 
support 
Scope for support Where and when support is needed (timing of decision aid, setting for decision aid, i.e. inside or 
outside clinic), who needs most support; comments about target audience; change of scope for 
support due to change in what is offered (e.g. no screening available) 
Decision aid content 
(information) 
Any comments about what should be included in a decision aid regarding information (on cancer, risk, 
options etc.), contact details, references; level of detail for information; evidence base, format for 
information (e.g. option grid / table) 
Decision aid content (coping 
and value clarification) 
Any comments regarding content for value clarification exercise, preference elicitation, coping advice 
and emotional support 
Decision aid format Remarks about the best / worst format (e.g. web-based vs. paper) for the decision aid, reasons why 
format is good / bad; remarks about colour, font type / size etc.; sub-formatting, e.g. blank spaces, 
interactivity 
Decision aid purpose Purpose of the decision aid, any comments about the importance of a decision aid for this context, 
main/minor purpose 
Other areas for decision 
support 
Any comments about other areas for decision support, changes in counselling content, timing, 
opportunities for peer-support etc. 
Problem areas Any comments regarding the current lack of support / information / trust; the way information / 
support is given; awareness of the need for a decision 
Potential effects of a decision 
aid 
Remarks about the potential effects of the decision aid on patients, clinicians, individually or together; 
on interactions in- or outside the clinic 
Recommendations for 
decision aid development 
Any comments regarding the development process; who should be involved; why; how it could be 
supported / designed 
Clinician attitude to options 
(professionals ONLY
1
) 
Any remarks on what women should do, what the medically preferred option is, whether options 
work 
 
  
 
4
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Miscellaneous 
Participant questions Any questions asked by participants 
Misunderstandings Any misunderstandings / clarifications due to miss-understandings 
References / things to look at References / websites / tools mentioned by participants which might be helpful for the decision aid 
development process  
GPs / healthcare system Any comments regarding difficulties with or criticism of GPs and/or the healthcare system when 
dealing with patients, ideas for improvements of the healthcare system / service; comments regarding 
referral procedures between services, clinical guidelines / protocols / recommendations 
4
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Appendix 4.5 - Extract of Coded Transcript (Focus Group) 
P1: Well I guess, you know, if you have your ovaries out what are the knock – 
what are the im-, first of all, what are the implications of that. You know, 
because I know from having discussed it, that it throws you into an early 
menopause, which for me is what is making me stick my head in the sand a 
bit at the moment. You know, but I think that’s really what my primary 
concern would be. 
P2: Yea, I think it’s the effects of it really, isn’t it? … 
P1: Yeah. 
P2: And some of the questions that I have had answered have been, well “You 
are just as likely to be knocked down by a bus, so do you want to take that 
course of action?”  That’s what my GP told me.  Even through, you know, my 
mum and my gran both had it and that’s what he said.  You are just as likely 
to be knocked over by a bus so that choice is entirely yours and when you get 
that off your GP you think: “Oh I don’t know if I’ll consider that any further 
now.”  You know I had gone with a serious conversation of considering it.   
M: Yeah, and that kind of put you off, did it? 
P2: Yeah, because I, I mean I, I have just been feeling very vulnerable since the 
end of the programme.  Very vulnerable.   
M: So surgical menopause, kind of these kinds of effects of surgery? 
P1: Yeah and because I think my, you know it is primarily breast cancer where my 
family tree goes, but there was, my mother’s cousin had ovarian cancer and 
so that’s why I think that the, and I forget the name the doctor who sort of 
heads up the genetics unit, who got in touch with me initially.   
M: In [Place 1] is it?   
P1: No, in [Place 2], I can’t remember her name.  But she invited me anyway.  But 
I know that you know when I discussed it with, with her and she said you 
know you could have your ovaries out and she said you know you could go 
onto HRT but of course HRT then brings up the increased risk of breast 
cancer. And you know, where to do you, where do you pitch it? 
P3: Yea, where is the risk? 
P1: Yeah, you know.   
M: Yeah.  Do you agree with that or?   
P3: I haven’t actually discussed it with anybody at all, haven’t had any 
conversations with anybody apart from my mother’s doctor, who told - a 
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doctor here, a cancer doctor - who told me that basically I should have the 
surgery straight away as soon as I can.   
M: So that’s very dissimilar to what you [P2] were just saying about your GP 
telling you.   
P3: Well I wouldn’t discuss it with my GP I don’t think. But I haven’t got that kind 
of relationship with my GP and I always find that they are a bit general.  You 
know, they are, aren’t they? 
P2: Yea well, it might have been, that was my position, you know, I mean you 
never see the same GP twice anyway so.   
P3: No you don’t.   
P2: They don’t, you know your notes are on, your history is on your notes but I 
don’t think any of them would have thought “Right, let’s have a look what 
she’s got in her family” and before they sort of gave me that advice.   
M: So you didn’t really talk to anyone about the surgery itself, did you?   
P3: No. 
M:  Okay, right.  Okay but if you, if you think about it now what are your 
questions?  What would you want to know? 
P3:  My main thing would be the menopause, exactly the same as you [P1].  
Would be that starting because every time I read about it on the internet 
everybody, because it happens gradually, your body sort of gets used to what 
is going on but where you have your ovaries out it literally starts straight 
away doesn’t it? And I think that would be, for me anyway, the last couple of 
years hasn’t really been an option because there has been other things to 
deal with and I haven’t wanted to concentrate on myself.   
P2: Come to that, yeah.   
M: Mmm, yeah, yeah.  So are you, so now that the screening programme has 
finished, it has finished for all of you has it?   
P3: Yeah. / P2: Yes.   
M: Right, okay.  Do you find yourself starting to think about this decision more 
again?   
P2: Yes.  It’s the first time I have ever given it any serious thought. Because 
wrongly or rightly I always felt that it was a little bit of a safety net…  
P1: Yea. 
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Appendix 4.6 – Extract of Coded Transcript (Interview with Health Professional) 
J: That’s no problem, I was asking how women react when you tell them that... 
R: ...that surgery is the option. Well, mixed reactions, some of them come – 
especially if they come through the genetics clinics – some of them, uhm, sort 
of have, you know, they are very clear there’s the usual bell-shaped curve 
involved, yes? So this is the end of women who come from the genetics team 
and they yes, they already come knowing, they want surgery, so they hear the 
whole story, screening and surgery and everything, symptoms and everything, 
they say: “Yes, I think surgery is it.” And that’s pretty straight forward, it’s easy. 
And then there are those that are in the sort of average, in the, the larger 
proportion that are: “Yes”, you know, some are “Yes, yes…”, but they are not 
sure, some are sort of really indecisive, some of them are just sort of well… 
And then there are those on this end where it’s just not even something they 
are going to consider it’s quite extreme, in fact there are one or two that I 
know who get upset when you… and then one of them has written to say 
“Please don’t ask me this question again and could you let the hysteroscopy 
people know not to ask me when I come for my hysteroscopy, not, when I 
come for my hysteroscopy next year, don’t raise the issue of surgery with me.” 
So, you get the extreme reactions. Uhm, and then you got, have kind of the 
majority in this middle bit, where just a little bit of perhaps some peer-support 
or another visit would sort of tip them over into having surgery. And then 
there are some that come for years and years, have lots of chats and they are, 
they’re pretty resolute and I in a way kind of respect that because you have, 
you know, it’s a mature person, you have a sense of their, they have weighed it 
up and for them, you know what, they are not that worried about cancer, even 
though they know they are high risk and they are coming for their screens, 
they are comfortable with that and feel that perhaps, you know: “As long as I 
am healthy, why should I have a general anaesthetic, just happy to have a scan 
when I can.” And so there is a mixture, quite a broad spectrum of reactions 
really and responses to this idea of prophylactic surgery. 
J: And what are generally the questions or kind of concerns women raise when 
you start talking about this kind of issue? 
R: Uhm, well, for the younger ones it has to do with the menopause, uhm, and 
what it would mean for them, what the implications are, what the menopausal 
symptoms are like to be, they want to be reassured that HRT will make the 
symptoms, you know, control the symptoms, that they won’t be living in 
discomfort or distress as a result of having their ovaries out. Uhm, for that 
younger group the sort of most difficult will be if you like, are those who have 
had breast cancer in the past, that are hormone recep-, are hormone 
receptive, uhm, because obviously they can’t have HRT. And some of them, or 
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all of them are really dis-, can be distressed and anxious, you know, because 
they’ve, they’ve had breast cancer young, they don’t want to have ovarian 
cancer, but what are they going to do at 41 or 42, if they can’t have HRT? Uhm, 
and so what we would do in that scenario we will talk a lot with the breast 
team and just kind of support the person as far as we can really. Uhm, and so 
then the – sorry, and so the question was? [laughs] 
J: What women’s questions were, so… 
R: Yea, so their questions.  
 [Talk over each other - inaudible] 
 Menopause, HRT for the younger ones. And for the sort of over 45s, again 
menopause is an issue obviously, but we reassure them that, you know, HRT is 
kind of optional for them, because the mortality impact is in the younger 
women if they are not on HRT. Uhm, and they kind of want to know, uhm, you 
know, I suppose they all really in their 40s just want to be reassured from the 
breast cancer side of things. So, as soon as you say “HRT” then the next 
question that kind of comes up is: “Well, I thought HRT increases your risk of 
breast cancer” or “Isn’t it associated with breast cancer?” And so you have to 
kind of unravel and undo a lot of the stuff the stuff they have heard in the 
media, whatever… 
J: Yea. 
R: ... and contextualise it. Uhm, and just explain, you know that data is really in 
post-menopausal women on HRT. And even sort of explain that even in post-
menopausal women on HRT uhm, you know, the number – the extra cases of 
breast cancer – is actually, the risk is just a marginally increased risk, it’s not a 
huge increased risk. Uhm, so those are the main questions for the younger 
women. But the older women, one or two will still ask: “Will I start, will my hot 
flushed come back?” or something like that. [Laughs] 
J: [Laughs] They wouldn‘t, would they? 
R: No, they wouldn’t. [Laughs] No, they wouldn’t. 
J: [Laughs] 
R: No, they wouldn’t. And so you just say: “No, actually you have been 
menopausal for the last three years – x number of years – you probably will 
feel exactly the way you feel today. We wouldn’t expect any changes in that 
direction.” But those are the main questions. It’s usually around menopause 
obviously and the use of HRT and the control of menopausal symptoms. 
Women’s 
Needs 
Media Hype 
Decision Making 
Considerations 
(Medical & 
Physical) 
Women’s Needs 
Group and Time 
Differences 
Women’s Needs 
Group and Time 
Differences 
437 
 
 
 
Appendix 5 
5.1 Topic Guide for Interview (Retrospective account) 438 
5.2 Coding Frame based on CODE Framework 439 
5.3 Extract of Coded Transcript (Interview) 443 
438 
 
 
 
Appendix 5.1 - Topic Guide for Interview (Retrospective account) 
Explain purpose of interview and of wider study 
Ask whether participant has any questions before we start the interview 
How did you make the decision to have the surgery? Could you walk me through it? 
 Prompts (if needed) 
- What were the questions you were asking? 
- What support did you have? (Family, friends, peers, professionals) 
- How did you tell family / friends? 
- What was your experience of the surgery itself? 
- What is your life like now after the surgery? (worry, menopause, HRT, 
adjustment) 
- Is there anything you wished you had known beforehand? 
 
What are the kinds of support that you used and that you think women need when making 
this decision? 
 Prompts (if needed): 
- What kind of support did you receive from genetics services? 
- What do you think about peer support? 
- Would extra materials be helpful? 
 
What do you think of the idea of decision support materials for women making these 
decisions? 
 Prompts (if needed): 
- What kind of format do you think would work best?  
 
What should be covered by such materials? What would you have found useful? 
 Prompts (if needed): 
- These could be things like ‘how much will my risk be reduced?’ 
- or ‘how will surgery affect my life?’ and so on… 
- anything you can think of that is really important and should be discussed
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Overarching theme Code Included in Code 
Participant information 
Medical history Anything about the patient’s medical history; including family history of cancer 
Other Anything else about the patient (occupation, parity, age etc.) 
Primary appraisal 
Ovarian cancer risk 
Anything about how the patient appraised / appraises ovarian cancer risk 
Anything relating to exploring / finding out about or interpreting: What is ovarian cancer (OC)? 
What is OC risk? How high is my risk? What caused me to have an increased risk of OC? How 
does my family history influence OC risk? Do I have a faulty gene? Does my risk change over 
time? How could my risk affect my children? How will my risk affect my life? What can be 
done about my OC risk? 
Anything about how she felt /feels about ovarian cancer risk; 
Anything relating to exploring / finding out about, interpreting or appraising: What are my 
past experiences of OC? How do I feel about OC and my risk?  
Choice 
Anything about how the patient appraised / appraises choice;  
Anything relating to exploring / finding out about or interpreting: What does ‘choice’ mean in 
this context? Why is there a choice for women at risk of OC? When should I decide? 
What is at stake in this choice? Who can decide? Who else should I involve? Can I change my 
mind? How can I decide? 
Anything about how she felt /feels about choice; Anything relating to exploring / finding out 
about or interpreting: How do I feel about choosing? Can I deal with choosing myself?  
Options 
Anything about how the patient appraised / appraises RRSO or symptoms awareness or 
screening; 
Anything relating to exploring / finding out about or interpreting: What is risk-reducing 
bilateral salpingo oophorectomy (RRSO) What does RRSO involve? How long would it take to 
recover from RRSO? What are the risks and benefits of RRSO / symptom awareness? What are 
the complications of RRSO? Would I go into an early menopause? Would I have to take 
hormone replacement? How would RRSO affect my life? Do I need to have my womb removed 
as well? Is there a chance caner might be found during RRSO? What did others decide? How 
did they fare? Can I make sure I get a good surgeon in a good hospital? What is symptoms 
awareness? Why is symptom awareness the only alternative? What would happen if I do not 
4
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have surgery? Is there any screening available for OC? Is there anything else I can d to avoid 
OC? 
Anything about how she felt /feels about RRSO or symptoms awareness or screening; 
Anything relating to exploring / finding out about or interpreting: Do I have experiences that 
could help me imagine what it would be/feel if I had / didn’t have RRSO? How do I feel about 
having / not having RRSO? 
Preference construction 
Anything about how the patient differentiated / differentiates one option from the others, 
forming her preference; 
Anything relating to exploring / finding out about or interpreting: Is this the right time to 
decide? Is RRSO / not having RRSO congruent with my/my family’s/partner’s/doctor’s beliefs 
goals and values? Have I completed my family? Can I afford to take time off? Could I get 
screening or some other additional care? Do I think I could detect the symptoms of OC? 
Anything about how she felt when she was differentiating one option from the other, forming 
her preference; 
Anything relating to exploring / finding out about or interpreting: Do I feel ready to decide? 
How likely is it that I will regret having / not having RRSO?  
Secondary appraisal and 
coping resources used 
Ovarian cancer risk 
Anything about problem-focused coping resources she explored / used when she appraised / 
appraises ovarian cancer risk; 
Can I find out more? Can my doctor help and can I trust my doctor? Can I seek instrumental / 
informational support from my family / friends / a peer or support  group? 
Anything about emotion-focused coping resources she explored OR used when heard about 
cancer risk; 
Can I seek emotional support from my family / friends / a peer or support group? Can I turn to 
my faith? Can I change how I feel about knowing my OC risk? Can I express my fear of cancer? 
Can I do something to stop thinking about my OC risk? Can I do something to reduce the stress 
my OC risk is causing me? Could I ignore my OC risk? 
Choice 
Anything about problem-focused coping resources she explored / used when she appraised / 
appraises choice; 
Can I create an action plan to approach this decision? Can I seek instrumental / informational 
4
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support from my family / friends / a peer or support group? 
Anything about emotion-focused coping resources she explored OR used when faced with the 
choice; 
Can I seek emotional support from my family / friends / a peer or support group? Can I let 
someone else decide for me? Could I refuse to choose and just not make this decision?  
Options and preference 
construction 
Anything about problem-focused coping resources she explored / used when she appraised / 
appraises options and when opted for surgery; 
Is there someone or something that could help me to compare and weigh my options? Can I 
speak to someone who has already made this decision and is living with the consequences? 
Can I seek instrumental / informational support from my family / friends? 
Anything about emotion-focused coping resources she explored OR used when considering 
options and when opted for surgery; 
Can I seek emotional from my family / friends / a peer or support group? Can I do something 
to stop thinking about this decision? Can I do something to reduce the stress this decision is 
causing me?  
Post-surgery 
Experience 
Anything relating to her surgery and post-surgery experience (e.g. HRT experience, 
complications) or what she did after surgery 
Coping behaviours 
Anything about problem/emotion-focused coping resources she used AFTER having the 
surgery; anything about things that helped her cope; anything about why she still thinks 
surgery was the right option 
Service  Anything about the service she received from genetics and other healthcare facilities 
Decision support 
Scope for support 
Where and when support is needed (timing of decision aid, setting for decision aid, i.e. inside 
or outside clinic), who needs most support; comments about target audience; change of scope 
for support due to change in what is offered (e.g. no screening available) 
Decision aid content 
(information) 
Any comments about what should be included in a decision aid regarding information (on 
cancer, risk, options etc.), contact details, references; level of detail for information; evidence 
base, format for information (e.g. option grid / table) 
Decision aid content 
(coping and VCE) 
Any comments regarding content for value clarification exercise, preference elicitation, coping 
advice and emotional support 
4
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Decision aid format 
Remarks about the best / worst format (e.g. web-based vs. paper) for the decision aid, 
reasons why format is good / bad; remarks about colour, font type / size etc.; sub-formatting, 
e.g. blank spaces, interactivity 
Misc Participant questions Any questions asked by participants 
Misunderstandings Any misunderstandings / clarifications due to miss-understandings 
General decision making  Anything describing the complete process of decision making rather than individual aspects of 
it 
Related decisions Mastectomy Anything about decision making regarding mastectomy and how this related to / differs from 
decision making about RRSO 
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Appendix 5.3 - Extract of Coded Transcript (Interview) 
R:  …yes yeah, talking about the statistics of it we talked a lot about em, you 
know, statistically em, how likely it is that I would em, if I was BRCA 1 or not 
BRCA 1 you know, we talked about all the statistics of that em and then 
once we’d sort of decided, that you know I’ve got the result, I was BRCA 1, 
we’d, we’d sort of done all the talking almost you know and we were just at 
the stage of like well, decision making now really, Oh I know what I was 
going to say, yeah, the other thing that I did talk to them a lot about in the 
lead up to the operation was em, how to address it to other family 
members because that I, I’ve, I still find that quite hard because em, my 
parents weren’t together, so my dad em, didn’t see the whole thing as it 
unfolded with regards to my mum, you know although he was around, he 
didn’t you know live with it and he didn’t see how awful it was and stuff 
and so I think it’s more difficult for him to understand where I’m coming 
from because, and I think that for anybody who hasn’t actually been 
through it because I know I’ve got friends who are, just look at me and they 
just think well this all seems a bit kind of crazy bit kind of radical em, you 
know because they all sort of say, well, you know, you don’t know what’s 
going to happen to you in the future but then if you are given the statistics 
that you know, say, say somebody gave you the statistic that, statistic, 
you’re statistically likely, eighty five per cent likely to be run over by a bus 
or something today you might think, I’ll  just stay in ((laughter)) you know 
and that’s the way I’m sort of thinking about it but it’s hard for, it’s hard for 
people when they haven’t been through it, I think, you know, to em 
understand, you know, understand where I’m coming from so I talked to 
them a lot about that and they gave me a really helpful letter em, which I 
gave out to family members and I know that they, that my family could 
have contacted them if they’d wanted to and, and I’m, sometimes I still 
wonder if my dad perhaps did contact them ‘cos I don’t know, he did have a 
bit of a change of heart whether he did phone them and talk to them or 
whether he just did you know sort of do a bit of research himself and then 
thought you know, but I think that is quite difficult, to try and, ‘cos you 
need the support of your family and friends em and you don’t want people 
to just think, ‘oh, god, is she still banging on about this’ d’you know what I 
mean, you know, you do need the support, and you don’t want people to 
think that you’re just trying to make something out of nothing you know em 
and, you know because some people do sort of say, yeah, but everybody’s 
got something that they  to have to deal with and I think that’s absolutely 
right you know some people have heart conditions, some people have 
diabetes but you wouldn’t not do something if you… 
J:  Knew it beforehand 
Prim. 
Appraisal 
OC risk 
Prim. 
Appraisal 
OC risk 
Service 
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OC risk & 
Choice 
Prim. 
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Choice 
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R:  …had the option, yeah yeah, and that’s what I think is the difference you 
know em so yeah, we did talk a lot about that and I did find them very 
helpful in the sort of advice that they were give, giving and things  
J:  And did, did you tell your family er before you had the operations yeah  
R:  Yes, they all knew about it before and, and I think, I think I’d decided to 
have, like the you know we’d decided on the date and stuff in about July 
time and then I didn’t have it until October so everybody had a lot of time 
to sort of, sort of em, well not to really do anything but just to know that I 
was going to have it done and that was the decision made and I  think the 
same with the mastectomy you know em er, I think again, that’s more 
radical so it’s harder em and we haven’t actually told all our family about it 
yet because I, we just felt, actually we need to make the decision ourselves 
without, sort of, any other influences and then sort of say what the 
situation is. 
J:  So, ‘we’, is that you and your husband? 
R:  Me and my husband yeah me and my husband I mean I have talked to my 
brothers about it em and I, I do speak to [Name cousin] my cousin about it 
so obviously we’re all totally on the same page em and my dad and you 
know our outside family are very supportive it’s not that they’re not, they 
are, I mean they’re very kind and they, you know they want the best for, 
you know, for, for us em, but I think you know it is, it’s harder for people 
who haven’t directly seen the effects of ovarian and breast cancer on like, 
an individual person and then how it affects the whole family it’s difficult 
for them to understand perhaps where we’re coming from you know and I 
think there is the sort of, the, the mind set of like, why don’t you just enjoy 
your life and see what happens you know and I can understand that 
because I’ve sort of you know thought that myself, let’s just kind of, let’s 
just, sort of, put our heads down and just enjoy life you know ((coughs)) er, 
you know and just you know I, it’s just whether you really can do that or 
whether it would just always be at the back of your mind you know so  
J:  Yes, as you said earlier and then you, you, you would have been worrying 
and also you did er say that you found that lump which at which point you 
weren’t actually going to do anything but then you found the lump and that 
kind of changed changed your attitude  
R:  Yeah, it did, and, and again, with the mastectomy thing em, I mean I know 
we’re not, you know that’s not what the, the thing is about but with the, 
you know talking about making decision for the mastectomy now em, I 
think I thought after the hysterectomy, no, I’m not going to have a 
mastectomy I’ll just em, you know just have a, an MRI … 
Service 
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Appendix 6.1 - Data Extraction form based on IPDAS checklist 
Developer & associated publications: 
Intervention title: 
Target audience: 
Decision: 
Aspect Yes No 
 
1 Format 
   a Paper-based   
   b Web-based   
   c DVD-based   
   d Other   
   e Used independently (outside clinical encounter)   
   f Used together or by professional (inside clinical encounter)   
 
2 Accessibility 
   a Available freely online (as website or to download)   
   b Available freely as leaflet   
   c Available through practitioners   
   d Currently in trial   
   e Other:   
 
3 Information about decision making 
   a Explanation of preference-sensitive decisions and why choice exists   
   b Information on making ‘good’ decisions (e.g. how values affect 
decisions) 
  
   c Information on options for involvement in decisions   
   d Information on making choices under stress or anxiety   
   e Information on coping strategies   
   f Explanation / list of options available   
   g Other:    
 
4 Information about the health condition [ovarian cancer] 
   a Information about the function of ovaries   
   b Information about ovarian cancer (general information about the 
disease) 
  
   c Information about ovarian cancer (symptoms)   
 
5 Information about the health condition [increased ovarian cancer risk] 
   a Risk explained (in words)   
   b Risk explained (in numbers/probabilities)   
   c Risk explained (in pictures/diagrams)   
   d Explanation of familial/hereditary cancer   
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   e Information about genetic testing   
 
6 Information about option 1 [risk-reducing bilateral salpingo-oophorectomy] 
   a Information about what option entails (e.g. surgical procedures)   
   b Information about recovery time and post-operative period   
   c Information about surgical menopause   
   d Information about hormone replacement therapy (HRT)   
   e Information about infertility   
   f Information about psychosocial issues (e.g. femininity, sexuality)   
   g Information about residual risk after surgery (in words)   
   h Information about residual risk after surgery (in 
numbers/probabilities) 
  
   i Information about residual risk after surgery (in pictures/diagrams)   
   j Risks / Negative features explained (in words)   
   k Risks / Negative features explained (in numbers/probabilities)   
   l Risks / Negative features explained (in pictures/diagrams)   
   m Benefits / Positive features explained (in words)   
   n Benefits / Positive features explained (in numbers/probabilities)   
   o Benefits / Positive features explained (in pictures/diagrams)   
 
7 Information about option 2 [watchful waiting / symptom awareness] 
   a Information about what option entails (e.g. do nothing, knowing 
symptoms) 
  
   b Information about symptoms (types, frequency, when to consult GP)   
   c Risks / Negative features explained (in words)   
   d Risks / Negative features explained (in numbers/probabilities)   
   e Risks / Negative features explained (in pictures/diagrams)   
   f Benefits / Positive features explained (in words)   
   g Benefits / Positive features explained (in numbers/probabilities)   
   h Benefits / Positive features explained (in pictures/diagrams)   
 
8 Information about option 3 [ultrasound and CA125 screening] 
   a Information about what option entails (e.g. scans, blood tests)   
   b Risks / Negative features explained (in words)   
   c Risks / Negative features explained (in numbers/probabilities)   
   d Risks / Negative features explained (in pictures/diagrams)   
   e Benefits / Positive features explained (in words)   
   f Benefits / Positive features explained (in numbers/probabilities)   
   g Benefits / Positive features explained (in pictures/diagrams)   
 
9 Information about option 4 [oral contraceptive pill] 
   a Information about what option entails (e.g. taking oral 
contraceptives) 
  
   b Risks / Negative features explained (in words)   
   c Risks / Negative features explained (in numbers/probabilities)   
   d Risks / Negative features explained (in pictures/diagrams)   
   e Benefits / Positive features explained (in words)   
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   f Benefits / Positive features explained (in numbers/probabilities)   
   g Benefits / Positive features explained (in pictures/diagrams)   
 
10 Information about option 5 [other:                   ] 
   a Information about what option entails   
   b Risks / Negative features explained (in words)   
   c Risks / Negative features explained (in numbers/probabilities)   
   d Risks / Negative features explained (in pictures/diagrams)   
   e Benefits / Positive features explained (in words)   
   f Benefits / Positive features explained (in numbers/probabilities)   
   g Benefits / Positive features explained (in pictures/diagrams)   
 
11 General assessment of information presentation 
   a Presentation of positive and negative frames for probabilities   
   b Probabilities placed in the context of other events / risks   
   c Acknowledgement of uncertainty around probabilities   
   d Procedures and outcomes described in a way to help imagine the 
effects 
  
   e Overall, are probabilities presented in a balanced, unbiased way?   
   f Overall, is information provided within sufficient detail?   
 
12 Value clarification 
   a Information / step-by-step guidance to making the decision   
   b Are patients asked to consider which positive/negative features 
matter most? 
  
   c Explicit value clarification exercise included   
   d      i. Tallying (weighing of options)   
   e     ii. Ranking (in order of importance, “take the best”)   
   f    iii. Scoring different attributes (on scales)   
   g    iv. Other:     
   h Instructions on how to use the value clarification exercise   
 
13 Communication aid 
   a Recommends / helps with communication with practitioners   
   b Recommends / helps with communication with family/friends   
 
14 Personalisation 
   a Personalisation of probabilities possible (e.g. by age, other risk factors 
etc.) 
  
   b Personalisation of value clarification possible (e.g. enter own reasons)   
 
15 Additional outputs 
   a Space for personal notes   
   b Printable version   
   c Pictures and/or audiovisual material   
   d Personal stories (written)   
   e Personal stories (audio/visual)   
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   f Links and/or references to research evidence   
   g Target audience clearly stated   
   h Purpose of tool clearly stated   
   i Other:    
 
16 Usability 
   a Use of plain language (i.e. minimal use of jargon / scientific terms)   
   b Glossary included   
   c Contents page   
   d Knowledge check / exercise   
 
17 Design and Evaluation 
   a Theory base stated   
   b Evaluation before publication   
   c Version / Date last updated   
   d Date for next update   
 
18 Effectiveness 
   a Helps patients to recognise a decision needs to be made   
   b Helps patients to know their options and their features   
   c Helps patients to understand that values affect decisions   
   d Helps patients to be clear about option features that matter most to 
them 
  
   e Helps patients to discuss values with their practitioners   
   f Helps patients to become involved in preferred ways   
 
19 Additional comments 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This assessment framework was adapted from the International Patient Decision Aid Standards 
Checklist, available at: 
http://www.decisionlaboratory.com/resources/IPDAS%20Crieria%20Checklist.pdf 
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Appendix 7.1 - Coding scheme Focus Groups / Interviews  
[Decision support sub-theme] 
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Appendix 7.2 - Reviewer guide for Virtual Reference Group 
Below you can find a few questions that might be helpful when you give us feedback. 
Please make sure you explain why you answered yes or no to any of the questions: 
 
Please let us know if you chose to personalise OvDex: Yes / No 
If yes, which version did you view (please tick): 
 BRCA1 
 BRCA2 
 Lynch syndrome 
 Not tested / Unclear genetic test 
 Negative genetic test 
 
Was the website easy to use? Why / why not? (Please ignore if you did not view the 
decision aid online) Did you have any problems using it? 
 
 
Did the information cover the right topics in the right amount of detail? Why / why not? 
Please give examples. 
 
 
Was the information easy to understand? Why / why not? Please give examples. 
 
 
Was the information helpful? Why / why not? Please give examples. 
 
 
Was there any information that you did not know about before reading OvDex? What 
information was this?  
 
 
Was any important information missing? What information was this? 
 
 
Was any irrelevant information included? What information was this? 
 
 
What did you think of the exercise to weigh up different factors of the decision? Was this 
useful? Why / Why not? 
 
 
Any other comments and suggestions: 
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Appendix 7.3 - OvDex booklet prototype I (General version) 
Welcome to OvDex
OvDex D1 July 2012
©Cardiff University
OvDex (The Oophorectomy Decision Explorer) has been developed to help you find 
out more about your options for reducing your ovarian cancer risk. If you are viewing 
OvDex you should have been referred to it by a doctor or geneticist as you are at 
increased risk of ovarian cancer. 
Please note that OvDex can be personalised by answering three questions . You 
should have seen these questions before you opened these pages. If you do wish to 
personalise the information you get, please go back and answer the questions .
The information on the following pages has not been personalised. If you do not wish 
to personalise OvDex then please view the general information on the following 
pages.
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Questions in this chapter:
What is the ovarian cancer risk if I have a family history of ovarian cancer?
How can I find out whether I have a faulty gene?
What would my risk be if a faulty gene is found?
What if I cannot get tested or my genetic test is unclear?
Does my cancer risk change over time?
How will my ovarian cancer risk affect my life?
How will my ovarian cancer risk affect my children?
What can I do to reduce my risk?
What is the ovarian cancer risk if I have a family history of ovarian cancer?
Ovarian cancer occurs by chance in less than 2 of every 100 women. For women who
have a family history and/or a faulty gene, this number can be much higher. Generally
the risk is low in young women and rises with age.
Studies have shown that out of 100 women with one first degree relative (mother,
sister or daughter) with ovarian cancer, 5 will develop ovarian cancer themselves at
some point in their life. Women who have more than one relative with ovarian cancer
have an even higher chance with about 7 out of 100 women with 2 or more relatives
developing ovarian cancer themselves in their lifetime.
How can I find out whether I have a faulty gene?
Some women might come from families where cancer is even more common and
these women might have a faulty gene. Testing for a faulty gene in the family usually
begins with a test on a blood sample from a person who has had cancer. If a faulty
gene is found, other members of the family can have a genetic test to see if they also
carry the same gene.
What would my risk be if a faulty gene is found?
The most common faulty genes linked to ovarian cancer are called Breast Cancer
(BRCA) genes 1 and 2 and genes common in Lynch Syndrome (formerly known as
Hereditary Non-Polyposis Colorectal Cancer or HNPCC). The lifetime risk of
developing ovarian cancer can be much higher for women who have a faulty gene
compared to the general population.
Cancer risk
OvDex D1 July 2012
©Cardiff University
Less than 2 out of 100 
women in the general 
population get ovarian 
cancer in their lifetime
About 5 out of 100 women 
with a first degree relative 
with ovarian cancer get 
ovarian cancer in their 
lifetime
About 7 out of 100 women 
with two or more relatives 
with ovarian cancer get 
ovarian cancer in their 
lifetime
 
456 
 
 
 
Cancer risk
OvDex D1 July 2012
©Cardiff University
About 39 out of 100 
women with a BRCA1 
faulty gene get 
ovarian cancer by the 
time they are 70
About 16 out of 100 
women with a BRCA2 
faulty gene get 
ovarian cancer by the 
time they are 70
What if I cannot get tested or my genetic test is unclear?
For some women it might not be possible to get tested because they have no living
relative with cancer or their relative does not want to be tested. In other cases a
genetic test may come back as ‘unclear’ which means the result is not certain. In this
case the genetics service will estimate the woman’s risk based on her family history.
If you have been told that your family history looks like you might have a faulty gene
and you would like more specific information for people with that gene, you can look
at the information by personalising this aid and selecting the gene that most closely
resembles your family history as you have been told by your genetic counsellor.
Does my cancer risk change over time?
Your so-called ‘lifetime’ risk (which is the risk that you will get ovarian cancer at some
point in your life) stays the same over time. However, your ‘age-related’ ovarian
cancer risk (which is the risk that you will get ovarian cancer in a specified time
frame, for example one year or five years) increases with age. This means when you
are young your age-related risk is relatively low and rises when you get older. So for
example, your risk of getting ovarian cancer in the next year when you are 35 is quite
low, whereas your risk of getting ovarian cancer in the next year when you are 50 is
higher.
How will my ovarian cancer risk affect my life?
Being at risk for ovarian cancer does not necessarily mean that you will develop
ovarian cancer. However, knowing your risk will give you access to additional medical
services such as genetic counselling and means that you might be offered risk-
reducing surgery. Some people may feel worried or anxious after finding out about
their risk and their quality of life may be affected.
How will my ovarian cancer risk affect my children?
There is a chance that your children will also have an increased risk of ovarian cancer.
You can discuss your children‘s risk with your doctor to find out more. Your doctor
will also be able to advise you about how best to discuss this risk with your children.
What can I do to reduce my risk?
Your doctor has probably discussed with you the option of having risk-reducing
ovarian surgery to reduce your ovarian cancer risk. This decision aid is designed to
help you look at your options. Please refer to the sections ‘Options at a glance’, ‘Risk-
reducing surgery’ and ‘Other options’ for more information.
About 6 to 12 out of 100 
women with a HNPCC 
faulty gene get ovarian 
cancer by the time they 
are 70
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The Choice
OvDex D1 July 2012
©Cardiff University
Questions in this chapter:
What can I do to reduce my risk?
Why is there a choice?
Who should decide?
Who else should I involve in this decision?
When should I decide?
How can I decide?
What can I do to reduce my risk?
As you are at increased risk of ovarian cancer, you have the option of undergoing risk-
reducing surgery to remove your healthy ovaries (see ‘options at a glance’ and ‘risk-
reducing surgery’). You will need to decide if and when to have this surgery.
Unfortunately, there is no screening for ovarian cancer at the moment (see ‘Other
options’), therefore the only other choice is ‘watchful waiting’.
Why is there a choice?
Often when you go to your doctor, there is one clearly recommended treatment.
However, some situations are more complicated. These are situations in which your
personal preferences play an important role. In the case of cancer risk reduction, your
options have very different effects on your life. This means that you need to be clear
about what might happen if you choose one option over the other.
Who should decide?
As the best choice for you is based on your preferences, you should be closely
involved in the decision. You can either make the decision on your own or if you do
not wish to make this decision yourself, your doctor can help you. They will
encourage you to think about the options and your preferences, so that the final
choice is right for you. If you then don’t want to choose for yourself, just say so and
your doctor may make a recommendation.
Who else should I involve in this decision?
Whether or not you would like to bring anyone else into this decision is your choice.
Often it is helpful to speak to your partner, other members of your family or some
friends who could work through this decision with you. Especially with a decision
about risk-reducing ovarian surgery, the views of your partner can be important, so it
is recommended that you speak to your partner and try to reach a decision together.
Your doctor will also be happy for you to bring your partner along to appointments
and to answer any questions they might have.
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When should I decide?
The decision you are facing is not an easy one and you should not feel under any
pressure to decide quickly. Risk-reducing surgery has benefits and risks that need to
be weighed carefully, so take your time and make sure you are ready before making a
decision. It is important that you make sure that you have completed your family
before you make this choice.
How can I decide?
When it comes to important decisions everyone is different. Some people like to find
out as much as they can about their options, while others prefer to just know what is
absolutely necessary. Some might find it helpful to talk to their family and friends.
Some might like to speak to people who have made a similar decision. It really
depends on you. Have a think about other important decisions in your life and how
you managed to make those. That could give you an idea of how you like to decide
about things.
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Frequently asked questions Surgery to remove ovaries 
and fallopian tubes
No surgery
Will this reduce my ovarian 
cancer risk?
Yes, removing the ovaries will 
greatly reduce your lifetime 
risk of ovarian cancer
No, your risk of ovarian cancer 
will remain increased
Will I be able to become 
pregnant?
No. Yes.
Will this change how I feel 
about my risk of ovarian 
cancer? 
You may feel less worried 
about developing ovarian 
cancer.
You may worry about 
developing ovarian cancer.
Will I go into early 
menopause?
Yes, your oestrogen levels fall 
and the menopause will start 
immediately.
No.
What is menopause after 
surgery like?
Menopause after surgery is 
similar to natural menopause, 
but because it happens 
suddenly, the symptoms may 
be more severe. 
Not applicable.
Will this change how I feel 
about myself as a woman?
Most women do not notice any 
change in how they feel about 
themselves as a woman. Your 
desire for and/or enjoyment of 
sex may decrease a lot.
Not applicable.
Are there any risks linked to 
early menopause?
Yes, there is a risk of bone 
thinning (osteoporosis). Some 
patients report memory 
changes as well.
Not applicable.
Will I need hormone 
replacement therapy (HRT)?
HRT can reduce some of the 
effects of sudden menopause. 
You will need to discuss this 
possibility with your doctor.
Not applicable
Is HRT safe for women at 
increased familial risk?
HRT is safe to take for the 
majority of women until they 
are 50. It is not recommended 
for women who have had 
breast cancer themselves 
already.
Not applicable
What are the risks of surgery? There is a small risk of 
complications depending on 
the type of surgical procedure 
(key hole or open surgery) you 
have. Discuss this with your 
doctor.
Not applicable.
How long will it take me to 
recover from surgery?
Most women leave the hospital 
the same day or the day after 
key hole surgery and are back 
to normal in 4 weeks. For open 
surgery this is slightly longer.
Not applicable.
Can I get screened for ovarian 
cancer?
No, after surgery there is no 
need for any screening 
because your risk will be low
No, there is no routine 
screening available for ovarian 
cancer.
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Questions in this Chapter:
What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
What are the main advantages of this operation?
What are the main disadvantages of this operation?
What is my risk after surgery?
What does the surgery involve?
How long does it take to recover?
Do I need to have my womb removed as well?
What are the complications of RRSO?
Can women die from RRSO?
Could cancer be found during the surgery?
How would RRSO affect my life?
What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Risk-reducing bilateral salpingo-oophorectomy  (RRSO for short) is surgery to remove 
healthy ovaries and fallopian tubes to reduce the cancer risk. The term ‘bilateral’ 
means that the ovaries and fallopian tubes on both sides of the body are removed.  
The word ‘salpingo-oophorectomy’ means  removal of the fallopian tubes and 
ovaries. The aim of the surgery is to remove these tissues before cancer develops.
What are the main advantages of this operation?
1) This operation will reduce your ovarian and fallopian tube cancer risk greatly, as 
these are completely removed during surgery. For women with a faulty BRCA1 gene 
cancer might still develop in the peritoneum, which  is the lining of the pelvis and 
abdomen. This means RRSO will not prevent cancer in about 2 in every 100 women. 
This risk is about the same as the ovarian cancer risk in the general population.
2) For some women, not having to worry about ovarian cancer anymore comes as a 
great relief.
3) For the vast majority of women having RRSO could also reduce the risk of breast 
cancer.
4) Having the surgery will also prevent other, non-cancer related problems happening 
with the ovaries, such as cysts.
What are the main disadvantages of this operation?
1) You will no longer be able to become pregnant once you have had surgery, 
therefore it is important that you have completed your family before going for 
surgery.
2) After the operation you will immediately enter the menopause and may start to 
experience the typical menopausal symptoms, including hot flushes, mood swings, 
night sweats and vaginal dryness (Please see ‘Surgical Menopause’ for more details). 
Furthermore,  you may be at increased risk of bone thinning and you may experience 
some memory changes. These effects might be reduced by hormone replacement 
therapy (Please see ‘Hormone Replacement Therapy’ for more details).
3) There is a small risk of complications during and after surgery.
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What is my risk after surgery?
After surgery your risk of ovarian and fallopian tube cancer is effectively
eliminated. However, there is a rare type of cancer which may still develop after
surgery that is very similar to ovarian cancer. This is called primary peritoneal
cancer. Your risk of primary peritoneal cancer depends on whether or not you
have a faulty gene. The highest risk for primary peritoneal cancer is in women with
a BRCA1 faulty gene. Their risk is about 2 in every 100 women, which is similar to
the risk of ovarian cancer in the general population. For all other women the risk
of primary peritoneal cancer after surgery is close to zero.
What does the surgery involve?
Most often the operation is done as keyhole surgery (laparoscopy). This involves 3
or 4 small (about 1cm) cuts, usually one cut is close to your tummy button and 2-3
just below the bikini line, so they are not visible. Keyhole surgery itself usually
takes less than 2 hours.
In some cases it may not be possible to do keyhole surgery, because of previous
surgery on your tummy or because of your weight. Then surgeons use the more
traditional open surgery. This means a longer cut , usually along the bikini line.
Sometimes a surgeon might have to convert to an open surgery when doing
keyhole surgery because of complications or old scar tissue. This happens in
about 1 of every 100 keyhole operations.
How long does it take to recover?
75 of 100 patients who have keyhole surgery leave the hospital the day after
surgery. They are usually back to normal activity about 4 weeks after surgery. If
you have open surgery you are likely to stay in hospital a bit longer than with
keyhole surgery. Usually patients leave the hospital about 5 days after open
surgery and are back to normal in about 6 weeks. After surgery you are not
allowed to do any heavy lifting for a few weeks. You may also have to refrain from
driving until you can comfortably wear a seatbelt and make an emergency stop
without pain.
Do I need to have my womb removed as well?
Normally it is not recommended that you have your womb removed at the same
time as having RRSO, unless you know that you have Lynch Syndrome or you have
other problems with your womb and have been told by a doctor that removing the
womb would help you with those problems.
Type of procedure in 100 women who have the operation
The figure on the left shows how many of 100 women will 
have keyhole surgery , open surgery and planned keyhole 
which is converted to open surgery.
94 of 100 women will have planned keyhole surgery (dark 
teal dots). Five of 100 women will have planned open 
surgery (light teal dots). One of 100 women will have 
planned keyhole surgery which is converted to open 
surgery (striped dot).
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What are the complications of RRSO?
There is a small risk of complications linked to RRSO. About 4 in every 100 people
will experience some complication. Minor complications can include wound or
urinary tract infections and usually have no long-term effects on your health. More
serious complications might happen during surgery and can include damage to
blood vessels, the bowel or the bladder. If you are having keyhole surgery this
might mean that the surgeon has to convert to an open surgery to repair the
damage.
There are a number of other rare complications that might happen and your
surgeon will go through those with you if you wish before you go in for surgery.
Please note that about 96 of every 100 women do not experience any
complications at all.
Can women die from RRSO?
As with any surgery, there is a very small risk of death. However, this is highly
unlikely. The risk may be greater in women with health problems before surgery.
Could cancer be found during the surgery?
Once your ovaries and fallopian tubes have been removed they will be checked
thoroughly for any signs of cancer. There is a chance that cancer may be
discovered during this check. This happens in up to 4 out of every 100 operations
in the highest risk patients. For others the chance of finding cancer during the
surgery are much lower.
How would RRSO affect my life?
In the short-term, if you decide to go for surgery, you will have to take time off
work and will not be able to do some of the things you might usually do, such as
driving or heavy lifting. However most women recover fully within 4 to 6 weeks.
In the longer term there are a number of things you should consider. After surgery
you may feel less worried about ovarian cancer. You will no longer be able to
become pregnant and you will enter the menopause if you have not gone through
it yet (Please look at the ‘Surgical menopause’ section). You may opt to take
hormone replacement (Please look at ‘Hormone replacement therapy’ section).
These factors may affect your life after surgery and should be considered carefully
before making a decision.
Complications in 100 women who have the operation
The figure on the left shows how many of 100 women 
will experience complications during or after surgery.
4 of 100 women will experience some kind of 
complication either during or after surgery. 96 of 100 
women will not experience any complications.
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Questions in this Chapter:
What is surgical menopause?
What is surgical menopause like?
How could it affect my life?
How long does surgical menopause last?
Are there other problems linked to surgical menopause?
Is there anything I can do to prevent the long term health effects of surgical 
menopause?
What is surgical menopause?
Surgical menopause is the menopause you enter when your ovaries are removed by 
surgery and your body no longer produces oestrogen. Similar to the natural 
menopause, which is when the ovaries naturally stop producing oestrogen, the 
surgical menopause can have a range of symptoms.
What is surgical menopause like?
It is very difficult to describe what surgical menopause is like, because it is different 
for every person, just like the natural menopause. Some women have no or very few 
symptoms and cope very well. Other women can have very severe symptoms and 
their quality of life can be affected.
Symptoms you may experience are: Hot flushes, night sweats, difficulty sleeping, 
fatigue, mood swings, weight gain, vaginal dryness, loss of interest in sex and changes 
in memory.
The most commonly reported symptoms of surgical menopause are hot flushes, night 
sweats, mood swings, vaginal dryness and loss of interest in sex. The great majority of 
women who had surgery report that they have experienced one or more of these 
symptoms. However, any data available about surgical menopausal symptoms is from 
small studies and it is difficult to predict what surgical menopause will be like for you 
personally.
How could it affect my life?
While none of the menopausal symptoms mentioned above are dangerous for your 
health, they may affect you in different ways. Hot flushes can be very uncomfortable 
and may happen at inconvenient times, for example when you are giving a 
presentation at work. In one study two out of every three women reported having 
hot flushes after surgery. Night sweats can lead to problems with sleep and insomnia. 
Vaginal dryness  can lead to pain during sex and therefore you may enjoy sex less. 
Loss of interest in sex, which is also experienced by many women after surgery, may 
affect your relationship with your partner.  In one study just over half of women 
reported that they were not satisfied with their sexual functioning after having 
surgery and in another study one in every three patients felt that vaginal dryness was 
bothersome and reported pain with sex. The way that these symptoms might affect 
your life depends on your personal situation.
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How long does surgical menopause last?
Like the natural menopause it is impossible to say how long symptoms will last. Some 
women have hardly any problems and symptoms disappear quickly, while others have 
symptoms for many years. It really is different for everyone.
Are there other problems linked to surgical menopause?
The loss of oestrogen before natural menopause can cause long term health 
problems, particularly bone thinning. This can lead to fractures in older age. Bone 
thinning is mainly a problem in women who have surgery when they are under 45 
years old. Some women also report changes in memory following this surgery.
Is there anything I can do to prevent the long term health effects of surgical 
menopause?
Hormone replacement therapy (HRT) is usually recommended for women who have 
RRSO before the age of 45 and have not had breast cancer themselves (Please see 
‘Hormone replacement therapy’ for more details).
If you do not wish to or cannot take HRT then you can take dietary supplements to 
reduce bone thinning. You should speak to your doctor about this. Patients are also 
recommended to have a bone density scan about 18 months after their operation. An 
active lifestyle and healthy diet is also recommended.
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Questions in this Chapter:
What is Hormone Replacement Therapy (HRT)?
Why is HRT important?
Who should take HRT?
How long should I take HRT?
Can I take HRT if I have a family history of breast cancer?
But I have heard that HRT increases breast cancer risk?
Will HRT reduce all the symptoms of menopause?
Are there any alternatives to HRT?
What is Hormone Replacement Therapy (HRT)?
Hormone Replacement Therapy, or HRT for short, is a medical treatment that puts 
back the female hormones that are lost when the ovaries are removed or when they 
stop functioning. There are a number of ways that HRT can be used:
- It can be taken as oral tablets usually once  a day
- It can be applied as patches that are put on the tummy or bottom about once or 
twice a week
- It can be applied as a gel directly to the skin once a day (for example the lower 
abdomen or inner thigh)
Why is HRT important?
There are two main reasons why HRT is recommended after surgery:
1. To reduce the risk of bone thinning
2. To reduce symptoms of surgical menopause
Who should take HRT?
HRT is strongly recommended for women who have surgery before they are 45 years 
of age, as this group may experience bone thinning later in life as a result of the lack 
of hormones after surgery. This can lead to a risk of fractures in older age.
Women who have surgery when they are over 45 years of age can choose to have 
HRT to reduce the symptoms of surgical menopause. However these women do not 
have to have HRT if they do not want to, as the risk of bone thinning in later life in this 
group is reduced.
How long should I take HRT?
If you use HRT, it is recommended that you take it until the age of the natural 
menopause, which is 50 years in the UK.
Can I take HRT if I have a family history of breast cancer?
Yes, you should be able to take HRT even if you have a family history of breast cancer. 
Several studies have shown that HRT is safe to take for the vast majority of women 
with a family history of breast cancer as long as they have not had breast cancer 
themselves and they only use HRT until the age of the natural menopause. 
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But I have heard that HRT increases breast cancer risk?
The study that showed that HRT increases breast cancer risk was done with older 
women who had already gone through the natural menopause and were taking HRT 
beyond 50 years of age. These women did not have surgery to have their ovaries 
removed. Therefore this group of women is very different to women with a family 
history who choose to have their ovaries out before they are 50 years. Furthermore 
you should be aware that the findings of this study have now been widely critized.
Having your ovaries out removes all the natural hormone that your ovaries would 
have produced until the age of the natural menopause. The amount of hormone that 
is added back by taking HRT is less than the amount your ovaries would have 
produced naturally. If you stop taking HRT at the age of the natural menopause (so 
when you are 50) then there is no evidence that the breast cancer risk is increased.
Will HRT reduce all the symptoms of menopause?
Taking HRT is not the same as having your own hormones. HRT cannot reduce all 
symptoms of the menopause and women who have had surgery and are on HRT do 
report more symptoms than women who have not had surgery. However, HRT can 
relieve some of the symptoms of the menopause. For example, women who took 
HRT reduced the average number of hot flushes from about 4 to about 1 per day 
when compared to women who did not take HRT. Women on HRT also had fewer 
night sweats. 
Are there any alternatives to HRT?
There are numerous non-hormonal alternatives to HRT, none of which have been 
shown to be as effective in relieving menopausal symptoms. For people who cannot 
take HRT these alternatives may be a good option but for those who can, HRT is the 
best option. 
Alternatives include:
- Antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs)
- Gabapentin
- Red Clover
- Ginseng
- Evening primrose oil
- Agnus Castus
- And many more
Some of these options may be prescribed by your doctor, while others can be bought 
in health shops or over the internet. However, there is no medical proof that freely 
available herbal options work. These alternatives to HRT may have side-effects and 
you should always consult your doctor before deciding to use any of these options.
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Questions in this Chapter:
Is there any screening available for ovarian cancer?
What is the alternative to surgery?
What would happen if I do not have surgery?
Is there anything else I can do?
Is there any screening available for ovarian cancer?
No, unfortunately there is no medically proven screening available for ovarian cancer. 
A large trial of ovarian cancer screening finished in December 2011 and the results 
will not be available until 2013. Until then the NHS will not offer routine screening. 
Some areas may offer private, self-funded screening, however there is still no proof 
that this screening is effective.
What is the alternative to surgery?
At the moment the only alternative to surgery is to do nothing and simply be aware 
of the symptoms of ovarian cancer should they develop. However it is important to 
realise that these symptoms can be very vague and are not specific to ovarian cancer. 
The symptoms include:
Constant bloating (big or swollen tummy)
Feeling less hungry or feeling full quickly
Constant pain in your tummy or below
Needing the toilet more than usual
If any of these symptoms are prolonged, so last longer than usual, you should contact 
your GP.
What would happen if I do not have surgery?
If you decide not to have surgery, then nothing will really change. You will need to 
look out for any symptoms and if you think anything is wrong you need to go to your 
GP to get it checked. Make sure you tell your GP that you have a family history of 
ovarian cancer and are at increased risk when you talk to them.
Remember you can reconsider surgery at any time. 
Is there anything else I can do?
As there is no screening available there is very little else you can do apart from 
keeping an eye on any symptoms. Studies have found that a healthy diet with plenty 
of fruit and vegetables, keeping a healthy weight and an active lifestyle can improve 
overall well-being and might reduce your chances of getting cancer.
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Here are some links and contact details that you might find helpful (even though we 
have taken great care in choosing websites from reliable sources please note we are 
not responsible for the content of these websites):
The Cancer Genetics Story Bank – An online collection of stories told by patients and 
professionals about cancer genetics, developed by the Cancer Genetics Service for 
Wales (CGSW) 
www.cancergeneticsstorybank.co.uk 
Target Ovarian Cancer – A UK charity which supports research into ovarian cancer 
and provides useful information including an ‘Ask the Expert‘ feature. Available in 
several languages.
www.targetovariancancer.org.uk 
Ovacome – A UK charity providing information and support for everyone affected by 
ovarian cancer. Includes a symptom awareness tool and links to a number of patient 
blogs. 
www.ovacome.org.uk or call the helpline on 08453710554
Your GP and/or Genetics Service – There to help you with any questions or concerns. 
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OvDex (The Oophorectomy Decision Explorer) has been developed to help you find 
out more about your options for reducing your ovarian cancer risk. If you are viewing 
OvDex you should have been referred to it by a doctor or geneticist as you are at 
increased risk of ovarian cancer. 
Please note that OvDex can be personalised by answering three questions. You 
should have seen and answered these questions before viewing these pages, as the 
information on the following pages has been personalised and is only relevant to 
women who have had a negative genetic test result (no faulty gene was identified).
(Information on the following pages relates to the answers indicated in bold writing)
1. Do you have a faulty gene or a family history of Lynch Syndrome?
a) Yes, I have a BRCA1 faulty gene
b) Yes, I have a BRCA2 faulty gene
c) Yes, I am from a Lynch Syndrome family
d) Don’t know, I have not been tested for a faulty gene or my genetic test 
was unclear
e) No, I have been tested and no faulty gene was identified
2.  Have you ever had breast cancer?
a) No, I have never had breast cancer
b) Yes, I have had breast cancer
3. How old are you?
a) Under 35
b) 35-39
c) 40-49
d) Over 50
If the answers shown in bold do not apply to you then the information on the 
following pages may not be relevant to your situation. Please go back and answer the 
questions to see information relevant to you or go back and view the general 
information if you do not wish to personalise OvDex.
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Questions in this Chapter:
How can I find out whether I have a faulty gene?
What is my ovarian cancer risk if no faulty gene is found?
How can I find out whether I have a faulty gene?
Ovarian cancer occurs by chance in less than 2 of every 100 women. For women who
have a family history and/or a faulty gene, this can be much higher.
Testing for a faulty gene in the family usually begins with a test on a blood sample
from a person who has had cancer. If a faulty gene is found, other members of the
family can have a genetic test to see if they also carry the same gene.
What is my ovarian cancer risk if no faulty gene is found?
If no faulty gene is found your genetic test is said to be ‘negative’ and there are two 
possibilities:
1. Someone else in your family has already been tested and has been found to have 
the faulty gene. Now you have been found not to have this gene.
In this case your risk of ovarian cancer is likely to be low, therefore you do not need 
to consider the option of risk-reducing surgery any further at this point.
2. You were the first person to be tested in your family and were not found to have a 
faulty gene.
In this case your risk of ovarian cancer may still be higher than the general 
population, as science is not yet able to find all the faulty genes that might be linked 
to ovarian cancer. Therefore you may still want to consider risk-reducing surgery and 
should discuss this with your doctor.  They will estimate your risk based on your 
family history. You can also go back to the main page and have a look at the general  
information if you wish to find out more about surgery.
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Questions in this Chapter:
What are my choices?
What if my genetic test is negative and I am from a family where a faulty gene has
been found before?
What if my genetic test is negative and I am the first person to be tested?
What are my choices?
As you have not been found to carry a faulty gene, there are different situations that
might apply to you. Please find the situation below that applies to you.
What if my genetic test is negative and I am from a family where a faulty gene has
been found before?
If there is a faulty gene in your family and your genetic test is negative for that gene
(i.e. you do not have the faulty gene that other members of your family have), then
you are at low risk and will probably not have to make a choice about risk reduction.
What if my genetic test is negative and I am the first person to be tested?
If you are the first person to be tested in your family and no faulty gene is identified,
there might still be a gene that science cannot find yet. In this case you will need to
discuss your risk level and options with your genetic counsellor. You can come back
to this website once you have found out more about your situation and whether or
not risk-reducing ovarian surgeryis an option for you.
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Here are some links and contact details that you might find helpful (even though we 
have taken great care in choosing websites from reliable sources please note we are 
not responsible for the content of these websites):
The Cancer Genetics Story Bank – An online collection of stories told by patients and 
professionals about cancer genetics, developed by the Cancer Genetics Service for 
Wales (CGSW) 
www.cancergeneticsstorybank.co.uk 
Target Ovarian Cancer – A UK charity which supports research into ovarian cancer 
and provides useful information including an ‘Ask the Expert‘ feature. Available in 
several languages.
www.targetovariancancer.org.uk 
Ovacome – A UK charity providing information and support for everyone affected by 
ovarian cancer. Includes a symptom awareness tool and links to a number of patient 
blogs. 
www.ovacome.org.uk or call the helpline on 08453710554
Your GP and/or Genetics Service – There to help you with any questions or concerns. 
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Suggestions for improvements Exact action taken / Decision 
PATIENTS 
“I have had a read over the documents, they are 
very comprehensive and I wondered whether 
some sections could be condensed for example:  
I felt that the section entitled ‘Does my cancer 
risk change over time’ a simple yes may have 
sufficed?” 
- For closed questions added Yes/No responses 
to have a short / clear answer (but left longer 
responses as extra info) 
- Removed repetitions to condense info 
“On the Risk Reducing Surgery section the part 
detailing amount of women having surgery and 
those that are converted from keyhole to open 
surgery when I first read the explanation to the 
right of the grid in bold I thought the grid showed 
amount that was converted to open 
surgery…which would put a lot of people off the 
idea.” 
- Changed colour coding of dots 
- Moved dot representing “conversion from 
keyhole to open” to end, so dot order 
corresponds to order in text 
- Un-bolded “planned keyhole which is converted 
to open surgery…” to remove emphasis 
Section on Why is there a choice? Participant 
stated: “I am clearly given the indication from the 
gynecologist during my yearly hysteroscopy that I 
should have my ovaries and womb removed as 
the risk of cancer outweighs my fears on being 
on HRT after surgery.” 
- Added a sentence referring to potential health 
professional attitudes/recommendations to 
question “Why is there a choice” 
- Also added statement ‘should not feel 
pressured’ 
In option grid participant highlighted “No, your 
risk of ovarian cancer will remain increased.” And 
asked: “why??...is this because I am getting 
older?”  
- Replaced the word ‘increased’ in option grid 
with the word ‘high’ to avoid confusion with 
increasing risk with age etc.. 
In option grid participant highlighted “Are there 
any risks linked to early menopause?” and said: 
“+ heart disease + memory failure + depression (I 
think it is very important to mention these risks)”  
- Added references to possible increased risk of 
CVD in option grid, surgery disadvantages, 
menopause and HRT section 
- Added information about risk of CVD in 
menopause section under question ‘Are there 
any long term health effects linked to the 
menopause?’ 
- Removed refs to ‘surgical menopause’ from 
entire menopause section to emphasize that all 
effects and symptoms are equal to natural 
menopause and alleviate the fear of ‘surgical’ 
menopause a little 
- In HRT section added info on oestrogen + 
progesterone HRT and oestrogen only HRT and 
added that evidence regarding HRT against CVD 
risk is controversial 
- In menopause and HRT section mentioned that 
bone thinning & CVD risk depends on medical 
history and lifestyle and should be discussed 
with doctor 
- Left ‘memory changes’ instead of ‘failure’ in the 
option grid 
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- Added depression as menopausal symptom in 
Surgical Menopause chapter 
In option grid participant highlighted “HRT is safe 
to take for the majority of women until they are 
50.” And stated “I know someone who insists on 
continuing taking oestrogen only HRT, and has 
been doing so since her removal of ovaries at the 
age of 28 (she is now 54 - she had ovaries 
removed due to cysts not risk of cancer) as she 
will otherwise have masculine features such as 
becoming very hairy including facial hair, and a 
deep masculine voice.” 
- Added some explanation of why HRT should be 
stopped at 50 in HRT chapter  
- Added sentence to state that memory changes 
are also experienced by women going through 
the natural menopause and are a normal part 
of ageing 
Participant highlighted “The most commonly 
reported symptoms of surgical menopause are 
hot flushes, night sweats, mood swings, vaginal 
dryness and loss of interest in sex.” And stated 
“Osteoporosis, heart disease, memory failure, 
are the most worrying.”  
- Changed title of first question to include term 
‘short-term’ 
- Changed title for problem question to include 
term ‘long-term’ 
- Added references to possible increased risk of 
CVD in option grid, surgery disadvantages, 
menopause and HRT section (indicated in blue 
until confirmed) 
- Added sentence to state that memory changes 
are also experienced by women going through 
the natural menopause and are a normal part 
of ageing 
Participant highlighted “Are there other problems 
linked to surgical menopause?” and asked “Why 
is heart disease not mentioned?” 
- Added references to possible increased risk of 
CVD in option grid, surgery disadvantages, 
menopause and HRT section 
- Added information about risk of CVD in 
menopause section under question ‘Are there 
any long term health effects linked to the 
menopause?’ 
- Removed refs to ‘surgical menopause’ from 
entire menopause section to emphasize that all 
effects and symptoms are equal to natural 
menopause and alleviate the fear of ‘surgical’ 
menopause a little 
- In HRT section added info on oestrogen + 
progesterone HRT and oestrogen only HRT and 
added that evidence regarding HRT against CVD 
risk is controversial 
- In menopause and HRT section mentioned that 
bone thinning & CVD risk depends on medical 
history and lifestyle and should be discussed 
with doctor 
Participant highlighted “Hormone replacement 
therapy (HRT) is usually recommended for 
women who have RRSO before the age of 45” 
and stated “I thought this was before the age of 
52” 
- No action taken – after review of literature and 
clinical recommendations (left age at 45 and 
wording as ‘strongly recommended…’ and 
‘chose to…’ 
Participant highlighted “Women who have 
surgery when they are over 45 years of age can 
- No action taken – after review of literature and 
clinical recommendations (left age at 45 and 
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choose to have HRT to reduce the symptoms of 
surgical menopause. However these women do 
not have to have HRT if they do not want to…” 
and stated “Again, I thought the risks of bone 
thinning etc was for women up to 52 years (not 
45 years)” 
wording as ‘strongly recommended…’ and 
‘chose to…’ 
Participant highlighted “If you use HRT, it is 
recommended that you take it until the age of 
the natural menopause, which is 50 years in the 
UK” and asked “What will happen if I chose to 
continue taking HRT for many more years past 
the age of 52yrs?” 
- Added some explanation of why HRT should be 
stopped at 50 in HRT chapter 
Participant highlighted “If you stop taking HRT at 
the age of the natural menopause (so when you 
are 50) then there is no evidence that the breast 
cancer risk is increased” and asked “Sorry but I 
have a problem of understanding HRT and I get 
very confused when reading information on this 
subject.  Can you please simply clarify - "too 
much oestrogen in HRT taken over the age of 
52years / or too much oestrogen in the body 
causes breast cancer"??” 
- Clarified that high oestrogen levels increase BC 
risk in HRT chapter Question: “But I have 
heard…” 
- Added graph to explain oestrogen levels in 
surgical versus natural menopause in 
menopause chapter 
- In HRT chapter added graph to explain how HRT 
adds back oestrogen and increases oestrogen 
levels after pre-menopausal surgery and how it 
then is reduced gradually 
Participant highlighted “However, HRT can 
relieve some of the symptoms of the menopause” 
and asked “Will HRT also help keep at bay heart 
disease  and thinning of bones?” 
- Added new question in HRT chapter “Will HRT 
deal with the long-term effects of menopause?” 
with short explanatory answer 
- Also added in Menopause chapter question “Is 
there anything I can do” statement ‘HRT can 
may effectively reduce some of the short- and 
long-term effects of surgical menopause’ 
Participant highlighted “No, unfortunately there 
is no medically proven screening available for 
ovarian cancer” and “At the moment the only 
alternative to surgery is to do nothing and simply 
be aware of the symptoms of ovarian cancer 
should they develop.” And “If you decide not to 
have surgery, then nothing will really change. You 
will need to look out for any symptoms and if you 
think anything is wrong you need to go to your 
GP to get it checked.” And “As there is no 
screening available there is very little else you 
can do apart from keeping an eye on any 
symptoms.” and stated “Again, I need to 
reiterate internal vagina scan + CA125 blood 
test”  
- Changed wording of ‘Other options’ chapter 
question about screening to explain CA125 and 
TV scan policy and emphasize lack of proof 
- Added new question in ‘Other options’ asking: 
‘But I have been offered CA125/TV scans…’ 
“ There was some repetition” - Removed repeated question “What can I do…” 
from Cancer Risk section (now only in Choice 
section) 
- Removed repetition in menopause symptoms 
“It mentions genetic testing. I have personally 
not had this and have struggled to get it. More 
information on this would be useful.” [General 
- Added more detail in “How can I find out 
whether I have a faulty gene…” 
- Added link to Macmillan in Contacts & 
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version] Resources with specific pointer to ‘genetic 
testing’ section 
“Page numbers would be good.” - Added page numbers on top right hand corner 
of pdf docs 
“I would like to have seen Chapter numbers and 
individual paragraph / section numbers. A minor 
point, but this would be helpful as there are 
quite a lot of cross references to different 
sections throughout.” 
- Numbered all Chapters in pdf (1, 2, 3… etc.) 
- Numbered all questions (Q1, Q2… etc.) in each 
chapter 
- Added table of contents of first page of pdf 
- Changed all cross refs within pdfs to point to 
chapter number and page number 
“During the round table discussion session I 
attended, one of the participants mentioned that 
there would be an increased risk of heart disease 
following an oophorectomy. Whether this is 
correct I don’t know but if there are any other 
potential significant health risks associated with 
this surgery (other than cancer of the 
peritoneum) it would be helpful to refer to 
these.” 
- Added references to possible increased risk of 
CVD in option grid, surgery disadvantages, 
menopause and HRT section 
- Added information about risk of CVD in 
menopause section under question ‘Are there 
any long term health effects linked to the 
menopause?’ 
- Removed refs to ‘surgical menopause’ from 
entire menopause section to emphasize that all 
effects and symptoms are equal to natural 
menopause and alleviate the fear of ‘surgical’ 
menopause a little 
- In HRT section added info on oestrogen + 
progesterone HRT and oestrogen only HRT and 
added that evidence regarding HRT against CVD 
risk is controversial 
- In menopause and HRT section mentioned that 
bone thinning & CVD risk depends on medical 
history and lifestyle and should be discussed 
with doctor 
“For Lynch Syndrome women the surgery would 
involve hysterectomy as well as oophorectomy. 
It, therefore, doesn’t make complete sense to 
consider removal of the ovaries in isolation. It 
would be useful to either include more 
information on the hysterectomy or to link to it 
from another source at the relevant points in the 
text.  In addition, your links page could include 
links to more information about hysterectomy 
for Lynch Syndrome women.” [Lynch version] 
- Added hysterectomy as integral part of the 
RRSO decision for Lynch women by: 
- Changing information in ‘Cancer risk chapter’ to 
mention hysterectomy and link to ‘risk-reducing 
surgery’ section 
- Changing wording in ‘The choice’ to include 
hysterectomy 
- Changing ‘The surgery’ chapter to include 
information about hysterectomy throughout 
“It is stated that the alternative to surgery is 
‘watchful waiting.’ This doesn’t ring true for 
women with Lynch Syndrome. It may be correct 
to state that there is no effective screening. In 
practice however, Lynch Syndrome women 
receive (via the NHS) an annual transvaginal 
ultrasound scan for womb cancer screening. The 
ovaries are visible in this scan and so ovarian 
cysts are monitored and followed up with further 
scans and CA125 blood tests. This is my 
experience- it might not serve a useful purpose 
- Rewrote section about screening in ‘other 
options chapter’ to specifically address 
screening that Lynch women might receive and 
to emphasize again that it is not effective for 
ovarian cancer 
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but it is a kind of screening/monitoring.  Maybe 
this experience could be reflected in the text as 
something that does happen with Lynch 
Syndrome.” [Lynch version] 
“The information in this file was designed for all 
women over 50. However, in the text it states 
that ‘most ovarian cancers in women with Lynch 
Syndrome are diagnosed between the ages of 40 
and 55.’ Further down on the same page it is 
suggested that most ovarian cancers in Lynch 
women are diagnosed before the age of 50. 
Given these facts, I am not sure that it is 
coherent having all women over 50 looking at the 
same information when there are vastly differing 
rates of risk. Would it not make more sense to 
add an additional group?” [Lynch version] 
- Removed sentence that said: ’most OCs in lynch 
occur between 40 and 55’ and left sentence 
that read ‘before age 60’ to be more consistent 
- Included info on endometrial cancer in ‘Cancer 
Risk’ section; endometrial cancer risk is much 
higher for Lynch and combined with 
hysterectomy decision, so ovarian risk no longer 
stand-alone issue 
- Did not split into extra age group 
Participant highlighted sentence: “ but it is now 
understood that people from Lynch families do 
not necessarily need to have a confirmed faulty 
gene to be at risk, as many genes that might be 
linked to Lynch Syndrome are not yet known” and 
asked “My sisters who were also tested for MSH2 
faulty gene are clear and have not inherited this 
faulty gene - are they ok?” [Lynch version] 
- Yes, if a faulty gene is found in a member of the 
family, any member who is not found to have 
that gene is then at low risk. 
- Added sentence to Cancer Risk chapter 
question about faulty genes: ‘However if a 
faulty gene is found in a member of the family 
and other members of the family do not have 
this gene, then those members are at low risk.’ 
Participant highlighted: “Lynch Syndrome (for 
example: MLH1, MSH2, MSH6 and PMS2).” And 
asked “please give ovarian cancer risk in 
percentage for each Lynch Syndrome)” [Lynch 
version] 
- Added exact risk estimates for MSH1, MSH2 
and MSH6, which were available form 2009 
paper; no further exact ovarian cancer risk 
estimates available for other mutations 
 
 
Participant highlighted: “However, knowing your 
risk will give you access to additional medical 
services such as…” and said “need to mention 
surveillance for internal vagina scan, 
hysteroscopy, CA125 blood test.” 
- Added ‘…and screening’ to the paragraph about 
‘how will this affect my life’, but did not specify 
types of screening etc., as this is discussed later 
in the decision aid 
Participant highlighted: “ To reduce your risk of 
endometrial cancer you may consider a risk-
reducing hysterectomy (removal of healthy 
uterus). This you will need to discuss with your 
doctor.” And said “1. Need to mention the higher 
risk of endometrial cancer (i think this is about 
60% for MSH2 carriers) compared to ovarian 
cancer risk of 6-12%.  Therefore if you are 
considering having your ovaries removed, it is 
probably best to have a hysterectomy at the 
same time. 
2.  MSH2 carriers are also at risk of skin cancer I 
believe.” [Lynch version] 
- Have now mentioned endometrial cancer risk 
estimates for MSH1, 2 and 6 in cancer risk 
chapter 
- Did mention ‘other cancers’ for Lynch, so that I 
won’t have to specify all cancers they may be at 
risk for and recommended discussion with 
doctor 
- Added hysterectomy as integral part of the 
RRSO decision for Lynch women by: 
- Changing information in ‘Cancer risk chapter’ to 
mention hysterectomy and link to ‘risk-reducing 
surgery’ section 
- Changing wording in ‘The choice’ to include 
hysterectomy 
- Changing ‘The surgery’ chapter to include 
information about hysterectomy throughout 
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Participant highlighted: “Unfortunately, there is 
no screening for ovarian cancer at the moment” 
and said: “Internal vagina scan, and CA125 blood 
test is available.” 
- Rewrote section about screening in ‘other 
options chapter’ to specifically address 
screening that Lynch women might receive and 
to emphasize again that it is not effective for 
ovarian cancer 
In option grid participant highlighted “Yes, you 
can have your ovaries taken out at the same time 
as having your hysterectomy.” And asked “Will 
this then be 'open' surgery or 'key hole' 
surgery?” [Lynch version] 
- In Surgery chapter now have detailed 
description of hysterectomy surgical techniques 
(open, vaginal and laparoscopic) 
In option grid participant highlighted “No, there 
is no routine screening available for ovarian 
cancer” and stated “There is internal vagina scan 
and also CA125 blood test” 
- Rewrote section about screening in ‘other 
options chapter’ to specifically address 
screening that Lynch women might receive and 
to emphasize again that it is not effective for 
ovarian cancer 
Participant highlighted entire paragraph on “Do I 
need to have my womb removed as well?” and 
asked “More onus on this point to stress the 
riskier considerably higer percentage of womb 
cancer for MSH2 carriers.  Therefore if going 
through surgery and removing ovaries - the 
uterus should be removed at the same time 
rather than go through two surgery/operations.” 
[Lynch version] 
- Added hysterectomy as integral part of the 
RRSO decision for Lynch women by: 
- Changing information in ‘Cancer risk chapter’ to 
mention hysterectomy and link to ‘risk-reducing 
surgery’ section 
- Changing wording in ‘The choice’ to include 
hysterectomy 
- Changing ‘The surgery’ chapter to include 
information about hysterectomy throughout 
“I strongly believe the two procedures [RRSO and 
hysterectomy] are linked and information on 
hysterectomy should certainly be included.” 
[Lynch version] 
- Added hysterectomy as integral part of the 
RRSO decision for Lynch women by: 
- Changing information in ‘Cancer risk chapter’ to 
mention hysterectomy and link to ‘risk-reducing 
surgery’ section 
- Changing wording in ‘The choice’ to include 
hysterectomy 
Changing ‘The surgery’ chapter to include 
information about hysterectomy throughout 
Suggestions for improvements Exact action taken / Decision 
PROFESSIONALS 
“The Ovacome symptom awareness tool is not 
NICE compliant, in that it does not highlight 
urinary symptoms.” 
- Removed reference to Ovacome  symptom 
awareness tool in Contacts and Resources 
section 
- Added reference to symptoms appearing more 
than 12 times a month in ‘Other options’ 
section on symptoms in agreement with NICE 
guidance 
- Changed ‘needing the toilet’ to ‘needing to 
urinate’ in symptoms list 
“Question: When should I decide?  I am not 
certain about the phrasing in this context – It is 
important you make sure you have completed 
your family before you make this choice.  It 
sounds like an instruction.  I think at this point it 
is important for women to understand that 
undergoing surgery will mean they cannot get 
- Rewrote the second part of the question to 
refer to ‘family planning’ and potential of 
meeting someone / remarrying to state: 
‘Therefore it is essential to consider your plans 
for a family and any potential future changes to 
these plans (for example if there is a chance you 
might meet a new partner / re-marry) before 
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pregnant, therefore it is important that they 
discuss implications and timing of any possible 
surgery on their plans to complete a family.” 
making a final decision’ 
- Also reworded in RRSO chapter disadvantages 
section on family planning into: “…have 
considered your plans for a family before 
making a final decision.” 
“Question:  How will my ovarian cancer risk 
affect my children? 
It would be useful to say what sort of chance that 
your children may have of developing ovarian 
cancer rather than just ‘there is a chance’ which 
would worry most parents.” 
- Rewrote section on children’s risk in Cancer Risk 
chapter to include risk of inheriting a faulty 
gene and resulting risk of cancer and age 
relationship 
- Added link to NHS Choices website info in 
inheritance / genetics in Cancer Risk chapter 
and in Contacts and Resources 
“Options at a glance: Will this change how I feel 
about myself as a woman?   I would suggest that 
if your desire for and/or enjoyment of sex may 
decrease a lot, then there is a pretty good chance 
it will change how you feel as a woman.” 
- Replaced the word ‘Most’ with ‘Many’ in option 
grid 
- Added “However, your desire….” So women can 
decide themselves whether they think their 
feeling of womanhood might be affected 
“Options at a glance – can I get screen for 
ovarian cancer – the answer is no on both 
counts,  If however you are thinking that this may 
change soon because of the UKFOCSS trial,   then 
the answer would surely be yes, as it has been 
stated that not all genes relating to lynch 
syndrome have been found?” 
- Changed wording in option grid to ask “Is there 
a routine screening programme to detect 
ovarian cancer?” 
- Changed answer to this question in option grid 
to read: ‘No, and….’ and ‘…no routine screening 
is available on the NHS to detect OC’ 
“Risk Reducing Surgery – What are the main 
advantages of this operation – again the word 
greatly needs quantifying (as above).” 
- Removed the word ‘greatly’ 
- Added information on BRCA1 PPC risk and non-
BRCA1 PPC risk (i.e. very low risk for all others) 
to emphasize this point 
“Risk Reducing Surgery – What are the main 
disadvantages of this operation 
Need to include potential loss of desire and/or 
enjoyment of sex.” 
- Added new point to disadvantage list to state: 
‘Your desire for sex will decrease and due to 
some menopausal symptoms, such as vaginal 
dryness, you may enjoy sex less as intercourse 
can be painful.’ 
“What is surgical menopause like? 
Need consistency when talking about the range 
of symptoms, and there is repetition.  Could say 
the most commonly experienced symptoms are 
x, y, z.  Other symptoms which may be 
experienced are …..” 
- Deleted repetition and split sentence to 
distinguish ‘most common’ and ‘other’ 
symptoms. 
“How could it affect my life?  Would it be 
appropriate here to include some information 
about help that can be sought?” 
- Added paragraph to ‘How will it affect my life’ 
question in Menopause chapter to refer to 
lubricant and other options such as CBT 
- Added ref to NHS choices website 
“What is the alternative to surgery? 
The symptoms should be the ones used in the 
NICE Guidance CG122.  In particular the 
reference to needing the toilet more than usual 
could be construed as bowel rather than bladder 
related.  There should always be a reference to 
frequency of symptoms as well (particularly more 
than 12 times a month) otherwise there is the 
- Added reference to symptoms appearing more 
than 12 times a month in ‘Other options’ 
section on symptoms in agreement with NICE 
guidance 
- Changed ‘needing the toilet’ to ‘needing to 
urinate’ in symptoms list 
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potential to cause undue concern over transient 
symptoms.” 
“Does my cancer risk change over time – a little 
bit difficult to understand” 
- Added simple one word answer ‘Yes’ to have a 
short / clear answer (but left longer responses 
as extra info) 
“What can I do to reduce my risk? Does there 
need to be some explanation about screening as 
some people will have heard about blood tests 
and scans and although the evidence is not 
proven they may not understand- or refer to the 
bit in Other Options section.” 
- Added ‘no medically proven screening’ 
sentence to Choice Chapter “What can I do?” 
question 
- Added reference to ‘Other options’ in “What 
can I do?” question 
- Changed wording of ‘Other options’ chapter 
question about screening to explain CA125 and 
TV scan policy and emphasize lack of proof 
“Page 4  
Does there need to be explanation as to why 
there is no screening available for ovarian cancer 
at present given that many people will have 
heard about scans Ca125 blood tests and trial?” 
- Changed wording of ‘Other options’ chapter 
question about screening to explain CA125 and 
TV scan policy and emphasize lack of proof and 
did specify that there is no evidence that 
screening detects ovarian cancer early 
- Added new question in ‘Other options’ asking: 
‘But I have been offered CA125/TV scans…’ 
“Page 7  
Risk Reducing Surgery 
Although most people considering this surgery 
will be pre menopausal there will be some who 
have already gone through the menopause (and 
having spoken to several they are really 
concerned about the effects of surgery when 
most of what they read applies to 
premenopausal women- strangely they seem to 
be even more worried than premenopausal 
women)” 
- Wrote ‘Surgical menopause’ chapter for post-
menopausal docs to specify how surgical 
menopause might affect peri- and post-
menopausal women 
- Added new graph with oestrogen levels in 
surgical & natural menopause and with surgery 
during natural menopause to demonstrate 
difference in drop 
“Page 8  
The stripped dot in the dot matrix – conversion 
to open surgery is not very clear” 
- Changed colour coding of dots 
- Moved dot representing “conversion from 
keyhole to open” to end, so dot order 
corresponds to order in text 
- Un-bolded “planned keyhole which is converted 
to open surgery…” to remove emphasis 
“What are the complications of RRSO 
Last sentence of the first paragraph …….the 
surgeon has to convert to an operation or to 
open surgery.” 
- Removed the word “an” 
“Can women die? 
Is it possible to make this less prominent?” 
- Removed individual question “Can women 
die…?” and instead integrated risk of death at 
the end of previous question about 
complications 
“Page 9  
What is surgical menopause? 
I think a lot of people who have had a surgically 
induced menopause will find that they 
experience symptoms much more suddenly than 
those who experience the menopause naturally 
- Added statement to explain that surgical 
menopause is more sudden and severe in 
Chapter Menopause under what is it like 
- Also added paragraph explaining that surgical 
menopause is essentially the same as natural 
menopause, only more sudden 
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particularly amongst younger women” - Added graph to explain oestrogen levels in 
surgical versus natural menopause in 
menopause chapter 
- Added highlighted statement at beginning of 
menopause chapter to alert readers that 
symptoms are described for women who are 
not taking HRT 
“Page 12 
What is the alternative to surgery? 
‘If any of these symptoms are prolonged’ it might 
be helpful to give an indication of how long it 
should be before some one goes to the doctors – 
3 weeks is usually the suggested length of time.” 
- Added reference to symptoms appearing more 
than 12 times a month in ‘Other options’ 
section on symptoms in agreement with NICE 
guidance 
- Changed ‘needing the toilet’ to ‘needing to 
urinate’ in symptoms list 
“Page 13 Ovacome  
…….call the support line rather than helpline.” 
- Changed to ‘support-line’ 
Participant highlighted “and/or enjoyment of sex 
may decrease…” and said “think may need 
qualification” 
- Did not change content of option grid, but: in 
chapter ‘RRSO’ added new point to 
disadvantage list to state: ‘Your desire for sex 
will decrease and due to some menopausal 
symptoms, such as vaginal dryness, you may 
enjoy sex less as intercourse can be painful.’ 
Participant highlighted “For the vast majority of 
women having RRSO…” and added “before the 
menopause”  
- Added ‘before the natural menopause’ to RRSO 
chapter advantages section about BC risk 
Participant highlighted “…it is important that you 
have completed your family before going for 
surgery.” And added “or not in a time of your 
life where you may remarry etc”  
- Rewrote the second part of the question to 
refer to ‘family planning’ and potential of 
meeting someone / remarrying to state: 
‘Therefore it is essential to consider your plans 
for a family and any potential future changes to 
these plans (for example if there is a chance you 
might meet a new partner / re-marry) before 
making a final decision’ 
Participant highlighted “These effects might be 
reduced by hormone replacement therapy” and 
said “can be effectively treated...not all women 
can take hrt however. This should be discussed 
before surgery” 
- Reworded answer to say ‘effectively treated’ in 
RRSO chapter disadvantages, as suggested by 
respondent 
- Added statement that HRT should be discussed 
before surgery in RRSO chapter, menopause 
chapter and HRT chapter where appropriate  
Participant highlighted “For all other women the 
risk of primary peritoneal cancer after surgery is 
close to zero.” And said “Repeated info in this 
paragraph” 
- Simply underlined types of cancer, as this was 
not a repetition: first sentence refers to ovarian 
cancer & fallopian tube cancer risk and last 
sentence to PPC 
Participant highlighted “The most commonly 
reported symptoms of surgical menopause are 
hot flushes, night sweats, mood swings, vaginal 
dryness and loss of interest in sex.” And said 
“repeated” 
- Deleted repetition and split sentence to 
distinguish ‘most common’ and ‘other’ 
symptoms 
Participant highlighted “The way that these 
symptoms might affect your life depends on your 
personal situation.” And asked “was this study 
- Added highlighted statement at beginning of 
menopause chapter to alert readers that 
symptoms are described for women who are 
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with or without  hrt...as it seems very off-
putting??” 
not taking HRT 
Participant highlighted “…about 18 months after 
their operation…” and stated “curios about this 
one as to where you got this info...not sure 
our patients get this ..is it from london?” 
- Changed paragraph in ‘menopause’ chapter to 
say that some regions recommend BDS and that 
women should ask their doctor 
“How will my cancer risk affect my life? – this 
seems to be aimed at women at an earlier stage 
than the OVDEX tool - …means you might be 
offered risk reducing surgery…. Over the page 
you say  = you have the option of undergoing risk 
reducing surgery…” 
- Changed wording in Cancer risk chapter “How 
will my risk affect my life” to read ‘you are 
offered…’ (changed tense) 
“[Options at a glance] There is no mention of the 
increased cardiovascular risk of early 
menopause.“ 
- Added references to possible increased risk of 
CVD in option grid, surgery disadvantages, 
menopause and HRT section 
- Added information about risk of CVD in 
menopause section under question ‘Are there 
any long term health effects linked to the 
menopause?’ 
- Removed refs to ‘surgical menopause’ from 
entire menopause section to emphasize that all 
effects and symptoms are equal to natural 
menopause and alleviate the fear of ‘surgical’ 
menopause a little 
- In HRT section added info on oestrogen + 
progesterone HRT and oestrogen only HRT and 
added that evidence regarding HRT against CVD 
risk is controversial 
In menopause and HRT section mentioned that 
bone thinning & CVD risk depends on medical 
history and lifestyle and should be discussed 
with doctor 
“A picture of the anatomy might be helpful as 
many women do not know their anatomy or 
understand the difference between the ovary 
uterus and cervix! It would also be sensible to 
explain somewhere where the cervix is and that 
cervical cancer is not raised in LS and that 
cervical screening will not detect ovarian or 
endometrial cancer.” 
- Added question ‘where does Ovarian cancer 
develop’ in Cancer Risk chapter and included 
sketch of anatomy with labels and legend 
explaining difference between OC/fallopian 
tube cancer and cervical / uterine cancer 
- Added emphasis that surgical smear does not 
detect ovarian cancer in other options chapter 
(screening paragraph) 
“If they do have a family history of breast cancer 
they should be advised to seek advice about this 
from the genetics service. This is referred to in 
the last question about HRT.” 
- Added statement that HRT should be discussed 
before surgery in RRSO chapter, menopause 
chapter and HRT chapter where appropriate 
- Added in HRT chapter in question “Is there 
anything I can do…” statement: ‘However, not 
all women can take hormone replacement and 
this should be discussed before having surgery.’ 
“You have not mentioned the protective effect of 
the oral contraceptive Pill for ovarian cancer.” 
- No official guidelines regarding use of OCP in UK 
- Added paragraph in ‘other options’ section 
under ‘is there anything else…’ to mention that 
some countries recommend OCP use and that it 
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decreases OC risk but increases BC risk and 
should be discussed with doctor 
“The information about ovarian symptom 
awareness is vague. You've said if the symptoms 
last longer than usual. I suggest you use the same 
terminology as the NHS choices website ie ‘if the 
symptoms occur on most days’. You could also 
direct women to the NHS choices link for ovarian 
symptom awareness.” 
- Added reference to symptoms appearing more 
than 12 times a month in ‘Other options’ 
section on symptoms in agreement with NICE 
guidance 
- Changed ‘needing the toilet’ to ‘needing to 
urinate’ in symptoms list 
“Although perhaps for this age group you do not 
need to give so much information about surgery 
as I would suggest that they really should be 
counselled against RRBSO until their risk is 
higher.” 
- Changed info for under 35s to say: “therefore 
you do not need to make a decision about risk-
reducing surgery right now. The information in 
the rest of this document describes the 
different options and focuses on surgery, 
therefore you may wish to come back to this at 
a later point when it is more relevant to you” 
“There is mention of the ovarian cancer risk if 
there is a family history of ovarian cancer but 
some families have a mixed history of breast and 
ovarian cancer – should the information for this 
group be different? [General version] 
- Reworded section on family history to include 
ovarian, breast and bowel 
- Added paragraph in RRSO chapter question 
about family history and risk to emphasise 
other family history ‘The number of relatives 
with cancers other than ovarian cancer, such as 
breast and bowel cancer, can also affect…’ 
‘Women who have more than one relative with 
ovarian cancer…..’ should there be mention of 
whether this is first or second degree 
relationships” [General version] 
- Reworded sentence in RRSO chapter question 
about family history and risk to state: ‘Women 
who have 2 or more first (mother, sister or 
daughter) and/or second degree (aunt, 
grandmother etc.) relatives…’ 
“Page 2 ‘How can I find out whether I have a 
faulty gene…. 
Some women might come from families ….is 
even more common’ –than ? the general 
population or than those with a first degree or 
second relatives. Should there be an explanation 
somewhere as to what 1st and 2nd degree 
means? 
 ( there may already be )” [General version] 
- Reworded sentence in RRSO chapter question 
about faulty gene to state: ‘… [where cancers] 
have affected more than just one or two 
relatives and these women…’ 
- Reworded sentence in RRSO chapter question 
about family history and risk to state: ‘Women 
who have 2 or more first (mother, sister or 
daughter) and/or second degree (aunt, 
grandmother etc.) relatives…’ to give indication 
of what 1st and 2nd degree mean 
Participant highlighted “Some women might 
come from families where cancer is…” and stated 
“i would say certain types of cancer such as 
breast/ovary or ovary/womb/bowel” [General 
version] 
- Reworded RRSO chapter question about faulty 
gene and risk to state: ‘Some women might 
come from families where certain types of 
cancer (e.g. ovarian, breast, bowel) have 
affected…’ 
“Question on how can I find out whether I have a 
faulty BRCA1 gene is irrelevant at this point, they 
already have it confirmed.” [BRCA version] 
- Removed question 
“Graph on risk of ovarian cancer – legend on 
graph says ovarian cancer, but the text on the 
right is all about breast cancer. And the graph 
matches the next one for breast cancer.” [BRCA 
- Removed wrong graph and legend and inserted 
ovarian cancer risk for 35-39 year old BRCA1 
carrier graph 
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version] 
“Will my cancer risk affect my children.   Should 
quantify the risk here.” [BRCA version] 
- Copied new ‘children risk’ paragraph from 
General file and adapted for BRCA1 risk (i.e. risk 
of inheritance of faulty BRCA1/2 gene and 
resulting cancer risk) 
“Options at a glance – will this affect my ovarian 
and breast cancer risk? 
You have a better explanation here of the 
reduction in risk (see comments above) but 
needs qualifying somewhere as to why it is not 
100%. Other comments are as per previously. 
[BRCA version] 
- No action taken here, there is explanation 
about PPC later-on in RRSO chapter and OG 
needs to stay compact. 
“Options at a glance:    Will this reduce my 
ovarian cancer risk?  The answer Yes, removing 
the ovaries will greatly reduce your lifetime risk 
of ovarian cancer is not clear enough.  What do 
you mean by greatly?  Reference is made later on 
that there is a small chance ovarian cancer is 
found when they operate, but it does not 
address the risk of Primary Peritoneal Cancer.” 
- Removed the word ‘greatly from surgery 
section questions about advantages, but left in 
the option grid, as it is not possible to quantify 
- No action taken in OG, there is explanation 
about PPC later-on in Surgery chapter and OG 
needs to stay compact. 
“What is my risk after surgery? – Here you say 
the risk is effectively eliminated.  Again this is not 
so, and even at odds with greatly reduced.  Note 
point about Primary Peritoneal Cancer which is 
classified as a type of ovarian cancer.” [Lynch 
version] 
- Added explanation about PPC in Surgery 
chapter ‘advantages’ to quantify PPC risk after 
RRSO for Lynch as below 2/100 
- Reworded answer to question “What is my risk 
after…” to say specifically: ‘risk of endometrial, 
ovarian and fallopian tube cancer is effectively 
eliminated‘ and to then include description of 
what PPC is and specify risk of PPC after surgery 
“Could cancer be found during the surgery – this 
is a good explanation (especially if you quantify 
the risk) that should be used elsewhere. However 
it does not explain that even so there is still a 
residual risk from PPC, which often has a genetic 
connection.” [Lynch version] 
- Added explanation about PPC in Surgery 
chapter ‘advantages’ to quantify PPC risk after 
RRSO for Lynch as below 2/100 
- Reworded answer to question “What is my risk 
after…” to say specifically: ‘risk of endometrial, 
ovarian and fallopian tube cancer is effectively 
eliminated‘ and to then include description of 
what PPC is and specify risk of PPC after surgery 
- Because the incidence of cancer during surgery 
or of PPC after surgery is so low there are no 
stats available with exact numbers for Lynch 
“I appreciate that you wish to focus on surgery 
for ovarian cancer but it seems odd to have such 
a lot of information focusing on surgery for one 
type of cancer when others are more relevant to 
these patients and may make the other cancers 
seem less relevant. Although the risk of ovarian 
cancer is raised above the population risk in LS, it 
is in fact significantly lower than the risk of other 
cancers. Given that the management of 
colorectal cancer risk in Lynch Syndrome tends to 
be screening rather than surgery, perhaps this is 
less of a problem for colorectal cancer but I do 
- Added hysterectomy as integral part of the 
RRSO decision for Lynch women by: 
- Changing information in ‘Cancer risk chapter’ to 
mention hysterectomy and link to ‘risk-reducing 
surgery’ section 
- Changing wording in ‘The choice’ to include 
hysterectomy 
- Changing ‘The surgery’ chapter to include 
information about hysterectomy throughout 
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think that equal weight should be given in this 
document to decision-making about a 
hysterectomy.” [Lynch version] 
“The risk for ovarian cancer is still low at age 35 
(your graph is rather misleading as quick glance 
by someone who doesn't understand it may 
suggest that it is higher than it is). For this reason 
I would suggest that you change the scale of the 
graph. You talk about women having an option to 
have surgery at age 35 but I am concerned that 
the risk at this age is not sufficiently raised. This 
tool may lead some young women to go ahead 
with surgery at a younger age than the guidance 
recommends. In addition, BSO at age 35, even if 
a woman has completed her family, means a lot 
of years of HRT which would carry its own risks 
(eg cardiovascular disease).” [Lynch version] 
- Replaced graph in Lynch syndrome version 
completely with pictogram for different 
mutations instead 
- Changed info for under 35s to say: “therefore 
you do not need to make a decision about risk-
reducing surgery right now. The information in 
the rest of this document describes the 
different options and focuses on surgery, 
therefore you may wish to come back to this at 
a later point when it is more relevant to you” 
“You only refer to the uterus and endometrial 
cancer. I think you may need to explain that this 
is often called the ‘womb’ so that women know 
what you are talking about.” 
- Added ‘womb’ to picture of female anatomy in 
cancer risk chapter 
- Added the words uterus/womb throughout text 
“The greatest risk for these women is 
endometrial cancer (particularly for those with 
MSH6 mutations) yet this is only mentioned in 
passing ie you could think about having your 
uterus removed as well. If women read this they 
may decide to go ahead with RRBSO and not 
have a hysterectomy and then have to go back 
for that. The tool really needs to focus on 
gynaecological risk reducing surgery for these 
women rather than just BSO.” [Lynch version] 
- Added hysterectomy as integral part of the 
RRSO decision for Lynch women by: 
- Changing information in ‘Cancer risk chapter’ to 
mention hysterectomy and link to ‘risk-reducing 
surgery’ section 
- Changing wording in ‘The choice’ to include 
hysterectomy 
- Changing ‘The surgery’ chapter to include 
information about hysterectomy throughout 
“You need to be more clear about the fact that, 
although the BC risk is reduced by RRBSO, this is 
not actually increased in Lynch Syndrome.” 
[Lynch version] 
- Changed sentence structure in Surgery section 
advantages to read: “Even though Lynch 
women are not thought to be at higher risk for 
breast cancer, RRSO before the natural 
menopause could also reduce the risk of breast 
cancer” to clarify Lynch does not predispose to 
BC 
“You have not mentioned the symptoms of 
endometrial cancer. This is very important for 
these women.” [Lynch version] 
- Added endometrial cancer symptoms to Lynch 
document ‘other options’ 
“Questions in this chapter: about faulty genes- 
the first question and answer is irrelevant at this 
point (How can I find out whether I have a faulty 
gene).  They have already been tested.” 
- Removed question 
“The second question is relevant but needs the 
tense changing (What is my ovarian cancer risk if 
no faulty gene WAS found). 
In the answer it says ‘they will estimate your risk’ 
– but at this point it will have already been 
assessed unless I am mistaken.” 
- Changed wording of question in Cancer Risk 
chapter to past tense: ‘What is my ovarian 
cancer risk if no faulty gene was found’ 
- Removed sentence ‘They will estimate your 
risk….’ 
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“Questions in this chapter on choice: What if my 
genetic test is negative and I am from a family 
where a faulty gene has been found before – the 
answer here is not as clear as on the previous 
page….  Saying you will probably not have to 
make a choice about risk reduction is very 
unclear.” 
- Reworded sections in Chapter on Cancer risk 
and Choice (Cancer Risk chapter now only about 
risk, i.e. for point 1 risk is low, for point 2 risk 
might still be high; and Choice is about whether 
they still need to make a decision about RRSO, 
i.e. for point 1 no choice needed, for point 2 
might need to make choice) 
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Appendix 7.6 - OvDex booklet prototype II (General version) 
OvDex D2 Oct 2012
©Cardiff University
A decision aid designed to help you 
and your doctor make a decision 
about risk-reducing ovarian surgery
For women at increased risk of ovarian cancer
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Welcome to OvDex
OvDex (The Oophorectomy Decision Explorer) has been developed to help you find 
out more about your options for reducing your ovarian cancer risk. If you are viewing 
OvDex you should have been referred to it by a doctor or geneticist as you are at 
increased risk of ovarian cancer. 
Please note that OvDex can be personalised by answering three questions . You 
should have seen these questions before you opened these pages. If you do wish to 
personalise the information you get, please go back and answer the questions .
The information on the following pages has not been personalised. If you do not wish 
to personalise OvDex then please view the general information on the following 
pages.
Chapter Page
1. Cancer risk............................................................................................. 2
2. The choice.............................................................................................. 6
3. Options at a glance................................................................................ 8
4. Risk-reducing surgery............................................................................. 10
5. The menopause..................................................................................... 14
6. Hormone replacement........................................................................... 17
7. Other options......................................................................................... 20
8. Your decision.......................................................................................... 22
9. Contacts and Resources......................................................................... 27
10. References.............................................................................................. 28
1
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Questions in chapter 1:
Q1 Where does ovarian cancer develop?
Q2 What is the ovarian cancer risk if I have a family history of ovarian cancer?
Q3 How can I find out whether I have a faulty gene?
Q4 What would my risk be if a faulty gene is found?
Q5 What if I cannot get tested or my genetic test is unclear?
Q6 Does my cancer risk change over time?
Q7 How will my ovarian cancer risk affect my life?
Q8 How will my ovarian cancer risk affect my children?
Q9 How can I deal with my cancer risk?
Q1 - Where does ovarian cancer develop?
Q2 - What is the ovarian cancer risk if I have a family history of ovarian cancer?
Ovarian cancer occurs by chance in less than 2 of every 100 women. For women who
have a family history of ovarian, breast and/or bowel cancer and/or a faulty gene, the
risk can be much higher then 2 in 100. Generally the risk is quite low in young women
and rises with age.
Studies have shown that out of 100 women with one first degree relative (mother,
sister or daughter) with ovarian cancer, 5 will develop ovarian cancer themselves at
some point in their life. Women who have 2 or more first (mother, sister or daughter)
and/or second degree (aunt, grandmother etc.) relatives with ovarian cancer have an
even higher chance of developing ovarian cancer themselves of about 7 out of 100.
1. Cancer risk
Less than 2 out of 100 
women in the general 
population get ovarian 
cancer in their lifetime
About 5 out of 100 women 
with a first degree relative 
with ovarian cancer get 
ovarian cancer in their 
lifetime
About 7 out of 100 women 
with two or more relatives 
with ovarian cancer get 
ovarian cancer in their 
lifetime
2
The picture on the left shows the 
female reproductive system. The 
ovaries are connected to the 
uterus by the fallopian tubes. 
Ovarian-type cancer can develop 
in the ovaries, the fallopian tubes 
or the lining of the abdomen 
(called the ‘peritoneum‘). 
Other female cancers, such as 
cancer of the endometrium, 
uterus/womb or cervix, are very 
different and should not be 
confused with ovarian cancer.
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The number of relatives with cancers other than ovarian cancer, such as breast and
bowel cancer, can also affect a woman’s chances of developing ovarian cancer. A
woman’s risk is estimated by genetics services once the full family history is available.
Q3 - How can I find out whether I have a faulty gene?
Some women might come from families where certain types of cancer (e.g. ovarian,
breast, bowel) have affected more than just one or two relatives and these women
might have a faulty gene. To get tested for a faulty gene you will need to be referred
to genetics services (usually by your GP). There your family history of cancer will be
assessed in detail and you will be told whether there might be a faulty gene involved.
Testing for a faulty gene in the family then usually begins with a test on a blood
sample from a person who has had cancer. If you have had cancer yourself you may
be offered a genetic test as the first person in your family. If you have not had cancer
yourself, then a relative who has had cancer will be offered a genetic test first. If a
faulty gene is found, other members of the family can then have a genetic test to see
whether they also have the same gene. If there is no living relative with cancer, or the
relative doesn‘t want to get tested, then it may not be possible to do a genetic test
for you. For sources of more information see chapter 9 (Contacts and Resources),
page 27.
Q4 - What would my risk be if a faulty gene is found?
The most common faulty genes linked to ovarian cancer are called Breast Cancer
(BRCA) genes 1 and 2 and genes common in Lynch Syndrome (formerly known as
Hereditary Non-Polyposis Colorectal Cancer or HNPCC). The lifetime risk of
developing ovarian cancer can be much higher for women who have a faulty gene
compared to the general population.
1. Cancer risk
About 39 out of 100 
women with a BRCA1 
faulty gene get 
ovarian cancer by the 
time they are 70
About 16 out of 100 
women with a BRCA2 
faulty gene get 
ovarian cancer by the 
time they are 70
About 6 to 12 out of 100 
women with Lynch 
Syndomre get ovarian 
cancer by the time they 
are 70
3
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Q5 - What if I cannot get tested or my genetic test is unclear?
For some women it might not be possible to get tested because they have no living
relative with cancer or their relative does not want to be tested. In other cases a
genetic test may come back as ‘unclear’ which means the result is not certain. In this
case the genetics service will estimate the woman’s risk based on her family history.
If you have been told that your family history looks like you might have a faulty gene
and you would like more specific information for people with that gene, you can look
at the information by personalising this aid and selecting the gene that most closely
resembles your family history as you have been told by your genetic counsellor
Q6 - Does my cancer risk change over time?
Yes. Your so-called ‘lifetime’ risk (which is the risk that you will get ovarian cancer at
some point in your life) stays the same over time. However, your ‘age-related’ ovarian
cancer risk (which is the risk that you will get ovarian cancer in a specified time
frame, for example one year or five years) increases with age. This means when you
are young your age-related risk is relatively low and rises when you get older. So for
example, your risk of getting ovarian cancer in the next year when you are 35 is quite
low, whereas your risk of getting ovarian cancer in the next year when you are 50 is
higher.
Q7 - How will my ovarian cancer risk affect my life?
Being at risk for ovarian cancer does not necessarily mean that you will develop
ovarian cancer. However, knowing your risk will give you access to additional medical
services such as genetic counselling and means that you are offered risk-reducing
surgery. Some people may feel worried or anxious after finding out about their risk
and their quality of life may be affected.
Q8 - How will my ovarian cancer risk affect my children?
There is a chance that your children will also have an increased risk of ovarian cancer.
Their risk depends on how high your own risk is and on whether or not you have a
faulty gene. If you have a faulty gene, then your children have a 50/50 chance to
inherit this gene. If they inherited the gene, then their cancer risk would be the same
as yours. If they did not inherit the gene, then their cancer risk would be low. Boys
who inherit the gene are not at risk of ovarian cancer. Please also note that cancer
risk increases with age and therefore children’s risk only starts to rise in later life.
More information about genetics can be found on the NHS choices website (see
Chapter 9 Contacts and Resources, page 27).
You can discuss your children‘s risk with your doctor to find out more. Your doctor
will also be able to advise you about how best to discuss this risk with your children.
1. Cancer risk 4
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Q9 - How can I deal with my cancer risk?
If you would like to find out more about your risk and what it means, you can use the
resources provided in OvDex and talk to your doctor or genetic counsellor.
Knowing that you are at increased risk of cancer might make you feel worried or
angry or frustrated. This is completely normal and there is no need to bottle those
feelings up. It can actually help to talk about them. You can try to find someone you
trust to talk to or if you prefer to talk to someone you don’t know, you can use the
contact details for charities and patient support networks under Contacts &
Resources.
If you have a partner, sharing your thoughts and concerns with your partner can be
useful in helping them understand what you are going through and in helping you
cope together as a couple. It may also help to see a positive side to knowing your risk
status. For example, this means that you will get access to genetics services and have
the chance to do something about your risk. Other women have found it helpful to
stay optimistic, have joined patient networks or have found strength in their faith.
Being at risk of cancer may sometimes lead to unwanted thoughts and worry,
especially at times when there are no active steps you can take, for example when
you are waiting for genetic test results. There are useful techniques you can use to
reduce such thoughts. One such method is active distraction, which means actively
thinking about something else whenever unwanted thoughts pop in your head.
Watch the 'How do I cope' video on the Cancer Genetics Storybank website for a
guide of how to do this.
Relaxation techniques, meditation and guided imagery may also help you deal with
any stress you might experience relating to your cancer risk. Examples include
progressive muscle relaxation and certain breathing exercises. Visit the 'Mind-body
therapy' section on the Macmillan website for more information on and guides to
mind-body therapies.
1. Cancer risk 5
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2. The Choice
Questions in chapter 2:
Q1 What can I do to reduce my risk?
Q2 Why is there a choice?
Q3 Who should decide?
Q4 Who else should I involve in this decision?
Q5 When should I decide?
Q6 How can I decide?
Q7 How can I deal with the choice?
Q1 - What can I do to reduce my risk?
Your doctor has probably discussed with you the option of having risk-reducing
ovarian surgery to reduce your ovarian cancer risk. You will need to decide if and
when to have this surgery. Unfortunately, there is no medically proven screening
available on the NHS for ovarian cancer at the moment.
This decision aid is designed to help you look at your options. Please refer to chapter
3 (Options at a glance) page 8, chapter 4 (Risk-reducing surgery) page 10 and chapter
7 (Other options) page 20 for more information about surgery, screening and other
alternatives.
Q2 - Why is there a choice?
Often when you go to your doctor, there is one clearly recommended treatment.
However, some situations are more complicated. These are situations in which your
personal preferences play an important role. In the case of cancer risk reduction, your
options have very different effects on your life. This means that you need to be clear
about what might happen if you choose one option over the other.
Some health professionals may recommend surgery quite strongly; however you
need to make the final decision and should be aware of the possible benefits and
risks before you do. You should certainly not feel pressured to opt for surgery.
Q3 - Who should decide?
As the best choice for you is based on your preferences, you should be closely
involved in the decision. You can either make the decision on your own or if you do
not wish to make this decision yourself, your doctor can help you. They will
encourage you to think about the options and your preferences, so that the final
choice is right for you. If you then don’t want to choose for yourself, just say so and
your doctor may make a recommendation.
Q4 - Who else should I involve in this decision?
Whether or not you would like to bring anyone else into this decision is your choice.
Often it is helpful to speak to your partner, other members of your family or some
friends who could work through this decision with you. Especially with a decision
about risk-reducing ovarian surgery, the views of your partner can be important, so it
is recommended that you speak to your partner and try to reach a decision together.
Your doctor will also be happy for you to bring your partner along to appointments
and to answer any questions they might have.
6
 
494 
 
 
 
OvDex D2 Oct 2012
©Cardiff University
2. The Choice
Q5 - When should I decide?
The decision you are facing is not an easy one and you should not feel under any
pressure to decide quickly. Risk-reducing surgery has benefits and risks that need to
be weighed carefully, so take your time and make sure you are ready before making a
decision. It is important that you understand that undergoing surgery will mean you
can no longer get pregnant. Therefore it is essential to consider your plans for a
family and any potential future changes to these plans (for example if there is a
chance you might meet a new partner / re-marry) before making a final decision.
Q6 - How can I decide?
When it comes to important decisions everyone is different. Some people like to find
out as much as they can about their options, while others prefer to just know what is
absolutely necessary. Some might find it helpful to talk to their family and friends.
Some might like to speak to people who have made a similar decision. It really
depends on you. Have a think about other important decisions in your life and how
you managed to make those. That could give you an idea of how you like to decide
about things.
Q7 - How can I deal with the choice?
It can be helpful to create a plan of how and when you will make this choice. If you
are not ready to decide right now, it might be useful to set yourself a deadline of
when you will revisit this decision. For example: “Just after my 40th birthday I will
look at this information again.” or “Once I have completed my family I will revisit this
decision.” Once you are ready you can decide how you want to make this choice:
1. I will decide by myself using everything I have learnt
2. I will decide but seriously consider my doctor’s opinion
3. The doctor and I should decide together
4. The doctor should decide but seriously consider my opinion
5. The doctor should decide for me
One constructive way to deal with a difficult decision is to empower yourself with
information. OvDex is designed to help you to learn more about ovarian cancer risk
and your options. With the wealth of information that is available on the internet, it
can be difficult to find reliable and trustworthy information. The information in OvDex
is supported by recent scientific findings and has been carefully reviewed by health
professionals to make sure it is accurate. You should at least understand your options
and their benefits and risks before making a decision. Find out more about the most
important questions to ask at: www.ask3questions.co.uk. Once you have read the
information in OvDex, it could help to make a note of any remaining questions and
take those to your doctor or genetic counsellor for a more detailed discussion.
You may feel that you are not comfortable making decisions about your health. This is
okay. You do not need to make the choice alone if you don’t want to. You can decide
together with your doctor or ask them to make the choice for you. But you need to
remember that you are the expert when it comes to your own life and that only you
know what is important to you. So even if you decide to let the doctor make the
decision for you, make sure they know about your goals and values. Tell them what is
important to you.
7
 
495 
 
 
 
OvDex D2 Oct 2012
©Cardiff University
3. Options at a Glance
Frequently asked questions Surgery to remove ovaries 
and fallopian tubes
No surgery
Will this reduce my ovarian 
cancer risk?
Yes, removing the ovaries and 
fallopian tubes will greatly 
reduce your lifetime risk of 
ovarian-type cancer to less than 
2 in 100.
No, your risk of ovarian 
cancer will remain high.
Will I be able to become 
pregnant?
No. Yes.
Will this change how I feel 
about my risk of ovarian 
cancer? 
You may feel less worried about 
developing ovarian cancer.
You may worry about 
developing ovarian cancer.
Will I go into menopause? Yes, your oestrogen levels fall 
and the menopause will start 
immediately.
No.
What is menopause after 
surgery like?
Menopause after surgery is 
similar to natural menopause, 
but because it happens 
suddenly, the symptoms may be 
more severe. 
Not applicable.
Will this change how I feel 
about myself as a woman?
Many women do not notice any 
change in how they feel about 
themselves as a woman. 
However, your desire for and/or 
enjoyment of sex may decrease a 
lot.
Not applicable.
Are there any risks linked to 
menopause?
Yes, there is a risk of bone 
thinning and cardiovascular 
disease. Some patients report 
memory changes as well.
Not applicable.
Will I need hormone 
replacement therapy (HRT)?
HRT can reduce some of the 
effects of sudden menopause. 
You will need to discuss this 
possibility with your doctor.
Not applicable
Is HRT safe for women at 
increased familial risk?
HRT is safe to take for the 
majority of women until they are 
50. It is not recommended for 
women who have had breast 
cancer themselves already.
Not applicable
What are the risks of surgery? There is a small risk of 
complications depending on the 
type of surgical procedure (key 
hole or open surgery) you have. 
Discuss this with your doctor.
Not applicable.
How long will it take me to 
recover from surgery?
Most women leave the hospital 
the same day or the day after 
key hole surgery and are back to 
normal in 4 weeks. For open 
surgery this is slightly longer.
Not applicable.
Is there a routine screening 
programme to detect ovarian 
cancer?
No, and after surgery there is no 
need for any screening because 
your risk will be low.
No, there is no routine 
screening available on the 
NHS to detect ovarian 
cancer.
8
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3. Options at a Glance 9
Q1 – How can I deal with this decision?
Some women may find it useful to discuss surgery with others, who have already 
made this decision. In some areas your genetic counsellor may be able to put you in 
touch with someone who has already gone through the decision, otherwise you can 
use the contact details for charities and patient support networks under Contacts & 
Resources to read about or get in touch with others in a similar situation. Going over 
the decision with someone who knows you well, such as your partner or a member 
of your family can also help you clarify your decision. If you decide to opt for surgery 
and you are in a relationship, preparing yourself together with your partner for the 
time after surgery can help you both deal better with any consequences of the 
operation. 
Being clear about the reasons why surgery could be the right or wrong thing for you 
can help you make a decision and avoid regretting it later. The information in OvDex 
is designed to help you identify the benefits and the risks of surgery and any other 
options, so you can decide for yourself. The exercise called ‘Your Decision’ (page 22) 
can help you clarify what is most important to you.
Being at risk of cancer may sometimes lead to unwanted thoughts and worry, 
especially at times when there are no active steps you can take, for example if you 
have decided to defer surgery or while you are waiting for you surgery appointment. 
There are useful techniques you can use to reduce such thoughts. One such method 
is active distraction, which means actively thinking about something else whenever 
unwanted thoughts pop in your head. Watch the 'How do I cope' video on the Cancer 
Genetics Storybank website for a guide of how to do this.
Relaxation techniques, meditation and guided imagery may also help you deal with 
any stress you might experience relating to your cancer risk. Examples include 
progressive muscle relaxation and certain breathing exercises. Visit the 'Mind-body 
therapy' section on the Macmillan website for more information on and guides to 
mind-body therapies. 
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4. Risk-reducing Surgery
Questions in chapter 4:
Q1 What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Q2 What are the main advantages of this operation?
Q3 What are the main disadvantages of this operation?
Q4 What is my risk after surgery?
Q5 What does the surgery involve?
Q6 How long does it take to recover?
Q7 Do I need to have my womb removed as well?
Q8 What are the complications of RRSO?
Q9 Could cancer be found during the surgery?
Q10 How would RRSO affect my life?
Q11 How could I deal with RRSO?
Q1 - What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Risk-reducing bilateral salpingo-oophorectomy  (RRSO for short) is surgery to remove 
healthy ovaries and fallopian tubes to reduce the cancer risk. The term ‘bilateral’ 
means that the ovaries and fallopian tubes on both sides of the body are removed.  
The word ‘salpingo-oophorectomy’ means  removal of the fallopian tubes and 
ovaries. The aim of the surgery is to remove these tissues before cancer develops.
Q2 - What are the main advantages of this operation?
1) This operation will reduce your ovarian and fallopian tube cancer risk, as these are 
completely removed during surgery. For women with a faulty BRCA1 gene cancer 
might still develop in the peritoneum, which  is the lining of the pelvis and abdomen. 
This means RRSO will not prevent cancer in about 2 in every 100 women with a 
BRCA1 faulty gene. This risk is about the same as the ovarian cancer risk in the 
general population. Even fewer cancers of the peritoneum have been found in 
women without a faulty BRCA1 gene who have had this surgery, therefore their risk is 
likely to be much lower than 2 in 100 after surgery.
2) For some women, not having to worry about ovarian cancer anymore comes as a 
great relief.
3) For the vast majority of women having RRSO before the natural menopause could 
also reduce the risk of breast cancer.
4) Having the surgery will also prevent other, non-cancer related problems happening 
with the ovaries, such as cysts.
10
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4. Risk-reducing Surgery
Q3 - What are the main disadvantages of this operation?
1) You will no longer be able to become pregnant once you have had surgery, 
therefore it is important that you have considered your plans for a family before 
making a final decision.
2) After the operation you will immediately enter the menopause and may start to 
experience the typical menopausal symptoms, including hot flushes, mood swings, 
night sweats and vaginal dryness (Please see Chapter 5 (The Menopause), page 14 
for more details). Furthermore,  you may be at increased risk of bone thinning, 
cardiovascular (heart & blood vessel) disease and memory changes. These effects 
may be effectively treated with hormone replacement therapy (Please see chapter 
6 (Hormone Replacement), page 17 for more details), however not all women can 
take hormone replacement and this should be discussed before having surgery.
3) Your desire for sex will decrease and due to some menopausal symptoms, such 
as vaginal dryness, you may enjoy sex less as intercourse can be painful.
4) There is a small risk of complications during and after surgery.
Q4 - What is my risk after surgery?
After surgery your risk of ovarian and fallopian tube cancer is greatly reduced,
however, there is a rare type of cancer which may still develop after surgery that is
very similar to ovarian cancer. This is called primary peritoneal cancer and
develops in the lining of the abdomen and pelvis. Your risk of primary peritoneal
cancer depends on whether or not you have a faulty gene. The highest risk for
primary peritoneal cancer is in women with a BRCA1 faulty gene. Their risk is
about 2 in every 100 women, which is similar to the risk of ovarian cancer in the
general population. For women who do not have a BRCA1 faulty gene the risk of
primary peritoneal cancer after surgery is much lower than 2 in 100.
Q5 - What does the surgery involve?
Most often the operation is done as keyhole surgery (laparoscopy). This involves 3
or 4 small (about 1cm) cuts, usually one cut is close to your tummy button and 2-3
just below the bikini line, so they are not visible. Keyhole surgery itself usually
takes less than 2 hours.
In some cases it may not be possible to do keyhole surgery, because of previous
surgery on your tummy or because of your weight. Then surgeons use the more
traditional open surgery. This means a longer cut , usually along the bikini line.
Sometimes a surgeon might have to convert to an open surgery when doing
keyhole surgery because of complications or old scar tissue. This happens in
about 1 of every 100 keyhole operations.
Type of procedure in 100 women who have the operation
The figure on the left shows how many of 100 women will 
have keyhole surgery , open surgery and planned keyhole 
which is converted to open surgery.
94 of 100 women will have planned keyhole surgery (white 
dots). Five of 100 women will have planned open surgery 
(light teal dots). One of 100 women will have planned 
keyhole surgery which is converted to open surgery (dark 
dot).
11
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Q6 - How long does it take to recover?
75 of 100 patients who have keyhole surgery leave the hospital the day after
surgery. They are usually back to normal activity about 4 weeks after surgery. If
you have open surgery you are likely to stay in hospital a bit longer than with
keyhole surgery. Usually patients leave the hospital about 5 days after open
surgery and are back to normal in about 6 weeks. After surgery you are not
allowed to do any heavy lifting for a few weeks. You may also have to refrain from
driving until you can comfortably wear a seatbelt and make an emergency stop
without pain.
Q7 - Do I need to have my womb removed as well?
No, normally it is not necessary that you have your womb removed at the same
time as having RRSO, unless you know that you have Lynch Syndrome or you have
other problems with your womb and have been told by a doctor that removing the
womb would help you with those problems. However, you may chose to have your
womb removed at the time of RRSO, as it may affect the type of hormone
replacement you would be given (see Chapter 6 (Hormone replacement), page
17). You should discuss this with your doctor.
Q8 - What are the complications of RRSO?
There is a small risk of complications linked to RRSO. About 4 in every 100 people
will experience some complication. Minor complications can include wound or
urinary tract infections and usually have no long-term effects on your health. More
serious complications might happen during surgery and can include damage to
blood vessels, the bowel or the bladder. If you are having keyhole surgery this
might mean that the surgeon has to convert to open surgery to repair the damage.
There are a number of other rare complications that might happen and your
surgeon will go through those with you if you wish before you go in for surgery.
Please note that about 96 of every 100 women do not experience any
complications at all.
As with any surgery, there is a very small risk of death. However, this is highly
unlikely. The risk may be greater in women with health problems before surgery.
4. Risk-reducing Surgery
Complications in 100 women who have the operation
The figure on the left shows how many of 100 women 
will experience complications during or after surgery.
4 of 100 women will experience some kind of 
complication either during or after surgery. 96 of 100 
women will not experience any complications.
12
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Q9 - Could cancer be found during the surgery?
Yes, although this is rare. Once your ovaries and fallopian tubes have been
removed they will be checked thoroughly for any signs of cancer. There is a chance
that cancer may be discovered during this check. This happens in up to 4 out of
every 100 operations in the highest risk patients. For others the chance of finding
cancer during the surgery are much lower.
Q10 - How would RRSO affect my life?
In the short-term, if you decide to go for surgery, you will have to take time off
work and will not be able to do some of the things you might usually do, such as
driving or heavy lifting. However most women recover fully within 4 to 6 weeks.
In the longer term there are a number of things you should consider. After surgery
you may feel less worried about ovarian cancer. You will no longer be able to
become pregnant and you will enter the menopause if you have not gone through
it yet (Please see chapter 5 (Surgical menopause), page 14). You may opt to take
hormone replacement (Please see chapter 6 (Hormone replacement), page 17).
These factors may affect your life after surgery and should be considered carefully
before making a decision.
4. Risk-reducing Surgery 13
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Questions in chapter 5:
Q1 What is surgical menopause?
Q2 What is the menopause like?
Q3 How could the menopause affect my life in the short term?
Q4 How long does surgical menopause last?
Q5 Are there any long term health effects linked to surgical menopause?
Q6 Is there anything I can do to reduce the effects of surgical menopause?
Q1 - What is surgical menopause?
Surgical menopause is the menopause you enter when your ovaries are removed by 
surgery and your body no longer produces the female hormone oestrogen. The 
surgical menopause is essentially the same as the natural menopause, it only 
happens earlier and more suddenly. Therefore surgical menopause results in the 
same symptoms as the natural menopause. These symptoms are caused by the lack 
of oestrogen. As oestrogen levels drop suddenly after surgery, the symptoms of 
surgical menopause start instantly and can be more severe than those of the natural 
menopause, in which oestrogen levels fall gradually.
!
5. The Menopause 14
The graph above shows the drop in the levels of the female hormone oestrogen 
during surgical and natural menopause. Potential menopausal symptom duration 
and severty are indicated in shades of grey.
Please note that the information about symptoms of the 
menopause in this chapter describes symptoms experienced by 
women who do not take hormone replacement therapy (HRT). 
Most symptoms of the menopause are reduced by hormone 
replacement therapy (for more information see Chapter 6 
(Hormone Replacement) on page 17).
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Q2 - What is the menopause like?
It is very difficult to describe what the menopause is like, because it is different for 
every person. Some women have no or very few symptoms and cope very well. Other 
women can have very severe symptoms and their quality of life can be affected.
Common menopausal symptoms you may experience are: Hot flushes, night sweats, 
mood swings, vaginal dryness and loss of interest in sex. Other symptoms include 
difficulty sleeping, fatigue, weight gain, changes in memory and depression.
The great majority of women who had surgery report that they experience one or 
more of the common symptoms. However, any data available about menopausal 
symptoms is from small studies and each study uses different ways to assess what 
women experienced, so it is difficult to predict what the menopause will be like for 
you personally. The pictures below show how common different types of symptoms 
are according to one study of women with a family history of ovarian cancer.
Q3 - How could menopause affect my life in the short term?
While none of the menopausal symptoms mentioned above are dangerous for your 
health, they may affect you in different ways. Hot flushes can be very uncomfortable 
and may happen at inconvenient times, for example when you are giving a 
presentation at work. In one study two out of every three women reported having 
hot flushes after surgery. Night sweats can lead to problems with sleep and insomnia. 
Vaginal dryness can lead to pain during sex and therefore you may enjoy sex less. Loss 
of interest in sex, which is also experienced by many women after surgery, may affect 
your relationship with your partner.  In one study just over half of women reported 
that they were not satisfied with their sexual functioning after having surgery and in 
another study one in every three patients felt that vaginal dryness was bothersome 
and reported pain with sex. The way that these symptoms might affect your life 
depends on your personal situation. 
There are several options available to help you deal with the short-term symptoms of 
the menopause. These include physical options, such as lubricant to counteract 
vaginal dryness, or psychological options, such as sex counselling and cognitive 
behavioural therapy to improve emotional and physical functioning. You can get more 
information about these options from your genetics services. The NHS choices 
website also has information about dealing with the menopause (See Chapter 9 
(Contacts & Resources), page 27). 
155. The Menopause
About 72 of 100 women 
experience vasomotor 
symptoms (hot flushes 
and night sweats)
About 92 of 100 women 
experience psychosocial 
symptoms (mood swings, 
feeling depressed or 
down)
About 87 of 100 women 
experience physical and 
sexual symptoms (aching, 
vaginal dryness, loss of 
libido)
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Q4 - How long does the menopause last?
It is impossible to say how long symptoms will last. Some women have hardly any 
problems and symptoms disappear quickly, while others have symptoms for many 
years. It really is different for everyone.
Q5 - Are there any long term health effects linked to the menopause?
Yes. The loss of oestrogen is thought to affect long term health, particularly the bones 
and  the cardiovascular system (heart and blood vessels). In older age this can lead to 
a higher risk of fractures due to bone thinning (osteoporosis) and a higher risk of 
cardiovascular disease (heart disease, stroke). It should be noted that these effects 
are seen in all women after the menopause, whether it was a surgical or natural 
menopause. Your personal risk depends on your lifestyle and personal and family 
history of osteoporosis and cardiovascular disease and should be discussed with your 
doctor.
Due to the sudden lack of oestrogen after surgery, the risk of bone thinning and 
cardiovascular disease may start to rise immediately after surgery. This could be 
before the woman has reached the age of the natural menopause. Therefore, women 
who undergo surgery before the age of 45 are recommended to take hormone 
replacement to reduce these effects until they reach the age of the natural 
menopause (See Chapter 6 (Hormone replacement) page 17). 
Some women also report changes in memory following the menopause, which is 
again due to the lack of oestrogen.
Q6 - Is there anything I can do to reduce the effects of the menopause?
Yes. Hormone replacement therapy (HRT) is usually recommended for women who 
have RRSO before the age of 45 and have not had breast cancer themselves (See 
Chapter 6 (Hormone replacement) page 17). HRT may effectively reduce some of the 
short- and long-term effects of surgical menopause. However, not all women can take 
hormone replacement and this should be discussed before having surgery.
If you do not wish to or cannot take HRT then you can take dietary supplements to 
reduce bone thinning. You should speak to your doctor about this. In some regions in 
the UK patients are also recommended to have a bone density scan about 18 months 
after their operation. You can discuss this with your doctor.
An active lifestyle and healthy diet is also recommended.
165. The Menopause
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6. Hormone Replacement
Questions in chapter 6:
Q1 What is Hormone Replacement Therapy (HRT)?
Q2 Why is HRT important?
Q3 Who should take HRT?
Q4 How long should I take HRT?
Q5 Can I take HRT if I have a family history of breast cancer?
Q6 But I have heard that HRT increases breast cancer risk?
Q7 Will HRT reduce all the symptoms of menopause?
Q8 Will HRT deal with the long term health effects of the menopause?
Q9 Are there any alternatives to HRT?
Q1 - What is Hormone Replacement Therapy (HRT)?
Hormone Replacement Therapy, or HRT for short, is a medical treatment that puts 
back the female hormones that are lost when the ovaries are removed or when they 
stop functioning. 
There are a number of ways that HRT can be used:
- It can be taken as oral tablets usually once  a day
- It can be applied as patches that are put on the tummy or bottom about once or 
twice a week
- It can be applied as a gel directly to the skin once a day (for example the lower 
abdomen or inner thigh)
There are two types of hormone replacement, one includes oestrogen and 
progesterone and the other includes oestrogen only. Women who only have their 
ovaries removed will usually be given oestrogen and progesterone HRT, while women 
who have their womb/uterus and ovaries removed (RRSO plus hysterectomy) are 
usually given oestrogen only HRT. 
17
The graph above shows the oestrogen levels after surgical and natural 
menopause. It also shows the effect of HRT on the oestrogen levels after 
the operation if surgery was performed before the natural menopause.
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6. Hormone Replacement
Q2 - Why is HRT important?
There are two main reasons why HRT is recommended after surgery:
1. To reduce the risk of bone thinning
2. To reduce symptoms of the menopause
Q3 - Who should take HRT?
HRT is strongly recommended for women who have surgery before they are 45 years 
of age, as this group is most affected by the long term health issues that are linked to 
loss of oestrogen, especially bone thinning (osteoporosis).
Women who have surgery when they are over 45 years of age can choose to have 
HRT to reduce the symptoms of surgical menopause. However these women do not 
have to have HRT if they do not want to, as the long term health effects of early loss 
of oestrogen do not affect them, as their oestrogen levels would have started to fall 
anyway.
It is impotant that the possibility of HRT is discussed before you decide about surgery.
Q4 - How long should I take HRT?
If you use HRT, it is recommended that you take it until the age of the natural 
menopause, which is 50 years in the UK. From the age of 50 your oestrogen levels 
would have declined naturally, so taking HRT for many years beyond 50 is not 
recommended. This is because there is controversial evidence about the benefits and 
risks of HRT if it is taken beyond the age of natural menopause. Therefore the health 
effects are unclear and HRT may cause more harm than good if taken beyond 50.
Q5 - Can I take HRT if I have a family history of breast cancer?
Yes. You should be able to take HRT even if you have a family history of breast cancer. 
Several studies have shown that HRT is safe to take for the vast majority of women 
with a family history of breast cancer as long as they have not had breast cancer 
themselves and they only use HRT until the age of the natural menopause. You 
should discuss your family history of breast cancer with your genetics service before 
deciding to have surgery.
Q6 - But I have heard that HRT increases breast cancer risk?
Yes, HRT contains oestrogen and there is some evidence that higher amounts of 
oestrogen in the body can increase the risk of breast cancer. However, the study that 
showed that HRT increases breast cancer risk was done with older women who had 
already gone through the natural menopause and were taking HRT beyond 50 years 
of age. Therefore these women were taking oestrogen when their body has naturally 
stopped producing this hormone. Furthermore, these women did not have surgery to 
have their ovaries removed. Therefore this group of women is very different to 
women with a family history who choose to have their ovaries out before they are 50 
years. Furthermore you should be aware that the findings of this study have now 
been widely critized.
Having your ovaries out removes all the natural oestrogen that your ovaries would 
been producing until the age of the natural menopause. The amount of oestrogen 
that is added back by taking HRT is less than the amount your ovaries would have 
produced naturally. If you stop taking HRT at the age of the natural menopause (so 
when you are 50) then there is no evidence that the breast cancer risk is increased.
18
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6. Hormone Replacement
Q7 - Will HRT reduce all the symptoms of menopause?
No. Taking HRT is not the same as having your own hormones. HRT cannot reduce all 
symptoms of the menopause and women who have had surgery and are on HRT do 
report more symptoms than women who have not had surgery. However, HRT can 
relieve some of the symptoms of the menopause. For example, women who took 
HRT reduced the average number of hot flushes from about 4 to about 1 per day 
when compared to women who did not take HRT. Women on HRT also had fewer 
night sweats. 
Q8 - Will HRT deal with the long term health effects of the menopause?
Yes. HRT will recude the risk of bone thinning and changes in memory functioning 
linked to the loss of oestrogen. However, the evidence of HRT‘s effects on 
cardiovascular disease (heart disease and stroke) is more controversial and should be 
discussed with your doctor in terms of your personal and family history of 
cardiovascular disease as well as your lifestyle, which can also affect your risk of 
cardiovascular disease.
Q9 - Are there any alternatives to HRT?
Yes. There are numerous non-hormonal alternatives to HRT, none of which have been 
shown to be as effective in relieving menopausal symptoms. For people who cannot 
take HRT these alternatives may be a good option but for those who can, HRT is the 
best option. 
Alternatives include:
- Antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs)
- Gabapentin
- Red Clover
- Ginseng
- Evening primrose oil
- Agnus Castus
- And many more
Some of these options may be prescribed by your doctor, while others can be bought 
in health shops or over the internet. However, there is no medical proof that freely 
available herbal options work. These alternatives to HRT may have side-effects and 
you should always consult your doctor before deciding to use any of these options.
19
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7. Other Options
Questions in chapter 7:
Q1 Is there any screening available for ovarian cancer?
Q2 What is the alternative to surgery?
Q3 But I have been offered CA125 blood tests and/or trans-vaginal scans?
Q4 What would happen if I do not have surgery?
Q5 Is there anything else I can do?
Q1 - Is there any screening available for ovarian cancer?
No. Unfortunately there is no medically proven screening available for ovarian cancer. 
A large trial of ovarian cancer screening finished in December 2011 and the results 
will not be available until 2013, so we do not yet know whether this screening is 
effective and can detect ovarian cancer early. Until the results of the trial are available 
the NHS will not offer routine screening. The trial offered women CA125 blood tests 
every four months and one yearly trans-vaginal ultrasound scan. Some areas or GPs 
may offer private, self-funded CA125 and/or trans-vaginal screening to high risk 
women, however women need to be aware that there is still no proof that this 
screening is effective in detecting ovarian cancer early. You should also be aware that 
the yearly smear test you receive is designed to detect cervical cancer and will not 
detect ovarian cancer.
Women from families with Lynch syndrome may receive trans-vaginal ultrasound 
screening to look for womb cancer. The ovaries may be visible on these scans and if 
something is found the GP may order a CA125 blood test. In this case the CA125 
blood test is a diagnostic test and not a screening test. 
Any woman with symptoms of ovarian cancer will be offered a diagnostic CA125 test 
and trans-vaginal ultrasound scan, however this is not part of a screening 
programme. Women with no symptoms will not be offered routine screening on the 
NHS until the screening has been shown to be effective.
Q2 - What is the alternative to surgery?
At the moment the official alternative to surgery is to do nothing and simply be aware 
of the symptoms of ovarian cancer should they develop. However it is important to 
realise that these symptoms can be very vague and are not specific to ovarian cancer. 
If any of these symptoms happen more than 12 times a month you should contact 
your GP.
The symptoms include: 
Persistent bloating (big or swollen tummy)
Feeling less hungry or feeling full quickly
Persistent pain in your tummy or below
Needing to urinate more than usual
20
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7. Other Options
Q3 – But I have been offered CA125 blood tests and/or trans-vaginal scans?
Some centres and/or GPs may offer private CA125 tests or trans-vaginal scans to 
women at high risk of ovarian cancer. As these are not offered as screening tests by 
the NHS you may have to pay for these yourself. You can choose to have these tests 
done, but you should be aware that there is no evidence that these screening tests 
are effective at detecting ovarian cancer early.
Women from Lynch syndrome families, may be offered hysteroscopies or trans-
vaginal ultrasound scans to detect uterus/womb cancer, which these women are at 
higher risk for. However usually these tests are designed to detect womb cancer only 
and not ovarian cancer.
Q4 - What would happen if I do not have surgery?
If you decide not to have surgery, then nothing will really change. You will need to 
look out for any symptoms and if you think anything is wrong you need to go to your 
GP to get it checked. Make sure you tell your GP that you have a family history of 
ovarian cancer and are at increased risk when you talk to them.
Remember you can reconsider surgery at any time. 
Q5 - Is there anything else I can do?
As there is no routine screening available, you can choose to have screening privately, 
but you should be aware that this has not yet been shown to be effective. You should 
also keep an eye on any symptoms. Studies have found that a healthy diet with plenty 
of fruit and vegetables, keeping a healthy weight and an active lifestyle can improve 
overall well-being and might reduce your chances of getting cancer.
In some countries it is recommended that women at high risk of ovarian cancer take 
the oral contraceptive pill when they are pre-menopausal. The oral contraceptive pill 
reduces ovarian cancer risk by up to half, but it has also been found to increase breast 
cancer risk slightly. For women at high risk the reduction in ovarian cancer risk is 
thought to outweigh the slight increase in breast cancer risk. Whether the oral 
contraceptive pill might be an option for you depends on your risk and family history 
of breast cancer and should be discussed with your doctor.
21
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8. Your Decision (Example) 22
Makes me want 
to have surgery
Makes me want to 
avoid surgery
Does not 
come into 
my decision
…surgery will reduce my 
ovarian cancer risk
…surgery will reduce my breast 
cancer risk
I might enjoy sex less after 
surgery
…I will not be able to become 
pregnant after surgery
I will go into surgical 
menopause after surgery
There is no effective screening 
for ovarian cancer
The symptoms of ovarian 
cancer are very vague
I might feel different about my 
body after surgery
Enter you own reasons:
The fact that…
Add together the numbers in 
each column:
In the exercise on the next few pages you can rate some facts depending on how 
much they make you want to have or want to avoid surgery.  Give each fact a 
ranking number (e.g. from 1 (a little) to 3 (a lot), then add the numbers up to see 
where you stand.
The table below is already filled in to give you an example. On page 24 you will find 
an empty table for you to fill in.
X
3
2
3
2
1
2
1
Have to take time off 
work 1
78
 
510 
 
 
 
OvDex D2 Oct 2012
©Cardiff University
8. Your Decision (Example) 23
Below you can enter the overall number into the scales. Then note down how you 
feel about the decision and where you stand.
The scales below are already filled in to give you an example. On page 25 you will 
find an empty scale for you to fill in.
For Surgery Against Surgery
8 7
Next steps: I will make an appointment with my genetic 
counsellor to discuss the menopause and find out 
whether I can take HRT. 
Will talk to my boss about taking time off and 
whether it would cause any problems.
Overall your answers show that at this moment in time you are leaning towards having the
surgery. Even though you may have some reasons why you would want to avoid surgery,
they are not as important to you as the reasons that make you want surgery. Therefore you
could now make an appointment to discuss this decision with your doctor and go through
any concerns you might have.
Overall your answers show that at this moment you are completely undecided about
whether or not to have surgery. Your reasons for why you would want to have and why
you would want to avoid surgery balance each other out. Therefore you may want to
discuss your options further with your doctor/genetic counsellor.
Overall your answers show that at this moment in time you are leaning towards not having
surgery. Even though you may have some reasons why you would want to have surgery,
they are not as important to you as the reasons that make you want to avoid surgery.
Therefore at this moment in time surgery is probably not the right option. However, keep
in mind that things may change over time and that eventually you may lean more towards
surgery. You can come back to OvDex and do this exercise again in a years time to see
whether anything has changed.
Overall decision: My reasons for surgery weigh more than those 
against surgery, but I am still not sure. The 
numbers are very similar.
More weight for than against surgery:
Same weights both sides:
More weight against than for surgery:
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8. Your Decision 24
Makes me want 
to have surgery
Makes me want to 
avoid surgery
Does not 
come into 
my decision
…surgery will reduce my 
ovarian cancer risk
…surgery will reduce my breast 
cancer risk
I might enjoy sex less after 
surgery
…I will not be able to become 
pregnant after surgery
I will go into surgical 
menopause after surgery
There is no effective screening 
for ovarian cancer
The symptoms of ovarian 
cancer are very vague
I might feel different about my 
body after surgery
Enter you own reasons:
The fact that…
Add together the numbers in 
each column:
In the exercise on the next few pages you can rate some facts depending on how 
much they make you want to have or want to avoid surgery.  Give each fact a 
ranking number (e.g. from 1 (a little) to 3 (a lot), then add the numbers up to see 
where you stand.
Make sure you give the score on the correct side of the table.
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8. Your Decision 25
Below you can enter the overall number into the scales. Then note down how you 
feel about the decision and where you stand.
For Surgery Against Surgery
Overall your answers show that at this moment in time you are leaning towards having the
surgery. Even though you may have some reasons why you would want to avoid surgery,
they are not as important to you as the reasons that make you want surgery. Therefore you
could now make an appointment to discuss this decision with your doctor and go through
any concerns you might have.
Overall your answers show that at this moment you are completely undecided about
whether or not to have surgery. Your reasons for why you would want to have and why
you would want to avoid surgery balance each other out. Therefore you may want to
discuss your options further with your doctor/genetic counsellor.
Overall your answers show that at this moment in time you are leaning towards not having
surgery. Even though you may have some reasons why you would want to have surgery,
they are not as important to you as the reasons that make you want to avoid surgery.
Therefore at this moment in time surgery is probably not the right option. However, keep
in mind that things may change over time and that eventually you may lean more towards
surgery. You can come back to OvDex and do this exercise again in a years time to see
whether anything has changed.
More weight for than against surgery:
Same weights both sides:
More weight against than for surgery:
Next steps:
Overall decision:
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8. Your Decision 26
Q1 – How can I deal with my decision?
If you are considering surgery, it can help to think about the support you do have and 
how different people might be able to help you. This can include simple things such 
as driving you to and from the hospital, helping you out with household chores or 
childcare issues right after surgery. 
Before committing fully to surgery you can discuss any further questions with your 
doctor or genetic counsellor and you can also seek a second professional opinion at 
any time if you wish.
If you decide not to have surgery it might be helpful speak to your GP and let them 
know about your risk. Some women also find it reassuring to have an action plan in 
case they feel like any symptoms develop. This can be a simple reminder, such as a 
plan to contact your doctor if symptoms last 2 weeks or longer.
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9. Contacts and Resources
Here are some links and contact details that you might find helpful (even though we 
have taken great care in choosing websites from reliable sources please note we are 
not responsible for the content of these websites):
The Cancer Genetics Story Bank – An online collection of stories told by patients and 
professionals about cancer genetics, developed by the Cancer Genetics Service for 
Wales (CGSW) 
www.cancergeneticsstorybank.co.uk 
Macmillan –A UK charity for anyone affected by cancer with good information about 
genetic testing for cancer and mind-body therapies
www.macmillan.org.uk or call the support line on 0808 808 00 00
NHS Choices – A website created by the NHS to provide information to patients. 
Includes information on ovarian cancer and genetics.
www.nhs.uk
Target Ovarian Cancer – A UK charity which supports research into ovarian cancer 
and provides useful information including an ‘Ask the Expert‘ feature. Available in 
several languages.
www.targetovariancancer.org.uk 
Ovacome – A UK charity providing information and support for everyone affected by 
ovarian cancer. Includes links to a number of patient blogs. 
www.ovacome.org.uk or call the supportline on 08453710554
Your GP and/or Genetics Service – There to help you with any questions or concerns. 
27
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10. Research Evidence 28
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10. Research Evidence 29
Evidence for menopause and symptoms
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Evidence for other options
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Appendix 7.7 - Actions in response to suggestions for improvements – Round 2 
Suggestions for improvements Exact action taken / Decision 
PATIENTS 
I thought it was not quite so helpful in the 
'negative genetic test, but the first one in the 
family to be tested' section (which is my 
personal situation). I thought that the comment 
about coming back when you'd got more 
information about the risk from your doctor 
might be unrealistic as you don't always get 
much more information that could be brought 
back to the tool. In practice, it might be good to 
refer to a discussion with a genetic counsellor as 
I found mine to be far more knowledgeable and 
helpful than any of the doctors!  
- Changed wording to: “You can come back to 
this website once you have had a discussion 
with your genetic counsellor about your risk 
and about whether risk-reducing surgery is still 
something you might want to consider.” 
I thought that the initial surgery/no surgery 
section was rather weighted for surgery. There 
could have been a mention of the possibility of 
privately funded screening at this point. 
- Added statements in the ‘no surgery’ column 
of the Option Grid to visually balance it more 
- Decided not to add information about 
screening as it is not medically proven nor 
recommended 
The other place I did not find it helpful was the 
assumption that everyone has a partner. Not 
only was this unhelpful, it is also extremely 
irritating. Many women on their own find the 
'Noah's Ark Mentality' tedious to say the least. 
- Checked all docs that mentioned the word 
‘partner’ and ensured that there is never an 
assumption that there is a partner (always ‘if’ 
statement) 
- In menopause docs reworded entire section: 
“Vaginal dryness can lead to pain during sex 
and therefore you may enjoy sex less. 
Additionally, many women also experience a 
loss of interest in sex after surgery. In one 
study just over half of women reported that 
they were not satisfied with their sexual 
functioning after having surgery and in another 
study one in every three patients felt that 
vaginal dryness was bothersome and reported 
pain with sex. If you are in a relationship, these 
factors may affect your relationship with your 
partner.” Moved ref to partner to the end and 
added an ‘if’ statement. 
- In the choice changed wording to: “Whether or 
not you would like to bring anyone else into 
this decision is your choice. Often it is helpful 
to speak to someone who knows you well, 
such as a partner, other members of your 
family or a friend, who could work through this 
decision with you. If you are in a relationship 
the views of your partner can be important, 
especially in the context of risk-reducing 
ovarian surgery, so it is recommended that you 
speak to your partner and try to reach a 
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decision together.” To reduce the emphasis on 
partner 
I'm not sure if this is the place for it, but in 
practice it will be somewhere people might 
want to find it, but what about including some 
information about genetic testing? This is likely 
to be an issue for many women using this tool 
so information might be useful. I know that you 
have signed to Macmillan for this, but sadly they 
do take a much more patronising tone than this 
tool takes. 
- Genetic testing really is beyond the scope of 
this decision aid, however I re-arranged the 
contacts&resouces and added that CGSW story 
bank and NHS choices also have info about 
genetic testing, so that people do not only 
refer to Macmillan 
I'm still not totally convinced by the name, but I 
do appreciate the reasons for it! 
- No action taken 
the start of the text on the left hand side was 
missing all the way through 
- Browser issue fixed 
will the final format have scales, thus making 
the weighing up very evident? 
- Yes balance fixed 
I indicated that I had had breast cancer, I found 
a lot of the information on HRT irrelevant to me 
(I was ER+) 
- Shortened section about ‘What is HRT’ to 
remove types of HRT and modes of delivery 
info 
- As personalisation question 2 only asks about 
breast cancer (and not breast cancer type) a 
little information about HRT should be 
included, in case that breast cancer was ER 
negative…  
- Even ER+ women might be able to take HRT if 
their quality of life is seriously affected after 
surgery, so this needs to be mentioned 
Mentions Lynch Syndrome a lot, which does not 
apply to me 
- Removed all references to Lynch in ‘Other 
options’ websites for BRCA women 
(Other_options 2-13) 
Graph on page 10 was conflicting in that it 
talked about BRCA2 gene but had BRCA1 gene 
notated on the side (Possibly printing error?) 
- Checked and correct in online version 
- Corrected in print version 
Just wondered whether there was any 
information on the benefits of Zoladex 
injections to stop the ovaries working? I had 
them during my chemo in 2005 and again more 
recently due to ‘irratic ovaries’ picked up on 
several scans. 
- Discussed with expert – Zoladex is not offered 
to women at risk as a standard treatment. No 
information included 
As a lot of women would naturally go through 
the menopause at approx 45 anyway, I just 
wanted to know if the menopausal symptoms 
were the same? Since I would go through the 
menopause anyway it makes the decision to 
have my ovaries removed much easier. 
- Checked and stated clearly menopause is 
happening at 50, however it also says levels 
start to fall around 45 (without symptoms), but 
as this is true it should be included 
- Checked and it is clearly stated in ‘What is a 
surgical menopause’ that the symptoms are 
the same 
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Suggestions for improvements Exact action taken / Decision 
PROFESSIONALS 
Lynch Syndrome (in section on cancer risk in 
general / unknown) – have a look whether 
‘syndrome’ is spelt wrong anywhere 
- Checked but haven’t found miss-spelling 
Add an explanation of what the dotted lines are 
for Lynch women cancer risk in the general 
version 
- Added (striped dots indicate the range of 
cancer risk from 6 to 12 per 100) below 
pictogram 
- In General and all unclear websites 
If you have been told that your family history 
looks like you might have a faulty gene and you 
would like more specific information for people 
with that gene, you can look at the information 
by personalising this aid and selecting the gene 
that most closely resembles your family history 
as you have been told by your genetic 
counsellor. Add sth here to make it clearer what 
is meant e.g. example of  BRCA 
- Added “For example, if you have been told 
your family history suggests you might have a 
BRCA1 gene, personalise OvDex by answering 
the first question with "Yes, I have a faulty 
BRCA1 gene". to this section 
- If you have been told that your family history 
suggests you might have a faulty gene and you 
would like more specific information, you can 
personalise this aid by selecting the gene that 
most closely resembles your family history 
according to your genetic counsellor. 
- In General and all unclear websites 
How can I deal with my cancer risk? Change 
question to how can I change how I feel about 
my cancer risk. 
- Changed title of question to “How can I change 
how I feel about my cancer risk?” 
- Changed question in question index list 
- In all cancer risk websites 
When should I decide? Is there an age limit, 
what’s the best point in time with the best 
impact 
- Added statement “The operation is most 
effective if it is done at 40 years of age, but this 
may not be ideal for everyone. So, even if you 
decide not to have it at 40, the operation will 
still decrease your ovarian cancer risk if 
performed after that age.” Based on evidence 
from Kurian paper 
- In all websites (used past tense for postmeno 
sites) 
Complications in 100 women who have the 
operation pictogram Put dots at the top 
- Changed pictograms for “type of surgery” and 
“surgical complications”, so coloured dots are 
at the top 
Menopause warning change colour - Changed colour to light teal in CSS file 
On the generalise page it says you should have 
seen these questions (ie personalised) before 
you opened this page (but I hadn't) 
- Changed wording to “You should been given 
the option to personalise the decision aid 
before viewing this page. If you wish to 
personalise OvDex now, please Personalise 
OvDex.” 
- In General_home only 
On the Personalised page - the fourth option - 
appears to be missing something/error - 
says....faulty gene or my genetic test 
- Added “my genetic test was uninformative” 
On How will my risk affect children.... it says 
boys who inherit the gene are not at risk of 
ovarian caner (but does not say that they may 
- Added statement to say that they can carry the 
gene and pass in on to their children and may 
be at risk for other cancer: “Boys who inherit 
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however pass on the gene to their children) the faulty gene are not at risk of ovarian 
cancer, but may be at risk for other cancers. 
Boys who inherit the faulty gene may also pass 
it on to their children.” 
- In all websites 
Under main disadvantages of the operation - 
under sex can be painful - is it worth including 
the disclaimer on the menopause page, which 
gives some reassurance that help is at hand. 
Otherwise it is a very negative list! 
- Added additional short statement that 
hormone replacement can counteract this: 
“Your desire for sex will decrease and due to 
some menopausal symptoms, such as vaginal 
dryness, you may enjoy sex less as intercourse 
can be painful. Again, hormone replacement 
may counteract these effects.” 
- In all pre-meno websites 
Under alternatives to surgery, I suggest the 
symptoms are those used by NICE 
www.nice.org.uk/cg122 
- Added NICE guidance to references in Research 
evidence 
The Choice Section: When should I decide? ‘It is 
important that you understand that undergoing 
surgery will mean you can no longer get 
pregnant.’ I think it would be helpful to remind 
here that this is in relation to having your 
ovaries removed. ‘It is important that you 
understand that undergoing surgery to remove 
your ovaries will mean you can no longer get 
pregnant.’ 
- Changes wording to resemble suggestion: “It is 
important that you understand that 
undergoing surgery will mean you can no 
longer get pregnant.” 
- In all premeno documents 
You refer to “navigation menu”. Nothing is 
called that, and although I guessed what is 
meant by it I wonder if it needs to be identified 
as such? The counter argument is that anybody 
using a computer might be assumed to have a 
pretty good idea of what is meant by it anyway? 
- Changed by deleting “navigation” and just 
leaving ‘menu’ 
- In all websites 
I have to admit one of the things I don’t like is 
the “gynae” diagram – it may be because I am 
medical, or because I am male, but I don’t think 
so!! The shape and size is all wrong, it is 
dominated by the uterus and the cervix is wide 
open, and the vagina ridiculously short. You are 
just NOT shaped like that!? But I am prepared to 
admit that exact anatomical detail is not the 
main point, and if it is MORE helpful for women 
then disregard my comment. Although I have 
just asked one of the secretaries to look at it and 
she said it looks like a “cows head”!! But she 
also wasn’t bothered about anatomical detail as 
I would expect. 
- Drew new diagram with larger and longer 
vagina, smaller uterus and closed cervix 
 “How will my cancer risk affect my life? Being at 
risk for ovarian cancer does not necessarily 
mean that you will develop ovarian cancer. 
However, knowing your risk will give you access 
to additional medical services such as genetic 
counselling and means that you are offered risk-
- Changed wording to “may be offered” 
- In all websites 
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reducing surgery. Some people may feel worried 
or anxious after finding out about their risk and 
their quality of life may be affected” I think it 
preferable to say you may or might be offered 
risk-reducing surgery than that you are. Because 
they might not be offered it, and then wonder 
why they weren’t 
How will my cancer risk affect my children? 
There is a chance that your children will also 
have an increased risk of ovarian cancer [I would 
favour being less specific, and using BRCA1 
related cancers, because boys are not at risk of 
ovarian cancer]. As you have a faulty BRCA1 
gene, your children have a 50/50 chance to 
inherit this gene 
- Changed wording to just “cancer” in first 
sentence 
- In all websites 
- Took out “ovarian” in the question title and the 
question list at top of page 
- In General, Unclear and Lynch sites (BRCA 
already had only ‘cancer’) 
helpful to stay optimistic,have joined patient 
networks space or have found strength in their 
- Checked and added space in all BRCA websites 
(other sites were fine) 
Why is there a choice?  Often when you go to 
your doctor, there is one clearly recommended 
treatment. However, some situations are more 
complicated. These are situations in which your 
personal preferences play an important role. In 
the case of cancer risk reduction, your options 
have very different effects on your life. This 
means that you need to be clear about what 
might happen if you choose one option over the 
other. Some health professionals may 
recommend surgery quite strongly; however 
you need to make the final decision and should 
be aware of the possible benefits and risks 
before you do. You should certainly not feel 
pressured to opt for surgery. 
This paragraph seems to imply that women’s 
choices are going to be based mainly on 
factually balancing the risks. But a lot of their 
decisions will be based on personal experience, 
personal preference, and personal feelings. 
- Changed section to read: “Often when you go 
to your doctor, there is one clearly 
recommended treatment. However, some 
situations are more complicated. These are 
situations in which your personal preferences 
and feelings play an important role. In the case 
of cancer risk reduction, your options have 
very different effects on your life. This means 
that you need to be clear about what might 
happen if you choose one option over the 
other and how that would impact on your life. 
Some health professionals may recommend 
surgery quite strongly; however you need to 
make the final decision and before you do, you 
should consider the possible benefits and risks, 
how these might affect your life and how you 
feel about them.” 
- In all websites 
In some cases it may not be possible to do 
keyhole surgery, because of previous surgery on 
your tummy or because of your weight. Then 
surgeons use the more traditional open surgery. 
This means a longer cut , usually along the bikini 
line. Sometimes a surgeon might have to 
convert to an open surgery (operation) when 
doing keyhole surgery because of complications 
or old scar tissue. This happens in about 1 of 
every 100 keyhole operations 
- Reviewed the use of the words ‘surgery’ and 
‘operation’ and made changes: 
- In General, Unclear and BRCA websites: 
“Sometimes a surgeon might have to convert 
to an open operation when doing keyhole 
surgery because of complications or old scar 
tissue.” 
- In Lynch websites: “RRH plus RRSO can be 
done as laparoscopic (keyhole), vaginal or 
abdominal surgery. The type of surgery you 
will be offered depends on your personal 
medical history. Most often the operation is 
done as keyhole surgery (laparoscopic 
hysterectomy plus RRSO). This involves 3 or 4 
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small (about 1cm) cuts. Usually one cut is close 
to your belly button and 2-3 just below the 
bikini line, so they are not visible. This 
operation can take about an hour and a half. 
During vaginal hysterectomy plus RRSO, 
surgical instruments are inserted through the 
vagina, so that no cut is needed for the 
instruments. The uterus and cervix are then 
removed through a cut just above the vagina. 
This operation takes less than an hour. 
Abdominal hysterectomy plus RRSO is an 
'open' operation and involves a cut (several 
inches) in the tummy, either horizontally just 
above the bikini line or vertically from your 
belly button down to the bikini line. This 
operation takes less than an hour.” 
What is a surgical menopause? A surgical 
menopause is the a menopause you enter when 
your ovaries are removed by surgery and your 
body no longer produces the female hormone 
oestrogen. The A surgical menopause is 
essentially the same as the natural menopause, 
it only happens earlier and more suddenly. 
Therefore a surgical menopause results in the 
same symptoms as the natural menopause. 
These symptoms are caused by the lack of 
oestrogen. As oestrogen levels drop suddenly 
after surgery, the symptoms of a surgical 
menopause start instantly and can be more 
severe than those of the natural menopause, in 
which oestrogen levels fall gradually 
- Made changes in all menopause websites: 
“What is a surgical menopause? A surgical 
menopause is a menopause you enter when 
your ovaries are removed by surgery and your 
body no longer produces the female hormone 
oestrogen. A surgical menopause is essentially 
the same as a natural menopause, it only 
happens earlier and more suddenly. Therefore 
a surgical menopause results in the same 
symptoms as a natural menopause. These 
symptoms are caused by the lack of oestrogen. 
As oestrogen levels drop suddenly after 
surgery, the symptoms of a surgical 
menopause start instantly and can be more 
severe than those of a natural menopause, in 
which oestrogen levels fall gradually.” 
The great majority of women who had surgery 
report that they  - “had surgery reported” or 
“have surgery report” 
- Changed tense to: “The great majority of 
women who had surgery reported that they 
experienced one or more…” 
- In all pre-meno websites 
There are several options available to help you 
deal with the short-term symptoms of the 
menopause. These include physical options, 
such as lubricant to counteract vaginal dryness, 
or psychological options, such as sex counselling 
and cognitive behavioural therapy to improve 
emotional and physical functioning. You can get 
more information about these options from 
your genetics services. I think it would be better 
to state from your doctor or gynaecologist. This 
did raise an eyebrow from the GCs. 
- Made change and referred to doctor or 
gynaecologist. 
- In all pre-meno websites 
Are there any long term health effects linked to 
the menopause? ……..Therefore, women who 
undergo surgery before the age of 45 are usually 
recommended to take hormone replacement to 
- Added the word ‘usually’ to sentence as 
proposed  
- In all pre-meno websites 
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reduce these effects 
Women who have surgery when they are over 
45 years of age can choose to have HRT to 
reduce the symptoms of surgical menopause. 
However these women do not have to have HRT 
if they do not want to, as the long term health 
effects of early loss of oestrogen do not affect 
them as much as a women having surgery 
before 45, as their oestrogen levels would have 
started to fall. It is important that the possibility 
of HRT is discussed before you decide making a 
decision about surgery 
- Made changes: “Women who have surgery 
when they are over 45 years of age can choose 
to have HRT to reduce the symptoms of 
surgical menopause. However these women do 
not have to have HRT if they do not want to, as 
the long term health effects of early loss of 
oestrogen do not affect them as much as a 
women having surgery before 45, because 
their oestrogen levels would have started to 
fall anyway. It is important that the possibility 
of HRT is discussed before making a decision 
about surgery.” 
- In all hormone replacement (noBC) 
Can I take HRT if I have a family history of breast 
cancer? – please can we discuss. I’m not 
disagreeing but just trying to think of our advice 
outside of BRCA1/2 families. 
- Discussed with expert and decided that section 
should remain as it is 
Yes. HRT will recude reduce the risk - Corrected spelling mistake 
- In all hormone replacement (noBC) 
Is there any screening available for ovarian 
cancer? Any woman with symptoms of ovarian 
cancer will is likely to be offered a diagnostic… 
- Made change to ‘is likely to’ 
- In all websites 
If any of these symptoms happen more than 12 
times  - where did the “12 times” come from – 
surely not the NHS website? 
- No action 
What would happen if I do not have surgery? 
  Make sure you tell your GP that you have a 
family history of ovarian cancer and are at 
increased risk  - this paragraph came up when I 
was in as a patient with a personal hx of BRCA1. 
I might not have a FHx of ovarian cancer. So may 
be   Make sure you tell your GP that you have a 
family history of cancer and are at increased risk 
of ovarian cancer.   
- Changed wording to “If you decide not to have 
surgery, then nothing will really change. You 
will need to look out for any symptoms and if 
you think anything is wrong you need to go to 
your GP to get it checked. Make sure you tell 
your GP that you have a family history of 
cancer and are at increased risk of ovarian 
cancer.” 
- In all websites 
You can come back to OvDex and do this 
exercise again in a years time  - why specify a 
years time. Surely we would be happy for 
someone to revisit their decision as often as 
they wish?? 
- Removed time frame and replace with “you 
can come back to OvDerx anytime and do this 
exercise again.” 
Having got this far I tried the decision aid – I 
assume/hope the balance will become an actual 
balance that tilts!?? 
- Yes balance will be fixed – Digital Morphopsis 
Finally having seen “my choice” it all seemed to 
end a bit abruptly – a bit like the criticism of 
when running out of time the student writing an 
essay then says ….. “and then he fell off a cliff. 
The end…” So is there a way of letting people 
come to the end more gently… even if it is only 
to return them to the menu or direct them 
- Added link to Contacts and Resources at the 
end of each ‘Your Decision’ page 
- Added “My plan” section 
- Web developer will add free text fields and 
print results option to enable users to keep a 
summary of their decision 
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straight to the list of alternative sources of 
information? 
I thought some of the grammar could have been 
improved. Some of it was repetitive and some of 
the sentences were a bit long and clumsy. I also 
wasn't sure about using words like ‘tummy’. I 
assume you have taken this to a focus group of 
patients or something but I think you have to be 
careful not to patronise. 
- Removed some repetitions (e.g. about primary 
peritoneal risk) and checked grammar and 
spelling again (e.g. uses of terms ‘operation’ 
and ‘surgery’; missing spaces etc.) 
‘Studies have shown that out of 100 women 
with one first degree relative (mother, sister or 
daughter) with ovarian cancer, 5 will develop 
ovarian cancer themselves at some point in their 
life. Women who have 2 or more first (mother, 
sister or daughter) and/or second degree (aunt, 
grandmother etc.) relatives with ovarian cancer 
have an even higher chance of developing 
ovarian cancer themselves of about 7 out of 
100.’ I think this paragraph is confusing and as 
its right at the beginning may it some people off 
using the tool. Perhaps you could explain what a 
first or second-degree relative is elsewhere or 
earlier in the paragraph so that you don't have 
to use the brackets in the middle of the 
sentence. I also think you could put the figures 
showing the circles in the text rather than all 
together which would make the numbers 
clearer. Later on you just show the diagram 
which is clearer so you may not need this text. 
- Deleted section that reiterates cancer risks out 
of 100 and changed paragraph to just explain 
first/second degree relatives: “Your risk 
depends on how many of your relatives had 
cancer and on how closely related they are to 
you. 'First degree relatives' are those directly 
related to you, for example, mother, sister or 
daugther. 'Second degree relatives' are those 
who are less closely related, for example your 
aunt or your grandmother. The diagrams 
below show how risk changes depending on 
the number of relatives with ovarian cancer.” 
- Also changed wording under third pictogram: 
“About 7 out of 100 women with two or more 
first and/or second degree relatives with 
ovarian cancer get ovarian cancer in their 
lifetime.” 
This sentence is also confusing  ‘ The number of 
relatives with cancers other than ovarian cancer, 
such as breast and bowel cancer, can also affect 
a woman’s chances of developing ovarian 
cancer.’ I would turn the sentence round ie ‘a 
woman’s chances of developing ovarian cancer 
can also be increased by …. 
- Changed sentence structure to “A woman’s 
chances of developing ovarian cancer can also 
be increased if she has relatives with cancers 
other than ovarian cancer, such as breast and 
bowel cancer.” 
- In General and Unclear websites 
I found the section below repetitive and a bit 
clumsy. It might be best to talk about you rather 
them ‘some women’ sometimes and ‘you’ at 
others. And it had lots of ‘thens’ How can I find 
out whether (or not) I have a faulty gene? Some 
women might come from families where certain 
types of cancer (e.g. ovarian, breast, bowel) 
have affected more than just one or two 
relatives and these women might have a faulty 
gene. To get tested for a faulty gene you will 
need to be referred to genetics services (usually 
by your GP). There your family history of cancer 
will be assessed in detail and you will be told 
whether there might be a faulty gene involved. 
Testing for a faulty gene in the family then 
- Changed wording to add “or not” to question 
title 
- Removed ‘might’ and ‘then’ in most sections 
- Reworded some parts to make it less clumsy 
- Made consistent by using “you” throughout: “If 
you come from a family where certain types of 
cancer (e.g. ovarian, breast, bowel) have 
affected more than just one or two relatives, 
you might have a faulty gene. To get tested for 
a faulty gene you will need to be referred to 
genetics services (usually by your GP). The 
genetics service will assess your family history 
in detail and you will be told whether there 
might be a faulty gene involved. Testing for a 
faulty gene in the family usually begins with a 
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usually begins with a test on a blood sample 
from a person who has had cancer. If you have 
had cancer yourself you may be offered a 
genetic test as the first person in your family. If 
you have not had cancer yourself, then a 
relative who has had cancer will be offered a 
genetic test first. If a faulty gene is found, other 
members of the family can then have a genetic 
test to see whether they also have the same 
gene. If there is no living relative with cancer, or 
the relative doesn‘t want to get tested, then it 
may not be possible to do a genetic test for you. 
For sources of more information see Contacts 
and Resources. 
test on a blood sample from a person who has 
had cancer. If you have had cancer yourself 
you may be offered a genetic test as the first 
person in your family. If you have not had 
cancer yourself a relative who has had cancer 
will be offered a genetic test first. If a faulty 
gene is found, other members of the family 
can then have a genetic test to see whether 
they also have the same faulty gene. If there is 
no living relative with cancer, or the relative 
doesn‘t want to get tested, it may not be 
possible to do a genetic test for you.” 
- In General and Unclear websites 
A genetic test result does not come back as 
‘unclear’. Do you mean a variant of uncertain 
significance? If so I think its best to say this and 
then explain that this is an unclear result. If no 
mutation is detected this would be 
uninformative rather than unclear. 
- Changed first personalisation question to read 
“my genetic test was uninformative” 
- In Cancer Risk section changed question 5 to: 
“What if I cannot get tested or my genetic test 
is uninformative? For some women it might 
not be possible to get tested because they 
have no living relative with cancer or their 
relative does not want to be tested. In other 
cases a genetic test may come back as 
‘uninformative’ which means a gene variant of 
uncertain significance has been found, but it is 
not clear whether this variant increases the 
risk of cancer or not. In these cases the 
genetics service will estimate the woman’s risk 
based on her family history.” 
- In General and Unclear websites 
Suggestions to improve the sense of this section  
‘If you have been told that your family history 
looks like (suggests?) you might have a faulty 
gene and you would like more specific 
information (for people with that gene - 
?delete), you can (delete? look at the 
information by) personalize (ing) this aid and 
select (ing) the gene that most closely resembles 
your family history (????as you have been told 
by your genetic counsellor.) 
- Changed wording of this section to “If you have 
been told that your family history suggests you 
might have a faulty gene and you would like 
more specific information, you can personalise 
this aid by selecting the gene that most closely 
resembles your family history according to 
your genetic counsellor.” 
- Added “For example, if you have been told 
your family history suggests you might have a 
BRCA1 gene, personalise OvDex by answering 
the first question with "Yes, I have a faulty 
BRCA1 gene". to this section 
- In General and Unclear websites 
So for example, your risk of getting ovarian 
cancer in the next year when you are 35 is quite 
low, whereas your risk of getting ovarian cancer 
in the next year when you are 50 is higher. 
Repeats ‘in the next year’ 
- Reviewed section and reworded to make it 
clearer: “This means when you are young your 
age-related risk is relatively low and rises when 
you get older. So for example, if you are 35, 
your risk of getting ovarian cancer in the next 
year (i.e. by the time you are 36) is quite low, 
whereas if you are 50, your risk of getting 
ovarian cancer in the next year (i.e. by the time 
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you are 51) is higher.” 
Which Dr? GPs will have no idea – suggest 
advise to get back in touch with genetics ‘You 
can discuss your children‘s risk with your doctor 
to find out more. Your doctor will also be able to 
advise you about how best to discuss this risk 
with your children’. 
- Changed to say “genetic counsellor” 
- In all websites 
It doesn't make sense to talk about ‘the gene’. It 
should be ‘the gene fault’ – ‘If they inherited the 
gene, then their cancer risk would be the same 
as yours. If they did not inherit the gene, then 
their cancer risk would be low. Boys who inherit 
the gene are not at risk of ovarian cancer. ‘ 
- Changed to “faulty gene” 
- In all websites 
Who should decide? As the best choice for you 
is based on your preferences, you should be 
closely involved in the decision. You can either 
make the decision on your own or if you do not 
wish to make this decision yourself, your doctor 
can help you. (They) Your doctor will encourage 
you to think about the options and your 
preferences, so that the final choice is right for 
you. If you then don’t want to choose for 
yourself, just say so and your doctor may make a 
recommendation. Better to you ‘your doctpr’ or 
he or she than they? Also which dr is this? The 
surgeon, gp, genetics clinician??? 
- Specified type of doctor: “You can either make 
the decision on your own or if you do not wish 
to make this decision yourself, your genetic 
counsellor or gynaecologist can help you.” 
- Left the “they” 
- In all websites 
Option grid: HRT is safe to take for the majority 
of women until they are 50. It is not 
recommended for women who have had breast 
cancer themselves already Careful with this 
statement as women who have had ER-ve BC 
(more commonly seen in BRCA1) may be able to 
take HRT 
- Changed wording to “HRT is safe to take for 
the majority of women until they are 50. It is 
not recommended for women who have had 
oestrogen receptor positive breast cancer 
themselves already.” 
The term ‘bilateral’ means both (otherwise you 
are saying the same thing twice!) 
- Reviewed use of the term ‘both’ to describe 
what bilateral means 
- Reworded section so it is clearer, but left the 
word ‘both’ in: “Risk-reducing bilateral 
salpingo-oophorectomy (RRSO for short) is an 
operation to remove healthy ovaries and 
fallopian tubes to reduce the cancer risk. The 
word ‘salpingo-oophorectomy’ means surgical 
removal of the fallopian tubes (salpinges) and 
ovaries. The term ‘bilateral’ in this context 
describes the fact that the ovaries and 
fallopian tubes on both sides of the body are 
removed. The aim of the operation is to 
remove these tissues before cancer develops.” 
RRSO section: ‘Even fewer cancers of the 
peritoneum have been found in women without 
- Completely removed this section as it was a 
repetition 
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a faulty BRCA1 gene who have had this surgery, 
therefore their risk is likely to be much lower 
than 2 in 100 after surgery.’ Confusing 
The highest risk for primary peritoneal cancer is 
in women with a BRCA1 faulty gene. Their risk is 
about 2 in every 100 women, which is similar to 
the risk of ovarian cancer in the general 
population. For women who do not have a 
BRCA1 faulty gene the risk of primary peritoneal 
cancer after surgery is much lower than 2 in 
100. You say this twice ie also in:What are the 
main advantages of this operation? […]For 
women with a faulty BRCA1 gene cancer might 
still develop in the peritoneum, which is the 
lining of the pelvis and abdomen. This means 
RRSO will not prevent cancer 6  in about 2 in 
every 100 women with a BRCA1 faulty gene. 
This risk is about the same as the ovarian cancer 
risk in the general population. Even fewer 
cancers of the peritoneum have been found in 
women without a faulty BRCA1 gene who have 
had this surgery, therefore their risk is likely to 
be much lower than 2 in 100 after surgery. 
- Completely removed section on primary 
peritoneal cancer under ‘disadvantages’ and 
only left detailed explanation in ‘What is my 
risk after surgery’. 
Other options: I wouldn't put in dates as some 
of this data is now published! It also still doesn't 
mean it will be introduced as a screening test 
even once the results of the trial are available – 
that could take years even if it detects cancer 
early.  ‘A large trial of ovarian cancer screening 
finished in December 2011 and the results will 
not be available until 2013, so we do not yet 
know whether this screening is effective and can 
detect ovarian cancer early. Until the results of 
the trial are available the NHS will not offer 
routine screening. The trial offered women 
CA125 blood tests every four months and one 
yearly trans-vaginal ultrasound scan.’ 
- Removed reference to the exact year: “A large 
trial of ovarian cancer screening finished in 
December 2011 and the results are not yet 
available, so we do not yet know whether this 
screening is effective and can detect ovarian 
cancer early.” 
- In all websites 
You should also be aware that the yearly smear 
test you receive is designed to detect cervical 
cancer and will not detect ovarian cancer. - I 
would give this a separate paragraph and make 
the not bold!  
- Made separate paragraph 
- Added em for emphasis to the ‘not’ (bold is not 
used for emphasis on websites) 
Women from families with Lynch syndrome may 
receive trans-vaginal ultrasound screening to 
look for womb cancer. And Women from Lynch 
syndrome families, may be offered 
hysteroscopies or trans-vaginal ultrasound scans 
to detect uterus/womb cancer, which these 
women are at higher risk for. However usually 
these tests are designed to detect womb cancer 
only and not ovarian cancer. - should be 
- Added statement: “Additionally, the value of 
these tests in detecting womb cancer is also 
not fully proven.” 
- In Lynch, general and unclear websites 
- Deleted any sections on Lynch in BRCA linked 
other options sites 
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emphasized that this is not proven to be an 
effective screening test  
In some countries it is recommended that 
women at high risk of ovarian cancer take the 
oral contraceptive pill when they are pre-
menopausal. The oral contraceptive pill reduces 
ovarian cancer risk by up to half, but it has also 
been found to increase breast cancer risk 
slightly. For women at high risk the reduction in 
ovarian cancer risk is thought to outweigh the 
slight increase in breast cancer risk. I would have 
major concerns about this bit. If a woman 
carries a BRCA1/2 mutation it would not be 
recommended for her to go on the pill to reduce 
her risk of ovarian cancer and she could be 
significantly increasing her risk of breast cancer. 
Certainly for BRCA1/2 carriers this should be 
discussed with the genetics clinician not just the 
GP. 
- Reviewed section and removed reference to 
safety in line with feedback: “In some countries 
it is recommended that women at high risk of 
ovarian cancer take the oral contraceptive pill 
when they are pre-menopausal. The oral 
contraceptive pill reduces ovarian cancer risk 
by up to half, but it has also been found to 
increase breast cancer risk.” 
- Added that women should consult their 
genetics clinician as well: “Whether the oral 
contraceptive pill might be an option for you 
depends on your risk and family history of 
breast cancer and should be discussed with 
your genetic counsellor and GP.” 
- In all pre-meno websites 
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Appendix 7.9 - OvDex booklet Final (General version) 
OvDexD4 Feb 2013
©Cardiff University
Next update: 
July 2013
A decision aid designed to help you 
and your doctor make a decision 
about risk-reducing ovarian surgery
For women at increased risk of ovarian cancer
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Welcome to OvDex
OvDex (The Oophorectomy Decision Explorer) has been developed to help you find 
out more about your options for reducing your ovarian cancer risk. If you are viewing 
OvDex you should have been referred to it by a doctor or geneticist as you are at 
increased risk of ovarian cancer. 
Please note that OvDex can be personalised by answering three questions . You 
should have seen these questions before you opened this document. If you do wish 
to personalise the information you get, please go to the OvDex website and answer 
the questions .
The information the following pages has not been personalised. If you do not wish to 
personalise OvDex then please view the general information on the following pages.
Chapter Page
1. Cancer risk............................................................................................. 3
2. The choice.............................................................................................. 7
3. Options at a glance................................................................................ 10
4. Risk-reducing surgery............................................................................. 12
5. The menopause..................................................................................... 16
6. Hormone replacement........................................................................... 19
7. Other options......................................................................................... 22
8. Your decision.......................................................................................... 24
9. Contacts and Resources......................................................................... 29
10. References.............................................................................................. 30
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Questions in chapter 1:
Q1 Where does ovarian cancer develop?
Q2 What is the ovarian cancer risk if I have a family history of ovarian cancer?
Q3 How can I find out whether I have a faulty gene?
Q4 What would my risk be if a faulty gene is found?
Q5 What if I cannot get tested or my genetic test is uninformative?
Q6 Does my cancer risk change over time?
Q7 How will my ovarian cancer risk affect my life?
Q8 How will my ovarian cancer risk affect my children?
Q9 How can I change how I feel about my cancer risk?
Q1 - Where does ovarian cancer develop?
Q2 - What is the ovarian cancer risk if I have a family history of ovarian cancer?
Ovarian cancer occurs by chance in less than 2 of every 100 women. For women who
have a family history of ovarian, breast and/or bowel cancer and/or a faulty gene, the
risk can be much higher than 2 in 100. Generally the risk is quite low in young women
and rises with age.
Your risk depends on how many of your relatives had cancer and on how closely
related they are to you. 'First degree relatives' are those directly related to you, for
example, mother, sister or daughter. 'Second degree relatives' are those who are less
closely related, for example your aunt or your grandmother. The diagrams below
show how risk changes depending on the number of relatives with ovarian cancer.
1. Cancer risk
Less than 2 out of 100 
women in the general 
population get ovarian 
cancer in their lifetime. 
98 women will not.
About 5 out of 100 women 
with a first degree relative 
with ovarian cancer get 
ovarian cancer in their 
lifetime. 95 women will not.
About 7 out of 100 women 
with two or more relatives 
with ovarian cancer get 
ovarian cancer in their 
lifetime. 93 women will not.
The picture shows the female 
reproductive system. The ovaries 
are connected to the uterus by 
the fallopian tubes. Ovarian-type 
cancer can develop in the ovaries, 
the fallopian tubes or the lining of 
the abdomen (called the 
‘peritoneum‘). Other female 
cancers, such as cancer of the 
endometrium, uterus/womb or 
cervix, are very different and 
should not be confused with 
ovarian cancer. 
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A woman’s chances of developing ovarian cancer can also be increased if she has
relatives with cancers other than ovarian cancer, such as breast and bowel cancer. A
woman’s risk is estimated by genetics services once the full family history is available.
Q3 - How can I find out whether I have a faulty gene?
If you come from a family where certain types of cancer (e.g. ovarian, breast, bowel)
have affected more than just one or two relatives, you might have a faulty gene. To
get tested for a faulty gene you will need to be referred to genetics services (usually
by your GP). The genetics service will assess your family history in detail and you will
be told whether there might be a faulty gene involved.
Testing for a faulty gene in the family usually begins with a test on a blood sample
from a person who has had cancer. If you have had cancer yourself you may be
offered a genetic test as the first person in your family. If you have not had cancer
yourself a relative who has had cancer will be offered a genetic test first. If a faulty
gene is found, other members of the family can then have a genetic test to see
whether they also have the same faulty gene. If there is no living relative with cancer,
or the relative doesn‘t want to get tested, it may not be possible to do a genetic test
for you. For sources of more information see chapter 9 (Contacts and Resources),
page 29.
Q4 - What would my risk be if a faulty gene is found?
The most common faulty genes linked to ovarian cancer are called Breast Cancer
(BRCA) genes 1 and 2 and genes common in Lynch Syndrome (formerly known as
Hereditary Non-Polyposis Colorectal Cancer or HNPCC). The lifetime risk of
developing ovarian cancer can be much higher for women who have a faulty gene
compared to the general population.
1. Cancer risk
About 39 out of 100 
women with a BRCA1 
faulty gene get ovarian 
cancer by the time they 
are 70. About 61 women 
with a BRCA1 faulty gene 
will not.
About 16 out of 100 
women with a BRCA2 
faulty gene get ovarian 
cancer by the time they 
are 70. About 84 women 
with a BRCA2 faulty gene 
will not.
About 6 to 12 out of 100 
women with Lynch 
Syndrome get ovarian 
cancer by the time they 
are 70. About 88-94 
women with Lynch 
Syndrome will not.
4
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Q5 - What if I cannot get tested or my genetic test is uninformative?
For some women it might not be possible to get tested because they have no living
relative with cancer or their relative does not want to be tested. In other cases a
genetic test may come back as ‘uninformative’ which means a gene variant of
uncertain significance has been found, but it is not clear whether this variant
increases the risk of cancer or not. In these cases the genetics service will estimate
the woman’s risk based on her family history.
If you have been told that your family history suggests you might have a faulty gene
and you would like more specific information, you can personalise this aid by
selecting the gene that most closely resembles your family history according to your
genetic counsellor. For example, if you have been told your family history suggests
you might have a BRCA1 gene, personalise OvDex by going to the website and
answering the first question with "Yes, I have a faulty BRCA1 gene".
Q6 - Does my cancer risk change over time?
Yes. While your so-called ‘lifetime’ risk (which is the risk that you will get ovarian
cancer at some point in your life) will stay the same over time, your ‘age-related’
ovarian cancer risk (which is the risk that you will get ovarian cancer in a specified
time frame, for example one year or five years) increases with age. This means when
you are young your age-related risk is relatively low and rises when you get older. So
for example, if you are 35, your risk of getting ovarian cancer in the next year (i.e. by
the time you are 36) is quite low, whereas if you are 50, your risk of getting ovarian
cancer in the next year (i.e. by the time you are 51) is higher.
Q7 - How will my ovarian cancer risk affect my life?
Being at risk for ovarian cancer does not necessarily mean that you will develop
ovarian cancer. However, knowing your risk will give you access to additional medical
services such as genetic counselling and means that you may be offered risk-reducing
surgery. Some people may feel worried or anxious after finding out about their risk
and their quality of life may be affected.
Q8 - How will my ovarian cancer risk affect my children?
There is a chance that your children will also have an increased risk of cancer. Their
risk depends on how high your own risk is and on whether or not you have a faulty
gene. If you have a faulty gene, then your children have a 50/50 chance to inherit
this. If they inherited the faulty gene, then their cancer risk would be the same as
yours. If they did not inherit the faulty gene, then their cancer risk would be low. Boys
who inherit the faulty gene are not at risk of ovarian cancer, but may be at risk for
other cancers. Boys who inherit the faulty gene may also pass it on to their children.
Please also note that cancer risk increases with age and therefore children’s risk only
starts to rise in later life. More information about genetics can be found on the NHS
choices website (see Chapter 9 Contacts and Resources, page 29).
You can discuss your children‘s risk with your genetic counsellor to find out more.
Your genetic counsellor will also be able to advise you about how best to discuss this
risk with your children.
1. Cancer risk 5
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Q9 - How can I change how I feel about my cancer risk?
If you would like to find out more about your risk and what it means, you can use the
resources provided in OvDex and talk to your doctor or genetic counsellor.
Knowing that you are at increased risk of cancer might make you feel worried or
angry or frustrated. This is completely normal and there is no need to bottle those
feelings up. It can actually help to talk about them.
You can try to find someone you trust to talk to or if you prefer to talk to someone
you don’t know, you can use the contact details for charities and patient support
networks under Contacts & Resources. If you have a partner, sharing your thoughts
and concerns with your partner can be useful in helping them understand what you
are going through and in helping you cope together as a couple.
It may also help to see a positive side to knowing your risk status. For example, this
means that you will get access to genetics services and have the chance to do
something about your risk. Other women have found it helpful to stay optimistic,
have joined patient networks or have found strength in their faith.
Being at risk of cancer may sometimes lead to unwanted thoughts and worry,
especially at times when there are no active steps you can take, for example when
you are waiting for genetic test results. There are useful techniques you can use to
reduce such thoughts. One such method is active distraction, which means actively
thinking about something else whenever unwanted thoughts pop in your head.
Watch the 'How do I cope' video on the Cancer Genetics storybank website for a
guide of how to do this (see Contacts & Resources).
Relaxation techniques, meditation and guided imagery may also help you deal with
any stress you might experience relating to your cancer risk. Examples include
progressive muscle relaxation and certain breathing exercises. Visit the 'Mind-body
therapy' section on the Macmillan website for more information on and guides to
mind-body therapies (see Contacts & Resources).
1. Cancer risk 6
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2. The Choice
Questions in chapter 2:
Q1 What can I do to reduce my risk?
Q2 Why is there a choice?
Q3 Who should decide?
Q4 Who else should I involve in this decision?
Q5 When should I decide?
Q6 How can I decide?
Q7 How can I deal with the choice?
Q1 - What can I do to reduce my risk?
Your doctor has probably discussed with you the option of having risk-reducing
ovarian surgery to reduce your ovarian cancer risk. You will need to decide whether
and when to have this surgery. Unfortunately, there is no medically proven screening
available on the NHS for ovarian cancer at the moment.
This decision aid is designed to help you look at your options. Please refer to chapter
3 (Options at a glance) page 10, chapter 4 (Risk-reducing surgery) page 12 and
chapter 7 (Other options) page 22 for more information about surgery, screening and
other alternatives.
Q2 - Why is there a choice?
Often when you go to your doctor, there is one clearly recommended treatment.
However, some situations are more complicated. These are situations in which your
personal preferences and feelings play an important role. In the case of cancer risk
reduction, your options have very different effects on your life. This means that you
need to be clear about what might happen if you choose one option over the other
and how that would impact on your life.
Some health professionals may recommend surgery quite strongly; however you
need to make the final decision and before you do, you should consider the possible
benefits and risks, how these might affect your life and how you feel about them.
Q3 - Who should decide?
As the best choice for you is based on your preferences, you should be closely
involved in the decision. You can either make the decision on your own or if you do
not wish to make this decision yourself, your genetic counsellor or gynaecologist can
help you. They will encourage you to think about the options and your preferences,
so that the final choice is right for you. If you then don’t want to choose for yourself,
just say so andthey may make a recommendation.
Q4 - Who else should I involve in this decision?
Whether or not you would like to bring anyone else into this decision is your choice.
Often it is helpful to speak to someone who knows you well, such as a partner, other
members of your family or a friend, who could work through this decision with you. If
you are in a relationship the views of your partner can be important, especially in the
context of risk-reducing ovarian surgery, so it is recommended that you speak to your
partner and try to reach a decision together. Your doctor will also be happy for you to
bring your partner along to appointments and to answer any questions they might
have.
7
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2. The Choice
Q5 - When should I decide?
The operation is most effective if it is done at 40 years of age, but this may not be
ideal for everyone. So, even if you decide not to have it at 40, the operation will still
decrease your ovarian cancer risk if performed after that age.
The decision you are facing is not an easy one and you should not feel under any
pressure to decide quickly. Risk-reducing surgery has benefits and risks that need to
be weighed carefully, so take your time and make sure you are ready before making a
decision.
It is important that you understand that undergoing surgery to remove your ovaries
will mean you can no longer get pregnant. Therefore it is essential to consider your
plans for a family and any potential future changes to these plans (for example if
there is a chance you might meet a new partner / re-marry) before making a final
decision.
Q6 - How can I decide?
When it comes to important decisions everyone is different. Some people like to find
out as much as they can about their options, while others prefer to just know what is
absolutely necessary. Some might find it helpful to talk to their family and friends.
Some might like to speak to people who have made a similar decision. It really
depends on you. Have a think about other important decisions in your life and how
you managed to make those. That could give you an idea of how you like to decide
about things.
Q7 - How can I deal with the choice?
It can be helpful to create a plan of how and when you will make this choice. If you
are not ready to decide right now, it might be useful to set yourself a deadline of
when you will revisit this decision. For example: “Just after my 40th birthday I will
look at this information again.” or “Once I have completed my family I will revisit this
decision.”
Once you are ready you can decide how you want to make this choice:
1. I will decide by myself using everything I have learnt
2. I will decide but seriously consider my doctor’s opinion
3. The doctor and I should decide together
4. The doctor should decide but seriously consider my opinion
5. The doctor should decide for me
One constructive way to deal with a difficult decision is to empower yourself with
information. OvDex is designed to help you to learn more about ovarian cancer risk
and your options. With the wealth of information that is available on the internet, it
can be difficult to find reliable and trustworthy information. The information in OvDex
is supported by recent scientific findings and has been carefully reviewed by health
professionals to make sure it is accurate. You should at least understand your options
and their benefits and risks before making a decision. Find out more about the most
important questions to ask at: www.Ask3Questions.co.uk. Once you have read the
information in OvDex, it could help to make a note of any remaining questions and
take those to your doctor or genetic counsellor for a more detailed discussion.
8
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2. The Choice
You may feel that you are not comfortable making decisions about your health. This is
okay. You do not need to make the choice alone if you don’t want to. You can decide
together with your doctor or ask them to make the choice for you. But you need to
remember that you are the expert when it comes to your own life and that only you
know what is important to you. So even if you decide to let the doctor make the
decision for you, make sure they know about your goals and values. Tell them what is
important to you.
9
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3. Options at a Glance
Frequently asked questions
Surgery to remove ovaries and 
fallopian tubes
No surgery
Will this reduce my risk of 
ovarian cancer?
Yes, removing the ovaries and 
fallopian tubes will greatly 
reduce your lifetime risk of 
ovarian-type cancer to that of 
the general population, which is 
about 2 in 100.
No, your risk of ovarian 
cancer will remain increased.
Will I be able to become 
pregnant?
No, therefore it is important that 
you feel you have completed 
your family before having 
surgery.
Yes, your ability to become 
pregnant will be unaffected.
Will this change how I feel 
about my risk of ovarian 
cancer? 
You may feel less worried about 
developing ovarian cancer.
You may worry about 
developing ovarian cancer.
Will this change how I feel 
about myself as a woman?
Many women do not notice any 
change in how they feel about 
themselves as a woman. 
However, your desire for and/or 
enjoyment of sex may decrease.
Not applicable.
Will I go into menopause?
Yes, after surgery your oestrogen 
levels fall and the menopause 
will start immediately.
Yes, you will go through a 
natural menopause when you 
are around 50 years.
What is menopause like?
Menopause after surgery is 
similar to natural menopause, 
but because it happens 
suddenly, the symptoms may be 
more severe. 
Natural menopause is a 
gradual decline of oestrogen 
levels. Typical symptoms 
include hot flushes, night 
sweats, mood swings and 
vaginal dryness.
Are there any long-term 
health risks linked to surgery?
Yes, if surgery is done before age 
45 there is a higher risk of bone 
thinning and cardiovascular 
disease. Some patients report 
memory changes as well.
Not applicable.
Will I need hormone 
replacement therapy (HRT)?
HRT can reduce some of the 
effects of surgery and is 
recommended for women who 
have surgery before age 45. 
No, if you go through a 
natural menopause you 
would not be expected to 
need HRT, unless your 
symptoms are very severe.
Is HRT safe for women at 
increased familial risk?
HRT is safe to take for the 
majority of women until they are 
50. Discuss this with your 
clinician. It is not usually 
recommended for women who 
have had breast cancer.
HRT is safe to take for the 
majority of women until they 
are 50. Discuss this with your 
clinician. It is not usually 
recommended for women 
who have had breast cancer.
10
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3. Options at a Glance
Q1 – How can I deal with this decision?
Some women may find it useful to discuss surgery with others, who have already 
made this decision. In some areas your genetic counsellor may be able to put you in 
touch with someone who has already gone through the decision, otherwise you can 
use the contact details for charities and patient support networks under Contacts & 
Resources to read about or get in touch with others in a similar situation. Going over 
the decision with someone who knows you well, such as your partner or a member 
of your family can also help you clarify your decision. If you decide to opt for surgery 
and you are in a relationship, preparing yourself together with your partner for the 
time after surgery can help you both deal better with any consequences of the 
operation.
Being clear about the reasons why surgery could be the right or wrong thing for you 
can help you make a decision and avoid regretting it later. The information in OvDex 
is designed to help you identify the benefits and the risks of surgery and any other 
options, so you can decide for yourself. The exercise called ‘Your Decision’ can help 
you clarify what is most important to you.
Being at risk of cancer may sometimes lead to unwanted thoughts and worry, 
especially at times when there are no active steps you can take, for example if you 
have decided to defer surgery or while you are waiting for your surgery appointment. 
There are useful techniques you can use to reduce such thoughts. One such method 
is active distraction, which means actively thinking about something else whenever 
unwanted thoughts pop in your head. Watch the 'How do I cope' video on the Cancer 
Genetics storybank website for a guide of how to do this.
Relaxation techniques, meditation and guided imagery may also help you deal with 
any stress you might experience relating to your cancer risk. Examples include 
progressive muscle relaxation and certain breathing exercises. Visit the 'Mind-body 
therapy' section on the Macmillan website for more information on and guides to 
mind-body therapies.
Frequently asked questions
Surgery to remove ovaries 
and fallopian tubes
No surgery
What are the risks of surgery?
About 4 in every 100 patients 
experience a complication 
during or after surgery. These 
can be minor infections or 
major complications. Discuss 
this with your clinician.
Not applicable.
How long will it take me to 
recover from surgery?
Most women leave the 
hospital the same day or the 
day after key hole surgery and 
are back to normal in 4 weeks. 
For open surgery time in 
hospital and recovery will be 
longer.
Not applicable.
Is there a routine screening 
programme to detect ovarian 
cancer?
No, after surgery there is no 
need for screening because 
your risk will be similar to that 
of the general population.
No, there is no evidence that 
screening for ovarian cancer is 
effective.
11
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4. Risk-reducing Surgery
Questions in chapter 4:
Q1 What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Q2 What are the main advantages of this operation?
Q3 What are the main disadvantages of this operation?
Q4 What is my risk after surgery?
Q5 What does the surgery involve?
Q6 How long does it take to recover?
Q7 Do I need to have my womb removed as well?
Q8 What are the complications of RRSO?
Q9 Could cancer be found during the surgery?
Q10 How would RRSO affect my life?
Q1 - What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Risk-reducing bilateral salpingo-oophorectomy (RRSO for short) is an operation to 
remove healthy ovaries and fallopian tubes to reduce the cancer risk. The word 
‘salpingo-oophorectomy’ means surgical removal of the fallopian tubes (salpinges) 
and ovaries. The term ‘bilateral’ in this context describes the fact that the ovaries and 
fallopian tubes on both sides of the body are removed. The aim of the operation is to 
remove these tissues before cancer develops.
Q2 - What are the main advantages of this operation?
1) This operation will reduce your ovarian and fallopian tube cancer risk, as these 
are completely removed during surgery. 
2) For some women, not having to worry about ovarian cancer anymore comes as a 
great relief.
3) For the vast majority of women having RRSO before the natural menopause could 
also reduce the risk of breast cancer.
4) Having the surgery will also prevent other, non-cancer related problems 
happening with the ovaries, such as cysts.
12
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4. Risk-reducing Surgery
Q3 - What are the main disadvantages of this operation?
1) You will no longer be able to become pregnant once you have had surgery, 
therefore it is important that you have considered your plans for a family 
before making a final decision. 
2) After the operation you will immediately enter the menopause and may start 
to experience the typical menopausal symptoms, including hot flushes, mood 
swings, night sweats and vaginal dryness (Please see Chapter 5 (The 
Menopause), page 16 for more details). Furthermore, you may be at increased 
risk of bone thinning, cardiovascular (heart and blood vessel) disease and 
memory changes. These effects may be effectively treated with hormone 
replacement therapy (Please see chapter 6 (Hormone Replacement), page 19 
for more details), however not all women can take hormone replacement and 
this should be discussed before having surgery.
3) Your desire for sex will decrease and due to some menopausal symptoms, such 
as vaginal dryness, you may enjoy sex less as intercourse can be painful. Again, 
hormone replacement may counteract these effects.
4) There is a small risk of complications during and after surgery.
Q4 - What is my risk after surgery?
After surgery your risk of ovarian and fallopian tube cancer is greatly reduced,
however, there is a rare type of cancer which may still develop after surgery that is
very similar to ovarian cancer. This is called primary peritoneal cancer and
develops in the lining of the abdomen and pelvis. Your risk of primary peritoneal
cancer depends on whether or not you have a faulty gene. The highest risk for
primary peritoneal cancer is in women with a BRCA1 faulty gene. Their risk is
about 2 in every 100 women, which is similar to the risk of ovarian cancer in the
general population. For women who do not have a BRCA1 faulty gene the risk of
primary peritoneal cancer after surgery is much lower than 2 in 100.
Q5 - What does the surgery involve?
Most often the operation is done as keyhole surgery (laparoscopy). This involves 3
or 4 small (about 1cm) cuts, usually one cut is close to your belly button and 2-3
just below the bikini line, so they are not visible. Keyhole surgery itself usually
takes less than 2 hours.
In some cases it may not be possible to do keyhole surgery, because of previous
surgery on your tummy or because of your weight. Then surgeons use the more
traditional open surgery. This means a longer cut , usually along the bikini line.
Sometimes a surgeon might have to convert to an open operation when doing
keyhole surgery because of complications or old scar tissue. This happens in about
1 of every 100 keyhole operations.
13
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Q6 - How long does it take to recover?
75 of 100 patients who have keyhole surgery leave the hospital the day after
surgery. They are usually back to normal activity about 4 weeks after surgery. If
you have open surgery you are likely to stay in hospital a bit longer. Usually
patients leave the hospital about 5 days after open surgery and are back to normal
in about 6 weeks. After surgery you are not allowed to do any heavy lifting for a
few weeks. You may also have to refrain from driving until you can comfortably
wear a seatbelt and make an emergency stop without pain.
Q7 - Do I need to have my womb removed as well?
No, normally it is not necessary that you have your womb removed at the same
time as having RRSO, unless you know that you have Lynch Syndrome or you have
other problems with your womb and have been told by a doctor that removing the
womb would help you with those problems. However, you may choose to have
your womb removed at the time of RRSO, as it may affect the type of hormone
replacement you would be given. You should discuss this with your doctor.
Q8 - What are the complications of RRSO?
There is a small risk of complications linked to RRSO. About 4 in every 100 people
will experience some complication. Minor complications can include wound or
urinary tract infections and usually have no long-term effects on your health. More
serious complications might happen during surgery and can include damage to
blood vessels, the bowel or the bladder. If you are having keyhole surgery this
might mean that the surgeon has to convert to open surgery to repair the damage.
There are a number of other rare complications that might happen and your
surgeon will go through those with you if you wish before you go in for surgery.
Please note that about 96 of every 100 women do not experience any
complications at all.
4. Risk-reducing Surgery
Type of procedure in 100 women who have the 
operation
The figure on the left shows how many of 100 women 
will have keyhole surgery , open surgery and planned 
keyhole which is converted to open surgery.
94 of 100 women will have planned keyhole surgery 
(white dots). Five of 100 women will have planned 
open surgery (light teal dots). One of 100 women will 
have planned keyhole surgery which is converted to 
open surgery (dark dot).
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As with any surgery, there is a very small risk of death. However, this is highly
unlikely. The risk may be greater in women with health problems before surgery.
Q9 - Could cancer be found during the surgery?
Yes, although this is rare. Once your ovaries and fallopian tubes have been
removed they will be checked thoroughly for any signs of cancer. There is a chance
that cancer may be discovered during this check. This happens in up to 4 out of
every 100 operations in the highest risk patients. For others the chances of finding
cancer during the surgery are much lower.
Q10 - How would RRSO affect my life?
In the short-term, if you decide to go for surgery, you will have to take time off
work and will not be able to do some of the things you might usually do, such as
driving or heavy lifting. However most women recover fully within 4 to 6 weeks.
In the longer term there are a number of things you should consider. After surgery
you may feel less worried about ovarian cancer. However you may feel differently
about your body and you may loose interest in sex. You will also no longer be able
to become pregnant and you will enter the menopause if you have not gone
through it yet (Please see chapter 5 (Surgical menopause), page 16). You may opt
to take hormone replacement (Please see chapter 6 (Hormone replacement), page
19). These factors may affect your life after surgery and should be considered
carefully before making a decision.
4. Risk-reducing Surgery
Complications in 100 women who have the operation
The figure on the left shows how many of 100 women 
will experience complications during or after surgery.
4 of 100 women will experience some kind of 
complication either during or after surgery. 96 of 100 
women will not experience any complications.
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The graph above shows the drop in the levels of the female hormone oestrogen 
during surgical and natural menopause. Potential menopausal symptom duration 
and severity are indicated in shades of grey.
Questions in chapter 5:
Q1 What is surgical menopause?
Q2 What is the menopause like?
Q3 How could the menopause affect my life in the short term?
Q4 How long does surgical menopause last?
Q5 Are there any long term health effects linked to surgical menopause?
Q6 Is there anything I can do to reduce the effects of surgical menopause?
Q1 - What is surgical menopause?
A surgical menopause is a menopause you enter when your ovaries are removed by 
surgery and your body no longer produces the female hormone oestrogen. A surgical 
menopause is essentially the same as a natural menopause, it only happens earlier 
and more suddenly. Therefore a surgical menopause results in the same symptoms as 
a natural menopause. These symptoms are caused by the lack of oestrogen. As 
oestrogen levels drop suddenly after surgery, the symptoms of a surgical menopause 
start instantly and can be more severe than those of a natural menopause, in which 
oestrogen levels fall gradually.
5. The Menopause
Note that the information about symptoms of the menopause in this 
chapter describes symptoms experienced by women who do not take 
hormone replacement therapy (HRT). Most symptoms of the 
menopause are reduced by hormone replacement therapy (for more 
information see Chapter 6 (Hormone Replacement) on page 19).
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Q2 - What is the menopause like?
It is very difficult to describe what the menopause is like, because it is different for 
every person. Some women have no or very few symptoms and cope very well. Other 
women can have very severe symptoms and their quality of life can be affected.
Common menopausal symptoms you may experience are: Hot flushes, night sweats, 
mood swings, vaginal dryness and loss of interest in sex. Other symptoms include 
difficulty sleeping, fatigue, weight gain, changes in memory and depression.
The great majority of women who had surgery reported that they experienced one or 
more of the common symptoms. However, any data available about menopausal 
symptoms is from small studies and each study uses different ways to assess what 
women experienced, so it is difficult to predict what the menopause will be like for 
you personally. The pictures below show how common different types of menopausal 
symptoms are according to one study of women after RRSO.
Q3 - How could menopause affect my life in the short term?
While none of the menopausal symptoms mentioned above are dangerous for your 
health, they may affect you in different ways. Hot flushes can be very uncomfortable 
and may happen at inconvenient times, for example when you are giving a 
presentation at work. In one study two out of every three women reported having 
hot flushes after surgery. Night sweats can lead to problems with sleep and insomnia.
Vaginal dryness can lead to pain during sex and therefore you may enjoy sex less. 
Additionally, many women also experience a loss of interest in sex after surgery. In 
one study just over half of women reported that they were not satisfied with their 
sexual functioning after having surgery and in another study one in every three 
patients felt that vaginal dryness was bothersome and reported pain with sex. If you 
are in a relationship, these factors may affect your relationship with your partner. The 
way that these symptoms might affect your life depends on your personal situation.
There are several options available to help you deal with the short-term symptoms of 
the menopause. These include physical options, such as lubricant to counteract 
vaginal dryness, or psychological options, such as sex counselling and cognitive 
behavioural therapy to improve emotional and physical functioning. You can get more 
information about these options from your doctor or gynaecologist. The NHS choices 
website also has information about dealing with the menopause (See Chapter 9 
(Contacts & Resources), page 29. 
5. The Menopause
About 72 of 100 women 
experience vasomotor 
symptoms (hot flushes 
and night sweats). 28 
women do not.
About 92 of 100 women 
experience psychosocial 
symptoms (mood swings, 
feeling depressed or 
down). 8 women do not.
About 87 of 100 women 
experience physical and 
sexual symptoms (aching, 
vaginal dryness, loss of 
libido). 13 women do not.
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Q4 - How long does the menopause last?
It is impossible to say how long symptoms will last. Some women have hardly any 
problems and symptoms disappear quickly, while others have symptoms for many 
years. It really is different for everyone.
Q5 - Are there any long term health effects linked to the menopause?
Yes. The loss of oestrogen is thought to affect long term health, particularly the bones 
and the cardiovascular system (heart and blood vessels). In older age this can lead to 
a higher risk of fractures due to bone thinning (osteoporosis) and a higher risk of 
cardiovascular disease (heart disease, stroke).
It should be noted that these effects are seen in all women after the menopause, 
whether it was a surgical or natural menopause. Your personal risk depends on your 
lifestyle and personal and family history of osteoporosis and cardiovascular disease 
and should be discussed with your doctor.
Due to the sudden lack of oestrogen after surgery, the risk of bone thinning and 
cardiovascular disease may start to rise immediately after surgery. This could be 
before the woman has reached the age of the natural menopause. Therefore, women 
who undergo surgery before the age of 45 are usually recommended to take 
hormone replacement to reduce these effects until they reach the age of the natural 
menopause (See Chapter 6 (Hormone replacement) page 19). 
Some women also report changes in memory following the menopause, which is 
again due to the lack of oestrogen.
Q6 - Is there anything I can do to reduce the effects of the menopause?
Yes. Hormone replacement therapy (HRT) is usually recommended for women who 
have RRSO before the age of 45 and have not had breast cancer themselves (See 
Chapter 6 (Hormone replacement) page 19). HRT may effectively reduce some of the 
short- and long-term effects of surgical menopause. However, not all women can take 
hormone replacement and this should be discussed before having surgery.
If you do not wish to or cannot take HRT then you can take dietary supplements to 
reduce bone thinning. You should speak to your doctor about this. In some regions in 
the UK patients are also recommended to have a bone density scan about 18 months 
after their operation. You can discuss this with your doctor.
An active lifestyle and healthy diet is also recommended.
5. The Menopause 18
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6. Hormone Replacement 19
Questions in chapter 6:
Q1 What is Hormone Replacement Therapy (HRT)?
Q2 Why is HRT important?
Q3 Who should take HRT?
Q4 How long should I take HRT?
Q5 Can I take HRT if I have a family history of breast cancer?
Q6 But I have heard that HRT increases breast cancer risk
Q7 Will HRT reduce all the symptoms of menopause?
Q8 Will HRT deal with the long term health effects of the menopause?
Q9 Are there any alternatives to HRT?
Q1 - What is Hormone Replacement Therapy (HRT)?
Hormone Replacement Therapy, or HRT for short, is a medical treatment that puts 
back the female hormones that are lost when the ovaries are removed or when they 
stop functioning. 
There are a number of ways that HRT can be used:
- It can be taken as oral tablets usually once  a day
- It can be applied as patches that are put on the tummy or bottom about once or 
twice a week
- It can be applied as a gel directly to the skin once a day (for example the lower 
abdomen or inner thigh)
There are two types of hormone replacement, one includes oestrogen and 
progesterone and the other includes oestrogen only. Women who only have their 
ovaries removed will usually be given oestrogen and progesterone HRT, while women 
who have their womb/uterus and ovaries removed (RRSO plus hysterectomy) are 
usually given oestrogen only HRT.
The graph above shows the oestrogen levels after surgical and natural 
menopause. It also shows the effect of HRT on the oestrogen levels after 
the operation if surgery was performed before the natural menopause.
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6. Hormone Replacement 20
Q2 - Why is HRT important?
There are two main reasons why HRT is recommended after surgery:
1. To reduce the risk of bone thinning
2. To reduce symptoms of the menopause
Q3 - Who should take HRT?
HRT is strongly recommended for women who have surgery before they are 45 years 
of age, as this group is most affected by the long term health issues that are linked to 
loss of oestrogen, especially bone thinning (osteoporosis).
Women who have surgery when they are over 45 years of age can choose to have 
HRT to reduce the symptoms of surgical menopause. However these women do not 
have to have HRT if they do not want to, as the long term health effects of early loss 
of oestrogen do not affect them as much as a women having surgery before 45, 
because their oestrogen levels would have started to fall anyway.
It is important that the possibility of HRT is discussed before making a decision about 
surgery.
Q4 - How long should I take HRT?
If you use HRT, it is recommended that you take it until the age of the natural 
menopause, which is 50 years in the UK. From the age of 50 your oestrogen levels 
would have declined naturally, so taking HRT for many years beyond 50 is not 
recommended. This is because there is controversial evidence about the benefits and 
risks of HRT if it is taken beyond the age of natural menopause. Therefore the health 
effects are unclear and HRT may cause more harm than good if taken beyond 50.
Q5 - Can I take HRT if I have a family history of breast cancer?
Yes. You should be able to take HRT even if you have a family history of breast cancer. 
Several studies have shown that HRT is safe to take for the vast majority of women 
with a family history of breast cancer as long as they have not had breast cancer 
themselves and they only use HRT until the age of the natural menopause. You 
should discuss your family history of breast cancer with your genetics service before 
deciding to have surgery.
Q6 - But I have heard that HRT increases breast cancer risk?
Yes, HRT contains oestrogen and there is some evidence that higher amounts of 
oestrogen in the body can increase the risk of breast cancer.
However, the study that showed that HRT increases breast cancer risk was done with 
older women who had already gone through the natural menopause and were taking 
HRT beyond 50 years of age. Therefore these women were taking oestrogen when 
their body has naturally stopped producing this hormone.
Furthermore, these women did not have surgery to have their ovaries removed. 
Therefore this group of women is very different to women with a family history who 
choose to have their ovaries out before they are 50 years. Furthermore you should be 
aware that the findings of this study have now been widely criticised.
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6. Hormone Replacement 21
Having your ovaries out removes all the natural oestrogen that your ovaries would 
been producing until the age of the natural menopause. The amount of oestrogen 
that is added back by taking HRT is less than the amount your ovaries would have 
produced naturally. If you stop taking HRT at the age of the natural menopause (so 
when you are 50) then there is no evidence that the breast cancer risk is increased.
Q7 - Will HRT reduce all the symptoms of menopause?
No. Taking HRT is not the same as having your own hormones. HRT cannot reduce all 
symptoms of the menopause and women who have had surgery and are on HRT do 
report more symptoms than women who have not had surgery. However, HRT can 
relieve some of the symptoms of the menopause. For example, women who took 
HRT reduced the average number of hot flushes from about 4 to about 1 per day 
when compared to women who did not take HRT. Women on HRT also had fewer 
night sweats.
Q8 - Will HRT deal with the long term health effects of the menopause?
Yes. HRT will reduce the risk of bone thinning and changes in memory functioning 
linked to the loss of oestrogen. However, the evidence of HRT‘s effects on 
cardiovascular disease (heart disease and stroke) is more controversial and should be 
discussed with your doctor in terms of your personal and family history of 
cardiovascular disease as well as your lifestyle, which can also affect your risk of 
cardiovascular disease.
Q9 - Are there any alternatives to HRT?
Yes. There are numerous non-hormonal alternatives to HRT, none of which have been 
shown to be as effective in relieving menopausal symptoms. For people who cannot 
take HRT these alternatives may be a good option but for those who can, HRT is the 
best option. 
Alternatives include:
- Antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs)
- Gabapentin
- Red Clover
- Ginseng
- Evening primrose oil
- Agnus Castus
- And many more
Some of these options may be prescribed by your doctor, while others can be bought 
in health shops or over the internet. However, there is no medical proof that freely 
available herbal options work. These alternatives to HRT may have side-effects and 
you should always consult your doctor before deciding to use any of these options.
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7. Other Options
Questions in chapter 7:
Q1 Is there any screening available for ovarian cancer?
Q2 What is the alternative to surgery?
Q3 But I have been offered CA125 blood tests and/or trans-vaginal scans?
Q4 What would happen if I do not have surgery?
Q5 Is there anything else I can do?
Q1 - Is there any screening available for ovarian cancer?
No. Unfortunately there is no medically proven screening available for ovarian cancer.
A large trial of ovarian cancer screening finished in December 2011 and the results 
are not yet available, so we do not yet know whether this screening is effective and 
can detect ovarian cancer early. Until the results of the trial are available the NHS will 
not offer routine screening. The trial offered women CA125 blood tests every four 
months and one yearly trans-vaginal ultrasound scan.
Some areas or GPs may offer private, self-funded CA125 and/or trans-vaginal 
screening to high risk women, however women need to be aware that there is still no 
proof that this screening is effective in detecting ovarian cancer early.
You should also be aware that the yearly smear test you receive is designed to detect 
cervical cancer and will not detect ovarian cancer.
Women from families with Lynch syndrome may receive trans-vaginal ultrasound 
screening to look for womb cancer. The ovaries may be visible on these scans and if 
something is found the GP may order a CA125 blood test. In this case the CA125 
blood test is a diagnostic test and not a screening test.
Any woman with symptoms of ovarian cancer is likely to be offered a diagnostic 
CA125 test and trans-vaginal ultrasound scan, however this is not part of a screening 
programme. Women with no symptoms will not be offered routine screening on the 
NHS until the screening has been shown to be effective.
Q2 - What is the alternative to surgery?
At the moment the official alternative to surgery is to do nothing and simply be aware 
of the symptoms of ovarian cancer should they develop. However it is important to 
realise that these symptoms can be very vague and are not specific to ovarian cancer. 
If any of these symptoms happen more than 12 times a month you should contact 
your GP.
The symptoms include: 
Persistent bloating (big or swollen tummy)
Feeling less hungry or feeling full quickly
Persistent pain in your tummy or below
Needing to urinate more than usual
22
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Q3 – But I have been offered CA125 blood tests and/or trans-vaginal scans?
Some centres and/or GPs may offer private CA125 tests or trans-vaginal scans to 
women at high risk of ovarian cancer. As these are not offered as screening tests by 
the NHS you may have to pay for these yourself. You can choose to have these tests 
done, but you should be aware that there is no evidence that these screening tests 
are effective at detecting ovarian cancer early.
Women from Lynch syndrome families may be offered hysteroscopies or trans-vaginal 
ultrasound scans to detect uterus/womb cancer, which these women are at higher 
risk for. However usually these tests are designed to detect womb cancer only and 
not ovarian cancer.
Q4 - What would happen if I do not have surgery?
If you decide not to have surgery, then nothing will really change. You will need to 
look out for any symptoms and if you think anything is wrong you need to go to your 
GP to get it checked. Make sure you tell your GP that you have a family history of 
ovarian cancer and are at increased risk  of ovarian cancer when you talk to them.
Remember you can reconsider surgery at any time. If screening for ovarian cancer is 
shown to be effective in the future, you may then be offered screening as an 
alternative to surgery.
Q5 - Is there anything else I can do?
As there is no routine screening available, you can choose to have screening privately, 
but you should be aware that this has not yet been shown to be effective. You should 
also keep an eye on any symptoms.
Studies have found that a healthy diet with plenty of fruit and vegetables, keeping a 
healthy weight and an active lifestyle can improve overall well-being and might 
reduce your chances of getting cancer.
In some countries it is recommended that women at high risk of ovarian cancer take 
the oral contraceptive pill when they are pre-menopausal. The oral contraceptive pill 
reduces ovarian cancer risk by up to half, but it has also been found to increase breast 
cancer risk. The guidelines in the UK do not recommend taking the oral contraceptive 
pill solely for the prevention of ovarian cancer at the moment, although in some 
situations reduction in ovarian cancer risk may outweigh any increase in risk of breast 
cancer. Whether the oral contraceptive pill might be an option for you depends on 
your risk and family history of breast cancer and should be discussed with your 
genetic counsellor and GP. 
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8. Your Decision (Example)
Makes me want 
to have surgery
Makes me want to 
avoid surgery
Does not 
come into 
my decision
…surgery will reduce my 
ovarian cancer risk
…surgery will reduce my breast 
cancer risk
I might enjoy sex less after 
surgery
…I will not be able to become 
pregnant after surgery
I will go into surgical 
menopause after surgery
There is no effective screening 
for ovarian cancer
The symptoms of ovarian 
cancer are very vague
I might feel different about my 
body after surgery
Enter you own reasons:
The fact that…
Add together the numbers in 
each column:
In the exercise on the next few pages you can rate some facts depending on how 
much they make you want to have or want to avoid surgery.  Give each fact a 
ranking number (e.g. from 1 (a little) to 3 (a lot), then add the numbers up to see 
where you stand.
The table below is already filled in to give you an example. On page 26 you will find 
an empty table for you to fill in.
X
3
2
3
2
1
2
1
Have to take time off 
work 1
78
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Below you can enter the overall number into the scales. Then note down how you 
feel about the decision and where you stand.
The scales below are already filled in to give you an example. On page 27 you will 
find an empty scale for you to fill in.
For Surgery Against Surgery
8 7
My action plan: I will make an appointment with my genetic 
counsellor to discuss the menopause and find out 
whether I can take HRT. 
Will talk to my boss about taking time off and 
whether it would cause any problems.
Overall your answers show that at this moment in time you are leaning towards having the
surgery. Even though you may have some reasons why you would want to avoid surgery,
they are not as important to you as the reasons that make you want surgery. Therefore you
could now make an appointment to discuss this decision with your doctor and go through
any concerns you might have.
Overall your answers show that at this moment you are completely undecided about
whether or not to have surgery. Your reasons for why you would want to have and why
you would want to avoid surgery balance each other out. Therefore you may want to
discuss your options further with your doctor/genetic counsellor.
Overall your answers show that at this moment in time you are leaning towards not having
surgery. Even though you may have some reasons why you would want to have surgery,
they are not as important to you as the reasons that make you want to avoid surgery.
Therefore at this moment in time surgery is probably not the right option. However, keep
in mind that things may change over time and that eventually you may lean more towards
surgery. You can come back to OvDex and do this exercise again anytime to see whether
anything has changed.
Overall decision: My reasons for surgery weigh more than those 
against surgery, but I am still not sure. The 
numbers are very similar.
More weight for than against surgery:
Same weights both sides:
More weight against than for surgery:
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8. Your Decision
Makes me want 
to have surgery
Makes me want to 
avoid surgery
Does not 
come into 
my decision
…surgery will reduce my 
ovarian cancer risk
…surgery will reduce my breast 
cancer risk
I might enjoy sex less after 
surgery
…I will not be able to become 
pregnant after surgery
I will go into surgical 
menopause after surgery
There is no effective screening 
for ovarian cancer
The symptoms of ovarian 
cancer are very vague
I might feel different about my 
body after surgery
Enter you own reasons:
The fact that…
Add together the numbers in 
each column:
In the exercise on the next few pages you can rate some facts depending on how 
much they make you want to have or want to avoid surgery.  Give each fact a 
ranking number (e.g. from 1 (a little) to 3 (a lot), then add the numbers up to see 
where you stand.
Make sure you give the score on the correct side of the table.
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8. Your Decision
Below you can enter the overall number into the scales. Then note down how you 
feel about the decision and where you stand.
For Surgery Against Surgery
Overall your answers show that at this moment in time you are leaning towards having the
surgery. Even though you may have some reasons why you would want to avoid surgery,
they are not as important to you as the reasons that make you want surgery. Therefore you
could now make an appointment to discuss this decision with your doctor and go through
any concerns you might have.
Overall your answers show that at this moment you are completely undecided about
whether or not to have surgery. Your reasons for why you would want to have and why
you would want to avoid surgery balance each other out. Therefore you may want to
discuss your options further with your doctor/genetic counsellor.
Overall your answers show that at this moment in time you are leaning towards not having
surgery. Even though you may have some reasons why you would want to have surgery,
they are not as important to you as the reasons that make you want to avoid surgery.
Therefore at this moment in time surgery is probably not the right option. However, keep
in mind that things may change over time and that eventually you may lean more towards
surgery. You can come back to OvDex and do this exercise again anytime to see whether
anything has changed.
More weight for than against surgery:
Same weights both sides:
More weight against than for surgery:
Overall decision:
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8. Your Decision
Q1 – How can I deal with my decision?
If you are considering surgery, it can help to think about the support you do have and 
how different people might be able to help you. This can include simple things such 
as driving you to and from the hospital, helping you out with household chores or 
childcare issues right after surgery. 
Before committing fully to surgery you can discuss any further questions with your 
doctor or genetic counsellor and you can also seek a second professional opinion at 
any time if you wish.
If you decide not to have surgery it might be helpful to speak to your GP and let them 
know about your risk. Some women also find it reassuring to have an action plan in 
case they feel like any symptoms develop. This can be a simple reminder, such as a 
plan to contact your doctor if symptoms last 2 weeks or longer.
My action plan:
28
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9. Contacts and Resources
Here are some links and contact details that you might find helpful (even though we 
have taken great care in choosing websites from reliable sources please note we are 
not responsible for the content of these websites):
The Cancer Genetics Story Bank – An online collection of stories told by patients and 
professionals about cancer genetics, genetic testing and risk-reduction decisions. 
Developed by the Cancer Genetics Service for Wales (CGSW) 
www.cancergeneticsstorybank.co.uk 
NHS Choices – A website created by the NHS to provide information to patients. 
Includes information on ovarian cancer, genetics and genetic testing.
www.nhs.uk
Macmillan –A UK charity for anyone affected by cancer with good information about 
genetic testing for cancer and mind-body therapies
www.macmillan.org.uk or call the support line on 0808 808 00 00
Target Ovarian Cancer – A UK charity which supports research into ovarian cancer 
and provides useful information including an ‘Ask the Expert‘ feature. Available in 
several languages.
www.targetovariancancer.org.uk 
Ovacome – A UK charity providing information and support for everyone affected by 
ovarian cancer. Includes links to a number of patient blogs. 
www.ovacome.org.uk or call the supportline on 08453710554
Your GP and/or Genetics Service – There to help you with any questions or concerns. 
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Appendix 8.1 - Multi-Centre Ethics Committee for Wales Favourite Opinion Letter  
(Amd. 3) 
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Appendix 8.2 – Topic Guide for Interviews (Usability testing)  
 
 
 
 
First of all I would like to talk about the Option Grid, so that’s the A4 sheet of 
paper with the table of options, is that okay? 
 
- What did you think of the ‘Options Grid’ table?  
 Probes: 
 What did you expect when you first saw that?  
 Why do you think you expected that? 
 What were the questions that came to mind when you  read the 
 grid? 
 Were there any questions that you think should have  been 
 included but weren’t covered? 
 What did you think about the order of questions in the Option 
 Grid? 
 
Now I would like to move on and talk about the longer OvDex decision aid, okay? 
 
- First of all, did you look at the online or printed version? 
- Did you find it easy to access the online decision aid?  
 Probe: 
 If not: What problems did you encounter? 
- How long did you look at it approximately?  
 Probe: 
 Did you look at it more than once, if yes, how often? 
- Can you walk me through how you used the website?   
- Probes:  
 Did you personalise it?  
 What did you expect from that part?  
 What did you think when you read that?  
 Why do you think you thought that?  
 How did that make you feel?  
 Was this what you expected? 
- What did you expect [name of section / question heading] to include?  
 Probes: 
 What do you think … means?  
 Why do you think that might be important to include? 
- Did you use the weighing up exercise in the tool?  
 Probes: 
 What did you think of it?  
 If you were a woman at risk of ovarian cancer, would you 
 trust the output? Why / Why not? 
 
 
 
Questions 
regarding 
Option Grid 
Questions 
regarding 
OvDex 
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For further prompting if needed: 
Did you find the tool easy to navigate? Why / why not? 
What did you think of the design / format? (i.e. layout, colour etc.) 
Was the content easy to understand? Can you give examples? 
Was the language straightforward enough, or perhaps too simplistic 
or too complex? 
Was there the right balance between text and diagrams/graphs? 
Which parts did you find most interesting? Why? 
Where there any parts you struggled with or didn’t understand? 
Which parts? 
Did you have a look at any of the additional resources? What did you 
think of them? 
 
 
To finish off this part of the interview, could I just ask… 
 
- Overall, what did you think about the amount of information given (in 
the grid and/or decision aid)?  
 Probes: 
 If too much info, what would you have liked less on?  
 If not enough info, what would you have liked more on? 
- Do you have any suggestions for improvement of the option grid or 
the website?  
 
Do you think the tool would be helpful/not helpful for patients at risk of ovarian 
cancer and if so how/why? 
 
- What do you think is especially helpful / least helpful?  
 Probe: 
 Why? 
- How do you think patients might react to the tool?  
 Probes:  
 Why do you think that?  
 Feel free to use your own feelings as examples. 
 
And the final part of the interview is about how we should use this tool in clinical 
practice. How do you think this tool should be used in practice, how should it be 
introduced to patients? 
 
- Who should give it to patients? 
- When should it be given to patients? 
- Do you think the tool is going to help patients in making a decision? 
Why?
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Theme Code Details of code 
Option Grid (OG) content 
Layout / Structure 
Any comments about what they thought about the layout / structure of the Option Grids; 
comments about table format, possibility for direct comparison, what they expected when 
they first saw the format, whether they understood how to read the grid etc. 
Understanding 
Any comments about whether the information in the Option Grid(s) was clear / unclear, easy 
to understand etc., any details about what was easy or difficult to understand, any 
comments on whether something had to be read multiple times to be understood, any 
comments about cognitive processing of questions / individual terms (i.e. what they thought 
when they read question / term etc.). 
Questions 
Any comments about questions that came to mind when reading the information in the grid, 
questions which they wanted to explore further in response to reading the information in 
the grid; (NOT questions they think need to be added to the grid [see ‘improvements’]), 
Improvements 
Any comments about possible improvements to grids (e.g. ideas for adding content, 
expanding content, restructuring content and deleting confusing / unnecessary content); 
comments about questions that might be missing in the grid (incl. if participant feels no 
questions are missing) (EXCEPT recommendations about changing the order of questions, 
see code ‘Question order/) 
Question order 
Any comments relating to the order of the questions in the option grid, including any ideas 
for changing / improving the order 
   
5
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OvDex content (OvDex) 
(web- and paper-based 
version) 
 
 
 
 
 
 
 
Layout / Structure 
Any comments about what they thought about the layout / structure of OvDex; comments 
about what they thought of the format (paper / website), what they expected to find under 
each section heading; any comments about section structure (i.e. questions at the top, then 
answers below etc.); any comments about colour scheme and branding; any comments 
about graphs / pictograms 
Usage 
Any comments about time spent using the decision aid, how long they looked at the Option 
Grids and/or website, how many times they looked at it, whether they came back to it more 
than once etc.; any comments about using it with someone else 
Understanding 
Any comments about whether the information in OvDex was clear / unclear, easy to 
understand etc., any details about what was easy or difficult to understand, any comments 
on whether something had to be read multiple times to be understood, any comments 
about cognitive processing of sections / individual terms (i.e. what they thought when they 
read section / term etc.) 
Value clarification (website) 
Any comments specifically relating to the content (NOT functionality) of the online value 
clarification exercise, whether they understood the instructions and how to use it, whether 
they tried it out, what they thought when they did, whether they found it helpful or not, why 
they found it helpful / not helpful (any comments about problems with functionality must be 
coded ‘OvDex website, functionality’) 
 
5
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OvDex content (OvDex) 
(web- and paper-based 
version) cont. 
Value clarification (paper) 
Any comments specifically relating to the content of the paper value clarification exercise, 
whether they understood the instructions and how to use it, whether they tried it out, what 
they thought when they did, whether they found it helpful or not, why they found it helpful / 
not helpful 
Other sections 
Any comments on sections other than the information content and value clarification 
exercise; e.g. comments on contacts and resources, comments on external links they 
followed, comments on research evidence section, comments on ‘about OvDex’ section with 
disclosure of funding sources and collaborators. 
Improvements 
Any comments about possible improvements to OvDex (e.g. ideas for adding content, 
expanding content, restructuring content and deleting confusing / unnecessary content). 
   
OvDex website 
Accessibility 
Any positive / negative comments relating to getting access to the online decision aid on a 
PC, iPad, mobile phone 
Functionality 
Any comments on interacting with the decision aid’s interactive functions (particularly the 
personalisation and value clarification sections); did user try to personalise OvDex, did user 
do the value clarification exercise and found it easy to interact with; any comments on things 
that worked / did not work (e.g. broken links, limited interactivity) 
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Navigation 
Any comments on navigating the decision aid; any descriptions of how participant read 
through the decision aid and individual pages (did they read through sequentially, did they 
skip sections, did they follow links, did they go backward and forward between pages or 
jump to questions) 
   
OvDex paper Navigation 
Any comments on navigating the decision aid booklet; any descriptions of how participant 
read through the decision aid and individual pages (did they read through sequentially, did 
they skip sections, did they go backward and forward between pages or jump to questions) 
   
 
 
 
 
Overall 
 
 
 
Impact / Effects 
(general, encompassing the 
whole decision aid) 
Any comments about whether participant thinks the tool would be helpful / useful for 
themselves and/or women at risk of ovarian cancer and why they think this, any comments 
about how they or patients reacted / might react to the tool, any comments about feelings 
experienced whilst using the tool; any comments regarding how or whether the decision aid 
would facilitate decision making; any comments about wanting to or having recommended 
the decision aid to others 
Information amount 
Any comments regarding the amount of information on the decision aid, whether it is too 
little, too much (specific ideas for improvements must be coded as such, i.e. under 
‘Improvements’ for Option Grid or website) 
5
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Most helpful 
 (specific to certain sections) 
Any comments that are particularly positive, refer to sections / items they liked and found 
particularly helpful (can be both Option Grids and OvDex) 
Least helpful 
(specific to certain sections) 
Any comments that are particularly negative, refer to sections they did not like and found 
particularly unhelpful (can be both Option Grids and OvDex) (specific ideas for 
improvements must be coded as ‘Improvements’) 
   
Implementation 
Provider 
Any comments about who should give the decision aid to patients, e.g. doctor, nurse, 
genetics specialist, oncologist etc. and where it should be given to patients, e.g. surgery, 
genetics service consultation etc. 
Timescale 
Any comments about when the decision aid should be provided during the decision making 
pathway and why they think this time point is suitable 
   
Other 
Medical History Comments relating to personal or family history of diseases (incl. cancer and other diseases) 
Decision 
Any comments about what the participant would decide for herself before / after using the 
tool 
5
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Question Any questions asked by participants and answers given by interviewer 
Reference Any comments about things the interviewer, researcher should look up 
Misc Any comments that do NOT readily fit with the suggested codes 
 
5
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Appendix 8.4 - Extract of Coded Transcript (Usability testing) 
R:  Yeah, it’s a really great looking website as well, it’s really nice looking so it’s 
really easy to surf through  
I:  Oh great, OK so you em, you found it quite em, easy to access it and then 
navigate around it did you?  
R:  Yeah, really easy to use, yeah and really not patronising, it gave you the 
information that you required and it gave you more detail if you wanted it, so 
it was good  
I:  Oh good, OK and how long, approximately, if you remember did it take you to 
go through it? 
R:  It took me about an hour I’d say  
I:  OK  
R:  But I had to go through the general ‘cos obviously I don’t have the symptoms, 
I, I’m not one of these people, I couldn’t say, I couldn’t specify it for me. And I 
think it probably takes less time if you knew which faulty gene you had. 
I:  Yeah, yes, yeah, and I mean, you did see the personalised option em on the 
website did you?  
R:  Yeah  
I:  OK, great, yeah  
R:  Yes, I tried, I tried to do that first, I thought oh, maybe I’ll pretend I’ve got 
Lynch Syndrome. 
I:  Yeah, you could have, yeah  
R:  That’s right, then I thought well I wont, I wont, I don’t know what that’s going 
to miss out and I’ll probably end up having to go through it a few times so I just 
did it generally but if I had, if I was one of the people who had been told…  
(I:  Yeah) 
R:  …that I was at high risk and knew what it is, I would absolutely use the em the 
one that’s restricted to you because it’s giving you the information that’s 
particularly relevant to you and I think you can get a bit scared or overly 
concerned if you’re reading about something that doesn’t even actually apply 
to you. 
Overall 
Impact / Effect 
OvDex (web) 
Function 
Other 
Medical 
History 
OvDex 
Usage 
OvDex 
Understanding 
OvDex 
Layout / Structure 
+ 
OvDex (web) 
Navigation 
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I:  Yes, yes I mean that’s partially why we did the personalisation option em, for 
those women, yeah, you’re absolutely right and if you had had the information 
then you probably would have done that, that’s good to know ((laughs)) and it 
all seemed to work  
R:  Yes 
I:  As well which is also good to know  
R:  Yeah, yes  
I:  Em, could you just er, walk me through how you used the website? Did you 
look at everything in, in sequence, these kind of things  
R:  Yeah, I mainly looked at things, I tried to look at things in sequence, so I went 
into the first section with the hyperlink that’s used y’know, if this does not 
apply to you then you can browse the information using our menu or view the 
first section on cancer risk so I clicked on the cancer risk hyperlink there. Em, 
and I worked through most of it in the logical order, so I’d get to the end of the 
page and I’d click on the, y’know I’d click on the next page tab at the end, but 
in a few occasions there was a hyperlink, though I definitely remember I went 
to the menopause one early so I think in the, when I was looking at something 
and it had a hyperlink to the menopause that I, or the HRT bit, the hormone 
replacement bit, I clicked on that and then I realised later on, oh I would have 
come to that page anyway  
I:  Oh, OK yes, I see now , yeah OK so you, you em realised later that you would 
have come to it naturally but you  
R:  Yes  
I:  Skipped it in the first instance  
R:  Yeah, and I guess because it was one of the areas I knew the least about  
I:  Yeah  
R:  And, and it was mentioned early on, and I thought, ooh, whilst that’s fresh in 
my mind I’ll look at that, so I like that because you can do it both ways can’t 
you, if you miss the hyperlink or whatever you’re gonna come across the 
information anyway but equally if that’s all you want to know about then you 
can just go straight to it  
I:  Yeah, yes, I mean that’s er, the idea behind the hyperlinks and you can go 
backwards as well if you feel like you might have missed something em  
R:  Ah yeah, cool, yeah 
OvDex (web) 
Navigation 
OvDex (web) 
Function 
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Comments from lay reviewers Potential amendment(s) Management team decision 
R1: I thought they were quite good […]. I think just from an ease to read 
point of view, there just needs to be a line to separate the frequently 
asked questions and then […] what the options were because I read it 
first off and then was a little bit confused. (35to39, noOC, B&OCFH, 
BRCA2) 
Make the Frequently Asked Questions 
column more distinct 
Frequently Asked Questions column 
was coloured in light orange 
R6: Most people will read this and think: ‘Hang on, I’m getting my ovaries 
taken out so surely that’s going to completely remove the risk of ovarian 
cancer.’ But you do […] later on explain that peritoneal cancer is part of 
the ovarian cancer class […]. I wonder if that’s really clear to your 
average person on the street.  (40to49, yesOC, BCFH, BRCA1) 
R6: I suppose again in the first part of the Grid when you’re saying: ‘Yes 
removing the ovaries and fallopian tubes will reduce your lifetime risk of 
ovarian type cancer.’ Again you’ve got ‘ovarian type cancer’ and I’ve just 
kind of put again primary peritoneal question mark there. So I guess if 
you kind of explain a little bit more in the first paragraph then that’s fine. 
(40to49, yesOC, BCFH, BRCA1) 
Change wording in opening paragraph 
to clarify that surgery reduces risk of 
ovarian-type cancer;  
Explain what is defined as ‘ovarian-
type’ cancer 
Wording of opening paragraph was 
changed to “…surgery reduces risk of 
ovarian-type cancer…” 
No explanation was added to describe 
‘ovarian-type’ cancer, as this is 
included in the full OvDex tool and as 
the Option Grid would be used 
together with a health professionals 
who could explain the term if required 
R4: I think that flows quite well too really, except maybe the very last 
question should go first. (Over50, yesOC, noFH, unknown) 
R8: I think the routine screening question should probably be closer to 
the top. Although it’s a bit of a negative then but it’s still I think one of 
the first things you think about. (35to39, noOC, OCFH, unknown) 
R1: [The grids] are fairly logical […]. It sort of works its way through the 
different questions, I think the order is okay. […] You could put the 
screening question up at the front, […] because I suppose really that 
might be an early question. (35to39, noOC, B&OCFH, BRCA2) 
R5: I think possibly I would say the routine screening programme should 
Move screening question further 
towards the top of the grid 
Screening question was moved up to 
be the second question in the grid 
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be higher, because that’s a major thing, because if there's some 
screening programme you wouldn’t want to go any further. (Over50, 
yesOC, noFH, unknown) 
R2: My concerns were the menopause, the HRT and the health risks if I 
had surgery. For me they are the most important. For me they would 
want to be at the top. That’s my feeling anyway. (Under35, noOC, 
B&OCFH, BRCA2) 
Move ‘How I feel about my cancer risk’ 
and ‘How I feel about myself’ questions 
further down the grid 
Not actioned, as all other respondents 
were satisfied with the order of 
questions in the Option Grids and the 
respondent herself admitted later that 
the order did not make a difference 
R12: The ‘how I feel’ question […], I can see why it’s in there, but I wasn’t 
entirely sure that […] the answers actually added anything. […] It doesn’t 
give you any facts, […] it’s quite bland. […] Have women who have had to 
have this operation at thirty-three, or chosen to have this operation at 
forty-three or whatever, have they come back and said: Oh god, I really 
regret it, I wish I hadn’t had it?  I think that sort of information would be 
more useful (Under35, noOC, OCFH, unknown) 
Add factual information to ‘Will this 
change how I feel about my risk…’ 
question ;  
Move ‘How I feel’ question further 
down the grid 
Factual information about satisfaction 
with RRSO was added (Finch, 2011; 
Tiller 2002; Westin 2010); 
The question was not moved further 
down the grid, as all other respondents 
were satisfied with the order of 
questions in the Option Grids 
R12: The only thing that I didn’t know in much detail when I was looking 
at the option grid, is what the actual operation was. But I’m assuming 
that these people would have been talked through the operation before 
they see the grid. (Under35, noOC, OCFH, unknown) 
Provide clearer definition of what the 
surgery is in Option Grid. 
Not actioned, as this is included in the 
full OvDex tool and as the Option Grid 
would be used together with a health 
professionals who could explain what 
surgery is 
R6: The question ‘Will surgery change how I feel about myself as a 
woman?’ And you’ve said ‘However your desire for and or enjoyment of 
sex may decrease’ and I’ve put yes exclamation mark, because sorry I 
don’t know you but I am totally not interested now. […] And I just 
thought well maybe you should be a little bit stronger about that. 
(40to49, yesOC, BCFH, BRCA1) 
R3: I think yes it does give your sexuality a bit of a knock. That’s all I’d say 
Change wording of ‘How I feel’ 
question to be stronger regarding 
sexual functioning 
Wording changed to “…is likely to 
decrease” 
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really there. (Over50, yesOC, BCFH, BRCA2) 
R10: Generally speaking I’ve had a very normal sex life and although we 
don’t shall we say have conventional sex now but we do have intimate 
moments shall we say […]. There are ways round things. […] We’re all 
different and ‘Your desire for sex’ it says ‘will decrease’. It might not, 
might it? That’s on page 13, number 3.  (Over50, yesOC, BCFH, unknown) 
Reduce emphasis on reduced sexual 
functioning 
Wording changed to “…is likely to 
decrease” 
R12: In what percentage of cases I guess does it go from keyhole to full 
surgery? (Under35, noOC, OCFH, unknown) 
Add statistical info about number of 
keyhole versus open surgeries 
Not actioned, as this is included in the 
full OvDex tool and as the Option Grid 
would be used together with a health 
professionals who could explain, if 
required 
R13: It might be a good idea just to mention that it can be quite 
traumatic afterwards for a few weeks. I wasn’t too bad, but a lot of 
women can experience extreme tiredness […]. They need to know all 
this, especially if they’re looking after somebody or they need to work. 
(Over50, yesOC, BCFH, unknown) 
Add information about post-surgical 
pain, tiredness and other issues 
affecting functioning 
Added statement about post-surgical 
effects during recovery saying 
“…during which time you may feel pain 
/ tiredness and need help with 
everyday tasks.” 
R6: It says: ‘No after surgery there is no need for screening because your 
risk will be similar to that of the general population’ and I thought: ‘Well 
surely it’s going to be lower actually?’ […] So I just thought well maybe 
using the word similar there isn’t really showing that there’s much of a 
difference between you having gone through the operation and 
somebody out of the general population who has not. So it’s almost like 
making you think: ‘Oh hang on a minute there’s really no benefit then of 
having the operation.’  (40to49, yesOC, BCFH, BRCA1) 
Reword / clarify answer to screening 
question in surgery column to avoid 
confusion, e.g. remove/reword “similar 
to that of the general population” 
Reworded answer to screening 
question to “No, there is no evidence 
that screening for ovarian cancer is 
effective and after surgery there is no 
need for screening as your risk will be 
low.” 
R1: [The grid] was very black and white, [either] you have surgery or you 
don’t. And it’s almost like if you don’t have surgery you take your life in 
your own hands, whereas there is the possibility of having ultrasounds 
Clarify why there is no evidence that 
screening is effective (i.e. no proven 
survival benefit due to early detection) 
Reworded answers to screening 
question to “No, there is no evidence 
that screening for ovarian cancer is 
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for early detection […]. I’m lucky that I can get that done but I don’t 
know if other [NHS] Trusts […] do that, so I suppose that’s quite a tricky 
thing. (35to39, noOC, B&OCFH, BRCA2) 
R13: I know the CA125 isn’t a screening [test], it’s more of a diagnostic 
[test], but […] why can it not be a screening [test]? (Over50, yesOC, 
BCFH, unknown) 
effective in saving lives.” and “No, 
there is no evidence that screening for 
ovarian cancer is effective and after 
surgery there is no need for screening 
as your risk will be low.” 
R10: If you were having surgery [the answer] didn’t answer the question. 
[…] Whereas if you were not having surgery it did answer the question, 
because there isn’t [a screening programme]. It should have said: ‘No 
there isn’t a screening programme and after surgery anyway...’ I feel it 
needs a little addition. (Over50, yesOC, BCFH, unknown) 
Reword answer to screening question 
in surgery column 
Reworded answer to screening 
question to “No, there is no evidence 
that screening for ovarian cancer is 
effective and after surgery there is no 
need for screening as your risk will be 
low.” 
R5: Lots of women seem to think that if you have your smear test you’re 
being checked for ovarian cancer at the same time so I think to make it 
very clear that that is not the case and there is no screening. There is no 
way of telling from any sort of check that is done. I think that needs to be 
something that would then concentrate their minds. (Over50, yesOC, 
noFH, unknown) 
Make it even clearer that there is no 
screening for ovarian cancer; 
Emphasise that the smear test does 
not test for ovarian cancer 
Reworded answers to screening 
question to “No, there is no evidence 
that screening for ovarian cancer is 
effective in saving lives.” and “No, 
there is no evidence that screening for 
ovarian cancer is effective and after 
surgery there is no need for screening 
as your risk will be low.”; 
Information about smear test was not 
added, as this is included in the full 
OvDex tool and as the Option Grid 
would be used together with a health 
professionals who could explain, if 
required 
R4: On the post menopausal women thing I think that there could be For post-menopausal grid, add Not actioned, as current guidelines do 
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something added about taking HRT […] afterwards, because I am post 
menopausal obviously, but I was on HRT before I was diagnosed and 
have had to go back onto some oestrogen only HRT after. (Over50, 
yesOC, noFH, unknown) 
information on hormone treatment 
options 
not recommend any HRT for women 
who are over 50 / postmenopausal 
R5: [In the pre-menopausal grid] it talks about the risk of bone thinning 
and cardiovascular disease, but that I think would be […] reassuring to 
me if I only looked at the one for after the menopause to be told that 
actually the risk is t[…]to women before age 45. […] Because that would 
actually be quite reassuring and would quite possibly help to make me 
make a decision. (Over50, yesOC, noFH, unknown) 
For post-menopausal grid, add section 
on long-term health effects due to 
hormone deprivation, which are not 
relevant to this population 
Not actioned, as Option Grids are 
designed to be uncomplicated and 
inclusion of irrelevant data for the 
target population may confuse users. 
Postmenopausal women will only 
receive the postmenopausal grid, 
hence they would not be alerted to the 
long term health risks affecting 
premenopausal women, as were 
participants in this study who viewed 
both grids. 
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Comments from lay reviewers Suggested amendment Management team decision / action 
Personalisation 
R5: Right at the beginning it confused me, once I got into it, it didn’t at 
all, but the very beginning confused me. […] The way it comes in at the 
moment it just says: ‘Welcome to OvDex, please note it can be 
personalised you should have seen and answered these questions before 
viewing these pages.’ […] You think ‘Oh hang on what questions then?’. 
(Over50, yesOC, noFH, unknown) 
Ensure that Index page appears first 
when www.OvDex.co.uk is opened 
Index page was made default home 
page for URL www.OvDex.co.uk 
R6: I actually tried to use the online thing because I thought: ‘Well I’ll 
personalise it to myself obviously, because I’ve got a BRCA 1 mutation.’ 
[…] And it didn’t seem to want to work, so it […] just came back to the 
original question. (40to49, yesOC, BCFH, BRCA1) 
Review personalise functionality and 
ensure it is working correctly (if Return 
button does not work, add instructions 
that users need to use the ‘Submit’ 
button at the bottom of the screen) 
Personalise functionality was reviewed 
in available browsers 
R5: The thing that I thought was a bit odd at first is the ‘it can be 
personalised’. I would have thought you would want it to be 
personalised really. […] I don’t know [under] what circumstances you 
wouldn’t want to personalise it. (Over50, yesOC, noFH, unknown) 
R5: It says you can personalise or visit the general version if you don’t 
want to personalise. […] There’s nothing there to tell people what that 
means. (Over50, yesOC, noFH, unknown) 
R9: I kind of wished that I’d been directed to personalise it first. (Over50, 
yesOC, noFH, unknown) 
R9: I wasn’t quite sure, because it doesn’t really give you very much 
information at all as to whether it’s gonna be more helpful to personalise 
Emphasise that personalisation is 
advantageous in the instructions and 
guide people further towards using the 
personalise function rather than 
viewing the general version. 
Section on Index page was reworded 
to: “The information in OvDex can be 
tailored to your personal situation by 
answering three simple questions. We 
recommend that you use this function, 
so that the information displayed is 
more relevant to you. You can 
Personalise OvDex by clicking here. 
If you do not wish to personalise 
OvDex, you can visit a General Version 
here, but please be aware that some of 
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it or visit the general version. (Over50, yesOC, noFH, unknown) 
R9: I kind of wonder whether it might be [useful] as well to guide people 
a bit more there and say that by personalising it, [it] is gonna be exactly 
that, it’s gonna be personalised more, the information will be most 
relevant to what you need. (Over50, yesOC, noFH, unknown) 
R9: it might have been better to say: There is general information, but it 
will probably be most helpful to you to personalise it to your situation 
and read that first’. (Over50, yesOC, noFH, unknown) 
R9: I would definitely try and sort it round so that you personalise it and 
then, if after you’ve read your personalised information you would like 
to just look at the general version you can do so, but try and get people 
not to waste time on the general version. (Over50, yesOC, noFH, 
unknown) 
R9: There’s nothing on that open page that tells you how simple it’s 
gonna be to personalise it. (Over50, yesOC, noFH, unknown) 
R13: I didn’t realise, I’m not very good with the internet, I don’t know 
why, why I didn’t see the personalised one. (Over50, yesOC, BCFH, 
unknown) 
the information in this version may not 
apply to you.”; 
Size of text was changed to be bigger 
R5: ‘The information on the following pages has not been personalised. If 
you do not wish to personalise OvDex then you can view the general 
information using the menu or see the first section on cancer risk.’ That 
doesn’t tell you you’re actually going to go in to it. […] It’s not clear that 
you’re actually going to go into, at this point now. (Over50, yesOC, noFH, 
unknown) 
On home pages once personalisation 
has been done / general version 
selected, make it clearer that the users 
are now accessing the decision aid 
content. 
Added statement on introductory 
home page after personalisation / in 
General version saying: “You have now 
entered the decision aid.” 
 
OvDex content 
R13: It was helpful, but far too much. It could have been condensed and Remove repetitions; OvDex tool was checked for repetitions 
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[…] probably been a lot clearer […]. Just far too much reading. (Over50, 
yesOC, BCFH, unknown) 
R13: I thought that was […] [a] bit ambiguous, I thought it was too much, 
too much in there actually. […] Sometimes less is more. […] Sometimes 
people give up because it’s just too much information. (Over50, yesOC, 
BCFH, unknown) 
Shorten content and those were removed; 
Content was not shortened, as all other 
respondents were satisfied with the 
information amount 
R6: Personally I think a section about the disease would be really useful, 
You know and statistics of how much treatment people have to have and 
all this, that and the other. (40to49, yesOC, BCFH, BRCA1) 
R6: I thought I wonder if I don’t know you should really include 
somewhere about the cancer and you know basically if you don’t catch it 
early then what can potentially happen to you as well. […] I mean I’m not 
saying you should sort of frighten women into having the surgery but I 
think they need all the facts in front of them. (40to49, yesOC, BCFH, 
BRCA1) 
Add information / section about 
ovarian cancer or add links to this 
information 
Added statement “For more 
information about ovarian cancer, 
check out the Cancer Research UK 
statistics and other websites under 
Contacts and Resources” with links to 
CRUK statistics and Contacts & 
Resources (e.g. NHS, Ovacome, Target 
Ovarian Cancer) for information about 
ovarian cancer 
R11: You know the little bits with all the circles on? […] I would change 
those to little people. […] It says the pictures below, but they’re not 
pictures and they’re sort of blobs. I like more sort of pictury things. 
(Over50, yesOC, noFH, unknown) 
R5: It reminded me of a theatre seating plan yeah. It looks exactly like an 
online booking service doesn’t it? […] But no, I think that’s really good 
because it’s a good clear display […]. The dots indicate the risk that 
you’re talking about.  (Over50, yesOC, noFH, unknown) 
Change dots in pictograms to small 
female signs 
Changed dots to small female signs in 
pictograms 
R6: What I wasn’t really sure about was your pictures showing the 
chances of getting cancer […]. You seem to do this quite a lot all the way 
through. […] I suppose it’s quite a nice indication, but it’s taking up quite 
a lot of room. I don’t know if it’s totally necessary, because people can 
Remove pictograms Not actioned, as positive feedback 
from a number of other respondents 
indicated that the pictograms are 
valued by many women 
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just as easily look at numbers. (40to49, yesOC, BCFH, BRCA1) 
R12: The only thing I was surprised about was that it went in at cancer 
risk. […] It was appropriate for me as somebody who hadn’t been told 
that I’d got a high risk. […] surely everyone who’s using this website has 
already gone through that process so is the explanation at the beginning 
necessary? (Under35, noOC, OCFH, unknown) 
In general / untested version, add that 
some questions are not relevant to 
people who have already been tested; 
Add intro sentence to each section 
before question list to explain what 
section is about (so users can decide 
whether they want to read on) 
Not actioned, as section layout already 
lists questions included in the section 
at the start and allows users to jump to 
questions, ignoring those that they feel 
are irrelevant 
R11: How could I get tested you know without having a family history 
and that kind of thing. (Over50, yesOC, noFH, unknown) 
R6: I know I’m an unusual case but basically I don’t have any family. […] 
There might be other people in my situation who are not being offered 
the genetic test and in fact they could probably benefit from it. […] [Say] 
if there’s some sort of private test thing that people could go and have 
done if the NHS won’t cover it. (40to49, yesOC, BCFH, BRCA1) 
Add info about who can / can’t get 
tested for BRCA and why. 
Added information about possibility of 
private testing “For anyone who 
cannot get tested on the NHS, there 
are some companies offering private 
testing, however this can be expensive 
and without a family history, there may 
be no need for testing.”; 
Emphasised requirements for testing 
on the NHS 
R11: I wanted to know a little bit more about the BRCA test and whether 
or not it was available if I just walked in […] And also probably another 
question about how quickly results would come back and about what 
that would involve. (Over50, yesOC, noFH, unknown) 
Add information about what gene test 
involves and how long results take to 
come back. 
Added statement about gene test, 
timeline and possible outcomes. 
R12: Adding a sentence in to say, if you definitely have the gene then 
your child can be tested in the future or something. (Under35, noOC, 
OCFH, unknown) 
Add information that if a gene 
mutation is confirmed in the family, 
children can choose to get tested 
Added information that if a gene 
mutation is confirmed in the family, 
children can choose to get tested 
R12: [Speaking about ‘Does my risk change with age?’ question] it’s the 
only thing I had to read twice. […] I would say that and if there’s any way 
you could show it in […]diagram form, like you have with the circles we 
Shorten answer to ‘Does my risk 
change with age?’ question and 
replace with diagram / graph. 
Shortened answer to “Does my risk 
change with age?” question to: “Yes, 
cancer risk increases with age”; 
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talked about, […] that would be really useful. (Under35, noOC, OCFH, 
unknown) 
R12: It does get more risky the older you get, that’s all you need to know 
really. (Under35, noOC, OCFH, unknown) 
Added graph showing risk curve  
R6: Why is the operation most effective if it’s done at 40 years of age? 
(40to49, yesOC, BCFH, BRCA1) 
Add information about why surgery is 
most effective at that age 
Added statement about why surgery is 
most effective at 40 years of age: “The 
operation is most effective if it is done 
at 40 years of age, because ovarian 
cancer risk starts to rise from age 40 
onwards. Additionally, if done at 40, 
the surgery reduces the risk of breast 
cancer. However, age 40 may…” 
R1: ‘If you’re unsure about it you could let  a doctor make the decision’ 
[…] I felt quite uncomfortable with that because, to my mind […], if you 
can’t make the decision whether to have surgery or not, then you 
shouldn’t be having surgery. […] Maybe it needs to be reworded or taken 
out or something. […] I wasn’t comfortable with that wording and I don’t 
think it’s that helpful for anybody. I think it’s definitely a decision the 
person that’s having the surgery has to make. (35to39, noOC, B&OCFH, 
BRCA2) 
Review wording of this section and 
reword 
Not actioned, as reviewed wording and 
only identified statement saying “If you 
then don’t want to choose for yourself, 
just say so and they [doctor] may make 
a recommendation.”; 
Did not change coping advice in “The 
Choice” which includes option ‘The 
doctor should decide for me’, as this is 
a valid option if a patient does not 
want to make the decision. 
R6: You go sort of straight into risk reducing surgery. And I thought you 
know a lot of people might be quite scared of having surgery […]. It’s 
quite good for people to see at the beginning other things that are 
available or aren’t available. (40to49, yesOC, BCFH, BRCA1) 
Mention screening earlier on Screening question was moved up to 
be the second question in the grid (and 
therefore “Options at a Glance” 
section) 
R10: The thing about feelings and anxiety […] gets reproduced a lot in Shorten, remove repetition in coping Reworded answers to make them more 
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this book. […] I think it could possibly be a little less. (Over50, yesOC, 
BCFH, unknown) 
advice ‘How can I deal with my cancer 
risk’ / ‘How can I deal with this 
decision’. 
distinct 
R9: My first thought was, hang on, ‘How can I DEAL with this decision?’ 
and I wasn’t sure if that was quite the right wording. Because I wasn’t 
sure what that meant, I wasn’t sure whether I was thinking with question 
one ‘How can I MAKE this decision?’ […], I did wonder whether it was 
something about: What will help me make the best decision for me? Or: 
What will help me make this decision? […] I wasn’t sure about the word 
‘deal’. (Over50, yesOC, noFH, unknown) 
Reword Q1 in Options at a Glance 
section 
Reworded question title to “How can I 
cope with this decision?” 
R6: You’re talking about watching the how do I cope video on the cancer 
genetics story bank website […]. I just wondered if it was an idea to sort 
of put the link to that at the end of that paragraph. […] And then also you 
are talking about the MacMillan website in the next paragraph and I 
thought I wonder if you’d put the link to that there. (40to49, yesOC, 
BCFH, BRCA1) 
Add link to Genetics Story Bank and 
Macmillan website to reference in text 
Added link to Genetics Story Bank and 
Macmillan website to reference in text 
R13: It might be a good idea just to mention that it can be quite 
traumatic afterwards for a few weeks. I wasn’t too bad, but a lot of 
women can experience extreme tiredness […]. They need to know all 
this, especially if they’re looking after somebody or they need to work. 
(Over50, yesOC, BCFH, unknown) 
Add information about post-surgical 
pain, tiredness and other issues 
affecting functioning, which wouldn’t 
be defined as complications but are all 
part of normal recovery. 
Added statement to “How would RRSO 
affect my life?” question about post-
surgical effects during recovery saying 
“... heavy lifting. Therefore you may 
need help with everyday tasks. During 
recovery, you may also feel some pain 
and discomfort and you may be more 
tired than usual. However most 
women…” 
R6: It says ‘having the surgery will also prevent other non-cancer related 
problems happening with the ovaries such as cysts’ and I just thought 
Add information about why it might be 
good to avoid other problems with 
Added statement to advantages of 
surgery list: “…such as cysts, which can 
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again maybe you should sort of expand on that a bit and maybe explain 
why it’s bad to have cysts. (40to49, yesOC, BCFH, BRCA1) 
ovaries. cause some discomfort and pain.”  
R6: some people might say oh well if you’re removing the ovaries why 
don’t you remove the peritoneal as well? […] You and I know that you 
just don’t, you can’t do that. […] So you might just want to explain why 
that can’t be done as well. (40to49, yesOC, BCFH, BRCA1) 
Add sentence about that peritoneum 
cannot be surgically removed. 
Added statement that peritoneum 
cannot be removed to “What is my risk 
after surgery? “ question: “…and pelvis. 
Unfortunately, the peritoneum cannot 
be routinely removed during RRSO.” 
R6: I just thought some people might be wondering, well they might 
even be scared that if they’re opened up for this surgery and cancer is 
found what actually happens then? (40to49, yesOC, BCFH, BRCA1) 
Add info about next steps / procedures 
if cancer is found during the surgery. 
Added information to “Could cancer be 
found during the surgery?” question 
saying: “If cancer is found during this 
check, you will be informed and might 
have to undergo further tests and 
possibly treatment for ovarian cancer.” 
R6: I just wondered if you would get hormone replacement if cancer had 
been found during the surgery and I thought well probably not. […] I just 
didn’t know whether you should sort of maybe say look you don’t get 
hormone replacement if you’ve actually got cancer. (40to49, yesOC, 
BCFH, BRCA1) 
Add statement about HRT if ovarian 
cancer is found. 
Added statement to “Could cancer be 
found during the surgery?” question 
saying: “If cancer is found you might be 
unable to take HRT.” 
R6: The question ‘Will surgery change how I feel about myself as a 
woman?’ And you’ve said ‘However your desire for and or enjoyment of 
sex may decrease’ and I’ve put yes exclamation mark, because sorry I 
don’t know you but I am totally not interested now. […] And I just 
thought well maybe you should be a little bit stronger about that. 
(40to49, yesOC, BCFH, BRCA1) 
R3: I think yes it does give your sexuality a bit of a knock. That’s all I’d say 
really there. (Over50, yesOC, BCFH, BRCA2) 
Increase emphasis on reduced sexual 
functioning 
Wording changed to “…is likely to 
decrease” 
R10: Generally speaking I’ve had a very normal sex life and although we Reduce emphasis on reduced sexual Wording changed to “…is likely to 
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don’t shall we say have conventional sex now but we do have intimate 
moments shall we say […]. There are ways round things. […] We’re all 
different and ‘Your desire for sex’ it says ‘will decrease’. It might not, 
might it? That’s on page 13, number 3.  (Over50, yesOC, BCFH, unknown) 
functioning decrease” 
R6: I mean if you’re restricted to length then I would definitely maybe 
reduce the menopause section a bit. (40to49, yesOC, BCFH, BRCA1) 
Reduce menopause section content. Not actioned, as results from the needs 
assessment indicated that information 
about the menopause is extremely 
important to many women and as 
other respondents during the usability 
testing indicated that they appreciated 
this section and detailed information. 
R9: There was one bit there, […] ‘the alternatives to HRT’ […] I didn’t 
know whether the ones that were listed were the most commonly used 
[…] I didn’t know why, in particular, you’d listed those. (Over50, yesOC, 
noFH, unknown) 
Add statement about how examples of 
alternatives were selected. (e.g. 
‘Alternatives frequently used include … 
however list is not exhaustive) 
Added statement to “Are there any 
alternatives to HRT?” question: 
“Alternatives that are frequently used 
include…” and “Please note that this 
list is not exhaustive and there may be 
other alternatives to HRT.” 
R9:[About ‘Alternatives to surgery’ question]: I think it’s that term 
‘alternative’, that I was thinking of something very different to surgery so 
I think maybe what I was thinking would be clearer for me would have 
been to say, ‘Are there other treatments apart from surgery’? […] Just on 
the previous page you’re reading about alternatives to HRT and you’re 
talking about herbal things and everything so I’ve just gone off on that 
track of thinking and then I was distracted by the use of the word 
alternative again. (Over50, yesOC, noFH, unknown) 
Reword question ‘What are the 
alternatives to surgery?’ 
Reworded question title to “Are there 
other options apart from surgery?” 
R13: I think it gives women, if they don’t know about the CA125 […] 
looking at that it seems as though […] there’s just nothing there […], 
Reword section on no effective 
screening again to emphasise that 
Reworded “Is there any screening 
available for ovarian cancer?” question 
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because in my mind if there’s that CA125 then there is an effective 
screening. (Over50, yesOC, BCFH, unknown) 
R1: [The Option Grid] was very black and white, […] it’s almost like if you 
don’t have surgery you take your life in your own hands, whereas there 
is the possibility of having ultrasounds for early detection. […] I’m lucky 
that I can get that done, but I don’t know if other [NHS] Trusts or 
anything do that so I suppose that’s quite a tricky thing. (35to39, noOC, 
B&OCFH, BRCA2) 
R4: I didn’t know that the screening tests were not offered by the NHS 
[…] and that you might have to pay for those because I had it, my GP just 
referred me for it. (Over50, yesOC, noFH, unknown) 
R5: I think that was good to say […] the bit about screening, that […] 
there isn’t really. […] This focuses your mind again after you’ve taken all 
that information in about all the different things. […] I’m a clear 
indication of what you’re saying here actually that the screening doesn’t 
work necessarily. It’s not you know, there isn’t a screening that is 
medically proven to work. There isn’t. (Over50, yesOC, noFH, unknown) 
although screening might be bought 
privately, it is not effective at detecting 
cancer early and might provide false 
reassurance; emphasise the difference 
between screening and diagnostic tests 
paragraph 2: “Two large trials of 
ovarian cancer screening were done 
recently and the results are not yet 
available, so we do not yet know 
whether this screening is effective and 
can detect ovarian cancer early. The 
UKFOCS trial offered high risk women 
CA125 blood tests every four months 
and one yearly trans-vaginal 
ultrasound scan. The UKCTOCS trial 
offered such screening to women over 
50, who were not at high risk. Both 
trials have not reported their final 
outcomes. Routine screening will not 
be offered until the results of these 
trials are available and only if these 
trials show that screening is effective 
and can save lives.” 
Added a link to UKFOCS and UKCTOCS 
study pages 
Added statement to “Is there any 
screening available for ovarian 
cancer?” question paragraph 3 
“…ovarian cancer early. Therefore 
going to private screening may provide 
false reassurance. Additionally, 
screening may result in unnecessary 
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worry and anxiety if any results show 
changes that turn out not to be 
cancer.” 
Reworded section in “Is there any 
screening available for ovarian 
cancer?” question paragraph 6 
“…CA125 test and trans-vaginal 
ultrasound scan. Please note that these 
diagnostic tests are not screening tests. 
Rather, they are designed to detect 
ovarian cancer when symptoms have 
already developed. Women with no…” 
Added statement to “But I have been 
offered CA125 blood tests and/or 
trans-vaginal scans?” question 
paragraph 1 “…ovarian cancer early. 
Therefore using such screening services 
might provide you with false 
reassurance.” 
R13: I think the most important thing is, is to push the symptoms 
because they are so vague and so near to what IBS or something could 
be. […] It needs to push the symptoms into people’s faces. (Over50, 
yesOC, BCFH, unknown) 
R4: I think it’s quite important to mention that actually symptoms can be 
anything that you wouldn’t necessarily think were to do with your 
abdomen. […] It’s important to realise these symptoms can be very 
vague and are not specific and yeah ‘something about be aware of 
Emphasise symptoms and their 
similarity to IBS more and encourage 
people to consult their GP if they 
notice anything unusual. Make these 
sections stand out more. 
Added statement “Note that often 
these symptoms are similar to 
symptoms of other diseases, such as 
Irritable Bowel Syndrome and might be 
easily confused. Therefore it is very 
important that you tell your GP that 
you have a family history cancer.” 
Added statement to “What would 
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changes in your body’. (Over50, yesOC, noFH, unknown) 
R8: I know the symptoms are vague but maybe more emphasis can be 
put on for women to go and get checked out. (35to39, noOC, OCFH, 
unknown) 
R8:Until there’s a screening there’s not a lot that can be said. […] It says 
you should contact your GP but I don’t know if a lot of women would. It 
could maybe be highlighted a wee bit more. […] Even if it was bold […] or 
in italics or something […] just to stand out a wee bit. (35to39, noOC, 
OCFH, unknown) 
R8: I just think the symptoms, that didn’t really stand out on the website. 
Although everything was green and grey and black, everything was kept 
uniform and the same. I just think something like that needs to stand out 
a wee bit. (35to39, noOC, OCFH, unknown) 
happen if I do not have surgery?” 
question: “You know your body best, 
so don’t be afraid to go to your GP if 
you notice anything unusual. Make 
sure…” 
Made symptoms box stand out more 
by adding colour and bold writing; 
Added link to “Key messages to the 
public” on ovarian cancer symptoms 
R4: You could put something in there about how they [TV scans] are not 
as scary as they sound. […] It’s not as terrifying as you think it’s going to 
be. The thought of it is worse than actually having it. (Over50, yesOC, 
noFH, unknown) 
Add sentence about what diagnostic TV 
scans involve. 
Not actioned, as we need to avoid 
confusion between diagnostic / 
screening tests and do not want to 
emphasise screening further. This is 
not directly relevant to the target 
population at the time of reading the 
decision aid. If they develop symptoms 
they will be consented for these 
diagnostic tests at which point these 
will be explained.  
R11: I didn’t know what a CA 125 was, so I could have done some [with] 
more questions and information about those tests. (Over50, yesOC, 
noFH, unknown) 
R11: The screening page is quite interesting and everything else is and 
Add information about how the 
diagnostic CA125 test is done, what it 
stands for and what results mean. 
Not actioned, as we need to avoid 
confusion between diagnostic / 
screening tests and do not want to 
emphasise screening further. This is 
5
98
 
599 
 
 
 
the CA 125 blood tests […] That might be quite nice to actually say what 
that is. (Over50, yesOC, noFH, unknown) 
R11: It would be nice to sort of say what the blood test - you don’t need 
to go into scary figures - but it just might be quite nice to go into what it 
was. (Over50, yesOC, noFH, unknown) 
not directly relevant to the target 
population at the time of reading the 
decision aid. If they develop symptoms 
they will be consented for these 
diagnostic tests at which point these 
will be explained. 
R11: I think the only question I’ve got is how soon could I have got 
listened to and got treatment? (Over50, yesOC, noFH, unknown) 
Add timeline of CA125 / ultrasound 
diagnostic test to treatment if OC is 
found. 
Not actioned, as we need to avoid 
confusion between diagnostic / 
screening tests and do not want to 
emphasise screening further. This is 
not directly relevant to the target 
population at the time of reading the 
decision aid. If they develop symptoms 
they will be consented for these 
diagnostic tests at which point these 
will be explained. 
 
Value clarification exercise 
R12: I wonder if it’s worth saying somewhere at the beginning that you 
have that [VCE] to come at the end. […] At the beginning of the website 
maybe, if there’s somewhere you could almost just let people know that 
that’s coming, they don’t have to be writing this information down on a 
notepad […] or equally if they don’t want to read through it all because 
they’ve spoken to their GP about it in quite a lot of detail, […] if they just 
wanted to skip through. (Under35, noOC, OCFH, unknown) 
Add statement on home pages (after 
entering decision aid) that announces 
that VCE exists and add link 
Added statement to home pages 
saying “This website includes pages 
with information about the decision, 
an exercise in which you can weigh 
different factors according to your 
preferences (Your Decision [LINK]) and 
a list of useful Contacts and 
Resources.” 
R12: It took me a couple of goes to figure out how to move the little On website VCE, add instructions for Added instructions saying “If you are 
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circles around […] that’s because I was on an I-pad rather than a lap top. 
[…] I was expecting to be able to drag it across and I couldn’t […] You just 
had to click on the circle […] and then put your finger just on the line 
where you want the circle to go and it jumps there (Under35, noOC, 
OCFH, unknown) 
users of iPads that the slider function 
does not work and using the tool 
requires them to click on the slider and 
then click on the point in the scale they 
want the slider to jump to. 
viewing this website using an iPad, 
simply touch the slider, then touch the 
point in the scaled where you would 
like the slider to jump to.” 
R13: The vague one wasn’t too bad, because I suppose somebody say 
may be able to answer that, but it’s that one ‘there’s no effective 
screening for ovarian cancer’ […] I don’t know how you could answer 
that with a points system, whether it would [make you] want […] to have 
surgery. (Over50, yesOC, BCFH, unknown) 
R5: ‘The symptoms of ovarian cancer are very vague’. I’m not quite sure 
why that would affect your decision, though I suppose it would in the 
fact that if there was a family history of it you’re not that likely to pick it 
up from symptoms so therefore perhaps yeah maybe. (Over50, yesOC, 
noFH, unknown) 
Reword / expand on statements in VCE 
to clarify their relevance to the 
decision 
Expanded statements to clarify: “There 
is no effective screening for ovarian 
cancer, so I cannot get checked out 
regularly” and “The symptoms of 
ovarian cancer are very vague, so I may 
not notice them early.” 
R11: I think what’s missing then would be, once you’ve made your 
decision what do you do? (Over50, yesOC, noFH, unknown) 
Add information about what to do 
once decision is made. 
Reworded question “How can I deal 
with my decision?” to “How can I take 
my decision forward and how can I 
cope?” 
Reworded and expanded answer to 
this question to “If you are considering 
surgery, the next step is to make an 
appointment with a health 
professional. This can be your GP, 
genetic counsellor or gynaecologic 
surgeon. With them, you can discuss 
surgery further and get answers to any 
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additional questions, before booking 
an appointment with a hospital. You 
can also seek a second professional 
opinion at any time if you wish. 
Preparing yourself for having surgery, 
both mentally and physically, can help 
to cope with the operation and with 
recovery time.  It can also help to… […]. 
Before committing fully to surgery you 
can discuss any further questions with 
your doctor or genetic counsellor and “ 
 
R4: I thought I would like to be able to kind of obtain a […] booklet with 
all the information to pick up and put down as opposed to having to look 
at videos and PDF’s which could be time consuming. I’d like to be able to 
I don’t know click a button on things that I would want to have sent to 
me. (Over50, yesOC, noFH, unknown) 
Create option for users to order 
printed copy of booklet. 
Not actioned, as, unfortunately, this is 
not within the financial scope of the 
PhD and therefore we are unable to 
provide such a service at this time. 
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Welcome to OvDex
OvDex (The Oophorectomy Decision Explorer) has been developed to help you find 
out more about your options for reducing your ovarian cancer risk. If you are viewing 
OvDex you should have been referred to it by a doctor or geneticist as you are at 
increased risk of ovarian cancer. 
The information in OvDex can be tailored to your personal situation by answering 
three simple questions. We recommend that you use this function, so that the 
information displayed is more relevant to you. If you do wish to personalise the 
information you get, please go to the OvDex website at www.OvDex.co.uk and 
answer the questions .
The information the following pages has not been personalised. If you do not wish to 
personalise OvDex then please view the general information on the following pages.
Chapter Page
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2. The choice.............................................................................................. 8
3. Options at a glance................................................................................ 11
4. Risk-reducing surgery............................................................................. 13
5. The menopause..................................................................................... 17
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7. Other options......................................................................................... 23
8. Your decision.......................................................................................... 26
9. Contacts and Resources......................................................................... 31
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Questions in chapter 1:
Q1 Where does ovarian cancer develop?
Q2 What is the ovarian cancer risk if I have a family history of ovarian cancer?
Q3 How can I find out whether I have a faulty gene?
Q4 What would my risk be if a faulty gene was found?
Q5 What if I cannot get tested or my genetic test is uninformative?
Q6 Does my cancer risk change over time?
Q7 How will my ovarian cancer risk affect my life?
Q8 How will my ovarian cancer risk affect my children?
Q9 How can I change how I feel about my cancer risk?
Q1 - Where does ovarian cancer develop?
For more information about ovarian cancer check out the Cancer Research
UK website at www.cancerresearchuk.org and other websites under Contacts &
Resources.
Q2 - What is the ovarian cancer risk if I have a family history of ovarian cancer?
Ovarian cancer occurs by chance in less than 2 of every 100 women. For women who
have a family history of ovarian, breast and/or bowel cancer and/or a faulty gene, the
risk can be much higher than 2 in 100. Generally the risk is quite low in young women
and rises with age.
Your risk depends on how many of your relatives had cancer and on how closely
related they are to you. 'First degree relatives' are those directly related to you, for
example, mother, sister or daughter. 'Second degree relatives' are those who are less
closely related, for example your aunt or your grandmother. The diagrams on the next
page show how risk changes depending on the number of relatives with ovarian
cancer.
1. Cancer risk
This picture shows the female 
reproductive system. The ovaries 
are connected to the uterus 
(womb) by the fallopian tubes. 
Ovarian-type cancer can develop 
in the ovaries, the fallopian tubes 
or the lining of the abdomen 
(called the ‘peritoneum‘). Other 
female cancers, such as cancer of 
the endometrium (the lining of 
the uterus/womb) or cervix, are 
very different and should not be 
confused with ovarian cancer. 
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A woman’s chances of developing ovarian cancer can also be increased if she has
relatives with cancers other than ovarian cancer, such as breast and bowel cancer. A
woman’s risk is estimated by genetics services once the full family history is available.
Q3 - How can I find out whether I have a faulty gene?
If you come from a family where certain types of cancer (e.g. ovarian, breast, bowel) 
have affected more than just one or two relatives, you might have a faulty gene. To 
get tested for a faulty gene you will need to be referred to genetics services (usually 
by your GP). The genetics service will assess your family history in detail and you will 
be told whether there might be a faulty gene involved.
Within the NHS, testing for a faulty gene in the family usually begins with a test on a 
blood sample from a person who has had cancer. If you have had cancer yourself, you 
may be offered a genetic test as the first person in your family. If you have not had 
cancer yourself, a relative who has had cancer will be offered a genetic test first. For 
the test, a blood sample will be taken and sent to a laboratory for analysis. Test 
results then usually come back within 2 to 3 months. For more information about 
what the test involves see Contacts and Resources.
Results of this test may show that you either have a faulty gene that predisposes you 
to cancer (in this case, the gene test is said to be 'positive') or that you do not have a 
faulty gene that predisposes you to cancer (in this case, the gene test is said to be 
'negative'). In some cases, test results may show that you have a 'variant of unknown 
significance', which means the test detected a change in your gene, but it is not 
known whether this change predisposes you to cancer or whether it is harmless. If a 
faulty gene is found, other members of the family can then have a genetic test to see 
whether they also have the same faulty gene.
If there is no living relative with cancer, or the relative doesn‘t want to get tested, it 
may still be possible to do a genetic test for you on the NHS , if your genetic 
counsellor thinks that your chances of carrying a faulty gene are higher than 10 in 
100 based on your family history. For anyone who cannot get tested on the NHS, 
there are some companies offering private testing. However, this can be very 
expensive and without a strong family history, there may be no need for testing.
1. Cancer risk 4
Less than 2 out of 100 
women in the general 
population get ovarian 
cancer in their lifetime. 
98 women will not.
About 5 out of 100 women 
with a first degree relative 
with ovarian cancer get 
ovarian cancer in their 
lifetime. 95 women will not.
About 7 out of 100 women 
with two or more relatives 
with ovarian cancer get 
ovarian cancer in their 
lifetime. 93 women will not.
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Q4 - What would my risk be if a faulty gene was found?
The most common faulty genes linked to ovarian cancer are called Breast Cancer
(BRCA) genes 1 and 2 and genes common in Lynch Syndrome (formerly known as
Hereditary Non-Polyposis Colorectal Cancer or HNPCC). The lifetime risk of
developing ovarian cancer can be much higher for women who have a faulty gene
compared to the general population.
Q5 - What if I cannot get tested or my genetic test is uninformative?
For some women it might not be possible to get tested because they have no living
relative with cancer or their relative does not want to be tested. In other cases a
genetic test may come back as ‘uninformative’ which means a gene variant of
uncertain significance has been found, but it is not clear whether this variant
increases the risk of cancer or not. In these cases the genetics service will estimate
the woman’s risk based on her family history.
If you have been told that your family history suggests you might have a faulty gene
and you would like more specific information, you can personalise this aid by
selecting the gene that most closely resembles your family history according to your
genetic counsellor. For example, if you have been told your family history suggests
you might have a BRCA1 gene, personalise OvDex by going to the website and
answering the first question with "Yes, I have a faulty BRCA1 gene".
Q6 - Does my cancer risk change over time?
Yes. Your cancer risk increases with age. While your so-called ‘lifetime’ risk (which is
the risk that you will get ovarian cancer at some point in your life) will stay the same
over time, your ‘age-related’ ovarian cancer risk (which is the risk that you will get
ovarian cancer in a specified time frame, for example within the next 5 years)
increases with age.
1. Cancer risk 5
About 39 out of 100 
women with a BRCA1 
faulty gene get ovarian 
cancer by the time they 
are 70. About 61 women 
with a BRCA1 faulty gene 
will not.
About 16 out of 100 
women with a BRCA2 
faulty gene get ovarian 
cancer by the time they 
are 70. About 84 women 
with a BRCA2 faulty gene 
will not.
About 6 to 12 out of 100 
women with Lynch 
Syndrome get ovarian 
cancer by the time they 
are 70. About 88-94 
women with Lynch 
Syndrome will not.
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Q7 - How will my ovarian cancer risk affect my life?
Being at risk for ovarian cancer does not necessarily mean that you will develop
ovarian cancer. However, knowing your risk will give you access to additional medical
services such as genetic counselling and means that you may be offered risk-reducing
surgery. Some people may feel worried or anxious after finding out about their risk
and their quality of life may be affected.
Q8 - How will my ovarian cancer risk affect my children?
There is a chance that your children will also have an increased risk of cancer. Their
risk depends on how high your own risk is and on whether or not you have a faulty
gene. If you have a faulty gene, then your children have a 50/50 chance to inherit
this. If a faulty gene has been confirmed in the family, children can choose to get
tested for this gene at any time. The best time to get tested should be discussed with
your genetic counsellor. If your child/children inherited the faulty gene, then their
cancer risk would be the same as yours. If they did not inherit the faulty gene, then
their cancer risk would be low. Boys who inherit the faulty gene are not at risk of
ovarian cancer, but may be at risk for other cancers. Boys who inherit the faulty gene
may also pass it on to their children.
Please also note that cancer risk increases with age and therefore children’s risk only
starts to rise in later life. More information about genetics can be found on the NHS
choices website (see Contacts and Resources).
You can discuss your children‘s risk with your genetic counsellor to find out more.
Your genetic counsellor will also be able to advise you about how best to discuss this
risk with your children.
Q9 - How can I change how I feel about my cancer risk?
If you would like to find out more about your risk and what it means, you can use the
resources provided in OvDex and talk to your doctor or genetic counsellor.
Knowing that you are at increased risk of cancer might make you feel worried or
angry or frustrated. This is completely normal and there is no need to bottle those
feelings up. It can actually help to talk about them.
1. Cancer risk 6
This graph shows how 
cancer risk rises over time.
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You can try to find someone you trust to talk to or if you prefer to talk to someone
you don’t know, you can use the contact details for charities and patient support
networks under Contacts & Resources. If you have a partner, sharing your thoughts
and concerns with your partner can be useful in helping them understand what you
are going through and in helping you cope together as a couple.
It may also help to see a positive side to knowing your risk status. For example, this
means that you will get access to genetics services and have the chance to do
something about your risk. Other women have found it helpful to stay optimistic,
have joined patient networks or have found strength in their faith.
Being at risk of cancer may sometimes lead to unwanted thoughts and worry,
especially at times when there are no active steps you can take, for example when
you are waiting for genetic test results. There are useful techniques you can use to
reduce such thoughts. One such method is active distraction, which means actively
thinking about something else whenever unwanted thoughts pop in your head.
Watch the 'How do I cope' video on the Cancer Genetics Storybank website for a
guide of how to do this (see Contacts & Resources).
Relaxation techniques, meditation and guided imagery may also help you deal with
any stress you might experience relating to your cancer risk. Examples include
progressive muscle relaxation and certain breathing exercises. Visit the 'Mind-body
therapy' section on the Macmillan website for more information on and guides to
mind-body therapies (see Contacts & Resources).
1. Cancer risk 7
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2. The Choice
Questions in chapter 2:
Q1 What can I do to reduce my risk?
Q2 Why is there a choice?
Q3 Who should decide?
Q4 Who else should I involve in this decision?
Q5 When should I decide?
Q6 How can I decide?
Q7 How can I deal with the choice?
Q1 - What can I do to reduce my risk?
Your doctor has probably discussed with you the option of having risk-reducing
ovarian surgery to reduce your ovarian cancer risk. You will need to decide whether
and when to have this surgery. Unfortunately, there is no medically proven screening
available on the NHS for ovarian cancer at the moment.
This decision aid is designed to help you look at your options. Please refer to chapter
3 (Options at a glance), chapter 4 (Risk-reducing surgery) and chapter 7 (Other
options) for more information about surgery, screening and other alternatives.
Q2 - Why is there a choice?
Often when you go to your doctor, there is one clearly recommended treatment.
However, some situations are more complicated. These are situations in which your
personal preferences and feelings play an important role. In the case of cancer risk
reduction, your options have very different effects on your life. This means that you
need to be clear about what might happen if you choose one option over the other
and how that would impact on your life.
Some health professionals may recommend surgery quite strongly; however you
need to make the final decision and before you do, you should consider the possible
benefits and risks, how these might affect your life and how you feel about them.
Q3 - Who should decide?
As the best choice for you is based on your preferences, you should be closely
involved in the decision. You can either make the decision on your own or if you do
not wish to make this decision yourself, your genetic counsellor or gynaecologist can
help you. They will encourage you to think about the options and your preferences,
so that the final choice is right for you. If you then don’t want to choose for yourself,
just say so and they may make a recommendation.
Q4 - Who else should I involve in this decision?
Whether or not you would like to bring anyone else into this decision is your choice.
Often it is helpful to speak to someone who knows you well, such as a partner, other
members of your family or a friend, who could work through this decision with you. If
you are in a relationship the views of your partner can be important, especially in the
context of risk-reducing ovarian surgery, so it is recommended that you speak to your
partner and try to reach a decision together. Your doctor will also be happy for you to
bring your partner along to appointments and to answer any questions they might
have.
8
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2. The Choice
Q5 - When should I decide?
The operation is most effective if it is done at 40 years of age, because ovarian
cancer risk starts to rise from age 40 onwards. Additionally, if done at 40, the surgery
reduces the risk of breast cancer. However, age 40 may not be ideal for everyone. So,
even if you decide not to have it at 40, the operation will still decrease your ovarian
cancer risk if performed after that age.
The decision you are facing is not an easy one and you should not feel under any
pressure to decide quickly. Risk-reducing surgery has benefits and risks that need to
be weighed carefully, so take your time and make sure you are ready before making a
decision.
It is important that you understand that undergoing surgery to remove your ovaries
will mean you can no longer get pregnant. Therefore it is essential to consider your
plans for a family and any potential future changes to these plans (for example if
there is a chance you might meet a new partner / re-marry) before making a final
decision.
Q6 - How can I decide?
When it comes to important decisions everyone is different. Some people like to find
out as much as they can about their options, while others prefer to just know what is
absolutely necessary. Some might find it helpful to talk to their family and friends.
Some might like to speak to people who have made a similar decision. It really
depends on you. Have a think about other important decisions in your life and how
you managed to make those. That could give you an idea of how you like to decide
about things.
Q7 - How can I deal with the choice?
It can be helpful to create a plan of how and when you will make this choice. If you
are not ready to decide right now, it might be useful to set yourself a deadline of
when you will revisit this decision. For example: “Just after my 40th birthday I will
look at this information again.” or “Once I have completed my family I will revisit this
decision.”
Once you are ready you can decide how you want to make this choice:
1. I will decide by myself using everything I have learnt
2. I will decide but seriously consider my doctor’s opinion
3. The doctor and I should decide together
4. The doctor should decide but seriously consider my opinion
5. The doctor should decide for me
9
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2. The Choice
One constructive way to deal with a difficult decision is to empower yourself with
information. OvDex is designed to help you to learn more about ovarian cancer risk
and your options. With the wealth of information that is available on the internet, it
can be difficult to find reliable and trustworthy information. The information in OvDex
is supported by recent scientific findings and has been carefully reviewed by health
professionals to make sure it is accurate. You should at least understand your options
and their benefits and risks before making a decision. Find out more about the most
important questions to ask at: www.Ask3Questions.co.uk. Once you have read the
information in OvDex, it could help to make a note of any remaining questions and
take those to your doctor or genetic counsellor for a more detailed discussion.
You may feel that you are not comfortable making decisions about your health. This is
okay. You do not need to make the choice alone if you don’t want to. You can decide
together with your doctor or ask them to make the choice for you. But you need to
remember that you are the expert when it comes to your own life and that only you
know what is important to you. So even if you decide to let the doctor make the
decision for you, make sure they know about your goals and values. Tell them what is
important to you.
10
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3. Options at a Glance
Frequently asked questions
Surgery to remove ovaries and 
fallopian tubes
No surgery
Will this reduce my risk of 
ovarian cancer?
Yes, removing the ovaries and 
fallopian tubes will greatly reduce 
your lifetime risk of ovarian-type 
cancer to that of the general 
population, which is about 2 in 100.
No, your risk of ovarian 
cancer will remain increased.
Is there a routine screening 
programme to detect 
ovarian cancer?
No, there is no evidence that 
screening for ovarian cancer is 
effective and after surgery there is 
no need for screening as your risk 
will be low.
No, there is no evidence that 
screening for ovarian cancer 
is effective in saving lives.
Will I be able to become 
pregnant?
No, therefore it is important that 
you feel you have completed your 
family before having surgery.
Yes, your ability to become 
pregnant will be unaffected.
Will this change how I feel 
about my risk of ovarian 
cancer? 
You may feel less worried about 
developing ovarian cancer. Most 
women report feeling satisfied with 
their decision after surgery.
You may worry about 
developing ovarian cancer.
Will this change how I feel 
about myself as a woman?
Many women do not notice any 
change in how they feel about 
themselves as a woman. However,
your desire for and/or enjoyment 
of sex is likely to decrease.
Not applicable.
Will I go into menopause?
Yes, after surgery your oestrogen 
levels fall and the menopause will 
start immediately.
Yes, you will go through a 
natural menopause when you 
are around 50 years.
What is menopause like?
Menopause after surgery is similar 
to natural menopause, but because 
it happens suddenly, the symptoms 
may be more severe. 
Natural menopause is a 
gradual decline of oestrogen 
levels. Typical symptoms 
include hot flushes, night 
sweats, mood swings and 
vaginal dryness.
Are there any long-term 
health risks linked to 
surgery?
Yes, if surgery is done before age 45 
there is a higher risk of bone 
thinning and cardiovascular disease. 
Some patients report memory 
changes as well.
Not applicable.
Will I need hormone 
replacement therapy 
(HRT)?
HRT can reduce some of the effects 
of surgery and is recommended for 
women who have surgery before 
age 45. Discuss this with your 
clinician before your surgery. 
No, if you go through a 
natural menopause you 
would not be expected to 
need HRT, unless your 
symptoms are very severe.
11
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3. Options at a Glance
Q1 – How can I cope with this decision?
Some women may find it useful to discuss surgery with others, who have already
made this decision. In some areas your genetic counsellor may be able to put you in
touch with someone who has already gone through the decision, otherwise you can
use the contact details for charities and patient support networks under Contacts &
Resources to read about or get in touch with others in a similar situation. Going over
the decision with someone who knows you well, such as your partner or a member
of your family can also help you clarify your decision. If you decide to opt for surgery
and you are in a relationship, preparing yourself together with your partner for the
time after surgery can help you both deal better with any consequences of the
operation.
Being clear about the reasons why surgery could be the right or wrong thing for you
can help you make a decision and avoid regretting it later. The information in OvDex
is designed to help you identify the benefits and the risks of surgery and any other
options, so you can decide for yourself. The exercise called ‘Your Decision’ can help
you clarify what is most important to you.
There may be times when there are no active steps you can take, for example if you
have decided to defer surgery or while you are waiting for your surgery appointment.
During these times you may sometimes worry about your risk or experience
unwanted thoughts. Useful techniques to reduce such worries and thoughts,
especially at times when you cannot do anything but wait, include active distraction,
relaxation techniques, meditation and guided imagery. Check out the 'How do I cope'
video on the Cancer Genetics Storybank website and the Macmillan website for more
information on these techniques (see Contacts & Resources).
Frequently asked 
questions
Surgery to remove ovaries 
and fallopian tubes
No surgery
Is HRT safe for women at 
increased familial risk?
HRT is safe to take for the 
majority of women until they are 
50. Discuss this with your clinician 
before your surgery. 
It is not usually recommended for 
women who have had breast 
cancer.
HRT is safe to take for the 
majority of women until they 
are 50. Discuss this with your 
clinician. It is not usually 
recommended for women 
who have had breast cancer.
What are the risks of 
surgery?
About 4 in every 100 patients 
experience a complication during 
or after surgery. These can be 
minor infections or major 
complications. Discuss this with 
your clinician.
Not applicable.
How long will it take me to 
recover from surgery?
Most women leave the hospital 
the same day or the day after key 
hole surgery and are back to 
normal in 4 weeks. For open 
surgery time in hospital and 
recovery will be longer. During 
recovery you may feel pain / 
tiredness and may need help with 
everyday tasks.
Not applicable.
12
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4. Risk-reducing Surgery
Questions in chapter 4:
Q1 What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Q2 What are the main advantages of this operation?
Q3 What are the main disadvantages of this operation?
Q4 What is my risk after surgery?
Q5 What does the surgery involve?
Q6 How long does it take to recover?
Q7 Do I need to have my womb removed as well?
Q8 What are the complications of RRSO?
Q9 Could cancer be found during the surgery?
Q10 How would RRSO affect my life?
Q1 - What is risk-reducing bilateral salpingo-oophorectomy (RRSO)?
Risk-reducing bilateral salpingo-oophorectomy (RRSO for short) is an operation to 
remove healthy ovaries and fallopian tubes to reduce the cancer risk. The word 
‘salpingo-oophorectomy’ means surgical removal of the fallopian tubes (salpinges) 
and ovaries. The term ‘bilateral’ in this context describes the fact that the ovaries and 
fallopian tubes on both sides of the body are removed. The aim of the operation is to 
remove these tissues before cancer develops.
Q2 - What are the main advantages of this operation?
1) This operation will reduce your ovarian and fallopian tube cancer risk, as these 
are completely removed during surgery. 
2) For some women, not having to worry about ovarian cancer anymore comes as a 
great relief.
3) For the vast majority of women having RRSO before the natural menopause could 
also reduce the risk of breast cancer.
4) Having the surgery will also prevent other, non-cancer related problems 
happening with the ovaries, such as cysts, which can cause some discomfort and 
pain.
13
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4. Risk-reducing Surgery
Q3 - What are the main disadvantages of this operation?
1) You will no longer be able to become pregnant once you have had surgery, 
therefore it is important that you have considered your plans for a family 
before making a final decision. 
2) After the operation you will immediately enter the menopause and may start 
to experience the typical menopausal symptoms, including hot flushes, mood 
swings, night sweats and vaginal dryness (Please see Chapter 5 “The 
Menopause” for more details). Furthermore, you may be at increased risk of 
bone thinning, cardiovascular (heart and blood vessel) disease and memory 
changes. These effects may be effectively treated with hormone replacement 
therapy (Please see chapter 6 “Hormone Replacement” for more details), 
however not all women can take hormone replacement and this should be 
discussed before having surgery.
3) Your desire for sex is likely to decrease and due to some menopausal 
symptoms, such as vaginal dryness, you may enjoy sex less as intercourse can 
be painful. Again, hormone replacement may counteract these effects.
4) There is a small risk of complications during and after surgery.
Q4 - What is my risk after surgery?
After surgery your risk of ovarian and fallopian tube cancer is greatly reduced,
however, there is a rare type of cancer which may still develop after surgery that is
very similar to ovarian cancer. This is called primary peritoneal cancer and
develops in the lining of the abdomen and pelvis. Unfortunately, the peritoneum
cannot routinely be removed during RRSO. Your risk of primary peritoneal cancer
depends on whether or not you have a faulty gene. The highest risk for primary
peritoneal cancer is in women with a BRCA1 faulty gene. Their risk is about 2 in
every 100 women, which is similar to the risk of ovarian cancer in the general
population. For women who do not have a BRCA1 faulty gene the risk of primary
peritoneal cancer after surgery is much lower than 2 in 100.
Q5 - What does the surgery involve?
Most often the operation is done as keyhole surgery (laparoscopy). This involves 3
or 4 small (about 1cm) cuts, usually one cut is close to your belly button and 2-3
just below the bikini line, so they are not visible. Keyhole surgery itself usually
takes less than 2 hours.
In some cases it may not be possible to do keyhole surgery, because of previous
surgery on your tummy or because of your weight. Then surgeons use the more
traditional open surgery. This means a longer cut , usually along the bikini line.
Sometimes a surgeon might have to convert to an open operation when doing
keyhole surgery because of complications or old scar tissue. This happens in about
1 of every 100 keyhole operations.
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Q6 - How long does it take to recover?
75 of 100 patients who have keyhole surgery leave the hospital the day after
surgery. They are usually back to normal activity about 4 weeks after surgery. If
you have open surgery you are likely to stay in hospital a bit longer. Usually
patients leave the hospital about 5 days after open surgery and are back to normal
in about 6 weeks. After surgery you are not allowed to do any heavy lifting for a
few weeks. You may also have to refrain from driving until you can comfortably
wear a seatbelt and make an emergency stop without pain.
Q7 - Do I need to have my womb removed as well?
No, normally it is not necessary that you have your womb removed at the same
time as having RRSO, unless you know that you have Lynch Syndrome or you have
other problems with your womb and have been told by a doctor that removing the
womb would help you with those problems. However, you may choose to have
your womb removed at the time of RRSO, as it may affect the type of hormone
replacement you would be given. You should discuss this with your doctor.
Q8 - What are the complications of RRSO?
There is a small risk of complications linked to RRSO. About 4 in every 100 people
will experience some complication. Minor complications can include wound or
urinary tract infections and usually have no long-term effects on your health. More
serious complications might happen during surgery and can include damage to
blood vessels, the bowel or the bladder. If you are having keyhole surgery this
might mean that the surgeon has to convert to open surgery to repair the damage.
There are a number of other rare complications that might happen and your
surgeon will go through those with you if you wish before you go in for surgery.
Please note that about 96 of every 100 women do not experience any
complications at all.
4. Risk-reducing Surgery
Type of procedure in 100 women who have the 
operation
The figure on the left shows how many of 100 women 
will have keyhole surgery , open surgery and planned 
keyhole which is converted to open surgery.
94 of 100 women will have planned keyhole surgery 
(white figures). Five of 100 women will have planned 
open surgery (light teal figures). One of 100 women 
will have planned keyhole surgery which is converted 
to open surgery (dark figure).
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As with any surgery, there is a very small risk of death. However, this is highly
unlikely. The risk may be greater in women with health problems before surgery.
Q9 - Could cancer be found during the surgery?
Yes, although this is rare. Once your ovaries and fallopian tubes have been
removed they will be checked thoroughly for any signs of cancer. There is a chance
that cancer may be discovered during this check. This happens in up to 4 out of
every 100 operations in the highest risk patients. For others the chances of finding
cancer during the surgery are much lower.
If cancer is found during the surgery, you will be informed as soon as possible and
might have to undergo further tests, treatment and surveillance. If cancer is found
you might be unable to take HRT after the operation.
Q10 - How would RRSO affect my life?
In the short-term, if you decide to go for surgery, you will have to take time off
work and will not be able to do some of the things you might usually do, such as
driving or heavy lifting. Therefore you may need help with everyday tasks. During
recovery you may also feel some pain and discomfort and you may be more tired
than usual. However most women recover fully within 4 to 6 weeks.
In the longer term there are a number of things you should consider. After surgery
you may feel less worried about ovarian cancer. However you may feel differently
about your body and you may loose interest in sex. You will also no longer be able
to become pregnant and you will enter the menopause if you have not gone
through it yet (Please see chapter 5 “The menopause”). You may opt to take
hormone replacement (Please see chapter 6 “Hormone replacement”). These
factors may affect your life after surgery and should be considered carefully before
making a decision.
4. Risk-reducing Surgery
Complications in 100 women who have the operation
The figure on the left shows how many of 100 women 
will experience complications during or after surgery.
4 of 100 women will experience some kind of 
complication either during or after surgery. 96 of 100 
women will not experience any complications.
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The graph above shows the drop in the levels of the female hormone oestrogen 
during surgical and natural menopause. Potential menopausal symptom duration 
and severity are indicated in shades of grey.
Questions in chapter 5:
Q1 What is a surgical menopause?
Q2 What is the menopause like?
Q3 How could the menopause affect my life in the short term?
Q4 How long does surgical menopause last?
Q5 Are there any long term health effects linked to surgical menopause?
Q6 Is there anything I can do to reduce the effects of surgical menopause?
Q1 - What is a surgical menopause?
A surgical menopause is a menopause you enter when your ovaries are removed by
surgery and your body no longer produces the female hormone oestrogen. A surgical
menopause is essentially the same as a natural menopause, it only happens earlier
and more suddenly. Therefore a surgical menopause results in the same symptoms as
a natural menopause. These symptoms are caused by the lack of oestrogen. As
oestrogen levels drop suddenly after surgery, the symptoms of a surgical menopause
start instantly and can be more severe than those of a natural menopause, in which
oestrogen levels fall gradually.
5. The Menopause
Note that the information about symptoms of the menopause in this 
chapter describes symptoms experienced by women who do not take 
hormone replacement therapy (HRT), unless stated otherwise. Most 
symptoms of the menopause are reduced by hormone replacement 
therapy (for more information see Chapter 6 “Hormone Replacement”.
17
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Q2 - What is the menopause like?
It is very difficult to describe what the menopause is like, because it is different for
every person. Some women have no or very few symptoms and cope very well. Other
women can have very severe symptoms and their quality of life can be affected.
Common menopausal symptoms you may experience are: Hot flushes, night sweats,
mood swings, vaginal dryness and loss of interest in sex. Other symptoms include
difficulty sleeping, fatigue, weight gain, changes in memory and depression.
The great majority of women who had surgery reported that they experienced one or
more of the common symptoms. However, any data available about menopausal
symptoms is from small studies and each study uses different ways to assess what
women experienced, so it is difficult to predict what the menopause will be like for
you personally. The pictures below show how common different types of menopausal
symptoms are according to one study of women after RRSO.
Q3 - How could menopause affect my life in the short term?
While none of the menopausal symptoms mentioned above are dangerous for your 
health, they may affect you in different ways. Hot flushes can be very uncomfortable 
and may happen at inconvenient times, for example when you are giving a 
presentation at work. In one study two out of every three women reported having 
hot flushes after surgery. Night sweats can lead to problems with sleep and insomnia.
Vaginal dryness can lead to pain during sex and therefore you may enjoy sex less. In 
one study, one in every three patients felt that vaginal dryness was bothersome and 
reported pain with sex. Additionally, many women also experience a loss of interest 
in sex after surgery. In one study just over half of women reported that they were not 
satisfied with their sexual functioning after having surgery. In that study, the decrease 
in sexual functioning seemed to persist even when women were taking hormone 
replacement. If you are in a relationship, these factors may affect your relationship 
with your partner. The way that these symptoms might affect your life depends on 
your personal situation.
5. The Menopause
About 72 of 100 women 
experience vasomotor 
symptoms (hot flushes 
and night sweats). 28 
women do not.
About 92 of 100 women 
experience psychosocial 
symptoms (mood swings, 
feeling depressed or 
down). 8 women do not.
About 87 of 100 women 
experience physical and 
sexual symptoms (aching, 
vaginal dryness, loss of 
libido). 13 women do not.
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There are several options available to help you deal with the short-term symptoms of 
the menopause. These include physical options, such as lubricant to counteract 
vaginal dryness, or psychological options, such as sex counselling and cognitive 
behavioural therapy to improve emotional and physical functioning. You can get more 
information about these options from your doctor or gynaecologist. The NHS choices 
website also has information about dealing with the menopause (See Chapter 9 
“Contacts & Resources”). 
Q4 - How long does the menopause last?
It is impossible to say how long symptoms will last. Some women have hardly any 
problems and symptoms disappear quickly, while others have symptoms for many 
years. It really is different for everyone.
Q5 - Are there any long term health effects linked to the menopause?
Yes. The loss of oestrogen is thought to affect long term health, particularly the bones 
and the cardiovascular system (heart and blood vessels). In older age this can lead to 
a higher risk of fractures due to bone thinning (osteoporosis) and a higher risk of 
cardiovascular disease (heart disease, stroke).
It should be noted that these effects are seen in all women after the menopause, 
whether it was a surgical or natural menopause. Your personal risk depends on your 
lifestyle and personal and family history of osteoporosis and cardiovascular disease 
and should be discussed with your doctor.
Due to the sudden lack of oestrogen after surgery, the risk of bone thinning and 
cardiovascular disease may start to rise immediately after surgery. This could be 
before the woman has reached the age of the natural menopause. Therefore, women 
who undergo surgery before the age of 45 are usually recommended to take 
hormone replacement to reduce these effects until they reach the age of the natural 
menopause (See Chapter 6 “Hormone replacement”). 
Some women also report changes in memory following the menopause, which is 
again due to the lack of oestrogen.
Q6 - Is there anything I can do to reduce the effects of the menopause?
Yes. Hormone replacement therapy (HRT) is usually recommended for women who 
have RRSO before the age of 45 and have not had breast cancer themselves (See 
Chapter 6 (Hormone replacement) page 19). HRT may effectively reduce some of the 
short- and long-term effects of surgical menopause. However, not all women can take 
hormone replacement and this should be discussed before having surgery.
If you do not wish to or cannot take HRT then you can take dietary supplements to 
reduce bone thinning. You should speak to your doctor about this. In some regions in 
the UK patients are also recommended to have a bone density scan about 18 months 
after their operation. You can discuss this with your doctor.
An active lifestyle and healthy diet is also recommended.
5. The Menopause 19
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6. Hormone Replacement 20
Questions in chapter 6:
Q1 What is Hormone Replacement Therapy (HRT)?
Q2 Why is HRT important?
Q3 Who should take HRT?
Q4 How long should I take HRT?
Q5 Can I take HRT if I have a family history of breast cancer?
Q6 But I have heard that HRT increases breast cancer risk
Q7 Will HRT reduce all the symptoms of menopause?
Q8 Will HRT deal with the long term health effects of the menopause?
Q9 Are there any alternatives to HRT?
Q1 - What is Hormone Replacement Therapy (HRT)?
Hormone Replacement Therapy, or HRT for short, is a medical treatment that puts 
back the female hormones that are lost when the ovaries are removed or when they 
stop functioning. 
There are a number of ways that HRT can be used:
- It can be taken as oral tablets usually once  a day
- It can be applied as patches that are put on the tummy or bottom about once or 
twice a week
- It can be applied as a gel directly to the skin once a day (for example the lower 
abdomen or inner thigh)
There are two types of hormone replacement, one includes oestrogen and 
progesterone and the other includes oestrogen only. Women who only have their 
ovaries removed will usually be given oestrogen and progesterone HRT, while women 
who have their womb/uterus and ovaries removed (RRSO plus hysterectomy) are 
usually given oestrogen only HRT.
The graph above shows the oestrogen levels after surgical and natural 
menopause. It also shows the effect of HRT on the oestrogen levels after 
the operation if surgery was performed before the natural menopause.
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6. Hormone Replacement 21
Q2 - Why is HRT important?
There are two main reasons why HRT is recommended after surgery:
1. To reduce the risk of bone thinning
2. To reduce symptoms of the menopause
Q3 - Who should take HRT?
HRT is strongly recommended for women who have surgery before they are 45 years 
of age, as this group is most affected by the long term health issues that are linked to 
loss of oestrogen, especially bone thinning (osteoporosis).
Women who have surgery when they are over 45 years of age can choose to have 
HRT to reduce the symptoms of surgical menopause. However these women do not 
have to have HRT if they do not want to, as the long term health effects of early loss 
of oestrogen do not affect them as much as a women having surgery before 45, 
because their oestrogen levels would have started to fall anyway.
It is important that the possibility of HRT is discussed before making a decision about 
surgery.
Q4 - How long should I take HRT?
If you use HRT, it is recommended that you take it until the age of the natural 
menopause, which is 50 years in the UK. From the age of 50 your oestrogen levels 
would have declined naturally, so taking HRT for many years beyond 50 is not 
recommended. This is because there is controversial evidence about the benefits and 
risks of HRT if it is taken beyond the age of natural menopause. Therefore the health 
effects are unclear and HRT may cause more harm than good if taken beyond 50.
Q5 - Can I take HRT if I have a family history of breast cancer?
Yes. You should be able to take HRT even if you have a family history of breast cancer. 
Several studies have shown that HRT is safe to take for the vast majority of women 
with a family history of breast cancer as long as they have not had breast cancer 
themselves and they only use HRT until the age of the natural menopause. You 
should discuss your family history of breast cancer with your genetics service before 
deciding to have surgery.
Q6 - But I have heard that HRT increases breast cancer risk?
Yes, HRT contains oestrogen and there is some evidence that higher amounts of 
oestrogen in the body can increase the risk of breast cancer.
However, the study that showed that HRT increases breast cancer risk was done with 
older women who had already gone through the natural menopause and were taking 
HRT beyond 50 years of age. Therefore these women were taking oestrogen when 
their body has naturally stopped producing this hormone.
Furthermore, these women did not have surgery to have their ovaries removed. 
Therefore this group of women is very different to women with a family history who 
choose to have their ovaries out before they are 50 years. Furthermore you should be 
aware that the findings of this study have now been widely criticised.
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6. Hormone Replacement 22
Having your ovaries out removes all the natural oestrogen that your ovaries would 
been producing until the age of the natural menopause. The amount of oestrogen 
that is added back by taking HRT is less than the amount your ovaries would have 
produced naturally. If you stop taking HRT at the age of the natural menopause (so 
when you are 50) then there is no evidence that the breast cancer risk is increased.
Q7 - Will HRT reduce all the symptoms of menopause?
No. Taking HRT is not the same as having your own hormones. HRT cannot reduce all 
symptoms of the menopause and women who have had surgery and are on HRT do 
report more symptoms than women who have not had surgery. However, HRT can 
relieve some of the symptoms of the menopause. For example, women who took 
HRT reduced the average number of hot flushes from about 4 to about 1 per day 
when compared to women who did not take HRT. Women on HRT also had fewer 
night sweats.
Q8 - Will HRT deal with the long term health effects of the menopause?
Yes. HRT will reduce the risk of bone thinning and changes in memory functioning 
linked to the loss of oestrogen. However, the evidence of HRT‘s effects on 
cardiovascular disease (heart disease and stroke) is more controversial and should be 
discussed with your doctor in terms of your personal and family history of 
cardiovascular disease as well as your lifestyle, which can also affect your risk of 
cardiovascular disease.
Q9 - Are there any alternatives to HRT?
Yes. There are numerous non-hormonal alternatives to HRT, none of which have been 
shown to be as effective in relieving menopausal symptoms. For people who cannot 
take HRT these alternatives may be a good option but for those who can, HRT is the 
best option. 
Alternatives that are frequently used include:
- Antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs)
- Gabapentin
- Red Clover
- Ginseng
- Evening primrose oil
- Agnus Castus
- And many more (please note that this list is not exhaustive and there may be other 
alternatives to HRT)
Some of these options may be prescribed by your doctor, while others can be bought 
in health shops or over the internet. However, there is no medical proof that freely 
available herbal options work. These alternatives to HRT may have side-effects and 
you should always consult your doctor before deciding to use any of these options.
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7. Other Options
Questions in chapter 7:
Q1 Is there any screening available for ovarian cancer?
Q2 Are there any other options apart from surgery?
Q3 But I have been offered CA125 blood tests and/or trans-vaginal scans?
Q4 What would happen if I do not have surgery?
Q5 Is there anything else I can do?
Q1 - Is there any screening available for ovarian cancer?
No. Unfortunately there is no medically proven screening available for ovarian cancer.
Two large trials of ovarian cancer screening were done recently and the results are 
not yet available, so we do not yet know whether this screening is effective and can 
detect ovarian cancer early. The UKFOCS trial offered high risk women CA125 blood 
tests every four months and one yearly trans-vaginal ultrasound scan. The UKCTOCS 
trial offered such screening to women over 50, who were not at high risk. Both trials 
have not reported their final outcomes. Routine screening will not be offered until 
the results of these trials are available and only if these trials show that screening is 
effective and can save lives.
Some areas or GPs may offer private, self-funded CA125 and/or trans-vaginal 
screening to high risk women, however women need to be aware that there is still no 
proof that this screening is effective in detecting ovarian cancer early. Therefore going 
to private screening may provide false reassurance. Additionally, screening may result 
in unnecessary worry and anxiety if any results show changes that turn out not to be 
cancer.
You should also be aware that the yearly smear test you receive is designed to detect 
cervical cancer and will not detect ovarian cancer.
Women from families with Lynch syndrome may receive trans-vaginal ultrasound 
screening to look for womb cancer. The ovaries may be visible on these scans and if 
something is found the GP may order a CA125 blood test. In this case the CA125 
blood test is a diagnostic test and not a screening test.
Any woman with symptoms of ovarian cancer is likely to be offered a diagnostic 
CA125 test and trans-vaginal ultrasound scan. Please note that these diagnostic tests 
are not screening tests. Rather, they are designed to detect ovarian cancer when 
symptoms have already developed. Women with no symptoms will not be offered 
routine screening on the NHS until the screening has been shown to be effective.
Q2 – Are there any other options apart from surgery?
At the moment the official alternative to surgery is to do nothing and simply be aware 
of the symptoms of ovarian cancer should they develop. However it is important to 
realise that these symptoms can be very vague and are not specific to ovarian cancer. 
If any of these symptoms happen more than 12 times a month you should contact 
your GP.
23
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The symptoms of ovarian cancer include: 
Persistent bloating (big or swollen tummy)
Feeling less hungry or feeling full quickly
Persistent pain in your tummy or below
Needing to urinate more than usual
Often these symptoms are similar to symptoms of other diseases, such as Irritable
Bowel Syndrome and might be easily confused. Therefore it is very important that
you tell your GP that you have a family history of cancer.
Q3 – But I have been offered CA125 blood tests and/or trans-vaginal scans?
Some centres and/or GPs may offer private CA125 tests or trans-vaginal scans to
women at high risk of ovarian cancer. As these are not offered as screening tests by
the NHS you may have to pay for these yourself. You can choose to have these tests
done, but you should be aware that there is no evidence that these screening tests
are effective at detecting ovarian cancer early. Therefore using such screening
services might provide you with false reassurance.
Women from Lynch syndrome families may be offered hysteroscopies or trans-vaginal
ultrasound scans to detect uterus/womb cancer, which these women are at higher
risk for. However usually these tests are designed to detect womb cancer only and
not ovarian cancer.
Q4 - What would happen if I do not have surgery?
If you decide not to have surgery, then nothing will really change. You will need to
look out for any symptoms and if you think anything is wrong you need to go to your
GP to get it checked. You know your body best, so don’t be afraid to go to your GP if
you notice anything unusual. Make sure you tell your GP that you have a family
history of ovarian cancer and are at increased risk of ovarian cancer when you talk to
them.
Remember you can reconsider surgery at any time. If screening for ovarian cancer is
shown to be effective in the future, you may then be offered screening as an
alternative to surgery.
Q5 - Is there anything else I can do?
As there is no routine screening available, you can choose to have screening privately,
but you should be aware that this has not yet been shown to be effective. You should
also keep an eye on any symptoms.
Studies have found that a healthy diet with plenty of fruit and vegetables, keeping a
healthy weight and an active lifestyle can improve overall well-being and might
reduce your chances of getting cancer.
7. Other Options 24
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In some countries it is recommended that women at high risk of ovarian cancer take
the oral contraceptive pill when they are pre-menopausal. The oral contraceptive pill
reduces ovarian cancer risk by up to half, but it has also been found to increase breast
cancer risk. The guidelines in the UK do not recommend taking the oral contraceptive
pill solely for the prevention of ovarian cancer at the moment, although in some
situations reduction in ovarian cancer risk may outweigh any increase in risk of breast
cancer. Whether the oral contraceptive pill might be an option for you depends on
your risk and family history of breast cancer and should be discussed with your
genetic counsellor and GP.
7. Other Options 25
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8. Your Decision (Example)
Makes me want 
to have surgery
Makes me want to 
avoid surgery
Does not 
come into 
my decision
Enter your own reasons:
The fact that…
Add together the numbers in 
each column:
In the exercise on the next few pages you can rate some facts depending on how 
much they make you want to have or want to avoid surgery.  Give each fact a 
ranking number (e.g. from 1 (a little) to 3 (a lot), then add the numbers up to see 
where you stand.
The table below is already filled in to give you an example. On page 28 you will find 
an empty table for you to fill in.
X
3
2
3
2
1
Have to take time off 
work 1
78
26
…surgery will reduce my 
ovarian cancer risk
…there is a risk of 
complications linked to surgery
…I might enjoy sex less after 
surgery
…I will not be able to become 
pregnant after surgery
…I will go into surgical 
menopause after surgery
…I might feel different about 
my body after surgery
…there is no effective screening 
for ovarian cancer, so I cannot 
get checked out regularly
…the symptoms of ovarian 
cancer are very vague, so I may 
not notice them early
1
2
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8. Your Decision (Example)
Below you can enter the overall number into the scales. Then note down how you 
feel about the decision and where you stand.
The scales below are already filled in to give you an example. On page 29 you will 
find an empty scale for you to fill in.
For Surgery Against Surgery
8 7
My action plan: I will make an appointment with my genetic 
counsellor to discuss the menopause and find out 
whether I can take HRT. 
Will talk to my boss about taking time off and 
whether it would cause any problems.
Overall your answers show that at this moment in time you are leaning towards having the
surgery. Even though you may have some reasons why you would want to avoid surgery,
they are not as important to you as the reasons that make you want surgery. Therefore you
could now make an appointment to discuss this decision with your doctor and go through
any concerns you might have.
Overall your answers show that at this moment you are completely undecided about
whether or not to have surgery. Your reasons for why you would want to have and why
you would want to avoid surgery balance each other out. Therefore you may want to
discuss your options further with your doctor/genetic counsellor.
Overall your answers show that at this moment in time you are leaning towards not having
surgery. Even though you may have some reasons why you would want to have surgery,
they are not as important to you as the reasons that make you want to avoid surgery.
Therefore at this moment in time surgery is probably not the right option. However, keep
in mind that things may change over time and that eventually you may lean more towards
surgery. You can come back to OvDex and do this exercise again anytime to see whether
anything has changed.
Overall decision: My reasons for surgery weigh more than those 
against surgery, but I am still not sure. The 
numbers are very similar.
More weight for than against surgery:
Same weights both sides:
More weight against than for surgery:
27
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8. Your Decision
Makes me want 
to have surgery
Makes me want to 
avoid surgery
Does not 
come into 
my decision
Enter your own reasons:
The fact that…
Add together the numbers in 
each column:
In the exercise on the next few pages you can rate some facts depending on how 
much they make you want to have or want to avoid surgery.  Give each fact a 
ranking number (e.g. from 1 (a little) to 3 (a lot), then add the numbers up to see 
where you stand.
Make sure you give the score on the correct side of the table.
28
…surgery will reduce my 
ovarian cancer risk
…surgery will reduce my breast 
cancer risk
…I might enjoy sex less after 
surgery
…I will not be able to become 
pregnant after surgery
…I will go into surgical 
menopause after surgery
…I might feel different about 
my body after surgery
…there is no effective screening 
for ovarian cancer, so I cannot 
get checked out regularly
…the symptoms of ovarian 
cancer are very vague, so I may 
not notice them early
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8. Your Decision
Below you can enter the overall number into the scales. Then note down how you 
feel about the decision and where you stand.
For Surgery Against Surgery
Overall your answers show that at this moment in time you are leaning towards having the
surgery. Even though you may have some reasons why you would want to avoid surgery,
they are not as important to you as the reasons that make you want surgery. Therefore you
could now make an appointment to discuss this decision with your doctor and go through
any concerns you might have.
Overall your answers show that at this moment you are completely undecided about
whether or not to have surgery. Your reasons for why you would want to have and why
you would want to avoid surgery balance each other out. Therefore you may want to
discuss your options further with your doctor/genetic counsellor.
Overall your answers show that at this moment in time you are leaning towards not having
surgery. Even though you may have some reasons why you would want to have surgery,
they are not as important to you as the reasons that make you want to avoid surgery.
Therefore at this moment in time surgery is probably not the right option. However, keep
in mind that things may change over time and that eventually you may lean more towards
surgery. You can come back to OvDex and do this exercise again anytime to see whether
anything has changed.
More weight for than against surgery:
Same weights both sides:
More weight against than for surgery:
Overall decision:
29
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8. Your Decision
Q1 – How can I take my decision forward and how can I cope?
If you are considering surgery, the next step is to make an appointment with a health 
professional. This can be your GP, genetic counsellor or gynaecologic surgeon. With 
them, you can discuss surgery further and get answers to any additional questions, 
before booking an appointment with a hospital. You can also seek a second 
professional opinion at any time if you wish.
Preparing yourself for having surgery, both mentally and physically, can help to cope 
with the operation and with recovery time. It can also help to think about the 
support you do have and how different people might be able to help you. This can 
include simple things such as driving you to and from the hospital, helping you out 
with household chores or childcare issues right after surgery. 
If you decide not to have surgery it might be helpful to speak to your GP and let them 
know about your risk. Some women also find it reassuring to have an action plan in 
case they feel like any symptoms develop. This can be a simple reminder, such as a 
plan to contact your doctor if symptoms last 2 weeks or longer.
My action plan:
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9. Contacts and Resources
Here are some links and contact details that you might find helpful (even though we 
have taken great care in choosing websites from reliable sources please note we are 
not responsible for the content of these websites):
The Cancer Genetics Story Bank – An online collection of stories told by patients and 
professionals about cancer genetics, genetic testing and risk-reduction decisions. 
Developed by the Cancer Genetics Service for Wales (CGSW) 
www.cancergeneticsstorybank.co.uk 
NHS Choices – A website created by the NHS to provide information to patients. 
Includes information on ovarian cancer, genetics and genetic testing.
www.nhs.uk
Macmillan –A UK charity for anyone affected by cancer with good information about 
genetic testing for cancer and mind-body therapies
www.macmillan.org.uk or call the support line on 0808 808 00 00
Target Ovarian Cancer – A UK charity which supports research into ovarian cancer 
and provides useful information including an ‘Ask the Expert‘ feature. Available in 
several languages.
www.targetovariancancer.org.uk 
Ovacome – A UK charity providing information and support for everyone affected by 
ovarian cancer. Includes links to a number of patient blogs. 
www.ovacome.org.uk or call the supportline on 08453710554
Your GP and/or Genetics Service – There to help you with any questions or concerns. 
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Appendix 9.2 - DelibeRATE scale 
 
 
 
From: Sivell S, Edwards A, Manstead A S, Reed M W R, Caldon L, Collins K, Clements A 
and Elwyn G (2012) Increasing readiness to decide and strengthening behavioral 
intentions: Evaluating the impact of a web-based patient decision aid for breast cancer 
treatment options (BresDex: www.bresdex.com). Patient Education and Counseling 88 
(2) 209-217
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Appendix 9.3 - Healthcare Evaluation Provider Satisfaction Questionnaire 
 
Please answer the following questions on a scale of 1 (poor) to 5 (excellent) 
 Poor    Excellent 
Item: 1 2 3 4 5 
How useful was the information provided?      
Did you find the information easy to understand?      
How effective are the graphics?      
What is your general satisfaction with this tool?      
      
      
Please rate the following statements on a scale of 1 (strongly disagree) 
to 5 (strongly agree) 
 Strongly 
disagree 
   
Strongly 
agree 
Item: 1 2 3 4 5 
This tool could improve patient-doctor encounters      
This tool could save me time      
I would use it regularly in practice      
I would recommend that patients use this tool      
 
Adapted from Schackmann E A, Munoz D F, Mills M A, Plevritis S K and Kurian A W (2013) 
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. 
Familial Cancer 12 (1) 65-73 
 
